0001193125-20-297076.txt : 20201118 0001193125-20-297076.hdr.sgml : 20201118 20201118171128 ACCESSION NUMBER: 0001193125-20-297076 CONFORMED SUBMISSION TYPE: S-1/A PUBLIC DOCUMENT COUNT: 14 FILED AS OF DATE: 20201118 DATE AS OF CHANGE: 20201118 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sotera Health Co CENTRAL INDEX KEY: 0001822479 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] IRS NUMBER: 473531161 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-1/A SEC ACT: 1933 Act SEC FILE NUMBER: 333-249648 FILM NUMBER: 201325932 BUSINESS ADDRESS: STREET 1: 9100 SOUTH HILLS BLVD, SUITE 300 CITY: BROADVIEW HEIGHTS STATE: OH ZIP: 44147 BUSINESS PHONE: 440-262-1410 MAIL ADDRESS: STREET 1: 9100 SOUTH HILLS BLVD, SUITE 300 CITY: BROADVIEW HEIGHTS STATE: OH ZIP: 44147 FORMER COMPANY: FORMER CONFORMED NAME: Sotera Health Topco, Inc. DATE OF NAME CHANGE: 20200824 S-1/A 1 d93452ds1a.htm S-1/A S-1/A
Table of Contents

As filed with the Securities and Exchange Commission on November 18, 2020

Registration No. 333-249648

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Amendment No. 4 to

Form S-1

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

Sotera Health Company

(Exact name of Registrant as specified in its charter)

 

Delaware   7389   47-3531161

(State or other jurisdiction of

incorporation or organization)

 

(Primary Standard Industrial

Classification Code Number)

  (I.R.S. Employer Identification Number)

 

 

9100 South Hills Blvd, Suite 300

Broadview Heights, Ohio 44147

(440) 262-1410

(Address including zip code, telephone number, including area code, of Registrant’s Principal Executive Offices)

 

 

Matthew J. Klaben, Esq.

Senior Vice President, General Counsel and Secretary

Sotera Health Company

9100 South Hills Blvd, Suite 300

Broadview Heights, Ohio 44147

(440) 262-1409

(Name, address including zip code, telephone number, including area code, of agent for service)

 

 

Copies To:

David Lopez, Esq.

Cleary Gottlieb Steen & Hamilton LLP

One Liberty Plaza

New York, New York 10006

(212) 225-2000

 

Arthur D. Robinson, Esq.

John C. Ericson, Esq.

Simpson Thacher & Bartlett LLP

425 Lexington Avenue

New York, New York 10017

(212) 455-2000

 

 

Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date hereof.

If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act, check the following box.  ☐

If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer      Accelerated filer  

 

Non-accelerated filer

     Smaller reporting company  
    

 

Emerging growth company

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

 

 

The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.

 

 

 


Table of Contents

The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.

 

SUBJECT TO COMPLETION, DATED NOVEMBER 18, 2020

Preliminary Prospectus

46,600,000 Shares

 

LOGO

Sotera Health Company

Common Stock

 

 

This is the initial public offering of shares of common stock of Sotera Health Company.

Prior to this offering, there has been no public market for our common stock. The initial public offering price of the common stock is expected to be between $20.00 and $23.00 per share. Our common stock has been approved for listing on the Nasdaq Global Select Market (“Nasdaq”) under the symbol “SHC.”

After the completion of this offering, investment funds and entities affiliated with Warburg Pincus LLC and investment funds and entities affiliated with GTCR, LLC together will own approximately 71.5% of the voting power of our common stock, assuming that the underwriters do not exercise their option to purchase additional shares. As a result, we may be considered a “controlled company” within the meaning of the Nasdaq corporate governance standards, and therefore we expect to also qualify for exemptions from certain corporate governance requirements. See “Management and Board of Directors.”

We are an “emerging growth company” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), and as such, have elected to comply with certain reduced public company reporting requirements. See “Prospectus Summary—Implications of Being an Emerging Growth Company.”

Investing in our common stock involves a high degree of risk. See “Risk Factors” beginning on page 22 to read about factors you should consider before deciding to invest in our common stock.

Neither the Securities and Exchange Commission (the “SEC”) nor any state securities commission has approved or disapproved these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

 

     Per share      Total  

Initial public offering price

   $                    $                

Underwriting discounts

   $        $    

Proceeds to us, before expenses

   $        $    

 

(1)

We have agreed to reimburse the underwriters for certain expenses in connection with this offering. See “Underwriting (Conflicts of Interest).”

We have granted the underwriters an option to purchase up to 6,990,000 additional shares of common stock at the initial public offering price less the underwriting discount for a period of 30 days after the date of this prospectus.

Delivery of the shares of common stock will be made on or about                 , 2020.

 

J.P. Morgan   Credit Suisse    Goldman Sachs & Co. LLC   

Jefferies

 

Barclays    Citigroup    RBC Capital Markets

 

BNP PARIBAS               KeyBanc Capital Markets    Citizens Capital Markets            ING

 

Academy Securities

   Loop Capital
Markets
   Penserra
Securities LLC
   Siebert Williams
Shank
   Tigress Financial
Partners

Prospectus dated                 , 2020.


Table of Contents

TABLE OF CONTENTS

 

     Page  

SUMMARY

     1  

RISK FACTORS

     22  

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

     54  

USE OF PROCEEDS

     56  

DIVIDEND POLICY

     57  

CAPITALIZATION

     58  

DILUTION

     60  

SELECTED CONSOLIDATED FINANCIAL INFORMATION

     62  

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

     65  

BUSINESS

     94  

MANAGEMENT AND BOARD OF DIRECTORS

     126  

EXECUTIVE COMPENSATION

     136  

CORPORATE REORGANIZATION

     151  

PRINCIPAL STOCKHOLDERS

     155  

CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

     158  

DESCRIPTION OF CAPITAL STOCK

     166  

DESCRIPTION OF CERTAIN INDEBTEDNESS

     172  

SHARES ELIGIBLE FOR FUTURE SALE

     177  

MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR NON-U.S. HOLDERS

     179  

UNDERWRITING (CONFLICTS OF INTEREST)

     181  

LEGAL MATTERS

     189  

EXPERTS

     189  

WHERE YOU CAN FIND MORE INFORMATION

     190  

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

     F-1  

Through and including                , 2020 (the 25th day after the date of this prospectus), all dealers effecting transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to a dealer’s obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription.

You should rely only on the information contained in this prospectus, any amendment or supplement to this prospectus and any free writing prospectus prepared by us or on our behalf that we have referred you to. We have not, and the underwriters have not, authorized anyone to provide you with different or additional information or to make any representations other than those contained in this prospectus or in any free writing prospectuses we have authorized for use with respect to this offering. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you or any representation that others may make to you. We are not making an offer of these securities in any state, country or other jurisdiction where the offer is not permitted. You should not assume that the information in this prospectus or any free writing prospectus is accurate as of any date other than the date of the applicable document regardless of its time of delivery or the time of any sales of our common stock. Our business, prospects, financial condition or results of operations may have changed since the date of the applicable document. Information contained in our web site does not constitute part of this prospectus.

No action is being taken in any jurisdiction outside the United States to permit a public offering of our common stock. Persons who come into possession of this prospectus in jurisdictions outside the United States are required to inform themselves about and to observe any restriction as to this offering and the distribution of this prospectus applicable to those jurisdictions.

 

ii


Table of Contents

Certain Trademarks, Service Marks and Trade Names

We own or otherwise have rights to the trademarks, service marks and trade names, including those mentioned in this prospectus, used in conjunction with the marketing and sale of our products and services. This prospectus includes trademarks, service marks and trade names, which are protected under applicable intellectual property laws and are our property and/or the property of our subsidiaries. This prospectus may also contain trademarks, service marks and trade names of other companies, which are the property of their respective owners. We do not intend our use or display of other companies’ trademarks, service marks or trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. Solely for convenience, trademarks, service marks and trade names referred to in this prospectus may appear without the ®, , or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor, to these trademarks, service marks and trade names.

Market, Industry and Other Data

Historical and current market data used throughout this prospectus were obtained from internal company analyses, consultants’ reports and industry publications. Industry surveys and publications generally state that the information contained therein has been obtained from sources believed to be reliable. This information involves many assumptions and limitations, and you are cautioned not to give undue weight to these estimates and information. We have not independently verified this market data. While we are not aware of any misstatements regarding any industry or similar data presented herein, such data involve risks and uncertainties and are subject to change based on various factors, including those discussed under the “Risk Factors” section in this prospectus.

 

iii


Table of Contents

SUMMARY

The following summary highlights selected information about our company and this offering that is included elsewhere in this prospectus in greater detail. It does not contain all of the information that you should consider before investing in our common stock. For a more comprehensive understanding of our company and this offering, you should read this entire prospectus carefully, including the information presented under the heading “Risk Factors,” “Cautionary Note Regarding Forward-Looking Statements,” “Selected Consolidated Financial Information,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and in our consolidated financial statements and notes thereto.

In this prospectus, unless we indicate otherwise or the context requires, “Sotera Health,” “Sotera Health Company,” “our company,” “the company,” “we,” “our,” “ours” and “us” refer to Sotera Health Company and its consolidated subsidiaries.

Our Company

Overview

 

 

LOGO

We are a leading global provider of mission-critical sterilization and lab testing and advisory services to the medical device and pharmaceutical industries. We are driven by our mission: Safeguarding Global Health®. We



 

1


Table of Contents

provide end-to-end sterilization as well as microbiological and analytical lab testing and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients and consumers in the United States and around the world. Our customers include more than 40 of the top 50 medical device companies and eight of the top ten global pharmaceutical companies (based on revenue). Our services are an essential aspect of our customers’ manufacturing process and supply chains, helping to ensure sterilized medical products reach healthcare practitioners and patients. Most of these services are necessary for our customers to satisfy applicable government requirements. We give our customers confidence that their products meet regulatory, safety and effectiveness requirements. With a combined tenure across our businesses of nearly 200 years and our industry-recognized scientific and technological expertise, we help to ensure the safety of millions of patients and healthcare practitioners around the world every year. Across our 63 facilities worldwide, we have nearly 2,900 employees who are dedicated to safety and quality. We are a trusted partner to more than 5,800 customers in over 50 countries.

Our Businesses

We serve our customers throughout their product lifecycles, from product design to manufacturing and delivery, helping to ensure the sterility, effectiveness and safety of their products for the end user. We operate across two core businesses: sterilization services and lab services. Each of our businesses has a long-standing record and is a leader in its respective market, supported and connected by our core capabilities including deep end market, regulatory, technical and logistics expertise. The combination of Sterigenics, our terminal sterilization business, and Nordion, our Cobalt-60 (“Co-60”) supply business, makes us the only vertically integrated global gamma sterilization provider in the sterilization industry. This provides us with additional insights and allows us to better serve our customers.

 

   

Sterilization Services (our Sterigenics and Nordion brands):

 

   

Under our Sterigenics brand, we provide outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets. Terminal sterilization is the process of sterilizing a product in its final packaging. It is an essential, and often government-mandated, step in the manufacturing process of healthcare products before they are shipped to end-users. These products include medical protective barriers, including personal protective equipment (“PPE”), procedure kits and trays, implants, syringes, catheters, wound care products, laboratory products and pharmaceuticals. We offer our customers a complete range of outsourced terminal sterilization services, primarily using the three major sterilization technologies: gamma irradiation, ethylene oxide (“EO”) processing and electron beam (“E-beam”) irradiation.

 

   

Gamma irradiation: A process in which products are exposed to gamma rays emitted by Co-60. Gamma rays can penetrate even dense materials to kill microbes. Gamma is particularly effective at sterilizing high-density medical products such as sutures, surgical tools and stents.

 

   

EO processing: A gas sterilization process in which pallets of packaged goods are loaded into a secure chamber that is then injected with EO gas to penetrate the packaging. EO is the most widely used gaseous sterilization agent in the world and has been in use for nearly 90 years. The broad application to a range of medical devices is attributed to the fact that EO is compatible with many materials that cannot tolerate or are degraded by radiation or moist heat sterilization. For this reason, it is commonly the only method available to safely and effectively sterilize procedure kits, PPE and many devices used in cardiac procedures.

 

   

E-beam irradiation: A process in which products are exposed to machine-generated radiation in the form of a stream of electrons. E-beam is particularly effective for low density homogenous products such as glass labware. Several medical devices products also rely on E-beam as an effective form of sterilization, including certain types of syringes. In addition to medical device



 

2


Table of Contents
 

sterilization, E-beam can also be used as an effective technology for materials modification, such as the crosslinking of certain polymers or for enriching the color of gemstones.

 

   

Under our Nordion brand, we are the leading global provider of Co-60 and gamma irradiators, which are key components to the gamma sterilization process. Co-60 is a radioactive isotope that is needed by medical device manufacturers and sterilizers including Sterigenics. Co-60 decays and must be replaced over time to produce the desired level of irradiation. We have the most comprehensive access to nuclear power reactor operators around the world which are able to produce Co-60. The capabilities that we provide to Nordion’s customers include handling and processing of Co-60, recycling of depleted sources and global logistics enabled by our licensed container fleet. We are integral to our customers’ operations due to highly coordinated and complex installation processes. In addition, under our Nordion brand, we are a leading supplier of Co-60 sources for stereotactic radiosurgery devices (such as the Gamma Knife®), which are used for certain oncology applications.

 

   

Lab Services (our Nelson Labs brand):

 

   

Under our Nelson Labs brand, we are a global leader in outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. We provide our customers mission-critical lab testing services, which assess the product quality, effectiveness, patient safety and end-to-end sterility of products. These services are necessary for our customers’ regulatory approvals, product releases and ongoing product performance evaluations.

 

   

Microbiology testing services help to identify and measure the potential risks of microbes to a product and ensure that the quality of the products is maintained.

 

   

Analytical chemistry lab testing is also a critical part of the pharmaceutical drug and medical device development and manufacturing process. This testing provides first-hand information as to the content, quality and safety of raw materials, intermediates and finished products.

 

   

We also provide expert advisory services to aid customers in navigating the regulatory requirements applicable throughout the product lifecycle.

Nelson Labs serves over 3,800 customers across 13 facilities in the United States, Mexico, Asia and Europe. We have a comprehensive array of over 800 laboratory tests supporting our customers from initial product development and sterilization validation, through regulatory approval and ongoing product testing for sterility, safety and quality assurance. Our customers rely on our expertise in their industries to get their medical device and pharmaceutical products to market.

 

   

Medical device lab testing services include: microbiology, biocompatibility and toxicology assessments, material characterization, sterilization validation, sterility assurance, packaging validation and distribution simulation, reprocessing validations, facility and process validation and performance validation and verification of PPE barriers and material.

 

   

Pharmaceutical lab testing services include: microbiology, biocompatibility and toxicology assessments, extractables and leachables evaluations of pharmaceutical containers, sterilization validation, sterility assurance, packaging validation and distribution simulation and facility and process validation.

Nelson Labs is highly complementary to our sterilization services business. In particular, microbiological testing validates the configuration and effectiveness of the sterilization process.

We believe that our sterilization service offerings, our Co-60 supply capabilities and the broad capabilities of our lab services business give us unique insights and technical expertise to serve the mission-critical needs of medical device and pharmaceutical manufacturers. We believe these provide us with a competitive advantage over other outsourced sterilization and lab testing service providers.



 

3


Table of Contents

Our Markets and Customers

Medical device and pharmaceutical manufacturers often outsource their sterilization and lab services needs, as the technical and regulatory expertise and infrastructure required to establish those capabilities in-house can result in significant cost and resource burden.

We estimate that the total global addressable market for terminal sterilization and outsourced medical device and pharmaceutical lab testing was approximately $33 billion in 2019. Global terminal sterilization accounted for $3 billion of our estimated total addressable market in 2019. Global outsourced medical device and pharmaceutical lab testing services accounted for approximately $29 billion of our estimated total addressable market in 2019, with approximately $3 billion attributable to medical devices and approximately $26 billion attributable to pharmaceuticals. We believe the following secular trends underpin increasing demand for medical devices and pharmaceuticals: an aging population, increased access to, and demand for, healthcare services globally, growth in healthcare R&D spending and innovation, intensifying regulatory requirements and heightened focus on personal safety. As a service provider to manufacturers, we are not directly exposed to risks associated with reimbursement by public or private payors. We expect that increasing utilization of medical devices, including the equipment and consumables that we sterilize and test, expansion in pharmaceutical development and a growing focus on microbial decontamination (including viruses) will continue to drive growth in our business and provide us the opportunity to expand within our markets.

Our customers depend upon the end-to-end services we provide throughout the lifecycle of their products, from research and development, to product manufacturing and sterilization, as well as ongoing quality control. We often maintain long-term relationships with our customers, which average over a decade across our top 25 customers in 2019. We also benefit from minimal customer concentration, as no single customer accounted for more than 4% of our total revenues in 2019. Given the critical nature of our services, a significant portion of our revenues is supported by multi-year contracts. More than 90% of our sterilization services revenues in each of the year ended December 31, 2019 and the nine months ended September 30, 2020 were from customers under multi-year contracts. The quality of our service offerings is evidenced by close to 100% renewal rates of our top ten sterilization services customers in 2019 over the past five years. Most of our services are government-mandated and mission-critical, and sterilization services generally represent a small fraction of the total end product cost of medical devices.

Our Network and Expertise

All of the services we provide are highly regulated and require significant technical expertise. To manage these strict regulatory requirements safely and effectively, we have a highly trained and skilled workforce that creates, implements and manages complex quality assurance and environmental health and safety programs, procedures and control systems. We coordinate and communicate with numerous regulatory agencies globally across our businesses on an ongoing and regular basis.

With 63 facilities across our businesses located in 13 countries, our network of global facilities represents a significant competitive advantage in serving the healthcare industry. Our sterilization facilities are often strategically located near our healthcare customers’ manufacturing sites or distribution hubs, which is intended to decrease our customers’ transportation costs and help them optimize their supply chain and logistics. Our laboratory testing facilities are strategically located in order to meet the demanding and often complex needs of our customers. Extensive capital, technical expertise and regulatory knowledge are required to build, maintain and operate facilities like ours. We estimate that one new sterilization facility can cost over $30 million to build, on average, and require extensive and complex licensing approval and regulatory compliance processes. We estimate that the cost to replace the facilities in our network alone could be as high as $1.5 billion or more, in addition to the technical and regulatory requirements.



 

4


Table of Contents

For the year ended December 31, 2019, we recorded net revenues of $778.3 million, net loss of $20.4 million, Adjusted Net Income of $100.4 million and Adjusted EBITDA of $379.9 million. In addition, for the nine months ended September 30, 2020, we recorded net revenues of $601.3 million, net income of $5.9 million, Adjusted Net Income of $77.1 million and Adjusted EBITDA of $306.8 million. For the definition of Adjusted Net Income and Adjusted EBITDA and the reconciliation of these measures from net income (loss), please see “Summary—Summary Historical Consolidated Financial and Other Data.”

Industry Overview

We expect several positive secular trends to drive increased demand for our services, including:

 

   

Favorable demographic trends for healthcare worldwide: Healthcare demand is increasing globally, driven primarily by an aging population and an increased prevalence of chronic diseases. According to data published by the United Nations in 2019, the world’s population is expected to increase by 2 billion people in the next 30 years. In addition, one in six people are projected to be over the age of 65 globally by 2050, up from one in eleven in 2019. United Nations projections from 2019 also show that the number of people aged 80 or older is expected to triple in the next 30 years. These trends are driven by declining fertility and increasing longevity, as well as international migration. In many regions, the population aged 65 is projected to double by 2050, while global life expectancy beyond 65 is expected to increase by 19 years. In March 2020, the Centers for Medicare & Medicaid Services (the “CMS”) estimated that health expenditures in the United States will increase from approximately 18% of gross domestic product in 2018 to approximately 20% in 2028.

 

   

Increased demand for healthcare services in global markets: Stricter healthcare standards coupled with heightened regulatory requirements, greater availability of care and increased patient purchasing power are driving increased demand for healthcare services. In emerging markets, rapid urbanization and rising income, combined with an increase in diseases such as diabetes and cancer, have fueled the growth in access to, and demand for, healthcare services. In addition, the coronavirus (“COVID-19”) pandemic has also increased awareness of the importance of decontamination and sterilization. In 2018, the CMS estimated global healthcare costs to be approximately $4 trillion in 2019 and projected they would reach more than $6 trillion by 2027.

 

   

Growth in R&D spending and innovation across healthcare: The pharmaceutical and medical device industries are continuously innovating and developing new products, which we anticipate will increase the demand for sterilization and lab services. Worldwide pharmaceutical R&D spend is forecasted to grow steadily at a compound annual growth rate (“CAGR”) of approximately 3% between 2019 and 2026, reaching $233 billion by 2026 (EvaluatePharma® July 2020, Evaluate Ltd.). In the medical devices market, the global top twenty companies based on R&D spending spent a combined $18 billion on R&D in 2017 (EvaluateMedTech® World Preview 2018, Evaluate Ltd.). This number is expected to grow at a 4% CAGR, reaching approximately $24 billion by 2024 (EvaluateMedTech® World Preview 2018, Evaluate Ltd.).

Key Strengths

We are a critical service provider in the healthcare value chain. Our customers rely on us to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients and consumers. We provide services, including sterility assurance, product safety and effectiveness validation, that our customers need to get their products to market and into the hands of their end-users. Our breadth of services, technical and regulatory expertise, as well as our global scale, enable us to provide these mission-critical services which are necessary for Safeguarding Global Health®. These key strengths make us a global leader in our markets.



 

5


Table of Contents

Comprehensive, global provider of mission-critical sterilization and lab services for the healthcare industry

Our customers value our scale and breadth of services. We offer customers comprehensive sterilization, lab testing and expert advisory services on a global scale. Our customers in the healthcare industry require these services to navigate and operate in an increasingly complex and technical regulatory environment, and we believe we provide a differentiated value proposition to our customers by offering these services in an integrated manner. Our robust sterilization capabilities across all key modalities allow our customers to help ensure the safety of their products prior to delivery to their end-users. We offer over 800 microbiology and analytical chemistry lab tests that, together with our expert advisory services, cover the entirety of the medical device and pharmaceutical product lifecycles to evaluate and ensure that our customers’ products meet regulatory requirements. Our frequent interactions with our customers across multiple facets of their products’ lifecycles give us deep and often early insights into the evolving needs of the manufacturers of medical devices and pharmaceuticals. We have a large, global and strategically-located network of facilities that allows us to deploy the full array of our services to our customers where they need us. These comprehensive and global services make us an essential player across the medical device and pharmaceutical value chain.

Industry leading participant in large and growing markets, underpinned by trends in global healthcare

We estimate that the total global addressable market for terminal sterilization and outsourced medical device and pharmaceutical lab testing was approximately $33 billion in 2019. Global terminal sterilization accounted for $3 billion of our estimated total addressable market in 2019. Global outsourced medical device and pharmaceutical lab testing services accounted for $29 billion of our total addressable market in 2019.

Given the mission-critical need for our services within the healthcare industry, our growth historically has been impacted by broader global healthcare trends as opposed to macroeconomic trends. Trends including an aging population and increased access to, and demand for, healthcare services globally, have driven increases in volume demand for medical device and pharmaceutical products. In addition, the need for product enhancement and innovation by manufacturers drives further demand for our services. We believe the sterilization and lab services markets will continue to benefit from these trends, as well as from the increasingly complex regulatory and compliance environment and heightened focus by consumers on personal safety. As our customers continue to focus on innovation of their own products, they have increasingly relied on our expertise and our outsourced services to help them get their products to market. We believe our ability to provide end-to-end sterilization and lab services makes us a trusted partner to our customers in these large and growing markets.

Sterilization services business with an established and durable customer base supported by long-term contracts provides highly recurring revenue streams

We provide expertise and end-to-end sterilization services for our customers leading to deep, trusted relationships that allow them to meet their global regulatory compliance needs. Our relationships with our Sterigenics and Nordion customers are typically governed by multi-year contracts with cost pass-through provisions, which have resulted in recurring revenue streams and accretive growth. In addition, these customers often look to us as a long-term provider given switching providers can be costly and burdensome. For example, in most circumstances, switching providers requires additional testing, re-validation and Food and Drug Administration (“FDA”) submissions and can take anywhere from six months to three years depending upon the class of product. Our relationships with our top ten sterilization services customers in 2019 had an average tenure of over a decade. Our partnerships with these customers have led to close to 100% renewal rates over the past five years.

Expertise and strong track record in highly regulated markets

We and our customers operate in highly complex and regulated markets that require deep knowledge and technical expertise. We believe that the operational discipline that we employ to manage intricate quality



 

6


Table of Contents

assurance and environmental health and safety (“EH&S”) programs in our own operations gives our customers confidence that we are the best partner to support them in their businesses. For example, we design and install emission controls in our EO facilities that often outperform the regulatory standards that we are required to meet. We also have a skilled team which has developed trusted relationships with numerous regulatory bodies around the world. For example, in 2019 we were selected by the FDA as one of eight participants to move to the next stage of a public innovation challenge to encourage the development of new approaches to medical device sterilization and new strategies to reduce EO emissions. We work closely with our customers, the FDA and others to consider enhanced EO cycle design and processes that would reduce EO emissions from the EO sterilization process to as close to zero as reasonably possible. Our relationships, combined with our thought leadership that is recognized by regulators and customers alike, enable us to inform the process of creating, interpreting and advising on safety standards. They also allow us to educate and advise our customers on current and newly evolving standards and requirements.

Global scale and integrated facility network provide differentiated services to our customers

We have a global network of 63 facilities, consisting of 50 sterilization services facilities and 13 labs, through which we provide services to more than 5,800 customers that have operations in over 50 countries. We have worked to standardize our enterprise resource planning, global quality and EH&S systems to integrate our network of facilities globally. This integration is critical for our customers, who operate globally and look for partners that can provide the same level of service, experience and expertise wherever they operate. We serve many of our sterilization customers at more than one facility, with more than 80% of Sterigenics’ net revenues attributable to customers using more than one of our facilities and more than 50% of Sterigenics’ net revenues attributable to customers using five or more of our facilities in 2019. The capital to replicate the scale of our global facility network, extensive and complex upfront licensing processes and intense regulatory compliance requirements make it extremely difficult for new competitors to easily enter our markets and replicate our scale. The combination of Sterigenics and Nordion makes us the only vertically integrated global supplier of gamma irradiation services, which allows Nordion to more confidently make long-term investments to expand Co-60 supply for the medical products sterilization industry. We believe our global scale, supported by our integrated facility network and core capabilities including deep end market, regulatory, technical and logistics expertise, will allow us to continue to expand our service offerings and customer base.

Experienced management team with proven track record of execution and financial performance

Our management team has significant industry expertise, an unwavering commitment to operational excellence and a proven track record of delivering financial performance. Our culture of accountability runs throughout the entire organization and has contributed meaningfully to our operational achievements and commercial success. Our management team is supported by nearly 2,900 team members around the world who are dedicated to safety and quality, which is why we are a trusted partner to our customers. We have delivered revenue growth every year since 2005, even through significant economic downturns, and have implemented productivity initiatives which have led to margin expansion. Our team brings extensive experience and is highly skilled at recognizing and acting upon market expansion opportunities. Our disciplined approach to M&A has enabled the successful integration of two transformational and seven bolt-on acquisitions over the past six years. In addition, we are disciplined in our capital deployment strategy, which is focused on achieving attractive returns on investment. We pursue capacity expansions that will allow us to consistently grow earnings.



 

7


Table of Contents

Our Strategy

Our strategy is designed to deliver on our mission of Safeguarding Global Health®, while generating sustainable growth, margins and cash flows for our business:

Drive organic growth by leveraging our leading capabilities, scale and global network

We believe that our established and durable relationships with our diverse customer base, along with the breadth and depth of our service offerings, provide us with a distinct leadership position within the markets that we serve. Our deep experience in sterilization and lab services allows us to be agile in identifying opportunities and decisive in deploying resources towards these opportunities to drive organic growth. We intend to continue capitalizing on our leadership position and integrated global facility network and capabilities to drive our growth by expanding existing customer relationships and attracting new customers. We also seek to accelerate our penetration in high-growth end-markets such as pharmaceuticals.

Deepen our customer relationships with our comprehensive service offerings in sterilization and lab services

Our customers around the world trust us to provide them with the highest quality sterilization and lab services. We are focused on broadening the number and range of services that each of our customers purchase from us by leveraging our core capabilities. We have continued to work on improving our customer interactions in order to deliver a “one company” experience across our sterilization and lab services so that we can further deepen our customer relationships. We provide comprehensive end-to-end services across our customers’ value chains so they can efficiently deliver the safest products to their end-users. We are the only industry player that offers the range of sterilization and lab services at the scale that we do. We strive for the full integration of our global operations to drive consistency across our services and provide our customers with a coordinated and seamless experience, designed to reduce cycle times for our services and improve efficiency. Our offerings facilitate long-term partnerships with our customers and make us an integral part of their product development and commercialization processes. We have multiple decades of deep expertise across key sterilization modalities as well as lab testing services across our customers’ full product lifecycles. We provide over 800 laboratory tests, which we believe is multiple times the number of offerings of our nearest competitor.

Expand footprint to meet the local needs of our growing global customer base

We are focused on aligning our facility network to best meet our customers’ requirements. We believe our valuable insight into our customers’ current and future needs will allow us to efficiently grow our business. Our global presence reflects our commitment to developing our footprint to serve our customers’ supply chains. Our integrated network of facilities is important to our customers as they can rely on the same level of service at each of our facilities, regardless of where they are around the world. We believe our sterilization services customers are seeking a partner that can operate near their manufacturing sites and distribution centers around the world, as transportation and logistics costs can be meaningful for our customers. In certain circumstances we will invest in projects to build capacity ahead of demand in alignment with the strategic plans of our customers. Our lab services customers are seeking expertise with both international and U.S. regulatory bodies. As our customers expand their global operations, we are well-equipped to expand with them and serve them where they need us.

Invest in technical and regulatory capabilities to enhance our leadership position

Our customers depend on our deep and extensive technical knowhow to get their products to market. We plan to continue to invest in our technical expertise and regulatory knowhow to stay ahead of the dynamic and increasingly complex regulatory landscape in the healthcare industry. Our combination of technical and regulatory expertise allows us to advance the standards of safety for crucial products whose end-users include



 

8


Table of Contents

healthcare practitioners and patients. As customers look to us for expertise, this landscape creates opportunities for us to drive growth in our advisory services offering. We believe that our position as a key industry thought leader makes us a trusted partner for customers as they are developing new products and a respected industry partner for regulators as they are defining industry standards of safety for the future.

Continue our commitment to operational excellence to drive business efficiency and results

Our focus on operational excellence has allowed us to increase capacity utilization and improve working capital, thereby growing our revenues while expanding margins and improving the customer experience. Our commitment to implementing and improving customer-experience enhancing initiatives and internal processes has been a key driver of our strong financial profile to date. Our customer-facing initiatives around cycle time reduction, quality self-service reporting, purchase order accuracy and scheduling efficiencies highlight our rigorous, detail-oriented approach to operational excellence and connectivity with our long-time customers. These initiatives are designed not only to reduce turnaround times and increase predictability of service for our customers, but also to maximize our financial results. We will continue to address our customers’ expectations through our internal processes centered on talent management, quality, EH&S and information technology. We believe that these processes will enable us to continue to deliver growth, profitability and cash generation.

Pursue value-creating strategic acquisitions to expand our addressable market and enhance our global capabilities and footprint

Our disciplined approach to M&A has resulted in our successful track record of identifying, completing and integrating strategic acquisitions into our company and we intend to continue to pursue value-creating strategic acquisitions. We have implemented a disciplined framework to support our acquisition efforts that focuses on quality businesses that are well-regarded by our customers and aligned with our culture of accountability, customer service and operating with integrity. Illustrating this highly disciplined acquisition framework are our two transformational acquisitions of Nordion and Nelson Labs. In addition to these major acquisitions, we acquired FTSI, Gammarad, CBE, REVISS, Toxikon Europe NV, Gibraltar Laboratories and Iotron Industries Canada, Inc. (“lotron”), which provided geographic, technical and service line expansions. Our acquisition of Nelson Labs expanded our capabilities by creating an enhanced lab services platform to provide microbiology testing within our existing customer end-markets and increasing the number of tests we could provide to our customers. We have a strong foundation to continually evaluate acquisition opportunities that would expand our addressable market and enhance our global capabilities and footprint. We are well positioned to evaluate other acquisitions that leverage our core capabilities while expanding our existing customer relationships. We currently have a significant pipeline of targets, ranging from small, owner operated businesses to larger businesses, and believe that we can identify the appropriate targets and integrate them seamlessly into our business.

Risk Factor Summary

Investing in our common stock involves a high degree of risk. These risks are discussed in more detail in “Risk Factors” beginning on page 22, and you should carefully consider these risks before making a decision to invest in our common stock. The following is a summary of some of the principal risks we believe we face:

 

   

disruption in the availability of, or increases in the price of, EO, Co-60 or our direct materials, services and supplies, including as a result of geopolitical instability arising from U.S. relations with Russia and related sanctions;

 

   

changes in industry trends, environmental, health and safety regulations or preferences and general economic, social and business conditions;



 

9


Table of Contents
   

health and safety risks associated with the use, transportation and disposal of potentially hazardous materials such as EO and Co-60;

 

   

the impact and outcome of current and future legal proceedings and liability claims, including tort lawsuits alleging personal injury or property devaluation by purported exposure to emissions of EO from our facility in Willowbrook and our facility in Atlanta, the possibility that other claims will be made in the future relating to these or other facilities and any inadequacy of our insurance coverage to pay any judgments rendered against us, including that our per occurrence limit for claims relating to Willowbrook’s EO emissions has been reached;

 

   

compliance with regulatory requirements to which we are subject and the related costs, and any failures to receive or maintain, or delays in receiving, required clearance or approvals;

 

   

competition we face;

 

   

business continuity hazards and other risks associated with our operations;

 

   

our ability to increase capacity at existing facilities, renew leases for our facilities and build new facilities in a timely and cost-effective manner;

 

   

the risks of doing business internationally;

 

   

cyber security breaches and data leaks, and our dependence on information technology systems;

 

   

any inability to pursue strategic transactions, including to find suitable acquisition targets, and our failure to integrate strategic acquisitions successfully into our existing business or realize anticipated cost savings or synergies;

 

   

any inability to implement effective internal controls over financial reporting;

 

   

our history of net operating losses, including a net loss of $20.8 million and $5.9 million for the years ended December 31, 2019 and 2018, and the risk that we may not achieve or maintain profitability in the future;

 

   

our substantial leverage could adversely affect our ability to raise additional capital, limit our ability to react to changes in the economy or our industry, limit our flexibility in operating our business through restrictions contained in our debt agreements and prevent us from meeting our obligations under our existing and future indebtedness. As of September 30, 2020, our indebtedness totaled approximately $2,910 million, and for the nine months ended September 30, 2020, our debt service obligations (principal and interest) represented approximately 66% of our net cash flows from operating activities (before giving effect to the payment of interest). As adjusted to give effect to this offering and the application of the net proceeds therefrom, as of September 30, 2020, our indebtedness would have totaled approximately $2,035 million, and for the nine months ended September 30, 2020, our debt service obligations (principal and interest) would have represented approximately 56% of our net cash flows from operating activities (before giving effect to the payment of interest);

 

   

the Sponsors will continue to have substantial control over us after this offering, which could limit your ability to influence the outcome of key transactions, including a change of control; and

 

   

the fact that we may be considered a “controlled company” within the meaning of the Nasdaq corporate governance standards and would qualify for exemptions from certain corporate governance requirements, which means that our stockholders may not have the same protections afforded to stockholders of companies that are subject to such requirements.



 

10


Table of Contents

Corporate Information and Structure

Sotera Health Company was incorporated in Delaware in November 2017 as the parent company for Sterigenics, Nordion and Nelson Labs. In May 2015, investment funds and entities affiliated with either Warburg Pincus LLC (“Warburg Pincus”) or GTCR, LLC (“GTCR”) acquired a controlling interest in our predecessor through Sterigenics-Nordion Topco Parent LLC, now known as Sotera Health Topco Parent, L.P. (“Topco Parent”). On October 23, 2020, we changed our name from Sotera Health Topco, Inc. to Sotera Health Company. The issuer in this offering, Sotera Health Company, is a Delaware corporation and is a direct wholly owned subsidiary of Topco Parent. Pursuant to the terms of the corporate reorganization that will be completed prior to the completion of this offering, Topco Parent will distribute the shares of Sotera Health Company common stock to its partners in accordance with the limited partnership agreement of Topco Parent. For more information on our corporate reorganization and ownership of our common stock, see “Corporate Reorganization” and “Principal Stockholders.”

Our principal executive offices are located at 9100 South Hills Blvd, Suite 300 Broadview Heights, Ohio 44147, and our telephone number is (440) 262-1410. Our corporate website address is www.soterahealth.com. We do not incorporate the information contained on, or accessible through, our corporate website into this prospectus, and you should not consider it part of this prospectus.

Our wholly owned subsidiary, Sotera Health Holdings, LLC (“SHH”) is the borrower under our senior secured first lien credit facilities and the issuer of our senior secured first lien notes and our senior secured second lien notes. We and certain of our domestic subsidiaries are guarantors of SHH’s obligations under our credit facilities and notes.

Principal Stockholders

Following this offering and based on an assumed initial public offering price of $21.50 per share (the midpoint of the estimated offering price range set forth on the cover page of this prospectus), certain investment funds and entities affiliates of Warburg Pincus and GTCR, which we refer to collectively as the “Sponsors,” will own approximately 42.9% and 28.6%, respectively, of our common stock (approximately 41.9% and 27.9%, respectively, if the underwriters’ option to purchase additional shares is exercised in full). Together the Sponsors will own, in the aggregate, approximately 71.5% of our common stock (approximately 69.8% if the underwriters’ option to purchase additional shares is exercised in full).

Warburg Pincus is a global private equity firm focused on growth investing. The firm’s active portfolio of more than 185 companies is highly diversified by stage, sector and geography. It has invested approximately $12.3 billion of equity in the healthcare industry, and possesses direct knowledge of the sterilization services industry’s end markets and medical device customers through its investments in other healthcare companies. Warburg Pincus is an experienced partner to management teams seeking to build durable companies with sustainable value. Founded in 1966, Warburg Pincus has raised over 20 private equity funds with capital commitments totaling $99 billion and has invested more than $88 billion in over 930 companies across 40 countries. The firm is headquartered in New York with offices in Beijing, Berlin, Hong Kong, Houston, London, Mumbai, San Francisco, São Paulo, Shanghai and Singapore.

Founded in 1980, GTCR is a private equity firm focused on investing in growth companies in the Healthcare, Technology, Media & Telecommunications, Financial Services & Technology and Growth Business Services industries. The Chicago-based firm pioneered The Leaders Strategy–finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through transformational acquisitions and organic growth. Since its inception, GTCR has invested more than $18 billion in over 200 companies. GTCR is an active investor in the healthcare products sector and has supported Sotera Health’s significant growth since 2011.



 

11


Table of Contents

Pursuant to certain agreements to be entered into prior to the consummation of this offering in connection with the corporate reorganization, we will be required to take all necessary action to cause our board of directors to include individuals designated by the Sponsors pursuant to certain ownership thresholds. Warburg Pincus and GTCR, individually, will be required to vote all of their shares, and take all other necessary actions, to cause our board of directors to include the individuals designated as directors by Warburg Pincus and GTCR, as applicable. After the completion of this offering, the Sponsors will control a majority of the voting power of shares of our common stock with respect to the election of directors and will control a majority of the board of directors.

Channels for Disclosure of Information

Following the completion of this offering, we intend to announce material information to the public through filings with the SEC, the investor relations page on our website (www.soterahealth.com), press releases, public conference calls and public webcasts.

Any updates to the list of disclosure channels through which we will announce information will be posted on the investor relations page on our website.

Implications of Being an Emerging Growth Company

We qualify as an “emerging growth company” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). As an emerging growth company, we may choose to take advantage of specified reduced disclosure and other requirements otherwise applicable generally to public companies that are not emerging growth companies.

We may take advantage of these exemptions until such time that we are no longer an emerging growth company. We will remain an emerging growth company until the earliest of (i) the last day of the fiscal year following the fifth anniversary of the completion of this offering, (ii) the last day of the fiscal year in which we have total annual gross revenue of at least $1.07 billion, (iii) the date on which we are deemed to be a large accelerated filer under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which means the market value of our common stock that is held by non-affiliates exceeds $700.0 million as of the prior June 30 and (iv) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period. We may choose to take advantage of some but not all of these reduced disclosure obligations in future filings. If we do, the information that we provide to stockholders may be different than you might get from other public companies in which you hold stock.

Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to take advantage of the extended transition period for complying with new or revised accounting standards until those standards would otherwise apply to private companies or at which time we conclude it is appropriate to avail ourselves of early adoption provisions of applicable standards. As a result, our results of operations and financial statements may not be comparable to the results of operations and financial statements of other companies who have adopted the new or revised accounting standards.



 

12


Table of Contents

The Offering

 

Common stock offered by us

46,600,000 shares.

 

Underwriters’ option to purchase additional shares

We may sell up to 6,990,000 additional shares if the underwriters exercise their option to purchase additional shares.

 

Common stock to be outstanding after this offering

277,331,078 shares (or 284,321,078 shares if the underwriters exercise their option to purchase additional shares in full).

 

Use of proceeds

We estimate that our net proceeds from this offering will be approximately $949.3 million (or approximately $1,091.7 million if the underwriters exercise their option to purchase additional shares in full) at an assumed initial public offering price of $21.50 per share, the midpoint of the estimated offering price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions.

 

  We intend to use a portion of the net proceeds of this offering to (i) redeem all of the outstanding aggregate principal amount of the Second Lien Notes at the applicable redemption premium, plus accrued and unpaid interest to, but excluding, the date of redemption and (ii) repurchase 1,669,122 shares of our common stock (based on an assumed initial public offering price of $21.50, the midpoint of the estimated offering price range set forth on the cover page of this prospectus) from certain of our executive officers at a purchase price per share equal to the initial public offering price per share of our common stock less an amount equal to the underwriting discounts and commissions payable thereon (the “repurchase”). We plan to use the balance of the net proceeds of this offering to repay a portion of the outstanding indebtedness under our Term Loan. See “Use of Proceeds.”

 

Dividend policy

We do not expect to pay dividends on our common stock for the foreseeable future. Instead, we anticipate that all of our earnings in the foreseeable future will be used for the operation and growth of our business and the repayment of indebtedness. See “Dividend Policy.”

 

Risk factors

Investing in our common stock involves a high degree of risk. See “Risk Factors” for a discussion of factors you should carefully consider before deciding to invest in our common stock.

 

Stockholders’ agreement

Following the completion of this offering, we will have a stockholders’ agreement with certain holders of our common stock, including the Sponsors, that will provide certain rights to those holders. See “Certain Relationships and Related Party Transactions—Stockholders’ Agreement.”

 

Registration rights agreement

Following the completion of this offering, we will have a registration rights agreement with certain holders of our common stock, including



 

13


Table of Contents
 

the Sponsors, whereby, following this offering and the expiration of the lock-up agreement with the underwriters in this offering, we may be required to register under the Securities Act the sale of shares of our common stock under specified circumstances. See “Certain Relationships and Related Party Transactions—Registration Rights Agreement.”

 

Conflicts of interest

Affiliates of Goldman Sachs & Co. LLC hold approximately $420 million aggregate principal amount of the Second Lien Notes, all of which will be redeemed at the applicable redemption premium, plus accrued and unpaid interest to, but excluding the date of redemption and less than $1.5 million of the aggregate principal amount of the Term Loan, a portion of which will be repaid, and as a result will receive approximately 45.1% of the net proceeds of this offering (at an assumed initial public offering price of $21.50, the midpoint of the estimated offering price range on the cover of this prospectus), assuming the underwriters do not exercise their option to purchase additional shares. See “Use of Proceeds.” Accordingly, Goldman Sachs & Co. LLC is deemed to have a conflict of interest within the meaning of Rule 5121 (“Rule 5121”) of the Financial Industry Regulatory Authority, Inc. (“FINRA”). Therefore, this offering is being made in compliance with the requirements of Rule 5121. This rule requires, among other things, that a “qualified independent underwriter” participate in the preparation of, and exercise the usual standards of “due diligence” with respect to, the registration statement and this prospectus. J.P. Morgan Securities LLC has agreed to act as qualified independent underwriter for this offering and to undertake the legal responsibilities and liabilities of an underwriter under the Securities Act. J.P. Morgan Securities LLC will not receive any additional fees for serving as qualified independent underwriter in connection with this offering. We have agreed to indemnify J.P. Morgan Securities LLC against liabilities incurred in connection with acting as qualified independent underwriter, including liabilities under the Securities Act. Pursuant to FINRA Rule 5121, Goldman Sachs & Co. LLC will not confirm sales of our common stock to any account over which it exercises discretionary authority without the prior written approval of the customer. For more information, see “Underwriting (Conflicts of Interest).”

 

Nasdaq symbol

“SHC”

The number of shares of common stock to be outstanding after the offering is based on 232,400,200 shares of common stock outstanding as of September 30, 2020, 1,669,122 shares to be repurchased from certain of our executive officers in the repurchase and 46,600,000 shares to be sold in the offering and an assumed initial public offering price of $ 21.50 per share (the midpoint of the estimated offering price range set forth on the cover page of this prospectus).

The number of shares of common stock to be outstanding after this offering does not take into account an aggregate of 27,900,000 shares of common stock reserved for future issuance under our 2020 Omnibus Incentive Plan (the “2020 Plan”), which we adopted in connection with this offering (including the IPO Awards (as defined below), which we expect to grant to certain of our employees and consultants in connection with this offering,



 

14


Table of Contents

including grants to our Named Executive Officers with an aggregate grant date value currently estimated to be approximately $19.8 million. See “Executive Compensation—2020 Omnibus Incentive Plan” and “Executive Compensation—Equity Grants Made in Connection with This Offering.”

In addition, except as otherwise noted, all information in this prospectus:

 

   

assumes the completion of our corporate reorganization prior to the completion of this offering, including a forward stock split to reclassify all 3,000 shares of our common stock outstanding as 232,400,200 shares. See “Corporate Reorganization”;

 

   

gives effect to the amendment and restatement of our certificate of incorporation and amendment and restatement of our bylaws prior to the closing of this offering;

 

   

gives effect to the repurchase of certain shares of common stock as described under “Use of Proceeds”; and

 

   

assumes the underwriters do not exercise their option to purchase additional shares of our common stock.



 

15


Table of Contents

Summary Historical Consolidated Financial and Other Data

The following tables present our summary historical consolidated financial and other data. The summary historical consolidated statements of operations data and statements of cash flows data for the years ended December 31, 2019 and 2018, and the summary historical balance sheet data as of December 31, 2019 and December 31, 2018, have been derived from our audited consolidated financial statements included elsewhere in this prospectus. The summary historical consolidated statements of operations data and statements of cash flows data for the nine months ended September 30, 2020 and 2019 and the summary historical consolidated balance sheet data as of September 30, 2020 have been derived from our unaudited interim condensed consolidated financial statements included elsewhere in this prospectus. Our unaudited interim condensed consolidated financial statements have been prepared on the same basis as our audited consolidated financial statements and, in the opinion of our management, reflect all adjustments, including normal recurring items, considered necessary for a fair presentation of this data.

The following summary consolidated financial data should be read in conjunction with the information contained in “Use of Proceeds,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the consolidated financial statements and related notes thereto included elsewhere in this prospectus. Our historical results are not necessarily indicative of our results in any future period and our results for any interim period are not necessarily indicative of results that may be expected for any full fiscal year.

 

Statement of Operations Data:   Year Ended December 31,     Nine Months Ended September 30,  
(in thousands, except per share amounts)           2019                     2018                     2020                     2019          

Revenues:

       

Service

  $ 673,037     $ 615,510     $ 524,025     $ 501,875  

Product

    105,290       130,639       77,288       82,967  
 

 

 

   

 

 

   

 

 

   

 

 

 

Total net revenues

    778,327       746,149       601,313       584,842  

Cost of revenues:

       

Service

    333,290       326,559       247,386       248,406  

Product

    49,606       62,338       30,932       38,226  
 

 

 

   

 

 

   

 

 

   

 

 

 

Total cost of revenues

    382,896       388,897       278,318       286,632  
 

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit

    395,431       357,252       322,995       298,210  

Operating expenses:

       

Selling, general and administrative expenses

    147,480       133,363       125,369       110,360  

Amortization of intangible assets

    58,562       57,975       43,989       43,942  

Impairment of long-lived assets

    5,792       34,981       —         5,781  

Impairment of GA-MURR intangible assets

    —         50,086       —         —    
 

 

 

   

 

 

   

 

 

   

 

 

 

Total operating expenses

    211,834       276,405       169,358       160,083  
 

 

 

   

 

 

   

 

 

   

 

 

 

Operating income

    183,597       80,847       153,637       138,127  

Interest expense, net

    157,729       143,326       167,142       114,478  

Loss on extinguishment of debt

    30,168       —         —         —    

Foreign exchange (gain) loss

    3,862       13,075       (5,370     8,444  

Gain on sale of Medical Isotopes business

    —         (95,910     —         —    

Other income, net

    (7,246     (3,866     (4,353     (4,746
 

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) before income taxes

    (916     24,222       (3,782     19,951  

Provision (benefit) for income taxes

    19,509       30,098       (9,677     12,630  
 

 

 

   

 

 

   

 

 

   

 

 

 

Net income (loss)

    (20,425     (5,876     5,895       7,321  

Less: Net income (loss) attributable to noncontrolling interests

    425       (6     832       271  
 

 

 

   

 

 

   

 

 

   

 

 

 

Net income (loss) attributable to the company

  $ (20,850   $ (5,870   $ 5,063     $ 7,050  
 

 

 

   

 

 

   

 

 

   

 

 

 


 

16


Table of Contents
Statement of Operations Data (continued):   Year Ended December 31,     Nine Months Ended September 30,  
(in thousands, except per share amounts)           2019                     2018                     2020                     2019          

Other comprehensive (loss) income, net of tax:

       

Pension and post-retirement benefits

  $ (12,126   $ 873     $ 700     $ (409

Interest rate swaps

    179       —         (179     509  

Foreign currency translation

    27,402       (67,917     (31,304     10,968  
 

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive income (loss)

    (4,970     (72,920     (24,888     18,389  
 

 

 

   

 

 

   

 

 

   

 

 

 

Less: comprehensive income attributable to noncontrolling interests

    310       (186     832       156  
 

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive income (loss) attributable to the company

  $ (5,280   $ (72,734   $ (25,720   $ 18,233  
 

 

 

   

 

 

   

 

 

   

 

 

 

Earnings (loss) per share:

       

Basic and Diluted

  $ (0.09   $ (0.03   $ 0.02     $ 0.03  
 

 

 

   

 

 

   

 

 

   

 

 

 

Weighted-average shares used to compute earnings (loss) per share:

       

Basic and Diluted

    232,400       232,400       232,400       232,400  
 

 

 

   

 

 

   

 

 

   

 

 

 

Pro forma as adjusted earnings (loss) per share (unaudited):(a)

       

Basic and Diluted

  $ 0.13       $ 0.20    
 

 

 

     

 

 

   

Pro forma as adjusted weighted-average shares used to compute earnings (loss) per share (unaudited):(b)

       

Basic and Diluted

    277,331         277,331    
 

 

 

     

 

 

   
       

Selected cash flow data:

       

Net cash provided by operating activities

  $ 149,041     $ 119,563     $ 98,740     $ 138,974  

Net cash provided by (used in) investing activities(c)

    (57,257     96,638       (139,920     (36,636

Net cash provided by (used in) financing activities

    (126,030     (191,857     83,961       (108,811

Other data:

       

Adjusted Net Income(d)

  $ 100,386     $ 75,315     $ 77,144     $ 87,897  

Adjusted EBITDA(d)

    379,932       340,637       306,797       285,457  

 

(a)

Pro forma as adjusted earnings (loss) per share for the year ended December 31, 2019 has been adjusted to reflect $56.1 million of lower interest expense, net of taxes, assuming the repayment of previously outstanding $425.0 million Senior PIK Toggle Notes, due 2021, $450.0 million Senior Notes, due 2023 and $14.1 million of principal amount outstanding of the Term Loan, due 2022, using a portion of the proceeds of this offering as if such indebtedness had been repaid as of the beginning of the period. Pro forma as adjusted earnings (loss) per share for the nine months ended September 30, 2020 has been adjusted to reflect $51.4 million of lower interest expense, net of taxes, assuming the repayment of the $770.0 million of principal amount outstanding of the Second Lien Notes, due 2027, and $129.9 million of principal amount outstanding of our Term Loan, due 2026, using a portion of the proceeds of this offering as if such indebtedness had been repaid as of the beginning of the period.

(b)

Pro forma as adjusted weighted-average shares has been adjusted to (i) include those shares of common stock to be issued in this offering necessary to pay down the debt referenced in footnote (a) above and (ii) reflect the number of shares of common stock that will be repurchased in the repurchase, in each case based on an assumed initial public offering price of $21.50 per share (the midpoint of the estimated offering price range set forth on the cover page of this prospectus), and after deducting the estimated underwriting discounts and commissions. Such shares are assumed to have been issued or repurchased, as applicable as of the beginning of the year ended December 31, 2019 and as of the beginning of the nine months ended September 30, 2020, respectively.



 

17


Table of Contents
(c)

Includes purchases of property, plant and equipment of $57,257, $72,613, $33,640 and $36,636, respectively (which includes Co-60 held at gamma irradiation sites).

(d)

Adjusted Net Income and Adjusted EBITDA are non-GAAP financial measures. For a definition of Adjusted Net Income and Adjusted EBITDA and a reconciliation to net income (loss), see “—Non-GAAP Financial Measures.”

 

    As of
December 31,
    As of September 30, 2020(a)  
    2019     2018     Actual     Pro
Forma As
Adjusted(a)(b)
 
Balance Sheet Data (as of period end):                        
(in thousands)                        

Cash and cash equivalents

  $ 62,863     $ 96,272     $ 108,276     $ 104,122  

Working capital(c)

    128,364       169,488       163,810       159,656  

Total assets

    2,580,674       2,708,584       2,700,004       2,695,850  

Total long-term debt (including current portion, less unamortized debt issuance costs and debt discounts)

    2,817,204       2,204,906       2,909,980       2,035,377  

Total liabilities

    3,221,806       2,663,093       3,362,005       2,484,202  

Total equity (deficit) attributable to the company

    (642,574     44,359       (663,858     237,570  

Noncontrolling interests

    1,442       1,132       1,857       1,857  

Total equity (deficit)

    (641,132     45,491       (662,001     239,427  

 

(a)

The pro forma as adjusted balance sheet data reflects the share-based compensation expense of $4.0 million, net of tax, associated with Class B-2 Units that we will recognize upon the listing and public trading of our common stock, reflected as a $4.9 million increase to additional paid-in capital with an offsetting $4.0 million (net of tax) increase to retained deficit. The pro forma as adjusted balance sheet data gives further effect to (i) the sale of 46,600,000 shares of our common stock in this offering at an assumed initial public offering price of $21.50 per share (the midpoint of the estimated offering price range on the cover page of this prospectus), after deducting estimated underwriting discounts and commissions, and the payment of approximately $4.1 million of incremental offering expenses and (ii) the application of the net proceeds from this offering to (a) repay $899.9 million of our outstanding indebtedness under our Second Lien Notes and our Term Loan, and reflect a write-off of associated unamortized debt issuance costs and debt discounts, and payment of the estimated redemption premium of $15.4 million on our Second Lien Notes, which is reflected as a net of tax adjustment of $11.7 million to retained earnings, and (b) repurchase certain shares of common stock (in each case, as described under “Use of Proceeds”).

(b)

Each $1.00 increase or decrease in the assumed initial public offering price of $21.50 per share, which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus, would decrease or increase each of our total long-term debt and total liabilities by $44.2 million and increase or decrease each of our total equity (deficit) attributable to the company and total equity (deficit) by $44.2 million, assuming no change in the assumed number of shares offered by us, and after deducting the estimated underwriting discounts and commissions. Each increase or decrease of 1.0 million shares in the number of shares offered would decrease or increase each of our total long-term debt and total liabilities by $20.4 million and increase or decrease each of our total equity (deficit) attributable to the company and total equity (deficit) by $20.4 million, assuming no change in the assumed initial public offering price and after deducting the estimated underwriting discounts and commissions payable.

(c)

Working capital represents current assets less current liabilities.

Non-GAAP Financial Measures

To supplement our consolidated financial statements presented in accordance with GAAP, we consider Adjusted Net Income and Adjusted EBITDA, financial measures that are not based on any standardized methodology prescribed by GAAP.



 

18


Table of Contents

We define Adjusted Net Income as net income (loss) before amortization and certain other adjustments that we do not consider in our evaluation of our ongoing operating performance from period to period as discussed further below. We define Adjusted EBITDA as Adjusted Net Income before interest expense, depreciation (including depreciation of Co-60 used in our operations) and income tax provision applicable to Adjusted Net Income.

We use Adjusted Net Income and Adjusted EBITDA, non-GAAP financial measures, as the principal measures of our operating performance. Management believes Adjusted Net Income and Adjusted EBITDA are useful because they allow management to more effectively evaluate our operating performance and compare the results of our operations from period to period without the impact of certain non-cash items and non-routine items that we do not expect to continue at the same level in the future and other items that are not core to our operations. We believe that these measures are useful to our investors because it provides a more complete understanding of the factors and trends affecting our business than could be obtained absent this disclosure. In addition, we believe Adjusted Net Income and Adjusted EBITDA will assist investors in making comparisons to our historical operating results and analyzing the underlying performance of our operations for the periods presented. Our management also uses Adjusted Net Income and Adjusted EBITDA in their financial analysis and operational decision-making and Adjusted EBITDA serves as the metric for attainment of our primary annual incentive program. Adjusted Net Income and Adjusted EBITDA may be calculated differently from, and therefore may not be comparable to, a similarly titled measure used by other companies.

Adjusted Net Income and Adjusted EBITDA should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. There are a number of limitations related to the use of Adjusted Net Income and Adjusted EBITDA rather than net income (loss), the nearest GAAP equivalent. For example, Adjusted Net Income and Adjusted EBITDA exclude:

 

   

certain recurring non-cash charges such as depreciation of fixed assets, although these assets may have to be replaced in the future, as well as amortization of acquired intangible assets and asset retirement obligations;

 

   

costs of acquiring and integrating businesses, which will continue to be a part of our growth strategy;

 

   

non-cash gains or losses from fluctuations in foreign currency exchange rates, primarily related to remeasurement of intercompany loans denominated in currencies other than subsidiaries’ functional currencies, and the mark-to-fair value of embedded derivatives relating to certain customer and supply contracts at Nordion;

 

   

impairment charges on long-lived assets and intangible assets;

 

   

expenses and charges related to the litigation and other activities associated with our ethylene oxide sterilization facilities in Willowbrook, Illinois and Atlanta, Georgia, even though that litigation remains ongoing;

 

   

in the case of Adjusted EBITDA, interest expense or the cash requirements necessary to service interest or principal payments on our indebtedness; and

 

   

share-based compensation expense, which has been, and will continue to be for the foreseeable future, a significant recurring expense and an important part of our compensation strategy.

In evaluating Adjusted Net Income and Adjusted EBITDA, you should be aware that in the future, we will incur expenses similar to the adjustments in this presentation. Our presentations of Adjusted Net Income and Adjusted EBITDA should not be construed as suggesting that our future results will be unaffected by these expenses or any unusual or non-recurring items. When evaluating our performance, you should consider Adjusted Net Income and Adjusted EBITDA alongside other financial performance measures, including our net income (loss) and other GAAP measures.



 

19


Table of Contents

The following table presents a reconciliation of net income (loss), the most directly comparable financial measure calculated and presented in accordance with GAAP to Adjusted Net Income and Adjusted EBITDA, for each of the periods indicated:

 

     Year Ended December 31,     Nine Months Ended September 30,  
(in thousands)          2019                 2018                 2020                 2019        

Net income (loss)

   $ (20,425   $ (5,876   $ 5,895     $ 7,321  

Amortization expense

     80,048       79,906       59,824       60,043  

Impairment of long-lived assets and intangible assets(a)

     5,792       85,067       —         5,781  

Gain on sale of Medical Isotopes business(b)

     —         (95,910     —         —    

Share-based compensation(c)

     16,882       6,943       4,019       15,120  

One-time bonuses(d)

     2,040       —         —         530  

(Gain) loss on foreign currency and embedded derivatives(e)

     2,662       14,095       (4,791     8,298  

Acquisition and divestiture related charges, net(f)

     (318     1,168       2,970       (704

Business optimization project expenses(g)

     4,195       8,805       2,484       1,485  

Plant closure expense(h)

     1,712       —         2,388       1,145  

Loss on extinguishment of debt(i)

     30,168       —         —         —    

Professional services relating to Willowbrook and Atlanta facilities(j)

     11,216       4,739       25,370       7,788  

Accretion of asset retirement obligation(k)

     2,051       1,366       1,476       1,457  

COVID-19 expenses(l)

     —         —         2,363       —    

Income tax benefit associated with pre-tax

adjustments(m)

     (35,637     (24,988     (24,854     (20,367
  

 

 

   

 

 

   

 

 

   

 

 

 

Adjusted Net Income

     100,386       75,315       77,144       87,897  
  

 

 

   

 

 

   

 

 

   

 

 

 

Interest expense, net

     157,729       143,326       167,142       114,478  

Depreciation(n)

     66,671       66,910       47,334       50,085  

Income tax provision (benefit) applicable to Adjusted Net Income(o)

     55,146       55,086       15,177       32,997  
  

 

 

   

 

 

   

 

 

   

 

 

 

Adjusted EBITDA

   $ 379,932     $ 340,637     $ 306,797     $ 285,457  
  

 

 

   

 

 

   

 

 

   

 

 

 

 

(a)

For 2019, represents impairment charges related to the decision to not reopen the Willowbrook facility in September 2019. For 2018, represents impairment charges associated with the withdrawal of the GA-MURR project.

(b)

Represents the gain on the divestiture of the Medical Isotopes business in July 2018.

(c)

Includes non-cash share-based compensation expense. In 2019, also includes $10.0 million of one-time cash share-based compensation expense related to the Class C Performance and Time Vesting Units, which vested in the third quarter of 2019 based on the achievement of the aggregate distributions to the Class A Unitholder Members and the approval of the board of Topco Parent for accelerated vesting.

(d)

Represents one-time cash bonuses for members of management relating to capital markets activity in 2019.

(e)

Represents the effects of (i) fluctuations in foreign currency exchange rates, primarily related to remeasurement of intercompany loans denominated in currencies other than subsidiaries’ functional currencies, and (ii) non-cash mark-to-fair value of embedded derivatives relating to certain customer and supply contracts at Nordion.

(f)

Represents (i) certain direct and incremental costs related to the acquisition of Toxikon Europe NV (“Nelson Europe”) in 2017, Gibraltar Laboratories, Inc. (“Nelson Fairfield”) in 2018 and Iotron Industries Canada, Inc. in July 2020, and certain related integration efforts as a result of those acquisitions, (ii) the earnings impact of fair value adjustments (excluding those recognized within amortization expense) resulting from



 

20


Table of Contents
  the businesses acquired, and (iii) transition services income and non-cash deferred lease income associated with the terms of the divestiture of the Medical Isotopes business in 2018.
(g)

Represents professional fees, contract termination and exit costs, severance and other payroll costs, and other costs associated with business optimization and cost savings projects relating to the integrations of Nordion and Nelson Labs, including the divestiture of Medical Isotopes, the withdrawal from the GA-MURR project, the Sotera Health rebranding, operating structure realignment and other process enhancement projects.

(h)

Represents professional fees, severance and other payroll costs, and other costs including ongoing lease and utility expenses associated with the closure of the Willowbrook facility.

(i)

Represents one-time expenses incurred in connection with the refinancing of our debt capital structure in December 2019, including accelerated amortization of prior debt issuance and discount costs, premiums paid in connection with early extinguishment and debt issuance and discount costs incurred for the new debt.

(j)

Represents professional fees related to litigation associated with our EO sterilization facilities in Willowbrook and Atlanta and other related activities. See “Business—Legal Proceedings.”

(k)

Represents the non-cash accretion of asset retirement obligations related to Co-60 and gamma processing facilities, which are based on estimated site remediation costs for any future decommissioning of these facilities (without regard for whether the decommissioning services would be performed by employees of Nordion, instead of by a third party) and are accreted over the life of the asset.

(l)

Represents non-recurring costs associated with the COVID-19 pandemic, including donations to related charitable causes and special bonuses for front-line personnel working on-site during lockdown periods.

(m)

Represents the tax benefit or provision associated with the reconciling items between net income (loss) and Adjusted Net Income. To determine the aggregate tax effect of the reconciling items, we utilized statutory income tax rates ranging from 0% to 35%, depending upon the applicable jurisdictions of each adjustment.

(n)

Includes depreciation of Co-60 held at gamma irradiation sites.

(o)

Represents the difference between income tax expense or benefit as determined under U.S. GAAP and the income tax benefit associated with pre-tax adjustments described in footnote (m).



 

21


Table of Contents

RISK FACTORS

Investing in our common stock involves a high degree of risk. You should carefully consider the following risks before deciding to invest in our common stock. The occurrence of any of the following risks could harm our business, revenue and financial results. In addition, risks and uncertainties that are not presently known to us or that we currently believe are immaterial could also harm our business, revenue and financial results. If any of these risks occur, the value of our common stock could decline and you may lose all or part of your investment.

Risks Related to the Company

We depend on a limited number of counterparties that provide the materials and resources we need to operate our business. Any disruption in the availability of, or increases in the price of, EO, Co-60 or our other direct materials, services and supplies, including as a result of current geopolitical instability arising from U.S. relations with Russia and related sanctions, may have a material adverse effect on our operating results.

We purchase certain direct materials, equipment and services necessary for the provision of our specialized products and services from a sole or limited number of suppliers and subcontractors, and purchase large quantities of product from an individual supplier in certain cases. If one or more of our significant suppliers or service providers were unable to meet their obligations under present arrangements, direct materials or equipment were to become unavailable within the geographic area from which they are now sourced, or supplies were otherwise constrained or disrupted for any reason (including as a result of a natural disaster or other adverse occurrence), we may incur increased costs for our direct materials or equipment and may be unable to accommodate new business or meet our current customer commitments. For example, in the United States there is a single supplier of EO for our sterilization business. Further, our reliance on a single or limited number of suppliers may limit our negotiating power, particularly during times of rising direct material costs.

We source a substantial portion of our Co-60 supply from three nuclear reactor operators in Canada and Russia under contracts that extend to between 2024 and 2064. See “Business—Our Businesses—Nordion—Nuclear Reactor Operators.” If there were a decrease in output or disruption at any of these reactors (including as a result of a natural disaster or other adverse occurrence), the counterparties failed to perform under their agreements with us or declined to enter into renewal contracts with us for our future supply needs and we are unable to obtain supply from other sources, or if such sources begin to compete with us in one or more geographies, this could have a material adverse effect on our business. In addition, a number of reactors that have the capacity to generate Co-60 are government owned. Priorities of governments can change. Any repurposing of a government-owned reactor that generates Co-60 for an alternative use has in the past and could in the future lead to a decrease in Co-60 availability, which could have a material adverse effect on our business, prospects, financial condition or results of operations.

Further, approximately 20% of our supply of Co-60 currently is generated by Russian nuclear reactors. Over the next few years, we expect that there will be periods when, due to planned or unplanned outages and variability in supply from individual reactors, the proportion of our supply from Russian reactors may increase to as much as 50% for a given year. The United States, Canada and the European Union have imposed sanctions against Russian officials and certain Russian companies and individuals. Russia has responded with countermeasures, including limiting the import of certain goods from the United States and other countries. Expanded sanctions could target government-owned operations, including Russian nuclear reactor operators, and could prevent us from doing business with them. The U.S. government has also implemented certain sanctions targeting non-U.S. persons for activities conducted outside the United States that involve specific sanctions targets or certain activities related to sanctioned countries, any of which could prohibit us from conducting routine commercial transactions with Russian entities that are engaged in certain transactions related to sanctioned countries or sanctioned parties. If the U.S. government significantly broadens the scope of, or Canada or the European Union imposes, sanctions against Russia and prevents the importation of Russian-sourced Co-60 or the Russian government responds with further countersanctions, it may make it generally more difficult to do

 

22


Table of Contents

business with Russian entities. Any sanctions or countermeasures could have a material adverse effect on our business, prospects, financial condition or results of operations.

Any interruptions that we experience with our key suppliers, regarding the availability of Co-60, changes in regulatory requirements regarding the use of Co-60 or unavailability or short-supply of raw materials or services, may disrupt or cause a shutdown of portions of our operations, materially increase our costs or have other adverse consequences on our business, prospects, financial condition or results of operations.

Industry trends could impact the demand for our products and services and could have a material adverse effect on our business.

Industry trends that affect medical device, pharmaceutical or biotechnology companies affect our business. The medical device industry is characterized by frequent product development and technological advances, which may reduce demand for our sterilizing and testing services if our existing services no longer meet our customers’ requirements. Any significant decrease in life science research and development expenditures by medical device, pharmaceutical and biotechnology companies, including as a result of a general economic slowdown, could in turn impact the volumes of medical products that require sterilization or lab testing services. Future demand for Co-60 or our sterilization services could also be adversely impacted by changes to preferred sterilization modalities. Our ability to adapt our business to meet evolving customer needs depends upon the development and successful commercialization of new services, new or improved technologies and additional applications of our technology for our customers’ new products. We can give no assurance that any such new services will be successful or that they will be accepted in the marketplace. Any failure to develop or commercialize new services and technologies and any decrease in demand for our products or services could have a material adverse effect on our business, prospects, financial condition or results of operations.

If changes in healthcare regulations or other developments in the healthcare industry, including concerns around single-use medical devices, were to lead to a material reduction in medical procedures or use of medical devices, demand for our services could be adversely affected. Demand for our products and services may also be affected by changes from time to time in the laws and regulations that govern our operations and industry, including the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, which in turn impact industry trends. New regulatory requirements could lead to changes in the medical device industry and the behavior of our customers that are difficult to predict but could have a material adverse effect on our business, prospects, financial condition or results of operations. Further, if any significant disposal restrictions or requirements are imposed that materially increase the cost or administrative burden of the disposal process for single-use medical devices, hospitals and other end-users of such devices might decrease their use of such devices in favor of reusable medical products, which would decrease the demand for our services, which could in turn have a material adverse effect on our business, prospects, financial condition or results of operations.

Changes in environmental, health and safety regulations or preferences may negatively impact our business.

Federal, state and international authorities regulate the operation of our gamma irradiation and EO processing plants, as well as the operations of our customers. If any of the regulators that govern our operations or the operations of our customers were to institute severely restrictive policies or regulations that increase our costs or change the preferences or requirements of our customers, demand for our products and services may be materially affected. Additionally, certain regulators, including the FDA, have started initiatives to encourage development of sterilization alternatives to EO processing. We have taken part in some of these initiatives. We have made proactive, voluntary investments to enhance emissions controls. However, new regulations or changes to existing or expected regulations may require additional investments in new emissions control technology or otherwise increase the cost of our gamma irradiation or EO processing. Reconfiguring a gamma irradiation or EO processing plant so that it is suitable for a different sterilization technology, in response to changes in demand or other factors, would require significant capital investment and require us to suspend operations at the affected

 

23


Table of Contents

facility during the conversion. Any of the foregoing could have a material adverse effect on our business, prospects, financial condition or results of operations.

Safety risks associated with the use and disposal of potentially hazardous materials, such as EO and Co-60, may result in accidents or liabilities that materially affect our results of operations.

EO is flammable and potentially explosive. An explosion or fire could occur at the sterilization facilities at which we use EO, including due to an accidental ignition of EO in an uncontrolled environment. Particular care must be exercised in order to avoid inadvertently causing an explosion or fire, which could interrupt our normal operations at or cause a shut-down of the affected facility while repairs are made. Any EO explosion or similar incident could result in the closure of our facilities, workplace injuries, property damage or otherwise adversely affect our business.

Because Co-60 is radioactive, its containment is very important in preventing contamination or improper exposure. If the double-encapsulated Co-60 pencils were to become damaged or corroded, Co-60 sources could develop a source leak, leading to radioactive contamination requiring comprehensive clean-up of the storage pool. Similarly, physical damage to the protective stainless-steel covering during the process of adding or removing Co-60 rods from an irradiator could also result in a source leak and contamination incident. Clean-up and disposal costs for damaged Co-60 rods and radioactive contamination could be significant. If any liability claims are made against us in the future, we could be liable for damages that are alleged to have resulted from such exposure or contamination.

In addition, these materials must be handled and disposed of properly. Accidents involving disposal or handling of these substances, including accidents resulting from employees failing to follow safety protocols, could result in injury to property, the environment and human health, as well as possible disruptions, restrictions or delays in production, and have in the past and could in the future result in claims relating to such events. For example, members of our workforce in the past have been injured in our facilities. Any injuries or damage to persons, equipment or property or other disruption in the disposal, production, processing or distribution of products could result in a significant decrease in operating revenue, a significant increase in costs to replace or repair and insure our assets and substantial reputational harm, which could materially adversely affect our business, prospects, financial condition or results of operations, and could have legal consequences that affect our ability to continue to operate the affected facility. Our customers served by an affected facility could choose to switch to an alternative sterilization service provider.

Any incident occurring at any of our EO or gamma facilities that causes harm to workers or others or the interruption of normal operations at the affected facility could result in substantial liability to us. We are currently the subject of lawsuits alleging that purported EO emissions from certain of our current and former facilities have resulted in toxicological or health-related impact on the environment, the communities that surround our facility and a customer’s employees. We deny these allegations and intend to vigorously defend against these claims. We have also from time to time been involved with workers’ compensation claims relating to potentially hazardous materials. We may be subject to similar claims in the future, and one or more adverse judgments could result in significant liability for us and have a material adverse effect on our business, financial condition and results of operations. See “—We are currently defending certain litigation, and we are likely to be subject to additional litigation in the future” and “—Potential health risks associated with the use of EO and Co-60 may subject us to future liability claims.”

Nordion contracts for the activation of Co-59 “targets” (cobalt pellets and slugs) into Co-60 in certain nuclear reactors in Canada and Russia. Our Co-59 targets (and in Canada, our adjuster rods provided to us by a supplier) function as part of the reactors’ reactivity control systems. While national laws or international conventions generally channel liability for nuclear incidents exclusively to reactor operators, equipment suppliers could be subject to lawsuits for damage to the nuclear installation or damages allegedly intentionally caused. While we make efforts to protect our interests through contractual provisions, quality assurance programs and the

 

24


Table of Contents

nature of our commercial relationships, there is no assurance that any of these measures will prove effective in shielding us from liability, and any such liability or consequences could have a material adverse impact on our business, results of operation and financial condition.

We currently carry pollution liability insurance for all our facilities and related operations and liability insurance, including from third party bodily injury or property damage allegedly arising from the storage, use, transportation or accident involving EO and Co-60 sources throughout our operations. However, such insurance may not cover all risks associated with the potential hazards of our business and is subject to limitations, including deductibles and maximum liabilities covered. We may incur losses beyond the limits, or outside the coverage, of our insurance policies. Additionally, our ability to increase pollution liability insurance limits or replace any policies upon their expiration without exclusions for claims related to alleged EO exposure may be adversely impacted by claims against us, including current claims alleging that purported EO emissions from certain of our facilities have resulted in toxicological or health-related impact on the environment, the communities that surround our facility and a customer’s employees. We deny these allegations and are vigorously defending against these claims. To the extent any pollution liability is not covered by our insurance or able to be recovered from other parties, our business, financial condition or results of operations could be materially adversely affected.

Safety risks associated with the transportation of potentially hazardous materials, such as EO and Co-60, may result in accidents or liabilities that materially affect our results of operations.

Our products, supplies and by-products are transported through a combination of ground, sea and air transport. Co-60 and EO are radioactive and potentially combustible, respectively, and must be handled carefully and in accordance with applicable laws and regulations. An incident in the transportation of our raw materials, products and by-products or our failure to comply with laws and regulations applicable to the transfer of such products could lead to human injuries or significant property damage, regulatory repercussions or could make it difficult to fulfill our obligations to our customers, any of which could have a material adverse effect on our business, prospects, financial condition or results of operations.

Our EO and Co-60 raw materials are potentially hazardous and could make our facilities and transportation vehicles targets for terrorists, which could have a material adverse effect on our operations. We are subject to stringent requirements regarding how we secure these materials. If our failure to adequately secure these materials leads to their being stolen or materially damaged, our licenses to operate could be suspended resulting in a material adverse effect to our business, prospects, financial condition or results of operations. Any such incident could also have legal consequences, such as violations of regulatory requirements and/or lawsuits for personal injuries, property damage or diminution, and similar claims could result in substantial liability to us. Additionally, loss of control of Co-60 sources by a customer could result in contamination and significant public health consequences.

Potential health risks associated with the use of EO may subject us to future liability claims and other adverse effects.

Potential health risks associated with exposure to EO under certain conditions subject us to the risk of liability claims being made against us by workers, contractors and others, including individuals who reside or have resided near our EO sterilization facilities and employees of our customers. Assessments of the potential health risks of exposure to EO have evolved over time. For example, although EO is present in the environment from a variety of sources and naturally produced by the human body, the U.S. Environmental Protection Agency (“USEPA”) has identified a potential for increased risk of certain cancers from exposure to EO. In 2016, the USEPA published its Integrated Risk Information System toxicity assessment of EO (the “IRIS Assessment”), and in 2018, the USEPA published its most recent National Air Toxics Assessment, which utilized the IRIS Assessment and data collected in 2014, identifying EO as a potential cancer concern in several areas across the country, including areas surrounding our Willowbrook facility and our facilities in Atlanta and Santa Teresa,

 

25


Table of Contents

New Mexico. Another organization has disagreed with aspects of the IRIS Assessment on the carcinogenic potency of EO, and we expect risk assessments related to EO will continue to evolve and be examined. We can give no assurance as to their impact on our business, prospects, financial condition or results of operations.

We are currently the subject of tort lawsuits alleging personal injury by purported exposure to emissions and releases of EO from our facility in Willowbrook and our facility in Atlanta. Additionally, we are defendants in a lawsuit by certain employees of a contract sterilization customer in Georgia who allege personal injury by workplace exposure to EO. We are also defendants in a lawsuit alleging that our Atlanta facility has devalued and harmed the plaintiffs’ use of a real property they own in Smyrna, Georgia and additional property devaluation claims have been threatened. We deny the allegations and are vigorously defending these claims. See “—We are currently defending certain litigation, and we are likely to be subject to additional litigation in the future.” and “Business—Legal Proceedings.” It is likely that we will be subject to other claims by similar groups of plaintiffs in the future relating to any of our current or former facilities. In addition, we have encountered and will likely continue to encounter resistance, protests or other actions in communities where our existing facilities are located or where we seek to establish or expand facilities based on the perceptions of the risk associated with exposure to EO held by some residents and officials of these communities. This publicity may also have other adverse impacts, including damage to our reputation and public pressure against our facilities that may affect our ability to conduct our business.

Our liability insurance coverage may not be adequate to cover any liabilities arising out of such allegations or remain available to us at acceptable costs. A successful claim brought against us in excess of the insurance coverage then available to us could have a material adverse effect on our business, prospects, financial condition or results of operations.

We are currently defending certain litigation, and we are likely to be subject to additional litigation in the future.

Our business exposes us to significant potential risk from lawsuits, investigations and other legal proceedings. We are currently pursuing and defending various proceedings and will likely be subject to additional proceedings in the future, including potential litigation regarding the products and services we provide or which we or our predecessors have provided.

We are currently the subject of tort lawsuits alleging personal injury by purported exposure to emissions and releases of EO from our facility in Willowbrook and our facility in Atlanta. Additionally, we are defendants in a lawsuit by certain employees of a contract sterilization customer in Georgia who allege personal injury by purported workplace exposure to EO. We are also defendants in a lawsuit alleging that our Atlanta facility has devalued and harmed the plaintiffs’ use of a real property they own in Smyrna, Georgia and additional property devaluation claims have been threatened. We deny the allegations and are vigorously defending against the claims. However, one or more adverse judgments could result in significant liability for us and have a material adverse effect on our business, financial condition and results of operations. In addition, we have been involved in litigation in Georgia against local officials to allow us to resume operations at our Atlanta facility that had been suspended while we installed enhancements to our EO emissions control systems, as well as to challenge local officials’ unsupported claims of loss of neighboring residential property values in tax assessments. See “Business—Legal Proceedings” for more detail on our pending litigation.

In litigation, including those described above, plaintiffs may seek various remedies, including without limitation declaratory and/or injunctive relief; compensatory or punitive damages; restitution, disgorgement, civil penalties, abatement, attorneys’ fees, costs and/or other relief. Settlement demands may seek significant monetary and other remedies, or otherwise be on terms that we do not consider reasonable under the circumstances. In some instances, even if we comply with applicable laws and regulations, including those relating to emission standards, an adverse judgment or outcome may occur based on other applicable laws or principles of common law, including negligence and strict liability, and result in significant liability and reputational damage for us. It is likely that we will be subject to other claims in addition to those described above

 

26


Table of Contents

by similar groups of plaintiffs in the future relating to any of our current or former facilities or activities. In addition, awards against and settlements by our competitors or publicity associated with our current litigation could incentivize parties to bring additional claims against us.

Any claim brought against us, regardless of its merits, could be costly to defend and could result in an increase of our insurance premiums and exhaust our available insurance coverage. The financial impact of litigation, particularly class action and mass action lawsuits, is difficult to assess or quantify. Some claims brought against us might not be covered by our insurance policies or might exhaust our available insurance coverage for such occurrences. Furthermore, an insurer might refuse coverage, and even where the claim should be covered by insurance, we have significant self-insured retention amounts, which we would have to pay in full before obtaining any insurance proceeds. To the extent our insurance coverage is inadequate and we are not successful in identifying or purchasing additional coverage for such claims, we would have to pay the amount of any settlement or judgment that is in excess of policy limits. We have reached the per occurrence limit of our insurance coverage for claims related to Willowbrook’s EO emissions due to legal costs associated with such claims and have not yet been and likely will not be successful in identifying or purchasing additional coverage for such claims. If any judgments are rendered against us and are upheld on appeal, we would not have insurance coverage to cover such judgment. Claims against us that result in entry of a judgment or we settle that are not covered or not sufficiently covered by insurance policies, or which fall within retained liability under our policies, could have a material adverse impact on our business, prospects, financial condition or results of operations.

Our business is highly competitive, and if we fail to compete successfully, our business, prospects, financial condition or results of operations may be adversely affected.

We face competition from other providers of outsourced sterilization and lab services. In addition, some manufacturers have in-house sterilization and lab testing and related capabilities, and further consolidation within our industry and within our customers’ industries could impact our ability to compete. Further, our competitors and potential competitors are attempting to develop alternate technologies, in particular improved x-ray sterilization technology, which would not be reliant on the availability of Co-60. If any of our competitors significantly expand their sterilization or lab testing facility capacity, including as a result of these alternative technologies, it could lead to price fluctuations and competitive pricing pressure, diminish our profitability or lead to changes in our customer relationships across our business segments. We generally compete on the basis of quality, reputation, the cost of sterilization services, the cost of transportation to and from the sterilization facility and processing turnaround time. If our services, supply, support, distribution or cost structure do not enable us to compete successfully, including against alternative technologies, or we are unable to successfully develop and adopt alternative technologies ourselves, our business, prospects, financial condition or results of operations could be materially adversely affected. The expansion of alternative sterilization technologies may require us to build new facilities, which can be time-consuming and costly.

If Co-60 source suppliers in other countries, including China, India or Russia, significantly increase their involvement in the global Co-60 sources market, it could have a material adverse effect on our business, prospects, financial condition or results of operations. Additionally, several customers of our Nordion business are themselves providers of sterilization services and therefore are competitors of our Sterigenics business. If these customers were to shift to a different source for their supply of Co-60 sources, because they prefer to use a supplier not affiliated with us or for any other reason, it could materially adversely affect our business, prospects, financial condition or results of operations. Further, if a Nordion customer were to lose market share to a competitor using an alternative sterilization provider, we would similarly lose sales volumes, which may have a material adverse effect on our business, prospects, financial condition or results of operations.

Additionally, Nelson Labs faces a wide variety of competitors, including small, specialized niche players, large, broad multinational corporations and internal laboratories that can perform the services that we provide. Shifts in the market that diminish our customers’ preference for outsourcing their testing and large, well-funded

 

27


Table of Contents

competitors entering more directly into the specialized lab services that we provide may adversely affect our business.

Certain of our long-term contracts include variable price clauses and are subject to market changes, which could have a material adverse effect on our business.

The aggregate cost of our direct materials and energy represents a significant portion of our cost of revenues. The prices of the direct materials we utilize vary with market conditions and may be highly volatile. Additionally, the cost of energy for some of our facilities is regulated, and we are required to work with the local utility provider, which prevents us from contracting for a lower rate or seeking an alternate supplier. Although we have attempted, and will continue to attempt, to match increases in the prices of direct materials or energy with corresponding increases in prices for our products and services, our ability to pass through increases in the cost of direct materials or energy to customers is highly dependent upon market conditions and we may not be able to immediately raise such prices, if at all. Most of our customer contracts for sterilization services allow us to pass through our direct material costs, but we may not be able to immediately or completely implement increases in the prices of our products and services. Specifically, there is a risk that raising prices charged to our customers could result in a loss of sales volume. Reactions by our customers and competitors to our price increases could cause us to reevaluate and possibly reverse or reduce such price increases. Any increase in the price of one of these materials or energy could have a material adverse effect on our business, prospects, financial condition or results of operations.

Allegations of our failure to properly perform our services may expose us to potential product liability claims, recalls, penalties and reputational harm or could otherwise cause a material adverse effect on our business.

We face the risk of financial exposure to product and other liability claims alleging that our failure to adequately perform our services resulted in adverse effects, including product recalls or seizures, adverse publicity and safety alerts. In our Sterigenics business, for example, while our customers are generally responsible for determining the cycle parameters (the levels of temperature, humidity and EO concentration to which products are exposed during the sterilization process and the duration of such exposure) or dosage specifications (the amount of gamma or E-beam irradiation to which products are exposed) for their products, we are required to certify that such cycle or dosage parameters were achieved. If we fail to process a customer’s product in accordance with the cycle parameters, dosage specifications or testing requirements prescribed by the customer, our standard contract requires us to inform our customer of the nonconformance, to reprocess or retest the product if that is a feasible alternative and to reimburse the customer (subject to a maximum) for the cost of any such product which is damaged as a result of the nonconformance. We could be held liable in the future for personal injury, contractual or other damages that are alleged to result from improper or incorrect processing, cycle parameters or dosage specifications, testing or product damage. Even where processing occurred within cycle parameters, we have faced in the past and may face in the future claims of personal injury resulting from processing. In our Nelson Labs business, if we fail to perform our services in accordance with regulatory requirements for medical products, regulatory authorities may take action against us or our customers. Regulatory authorities may disqualify certain analyses from consideration in connection with marketing authorizations, which could result in our customers not being able to rely on our services in connection with their submissions, may subject our customers to additional studies or testing and delays in the development or authorization process, and may lead our customers to take actions such as terminating their contracts with us. We could also face claims that we performed erroneous or out-of-specification testing or data integrity complaints, which could require retesting, and which could result in claims of economic or other loss or which could result in personal injury. We derive limited revenue from government customers and our government contracts may contain additional requirements that may increase our costs of doing business, subject us to additional government scrutiny and expose us to liability for failure to comply with contractual requirements. In our Nordion business, our processing and sale of medical-grade Co-60 used for radiation therapy involve an inherent risk of exposure to product liability claims, product recalls and product seizures. In addition, our installation of irradiators for our customers could expose us to design defect product liability claims, whether or not such claims are valid. A

 

28


Table of Contents

product liability judgment against us could also result in substantial and unexpected costs, affect customer confidence in our products, damage our reputation and divert management’s attention from other responsibilities.

Although we maintain product and professional liability insurance coverage in amounts we believe are customary, there can be no assurance that this level of coverage is adequate or that we will be able to continue to maintain our existing insurance or obtain comparable insurance at a reasonable cost, if at all. Our product and professional liability insurance also does not cover matters related to EO emissions. A product recall or seizure or a partially or completely uninsured judgment against us could have a material adverse effect on our business, prospects, financial condition or results of operations.

We are subject to extensive regulatory requirements and routine regulatory audits in our operations. We must receive permits, licenses and/or regulatory clearance or approval for our operations. Compliance with these regulations is costly, and failure to comply with all laws and regulations or to receive or maintain permits, licenses, clearances or approvals may hurt our revenues, profitability, financial condition or value.

Our industry is characterized by evolving regulations, and our operations are subject to extensive regulation in the United States and other countries where we do business. We are regulated by national and local agencies with jurisdiction over a number of areas directly or indirectly related to our businesses, including environmental, nuclear safety, homeland or national security, worker safety and health, food, drug and device manufacturing and marketing, transportation, drug enforcement (governing the handling of controlled substances) and agriculture, fish and wildlife. These laws and regulations regulate our use of potentially hazardous materials, such as EO and Co-60, and can require us to carefully manage, control emissions of or limit human exposure to, these materials. For example, Occupational Safety and Health Administration (“OSHA”) regulations and similar laws in other jurisdictions limit worker exposure to EO. In addition, FDA regulations dictate the acceptable amount of EO residue on different types of sterilized products. In most jurisdictions, we are required to maintain and operate pollution control equipment to minimize emissions and releases of EO. Regulations issued by OSHA, the U.S. Nuclear Regulatory Commission (the “NRC”) and other agencies also require that equipment used at our facilities be designed and operated in a manner that is safe. The use of EO for medical device sterilization is regulated by the USEPA under the Federal Insecticide, Fungicide and Rodenticide Act (“FIFRA”) and the Clean Air Act (the “CAA”). Our supplier maintains FIFRA registrations for EO as a medical device sterilant for users of EO across the United States. The USEPA is in the process of reviewing EO’s FIFRA re-registration eligibility in accordance with the provisions of FIFRA. As a condition of continued registration, the USEPA may require enhancements to the processes and equipment for use of EO as a medical device sterilant. The USEPA is also expected to propose updated National Emission Standards for Hazardous Air Pollutants (“NESHAP”) air emission regulations for commercial EO sterilization facilities, which have not yet been published and with which sterilization facilities like ours will be required to comply. We expect to incur capital costs for enhancements to our equipment and to implement process automation and emission control enhancements to comply with these and other changing requirements. If the future regulations differ from our current expectation, they may require additional modifications and capital costs beyond what we have budgeted for, which could be material. Any future failure of the USEPA to allow reregistration of EO would have a material adverse effect on our business, prospects, financial condition or results of operations.

In the United States, our gamma irradiation facilities are heavily regulated, including by the NRC and state regulations. These laws and regulations specify the requirements for, among other things, maximum radiation doses, system designs, safety features and alarms and employee monitoring, testing and reporting. While some specific requirements are different in the various jurisdictions other than the United States, the fundamental concepts are consistent, since all are signatories to the International Atomic Energy Agency (“IAEA”) conventions and have adopted safety standards from the IAEA and recommendations from the International Commission on Radiological Protection. The design, construction and operation of sterilization and lab testing facilities are highly regulated and require government licenses, including environmental approvals and permits, and may be subject to the imposition of related conditions that vary by jurisdiction. In some cases, these approvals and permits entail periodic review. We cannot predict whether all licenses required for a new facility

 

29


Table of Contents

will be granted or whether the conditions associated with such licenses will be achievable. Changes in these laws and regulations have the potential to increase our costs.

Additionally, our operations in the United States and the majority of our facilities outside the United States (to the extent we are processing a product in that facility that will end up in the U.S. market) are regulated by the FDA. We are also regulated by other health regulatory authorities in other countries. Specifically, these operations include some of our sterilization and product testing activities that may constitute “manufacturing” activities and are subject to FDA requirements. The FDA may issue Form 483 findings or warning letters or take other administrative or enforcement actions for noncompliance with FDA laws and regulations and the issues raised by such warning letters require significant resources and time to correct. Failure to comply with regulatory requirements could have a material adverse effect on our business.

To the extent Nordion in the future ceases to operate its facility in Kanata, Canada, Nordion will be responsible for the radiological decommissioning of such facility, including in respect of the portion leased by BWX Technologies, Inc. (“BWXT”) in connection with its acquisition of the Medical Isotopes business to the extent any contamination precedes such transaction. In addition, if Sterigenics in the future ceases to operate any of its irradiation facilities, it will be responsible for decommissioning costs in respect of such facilities. We currently provide financial assurance for approximately $50 million of such decommissioning liabilities in the aggregate in the form of letters of credit, surety bonds or other surety. Such potential decommissioning liabilities may be greater than currently estimated if additional irradiation facilities are licensed, unexpected radioactive contamination of those facilities occur, regulatory requirements change, waste volume increases, or decommissioning cost factors such as waste disposal costs increase.

See “Business—Regulation” for more information on the regulatory requirements of our businesses.

Compliance with these regulations, as well as our own voluntary programs that relate to maintaining the safety of our employees and facilities as well as the environment, may be difficult, burdensome or expensive. Any change in these regulations, the interpretation of such regulations as well as our customers’ perception of such changes will require us to make adaptations that may subject us to additional costs, and ultimate costs and the timing of such costs may be difficult to accurately predict and could be material. Regulatory agencies may refuse to grant approval or clearance or may require the provision of additional data, and regulatory processes may be time consuming and costly, and their outcome may be uncertain in certain of the countries in which we operate. Regulatory agencies may also change policies, adopt additional regulations or revise existing regulations, each of which could impact our ability to provide our services or increase our costs. Additionally, local regulatory authorities may change the way in which they interpret and apply local regulations in response to negative public pressure about our facilities. For example, officials stopped operations at one of our facilities purportedly to review our fire and building code status and certificate of occupancy.

Our failure to comply with the regulatory requirements of these agencies may subject us to administratively or judicially imposed sanctions. These sanctions include, among others, warning letters, fines, civil penalties, criminal penalties, injunctions, debarment, product seizure or detention and total or partial suspension of operations, sale and/or promotion. While we strive to comply with these regulatory requirements, we have not always been and may not always be in compliance and, as a result, can be subject to significant civil and criminal fines and penalties, including the shutdown of our operations or the suspension of our licenses, permits or registrations. See “Business—Legal Proceedings” and “—Potential health risks associated with the use of EO may subject us to future liability claims and other adverse effects.” The failure to receive or maintain, or delays in the receipt of, relevant U.S. or international regulatory qualifications could have a material adverse effect on our business, prospects, financial condition or results of operations.

 

30


Table of Contents

Our operations are subject to a variety of business continuity hazards and risks, including our reliance on the use and sale of products and services from single locations, any of which could interrupt production or operations or otherwise adversely affect our performance, results or value.

In addition to the other risks described in this prospectus, our operations are subject to business continuity hazards and risks that include explosions, fires, earthquakes, inclement weather and other natural disasters; utility or other mechanical failures; unscheduled downtime; labor difficulties; disruption of communications; terrorist, security breach or other workplace violence event; changes in the use of government-owned reactors, including repurposing nuclear facilities; and pandemics or other public health crises.

It can be costly to ship products long distances for the purpose of sterilization; therefore, our ability to offer a full range of sterilization services close to our customers’ manufacturing and distribution centers worldwide is critical for our business. An adverse occurrence at one of our facilities or the facilities of a supplier or customer could damage our business. While other facilities in our network may have the capacity to service our customers that had been served by an affected facility, we may not be able to transfer all interrupted services. The stringent regulations and requirements we are subject to regarding the manufacture of our products and provision of services and the complexities involved with processing of Co-60 may prevent or delay us from establishing additional or replacement sources for our production facilities. Any event, including those listed above or other circumstances that results in a prolonged business disruption or shutdown to one or more of our facilities, could create conditions that prevent, or significantly and adversely affect, our receiving, processing, manufacturing or shipping products at existing levels, or at all. Such events could adversely affect our sales, increase our expenses, create potential liabilities and/or damage our reputation, any of which could have a material adverse effect on our business, prospects, financial condition or results of operations.

In addition, since we obtain Co-60 from a limited number of reactors, if any of their facilities were to be seriously damaged or have their production materially decrease due to a natural disaster or other adverse occurrence, our access to Co-60 would be materially affected and we may be unable to meet all the needs of our customers. See “—We depend on a limited number of counterparties that provide the materials and resources we need to operate our business. Any disruption in the availability of, or increases in the price of, EO, Co-60 or our other direct materials, services and supplies, including as a result of current geopolitical instability arising from U.S. relations with Russia and related sanctions, may have a material adverse effect on our operating results.”

Further, governmental action may disrupt the operations of our facilities that process potentially hazardous materials. For example, in February 2019 the Illinois Environmental Protection Agency (“IEPA”) issued a seal order temporarily shutting down our sterilization activities at our Willowbrook facility, and in October 2019, county officials ordered our Atlanta facility, the operations of which we had voluntarily suspended at the time, remain closed until county approval is obtained. Although our Atlanta facility was allowed to resume operations under a Temporary Restraining Order imposed on county officials in April 2020, our facility could be forced to close again upon the resolution of related litigation. The occurrence of any of these or other events might disrupt or shut down operations or otherwise adversely impact the production or profitability of a particular facility or our operations as a whole.

While we maintain insurance policies covering, among other things, physical damage, business interruptions and liability resulting from our services in amounts that we believe are customary for our industries, our insurance coverage may be inadequate or unavailable and we could incur uninsured losses and liabilities arising from such events.

The COVID-19 pandemic has had and could continue to have adverse effects on our business, financial condition and results of operations, which could be material.

The global impact of the COVID-19 pandemic, including the governmental responses, has had a negative effect on the global economy, disrupting the financial markets and creating increasing volatility, and has

 

31


Table of Contents

disrupted our operations. For example, during the pandemic, there has been an increase in deferred elective procedures, which negatively impacts demand for some of our products and services as a result of a decrease in the need for sterilized medical devices used in these procedures. Further, although our operations are considered “essential” in all locations where we operate, we have experienced, and may experience in the future, temporary facility closures while awaiting appropriate government approvals in certain jurisdictions or delays in delivering products or services to customers. The extent to which our operations will be impacted by the outbreak will largely depend on future developments, which are highly uncertain and cannot be accurately predicted, including mandatory closures of our facilities imposed by government authorities, work-from-home orders and social distancing protocols or other currently unforeseen restrictions that could adversely affect our ability to adequately staff and maintain our operations, and those effects could be material. For example, we experienced delayed deliveries at certain locations as a result of governmental travel restrictions enacted in response to the COVID-19 pandemic. We have implemented business continuity planning, including to transition staff off-site to decrease exposure risk and to manage supply chain risk for critical materials, but we cannot guarantee that these measures will be successful. If the COVID-19 outbreak disrupts our supply chain, it could adversely impact our ability to secure supplies for our facilities, which could adversely affect our operations, and those effects could be material. The pandemic and the response thereto continue to evolve, and we cannot at this time forecast its ultimate duration, severity or impact to our business, our customers or our supply chain. This negative impact could continue for an extended period of time or more severely impact our financial condition and results of operations, and continued weak or worsening economic conditions could negatively impact consumer demand for our products and services. Future pandemics and public crises could impact our business in a similar or worse manner. See “—Our operations are subject to a variety of business continuity hazards and risks, including our reliance on the use and sale of products and services from single locations, any of which could interrupt production or operations or otherwise adversely affect our performance, results or value.”

If we are unable to increase capacity at existing facilities and build new facilities in a timely and cost-effective manner, we may not achieve our expected revenue growth or profitability or such revenue growth and profitability, if any, could be delayed.

Our growth strategy depends on expanding capacity in Europe, the Americas and Asia, which may include building new facilities and expanding existing facilities. The construction or expansion of modern and safe sterilization facilities requires significant expenditures. Delay in the review and licensing process for a new facility could impair or delay our ability to develop that facility or increase the cost so substantially that the facility becomes unattractive to us. Any failure to procure and maintain the necessary licenses would adversely affect ongoing development, construction and continuing operation of our facilities. Additionally, even when we maintain the necessary licenses and are in compliance with applicable regulations, we may be unable to maintain or expand our operations at existing facilities, or otherwise execute on our growth strategy, due to negative publicity or community resistance. Suspensions and closures of our facilities have in the past and may continue to impact our results of operations, and the effects could be material. Those new facilities that are constructed and begin operations may not meet our return expectations due to schedule delays, cost overruns or revenue shortfalls, or they may not generate the capacity that we anticipate or result in the receipt of revenue in the originally anticipated time period or at all. We may not maintain revenue growth or profitability, or such growth, if any, could be delayed if we are not successful in continuing to expand capacity. Additionally, if future demand trends warrant capacity in geographic areas that we have not targeted for new growth, we may be unable to capitalize on opportunities in a timely manner.

We occupy many of our facilities under long-term leases, and we may be unable to renew our leases at the end of their terms.

Many of our facilities, including many of our EO facilities and some of our gamma facilities, are located on leased premises. The terms of our leases vary in length and expire over a period ranging from 2021 to 2040, with options to renew for specified periods of time. At the end of the lease term and any renewal period for a facility, we may be unable to renew the lease without substantial additional cost, if at all. For example, in September

 

32


Table of Contents

2019, we were unable to reach an agreement to renew the lease on our EO processing facility in Willowbrook, following community pressure resulting from negative publicity surrounding our Willowbrook facility. If we are unable to renew our facility leases, we may be required to relocate or close a facility. Relocating a facility involves significant expense in connection with the movement and installation of specialized equipment and any necessary recertification or licensing with regulatory authorities. Closing a facility, even briefly to relocate, would reduce the sales that such facility would have contributed to our revenues and could negatively impact our customer relations. Any such relocation or closure could have a material adverse effect on our business, prospects, financial condition or results of operations.

We conduct sales and distribution operations on a worldwide basis and are subject to a variety of risks associated with doing business outside the United States.

We maintain significant international operations, including operations in China, Brazil, Canada, Mexico, Costa Rica and other countries in Europe and Asia. As a result, we are subject to a number of risks and complications associated with international sales, services and other operations, as well as risks associated with U.S. foreign policy. These include:

 

   

difficulties associated with compliance with numerous, potentially conflicting and frequently complex and changing laws in multiple jurisdictions, e.g., with respect to environmental matters, intellectual property, privacy and data protection, corrupt practices, embargoes, trade sanctions, competition, employment and licensing;

 

   

general economic, social and political conditions in countries where we operate, including international and U.S. trade policies and currency exchange rate fluctuations;

 

   

tax and other laws that restrict our ability to use tax credits, offset gains or repatriate funds;

 

   

currency restrictions, transfer pricing regulations and adverse tax consequences, which may affect our ability to transfer capital and profits;

 

   

inflation, deflation and stagflation in any country in which we have a manufacturing facility;

 

   

foreign customers with longer payment cycles than customers in the United States; and

 

   

imposition of or increases in customs duties and other tariffs.

We operate in a number of countries throughout the world, including in countries that do not have as strong a commitment to anti-corruption and ethical behavior that is required by U.S. laws or by our corporate policies. Based on the nature of our products, these activities involve potential interaction with government agencies, public officials or state-owned enterprises. We are subject to the risk that we, our U.S. employees or our employees located in other jurisdictions or any third party that we engage to do work on our behalf may take action determined to be in violation of anti-corruption laws in any jurisdiction in which we conduct business. The U.S. Foreign Corrupt Practices Act (the “FCPA”) and the Canadian Corruption of Foreign Public Officials Act (the “CFPOA”) prohibit corruptly providing anything of value to foreign officials for the purposes of obtaining or retaining business or securing any improper business advantage. We may deal with both governments and government-owned business enterprises, the employees of which are considered foreign officials for purposes of the FCPA and other applicable anti-corruption laws. The provisions of the Bribery Act extend beyond bribery of foreign public officials and are more onerous than the FCPA in a number of other respects. Any violation of the FCPA, the CFPOA, the U.K. Bribery Act of 2010 (the “Bribery Act”) or any similar anti-corruption law or regulation could result in substantial fines, sanctions or civil and/or criminal penalties, debarment from business dealings with certain governments or government agencies or restrictions on the marketing of our products in certain countries, which could harm our business, financial condition or results of operations. If these anticorruption laws or our internal policies were to be violated, our reputation and operations could also be substantially harmed. Further, detecting, investigating and resolving actual or alleged violations is expensive and can consume significant time and attention of our senior management.

 

33


Table of Contents

Compliance with multiple, and potentially conflicting, international laws and regulations, including anticorruption laws and exchange controls may be difficult, burdensome or expensive. While our employees and agents are required to comply with these laws, our internal policies and procedures may not always prevent violations. Further, in connection with past and future acquisitions by us, there is a risk of successor liability relating to such laws in connection with prior actions or alleged actions of an acquired company. Such matters or allegations related to such matters could adversely affect our reputation and the burden and cost associated with defending or resolving such matters could adversely affect our business, prospects, financial condition or results of operations.

Further, as a result of our global operations, we generate a significant portion of our revenue and incur a significant portion of our expenses in currencies other than the U.S. dollar, including the euro, the Brazilian real, the British pound sterling, the Chinese yuan, the Thai baht, the Mexican peso, the Danish krone, the Costa Rica colon and the Canadian dollar. Our results of operations are impacted by currency exchange rate fluctuations to the extent that we are unable to match net revenues received in foreign currencies with expenses incurred in the same currency. For example, where we have significantly more expenses than net revenues generated in a foreign currency, our profit from operations in that location would be adversely affected in the event that the U.S. dollar depreciates against that foreign currency.

We may be adversely affected by global and regional economic and political instability.

We may be adversely affected by global and regional economic and political conditions. The uncertainty or deterioration of the global economic and political environment could adversely affect us. Customers may modify, delay or cancel plans to purchase our products and services and suppliers may significantly and rapidly increase their prices or reduce their output because of cash flow problems. Any inability of current or potential customers to purchase or pay for our products due to, among other things, declining economic conditions as a result of inflation, rising interest rates, changes in spending patterns at medical device, pharmaceutical and biotechnology companies and the effects of governmental initiatives to manage economic conditions may have a negative impact on our business, prospects, financial condition or results of operations. Overall demand for our products could be reduced as a result of a global economic recession or political unrest, especially in such areas as the medical device, pharmaceutical, food safety and other end markets that we serve.

We depend upon our key personnel, the loss of whom could adversely affect our operations. If we fail to attract and retain the talent required for our business, our business could be materially harmed.

We depend to a significant degree on our ability to hire and retain highly qualified personnel with expertise in our industries. The loss of services from any of our key personnel may significantly delay or prevent the achievement of our business objectives. Competition for qualified employees in the industries in which we operate is intense. We may not be able to attract and retain these individuals on acceptable terms or at all, and our inability to do so could have a material adverse effect on our business, prospects, financial condition or results of operations.

We are subject to significant regulatory oversight of our import and export operations due to the nature of some of our product offerings.

Our products are subject to U.S. laws and regulations that may limit, restrict or require a license to import or export (or re-export from other countries). We are also subject to the export and import laws of those foreign jurisdictions in which we operate, sell our products into and from which we source our materials, including Co-60. In addition, if we introduce new products, we may need to obtain licenses or approvals from the United States and other governments to ship them into foreign countries. Because of increasing security controls and regulations regarding the shipment of materials including Co-60, it is likely that we may encounter additional regulations affecting the transportation, storage, sale and import/export of radioactive materials. Further, any delay or inability to obtaining these permits and licenses could delay our prevent us from fulfilling our obligations to our customers, which could harm our business, financial condition or results of operations.

 

34


Table of Contents

Additionally, the U.S. Department of the Treasury’s Office of Foreign Assets Control and other relevant agencies of the U.S. government administer certain laws and regulations that restrict U.S. persons and, in some instances, non-U.S. persons, from conducting activities, transacting business with or making investments in certain countries, or with governments, entities and individuals subject to U.S. economic sanctions. Our international operations subject us to these laws and regulations, which are complex, restrict our business dealings with certain countries, governments, entities and individuals and are constantly changing. Penalties for non-compliance with these complex laws and regulations can be significant and include substantial fines, sanctions or civil and/or criminal penalties and violations can result in adverse publicity, which could harm our business, financial condition or results of operations.

Our business may be subject to system interruptions, cyber security breaches and unauthorized data disclosures.

We increasingly rely upon technology systems and infrastructure. Our technology systems and infrastructure are potentially vulnerable to breakdowns or other interruptions by fire, power loss, system malfunction, unauthorized access and other events. Likewise, data privacy breaches by employees and others with both permitted and unauthorized access to our systems may pose a risk that sensitive data may be exposed to unauthorized persons or to the public, rendered inaccessible or permanently lost. The increasing use and evolution of technology creates additional opportunities for the unintentional dissemination or intentional destruction of confidential or proprietary information stored in our systems or portable media or storage devices. We could also experience a business interruption, information theft or reputational damage from industrial espionage attacks, malware or other cyber incidents or data breaches, which may compromise our system infrastructure or lead to data breaches, either internally or at our third-party providers or other business partners. Such incidents could compromise our trade secrets or other confidential information and result in such information being disclosed to third parties and becoming less valuable. Additionally, in response to the COVID-19 pandemic, a majority of our office employees are working remotely, which may increase the risk of cyber incidents or data breaches. Breaches in security, system interruptions and unauthorized disclosure of data, whether perceived or actual, could adversely affect our businesses, assets, revenues, brands and reputation and result in fines, litigation, regulatory proceedings and investigations, increased insurance premiums, remediation efforts, indemnification expenditures, lost revenues and other potential liabilities. We have taken steps to protect the security and integrity of the information we collect and have policies and procedures in place dealing with data privacy and security, but there can be no assurance that our efforts will prevent breakdowns, system failures, breaches in our systems or other cyber incidents or otherwise be fully effective. Any such breakdown, breach or incident could adversely affect our business, prospects, financial condition or results of operations, and our cyber insurance may not cover such risks or may be insufficient to compensate us for losses that may occur.

Part of our growth strategy is to pursue strategic transactions, including acquisitions, which subjects us to risks that could harm our business and we may not be able to find suitable acquisition targets or integrate strategic acquisitions successfully into our existing business.

As part of our strategy, we have in the past and may in the future seek to grow our business through acquisitions, and any such acquisition may be significant. Any future growth through acquisitions will depend in part upon the continued availability of suitable acquisition candidates at favorable prices and upon advantageous terms and conditions, which may not be available to us, as well as sufficient funds from our cash on hand, cash flow from operations, existing debt facilities and additional indebtedness to fund these acquisitions.

Not only is the identification of such suitable acquisition candidates difficult and competitive, but these transactions, including the acquisitions completed in recent years also involve numerous risks, including the diversion of management’s attention and their ability to:

 

 

successfully integrate acquired facilities, companies, products, systems or personnel into our existing business, especially with respect to businesses or operations that are outside of the United States;

 

35


Table of Contents
 

minimize any potential interruption to our ongoing business;

 

 

successfully enter categories and markets in which we may have limited or no prior experience;

 

 

achieve expected synergies and obtain the desired financial or strategic benefits;

 

 

detect and address any financial or control deficiencies of the acquired company;

 

 

retain key relationships with employees, customers, partners and suppliers of acquired companies as well as our own employees, customers, partners and suppliers; and

 

 

maintain uniform compliance standards, controls, procedures and policies throughout acquired companies.

Companies, businesses or operations acquired or joint ventures created may not be profitable or may not achieve revenue and profitability levels that would justify the investments made. Recent and future acquisitions could also result in the incurrence of indebtedness, subject to the restrictions contained in the documents governing our then-existing indebtedness. See “—Our substantial leverage could adversely affect our ability to raise additional capital to fund our operations, limit our ability to react to changes in the economy or our industry, expose us to interest rate risk to the extent the interest rate on variable rate debt increases and prevent us from meeting our obligations under our existing and future indebtedness.”

Recent and future acquisitions could also result in the assumption of contingent liabilities, material expenses related to certain intangible assets, increased operating expenses and compliance issues under international laws and regulations, including antitrust laws, anti-corruption laws, the FCPA and similar anti-bribery laws, which could adversely affect our business, prospects, financial condition or results of operations. In addition, to the extent that the economic benefits associated with any of our acquisitions diminish in the future, we may be required to record additional write-downs of goodwill, intangible assets or other assets associated with such acquisitions, which could adversely affect our business, prospects, financial condition or results of operations.

Certain of the acquisition agreements by which we have acquired companies require the former owners to indemnify us against certain liabilities related to the operation of the company before we acquired it. In most of these agreements, however, the liability of the former owners is limited, and certain former owners may be unable to meet their indemnification responsibilities. We cannot assure you that these indemnification provisions will protect us fully or at all, and as a result we may face unexpected liabilities that adversely affect our business, prospects, financial condition or results of operations.

In particular, as part of the acquisition by BWXT of our Medical Isotopes business, we lease one of our Canadian facilities to BWXT through July 2038, and BWXT operates under our Canadian Nuclear Safety Commission (“CNSC”) license in an arrangement we expect to continue through 2021. If BWXT fails to comply with CNSC regulations, we could be liable, and although we are indemnified by BWXT for any such failures, such indemnification may be insufficient to cover any liabilities.

Our ability to realize the benefits we anticipate from our strategic transactions, including acquisition activities, anticipated cost savings and additional sales opportunities, will depend in large part upon whether we are able to integrate such businesses efficiently and effectively. If we are unable to successfully integrate the operations of acquired businesses into our business or on the timeline we expect, including with respect to our ongoing integration of Iotron, we may be unable to realize the sales growth, cost synergies and other anticipated benefits we expect to achieve as a result of such transactions and our business, prospects, financial condition or results of operations could be adversely affected.

 

36


Table of Contents

Our internal controls over financial reporting may not be effective and our independent registered public accounting firm may not be able to certify as to their effectiveness, which could have a significant and adverse effect on our business and reputation.

Pursuant to the Sarbanes-Oxley Act, we will be required to furnish a report by our management on the effectiveness our internal control over financial reporting beginning with our second filing of an Annual Report on Form 10-K with the SEC after we become a public company. This assessment will need to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting. However, we may not be required to have our independent registered public accounting firm attest to the effectiveness of our internal controls until as late as our annual report for the fiscal year ending December 31, 2025. At such time, if we then have a material weakness, we would receive an adverse opinion regarding our internal control over financial reporting from our independent registered accounting firm.

We have begun the process to identify and implement actions to improve the effectiveness of our internal control over financial reporting and disclosure controls and procedures. The process of reviewing and improving our internal controls is both costly and challenging. We will need to (i) continue to dedicate internal resources, including through hiring additional financial and accounting personnel, (ii) potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, (iii) continue steps to improve control processes as appropriate, (iv) validate through testing that controls are functioning as documented and (v) implement a continuous reporting and improvement process for internal control over financial reporting. This process may also require substantial attention from our management team, which may negatively impact other matters that are important to our business.

If we identify a material weakness in connection with this ongoing assessment and we fail to remediate these identified material weaknesses within the prescribed period, we will be unable to assert that our internal controls over financial report are effective. We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition or results of operations. In addition, we may be required to incur costs in improving our internal control system and the hiring of additional personnel. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting, we could lose investor confidence in the accuracy and completeness of our financial reports, the market price of shares of our common stock could decline and we could be subject to sanctions or investigations by the Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.

We rely on intellectual property rights to maintain our competitive position and third parties may claim that we infringe or misappropriate their intellectual property rights.

We rely on proprietary technology and are dependent on our ability to protect such technology. We rely primarily on trade secrets and non-disclosure and confidentiality arrangements to protect our intellectual property rights, including such rights that relate to our Nelson Labs business and its lab testing services. The efforts we have taken to protect our intellectual property and proprietary technology may not be sufficient or effective. Third parties, including current or former employees, consultants, contractors, customers or partners, who have access to our confidential information (including our trade secrets and know-how), may unintentionally or willfully disclose our confidential information to others, and there can be no assurance that our trade secret rights and non-disclosure and confidentiality arrangements will provide meaningful protection of our proprietary technology. There can also be no assurance that others will not independently develop similar or superior technologies or duplicate any technology developed by us. Effective protection of intellectual property rights may not be available in every jurisdiction in which our products and services are made available, and monitoring

 

37


Table of Contents

unauthorized use and disclosures of our proprietary technology or confidential information can be difficult and expensive. Actions to enforce our intellectual property rights could lead to disputes with third parties, including our customers, and could impact our future ability to gain business. Furthermore, legal proceedings to protect or enforce our intellectual property rights could result in narrowing the scope of our intellectual property rights or substantial cost to us, and they may be time consuming and divert resources and the attention of management and key personnel, and the outcomes of such actions may be unpredictable.

Additionally, we cannot be certain that the conduct of our business does not and will not infringe or misappropriate intellectual property rights of others. From time to time, we may become subject to claims, allegations and legal proceedings, including by means of counterclaims, that we infringe or misappropriate intellectual property or other proprietary rights of third parties. Such legal proceedings involving intellectual property rights are highly uncertain, can involve complex legal and scientific questions and may divert resources and the attention of management and key personnel. Our failure to prevail against infringement or misappropriation claims brought against us could also result in judgments awarding substantial damages against us, including possible treble damages and attorneys’ fees, and could result in reputational harm. Judgments that result in equitable or injunctive relief could cause us to delay or cease selling or providing certain products or services or otherwise harm our operations. We also may have to seek third party licenses to intellectual property, which may be unavailable, require payment of significant royalties or be available only at commercially unreasonable, unfavorable or otherwise unacceptable terms.

If we are unable to adequately protect, establish, maintain or enforce our intellectual property rights or if we are subject to any infringement or misappropriation claims, our business, prospects, financial condition or results of operations may be adversely affected.

We are subject to complex and rapidly evolving data privacy and security laws and regulations and any ineffective compliance efforts with such laws and regulations may adversely impact our business.

We must comply with laws and regulations in federal and state governments in multiple jurisdictions governing the collection, dissemination, retention, access, use, protection, security and disposal of personal data, which mostly consists of our employees’ data. The interpretation and application of many existing or recently enacted privacy and data protection laws and regulations in the United States, the European Union and elsewhere are uncertain and fluid, and it is possible that such laws and regulations may be interpreted or applied in a manner that is inconsistent with our existing practices. Companies are under increased regulatory scrutiny relating to data privacy and security. Any actual or perceived breach of such laws or regulations may subject us to claims and may lead to administrative, civil or criminal lability, as well as reputational harm. Moreover, these laws are evolving and are generally becoming stricter. For example, activities conducted from our EU facilities or related to products and services that we may offer to EU users or customers are subject the General Data Protection Regulation (Regulation (EU) 2016/679), which provides for enhanced data privacy obligations and fines of up to the higher of 4% of annual worldwide revenues or €20 million. Outside of the United States and the European Union, many jurisdictions have adopted or are adopting new data privacy laws that impose further onerous compliance requirements, such as data localization, which prohibit companies from storing outside the jurisdiction data relating to resident individuals. The proliferation of such laws may result in conflicting and contradictory requirements and there can be no assurance that the measures we have taken will be sufficient for compliance with such various laws and regulations. Complying with these various laws is an ongoing commitment and could cause us to incur substantial costs or require us to change our business practices in a manner adverse to our business. Privacy-related claims or lawsuits initiated by governmental bodies, employees, customers or third parties, whether meritorious or not, could adversely affect our businesses, assets, revenues, brands and reputation and result in fines, litigation, regulatory proceedings, regulatory investigations, increased insurance premiums, remediation efforts, indemnification expenditures, lost revenues and other potential liabilities. We take steps to comply with applicable data privacy and security laws, regulations and standards and applicable privacy policies, but there can be no assurance that our compliance efforts will be effective. Any such failure to comply could adversely affect our business, prospects, financial condition or results of operations.

 

38


Table of Contents

We have a history of net losses and may not achieve or maintain profitability in the future.

We have a history of net operating losses, including a net loss of $20.8 million and $5.9 million for the years ended December 31, 2019 and 2018, respectively. We may not be able to achieve or maintain profitability for the current or any future fiscal year. Our ability to achieve and maintain profitability depends on a number of factors, including the growth rate of the sterilization and lab services industries, the price of our products and services, the cost to provide our products and services and the competitiveness of our products and services. We may incur significant losses in the future for a number of reasons, including due to principal and interest expense related to our substantial indebtedness and the other risks described in this prospectus, and we may encounter unforeseen expenses, difficulties, complications and delays and other unknown events. In addition, as a public company, we will incur significant legal, accounting and other expenses that we did not incur as a private company. As a result, our operations may not achieve profitability in the future and, even if we do achieve profitability, we may not be able to maintain or increase it.

We may incur impairment charges on our goodwill and other intangible assets with indefinite lives, which could negatively impact our business, financial condition or results of operations.

We are subject to Accounting Standards Codification Topic 350, Intangibles—Goodwill and Other, which requires that goodwill and other intangible assets that have an indefinite useful life be evaluated at least annually for impairment. Goodwill and other intangible assets with indefinite lives must also be evaluated for impairment between the annual tests if an event or change in circumstance occurs that would more likely than not reduce the fair value of the asset below its carrying amount. We have substantial goodwill and other intangible assets. If in the future, we determine that there has been an impairment, our financial results for the relevant period would be reduced by the amount of the non-cash impairment charge, net of any income tax effects, which could have an adverse effect on our financial condition or results of operations.

Unionization efforts and labor regulations in certain countries in which we operate could materially increase our costs or limit our flexibility.

Certain of our employees in non-U.S. markets are represented by works councils or labor unions and work under collective bargaining or similar agreements, some of which are subject to periodic renegotiation. Efforts have been made from time to time to unionize portions of our workforce in the United States. Unionization efforts, new collective bargaining agreements or work stoppages could materially increase our costs, reduce our net revenues or limit our flexibility. Certain legal obligations in these markets require us to contribute amounts to retirement funds and pension plans and restrict our ability to dismiss employees. Future regulations or court interpretations established in the countries in which we conduct our operations could increase our costs and materially adversely affect our business, financial condition or results of operations. Both of the collective bargaining agreements applicable to Brazilian employees were finalized and certified by the Ministry of Labor in 2017. The collective bargaining agreement applicable to Canadian employees located in Kanata expired on March 31, 2020. Negotiations have been postponed during the COVID-19 pandemic and are set to commence in December 2020. Failure to renew the agreements on similar terms could result in labor disruptions and/or increased labor costs, which could negatively affect our business and operations.

Our business is subject to a variety of laws involving the cannabis industry, many of which are unsettled and still developing and which could subject us to claims or otherwise harm our business.

We provide bioburden reduction irradiation services for the processing of cannabis, primarily in Canada and certain European countries. The commercial recreational cannabis industry is a relatively new industry in Canada, and in Canada, the Cannabis Regulations is a regime that has only been in effect in its current form since October 2018. Likewise, laws and regulations governing cannabis in European countries have evolved rapidly over recent years. In the United States, marijuana (all parts of the cannabis plant other than those parts that are exempt) is a Schedule I controlled substance under federal law. Our activity related to marijuana in the United

 

39


Table of Contents

States is de minimis and has been limited to the irradiation of marijuana for clinical research under Drug Enforcement Administration authorization in compliance with applicable U.S. federal law. In other countries in which the cultivation and use of marijuana is legalized, most notably in Canada, our operations include irradiation services for recreational and medical marijuana. As laws in the United States, Canada, Europe and other jurisdictions evolve, our activities in these spaces may face additional regulations that may be costly or burdensome to be in compliance.

Government or private civil antitrust actions could harm our business, results of operations, financial condition and cash flows.

The antitrust laws prohibit, among other things, any joint conduct among competitors that would lessen competition in the marketplace. We believe that we are in compliance with the legal requirements imposed by the antitrust laws. However, a governmental or private civil action alleging the improper exchange of information, or unlawful participation in price maintenance or other unlawful or anticompetitive activity, even if unfounded, could be costly to defend and could harm our business, prospects, financial condition or results of operations.

Challenges to our tax positions in U.S. or non-U.S. jurisdictions, the interpretation and application of recent U.S. tax legislation or other changes in U.S. or non-U.S. taxation of our operations could harm our business, revenue and financial results.

We operate in a number of tax jurisdictions globally, including in the United States at the federal, state and local levels, and in many other countries, and we therefore are subject to review and potential audit by tax authorities in these various jurisdictions. Significant judgment is required in determining our worldwide provision for income taxes and other tax liabilities, and tax authorities may disagree with tax positions we take and challenge our tax positions. Successful unilateral or multi-jurisdictional actions by various tax authorities, including in the context of our current or future corporate operating structure and third-party and intercompany arrangements, may increase our worldwide effective tax rate, result in additional taxes or other costs or have other material consequences, which could harm our business, revenue and financial results.

Our effective tax rate may also change from year to year or vary materially from our expectations based on changes or uncertainties in the mix of activities and income allocated or earned among various jurisdictions, changes in tax laws and the applicable tax rates in these jurisdictions (including future tax laws that may become material), tax treaties between countries, our eligibility for benefits under those tax treaties and the valuation of deferred tax assets and liabilities. Such changes could result in an increase in the effective tax rate applicable to all or a portion of our income, impose new limitations on deductions, credits or other tax benefits or make other changes that may adversely affect our business, cash flows or financial performance. For example, if we are unable to fully realize the benefit of interest expense incurred in future periods as a result of recent tax law changes (as discussed below), we may need to recognize a valuation allowance on any related deferred tax assets, which would impact our annual effective income tax rate.

In particular, on December 22, 2017, the Tax Cuts & Jobs Act (“TCJA”) was signed into law. The legislation significantly changed U.S. tax law by, among other things, lowering the U.S. federal corporate income tax rate from 35% to 21%, implementing a modified territorial tax system and imposing a transition tax on deemed repatriated earnings of foreign subsidiaries (“Section 965 Transition Tax”). Certain changes established by the TCJA increased our effective tax rate in prior years, including a new income inclusion item for global intangible low-taxed income (“GILTI”) and the Section 965 Transition Tax on our accumulated offshore earnings held in cash and illiquid assets. Additional changes have impacted the timing of our recognition of certain items of loss and deduction, including a new limitation on the company’s deduction for business interest expense and increased bonus depreciation from 50% to 100% for certain qualified property.

Furthermore, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted on March 27, 2020 in response to the outbreak of COVID-19 and its consequences. The CARES Act introduced

 

40


Table of Contents

substantial changes to the U.S. tax code, the overall impact of which on our business is uncertain. For example, among other changes, the CARES Act increased the interest expense deductibility limitations and waived certain limitations on the use of net operating losses, in each case, temporarily.

On July 23, 2020, final regulations were published that exempt certain income subject to a high rate of foreign tax from inclusion under GILTI for tax years beginning after December 31, 2017.

The cumulative impact of these and other changes in tax law is uncertain and our business and financial condition could be adversely affected.

Risks Related to Our Indebtedness and Liquidity

Our substantial leverage could adversely affect our ability to raise additional capital to fund our operations, limit our ability to react to changes in the economy or our industry, expose us to interest rate risk to the extent the interest rate on our variable rate debt increases and prevent us from meeting our obligations under our existing and future indebtedness.

We are highly leveraged. As of September 30, 2020, on an adjusted basis after giving effect to this offering and the application of the net proceeds therefrom, our total indebtedness (including that of our wholly owned subsidiaries) was approximately $2,035.4 million, all of which is indebtedness of Sotera Health Holdings, LLC that is guaranteed by the company and certain of its other subsidiaries. We also had an additional $190.0 million of unutilized capacity under our Revolving Credit Facility at that date (without giving effect to $64.3 million of letters of credit that were outstanding). See “Description of Certain Indebtedness.”

Our estimated debt service obligations for the next 12 months on an as adjusted basis after giving effect to this offering (based on an assumed initial public offering price at the midpoint of the estimated offering price range set forth on the cover page of this prospectus) and the application of the net proceeds therefrom would be $142.9 million, based on the outstanding principal amount of indebtedness of $2,035.4 million as of September 30, 2020. For the nine months ended September 30, 2020, our cash flow used for debt service totaled $174.6 million, which includes scheduled quarterly principal payments of the Term Loan (as defined below) of $10.6 million and interest payments on our debt of $164.0 million. For the nine months ended September 30, 2020, our cash flows from operating activities totaled $98.7 million, which includes interest paid of $164.0 million. As such, our cash flows from operating activities (before giving effect to the payment of interest) amounted to $262.7 million. For the nine months ended September 30, 2020, cash payments used to service our debt represented approximately 66% of our net cash flows from operating activities (before giving effect to the payment of interest). As adjusted to give effect to this offering and the application of net proceeds therefrom, for the nine months ended September 30, 2020, our cash flow used for debt service would have totaled $109.8 million (based on an assumed initial public offering price at the midpoint of the estimated offering price range set forth on the cover page of this prospectus), our cash flows from operating activities (before giving effect to the payment of interest) would have amounted to $197.9 million and cash payments used to service our debt would have represented approximately 56% of our net cash flows from operating activities (before giving effect to the payment of interest).

Our high degree of leverage could have important consequences for you, including:

 

   

making it more difficult for us to satisfy our obligations;

 

   

increasing our vulnerability to general economic and industry conditions;

 

   

requiring a substantial portion of cash flow from operations to be used to pay off principal and interest on our indebtedness, thereby reducing our ability to use our cash flow to fund our operations, capital expenditures and future business opportunities;

 

   

exposing us to the risk of increased interest rates as our indebtedness is at variable interest rates;

 

   

restricting us from making strategic acquisitions or causing us to make non-strategic divestitures;

 

41


Table of Contents
   

limiting our ability to obtain additional financing for working capital, capital expenditures, product development, debt service requirements, acquisitions and general corporate or other purposes;

 

   

limiting our ability to adjust to changing market conditions and placing us at a disadvantage compared to our competitors that are less highly leveraged; and

 

   

causing us to pay higher rates if we need to refinance our indebtedness at a time when prevailing market interest rates are unfavorable.

We and our subsidiaries may obtain substantial additional indebtedness in the future, subject to the restrictions contained in SHH’s senior secured credit facilities (the “Senior Secured Credit Facilities”) and the indentures governing SHH’s senior secured first-lien notes (the “First Lien Notes”) and SHH’s senior secured second-lien notes (the “Second Lien Notes”). If new indebtedness is added to our current debt levels, the related risks that we now face could intensify.

Because we are exposed to interest rate risk through our variable-rate borrowings, we have entered into and may, in the future, enter into additional interest rate swaps that involve the exchange of floating for fixed rate interest payments in order to reduce interest rate volatility and interest rate cap agreements. However, we may not maintain interest rate swaps with respect to any of our variable rate indebtedness, and any swaps we enter into may not fully mitigate our interest rate risk. Further, current interest rates are relatively low. If interest rates increase, our debt service obligations on any variable rate indebtedness will increase even if the amount borrowed remains the same, and our net income and cash flows, including cash available for servicing our indebtedness, will correspondingly decrease. Based on our indebtedness outstanding as of September 30, 2020, on an adjusted basis after giving effect to this offering and the application of the net proceeds therefrom, a 1% increase in interest rates would result in an approximately $1.4 million increase in total annual interest expense under our outstanding debt obligations.

Our debt agreements contain restrictions that limit our flexibility in operating our business.

The Senior Secured Credit Facilities and the indentures governing the First Lien Notes and the Second Lien Notes contain various covenants that limit our ability to engage in specified types of transactions. These covenants limit our ability and our restricted subsidiaries’ ability to, among other things:

 

   

incur additional indebtedness or issue certain shares of preferred stock;

 

   

pay dividends on, repurchase or make distributions in respect of our capital stock or make other restricted payments;

 

   

make certain investments and acquisitions;

 

   

sell or transfer assets;

 

   

grant liens on our assets;

 

   

consolidate, merge, sell or otherwise dispose of all or substantially all of our assets; and

 

   

enter into certain transactions with our affiliates.

In addition, under certain circumstances we are required to satisfy and maintain specified financial ratios and other financial condition tests under certain covenants in our Senior Secured Credit Facilities. See “Description of Certain Indebtedness.” Our ability to meet those financial ratios and tests can be affected by events beyond our control, including prevailing economic, financial market and industry conditions, and we cannot give assurance that we will be able to satisfy such ratios and tests when required.

A breach of any of these covenants could result in a default under each of our Senior Secured Credit Facilities and/or the indentures governing the First Lien Notes and the Second Lien Notes. Upon the occurrence

 

42


Table of Contents

of an event of default, the lenders and/or noteholders, as applicable, could elect to declare all amounts outstanding under the Senior Secured Credit Facilities, the First Lien Notes and the Second Lien Notes to be immediately due and payable and terminate all commitments to extend further credit. If we were unable to repay those amounts, the lenders under the Senior Secured Credit Facilities or the indentures governing the First Lien Notes and Second Lien Notes could foreclose on the collateral granted to them to secure each such indebtedness. We have pledged substantially all of our assets as collateral under the Senior Secured Credit Facilities and the indentures governing the First Lien Notes and Second Lien Notes.

Our cash flows may not be sufficient to service our indebtedness, and if we are unable to satisfy our obligations under our indebtedness, we may be required to seek other financing alternatives, which may not be successful.

Our ability to make timely payments of principal and interest on our debt obligations, including our obligations under the Senior Secured Credit Facilities, the First Lien Notes and the Second Lien Notes, depends on our ability to generate positive cash flows from operations, which is subject to general economic conditions, competitive pressures and certain financial, business and other factors beyond our control. If our cash flows and capital resources are insufficient to make these payments, we may be required to seek additional financing sources, reduce or delay capital expenditures, sell assets or operations or refinance our indebtedness. These actions could have a material adverse effect on our business, financial conditions and results of operations. In addition, we may not be able to take any of these actions, and even if successful, these actions may not permit us to meet our scheduled debt service obligations. Our ability to restructure or refinance our existing indebtedness will depend on, among other things, the condition of the capital markets and our financial condition at the time. We may not be able to restructure or refinance any of our indebtedness on commercially reasonable terms or at all. If we cannot make scheduled payments on our debt, we will be in default and the outstanding principal and interest on our debt could be declared to be due and payable, in which case we could be forced into bankruptcy or liquidation or required to substantially restructure or alter our business operations or debt obligations.

A lowering or withdrawal of the ratings assigned to our debt by rating agencies may increase our future borrowing costs and reduce our access to capital.

Any rating assigned to our debt by a rating agency could be lowered or withdrawn entirely if, in that rating agency’s judgment, future circumstances relating to the basis of the rating, such as adverse changes to our ability to service our debt obligations or our general financial condition, so warrant. Any future lowering of our ratings likely would make it more difficult or more expensive for us to obtain additional debt financing. Additionally, we enter into various forms of hedging arrangements against currency, interest rates or commodity price fluctuations. Financial strength and credit ratings are also important to the availability and pricing of any hedging activities we decide to undertake, and a downgrade of our credit ratings may make it more costly for us to engage in these activities.

LIBOR and certain other interest “benchmarks” may be subject to regulatory guidance and/or reform that could cause interest rates under our current or future debt agreements to perform differently than in the past or cause other unanticipated consequences.

Because our Senior Secured Credit Facilities, First Lien Notes and Second Lien Notes bear interest at variable interest rates, based on the London Interbank Offered Rate (“LIBOR”) and certain other benchmarks, fluctuations in interest rates could have a material effect on our business. We currently utilize, and may in the future utilize, derivative financial instruments such as interest rate swaps or interest rate caps to hedge some of our exposure to interest rate fluctuations, but such instruments may not be effective in reducing our exposure to interest fluctuations, and we may discontinue utilizing them at any time. As a result, we may incur higher interest costs if interest rates increase. These higher interest costs could have a material adverse impact on our financial condition and the levels of cash we maintain for working capital.

 

43


Table of Contents

In addition, LIBOR and certain other interest “benchmarks” may be subject to regulatory guidance and/or reform that could cause interest rates under our current or future debt agreements to perform differently than in the past or cause other unanticipated consequences. The United Kingdom’s Financial Conduct Authority, which regulates LIBOR, has announced that it intends to stop encouraging or requiring banks to submit LIBOR rates after 2021, and it is unclear if LIBOR will cease to exist or if new methods of calculating LIBOR will evolve. If LIBOR ceases to exist or if the methods of calculating LIBOR change from their current form, interest rates on our current or future debt obligations may be adversely affected. If a published U.S. dollar LIBOR rate is unavailable, the interest rates on our first and second lien secured notes indexed to LIBOR will be determined in a manner that gives due consideration to the then prevailing market convention for determining a rate of interest for high yield notes in the United States at such time, and the interest rates on our Senior Secured Credit Facilities debt indexed to LIBOR will be determined in a manner that gives due consideration to the then prevailing market convention for determining a rate of interest for syndicated loans in the United States at such time; any of which could result in interest obligations that are more than or that do not otherwise correlate over time with the payments that would have been made on this debt if U.S. dollar LIBOR were available in its current form. Any of these proposals or consequences could have a material adverse effect on our financing costs. Moreover, the phaseout of LIBOR may adversely affect our assessment of effectiveness or measurement of ineffectiveness for accounting purposes of any future interest rate hedging agreements indexed to LIBOR.

Sotera Health Holdings, LLC is a holding company, and therefore its ability to make any required payment on our credit agreements depends upon the ability of its subsidiaries to pay it dividends or to advance it funds.

Sotera Health Holdings, LLC, the borrower under our Senior Secured Credit Facilities and the issuer of our First Lien Notes and Second Lien Notes, has no direct operations and no significant assets other than the equity interests of its subsidiaries. Because it conducts its operations through its operating subsidiaries, Sotera Health Holdings, LLC depends on those entities to generate the funds necessary to meet its financial obligations, including its required obligations under our Senior Secured Credit Facilities. The ability of our subsidiaries to make transfers and other distributions to Sotera Health Holdings, LLC will be subject to, among other things, the terms of any debt instruments of such subsidiaries then in effect and applicable law. If transfers or other distributions from our subsidiaries to Sotera Health Holdings, LLC were eliminated, delayed, reduced or otherwise impaired, our ability to make payments on the obligations under our credit agreements would be substantially impaired.

Risks Related to this Offering and Ownership of Our Common Stock

There is no current trading market for our common stock and an active market may never develop or be sustained.

Before this initial public offering, there has been no public market for our common stock. An active public trading market may not develop after completion of this offering or, if developed, may not be sustained. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. An inactive market may also impair our ability to raise capital by selling shares and may impair our ability to acquire other businesses or assets using our shares as consideration. Furthermore, although our common stock has been approved for listing on the Nasdaq, there can be no guarantee that we will continue to satisfy the continued listing standards of the Nasdaq. If we fail to satisfy the continued listing standards, we could be de-listed, which would have a negative effect on the price of our common stock.

The market and trading volume of our common stock may be volatile, and you could lose all or part of your investment.

The initial public offering price for our common stock will be determined through negotiations between the underwriters and us and may vary substantially from the market price of our common stock following this offering. This price may not reflect the public trading price of our common stock following this offering. If the market price of our common stock declines significantly, you may be unable to resell your shares at or above

 

44


Table of Contents

your purchase price, if at all. The market price of our common stock may fluctuate or decline significantly in the future. Some of the factors that could negatively affect our share price or result in fluctuations in the price or trading volume of our common stock include those listed in “—Risks Related to the Company,” “—Risks Related to Our Indebtedness and Liquidity” and the following, some of which are beyond our control:

 

   

volatility or economic downturns in the markets in which we, our suppliers or our customers are located caused by pandemics, including the COVID-19 pandemic, and related policies and restrictions undertaken to contain the spread of such pandemics or potential pandemics;

 

   

developments in our litigation matters and governmental investigations or additional significant lawsuits or governmental investigations relating to our services or facilities;

 

   

regulatory or legal developments in the jurisdictions in which we operate;

 

   

adverse publicity about us or the industries in which we participate;

 

   

variations in our quarterly or annual results of operations, or in those of our competitors or of companies in the medical device and pharmaceutical industries;

 

   

the financial projections we may provide to the public, any changes in these projections or our failure to meet these projections;

 

   

sales of our common stock by us or our stockholders in the future or the perception that such sales may occur;

 

   

publication of research reports about the industries in which we participate;

 

   

changes in analysts’ estimates, investors’ perceptions, recommendations by securities analysts, our failure to achieve analysts’ estimates or failure of analysts to maintain coverage of us;

 

   

volatility in the trading prices and trading volumes of companies similar to us;

 

   

changes in operating performance and stock market valuations of companies in our industry;

 

   

changes in accounting principles, policies, guidance, interpretations or standards; and

 

   

general market conditions and other factors unrelated to our operating performance or the operating performance of our competitors.

Certain broad market and industry factors may decrease the market price of our common stock, regardless of our actual operating performance. The stock market in general has from time to time experienced extreme price and volume fluctuations, including in recent months. In addition, in the past, following periods of volatility in the overall market and the market price of a company’s securities, securities class action litigation has often been instituted against these companies. This litigation, if instituted against us, could result in substantial costs and a diversion of our management’s attention and resources.

If securities or industry analysts do not publish research or reports about our business, or publish negative reports about our business, our share price and trading volume could decline.

The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business, our market and our competitors. We do not have any control over these analysts. If one or more of the analysts who cover us downgrade our shares or change their opinion of our business, our share price would likely decline. If one or more of these analysts cease coverage of us or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline.

If you purchase our common stock in this offering, you will incur immediate and substantial dilution.

The assumed initial public offering price of $21.50 per share (the midpoint of the estimated offering price range set forth on the cover page of this prospectus) will be substantially higher than the pro forma net tangible

 

45


Table of Contents

book deficit per share of our outstanding common stock of $(10.33) per share as of September 30, 2020 after this offering. Investors purchasing shares of our common stock in this offering will pay a price per share that substantially exceeds the book deficit of our tangible assets after subtracting our liabilities. As a result, investors purchasing common stock in this offering will incur immediate dilution of $26.91 per share, based on the assumed initial public offering price of $21.50 per share, which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus.

This dilution is due to the substantially lower price paid by our stockholders who purchased shares prior to this offering as compared to the price offered to the public in this offering. As a result of the dilution to investors purchasing shares in this offering, investors may receive less than the purchase price paid in this offering, if anything, in the event of our liquidation. See “Dilution.”

The future issuance of additional common stock in connection with our incentive plans, acquisitions or otherwise will dilute all other stockholdings.

After this offering, we will have an aggregate of 893,099,800 shares of common stock authorized but unissued (excluding shares of our common stock reserved for issuance under our incentive plans), as well as 1,669,122 treasury shares. We may issue all of these shares of common stock without any action or approval by our stockholders, subject to certain exceptions. We also intend to continue to evaluate acquisition opportunities and may issue common stock in connection with these acquisitions. Any common stock issued in connection with our incentive plans, acquisitions or otherwise would dilute the percentage ownership held by the investors who purchase common stock in this offering.

Future offerings of debt or equity securities by us may adversely affect the market price of our common stock.

In the future, we may attempt to obtain financing or to further increase our capital resources by issuing additional shares of our common stock or offering debt or other equity securities. Future acquisitions could require substantial additional capital in excess of cash from operations. We would expect to finance any future acquisitions through a combination of additional issuances of equity, corporate indebtedness, asset-backed acquisition financing and/or cash from operations.

Issuing additional shares of our common stock or other equity securities or securities convertible into equity may dilute the economic and voting rights of our existing stockholders or reduce the market price of our common stock or both. Upon liquidation, holders of such debt securities and preferred shares, if issued, and lenders with respect to other borrowings would receive a distribution of our available assets prior to the holders of our common stock. Debt securities convertible into equity could be subject to adjustments in the conversion ratio pursuant to which certain events may increase the number of equity securities issuable upon conversion. Preferred shares, if issued, could have a preference with respect to liquidating distributions or a preference with respect to dividend payments that could limit our ability to pay dividends to the holders of our common stock. Our decision to issue securities in any future offering will depend on market conditions and other factors beyond our control, which may adversely affect the amount, timing or nature of our future offerings. Thus, holders of our common stock bear the risk that our future offerings may reduce the market price of our common stock and dilute their stockholdings in us. See “Description of Capital Stock.”

A sale of a substantial number of shares of our common stock, or the perception that such sales might occur, may cause the price of our common stock to decline.

Future sales of substantial amounts of our common stock in the public market after the lapse of lock-up and other legal or contractual restrictions on resale discussed in this prospectus, or the perception that such sales might occur, could cause the trading price of our common stock to decline. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate.

 

46


Table of Contents

Upon the completion of this offering, we will have a total of 277,331,078 shares of our common stock outstanding based on the number of shares outstanding as of September 30, 2020 and based on an assumed initial public offering price of $21.50 per share (the midpoint of the estimated offering price range set forth on the cover page of this prospectus). Of these shares, all of the shares of common stock sold in this offering will be freely tradable, without restriction, in the public market immediately after the offering.

Holders of 224,483,041 shares of our common stock, including each of our directors and officers, have entered into lock-up agreements with the underwriters that restrict their ability to sell or transfer their shares. The lock-up agreements pertaining to this offering will expire 180 days from the date of this prospectus. J.P. Morgan Securities LLC, however, may, in its sole discretion, waive the contractual lock-up prior to the expiration of the lock-up agreements. Therefore, after the lock-up agreements expire, an additional 224,483,041 shares of common stock will be eligible for sale in the public market, of which 26,143,668 shares will be subject to vesting requirements and the transfer restrictions contained in the Stockholders’ Agreement, unless such transfer restrictions are waived by a majority of the members of the compensation committee of the board of directors, as described below. In addition to the 26,143,668 shares, an additional 6,248,037 shares of our outstanding common stock as of September 30, 2020 are not subject to lock-up agreements but will be subject to vesting requirements and contractual restrictions on transfer under the terms of our Stockholders’ Agreement described below.

Further, after this offering, 212,599,684 shares of our outstanding common stock as of September 30, 2020 will be held by directors, executive officers and other affiliates and will be subject to volume limitations under Rule 144 under the Securities Act. All of such holders will have rights to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or our stockholders.

We intend to file one or more registration statements on Form S-8 under the Securities Act to register all of the shares of common stock issued or issuable under our 2020 Plan. This registration statement is expected to become effective upon filing, and shares covered by this registration statement will be eligible for sale in the public markets, subject to Rule 144 limitations applicable to affiliates and any applicable contractual restrictions described above. If these additional shares are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.

Any sales of securities by any of our stockholders described above could have a material adverse effect on the market price of our common stock.

In connection with this offering, we intend to enter into a stockholders’ agreement with certain holders of our common stock, including investment funds and entities affiliated with either Warburg Pincus or GTCR and members of our management team, which we refer to as the Stockholders’ Agreement. Under the Stockholders’ Agreement, stockholders party to the agreement (other than the Sponsors and their affiliates) are subject to contractual restrictions on transfer of shares of our common stock. Those restrictions, however, may be waived at any time by a majority of the members of the compensation committee of the board of directors. See “Certain Relationship and Related Party Transactions—Stockholders’ Agreement.”

In the future, we may also issue securities in connection with investments or acquisitions. In particular, the number of shares of our common stock issued in connection with an investment or acquisition could constitute a material portion of our then-outstanding shares of our common stock. Any such issuance of additional securities in the future may result in additional dilution to you or may adversely impact the price of our common stock.

Although we do not expect to rely on the “controlled company” exemption, if we are a “controlled company” within the meaning of the Nasdaq corporate governance standards we would qualify for exemptions from certain corporate governance requirements.

Because the Sponsors will own a majority of our outstanding common stock following the completion of this offering, we may be considered a “controlled company” as that term is set forth in the Nasdaq corporate

 

47


Table of Contents

governance standards. Under these rules, a company of which more than 50% of the voting power is held by another person or group of persons acting together is a “controlled company” and may elect not to comply with certain corporate governance requirements, including:

 

   

the requirement that a majority of our board of directors consist of independent directors;

 

   

the requirement that our director nominations be made, or recommended to the full board of directors, by our independent directors or by a nominations committee that is comprised entirely of independent directors with a written charter addressing the committee’s purpose and responsibilities;

 

   

the requirement that our compensation committee be composed entirely of independent directors with a written charter addressing the committee’s purpose and responsibilities; and

 

   

the requirement that we conduct an annual performance evaluation of the nominating and corporate governance and compensation committees.

These requirements would not apply to us as long as we remain a “controlled company.” Although we may qualify as a “controlled company” upon completion of this offering, we do not expect to rely on this exemption and intend to fully comply with all corporate governance requirements under the Nasdaq corporate governance standards. However, if we were to utilize some or all of these exemptions, you may not have the same protections afforded to stockholders of companies that are subject to all of the Nasdaq corporate governance requirements. The Sponsors’ significant ownership interest could adversely affect investors’ perceptions of our corporate governance.

If the ownership of our common stock continues to be highly concentrated, it may prevent minority stockholders from influencing significant corporate decisions and may result in conflicts of interest.

Following the completion of this offering, the Sponsors will own approximately 71.5% of our outstanding common stock, or 69.8% if the underwriters’ option to purchase additional shares is fully exercised, in each case based on an assumed initial public offering price of $21.50 per share (the midpoint of the estimated offering price range set forth on the cover page of this prospectus). As a result, the Sponsors will own shares sufficient for the majority vote over all matters requiring a stockholder vote. Our Stockholders’ Agreement will contain agreements among the parties with respect to certain matters, including the election of directors; mergers, consolidations and acquisitions; the sale of all or substantially all of our assets and other decisions affecting our capital structure; the amendment of our amended and restated certificate of incorporation and our amended and restated bylaws; the termination of our chief executive officer or designation of a new chief executive officer; changes in the composition of committees of our board of directors; entry into or changes to certain compensation agreements; and the issuance of additional shares of our common stock. This concentration of ownership, together with the Sponsors’ rights under our Stockholders’ Agreement, may delay, deter or prevent acts that would be favored by our other stockholders. The interests of the Sponsors may not always coincide with our interests or the interests of our other stockholders. For example, because the Sponsors purchased their shares at prices substantially below the price at which shares are being sold in this offering and have held their shares for a longer period, they may be more interested in selling our Company to an acquirer than other investors or may want us to pursue strategies that deviate from the interests of other stockholders. In addition, under the Stockholders’ Agreement we have agreed, subject to certain exceptions, to indemnify the Sponsors, and various affiliated persons and indirect equityholders of the Sponsors from certain losses arising out of any threatened or actual litigation by reason of the fact that the indemnified persons is or was a holder of our common stock or of equity interests in Sotera Health Company. Public stockholders will not benefit from this indemnification provision.

This concentration of ownership, together with the Sponsors’ rights under our Stockholders’ Agreement, may also have the effect of delaying, preventing or deterring a change in control. As a result, the market price of our common stock could decline or stockholders might not receive a premium over the then-current market price of our common stock upon a change in control. In addition, this concentration of ownership, together with the

 

48


Table of Contents

Sponsors’ rights under our Stockholders’ Agreement, may adversely affect the trading price of our common stock because investors may perceive disadvantages in owning shares in a company with significant stockholders.

Certain of our stockholders have the right to engage or invest in the same or similar businesses as us.

The Sponsors have other investments and business activities in addition to their ownership of us. The Sponsors have the right, and have no duty to abstain from exercising such right, to engage or invest in the same or similar businesses as us, do business with any of our customers or suppliers or employ or otherwise engage any of our officers, directors or employees. If the Sponsors or any of their officers, directors or employees acquire knowledge of a potential transaction that could be a corporate opportunity, they have no duty, to the fullest extent permitted by law, to offer such corporate opportunity to us, our stockholders or our affiliates. This right could adversely impact our business, prospects, financial condition or results of operations if attractive business opportunities are procured by the Sponsors or another party for their own benefit rather than for ours.

In the event that any of our directors and officers who is also a director, officer or employee of any Sponsor acquires knowledge of a corporate opportunity or is offered a corporate opportunity, such person is deemed to have fully satisfied such person’s fiduciary duties owed to us and is not liable to us, to the fullest extent permitted by law, if such Sponsor pursues or acquires the corporate opportunity or does not present the corporate opportunity to us, provided that this knowledge was not acquired solely in such person’s capacity as our director or officer and such person acts in good faith.

The requirements of being a public company, including compliance with the reporting requirements of the Exchange Act and the requirements of the Sarbanes-Oxley Act, may strain our resources, increase our costs and distract management, and we may be unable to comply with these requirements in a timely or cost-effective manner.

As a public company with shares listed on a U.S. exchange, we will need to comply with new laws, regulations and requirements, certain corporate governance provisions of the Sarbanes-Oxley Act, the Dodd-Frank Act, related regulations of the SEC, the requirements of the Nasdaq and other applicable rules and regulations, with which we are not required to comply as a private company. Complying with these statutes, regulations and requirements will occupy a significant amount of time of our board of directors and management and will significantly increase our legal and financial compliance costs and expenses. We will need to:

 

   

institute a more comprehensive compliance function;

 

   

comply with rules promulgated by the Nasdaq;

 

   

prepare and distribute periodic public reports in compliance with our obligations under the federal securities laws;

 

   

establish new internal policies, such as those relating to insider trading; and

 

   

involve and retain, to a greater degree, outside counsel and accountants in the above activities.

In addition, as a result of becoming a public company, we intend to add independent directors and create additional board committees. We also expect that being a public company subject to these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our board of directors or as executive officers. We are currently evaluating and monitoring developments with respect to these rules and regulations, and we cannot predict or estimate the amount of additional costs we may incur or the timing of such costs and the material effect they could have on our business, prospects, financial condition or results of operations.

 

49


Table of Contents

Because a substantial portion of our proceeds from this offering will be used to repay outstanding indebtedness, only a portion of our proceeds from this offering may be used to further invest in our business. We will have broad discretion in the use of net proceeds from this offering and may not use them effectively.

Our management will have broad discretion to use our net proceeds from this offering, and you will be relying on the judgment of our management regarding the application of these proceeds. We intend to use a portion of the net proceeds of this offering to redeem all of the outstanding aggregate principal amount of the Second Lien Notes and repurchase certain shares of our common stock. We plan to use the balance of the net proceeds of this offering to repay a portion of the outstanding indebtedness under our Term Loan. As a result, a significant portion of our net proceeds of this offering will not be invested in our business, and therefore the value of your investment may not be increased. Because we will have broad discretion in the application of the net proceeds from this offering, our management may fail to apply these funds effectively, which could adversely affect our ability to operate and grow our business. You will not have the opportunity to influence our decisions on how to use our net proceeds from this offering.

The reduced disclosure requirements applicable to us as an “emerging growth company” under the JOBS Act may make our common stock less attractive to investors.

We are an “emerging growth company,” as defined in the JOBS Act and may remain an emerging growth company until the earliest of (a) the last day of the fiscal year during which we had total annual gross revenues of $1.07 billion or more, (b) the last day of our fiscal year following the fifth anniversary of this offering, (c) the date on which we have issued more than $1.0 billion in non-convertible debt during the previous three-year period or (d) the date on which we are deemed a “large accelerated filer” as defined under the federal securities laws. For as long as we remain an “emerging growth company,” we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies, including, but not limited to, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on certain executive compensation matters, such as “say on pay” and “say on frequency” and stockholder approval of any golden parachute payments not previously approved. As a result, our stockholders may not have access to certain information that they may deem important.

We cannot predict if investors will find our common stock less attractive as a result of our taking advantage of these exemptions. If they do, there may be a less active trading market for our common stock and our stock price may be more volatile.

Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We are choosing to take advantage of this extended transition period and, as a result, we will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for private companies or at which time we conclude it is appropriate to avail ourselves of early adoption provisions of applicable standards. Accordingly, our financial statements may not be comparable to companies that comply with public company effective dates, and our stockholders and potential investors may have difficulty in analyzing our operating results by comparing us to such companies.

Anti-takeover provisions in our amended and restated certificate of incorporation, amended and restated bylaws and our Stockholders’ Agreement, as well as Delaware law, could discourage a change in control of our company or a change in our management.

Our amended and restated certificate of incorporation and amended and restated bylaws, our Stockholders’ Agreement and Delaware law will contain provisions that might discourage, delay or prevent a merger, acquisition, or other change in control that stockholders may consider favorable, including transactions in which

 

50


Table of Contents

you might otherwise receive a premium for your shares of our common stock. These provisions may also prevent or frustrate attempts by our stockholders to replace or remove our management. These provisions include:

 

   

limiting the liability of, and providing indemnification to, our directors and officers;

 

   

establishing a classified board of directors with three-year staggered terms, which could delay the ability of stockholders to change the membership of a majority of our board of directors;

 

   

providing that directors may be removed only for cause by the affirmative vote of the holders of at least 75% of the voting power of our outstanding common stock; provided that so long as investment funds and entities affiliated with either Warburg Pincus or GTCR, collectively, hold at least 50% of the outstanding shares of our common stock, a director designated by investment funds and entities affiliated with either Warburg Pincus or GTCR, respectively, may be removed with or without cause by the affirmative vote of the holders of at least a majority of the votes that all the stockholders would be entitled to cast in any annual election of directors or class of directors and with the consent of Warburg Pincus or GTCR, respectively;

 

   

limiting the determination of the number of directors on our board of directors and the filling of vacancies or newly created seats on the board to our board of directors then in office; provided that for so long as investment funds and entities affiliated with either Warburg Pincus or GTCR have the right to designate at least one director for election to our board of directors, (i) any vacancies will be filled in accordance with the designation provisions set forth in the Stockholders’ Agreement and (ii) the number of directors shall not exceed eleven without the consent of Warburg Pincus or GTCR;

 

   

advance notice requirements applicable to stockholders for matters to be brought before a meeting of stockholders and requirements as to the form and content of a stockholders’ notice; provided that no advance notice shall be required for nominations of candidates for election to our board of directors pursuant to the Stockholders’ Agreement;

 

   

requiring the affirmative vote of at least 66 2/3% of the voting power of our outstanding common stock to amend certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws; provided that so long as investment funds and entities affiliated with either Warburg Pincus or GTCR, collectively, hold at least a majority of our outstanding capital stock, only a majority stockholder vote requirement would apply to such matters;

 

   

providing that for so long as investment funds and entities affiliated with either Warburg Pincus or GTCR have the right (individually) to designate at least three directors for election to our board of directors, certain board approvals, including amendments to our amended and restated certificate of incorporation or amended and restated bylaws and certain specified corporate transactions, including certain acquisitions, mergers, other business combination transactions and dispositions, may be effected only with the affirmative vote of 75% of our board of directors, in addition to any other vote required by applicable law;

 

   

providing that for so long as investment funds and entities affiliated with Warburg Pincus have the right to designate at least one director for election to our board of directors and for so long as investment funds and entities affiliated with GTCR have the right to designate one director for election to our board of directors, in each case, a quorum of our board of directors (and committees of the board of directors on which a director designated by Warburg Pincus or GTCR will serve) will not exist without at least one director designee of each of Warburg Pincus and GTCR present at such meeting; provided that if a meeting of our board of directors (or a committee of the board of directors) fails to achieve a quorum due to the absence of a director designee of Warburg Pincus or GTCR, as applicable, the presence of a director designee of Warburg Pincus or GTCR, as applicable, will not be required in order for a quorum to exist at the next duly noticed meeting of our board of directors (or a committee thereof);

 

   

the right to issue blank check preferred stock without stockholder approval, which could be used to dilute the stock ownership of a potential hostile acquirer or adopt a stockholder rights plan;

 

51


Table of Contents
   

a requirement that our stockholders may only take action at annual or special meetings of our stockholders and may not act by written consent; provided that, for so long as investment funds and entities affiliated with either Warburg Pincus or GTCR, collectively, beneficially own a majority of our outstanding capital stock, a meeting and vote of stockholders may be dispensed with, and the action may be taken without prior notice and without such meeting and vote if a written consent is signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at the meeting of stockholders;

 

   

limiting the ability of stockholders to call and bring business before special meetings; provided that for so long as investment funds and entities affiliated with either Warburg Pincus or GTCR, collectively, beneficially own a majority of our outstanding capital stock, special meetings of our stockholders may be called by the affirmative vote of the holders of a majority of our outstanding voting stock; and

 

   

limiting the forum to Delaware or Federal Court for certain litigation against us.

In addition, our amended and restated certificate of incorporation will contain a provision that provides us with protections similar to Section 203 of the Delaware General Corporation Law (“DGCL”), and will prevent us from engaging in a business combination with a person (excluding the Sponsors and any of their respective direct or indirect transferees and any group as to which such persons are a party) who acquires at least 15% of our common stock for a period of three years from the date such person acquired such common stock, unless board or shareholder approval is obtained prior to the acquisition. See “Description of Capital Stock—Anti-Takeover Effects of Provisions of Our Amended and Restated Certificate of Incorporation, Our Amended and Restated Bylaws and Delaware Law.”

These provisions might discourage, delay or prevent a change in control of our company or a change in our management. For example, because investment funds and entities affiliated with either Warburg Pincus or GTCR together will own a majority of the voting power of our common stock upon the completion of this offering, they could prevent a third party from acquiring us, even if the third party’s offer may be considered beneficial by many of our stockholders. The existence of these provisions could adversely affect the voting power of holders of common stock and limit the price that investors might be willing to pay in the future for shares of our common stock.

Our amended and restated certificate of incorporation will designate specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders’ abilities to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.

Our amended and restated certificate of incorporation will provide that, unless we consent in writing to the selection of an alternative forum, the sole and exclusive forum, to the fullest extent permitted by law, for (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers or other employees or stockholders to us or our stockholders, (3) any action asserting a claim against us or any of our directors or officers or other employees or stockholders arising pursuant to, any action to interpret, apply, enforce any right, obligation or remedy under, any provision of the DGCL our amended and restated certificate of incorporation or amended and restated bylaws, (4) any action asserting a claim that is governed by the internal affairs doctrine, or (5) any other action asserting an “internal corporate claim” under the DGCL shall be the Court of Chancery of the State of Delaware (or any state or federal court located within the State of Delaware if the Court of Chancery does not have jurisdiction) (the “Delaware Forum Provision”). Notwithstanding the foregoing, our amended and restated certificate of incorporation will provide that the Delaware Forum Provision will not apply to suits brought to enforce a duty or liability created by the Exchange Act. Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Our amended and restated certificate of incorporation will further provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act (the “Federal Forum Provision”).

 

52


Table of Contents

The Delaware Forum Provision and the Federal Forum Provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. Alternatively, if a court were to find the Delaware Forum Provision or the Federal Forum Provision to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, financial condition or results of operations. Any person or entity purchasing or otherwise acquiring any interest in our shares of capital stock shall be deemed to have notice of and consented the Delaware Forum Provision and the Federal Forum Provision, but will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.

We do not anticipate paying any dividends on our common stock in the foreseeable future, and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock.

We do not expect to declare or pay dividends on our common stock in the foreseeable future. We currently expect to use any cash flow generated by operations to pay for our operations, repay existing indebtedness and grow our business. Any decisions to declare and pay dividends in the future will be made at the discretion of our board of directors and will depend on, among other things, our results of operations, financial condition, cash requirements, contractual restrictions, restrictions imposed by applicable law and other factors that our board of directors may deem relevant. Our ability to pay dividends on our common stock is limited by the terms of the Senior Secured Credit Facilities and the First Lien Notes and Second Lien Notes. As a result, capital appreciation, if any, of our common stock will be the sole source of potential gain for the foreseeable future, and you will have to sell some or all of your common stock to generate cash flow from your investment. See “Dividend Policy.”

 

53


Table of Contents

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Some of the statements made under the headings “Summary,” “Business” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the financial statements and elsewhere in this prospectus contains forward-looking statements that reflect our plans, beliefs, expectations and current views with respect to, among other things, future events and financial performance. Forward-looking statements are often characterized by the use of words such as “believes,” “estimates,” “expects,” “projects,” “may,” “intends,” “plans” or “anticipates,” or by discussions of strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause our actual results, performance or achievements, or industry results, to differ materially from historical results or any future results, performance or achievements expressed, suggested or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to:

 

   

any disruption in the availability of, or increases in the price of, EO, Co-60 or our other direct materials, services and supplies, including as a result of current geopolitical instability arising from U.S. relations with Russia and related sanctions;

 

   

adverse changes in industry trends;

 

   

adverse changes in environmental, health and safety regulations;

 

   

accidents resulting from the safety risks associated with the use and disposal of potentially hazardous materials such as EO and Co-60;

 

   

accidents resulting from the safety risks associated with the transportation of potentially hazardous materials such as EO and Co-60;

 

   

liability claims relating to health risks associated with the use of EO and Co-60;

 

   

current and future legal proceedings;

 

   

the intensity of competition we face;

 

   

any market changes that impact our long-term supply contracts with variable price clauses;

 

   

allegations of our failure to properly perform our services and any potential product liability claims, recalls, penalties and reputational harm;

 

   

the regulatory requirements to which we are subject, and any failures to receive or maintain, or delays in receiving, required clearance or approvals;

 

   

business continuity hazards and other risks associated with our operations, including our reliance on the use and sale of products and services from a single location;

 

   

the impact of the COVID-19 pandemic;

 

   

our ability to increase capacity at existing facilities and build new facilities in a timely and cost-effective manner;

 

   

our ability to renew the long-term leases for our facilities at the end of their terms;

 

   

the risks of doing business internationally;

 

   

instability in global and regional economic and political conditions;

 

   

our failure to retain key personnel and attract talent;

 

   

the significant regulatory oversight to which our import and export operations are subject, and any failure to comply with applicable regulations;

 

   

any cyber security breaches and data leaks as a result of our dependence on information technology systems;

 

54


Table of Contents
   

the risks of pursuing strategic transactions, including acquisitions, and our ability to find suitable acquisition targets or integrate strategic acquisitions successfully into our business;

 

   

our ability to implement effective internal controls over financial reporting;

 

   

our reliance on intellectual property to maintain our competitive position and the risk of claims from third parties that we infringe or misappropriate their intellectual property rights;

 

   

the data privacy and security laws and regulations to which we are subject, and any ineffective compliance efforts with such laws and regulations;

 

   

our ability to maintain profitability in the future;

 

   

impairment charges on our goodwill and other intangible assets with indefinite lives;

 

   

unionization efforts and labor regulations in certain countries in which we operate;

 

   

the variety of laws involving the cannabis industry to which we are subject, and any failure to comply with those laws;

 

   

the risk of government or private civil antitrust actions;

 

   

adverse changes to our tax positions in U.S. or non-U.S. jurisdictions, the interpretation and application of recent U.S. tax legislation or other changes in U.S. or non-U.S. taxation of our operations;

 

   

our substantial leverage could adversely affect our ability to raise additional capital, limit our ability to react to changes in the economy or our industry and prevent us from meeting our obligations under our existing and future indebtedness;

 

   

our ability to generate sufficient cash flows or access sufficient additional capital to meet our debt obligations or to fund our other liquidity needs; and

 

   

the other risks described in the “Risk Factors” section of this prospectus.

These statements are based on current plans, estimates and projections, and therefore you should not place undue reliance on them. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them publicly in light of new information or future events, except as required by law. The inclusion of this forward-looking information should not be regarded as a representation by us, the Sponsors, the underwriters or any other person that the future plans, estimates or expectations contemplated by us will be achieved.

You should carefully consider the “Risk Factors” and subsequent public statements, or reports filed with or furnished to the SEC, before making any investment decision with respect to our securities. If any of these trends, risks or uncertainties actually occurs or continues, our business, financial condition or operating results could be materially adversely affected, the trading prices of our securities could decline and you could lose all or part of your investment. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by this cautionary statement.

 

55


Table of Contents

USE OF PROCEEDS

We estimate that our net proceeds from the sale of 46,600,000 shares of common stock offered by us will be approximately $949.3 million or approximately $1,091.7 million if the underwriters exercise their option to purchase additional shares in full (at an assumed initial public offering price of $21.50 per share of common stock, the midpoint of the estimated offering price range set forth on the cover page of this prospectus), after deducting estimated underwriting discounts and commissions.

We intend to use a portion of the net proceeds of this offering to (i) redeem all of the outstanding aggregate principal amount of the Second Lien Notes at the applicable redemption premium, plus accrued and unpaid interest to, but excluding, the date of redemption and (ii) repurchase 1,669,122 shares of our common stock (based on an assumed initial public offering price of $21.50, the midpoint of the estimated offering price range set forth on the cover page of this prospectus) from certain of our executive officers at a purchase price per share equal to the initial public offering price per share of our common stock less the underwriting discounts and commissions payable thereon (the “repurchase”). See “Certain Relationships and Related Party Transactions—Transactions With Certain of Our Executive Officers.” We plan to use the balance of the net proceeds of this offering to repay a portion of the outstanding indebtedness under our Term Loan. Pending use of the proceeds as described above, we may invest the proceeds in short-term, interest bearing, investment-grade securities.

As of September 30, 2020, $770.0 million of the Second Lien Notes was outstanding and borrowings under the Term Loan were $2,109.4 million. The Second Lien Notes mature on December 13, 2027 and bear interest at a rate equal to LIBOR subject to a 1.00% floor plus 8.00% per annum. The Term Loan matures on December 13, 2026, and as of September 30, 2020, the weighted average interest rate on borrowings under the Term Loan was 5.50%. The Second Lien Notes were issued and the Term Loan was originally entered into by SHH on December 13, 2019. The proceeds from the Second Lien Notes and the Term Loan were used to refinance $2,565.6 million of existing debt and to fund the payment of a $295.6 million distribution to Topco Parent. See “Description of Certain Indebtedness.”

Affiliates of Goldman Sachs & Co. LLC, an underwriter in this offering, hold approximately $420 million aggregate principal amount of the Second Lien Notes, all of which will be redeemed at the applicable redemption premium, plus accrued and unpaid interest to, but excluding the date of redemption, as described above. In addition, affiliates of Goldman Sachs & Co. LLC and certain of the other underwriters and/or certain of their affiliates are lenders, and/or act as agents or arrangers, under our Senior Secured Credit Facilities, and as a result, will receive a portion of the net proceeds from this offering. For more information, see “Underwriting (Conflicts of Interest).”

Each $1.00 increase or decrease in the assumed initial public offering price of $21.50 per share, which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus, would increase or decrease the net proceeds to us from this offering by approximately $44.2 million, assuming no change in the assumed number of shares offered by us and after deducting the estimated underwriting discounts and commissions. Each increase or decrease of 1.0 million in the number of shares offered by us would increase or decrease the net proceeds to us from this offering by approximately $20.4 million, assuming no change in the assumed initial public offering price and after deducting the estimated underwriting discounts and commissions.

To the extent we raise more proceeds in this offering than currently estimated, we intend to repay additional indebtedness under our Term Loan or use the balance for working capital or other general corporate purposes. To the extent we raise less proceeds in this offering than currently estimated, we will reduce the amount of indebtedness we repay.

 

56


Table of Contents

DIVIDEND POLICY

We do not currently expect to pay any dividends on our common stock. Instead, we intend to use any future earnings for the operation and growth of our business and the repayment of indebtedness.

Future cash dividends, if any, will be at the discretion of our board of directors and will depend upon, among other things, our financial condition, earnings, capital requirements, level of indebtedness, statutory and contractual restrictions applicable to the payment of dividends and other considerations that our board of directors deems relevant. The timing and amount of future dividend payments will be at the discretion of our board of directors.

Because we are a holding company and have no direct operations, we will only be able to pay dividends from our available cash on hand and any funds we receive from our subsidiaries. The agreements governing our existing indebtedness contain negative covenants that limit, among other things, our ability to pay cash dividends on our common stock, and the terms of any future loan agreement into which we may enter or any additional debt securities we may issue are likely to contain similar restrictions on the payment of dividends. In addition, Delaware law may impose requirements that may restrict our ability to pay dividends. See “Description of Certain Indebtedness” and “Risk Factors—Risks Related to this Offering and Ownership of Our Common Stock—We do not anticipate paying any dividends on our common stock in the foreseeable future, and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock.”

In 2019, we paid dividends to Topco Parent in the aggregate amount of $691.2 million. We do not currently intend to declare or pay any similar special dividends in the foreseeable future.

For a discussion of the application of withholding taxes on dividends, see “Material U.S. Federal Income Tax Considerations for Non-U.S. Holders.”

 

57


Table of Contents

CAPITALIZATION

The following table sets forth our cash and cash equivalents and our capitalization as of September 30, 2020:

 

   

on an actual basis;

 

   

on a pro forma as adjusted basis to reflect:

 

   

share-based compensation expense of $4.0 million, net of tax, associated with Class B-2 Units that we will recognize upon the listing and public trading of our common stock, reflected as a $4.9 million increase to additional paid-in capital with an offsetting $4.0 million (net of tax) increase to retained deficit;

 

   

the sale of 46,600,000 shares of our common stock in this offering at an assumed initial public offering price of $ 21.50 per share (the midpoint of the estimated offering price range on the cover page of this prospectus), after deducting estimated underwriting discounts and commissions, and the payment of approximately $4.1 million of incremental offering expenses; and

 

   

the application of the net proceeds from this offering to (i) repay $899.9 million of our outstanding indebtedness under our Second Lien Notes and our Term Loan, and reflect a write-off of associated unamortized debt issuance costs and debt discounts, (ii) pay the estimated redemption premium of $15.4 million on our Second Lien Notes, which is reflected as a net of tax adjustment of $11.7 million to retained earnings, and (iii) to repurchase 1,669,122 shares of common stock (and as otherwise described under the heading “Use of Proceeds”).

You should read the following table in conjunction with the sections titled “Use of Proceeds,” “Selected Consolidated Financial Information,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and related notes included elsewhere in this prospectus.

 

     As of September 30, 2020  
     Actual      Pro Forma
As Adjusted
 
     (In thousands)  

Cash and cash equivalents

   $ 108,276      $ 104,122  
  

 

 

    

 

 

 

Long-term debt, including current portion:

     

Revolving credit facility(a)

     —          —    

Term Loan, due 2026

     2,109,400        1,979,500  

Second Lien Notes, due 2027

     770,000        —    

First Lien Notes, due 2026

     100,000        100,000  

Other long-term debt

     450        450  

Unamortized debt issuance costs and debt discounts

     (69,870      (44,573
  

 

 

    

 

 

 

Total debt

   $ 2,909,980      $ 2,035,377  

Stockholders’ equity:

     

Common stock, with $0.01 par value per share, 232,400 shares authorized, 232,400 shares issued and outstanding, actual; 1,200,000 shares authorized, 279,000 shares issued and 277,331 shares outstanding, pro forma as adjusted;

     2,324        2,790  

Treasury shares - at cost (0 actual; 1,669 shares, pro forma as adjusted)

     —          (34,000

Additional paid-in capital

     1,695        955,474  

Retained earnings (deficit)

     (543,124      (561,941

Accumulated other comprehensive loss

     (124,753      (124,753
  

 

 

    

 

 

 

Total equity (deficit) attributable to the company

     (663,858      237,570  
  

 

 

    

 

 

 

Noncontrolling interests

     1,857        1,857  
  

 

 

    

 

 

 

Total equity (deficit)

     (662,001      239,427  
  

 

 

    

 

 

 

Total capitalization

   $ 2,247,979      $ 2,274,804  
  

 

 

    

 

 

 

 

Numbers in table may not foot, due to rounding.

(a)

See “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources.”

 

58


Table of Contents

The pro forma as adjusted information is illustrative only and will change based on the actual initial public offering price and other final terms of this offering. To the extent we raise more proceeds in this offering than currently estimated, we will repay additional amounts of our indebtedness. To the extent we raise less proceeds in this offering than currently estimated, we will reduce the amount of indebtedness we repay. Each $1.00 increase or decrease in the assumed initial public offering price of $21.50 per share, which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus, would decrease or increase our long-term debt by $44.2 million, increase or decrease our additional paid-in capital and total equity (deficit) by $44.2 million, assuming no change in the assumed number of shares offered by us, and after deducting the estimated underwriting discounts and commissions payable. Each increase or decrease of 1.0 million shares in the number of shares offered by us would decrease or increase our long-term debt by $20.4 million, increase or decrease our additional paid-in capital and total equity (deficit) by $20.4 million, assuming no change in the assumed initial public offering price and after deducting the estimated underwriting discounts and commissions payable.

 

59


Table of Contents

DILUTION

If you invest in our common stock in this offering, your ownership interest will be diluted to the extent of the difference between the initial public offering price per share of our common stock and the net tangible book value per share of our common stock after this offering. Dilution results from the fact that the per share offering price of the common stock is substantially in excess of the net tangible book value per share attributable to the existing equity holders. Net tangible book value per share represents the amount of stockholders’ equity excluding intangible assets, divided by the number of shares of common stock outstanding at that date.

Our historical net tangible book deficit as of September 30, 2020 was $(2,400.7) million, or approximately $(10.33) per share of common stock (assuming 232,400,200 shares of common stock outstanding).

The dilution per share to new investors represents the difference between the amount per share paid by purchasers of common stock in this offering and the net tangible book deficit per share of common stock immediately after completion of this offering. Investors participating in this offering will incur immediate, substantial dilution. After giving effect to our sale of 46,600,000 shares of common stock in this offering at an assumed initial public offering price of $21.50 per share, the midpoint of the estimated offering price range set forth on the cover page of this prospectus, and the repurchase, and after deducting the estimated underwriting discounts and commissions, our net tangible book deficit as of September 30, 2020 would have been approximately $(1,526.1) million or approximately $(5.47) per share. This amount represents an immediate decrease in net tangible book deficit of $4.86 per share to existing stockholders and an immediate dilution in net tangible book deficit of $26.97 per share to purchasers of common stock in this offering, as illustrated in the following table.

 

Assumed initial public offering price per share

      $ 21.50  

Net tangible book deficit per share as of September 30, 2020

   $ (10.33   

Increase in net tangible book deficit per share attributable to this offering

   $ 4.86     
  

 

 

    

Net tangible book deficit per share after this offering

      $ (5.47
     

 

 

 

Dilution in net tangible book deficit per share to investors in this offering

      $ 26.97  
     

 

 

 

This dilution information is illustrative only, and following the completion of this offering, will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. Each $1.00 increase or decrease in the assumed initial public offering price of $21.50 per share, which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus would increase or decrease, as applicable, our net tangible book deficit by approximately $44.2 million or approximately $0.16 per share, and the dilution in the net tangible book deficit per share to investors in this offering by approximately $0.84 per share, assuming no change in the assumed number of shares offered by us, and after deducting the estimated underwriting discounts and commissions. Each increase or decrease of 1.0 million shares in the number of shares offered by us would increase or decrease our net tangible book deficit per share after this offering by $20.4 million, and increase or decrease dilution per share to new investors by $0.09, assuming no change in the initial public offering price and after deducting the estimated underwriting discounts and commissions.

To the extent the underwriters’ option to purchase additional shares is exercised, there will be further dilution to new investors.

The following table summarizes, as of September 30, 2020, the differences between existing stockholders and new investors with respect to the number of shares of common stock purchased from us (without reflecting the repurchase), the total consideration paid and the average price per share of our common stock paid by existing stockholders. The calculation reflects the issuance of shares of our common stock in this offering at an assumed initial public offering price of $21.50 per share, the midpoint of the range set forth on the cover page of this prospectus, before deducting the estimated underwriting discounts and commissions.

 

60


Table of Contents
     Shares Purchased     Total Consideration     Average Price
Per Share
 
     Number      Percent     Amount      Percent        

Existing stockholders

     232,400,200        83   $ 833.0        45   $ 3.58  

New investors

     46,600,000        17   $ 1,001.9        55   $ 21.50  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

Total

     279,000,200        100   $ 1,834.9        100   $ 6.58  

If the underwriters exercise their option to purchase additional shares in full, the number of shares of common stock held by new investors will increase to 53,590,000, or 19 percent, of the total number of shares of our common stock outstanding after this offering.

The discussion and table above exclude the repurchase and assume no issuance of shares reserved for issuance under our equity incentive plans. Following the closing of this offering, there will be 27,900,000 shares of common stock reserved for future issuance under the 2020 Plan.

 

61


Table of Contents

SELECTED CONSOLIDATED FINANCIAL INFORMATION

The following tables present our selected historical consolidated financial and other data. The selected historical consolidated statements of operations data and statements of cash flows data for the years ended December 31, 2019 and 2018, and the selected historical balance sheet data as of December 31, 2019 and December 31, 2018, have been derived from our audited consolidated financial statements included elsewhere in this prospectus. The selected historical consolidated statements of operations data and statements of cash flows data for the nine months ended September 30, 2020 and 2019 and the selected historical consolidated balance sheet data as of September 30, 2020 have been derived from our unaudited interim condensed consolidated financial statements included elsewhere in this prospectus. Our unaudited interim condensed consolidated financial statements have been prepared on the same basis as our audited consolidated financial statements and, in the opinion of our management, reflect all adjustments, including normal recurring items, considered necessary for a fair presentation of this data.

The following selected consolidated financial data should be read in conjunction with the information contained in “Use of Proceeds,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the consolidated financial statements and related notes thereto included elsewhere in this prospectus. Our historical results are not necessarily indicative of our results in any future period and our results for any interim period are not necessarily indicative of results that may be expected for any full fiscal year.

 

Statement of Operations Data:   Year Ended December 31,     Nine Months Ended September 30,  
(in thousands, except per share amounts)           2019                     2018                     2020                     2019          

Revenues:

       

Service

  $ 673,037     $ 615,510     $ 524,025     $ 501,875  

Product

    105,290       130,639       77,288       82,967  
 

 

 

   

 

 

   

 

 

   

 

 

 

Total net revenues

    778,327       746,149       601,313       584,842  

Cost of revenues:

       

Service

    333,290       326,559       247,386       248,406  

Product

    49,606       62,338       30,932       38,226  
 

 

 

   

 

 

   

 

 

   

 

 

 

Total cost of revenues

    382,896       388,897       278,318       286,632  
 

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit

    395,431       357,252       322,995       298,210  

Operating expenses:

       

Selling, general and administrative expenses

    147,480       133,363       125,369       110,360  

Amortization of intangible assets

    58,562       57,975       43,989       43,942  

Impairment of long-lived assets

    5,792       34,981       —         5,781  

Impairment of GA-MURR intangible assets

    —         50,086       —         —    
 

 

 

   

 

 

   

 

 

   

 

 

 

Total operating expenses

    211,834       276,405       169,358       160,083  
 

 

 

   

 

 

   

 

 

   

 

 

 

Operating income

    183,597       80,847       153,637       138,127  

Interest expense, net

    157,729       143,326       167,142       114,478  

Loss on extinguishment of debt

    30,168       —         —         —    

Foreign exchange (gain) loss

    3,862       13,075       (5,370     8,444  

Gain on sale of Medical Isotopes business

    —         (95,910     —         —    

Other income, net

    (7,246     (3,866     (4,353     (4,746
 

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) before income taxes

    (916     24,222       (3,782     19,951  

Provision (benefit) for income taxes

    19,509       30,098       (9,677     12,630  
 

 

 

   

 

 

   

 

 

   

 

 

 

Net income (loss)

    (20,425     (5,876     5,895       7,321  
 

 

 

   

 

 

   

 

 

   

 

 

 

Less: Net income (loss) attributable to noncontrolling interests

    425       (6     832       271  
 

 

 

   

 

 

   

 

 

   

 

 

 

Net income (loss) attributable to the company

  $ (20,850   $ (5,870   $ 5,063     $ 7,050  
 

 

 

   

 

 

   

 

 

   

 

 

 

 

62


Table of Contents
Statement of Operations Data (continued):   Year Ended December 31,     Nine Months Ended September 30,  
(in thousands, except per share amounts)           2019                     2018                     2020                     2019          

Other comprehensive (loss) income, net of tax:

       

Pension and post-retirement benefits

  $ (12,126   $ 873     $ 700     $ (409

Interest rate swaps

    179       —         (179     509  

Foreign currency translation

    27,402       (67,917     (31,304     10,968  
 

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive income (loss)

    (4,970     (72,920     (24,888     18,389  
 

 

 

   

 

 

   

 

 

   

 

 

 

Less: comprehensive income attributable to noncontrolling interests

    310       (186     832       156  
 

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive income (loss) attributable to the company

  $ (5,280   $ (72,734   $ (25,720   $ 18,233  
 

 

 

   

 

 

   

 

 

   

 

 

 

Earnings (loss) per share:

       

Basic and Diluted

  $ (0.09   $ (0.03   $ 0.02     $ 0.03  
 

 

 

   

 

 

   

 

 

   

 

 

 

Weighted-average shares used to compute earnings (loss) per share:

       

Basic and Diluted

    232,400       232,400       232,400       232,400  
 

 

 

   

 

 

   

 

 

   

 

 

 

Pro forma as adjusted earnings (loss) per share (unaudited)(a)

       

Basic and Diluted

  $ 0.13       $ 0.20    
 

 

 

     

 

 

   

Pro forma as adjusted weighted-average shares used to compute earnings (loss) per share (unaudited)(b)

       

Basic and Diluted

    277,331         277,331    
 

 

 

     

 

 

   

Selected cash flow data:

       

Net cash provided by operating activities

  $ 149,041     $ 119,563     $ 98,740     $ 138,974  

Net cash provided by (used in) investing activities(c)

    (57,257     96,638       (139,920     (36,636

Net cash provided by (used in) financing activities

    (126,030     (191,857     83,961       (108,811

Other data:

       

Adjusted Net Income(d)

  $ 100,386     $ 75,315     $ 77,144     $ 87,897  

Adjusted EBITDA(d)

    379,932       340,637       306,797       285,457  

 

(a)

Pro forma as adjusted earnings (loss) per share for the year ended December 31, 2019 has been adjusted to reflect $56.1 million of lower interest expense, net of taxes, assuming the repayment of previously outstanding $425.0 million Senior PIK Toggle Notes, due 2021, $450.0 million Senior Notes, due 2023 and $14.1 million of principal amount outstanding of the Term Loan, due 2022, using a portion of the proceeds of this offering as if such indebtedness had been repaid as of the beginning of the period. Pro forma as adjusted earnings (loss) per share for the nine months ended September 30, 2020 has been adjusted to reflect $51.4 million of lower interest expense, net of taxes, assuming the repayment of the $770.0 million of principal amount outstanding of the Second Lien Notes, due 2027 and $129.9 million of principal amount outstanding of our Term Loan, due 2026, using a portion of the proceeds of this offering as if such indebtedness had been repaid as of the beginning of the period.

(b)

Pro forma as adjusted weighted-average shares has been adjusted to (i) include those shares of common stock to be issued in this offering necessary to pay down the debt referenced in footnote (a) above, and (ii) reflect the number of shares of common stock that will be repurchased in the repurchase, in each case, based on an assumed initial public offering price of $21.50 per share (the midpoint of the estimated offering price range set forth on the cover page of this prospectus), and after deducting the estimated underwriting discounts and commissions. Such shares are assumed to have been issued or repurchased, as applicable as of the beginning of the year ended December 31, 2019 and as of the beginning of the nine months ended September 30, 2020, respectively.

 

63


Table of Contents
(c)

Includes purchases of property, plant and equipment of $57,257, $72,613, $33,640 and $36,636, respectively (which includes Co-60 held at gamma irradiation sites).

(d)

Adjusted Net Income and Adjusted EBITDA are non-GAAP financial measures. For a definition of Adjusted Net Income and Adjusted EBITDA and a reconciliation to net income (loss), see “Summary Historical Consolidated Financial and Other Data—Non-GAAP Financial Measures.”

 

     As of
December 31,
     As of
September 30,
 
     2019      2018      2020  

Balance Sheet Data (as of period end):

        

(in thousands)

        

Cash and cash equivalents

   $ 62,863      $ 96,272      $ 108,276  

Working capital(a)

     128,364        169,488        163,810  

Total assets

     2,580,674        2,708,584        2,700,004  

Total long-term debt (including current portion, less unamortized debt issuance costs and debt discounts)

     2,817,204        2,204,906        2,909,980  

Total liabilities

     3,221,806        2,663,093        3,362,005  

Total equity (deficit) attributable to the company

     (642,574      44,359        (663,858

Noncontrolling interests

     1,442        1,132        1,857  

Total equity (deficit)

     (641,132      45,491        (662,001

 

(a)

Working capital represents current assets less current liabilities.

 

64


Table of Contents

MANAGEMENT’S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis in conjunction with our selected consolidated financial information and consolidated financial statements and related notes included elsewhere in this prospectus. This discussion and analysis contains forward-looking statements that are based on management’s current expectations, estimates and projections about our business and operations. Our actual results may differ materially from those currently anticipated and expressed in such forward-looking statements as a result of various factors, including the factors we describe in the section entitled “Risk Factors” and elsewhere in this prospectus.

OVERVIEW

We are a leading global provider of mission-critical sterilization and lab testing and advisory services to the medical device and pharmaceutical industries. We are driven by our mission: Safeguarding Global Health®. We provide end-to-end sterilization as well as microbiological and analytical lab testing and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients and consumers in the United States and around the world. Our customers include more than 40 of the top 50 medical device companies and eight of the top ten global pharmaceutical companies (based on revenue). Our services are an essential aspect of our customers’ manufacturing process and supply chains, helping to ensure sterilized medical products reach healthcare practitioners and patients. Most of these services are necessary for our customers to satisfy applicable government requirements. We give our customers confidence that their products meet regulatory, safety and effectiveness requirements. With a combined tenure across our businesses of nearly 200 years and our industry-recognized scientific and technological expertise, we help to ensure the safety of millions of patients and healthcare practitioners around the world every year. Across our 63 facilities worldwide, we have nearly 2,900 employees who are dedicated to safety and quality. We are a trusted partner to more than 5,800 customers in over 50 countries.

We serve our customers throughout their product lifecycles, from product design to manufacturing and delivery, helping to ensure the sterility, effectiveness and safety of their products for the end user. We operate across two core businesses: sterilization services and lab services. Each of our businesses has a longstanding record and is a leader in its respective market, supported and connected by our core capabilities including deep end market, regulatory, technical and logistics expertise. The combination of Sterigenics, our terminal sterilization business, and Nordion, our Co-60 supply business, makes us the only vertically integrated global gamma sterilization provider in the sterilization industry. This provides us with additional insights and allows us to better serve our customers. For financial reporting purposes, our sterilization services business consists of two reportable segments, Sterigenics and Nordion, and our lab services business consists of one reportable segment, Nelson Labs.

 

   

Sterilization Services (Sterigenics and Nordion):

 

   

Under our Sterigenics brand, we provide outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets. Terminal sterilization is the process of sterilizing a product in its final packaging. It is an essential, and often government-mandated, step in the manufacturing process of healthcare products before they are shipped to end-users. These products include medical protective barriers, including PPE, procedure kits and trays, implants, syringes, catheters, wound care products, laboratory products and pharmaceuticals. Our sterilization facilities are often strategically located near our healthcare customers’ manufacturing sites or distribution hubs, which is intended to decrease our customers’ transportation costs and help them optimize their supply chain and logistics. We offer our customers a complete range of outsourced terminal sterilization services, primarily using the three major sterilization technologies: gamma irradiation, EO processing and E-beam irradiation.

 

65


Table of Contents
   

Under our Nordion brand, we are the leading global provider of Co-60 and gamma irradiators, which are key components to the gamma sterilization process. Co-60 is a radioactive isotope that is needed by medical device manufacturers and sterilizers including Sterigenics. Co-60 decays and must be replaced over time to produce the desired level of irradiation. We have the most comprehensive access to nuclear power reactor operators around the world, which are able to produce Co-60. The capabilities that we provide to Nordion’s customers include handling and processing of Co-60, recycling of depleted sources and global logistics enabled by our licensed container fleet. We are integral to our customers’ operations due to highly coordinated and complex installation processes. In addition, under our Nordion brand, we are a leading supplier of Co-60 sources for stereotactic radiosurgery devices (such as the Gamma Knife®), which are used for certain oncology applications.

 

   

Lab Services (Nelson Labs):

 

   

Under our Nelson Labs brand, we are a global leader in outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. We provide our customers mission-critical lab testing services, which assess the product quality, effectiveness, patient safety and end-to-end sterility of products. These services are necessary for our customers’ regulatory approvals, product releases and ongoing product performance evaluations.

Microbiology testing services help to identify and measure the potential risks of microbes to a product and ensure that the quality of the products is maintained. Analytical chemistry lab testing is also a critical part of the pharmaceutical drug and medical device development and manufacturing process. This testing provides first-hand information as to the content, quality and safety of raw materials, intermediates and finished products. We also provide expert advisory services to aid customers in navigating the regulatory requirements applicable throughout the product lifecycle.

Nelson Labs serves over 3,800 customers across 13 facilities in the United States, Mexico, Asia and Europe. We have a comprehensive array of over 800 laboratory tests supporting our customers from initial product development and sterilization validation, through regulatory approval and ongoing product testing for sterility, safety and quality assurance. Our customers rely on our expertise in their industries to get their medical device and pharmaceutical products to market.

For the year ended December 31, 2019, we recorded net revenues of $778.3 million, net loss of $20.4 million, Adjusted Net Income of $100.4 million and Adjusted EBITDA of $379.9 million. In addition, for the nine months ended September 30, 2020, we recorded net revenues of $601.3 million, net income of $5.9 million, Adjusted Net Income of $77.1 million and Adjusted EBITDA of $306.8 million. For the definition of Adjusted Net Income and Adjusted EBITDA and the reconciliation of these measures from net income (loss), please see “Summary—Summary Historical Consolidated Financial and Other Data.” More than 90% of our sterilization services revenues in each of the year ended December 31, 2019 and the nine months ended September 30, 2020 were from customers under multi-year contracts.

TRENDS AND KEY FACTORS AFFECTING OUR RESULTS OF OPERATIONS

We expect that our performance and financial condition will continue to be driven by the key trends impacting our industries, customers and their end markets, as outlined in “Business—Industry Overview.” In addition, we believe the following trends and key factors have underpinned our recent operating results and may continue to affect our performance and financial condition in future periods.

 

   

Continue to drive organic growth. We drive organic growth through increasing utilization of our existing capacity and expanding our capacity and service offerings. In our Sterigenics business, we are

 

66


Table of Contents
 

investing in additional capacity at existing facilities and building new facilities. In our Nordion business, we are developing further supply relationships and expanding our capabilities to source Co-60 from additional reactors. In our Nelson Labs business, we are investing to expand our geographic reach, technical expertise and regulatory knowhow to stay ahead of the dynamic and increasingly stringent regulatory landscape in the healthcare industry, and drive growth in our advisory services offering.

 

   

Disciplined and strategic M&A activity. We have completed several strategic transactions that have expanded our addressable market and enhanced our global capabilities and footprint. In 2017, we acquired Toxikon Europe NV (now known as Nelson Laboratories Europe), a lab services business with extractable and leachables testing services. In 2018, we acquired Gibraltar Laboratories, Inc. (now known as Nelson Laboratories Fairfield, Inc.) (“Nelson Fairfield”), a provider of microbiological and analytical chemistry testing. In July 2020, we acquired Iotron Industries Canada, Inc., an E-beam processing services and equipment provider. We also completed the sale of our former Medical Isotopes business to a subsidiary of BWX Technologies, Inc. in 2018 to monetize a noncore asset, the proceeds from which we reinvested in our core businesses. We are continuing to pursue strategic acquisitions to grow our footprint and expand our capabilities.

 

   

Business optimization and cost savings initiatives. We have conducted several business optimization and cost savings projects in connection with the integrations of Nordion and Nelson Labs, the divestiture of the Medical Isotopes business and the creation of the Sotera Health “One Company” platform. These projects included consolidation of certain back office functions into a shared service model, optimization and harmonization of certain systems, insurance lines and benefits programs and rebranding the company under the name Sotera Health. Additionally, we have realigned our operating structure and made enhancements to certain processes. We also withdrew from the GA-MURR project in 2018. These projects have resulted in more efficient operations, working capital improvement and a more integrated and robust control and governance environment. In 2018, 2019 and through September 30, 2020, we incurred $8.8 million, $4.2 million and $2.5 million, respectively, in connection with implementing these projects. These measures have contributed in part to our 12.8% operating margin improvement and 3.2% of Adjusted EBITDA margin improvement in 2019, and our 1.9% operating margin improvement and 2.2% of Adjusted EBITDA margin improvement in the nine-month period ended September 30, 2020. For the definition of Adjusted EBITDA and the reconciliation of these measures from net income (loss), please see “Summary—Summary Historical Consolidated Financial and Other Data.”

 

   

Exit activities and litigation costs. We are currently the subject of a series of tort lawsuits alleging personal injury by purported exposure to EO emitted by our facility in Willowbrook, Illinois. We are also the subject of tort lawsuits alleging personal injury and property devaluation by purported exposure to EO emitted by our facility in Atlanta, Georgia. We deny these allegations and are vigorously defending against these claims. In addition, we have been involved in litigation with local officials related to claims of loss of neighboring property value and to resume operations at our Atlanta facility that had been temporarily suspended to facilitate enhancements to our EO emissions control equipment. We expect that our litigation costs will increase during the pendency of these cases, particularly as the per occurrence limit of our environmental liability insurance had been reached for the Willowbrook litigation in the second quarter of 2020 and as we prepare for the commencement of the first personal injury trials for the Willowbrook litigation currently scheduled to occur in 2021. See “Business—Legal Proceedings.” On September 30, 2019, we announced plans to exit our EO sterilization operations in Willowbrook and recorded a fixed asset impairment and have continued to incur certain transitional costs during the closure process including lease costs, payroll and utility expenses. For the nine months ended September 30, 2020 and the year ended December 31, 2019, we recorded costs of $3.0 million and $1.7 million, respectively, relating to the closure of our Willowbrook facility.

 

67


Table of Contents
   

Impacts of being a public company. Following this offering, as a public company we will incur significant expenses on an ongoing basis that we did not incur as a private company. Those costs include additional board fees and director and officer liability insurance expenses, as well as third-party and internal resources related to accounting, auditing, Sarbanes-Oxley Act compliance, legal, and investor and public relations expenses. These costs will generally be classified as Selling, General & Administrative (“SG&A”) expenses. Additionally, in connection with this offering, we expect to implement a long-term equity incentive plan to align our equity compensation program with public company plans and practices.

 

   

Borrowings, financing costs and financial leverage. In December 2019, Sotera Health Holdings, LLC (“SHH”) entered into new Senior Secured Credit Facilities (which consist of a senior secured first lien term loan and senior secured first lien revolving credit facility) and issued $770.0 million of senior secured second lien notes to refinance SHH’s previously outstanding term loan and the redemption of the senior notes issued by us and SHH. In July 2020, SHH also issued $100.0 million of senior secured first lien notes to finance, in part, the Iotron acquisition. In connection with the 2019 refinancing, we wrote-off $13.5 million of debt issuance and discount costs and recognized $14.6 million representing premiums paid in connection with the early extinguishment of the senior notes. We also recognized an additional $2.1 million of expense related to debt issuance and discount costs. As a result, the majority of our long-term debt, all of which is prepayable, is not due until 2026 or later. Going forward, absent any changes in interest rates, we expect a decrease in cash interest expense in future periods following this offering due to lower debt balances outstanding, as we intend to use a portion of the net proceeds of this offering to repay a portion of our outstanding indebtedness.

 

   

Impact of U.S. tax reform. On December 22, 2017, the Tax Cuts & Jobs Act (“TCJA”) was signed into law. The legislation significantly changed U.S. tax law by, among other things, lowering corporate income tax rates to 21%, implementing an inclusion item for global intangible low-taxed income (“GILTI”) and limiting interest expense deductions to 30% of U.S. adjusted taxable income. The CARES Act was signed into law on March 27, 2020 and temporarily increases the interest expense deduction limitation to 50% of U.S. adjusted taxable income for both 2019 and 2020. On July 23, 2020, 951A final regulations were published that exempt income subject to a high rate of foreign tax from inclusion under GILTI for tax years beginning after December 31, 2017.

We currently estimate a 2020 GILTI current tax expense of approximately $1.5 million, a reduction of $11.2 million from prior estimates as result of final 951A regulations. In 2019 and 2018, we recognized GILTI current tax expense of $10.3 million and $5.6 million (after giving effect to a $0.7 million increase as reported on the 2018 federal return), respectively. As a result of final 951A regulations, the 2019 and 2018 GILTI tax was reduced to $2.4 million and $0, respectively, and reflected as a discrete benefit in the third quarter of 2020.

Although the TCJA limits the deductibility of interest expense in any given year, any amounts not currently deductible may be carried forward indefinitely. At December 31, 2019 we had $41.5 million of deferred tax assets, of which $5.6 million had a valuation allowance, relating to interest expense from 2019 and prior years that was not deductible in the originating period. As a result of the increased limitation provided by the CARES Act, we reversed the $5.6 million valuation allowance for the period ended March 31, 2020 and recorded a reduction in our 2019 and 2020 current income tax liability of $9.1 million in each period. The reduction in Adjusted Taxable Income (“ATI”) realized as a result of the final 951A regulations resulted in a $36.2 million valuation allowance recorded in the quarter ended September 30, 2020. We do not expect to fully realize the benefit of interest expense incurred in future periods and therefore may recognize a valuation allowance on any related deferred tax assets generated in those future periods that will impact our annual effective income tax rate.

 

   

Foreign currency exchange rates. As a result of our global operations, we generate a significant portion of our revenue and incur a significant portion of our expenses in currencies other than the U.S. dollar. We translate the assets, liabilities, net revenues and expenses of all of our operations into U.S.

 

68


Table of Contents
 

dollars at applicable exchange rates, and therefore we experience gains and losses related to exchange rate fluctuations. See “—Quantitative and Qualitative Disclosures About Market Risk—Foreign Currency Risk.” From time to time, as and when we determine it is appropriate and advisable to do so, we may seek to mitigate the cash effect of exchange rate fluctuations through the use of derivative financial instruments.

 

   

Impact of COVID-19 pandemic. The global impact of the COVID-19 pandemic, including the governmental responses, has affected our operations beginning in the first quarter of 2020. There has been an increase in deferred elective procedures, which has negatively impacted demand for some of our products and services as a result of a decrease in the need for sterilized medical devices used in these procedures. Although our operations are considered “essential” in all locations where we operate, we have experienced, and may experience in the future, temporary facility closures while awaiting appropriate government approvals in certain jurisdictions or delays in delivering products or services to customers. We have experienced delayed deliveries, primarily in our Nordion business, at certain locations as a result of governmental travel restrictions enacted in response to the COVID-19 pandemic. The extent to which our operations will continue to be impacted by the pandemic will largely depend on future developments, which are highly uncertain and cannot be predicted.

COMPONENTS OF OUR RESULTS OF OPERATIONS

Net Revenues

Service revenues consist of revenue generated from contract sterilization and lab testing and advisory services within our Sterigenics and Nelson Labs segments, respectively. Service revenues also consist of Co-60 installation and disposal revenues and production irradiator refurbishments and installation services within our Nordion segment. Product revenues consist of revenues generated from sales of Co-60 radiation sources and production irradiators. Provisions for discounts, rebates to customers, and other adjustments are provided for as reductions in net revenues. Refunds, returns, warranties and other related obligations are not material to any of our business units, nor do we incur material incremental costs to secure customer contracts.

Cost of Revenues

Our cost of revenues consists primarily of direct materials, utilities, labor and related benefit costs, and depreciation and amortization. Although the cost of utilities and direct materials can fluctuate, the remaining components of cost of revenues are generally more stable. Direct material costs relating to service revenues primarily includes EO gas, nitrogen gas and Co-60. The physical decay of Co-60 assets is included within depreciation expense as a cost of revenue. Direct material costs relating to product revenues also include the costs associated with acquiring Co-60 in finished or semi-finished form, acquiring Co-59 in a form ready for insertion into reactors for conversion into Co-60, the reactor time and associated services to convert Co-59 into Co-60, and parts and equipment associated with building and maintaining production irradiators.

Operating Expenses

SG&A Expenses

SG&A primarily consists of compensation and benefits costs and general operating and administrative expenses, including professional service fees (which include finance and legal costs), travel and entertainment expenses, and other general and administrative expenses. Share-based compensation expense is also included in SG&A. At September 30, 2020, unvested awards have remaining unrecognized share-based compensation expense of $15.1 million, which consists of $10.2 million related to time vesting awards (Class B-1 Units) to be recognized over a weighted average period of 2.6 years and $4.9 million related to performance vesting awards (Class B-2 Units). We expect to recognize the expense associated with the performance vesting awards (Class B-2 Units) upon the listing and public trading of our common stock.

 

69


Table of Contents

Amortization of Intangible Assets

Amortization of intangible assets primarily consists of expense associated with customer relationship intangibles, the majority of which relate to the fair values attributed to these assets upon the recapitalization of the Company in connection with the acquisition by the Sponsors in 2015. These customer relationship intangibles were initially assigned a useful life of ten years and have a remaining useful life of approximately five years. These customer relationship intangible assets account for $49.1 million of our current annual amortization expense and are expected to be fully amortized in 2025. Amortization expense fluctuates when we have an acquisition, disposition, impairment charge, or as their useful lives expire. We expect intangible assets related to future acquisitions and the associated amortization expense will increase over time as we execute on our strategy to pursue acquisition targets that are complementary to our businesses.

Impairment

We review tangible and intangible assets for impairment on a regular basis. Impairment charges in 2018 represented charges associated with our withdrawal from the Nordion GA-MURR project (as described below) and the divestiture of the Medical Isotopes business. Impairment charges in 2019 were incurred primarily in connection with the closure of the Willowbrook facility.

Operating Income

Operating income represents gross profit, less SG&A, amortization of intangible assets and impairment charges.

Interest Expense, Net

Interest expense, net, represents interest paid or accruing on our outstanding indebtedness and the amortization of debt discount and debt issuance costs. Interest expense is affected by changes in average outstanding indebtedness (including capital lease obligations) and variable interest rates. We present interest expense net of interest income, which primarily consists of interest earned on cash on hand.

Other Income, Net

Other income, net primarily consists of changes in the fair value of the embedded derivatives in Nordion’s contracts, the net impact of pension related benefits and income related to deferred income on a lease associated with the divestiture of the Medical Isotopes business.

Provision (Benefit) for Income Taxes

Provision for income taxes consists primarily of income taxes in foreign jurisdictions and U.S. federal and state income taxes.

Net Income (Loss) Attributable to Noncontrolling Interests

We conduct our operations through our subsidiaries. As of December 31, 2019, our subsidiaries were wholly owned by us, except for outstanding noncontrolling interests of 15% and 33% at our two China subsidiaries, respectively. In addition, a 15% noncontrolling interest remains from the August 2018 acquisition of Nelson Fairfield. Pursuant to the terms of the transaction, we acquired 85% of the equity interests of Nelson Fairfield and are required to acquire the 15% noncontrolling interest within three years from the date of the acquisition. For accounting purposes, we consolidate the results of operations of these subsidiaries with our results of operations and reflect the noncontrolling interests of our two China subsidiaries on our consolidated statements of operations and comprehensive income (loss) as net income (loss) attributable to noncontrolling interests. Because the purchase obligation for the remaining 15% ownership of Nelson Fairfield is mandatory (valued at $13.6 million as of September 30, 2020), none of its earnings are allocated to noncontrolling interests.

 

70


Table of Contents

Constant Currency Sales Growth

“Constant currency” is a non-GAAP financial measure we use to assess performance excluding the impact of foreign currency exchange rate changes. Constant currency sales growth is calculated by translating prior year sales in local currency at the average exchange rates applicable for the current period. The translated results are then used to determine year-over-year percentage increases or decreases. We generally refer to such amounts calculated on a constant currency basis as excluding the impact of foreign currency exchange rates. These results should be considered in addition to, not as a substitute for, results reported in accordance with U.S. GAAP. Results on a constant currency basis, as we present them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with U.S. GAAP.

Adjusted Net Income and Adjusted EBITDA

We use Adjusted Net Income and Adjusted EBITDA, non-GAAP financial measures, as the principal measures of our operating performance. Management believes Adjusted Net Income and Adjusted EBITDA are useful because they allow management to more effectively evaluate our operating performance and compare the results of our operations from period to period without the impact of certain non-cash items and non-routine items that we do not expect to continue at the same level in the future and other items that are not core to our operations. We believe that these measures are useful to our investors because they provide a more complete understanding of the factors and trends affecting our business than could be obtained absent this disclosure. In addition, we believe Adjusted Net Income and Adjusted EBITDA will assist investors in making comparisons to our historical operating results and analyzing the underlying performance of our operations for the periods presented. Our management also uses Adjusted Net Income and Adjusted EBITDA in their financial analysis and operational decision-making and Adjusted EBITDA serves as the metric for attainment of our primary annual incentive program. Adjusted Net Income and Adjusted EBITDA may be calculated differently from, and therefore may not be comparable to, a similarly titled measure used by other companies.

For more information regarding our definition and calculation of Adjusted Net Income and Adjusted EBITDA, including information about its limitations as a tool for analysis, please see “Summary—Summary Historical Consolidated Financial and Other Data.”

Segment Income

Segment Income is the primary earnings measure we use to evaluate the performance of our reportable segments, as disclosed in the Segment and Geographic Information note to our consolidated financial statements included elsewhere in this prospectus. Costs associated with support functions that are not directly associated with one of the three reportable segments, such as corporate operating expenses for executive management, accounting, information technology, legal, human resources, treasury, corporate development, tax, purchasing, and marketing are allocated to the segments based on net revenue. Segment Income excludes certain items which are included in income (loss) before tax as determined in our consolidated statement of operations and comprehensive income (loss).

 

71


Table of Contents

CONSOLIDATED RESULTS OF OPERATIONS

Nine Months Ended September 30, 2020 as compared to Nine Months Ended September 30, 2019

The following table sets forth the components of our results of operations for the nine months ended September 30, 2020 and 2019.

 

(thousands of U.S. dollars)

   2020      2019      $ Change      % Change  

Total net revenues

   $ 601,313      $ 584,842      $ 16,471        2.8

Total cost of revenues

     278,318        286,632        (8,314      (2.9 )% 

Total operating expenses

     169,358        160,083        9,275        5.8

Operating income

     153,637        138,127        15,510        11.2

Net income

     5,895        7,321        (1,426      (19.4 )% 

Adjusted Net Income(1)

     77,144        87,897        (10,753      (12.2 )% 

Adjusted EBITDA(1)

     306,797        285,457        21,340        7.5
  

 

 

    

 

 

    

 

 

    

 

 

 

 

  (1)

Adjusted Net Income and Adjusted EBITDA are non-GAAP financial measures. For more information regarding our calculation of Adjusted Net Income and Adjusted EBITDA, including information about their limitations as tools for analysis and a reconciliation of net income, the most directly comparable financial measure calculated and presented in accordance with GAAP, to Adjusted Net Income and Adjusted EBITDA, please see “Summary—Summary Historical Consolidated Financial and Other Data.”

Total Net Revenues

The following table compares our revenues by type for the nine months ended September 30, 2020 to the nine months ended September 30, 2019.

 

(thousands of U.S. dollars)

   2020      2019      $ Change      % Change  

Service

   $ 524,025      $ 501,875      $ 22,150        4.4

Product

     77,288        82,967        (5,679      (6.8 %) 
  

 

 

    

 

 

    

 

 

    

 

 

 

Total net revenues

   $ 601,313      $ 584,842      $ 16,471        2.8
  

 

 

    

 

 

    

 

 

    

 

 

 

Net revenues were $601.3 million in the nine months ended September 30, 2020, an increase of $16.5 million, or 2.8%, as compared with the same period in the prior year. Excluding the impact of foreign currency exchange rates, net revenues in the nine months ended September 30, 2020 increased approximately 3.9% compared with the same period in the prior year.

Service revenues

Service revenues increased $22.1 million, or 4.4%, to $524.0 million for the nine months ended September 30, 2020 as compared to $501.9 million for the same period in the prior year. The increase in net service revenues reflected a $14.7 million favorable impact from pricing in our Sterigenics segment, $12.6 million of increased demand for services related primarily to personal protective equipment used to provide protection against COVID-19 in our Nelson Labs segment, and a $6.8 million increase due to organic volume growth in our Sterigenics segment. This was partially offset by a $7.0 million unfavorable impact due to the temporary suspension of operations at our Atlanta facility and the permanent closure of the Willowbrook facility and a $4.6 million unfavorable impact from foreign exchange.

Product revenues

Product revenues decreased $5.7 million, or 6.8%, to $77.3 million for the nine months ended September 30, 2020 as compared to $83.0 million for the same period in the prior year. The decrease was

 

72


Table of Contents

primarily a result of a $10.6 million decrease in volume relating to the deferral of medical use Co-60 sales due to COVID-19 and the scheduled timing of industrial use Co-60 harvest and customer deliveries, partly offset by the impact from favorable pricing of $3.5 million.

Total Cost of Revenues

The following table compares our cost of revenues by type for the nine months ended September 30, 2020 to the nine months ended September 30, 2019.

 

(thousands of U.S. dollars)

   2020      2019      $ Change      % Change  

Service

   $ 247,386      $ 248,406      $ (1,020      (0.4 %) 

Product

     30,932        38,226        (7,294      (19.1 %) 
  

 

 

    

 

 

    

 

 

    

 

 

 

Total cost of revenues

   $ 278,318      $ 286,632      $ (8,314      (2.9 %) 
  

 

 

    

 

 

    

 

 

    

 

 

 

Total cost of revenues accounted for approximately 46.3% and 49.0% of our consolidated net revenues for the nine months ended September 30, 2020 and 2019, respectively.

Cost of service revenues

Cost of service revenues decreased $1.0 million, or 0.4%, for the nine months ended September 30, 2020 as compared to the prior year period. The decrease in cost of service revenues was primarily attributable to the closure of the Willowbrook facility, representing a decrease of $9.2 million, partially offset by incremental costs to support the organic revenue growth across the global network.

Cost of product revenues

Cost of product revenues decreased $7.3 million, or 19.1%, for the nine months ended September 30, 2020 as compared to the prior year period. The decrease was primarily a result of reduced sales volumes of both medical-use Co-60 and industrial-use Co-60 as referenced above.

Operating Expenses

The following table compares our operating expenses for the nine months ended September 30, 2020 to the nine months ended September 30, 2019.

 

(thousands of U.S. dollars)

   2020      2019      $ Change      % Change  

Selling, general and administrative expenses

   $ 125,369      $ 110,360      $ 15,009        13.6

Amortization of intangible assets

     43,989        43,942        47        0.1

Impairment of long-lived assets

     —          5,781        (5,781      (100 %) 
  

 

 

    

 

 

    

 

 

    

 

 

 

Total operating expenses

   $ 169,358      $ 160,083      $ 9,275        5.8
  

 

 

    

 

 

    

 

 

    

 

 

 

Operating expenses accounted for approximately 28.2% and 27.4% of our consolidated net revenues for the nine months ended September 30, 2020 and 2019, respectively.

SG&A

SG&A increased $15.0 million, or 13.6%, for the nine months ended September 30, 2020 as compared to the prior year period. The increase was driven primarily by the following:

 

   

a $19.3 million increase in third party professional fees, including $17.6 million of legal expenses, associated with EO litigation; the majority of these expenses were recorded in the second and third quarters of 2020, as the per occurrence limit of our environmental liability insurance had been reached for the Willowbrook litigation in the second quarter of 2020;

 

73


Table of Contents
   

$2.4 million in costs directly associated with the COVID-19 pandemic in the current year, including donations to related charitable causes and special bonuses for front-line personnel working on-site during lockdown periods;

 

   

$2.3 million in professional fees associated with the July 2020 acquisition of Iotron Industries Canada, Inc.; and

 

   

a $1.8 million increase in professional fees associated with preparation for an initial public offering.

Partially offsetting the above increases was an $11.1 million decrease in share-based compensation expense, $10.0 million of which related to the Class C Performance and Time Vesting Units of Topco Parent, which vested in the third quarter of 2019 based on the achievement of the aggregate distributions to Class A unitholders and the approval of the board of managers of Topco Parent.

Amortization of intangible assets

Amortization of intangible assets was $44.0 million for the nine months ended September 30, 2020 or 0.1% greater than the prior year period. The change was insignificant and there were only two months of amortization on newly acquired intangible assets related to the Iotron acquisition.

Impairment of long-lived assets

In 2019, we recorded long-lived asset impairment expenses due to the closure of our Willowbrook facility citing the expiration of the primary Willowbrook facility lease and the unstable legislative and regulatory landscape in Illinois.

Interest Expense, Net

Interest expense, net increased $52.7 million, or 46.0%, for the nine months ended September 30, 2020 as compared to the prior year period. The increase was largely due to a higher outstanding debt balance as a direct result of the December 2019 refinancing, a $50.0 million borrowing on the revolver during the first quarter of 2020, which was subsequently repaid in the second quarter of 2020, and the issuance of $100.0 million of First Lien Notes in July 2020 to fund the Iotron acquisition. The weighted average interest rate was 6.45% and 6.15% at September 30, 2020 and 2019, respectively.

Foreign exchange (gain) loss

Foreign exchange (gain) loss increased $13.8 million to a gain of $5.4 million for the nine months ended September 30, 2020 as compared to a loss of $8.5 million in the prior year period. In the third quarter of 2020, we identified an immaterial error in previously issued financial statements as a result of incorrectly recording the foreign exchange (gain) loss on a U.S. dollar denominated loan between a U.S. subsidiary and European subsidiary. We reflected the correction of this immaterial error within these financial statements for the period ended September 30, 2020, the effect of which increased foreign exchange gain by $2.2 million. The remainder of the variance is primarily due to a 7.4% change in the U.S. dollar to Euro exchange rate between September 2019 to September 2020.

Other Income, Net

Other income, net was $4.4 million for the nine months ended September 30, 2020 and $4.7 million for the nine months ended September 30, 2019. The fluctuation was primarily driven by the change in the fair value of the embedded derivatives in Nordion’s contracts. For the nine months ended September 30, 2020, we recorded an unrealized loss on embedded derivatives of $0.6 million as compared to an unrealized gain on embedded derivatives of $0.2 million for the nine months ended September 30, 2019.

 

74


Table of Contents

Provision for Income Taxes

For the nine months ended September 30, 2020 we had an income tax benefit of $9.7 million, compared to tax expense of $12.6 million recorded in the prior year period. The change is driven primarily by the $24.7 million cumulative tax benefit realized in September 2020 as a result of final 951A regulations, partially offset by the $36.2 million valuation allowance.

Provision for income taxes for the nine months ended September 30, 2020 and 2019 differed from the statutory rate of 21% primarily due to the impact of GILTI (including final 951A regulations), changes on items that are not expected to have a future tax benefit, and the foreign rate differential.

See “Trends and Key Factors Affecting our Results of Operations” above for further information on the provision for income taxes.

Net Income, Adjusted Net Income and Adjusted EBITDA

Net income for the nine months ended September 30, 2020 was $5.9 million, as compared to a net income of $7.3 million for the nine months ended September 30, 2019. Adjusted Net Income was $77.1 million for the nine months ended September 30, 2020, as compared to $87.9 million for the nine months ended September 30, 2019, due to the factors described above. Adjusted EBITDA was $306.8 million for the nine months ended September 30, 2020, as compared to $285.5 million for the nine months ended September 30, 2019, due to the factors described above. Please see “Summary—Summary Historical Consolidated Financial and Other Data” for a reconciliation of Adjusted EBITDA to its most directly comparable financial measure calculated and presented in accordance with GAAP.

Fiscal 2019 as compared to Fiscal 2018

The following table sets forth the components of our results of operations for the years ended December 31, 2019 and 2018.

 

(thousands of U.S. dollars)

   2019      2018      $ Change      % Change  

Total net revenues

   $ 778,327      $ 746,149      $ 32,178        4.3

Total cost of revenues

     382,896        388,897        (6,001      1.5

Total operating expenses

     211,834        276,405        (64,571      (23.4 %) 

Operating income

     183,597        80,847        102,750        127.1

Net loss

     (20,425      (5,876      (14,549      (247.6 %) 

Adjusted Net Income(1)

     100,386        75,315        25,071        33.3

Adjusted EBITDA(1)

     379,932        340,637        39,295        11.5
  

 

 

    

 

 

    

 

 

    

 

 

 

 

  (1)

Adjusted Net Income and Adjusted EBITDA are non-GAAP financial measures. For more information regarding our calculation of Adjusted Net Income and Adjusted EBITDA, including information about its limitations as a tool for analysis and a reconciliation of net loss, the most directly comparable financial measure calculated and presented in accordance with GAAP, to Adjusted Net Income and Adjusted EBITDA, please see “Summary—Summary Historical Consolidated Financial and Other Data.”

 

75


Table of Contents

Total Net Revenues

The following table compares our revenues by type for the year ended December 31, 2019 to the year ended December 31, 2018. Results from the Nelson Fairfield acquisition are included in the Nelson Labs segment for the post-acquisition periods beginning August 7, 2018. The Medical Isotopes business was included in 2018 through the date of its divestiture in July 2018.

 

(thousands of U.S. dollars)

Net revenues for the year ended December 31,

   2019      2018      $ Change      % Change  

Service

   $ 673,037      $ 615,510      $ 57,527        9.3

Product

     105,290        130,639        (25,349      (19.4 )% 
  

 

 

    

 

 

    

 

 

    

 

 

 

Total net revenues

   $ 778,327      $ 746,149      $ 32,178        4.3
  

 

 

    

 

 

    

 

 

    

 

 

 

Net revenues were $778.3 million in the year ended December 31, 2019, an increase of $32.2 million, or 4.3%, as compared with the prior year. Excluding the impact of foreign currency exchange rates, net revenues in the year ended December 31, 2019 increased approximately 5.9% compared with the same period in 2018.

Service revenues

Service revenues increased $57.5 million, or 9.3%, to $673.0 million in 2019 as compared to $615.5 million in 2018. The increase in net service revenues was primarily driven by organic volume growth of $27.9 million and $5.0 million in the Sterigenics and Nelson Labs segments, respectively, $16.5 million and $6.5 million favorable impacts related to pricing in the Sterigenics and Nelson Labs segments, respectively, and an $11.0 million increase from the impact of the Gibraltar Laboratories acquisition. These factors were partially offset by a $14.4 million decrease associated with the closure of the Willowbrook facility.

Product revenues

Product revenues decreased $25.3 million, or 19.4%, to $105.3 million in 2019 as compared to $130.6 million in 2018. The decrease in product revenues was primarily attributable to the divestiture of the Medical Isotopes business in July 2018, which resulted in a decrease in revenues of $25.4 million.

Total Cost of Revenues

The following table compares our cost of revenues by type for the year ended December 31, 2019 to the year ended December 31, 2018.

 

(thousands of U.S. dollars)

Cost of revenues for the year ended December 31,

   2019      2018      $ Change      % Change  

Service

   $ 333,290      $ 326,559      $ 6,731        2.1

Product

     49,606        62,338        (12,732      (20.4 )% 
  

 

 

    

 

 

    

 

 

    

 

 

 

Total cost of revenues

   $ 382,896      $ 388,897      $ (6,001      (1.5 )% 
  

 

 

    

 

 

    

 

 

    

 

 

 

Total cost of revenues accounted for approximately 49.2% and 52.1% of our consolidated net revenues for the years ended December 31, 2019 and 2018, respectively.

Cost of service revenues

Cost of service revenues increased $6.7 million, or 2.1%, for the year ended December 31, 2019 as compared to the prior year. The increase was primarily attributable to increased labor and other variable costs associated with higher sterilization processing and testing volumes referenced above. These increases were partially offset by a $2.2 million reduction in costs as a result of the Willowbrook facility closure.

 

76


Table of Contents

Cost of product revenues

Cost of product revenues decreased $12.7 million, or 20.4%, for the year ended December 31, 2019 as compared to the prior year. The decrease was primarily attributable to the divestiture of the Medical Isotopes business in July 2018.

Operating Expenses

The following table compares our operating expenses for the year ended December 31, 2019 to the year ended December 31, 2018:

 

(thousands of U.S. dollars)

Operating expenses for the Year Ended December 31,

   2019      2018      $ Change      % Change  

Selling, general and administrative expenses

   $ 147,480      $ 133,363      $ 14,117        10.6

Amortization of intangible assets

     58,562        57,975        587        1.0

Impairment of long-lived assets

     5,792        34,981        (29,189      (83.4 %) 

Impairment of GA-MURR intangible assets

     —          50,086        (50,086      (100 %) 
  

 

 

    

 

 

    

 

 

    

 

 

 

Total operating expenses

   $ 211,834      $ 276,405      $ (64,571      (23.4 %) 
  

 

 

    

 

 

    

 

 

    

 

 

 

Operating expenses accounted for approximately 27.2% and 37.0% of our consolidated net revenues for the year ended December 31, 2019 and 2018, respectively.

SG&A

SG&A increased $14.1 million, or 10.6%, for the year ended December 31, 2019 as compared to the prior year. The increase was driven primarily by the following:

 

   

a $10.0 million increase in share-based compensation expense related to the Class C Performance and Time Vesting Units, which vested in the third quarter of 2019 based on the achievement of the aggregate distributions to the A Unitholder partners and the approval of the Board of Sotera Health Topco Parent, L.P. for accelerated vesting;

 

   

an $8.6 million increase in third party professional fees, including $6.5 million of legal expenses, associated with EO litigation; and

 

   

$2.0 million of costs associated with preparation for an initial public offering.

The increase was partially offset by the following items which were expensed in 2018 but did not recur in 2019:

 

   

a $4.3 million settlement with a vendor in our sterilization services; and

 

   

$2.4 million of contract termination and exits costs related to GA-MURR (as described below).

Asset impairments

In 2019, we recorded long-lived asset impairment expenses due to the closure of our Willowbrook facility citing the unstable legislative and regulatory landscape in Illinois, as well as the expiration of the primary Willowbrook facility lease.

In 2018, we recorded aggregate long-lived asset and intangible asset impairments expense of $35.0 million and $50.1 million, respectively, primarily due to the withdrawal from the GA-MURR project in early April 2018, which resulted in impairment of the associated long-lived assets (approximately $32.7 million) and intangible asset related to our MURR supply agreement (approximately $50.1 million). As a result of a strategic review of the Medical Isotopes business and other factors, we withdrew from the GA-MURR project which was intended to replace our supply of Molybdenum-99 (“Mo-99”) utilized in our former Medical Isotopes business.

 

77


Table of Contents

Amortization of intangible assets

Amortization of intangible assets was $58.6 million for the year ended December 31, 2019, or 1.0% above the prior year. The change was insignificant as there were no significant changes to our finite-lived intangible assets.

Interest Expense, Net

Interest expense, net increased $14.4 million, or 10.0%, for the year ended December 31, 2019 as compared to the prior year. The increase was largely due to an increase in the outstanding amount of the Term Loan (due to a $320.0 million incremental borrowing in August 2019), the debt refinancing in December 2019 and an increase in the LIBOR rate in 2019. The weighted average interest rate was 6.08% and 5.92% at December 31, 2019 and 2018, respectively.

Other Income, Net

Other income, net was $7.2 million for the year ended December 31, 2019 and $3.9 million for the year ended December 31, 2018. The fluctuation was primarily driven by changes in the fair value of the embedded derivatives in Nordion’s contracts. We recorded an unrealized gain on embedded derivatives of $1.2 million for the year ended December 31, 2019 as compared to an unrealized loss on embedded derivatives of $1.0 million for the year ended December 31, 2018. Also, we recognized an additional $0.9 million of income associated with deferred income on a lease for the year ended December 31, 2019 versus the year ended December 31, 2018. The prior year only included approximately a half a year’s income compared to a full year in 2019.

Provision for Income Taxes

Provision for income tax expense decreased $10.6 million, or 35.2%, to $19.5 million for the year ended December 31, 2019 as compared to $30.1 million in the prior year primarily due to the income tax expense recognized on the sale of assets related to the Medical Isotopes business during 2018.

Provision for income taxes for the year ended December 31, 2019 differed from the statutory rate of 21% primarily due to the foreign rate differential, the partial valuation allowance against our excess interest expense carryforward balance, GILTI expense referenced above and non-deductible expenses. Provision for income taxes for the year ended December 31, 2018 differed from the statutory rate of 21% primarily due to the foreign rate differential, GILTI expense referenced above, an increase to our tax liability associated with the TCJA toll charge on unremitted foreign earnings, and the impact of the TCJA tax rate reduction on our deferred tax balances.

Net Loss, Adjusted Net Income and Adjusted EBITDA

Net loss for the year ended December 31, 2019 was $20.4 million, as compared to $5.9 million for the year ended December 31, 2018. Adjusted Net Income was $100.4 million for the year ended December 31, 2019, as compared to $75.3 million for the year ended December 31, 2018, due to the factors described above. Adjusted EBITDA was $379.9 million for the year ended December 31, 2019, as compared to $340.6 million for the year ended December 31, 2018, due to the factors described above. Please see “Summary—Summary Historical Consolidated Financial and Other Data” for a reconciliation of Adjusted Net Income and Adjusted EBITDA to their most directly comparable financial measure calculated and presented in accordance with GAAP.

SEGMENT RESULTS OF OPERATIONS

We currently have three reportable segments: Sterigenics, Nordion and Nelson Labs. Our chief operating decision maker evaluates performance and allocates resources within our business based on Segment Income,

 

78


Table of Contents

which excludes certain items which are included in income (loss) before tax as determined in our consolidated statement of operations and comprehensive income (loss). The accounting policies for our reportable segments are the same as those for the consolidated Company.

Our Segments

Sterigenics

Our Sterigenics business provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets using three major technologies: gamma irradiation, EO processing and E-beam irradiation.

Nordion

Our Nordion business is a global provider of Co-60 and gamma irradiators, which are the key components to the gamma sterilization process.

As a result of the time required to meet regulatory and logistics requirements for delivery of radioactive products, combined with accommodations made to our customers to minimize disruptions to their operations during the installation of Co-60, Nordion sales patterns can often vary significantly from one quarter to the next. However, timing-related impacts on our sales performance tend to be resolved within several quarters, resulting in more consistent performance over longer periods of time. In addition, sales of production irradiators occur infrequently and tend to be for larger amounts.

Results for our Nordion segment are also impacted by Co-60 supplier mix, harvest schedules and product and service mix.

Nelson Labs

Our Nelson Labs business provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries.

Other

The Other reportable segment consisted of the Medical Isotopes business, a global supplier of medical isotopes for research, healthcare diagnostic and therapeutic uses, prior to its divestiture on July 30, 2018. We finalized the sale of the assets of the Medical Isotopes business for $213.0 million.

For more information regarding our reportable segments please refer to “Business” and the Segment and Geographic Information note to consolidated financial statements elsewhere in this prospectus.

 

79


Table of Contents

Segment Results for the nine months ended September 30, 2020 and 2019

The following tables compare the net revenues and segment income of our reportable segments for the nine months ended September 30, 2020 to the same period in the prior year:

 

     Nine Months Ended September 30,               
     2020     2019     $ Change      % Change  

Net Revenues

         

Sterigenics

   $ 363,954     $ 350,387     $ 13,568        3.9

Nordion

     86,034       91,869       (5,835      (6.4 %) 

Nelson Labs

     151,325       142,586       8,739        6.1
  

 

 

   

 

 

   

 

 

    

 

 

 

Segment Income

         

Sterigenics

   $ 192,803     $ 180,362     $ 12,441        6.9

Nordion

     50,692       49,698       994        2.0

Nelson Labs

     63,302       55,397       7,905        14.3
  

 

 

   

 

 

   

 

 

    

 

 

 

Segment Income Margin

         

Sterigenics

     53.0     51.5     

Nordion

     58.9     54.1     

Nelson Labs

     41.8     38.9     
  

 

 

   

 

 

      

Net Revenues

Sterigenics net revenues were $364.0 million for the nine months ended September 30, 2020, an increase of $13.6 million, or 3.9%, as compared to the same prior year period. The increase reflects favorable impact from pricing of 4.2% and a 1.9% increase due to organic volume growth. This was partially offset by a 2.0% headwind associated with the temporary suspension of operations at our Atlanta facility and the permanent closure of the Willowbrook facility. Net revenues were also slightly negatively impacted by reduced demand for medical devices associated with elective procedures, which were deferred due to COVID-19.

Nordion net revenues were $86.0 million for the nine months ended September 30, 2020, a decrease of $5.8 million, or 6.4%, as compared to the same prior year period. Volume contributed to a decline of approximately 11.6% relating to timing of medical use Co-60 sales due to COVID-19 and the scheduled timing of industrial use Co-60 harvest and customer deliveries, partially offset by favorable pricing of 3.8%.

Nelson Labs net revenues were $151.3 million for the nine months ended September 30, 2020, an increase of $8.7 million, or 6.1%, as compared to the same prior year period, primarily driven by an 8.9% increase in demand for testing services related to personal protective equipment used to provide protection against COVID-19, partially offset by a reduction in other lab testing volumes.

Segment Income

Sterigenics segment income was $192.8 million for the nine months ended September 30, 2020, an increase of $12.4 million, or 6.9%, as compared to the same prior year period. The 6.9% increase in segment margin was primarily a result of favorable pricing referenced above.

Nordion segment income was $50.7 million for the nine months ended September 30, 2020, an increase of $1.0 million, or 2.0%, as compared to the same prior year period. The increase in segment income was primarily due to a decrease in costs of medical use Co-60 attributed to COVID-19 disruptions of $4.1 million and favorable mix of Co-60 suppliers of $3.6 million. This was partially offset by the impact from the decline in sales referenced above.

 

80


Table of Contents

Nelson Labs segment income was $63.3 million for the nine months ended September 30, 2020, an increase of $7.9 million, or 14.3%, as compared to the same prior year period, primarily due to the increase in sales relating to personal protective equipment referenced above.

Segment Results for the years ended December 31, 2019 and 2018

The following tables compare segment net revenue and segment income for the year ended December 31, 2019 to the year ended December 31, 2018:

 

     Year Ended December 31,               
     2019     2018     $ Change      % Change  

Net Revenues

         

Sterigenics

   $ 471,708     $ 435,733     $ 35,975        8.3

Nordion

     116,165       118,829       (2,664      (2.2 %) 

Nelson Labs

     190,454       166,217       24,237        14.6

Other

     —         25,370       (25,370      (100 %) 
  

 

 

   

 

 

   

 

 

    

 

 

 

Segment Income

         

Sterigenics

   $ 244,904     $ 216,490     $ 28,414        13.1

Nordion

     62,196       60,288       1,908        3.2

Nelson Labs

     72,832       58,915       13,917        23.6

Other

     —         4,944       (4,944      (100 %) 
  

 

 

   

 

 

   

 

 

    

 

 

 

Segment Income margin

         

Sterigenics

     51.9     49.7     

Nordion

     53.5     50.7     

Nelson Labs

     38.2     35.4     

Other

     —         19.5     
  

 

 

   

 

 

      

Net Revenues

Sterigenics net revenues were $471.7 million for the year ended December 31, 2019, an increase of $36.0 million, or 8.3%, as compared to the prior year. The increase was driven by favorable impacts from organic volume growth and pricing of 6.4% and 3.8%, respectively. This was partially offset by a 3.3% headwind associated with the closure of the Willowbrook facility.

Nordion net revenues were $116.2 million for the year ended December 31, 2019, a decrease of $2.7 million, or 2.2%, as compared to the prior year. The decrease reflects a 3.8% impact from lower volumes of industrial use Co-60 and a 1.6% impact from the weakening of the Canadian dollar compared to the U.S. dollar in 2019 as compared to the prior year, partially offset by a 3.7% impact from favorable pricing.

Nelson Labs net revenues were $190.5 million for the year ended December 31, 2019, an increase of $24.2 million, or 14.6%, as compared to the prior year. The increase is primarily attributable to a 6.6% impact from the acquisition of Gibraltar Laboratories, coupled with favorable pricing and growth in organic volumes of 3.9% and 3.0%, respectively.

We divested the Medical Isotopes business in July 2018 and as a result, no sales were recorded for the year ended December 31, 2019, as compared to net revenues of $25.4 million for the year ended December 31, 2018.

Segment Income

Sterigenics segment income was $244.9 million for the year ended December 31, 2019, an increase of $28.4 million, or 13.1%, as compared to the prior year. The 2.2% increase in segment margin was driven by improved operating leverage as facilities operate at higher levels of utilization due to organic volume growth referenced above as well as the favorable pricing referenced above.

 

81


Table of Contents

Nordion segment income was $62.2 million for the year ended December 31, 2019, an increase of $1.9 million, or 3.2%, as compared to the prior year. The increase in segment income was driven by the favorable pricing impact referenced above.

Nelson Labs segment income was $72.8 million for the year ended December 31, 2019, an increase of $13.9 million, or 23.6%, as compared to the prior year. The increase in segment income was driven by the acquisition of Gibraltar Laboratories, coupled with favorable pricing and improved operating leverage due to an increase in organic volume as referenced above.

LIQUIDITY AND CAPITAL RESOURCES

The primary sources of liquidity for our business are cash flows from operations and borrowings under our credit facilities. We expect that our primary liquidity requirements will be to service our debt, to invest in fixed assets to build and/or expand existing facilities, to fund selective business acquisitions, make capital expenditures and for other general corporate purposes.

As of September 30, 2020, we had $108.4 million of cash and cash equivalents, of which $0.2 million was restricted cash. This is an increase of $45.4 million from the balance at December 31, 2019. Our foreign subsidiaries held cash of approximately $84.7 million at September 30, 2020 and $43.4 million at December 31, 2019, to meet their liquidity needs. No material restrictions exist to accessing cash held by our foreign subsidiaries.

Our capital expenditure program is a component of our long-term strategy. This program includes, among other things, investments in new and existing facilities, business expansion projects, Co-60 used by Sterigenics at its gamma irradiation facilities and information technology enhancements. During 2019, our capital expenditures amounted to $57.3 million, compared to $72.6 million in 2018. Through the first nine months of 2020, our capital expenditures were $33.6 million. This amount includes approximately $5.0 million related to facility enhancements at EO sterilization facilities within our Sterigenics segment. Our capital expenditures through the first nine months of 2020 were lower than initially planned as a result of deferrals due largely to the COVID-19 pandemic.

In 2021, we expect to continue to invest in facility expansions, ongoing routine maintenance for existing facilities, and acquisition of Co-60 for use by our Sterigenics segment in its gamma irradiation facilities. In addition, we expect to invest in special projects related to development of new Co-60 supply sources and facility enhancements at our EO sterilization facilities. We currently expect our capital expenditures to be higher in 2021 than in recent years and remain elevated over the next several years as we execute on those special projects in addition to our normal growth and maintenance related investments. For 2021, considering our typical growth and maintenance projects, along with the special projects, we expect capital expenditures to exceed $100.0 million, approximately $12 million to $17 million of which relates to enhancements at EO sterilization facilities.

We may choose to temporarily defer planned capital expenditures due to fluctuations in demand for our products and services resulting from the COVID-19 pandemic and the needs of our customers.

We expect that cash on hand, operating cash flows and amounts available under our credit facilities will provide sufficient working capital to operate our business, make expected capital expenditures, meet litigation costs and meet foreseeable liquidity requirements, including debt service on our long-term debt, for at least the next twelve months. Subject to market conditions, we are considering upsizing our Revolving Credit Facility in the fourth quarter of 2020 to increase capacity under the facility by approximately $100-150 million. As of September 30, 2020, there were no borrowings on the Revolving Credit Facility. We expect to use cash provided by operations in excess of amounts needed for capital expenditures and required debt repayments to reduce our debt or to fund potential acquisitions, or for other general corporate purposes. Our ability to meet future working capital, capital expenditures and debt service requirements will depend on our future financial performance, which will be affected by a range of macroeconomic, competitive and business factors, particularly interest rates and changes in our industry, many of which are outside of our control.

 

82


Table of Contents

Cash Flow Information

Nine months ended September 30, 2020 compared to nine months ended September 30, 2019

 

(thousands of U.S. dollars)

   2020      2019  

Net Cash Provided by (Used in):

     

Operating activities

   $ 98,740      $ 138,974  

Investing activities

     (139,920      (36,636

Financing activities

     83,961        (108,811

Effect of foreign currency exchange rate changes on cash and cash equivalents

     2,639        (4,030
  

 

 

    

 

 

 

Net increase in cash and cash equivalents, including restricted cash, during the period

   $ 45,420      $ (10,503
  

 

 

    

 

 

 

Operating activities

Cash flows provided by operating activities decreased $40.3 million to net cash provided of $98.7 million in the nine months ended September 30, 2020 compared to $139.0 million for the nine months ended September 30, 2019. The primary driver was higher net interest expense in 2020 of $52.6 million, driven by a higher weighted average interest rate and a larger balance of debt outstanding.

Investing activities

Historically, our principal uses of cash for investing activities were related to acquisitions of property, plant and equipment, including Co-60 purchases, and business acquisitions. These investments support our growth activities, including capacity expansions and expenditures that extend the life or productivity of existing assets.

For the nine months ended September 30, 2020 cash used by investing activities increased $103.3 million to $139.9 million compared to $36.6 million for the nine-month period ended September 30, 2019. The increase is attributable to the July 2020 acquisition of Iotron.

Financing activities

Net cash provided by financing activities was $84.0 million for the nine months ended September 30, 2020 as compared to net cash used of $108.8 million for the nine months ended September 30, 2019. Proceeds of borrowings totaling $150.0 million were partially offset by payments on debt. In March 2020, we borrowed $50.0 million on our revolving credit facility to increase our cash balance in response to concerns regarding the COVID-19 impact to the financial markets; the $50.0 million was repaid in June 2020. In July 2020 we issued $100.0 million of First Lien Notes to fund the acquisition of Iotron. The primary use of cash in the nine months ended September 30, 2019 was dividends to shareholders and principal payments on debt.

Year ended December 31, 2019 compared to the year ended December 31, 2018

 

(thousands of U.S. dollars)

   2019      2018  

Net Cash Provided by (Used in):

     

Operating activities

   $ 149,041      $ 119,563  

Investing activities

     (57,257      96,638  

Financing activities

     (126,030      (191,857

Effect of foreign currency exchange rate changes on cash and cash equivalents

     485        (3,676
  

 

 

    

 

 

 

Net increase (decrease) in cash and cash equivalents, including restricted cash, during the period

   $ (33,761    $ 20,668  
  

 

 

    

 

 

 

 

83


Table of Contents

Operating activities

Cash flows provided by operating activities increased $29.4 million to net cash provided of $149.0 million in the year ended December 31, 2019 compared to $119.6 million for the prior year. The higher net loss in 2019 was impacted by a non-operating loss on extinguishment of debt of $30.2 million, lower deferred income taxes of $26.3 million and a non-cash impairment of long-lived assets of $5.8 million. This compares to non-cash impairments of $85.1 million in 2018 that were more than offset by a gain on the sale of the Medical Isotopes business of $95.9 million. This was partially offset by a $12.4 million decrease in net cash from operating assets and liabilities, resulting in a cash outflow of $8.4 million in the year ended December 31, 2019 compared to $4.0 million of cash inflows in the prior year. The remainder of the variance is due to a $10.1 million decrease in unrealized foreign exchange losses.

Investing activities

For the year ended December 31, 2019 cash used by investing activities was $57.3 million attributable to purchases of property, plant and equipment, compared to cash provided by investing activities of $96.6 million in the prior year. Cash from investing activities for the year ended December 31, 2018 was a direct result of proceeds from the sale of the Medical Isotopes business of $213.0 million, partially offset by the acquisition of Nelson Fairfield of $50.6 million and capital expenditures of $72.6 million.

Financing activities

Net cash used in financing activities was $126.0 million for the year ended December 31, 2019 as compared to $191.9 million for the year ended December 31, 2018. Our principal uses of cash for financing activities in 2019 were $2,561.1 million in payments on debt primarily in conjunction with the December 2019 refinancing as well as dividends and distributions to our sole stockholder of $691.2 million. This was partially offset by proceeds from borrowings totaling $3,144.6 million.

Debt Facilities

Senior Secured Credit Facilities

On December 13, 2019, Sotera Health Holdings, LLC (“SHH”), our wholly owned subsidiary, entered into new senior secured first lien credit facilities (the “Senior Secured Credit Facilities”) and settled its previously outstanding term loan and senior notes.

The Senior Secured Credit Facilities consist of both a senior secured first lien term loan (the “Term Loan”) and a $190 million senior secured first lien revolving credit facility (the “Revolving Credit Facility”). The Term Loan matures on December 13, 2026, and the Revolving Credit Facility matures on December 13, 2024. The Senior Secured Credit Facilities also provide SHH the right at any time and under certain conditions to request incremental term loans or incremental revolving credit commitments based on a formula defined in the Senior Secured Credit Facilities. As of September 30, 2020, total borrowings under the Term Loan were $2,109.4 million.

Beginning on June 30, 2020, the Term Loan is paid in equal quarterly installments in aggregate annual amounts equal to 1.00% of the Term Loan original principal amount, while the remaining balance matures on December 13, 2026. The Term Loan may bear interest at LIBOR or an alternate base rate (“ABR”) subject to a 1.00% floor plus, an incremental margin of 4.50% in the case of LIBOR loans and 3.50% in the case of ABR loans. The weighted average interest rate on borrowings under the Term Loan at September 30, 2020 was 5.50%.

As of September 30, 2020, and December 31, 2019, capitalized debt issuance costs totaled $4.3 million and $4.7 million, respectively, and debt discounts totaled $39.3 million and $44.0 million, respectively, related to the Senior Secured Credit Facilities. Such costs are recorded as a reduction of debt on our consolidated balance sheets and amortized as a component of interest expense over the term of the debt agreement.

 

84


Table of Contents

Borrowings under the Revolving Credit Facility bear interest at a rate per annum equal to an applicable margin, plus, at our option, either (a) an ABR or (b) a LIBOR rate. The applicable margin under the Revolving Credit Facility may be reduced by reference to a leverage-based pricing grid with step-downs of 0.25% at a specified senior secured first lien net leverage ratio. In addition to paying interest on any outstanding borrowings under the Revolving Credit Facility, SHH is required to pay a commitment fee to the lenders under the Revolving Credit Facility in respect of the unutilized commitments thereunder and customary letter of credit fees. The Revolving Credit Facility contains a maximum senior secured first lien net leverage ratio covenant of 9.00 to 1.00, tested on the last day of each fiscal quarter if, on the last day of such fiscal quarter, the sum of (i) the aggregate principal amount of the revolving loans then outstanding under the Revolving Credit Facility, plus (ii) the aggregate amount of letter of credit (“LC”) disbursements that have not been reimbursed within two business days following the end of the fiscal quarter, exceeds the greater of $76.0 million and 40.0% of the aggregate principal amount of the revolving commitments then in effect. Although this covenant did not apply as the conditions were not met, as of September 30, 2020 the first lien net leverage ratio, as defined in the Revolving Credit Facility, was approximately 5.10 to 1.00.

As of September 30, 2020, there were no borrowings on the Revolving Credit Facility. SHH borrowed $50.0 million on the Revolving Credit Facility during the first quarter of 2020 which was repaid in the second quarter of 2020. The interest rate on the borrowings under the Revolving Credit Facility averaged approximately 5.0%.

The Senior Secured Credit Facilities contain additional covenants that, among other things, restrict, subject to certain exceptions, our ability and the ability of our restricted subsidiaries to engage in certain activities, such as incur indebtedness or permit to exist any lien on any property or asset now owned or hereafter acquired, as specified in the debt facility. The Senior Secured Credit Facilities also contain certain customary affirmative covenants and events of default, including upon a change of control. As of September 30, 2020, we were in compliance with all the Senior Secured Credit Facilities covenants.

All of SHH’s obligations under the Senior Secured Credit Facilities are unconditionally guaranteed by the Company and each existing and subsequently acquired or organized direct or indirect wholly-owned domestic restricted subsidiary of SHH, with customary exceptions including, among other things, where providing such guarantees is not permitted by law, regulation or contract or would result in material adverse tax consequences. All obligations under the Senior Secured Credit Facilities, and the guarantees of such obligations, are secured by substantially all of the assets of the borrower and guarantors, subject to permitted liens and other exceptions and exclusions, as outlined in the Senior Secured Credit Facilities.

Outstanding letters of credit are collateralized by encumbrances against the Revolving Credit Facility and the collateral pledged thereunder, or by cash placed on deposit with the issuing bank. As of September 30, 2020, the Company had $64.3 million of letters of credit issued against the Revolving Credit Facility, resulting in total availability under the Revolving Credit Facility of $125.7 million.

First Lien Notes

On July 31, 2020, SHH issued $100.0 million aggregate principal amount of senior secured first lien notes due 2026 (the “First Lien Notes”), which mature on December 13, 2026. The First Lien Notes bear interest at a rate equal to LIBOR subject to a 1.00% floor plus 6.00% per annum. Interest is payable on a quarterly basis with no principal due until maturity. The weighted average interest rate on the First Lien Notes at September 30, 2020 was 7.00%.

SHH is entitled to redeem all or a portion of the First Lien Notes, at any time and from time to time, subject to certain premiums depending on the date of redemption: any time on or prior to July 31, 2021, a customary make-whole premium applies and, thereafter, specified premiums that decline to zero apply (in each case as described in the indenture governing the First Lien Notes).

 

85


Table of Contents

All of SHH’s obligations under the First Lien Notes are unconditionally guaranteed by the Company and each existing and subsequently acquired or organized direct or indirect wholly-owned domestic restricted subsidiary of SHH, with customary exceptions including, among other things, where providing such guarantees is not permitted by law, regulation or contract or would result in material adverse tax consequences. All obligations under the First Lien Notes, and the guarantees of such obligations, are secured by substantially all of the assets of the borrower and guarantors, subject to permitted liens and other exceptions and exclusions, as outlined in the First Lien Notes. Such collateral is substantially the same collateral that secures the Senior Secured Credit Facilities and Second Lien Notes. Such collateral securing the First Lien Notes ranks pari passu with that of the Senior Secured Credit Facilities and has priority over the collateral securing the Second Lien Notes.

At September 30, 2020, capitalized debt issuance costs were $0.7 million and debt discounts were $2.9 million, respectively, related to the First Lien Notes, which are recorded as a reduction of debt on our consolidated balance sheets and amortized into interest expense over the term of the debt agreement.

Second Lien Notes

On December 13, 2019, SHH issued $770.0 million aggregate principal amount of senior secured second lien notes due 2027 (the “Second Lien Notes”), which mature on December 13, 2027. The Second Lien Notes bear interest at a rate equal to LIBOR subject to a 1.00% floor plus 8.00% per annum. The weighted average interest rate on the Second Lien Notes at September 30, 2020 was 9.00%.

SHH is entitled to redeem all or a portion of the Second Lien Notes, at any time and from time to time, subject to certain premiums depending on the date of redemption: any time on or prior to December 13, 2020, a customary make-whole premium applies and, thereafter, specified premiums that decline to zero apply (in each case as described in the indenture governing the Second Lien Notes). In addition, under certain circumstances, such as an initial public offering or certain changes of control, SHH has certain additional redemption rights (as described in the indenture governing the Second Lien Notes).

All of SHH’s obligations under the Second Lien Notes are unconditionally guaranteed by the Company and each existing and subsequently acquired or organized direct or indirect wholly-owned domestic restricted subsidiary of SHH, with customary exceptions including, among other things, where providing such guarantees is not permitted by law, regulation or contract or would result in material adverse tax consequences. All obligations under the Second Lien Notes, and the guarantees of such obligations, are secured by substantially all of the assets of the borrower and guarantors, subject to permitted liens and other exceptions and exclusions, as outlined in the Second Lien Notes. Such collateral is substantially the same collateral that secures the Senior Secured Credit Facilities and the First Lien Notes, and any security interest or lien on shared collateral securing the Senior Secured Credit Facilities or the First Lien Notes shall have priority over any security interest or lien on shared collateral securing the Second Lien Notes.

At September 30, 2020 and December 31, 2019, capitalized debt issuance costs were $1.6 million and $1.8 million and debt discounts were $21.0 million and $23.2 million, respectively, related to the Second Lien notes, which are recorded as a reduction of debt on our consolidated balance sheets and amortized into interest expense over the term of the debt agreement.

2019 Refinancing

In conjunction with the December 2019 refinancing, the company redeemed, in full, the previously outstanding $1,659.0 million aggregate Term Loan due 2022, its $450.0 million Senior Notes due 2023 (“Senior Notes”) and $425.0 million Senior PIK (“paid in kind”) Toggle Notes due 2021. In total, we accelerated the amortization of $13.4 million of debt issuance and discount costs and recognized $14.6 million representing premiums paid in connection with the early extinguishment of the Senior Notes. In connection with the refinancing, we also recognized an additional $2.1 million of expense related to debt issuance and discount costs.

 

86


Table of Contents

We recognized these costs within the loss on extinguishment of debt in our consolidated statements of operations and comprehensive income (loss). Any additional proceeds were used to fund a dividend to our sole stockholder of $275.0 million.

CONTRACTUAL OBLIGATIONS AND COMMERCIAL COMMITMENTS

The following table describes our significant contractual cash obligations as of December 31, 2019:

 

     Payments due by period  

(thousands of U.S. dollars)

   Total      Less than
1 Year
     2-3 Years      4-5 Years      More than 5
Years
 

Long-term debt (a)

   $ 4,387,911      $ 235,566      $ 444,397      $ 446,296      $ 3,261,652  

Lease obligations:

              

Capital (b)

     31,172        1,288        2,204        2,506        25,174  

Operating (c)

     60,173        11,782        19,435        10,698        18,258  

Supply and service obligations (d)

     1,619,045        38,983        64,657        70,616        1,444,789  

Direct material costs (e)

     28,185        13,144        13,651        1,139        251  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 6,126,486      $ 300,763      $ 544,344      $ 531,255      $ 4,750,124  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

(a)

Represents principal and interest payments on the Senior Secured Credit Facilities and Second Lien Notes. We have calculated the interest payments on the Senior Secured Credit Facilities and Second Lien Notes at an average of 6.1% (the LIBOR floor plus 4.5%) and 9.7% (the LIBOR floor plus 8.00%), respectively. Subsequent to December 31, 2019, SHH issued $100.0 million of First Lien Notes, which are not reflected in the table above.

(b)

Consists of payments, net of interest, under our capital leases for various equipment and facilities.

(c)

Represents minimum lease payments under our operating leases for several of our facilities and other property and equipment, net of sublease payments. We elected to early adopt ASU 2016-02 Leases as of January 1, 2020, resulting in the recognition of right-of-use assets and lease liabilities of $47.4 million and $48.9 million, respectively on our consolidated balance sheet.

(d)

Consists of our best estimate of our obligations under various supply and service agreements, primarily Co-60, that are enforceable and legally binding on us.

(e)

Consists of our best estimate of our obligations to purchase EO gas under commitments that are enforceable and legally binding on us. We have excluded contracts to purchase energy and other supplies, which generally have terms of one year or less. Our contract to purchase EO gas in the U.S. requires us to purchase all our requirements from our supplier, and our contracts to purchase EO gas outside the U.S. generally require that we purchase a specified percentage of our requirements for our operations in the countries covered by those contracts. Although our EO gas contracts generally do not contain fixed minimum purchase volumes, we have calculated the amounts set forth in the table above based on the percentage of our requirements specified in the contracts and our budgeted purchase volumes for those periods.

OFF-BALANCE SHEET ARRANGEMENTS

We do not have any relationships with unconsolidated entities or financial partnerships, such as entities referred to as structured finance or special purpose entities, which are established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity or capital expenditures or capital resources that are material to investors other than operating leases.

At December 31, 2019 and 2018, we had $92.9 million and $90.5 million, respectively, of standby letters of credit, surety bonds and other bank guarantees outstanding, primarily in favor of local and state licensing

 

87


Table of Contents

authorities for future decommissioning costs, and to support the unfunded portion of our pension obligation. We are obligated to provide financial assurance to local and state licensing authorities for possible future decommissioning costs associated with the various facilities that hold Co-60. At December 31, 2019 and 2018, $49.3 million and $47.8 million, respectively, of the standby letters of credit and surety bonds referenced above were outstanding in favor of the various local and state licensing authorities in the event we defaulted on our decommissioning obligation.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to market risks, primarily from changes in commodity prices, interest rates and foreign currency exchange, in the ordinary course of business.

Commodity Price Risk

We purchase our supply of EO gas from various suppliers around the world, but in the United States there is a sole supplier for EO gas used for applications relevant to our business. We are exposed to market risk based on fluctuations in the price of EO gas.

We actively seek to manage the risk of fluctuating prices through long-term supply and service contracts. Most of our Sterigenics customer contracts contain provisions that permit us to pass all or a portion of our supply price increases to our customers, though some of our contracts do not contain these provisions. Even for contracts that do contain these provisions, there could be at least a brief lag between when we incur increased costs for supplies and when we can pass through these costs to our customers. In addition, even when we are contractually permitted to pass on price increases, we may decide not to do so to preserve our sales volumes.

Regulatory Risk

We are subject to extensive regulatory requirements and routine regulatory audits, and we must receive permits, licenses, and/or regulatory clearance or approval for our operations. Regulatory agencies may refuse to grant approval or clearance or may require the provision of additional data, and regulatory processes may be time consuming and costly, and their outcome may be uncertain in certain of the countries in which we operate. Regulatory agencies may also change policies, adopt additional regulations or revise existing regulations, each of which could impact our ability to provide our services. Our failure to comply with the regulatory requirements of these agencies may subject us to administratively or judicially imposed sanctions. These sanctions include, among others, warning letters, fines, civil penalties, criminal penalties, injunctions, debarment, product seizure or detention and total or partial suspension of operations. The failure to receive or maintain, or delays in the receipt of, relevant U.S. or international regulatory qualifications could have a material adverse effect on our business, prospects, financial condition or results of operations.

Interest Rate Risk

We are subject to interest rate risk on borrowings under our outstanding borrowings as the borrowings bear interest at floating rates. In October 2017, the company entered into two interest rate cap agreements with a total notional amount of $400.0 million for a total option premium of $0.6 million. The interest rate cap agreements terminated on September 30, 2020.

In June 2020, we entered into two interest rate cap agreements with notional amounts of $1,000.0 million and $500.0 million, respectively, for a total option premium of $0.3 million. These terminate on August 31, 2021 and February 28, 2022, respectively. The interest rate caps limit our cash flow exposure related to the LIBOR base rate under a portion of our variable rate borrowings to 1.0%.

During the third quarter of 2019, we entered into two interest rate swap agreements to hedge our exposure to interest rate movements and to manage interest expense related to our outstanding variable-rate debt. The

 

88


Table of Contents

notional amount of the interest rate swap agreements totaled $1,000.0 million and terminated on August 31, 2020. These swaps were designated as hedges against the changes in cash flows attributable to changes in LIBOR, the benchmark interest rate being hedged. We received interest at one-month LIBOR and paid a fixed interest rate under the terms of the swap agreement. After applying the effects of interest rate caps referenced above, a 1.0% increase in the interest rate under our outstanding obligations as of September 30, 2020, of $2,979.9 million, would increase interest expense by approximately $3.5 million per year.

See the Financial Instruments and Financial Risk note to consolidated financial statements included elsewhere in this prospectus for a summary of the activity of the interest rate caps for the periods presented.

Foreign Currency Risk

We are exposed to market risk from fluctuations in foreign currencies. We present our consolidated financial statements in U.S. dollars. Consequently, increases or decreases in the value of the U.S. dollar relative to the non-U.S. dollar functional currencies of the countries in which we operate may affect the value of these in our consolidated financial statements, even if their value has not changed in their local currency. We translate the financial statements of subsidiaries whose local currency is their functional currency to their U.S. dollar equivalents at end-of-period exchange rates for assets and liabilities and at average exchange rates for revenues and expenses. These translations could significantly affect the comparability of our results between financial periods and/or result in significant changes to the carrying value of our assets and liabilities. Translation adjustments are recorded as a component of accumulated other comprehensive income (loss) within equity.

Our results of operations are impacted by currency exchange rate fluctuations to the extent that we are unable to match net revenues received in foreign currencies with expenses incurred in the same currency. Transaction gains and losses arising from fluctuations in currency exchange rates on transactions denominated in currencies other than the functional currency are recognized in the consolidated statements of operations and comprehensive income (loss) as foreign exchange (gain) loss.

Approximately 39.6% of our revenues and 45.4% of our consolidated total assets as of September 30, 2020 are derived from operations outside the United States. Holding other variables constant (such as interest rates and debt levels), if the U.S. dollar had appreciated by 10% against the foreign currencies used by our operations in the combined nine months ended September 30, 2020, revenues would have been reduced by approximately $23.8 million and gross profit by approximately $11.5 million.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The following subsections describe our most critical accounting policies, estimates, and assumptions. Our discussion of critical accounting policies and estimates is intended to supplement, not duplicate, our summary of significant accounting policies so that readers will have greater insight into the uncertainties involved in these areas. Our accounting policies are more fully described in the Significant Accounting Policies note to consolidated financial statements included elsewhere in this prospectus.

The preparation of consolidated financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make judgments, estimates and assumptions at a specific point in time and in certain circumstances that affect amounts reported in the accompanying consolidated financial statements. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts, giving due consideration to materiality. The application of accounting policies involves the exercise of judgment and use of assumptions as to future uncertainties and, as a result, actual results could differ from these estimates.

Under the Jumpstart Our Business Startups Act of 2012, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. As an

 

89


Table of Contents

emerging growth company, we have elected to take advantage of the extended transition period for complying with new or revised accounting standards until those standards would otherwise apply to private companies or at which time we conclude it is appropriate to avail ourselves of early adoption provisions of applicable standards. As a result, our results of operations and financial statements may not be comparable to the results of operations and financial statements of other companies who have adopted the new or revised accounting standards.

Revenue Recognition. The majority of our sales agreements contain performance obligations satisfied at a point in time when control of promised goods or services have transferred to our customers. For agreements with multiple performance obligations, judgment is required to determine whether performance obligations specified in these agreements are distinct and should be accounted for as separate revenue transactions for recognition purposes. In these types of agreements, we generally allocate sales price to each distinct obligation based on the relative price of each item sold in stand-alone transactions. Revenues recognized over time are generally accounted for using an input measure to determine progress completed as of the end of the period.

Refunds, returns, warranties and other related obligations are not material to any of our business units, nor do we incur material incremental costs to secure customer contracts.

The Sterigenics segment provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets. We typically have multi-year service contracts with our significant customers, and these sales contracts are primarily based on a customer’s purchase order. Given the relatively short turnaround times, performance obligations are generally satisfied at a point-in-time upon the completion of sterilization or irradiation processing once approved by our quality assurance process at which time the service is complete.

The Nordion segment is a provider of Co-60 and gamma irradiators, which are key components to the gamma sterilization process. Revenue from the sale of Co-60 radiation sources is recognized at a point-in-time upon satisfaction of our performance obligations for delivery/installation and disposal of existing sources. Revenue from the production of equipment in our Nordion segment is recognized over time using an input measure of costs incurred and is immaterial to the overall business.

The Nelson Labs segment provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. We provide our customers mission-critical lab testing services, which assess the product quality, effectiveness, patient safety and end-to-end sterility of products. These services are necessary for our customers’ regulatory approvals, product releases and ongoing product performance evaluations. Nelson Labs services are generally provided on a fee-for-service or project basis, and we recognize revenues over time using an input measure of time incurred to determine progress completed at the end of the period.

We do not capitalize sales commissions as substantially all of our sales commission programs have an amortization period of one year or less. Furthermore, costs to fulfill a contract are not material.

Provisions for discounts, rebates to customers, and other adjustments are provided for as reductions in net revenues in the period the related sale was recorded. Shipping and handling charges billed to customers are included in net revenues, and the related shipping and handling costs are included in cost of net revenues on the consolidated statements of operations and comprehensive income (loss). Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by us from a customer, are excluded from net revenue.

Payment terms vary by the type and location of the customer and the products or services offered. Generally, the time between when revenue is recognized and when payment is due is not significant. We do not evaluate whether the selling price contains a financing component for contracts that have a duration of less than one year.

 

90


Table of Contents

Long-Lived Assets Other than Goodwill. We review long-lived assets, including finite-lived intangibles for impairment whenever events or circumstances indicate that the carrying amount of the assets may be impaired. Events or circumstances which would result in an impairment assessment include operating losses, a significant change in the use of an asset, or the planned disposal or sale of the asset. When we evaluate assets for impairment, we make certain judgments and estimates, including interpreting current economic indicators and market valuations, evaluating our strategic plans with regards to operations, historical and anticipated performance of operations, and other factors. If we incorrectly anticipate these factors, or unexpected events occur, our operating results could be materially affected. The asset or asset group would be considered impaired when the future net undiscounted cash flows generated by the asset or asset group are less than its carrying value.

An impairment loss would be recognized based on the amount by which the carrying value of the asset or asset group exceeds its estimated fair value. We provide additional information about our long-lived assets other than goodwill in notes titled Property, Plant and Equipment and Capital Leases and Goodwill and Other Intangible Assets of our consolidated financial statements included elsewhere in this prospectus.

Goodwill and Other Indefinite-Lived Intangibles. Assets and liabilities of the business acquired are accounted for at their estimated fair values as of the acquisition date. Any excess of the cost of the acquisition over the fair value of the net tangible and intangible assets acquired is recorded as goodwill. We generally supplement management expertise with valuation specialists in performing appraisals to assist us in determining the fair values of assets acquired and liabilities assumed. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We generally amortize our intangible assets over their useful lives with the exception of indefinite lived intangible assets. We do not amortize goodwill, but we evaluate it annually for impairment. Therefore, the allocation of the purchase price to intangible assets and goodwill has a significant impact on future operating results.

Goodwill and other indefinite-lived intangible assets, primarily certain regulatory licenses and tradenames, are tested for impairment annually as of October 1. If circumstances change during interim periods between annual tests that would indicate that the carrying amount of such assets may not be recoverable, the company would test such assets at an interim date for impairment. Factors which would necessitate an interim impairment assessment include prolonged negative industry or economic trends and significant underperformance relative to historical or projected future operating results.

We performed a quantitative assessment of all reporting units (Sterigenics, Nordion and Nelson Labs) as of October 1, 2019. The fair value of each reporting unit was calculated using a discounted cash flow analysis which was dependent on subjective market participant assumptions determined by management. Assumptions used in the analyses included discount rates and projected operating cash flows. Estimates of future cash flows are based upon relevant data at a point-in-time, are subject to change, and could vary from actual results. The estimated fair value of each reporting unit exceeded its carrying amount (including goodwill) by a minimum of 60% as of October 1, 2019. No factors were identified that would result in the potential impairment to the indefinite-lived intangible assets. In addition, there have been no significant events or circumstances that occurred since the annual assessment date of October 1 that would change the conclusions reached above. We provide additional information about our goodwill and other indefinite-lived intangible assets in the Goodwill and Other Intangible Assets note to consolidated financial statements included elsewhere in this prospectus.

Asset Retirement Obligations (“ARO”). ARO are legal obligations associated with the retirement of long-lived assets or the exit of a leased facility. We lease various facilities where sterilization and ionization services are performed. Under the lease agreements, we are required to return the facilities to their original condition and to perform decommissioning activities. In addition, certain of our owned facilities are required to be decommissioned when we vacate the facility. The decommissioning costs are paid in the period the expenditure is incurred. We recognize an initial liability for ARO’s at fair value, and the associated asset retirement costs are then capitalized as part of the carrying amount of the long-lived asset. Accounting for the ARO at inception and in subsequent periods includes the determination of the present value of the ARO liability and offsetting long-

 

91


Table of Contents

lived asset, the subsequent accretion of the ARO liability and depletion of the long-lived asset, and a periodic review of the ARO liability estimates and associated discount rates used in the analysis. We provide additional information about our ARO in the Asset Retirement Obligations (“ARO”) note to consolidated financial statements included elsewhere in this prospectus.

Income Taxes. We use the liability method of accounting for income taxes whereby we recognize deferred tax assets and liabilities for the future tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements. We periodically review our deferred tax assets for recoverability and establish a valuation allowance based on historical taxable income, projected future taxable income, expected timing of reversals of existing temporary timing differences and the implementation tax planning strategies. Deferred tax assets will be reduced by a valuation allowance if, based on management’s estimate, it is more likely than not that a portion of the deferred tax assets will not be realized in a future period. The estimates used in the recognition of deferred tax assets are subject to revision in future periods based on new facts and circumstances. If we are unable to generate sufficient future taxable income in certain tax jurisdictions, or if there is a material change in the effective income tax rates or time period within which the underlying temporary differences become taxable or deductible, we could be required to increase our valuation allowance, which would increase our effective income tax rate and could result in an adverse impact on our consolidated financial position or results of operations.

We determine whether it is more likely than not that a tax position will be sustained upon examination, including resolution of related appeals or litigation processes, based on the technical merits of the position. In evaluating whether a tax position has met the more likely-than-not recognition threshold, we presume that the position will be examined by the appropriate taxing authority and that the taxing authority will have full knowledge of all relevant information. A tax position that meets the more likely-than-not recognition threshold is measured at the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. Determining what constitutes an individual tax position and whether the more likely-than-not recognition threshold is met for a tax position are matters of judgment based on the individual facts and circumstances of that position evaluated in light of all available evidence. We review and adjust tax estimates periodically because of ongoing examinations by, and settlements with, the various taxing authorities, as well as changes in tax laws, regulations, and precedent.

We are subject to taxation from federal, state and local, and foreign jurisdictions. Tax positions are settled primarily through the completion of audits within each individual tax jurisdiction or the closing of a statute of limitation. Changes in applicable tax law or other events may also require us to revise past estimates. The United States Internal Revenue Service routinely conducts audits of our federal income tax returns. Additional information regarding income taxes is included in the Income Taxes note to consolidated financial statements.

Commitments and Contingencies. We are, and will likely continue to be, involved in a number of legal proceedings, government investigations and claims, which we believe generally arise in the course of our business, given our size, history, complexity and the nature of our business, products, customers, regulatory environment and industries in which we participate. These legal proceedings, investigations and claims generally involve a variety of legal theories and allegations, including, without limitation, personal injury (e.g., slip and falls, burns, vehicle accidents), regulation (e.g., failure to meet specification or failure to comply with regulatory requirements), commercial claims (e.g., breach of contract, economic loss, misrepresentation), financial (e.g., taxes, reporting), employment (e.g., wrongful termination, discrimination, benefits matters) and other claims for damage and relief.

We record a liability for such contingencies to the extent we conclude that their occurrence is both probable and estimable. We consider many factors in making these assessments, including the professional judgment of experienced members of management and our legal counsel. We have made estimates as to the likelihood of unfavorable outcomes and the amounts of such potential losses. In our opinion, the ultimate outcome of these proceedings and claims is not anticipated to have a material adverse effect on our consolidated financial position,

 

92


Table of Contents

results of operations, or cash flows. However, the ultimate outcome of proceedings, government investigations and claims is unpredictable and actual results could be materially different from our estimates. We record gain contingencies when realized, and expected recoveries under applicable insurance contracts when we are assured of recovery. Refer to the Commitments and Contingencies note of our consolidated financial statements included elsewhere in this prospectus for additional information.

NEW ACCOUNTING PRONOUNCEMENTS

For a description of recent accounting pronouncements applicable to our business, see the Recent Accounting Standards note to consolidated financial statements included elsewhere in this prospectus.

 

93


Table of Contents

BUSINESS

Overview

 

LOGO

We are a leading global provider of mission-critical sterilization and lab testing and advisory services to the medical device and pharmaceutical industries. We are driven by our mission: Safeguarding Global Health®. We provide end-to-end sterilization as well as microbiological and analytical lab testing and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients and consumers in the United States and around the world. Our customers include more than 40 of the top 50 medical device companies and eight of the top ten global pharmaceutical companies (based on revenue). Our services are an essential aspect of our customers’ manufacturing process and supply chains, helping to ensure sterilized medical products reach healthcare practitioners and patients. Most of these services are necessary for our customers to satisfy applicable government requirements. We give our customers confidence that their products meet regulatory, safety and effectiveness requirements. With a combined tenure across our businesses of nearly 200 years and our industry-recognized scientific and technological expertise, we help to ensure the safety of millions of patients and healthcare practitioners around the world every year. Across our 63 facilities worldwide, we have nearly 2,900 employees who are dedicated to safety and quality. We are a trusted partner to more than 5,800 customers in over 50 countries.

Our Businesses

We serve our customers throughout their product lifecycles, from product design to manufacturing and delivery, helping to ensure the sterility, effectiveness and safety of their products for the end user. We operate across two core businesses: sterilization services and lab services. Each of our businesses has a long-standing

 

94


Table of Contents

record and is a leader in its respective market, supported and connected by our core capabilities including deep end market, regulatory, technical and logistics expertise. The combination of Sterigenics, our terminal sterilization business, and Nordion, our Co-60 supply business, makes us the only vertically integrated global gamma sterilization provider in the sterilization industry. This provides us with additional insights and allows us to better serve our customers.

 

   

Sterilization Services (our Sterigenics and Nordion brands):

 

   

Under our Sterigenics brand, we provide outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets. Terminal sterilization is the process of sterilizing a product in its final packaging. It is an essential, and often government-mandated, step in the manufacturing process of healthcare products before they are shipped to end-users. These products include medical protective barriers, including PPE, procedure kits and trays, implants, syringes, catheters, wound care products, laboratory products and pharmaceuticals. We offer our customers a complete range of outsourced terminal sterilization services, primarily using the three major sterilization technologies: gamma irradiation, EO processing and E-beam irradiation.

 

   

Gamma irradiation: A process in which products are exposed to gamma rays emitted by Co-60. Gamma rays can penetrate even dense materials to kill microbes. Gamma is particularly effective at sterilizing high-density medical products such as sutures, surgical tools and stents.

 

   

EO processing: A gas sterilization process in which pallets of packaged goods are loaded into a secure chamber that is then injected with EO gas to penetrate the packaging. EO is the most widely used gaseous sterilization agent in the world and has been in use for nearly 90 years. The broad application to a range of medical devices is attributed to the fact that EO is compatible with many materials that cannot tolerate or are degraded by radiation or moist heat sterilization. For this reason, it is commonly the only method available to safely and effectively sterilize procedure kits, PPE and many devices used in cardiac procedures.

 

   

E-beam irradiation: A process in which products are exposed to machine-generated radiation in the form of a stream of electrons. E-beam is particularly effective for low density homogenous products such as glass labware. Several medical devices products also rely on E-beam as an effective form of sterilization, including certain types of syringes. In addition to medical device sterilization, E-beam can also be used as an effective technology for materials modification, such as the crosslinking of certain polymers or for enriching the color of gemstones.

 

   

Under our Nordion brand, we are the leading global provider of Co-60 and gamma irradiators, which are key components to the gamma sterilization process. Co-60 is a radioactive isotope that is needed by medical device manufacturers and sterilizers including Sterigenics. Co-60 decays and must be replaced over time to produce the desired level of irradiation. We have the most comprehensive access to nuclear power reactor operators around the world which are able to produce Co-60. The capabilities that we provide to Nordion’s customers include handling and processing of Co-60, recycling of depleted sources and global logistics enabled by our licensed container fleet. We are integral to our customers’ operations due to highly coordinated and complex installation processes. In addition, under our Nordion brand, we are a leading supplier of Co-60 sources for stereotactic radiosurgery devices (such as the Gamma Knife®), which are used for certain oncology applications.

 

   

Lab Services (our Nelson Labs brand):

 

   

Under our Nelson Labs brand, we are a global leader in outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. We provide our customers mission-critical lab testing services, which assess the product quality, effectiveness, patient safety and end-to-end sterility of products. These services are necessary for our customers’ regulatory approvals, product releases and ongoing product performance evaluations.

 

   

Microbiology testing services help to identify and measure the potential risks of microbes to a product and ensure that the quality of the products is maintained.

 

95


Table of Contents
   

Analytical chemistry lab testing is also a critical part of the pharmaceutical drug and medical device development and manufacturing process. This testing provides first-hand information as to the content, quality and safety of raw materials, intermediates and finished products.

 

   

We also provide expert advisory services to aid customers in navigating the regulatory requirements applicable throughout the product lifecycle.

Nelson Labs serves over 3,800 customers across 13 facilities in the United States, Mexico, Asia and Europe. We have a comprehensive array of over 800 laboratory tests supporting our customers from initial product development and sterilization validation, through regulatory approval and ongoing product testing for sterility, safety and quality assurance. Our customers rely on our expertise in their industries to get their medical device and pharmaceutical products to market.

 

   

Medical device lab testing services include: microbiology, biocompatibility and toxicology assessments, material characterization, sterilization validation, sterility assurance, packaging validation and distribution simulation, reprocessing validations, facility and process validation and performance validation and verification of PPE barriers and material.

 

   

Pharmaceutical lab testing services include: microbiology, biocompatibility and toxicology assessments, extractables and leachables evaluations of pharmaceutical containers, sterilization validation, sterility assurance, packaging validation and distribution simulation and facility and process validation.

Nelson Labs is highly complementary to our sterilization services business. In particular, microbiological testing validates the configuration and effectiveness of the sterilization process.

We believe that our sterilization service offerings, our Co-60 supply capabilities and the broad capabilities of our lab services business give us unique insights and technical expertise to serve the mission-critical needs of medical device and pharmaceutical manufacturers. We believe these provide us with a competitive advantage over other outsourced sterilization and lab testing service providers.

Our Markets and Customers

Medical device and pharmaceutical manufacturers often outsource their sterilization and lab services needs, as the technical and regulatory expertise and infrastructure required to establish those capabilities in-house can result in significant cost and resource burden.

We estimate that the total global addressable market for terminal sterilization and outsourced medical device and pharmaceutical lab testing was approximately $33 billion in 2019. Global terminal sterilization accounted for $3 billion of our estimated total addressable market in 2019. Global outsourced medical device and pharmaceutical lab testing services accounted for approximately $29 billion of our estimated total addressable market in 2019, with approximately $3 billion attributable to medical devices and approximately $26 billion attributable to pharmaceuticals. We believe the following secular trends underpin increasing demand for medical devices and pharmaceuticals: an aging population, increased access to, and demand for, healthcare services globally, growth in healthcare R&D spending and innovation, intensifying regulatory requirements and heightened focus on personal safety. As a service provider to manufacturers, we are not directly exposed to risks associated with reimbursement by public or private payors. We expect that increasing utilization of medical devices, including the equipment and consumables that we sterilize and test, expansion in pharmaceutical development and a growing focus on microbial decontamination (including viruses) will continue to drive growth in our business and provide us the opportunity to expand within our markets.

Our customers depend upon the end-to-end services we provide throughout the lifecycle of their products, from research and development, to product manufacturing and sterilization, as well as ongoing quality control. We often maintain long-term relationships with our customers, which average over a decade across our top 25 customers in 2019. We also benefit from minimal customer concentration, as no single customer accounted for more than 4% of our total revenues in 2019. Given the critical nature of our services, a significant portion of our

 

96


Table of Contents

revenues is supported by multi-year contracts. More than 90% of our sterilization services revenues in each of the year ended December 31, 2019 and the nine months ended September 30, 2020 were from customers under multi-year contracts. The quality of our service offerings is evidenced by close to 100% renewal rates of our top ten sterilization services customers in 2019 over the past five years. Most of our services are government-mandated and mission-critical, and sterilization services generally represent a small fraction of the total end product cost of medical devices.

Our Network and Expertise

All of the services we provide are highly regulated and require significant technical expertise. To manage these strict regulatory requirements safely and effectively, we have a highly trained and skilled workforce that creates, implements and manages complex quality assurance and environmental health and safety programs, procedures and control systems. We coordinate and communicate with numerous regulatory agencies globally across our businesses on an ongoing and regular basis.

With 63 facilities across our businesses located in 13 countries, our network of global facilities represents a significant competitive advantage in serving the healthcare industry. Our sterilization facilities are often strategically located near our healthcare customers’ manufacturing sites or distribution hubs, which is intended to decrease our customers’ transportation costs and help them optimize their supply chain and logistics. Our laboratory testing facilities are strategically located in order to meet the demanding and often complex needs of our customers. Extensive capital, technical expertise and regulatory knowledge are required to build, maintain and operate facilities like ours. We estimate that one new sterilization facility can cost over $30 million to build, on average, and require extensive and complex licensing approval and regulatory compliance processes. We estimate that the cost to replace the facilities in our network alone could be as high as $1.5 billion or more, in addition to the technical and regulatory requirements.

For the year ended December 31, 2019, we recorded net revenues of $778.3 million, net loss of $20.4 million, Adjusted Net Income of $100.4 million and Adjusted EBITDA of $379.9 million. In addition, for the nine months ended September 30, 2020, we recorded net revenues of $601.3 million, net income of $5.9 million, Adjusted Net Income of $77.1 million and Adjusted EBITDA of $306.8 million. For the definition of Adjusted Net Income and Adjusted EBITDA and the reconciliation of these measures from net income (loss), please see “Summary—Summary Historical Consolidated Financial and Other Data.”

Key Strengths

We are a critical service provider in the healthcare value chain. Our customers rely on us to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients and consumers. We provide services, including sterility assurance, product safety and effectiveness validation, that our customers need to get their products to market and into the hands of their end-users. Our breadth of services, technical and regulatory expertise, as well as our global scale, enable us to provide these mission-critical services which are necessary for Safeguarding Global Health®. These key strengths make us a global leader in our markets.

 

97


Table of Contents

LOGO

Comprehensive, global provider of mission-critical sterilization and lab services for the healthcare industry

Our customers value our scale and breadth of services. We offer customers comprehensive sterilization, lab testing and expert advisory services on a global scale. Our customers in the healthcare industry require these services to navigate and operate in an increasingly complex and technical regulatory environment, and we believe we provide a differentiated value proposition to our customers by offering these services in an integrated manner. Our robust sterilization capabilities across all key modalities allow our customers to help ensure the safety of their products prior to delivery to their end-users. We offer over 800 microbiology and analytical chemistry lab tests that, together with our expert advisory services, cover the entirety of the medical device and pharmaceutical product lifecycles to evaluate and ensure that our customers’ products meet regulatory requirements. Our frequent interactions with our customers across multiple facets of their products’ lifecycles give us deep and often early insights into the evolving needs of the manufacturers of medical devices and pharmaceuticals. We have a large, global and strategically-located network of facilities that allows us to deploy the full array of our services to our customers where they need us. These comprehensive and global services make us an essential player across the medical device and pharmaceutical value chain.

Industry leading participant in large and growing markets, underpinned by trends in global healthcare

We estimate that the total global addressable market for terminal sterilization and outsourced medical device and pharmaceutical lab testing was approximately $33 billion in 2019. Global terminal sterilization accounted for $3 billion of our estimated total addressable market in 2019. Global outsourced medical device and pharmaceutical lab testing services accounted for $29 billion of our total addressable market in 2019.

Given the mission-critical need for our services within the healthcare industry, our growth historically has been impacted by broader global healthcare trends as opposed to macroeconomic trends. Trends including an aging population and increased access to, and demand for, healthcare services globally, have driven increases in volume demand for medical device and pharmaceutical products. In addition, the need for product enhancement and innovation by manufacturers drives further demand for our services. We believe the sterilization and lab services markets will continue to benefit from these trends, as well as from the increasingly complex regulatory

 

98


Table of Contents

and compliance environment and heightened focus by consumers on personal safety. As our customers continue to focus on innovation of their own products, they have increasingly relied on our expertise and our outsourced services to help them get their products to market. We believe our ability to provide end-to-end sterilization and lab services makes us a trusted partner to our customers in these large and growing markets.

Sterilization services business with an established and durable customer base supported by long-term contracts provides highly recurring revenue streams

We provide expertise and end-to-end sterilization services for our customers leading to deep, trusted relationships that allow them to meet their global regulatory compliance needs. Our relationships with our Sterigenics and Nordion customers are typically governed by multi-year contracts with cost pass-through provisions, which have resulted in recurring revenue streams and accretive growth. In addition, these customers often look to us as a long-term provider given switching providers can be costly and burdensome. For example, in most circumstances, switching providers requires additional testing, re-validation and FDA submissions and can take anywhere from six months to three years depending upon the class of product. Our relationships with our top ten sterilization services customers in 2019 had an average tenure of over a decade. Our partnerships with these customers have led to close to 100% renewal rates over the past five years.

Expertise and strong track record in highly regulated markets

We and our customers operate in highly complex and regulated markets that require deep knowledge and technical expertise. We believe that the operational discipline that we employ to manage intricate quality assurance and EH&S programs in our own operations gives our customers confidence that we are the best partner to support them in their businesses. For example, we design and install emission controls in our EO facilities that often outperform the regulatory standards that we are required to meet. We also have a skilled team which has developed trusted relationships with numerous regulatory bodies around the world. For example, in 2019 we were selected by the FDA as one of eight participants to move to the next stage of a public innovation challenge to encourage the development of new approaches to medical device sterilization and new strategies to reduce EO emissions. We work closely with our customers, the FDA and others to consider enhanced EO cycle design and processes that would reduce EO emissions from the EO sterilization process to as close to zero as reasonably possible. Our relationships, combined with our thought leadership that is recognized by regulators and customers alike, enable us to inform the process of creating, interpreting and advising on safety standards. They also allow us to educate and advise our customers on current and newly evolving standards and requirements.

Global scale and integrated facility network provide differentiated services to our customers

We have a global network of 63 facilities, consisting of 50 sterilization services facilities and 13 labs, through which we provide services to more than 5,800 customers that have operations in over 50 countries. We have worked to standardize our enterprise resource planning, global quality and EH&S systems to integrate our network of facilities globally. This integration is critical for our customers, who operate globally and look for partners that can provide the same level of service, experience and expertise wherever they operate. We serve many of our sterilization customers at more than one facility, with more than 80% of Sterigenics’ net revenues attributable to customers using more than one of our facilities and more than 50% of Sterigenics’ net revenues attributable to customers using five or more of our facilities in 2019. The capital to replicate the scale of our global facility network, extensive and complex upfront licensing processes and intense regulatory compliance requirements make it extremely difficult for new competitors to easily enter our markets and replicate our scale. The combination of Sterigenics and Nordion makes us the only vertically integrated global supplier of gamma irradiation services, which allows Nordion to more confidently make long-term investments to expand Co-60 supply for the medical products sterilization industry. We believe our global scale, supported by our integrated facility network and core capabilities including deep end market, regulatory, technical and logistics expertise, will allow us to continue to expand our service offerings and customer base.

 

99


Table of Contents

Experienced management team with proven track record of execution and financial performance

Our management team has significant industry expertise, an unwavering commitment to operational excellence and a proven track record of delivering financial performance. Our culture of accountability runs throughout the entire organization and has contributed meaningfully to our operational achievements and commercial success. Our management team is supported by nearly 2,900 team members around the world who are dedicated to safety and quality, which is why we are a trusted partner to our customers. We have delivered revenue growth every year since 2005, even through significant economic downturns, and have implemented productivity initiatives which have led to margin expansion. Our team brings extensive experience and is highly skilled at recognizing and acting upon market expansion opportunities. Our disciplined approach to M&A has enabled the successful integration of two transformational and seven bolt-on acquisitions over the past six years. In addition, we are disciplined in our capital deployment strategy, which is focused on achieving attractive returns on investment. We pursue capacity expansions that will allow us to consistently grow earnings.

Our Strategy

Our strategy is designed to deliver on our mission of Safeguarding Global Health®, while generating sustainable growth, margins and cash flows for our business:

Drive organic growth by leveraging our leading capabilities, scale and global network

We believe that our established and durable relationships with our diverse customer base, along with the breadth and depth of our service offerings, provide us with a distinct leadership position within the markets that we serve. Our deep experience in sterilization and lab services allows us to be agile in identifying opportunities and decisive in deploying resources towards these opportunities to drive organic growth. We intend to continue capitalizing on our leadership position and integrated global facility network and capabilities to drive our growth by expanding existing customer relationships and attracting new customers. We also seek to accelerate our penetration in high-growth end-markets such as pharmaceuticals.

Deepen our customer relationships with our comprehensive service offerings in sterilization and lab services

Our customers around the world trust us to provide them with the highest quality sterilization and lab services. We are focused on broadening the number and range of services that each of our customers purchase from us by leveraging our core capabilities. We have continued to work on improving our customer interactions in order to deliver a “one company” experience across our sterilization and lab services so that we can further deepen our customer relationships. We provide comprehensive end-to-end services across our customers’ value chains so they can efficiently deliver the safest products to their end-users. We are the only industry player that offers the range of sterilization and lab services at the scale that we do. We strive for the full integration of our global operations to drive consistency across our services and provide our customers with a coordinated and seamless experience, designed to reduce cycle times for our services and improve efficiency. Our offerings facilitate long-term partnerships with our customers and make us an integral part of their product development and commercialization processes. We have multiple decades of deep expertise across key sterilization modalities as well as lab testing services across our customers’ full product lifecycles. We provide over 800 laboratory tests, which we believe is multiple times the number of offerings of our nearest competitor.

Expand footprint to meet the local needs of our growing global customer base

We are focused on aligning our facility network to best meet our customers’ requirements. We believe our valuable insight into our customers’ current and future needs will allow us to efficiently grow our business. Our global presence reflects our commitment to developing our footprint to serve our customers’ supply chains. Our integrated network of facilities is important to our customers as they can rely on the same level of service at each of our facilities, regardless of where they are around the world. We believe our sterilization services customers

 

100


Table of Contents

are seeking a partner that can operate near their manufacturing sites and distribution centers around the world, as transportation and logistics costs can be meaningful for our customers. In certain circumstances we will invest in projects to build capacity ahead of demand in alignment with the strategic plans of our customers. Our lab services customers are seeking expertise with both international and U.S. regulatory bodies. As our customers expand their global operations, we are well-equipped to expand with them and serve them where they need us.

Invest in technical and regulatory capabilities to enhance our leadership position

Our customers depend on our deep and extensive technical knowhow to get their products to market. We plan to continue to invest in our technical expertise and regulatory knowhow to stay ahead of the dynamic and increasingly complex regulatory landscape in the healthcare industry. Our combination of technical and regulatory expertise allows us to advance the standards of safety for crucial products whose end-users include healthcare practitioners and patients. As customers look to us for expertise, this landscape creates opportunities for us to drive growth in our advisory services offering. We believe that our position as a key industry thought leader makes us a trusted partner for customers as they are developing new products and a respected industry partner for regulators as they are defining industry standards of safety for the future.

Continue our commitment to operational excellence to drive business efficiency and results

Our focus on operational excellence has allowed us to increase capacity utilization and improve working capital, thereby growing our revenues while expanding margins and improving the customer experience. Our commitment to implementing and improving customer-experience enhancing initiatives and internal processes has been a key driver of our strong financial profile to date. Our customer-facing initiatives around cycle time reduction, quality self-service reporting, purchase order accuracy and scheduling efficiencies highlight our rigorous, detail-oriented approach to operational excellence and connectivity with our long-time customers. These initiatives are designed not only to reduce turnaround times and increase predictability of service for our customers, but also to maximize our financial results. We will continue to address our customers’ expectations through our internal processes centered on talent management, quality, EH&S and information technology. We believe that these processes will enable us to continue to deliver growth, profitability and cash generation.

Pursue value-creating strategic acquisitions to expand our addressable market and enhance our global capabilities and footprint

Our disciplined approach to M&A has resulted in our successful track record of identifying, completing and integrating strategic acquisitions into our company and we intend to continue to pursue value-creating strategic acquisitions. We have implemented a disciplined framework to support our acquisition efforts that focuses on quality businesses that are well-regarded by our customers and aligned with our culture of accountability, customer service and operating with integrity. Illustrating this highly disciplined acquisition framework are our two transformational acquisitions of Nordion and Nelson Labs. In addition to these major acquisitions, we acquired FTSI, Gammarad, CBE, REVISS, Toxikon Europe NV, Gibraltar Laboratories and Iotron, which provided geographic, technical and service line expansions. Our acquisition of Nelson Labs expanded our capabilities by creating an enhanced lab services platform to provide microbiology testing within our existing customer end-markets and increasing the number of tests we could provide to our customers. We have a strong foundation to continually evaluate acquisition opportunities that would expand our addressable market and enhance our global capabilities and footprint. We are well positioned to evaluate other acquisitions that leverage our core capabilities while expanding our existing customer relationships. We currently have a significant pipeline of targets, ranging from small, owner operated businesses to larger businesses, and believe that we can identify the appropriate targets and integrate them seamlessly into our business.

Industry Overview

We operate in the terminal sterilization and outsourced lab testing industries. We estimate that the total global addressable market for terminal sterilization and outsourced medical device and pharmaceutical lab testing

 

101


Table of Contents

was approximately $33 billion in 2019. Global terminal sterilization accounted for $3 billion of our estimated total addressable market in 2019 and we believe it is growing. Global outsourced medical device and pharmaceutical lab testing services accounted for $29 billion of our estimated total addressable market in 2019, with approximately $3 billion attributable to medical devices and approximately $26 billion attributable to pharmaceuticals, and we believe it is growing.

We expect several positive secular trends to drive increased demand for our services, including:

 

   

Favorable demographic trends for healthcare worldwide: Healthcare demand is increasing globally, driven primarily by an aging population and an increased prevalence of chronic diseases. According to data published by the United Nations in 2019, the world’s population is expected to increase by 2 billion people in the next 30 years. In addition, one in six people are projected to be over the age of 65 globally by 2050, up from one in eleven in 2019. United Nations projections from 2019 also show that the number of people aged 80 or older is expected to triple in the next 30 years. These trends are driven by declining fertility and increasing longevity, as well as international migration. In many regions, the population aged 65 is projected to double by 2050, while global life expectancy beyond 65 is expected to increase by 19 years. In March 2020, the CMS estimated that health expenditures in the United States will increase from approximately 18% of gross domestic product in 2018 to approximately 20% in 2028.

 

   

Increased demand for healthcare services in global markets: Stricter healthcare standards coupled with heightened regulatory requirements, greater availability of care and increased patient purchasing power are driving increased demand for healthcare services. In emerging markets, rapid urbanization and rising income, combined with an increase in diseases such as diabetes and cancer, have fueled the growth in access to, and demand for, healthcare services. In addition, the COVID-19 pandemic has also increased awareness of the importance of decontamination and sterilization. In 2018, the CMS estimated global healthcare costs to be approximately $4 trillion in 2019 and projected they would reach more than $6 trillion by 2027.

 

   

Growth in R&D spending and innovation across healthcare: The pharmaceutical and medical device industries are continuously innovating and developing new products, which we anticipate will increase the demand for sterilization and lab services. Worldwide pharmaceutical R&D spend is forecasted to grow steadily at a CAGR of approximately 3% between 2019 and 2026, reaching $233 billion by 2026 (EvaluatePharma® July 2020, Evaluate Ltd.). In the medical devices market, the global top twenty companies based on R&D spending spent a combined $18 billion on R&D in 2017 (EvaluateMedTech® World Preview 2018, Evaluate Ltd.). This number is expected to grow at a 4% CAGR, reaching approximately $24 billion by 2024 (EvaluateMedTech® World Preview 2018, Evaluate Ltd.).

Sterilization overview

Sterilization is a process used to render a product free of viable organisms that may lead to infectious diseases. Terminal sterilization refers to sterilization of the product in its final packaging and is the last step in production before the product is shipped to the end-users. Sterilization is a highly technical and regulated industry in which companies are subject to environmental, health and safety regulations in the jurisdictions in which they operate. With an increased focus on sterilization and de-contamination, particularly in light of the COVID-19 pandemic, we expect the importance of the sterilization industry to continue to grow. In the medical device and pharmaceutical industries, sterilization is a regulatory requirement and essential step in the manufacturing and distribution process. Sterilization services, primarily decontamination, are also critical for the food safety end market, as stricter regulations have been introduced to ensure the safety and quality of products. Due to the technical and regulatory expertise needed for sterilization, outsourced sterilization service providers add significant value to their customers. Medical device and pharmaceutical manufacturers often outsource their sterilization needs, as the technical and regulatory expertise and infrastructure required to establish those capabilities in-house can result in significant cost and resource burden.

 

102


Table of Contents

The three main sterilization technologies are gamma irradiation, EO processing and E-beam irradiation. Other developing or niche sterilization technologies include x-ray, nitrogen dioxide (NO2) and hydrogen peroxide sterilization. In determining the optimal sterilization method for any given product, the type of product, its physical properties and designated use, the type and quantity of bioburden measured on the product, applicable regulatory requirements, how the product will be packaged, as well as the size, weight and density are all considered.

 

   

Gamma irradiation: A process in which products are exposed to gamma rays emitted by Co-60. Gamma rays can penetrate even dense materials to kill microbes. Co-60 is a particularly effective consumable used for sterilizing high-density medical products, such as sutures, surgical tools and stents. The natural decay of Co-60 at approximately 12% a year leads to steady replacement demand for the isotope.

Below is an example of a gamma irradiation facility.

 

LOGO

 

103


Table of Contents
   

EO processing: A gas sterilization process in which pallets of packaged goods are loaded into a secure chamber that is then injected with EO gas to penetrate the packaging. EO is the most widely used gaseous sterilization agent in the world and has been in use for nearly 90 years. The broad application to a range of medical devices is attributed to the fact that EO is compatible with many materials that cannot tolerate or are degraded by radiation and moist heat sterilization. For this reason, it is commonly the only method available to safely and effectively sterilize procedure kits, PPE and many devices used in cardiac procedures.

Below is an example of an EO processing facility:

 

LOGO

 

104


Table of Contents
   

E-beam irradiation: A process in which products are exposed to machine-generated radiation in the form of a stream of electrons. E-beam is particularly effective for low density homogenous products such as glass labware. Several medical devices products also rely on E-beam as an effective form of sterilization, including certain types of syringes. In addition to medical device sterilization, E-beam can also be used as an effective technology for materials modification, such as the crosslinking of certain polymers or for enriching the color of gemstones.

Below is an example of an E-beam processing facility:

 

LOGO

 

   

Other modalities: X-ray irradiation is a process in which products such as medical devices and labware are exposed to machine generated radiation in the form of X-rays for the purpose of sterilization and decontamination. NO2-based sterilization, which offers ultra-low temperature and minimal pressure requirements, can be effective in the sterilization of prefilled syringes, drug-device combination products and custom implants, but is limited as it cannot be used with cellulose materials such as cardboard. Hydrogen peroxide sterilization is a low temperature process that is also incompatible with cellulose material. This technology has historically been focused on competing with autoclaves in the hospital for re-sterilization of surgical tools and devices. Challenges for NO2 and hydrogen peroxide for commercial sterilization also include smaller chamber sizes and load limitations.

Entry into the sterilization business requires significant capital investment, extensive process development and access to supplies of raw materials. The high cost of technology and capital expenditure required, combined with stringent regulations, create high barriers to entry for new outsourced sterilization providers.

We estimate that the global demand for terminal sterilization was approximately $3 billion in 2019.

 

105


Table of Contents

Lab services overview

Companies use microbiological and analytical chemistry lab testing and advisory services to ensure safety and compliance of key product attributes across the medical device, pharmaceutical and food safety end markets. Microbiology tests help identify and measure the potential risks of microbes to a product and ensure that the quality of the products is maintained. Key testing techniques used include chemical, microbiological, biochemical and molecular methods to quantify, identify and assess the risk of microbes present on samples. Analytical chemistry lab testing is also a critical part of the drug development and the manufacturing process. The qualitative and quantitative results generated from validated analytical testing provide first-hand information as to the content, quality and safety of raw materials, intermediates and finished products. Lab testing is critical for ensuring product quality, patient safety, effectiveness and end-to-end sterility for customers.

Expert advisory services offered in the lab services industry aid customers in navigating the appropriate regulatory standards at any stage of the product life cycle, including supporting them through the regulatory submission process. Medical device manufacturers, who are seeking to maximize efficiency of capital, supply chain, reach and regulatory compliance, are increasingly using lab services providers for testing and advisory services. Technological advancements, rising cases of infectious diseases and increasing stringency and complexity of regulatory standards have continued to drive growth in this market. The high cost of reagents, instruments, equipment and validation requirements create high barriers to entry for emerging competitors.

Laboratory testing must be performed in accordance with applicable standards and regulatory requirements around the world, including those set by the FDA, Health Canada, Medicines and Health products Regulatory Agency, Therapeutic Goods Administration and China’s National Medical Products Administration as well as those of standards organizations like the ISO, American National Standards Institute and Association for the Advancement of Medical Instrumentation (“AAMI”).

We estimate that the global medical device and pharmaceuticals lab testing segment size was approximately $59 billion in 2019. Of that demand, we estimate that the outsourced component, which represents our addressable market in lab services, represented approximately $29 billion of that total.

End markets we serve

We primarily serve the medical device, pharmaceutical and, to a lesser extent, food safety end markets with our sterilization and lab services. Through our Sterigenics brand, we provide sterilization services which are essential to the manufacturing process of medical device and pharmaceutical products such as procedure kits and trays, implants, syringes, catheters, wound care products, medical protective barriers including PPE, laboratory equipment and pharmaceuticals. Through our Nordion brand, we are the leading global provider of Co-60 and gamma irradiators, which are the key components in the gamma sterilization process, and we are also a leading supplier of Co-60 sources for stereotactic radiosurgery devices (such as the Gamma Knife®), which are used for certain oncology applications. Through our Nelson Labs brand, we provide microbiological and analytical chemistry lab testing services to medical device and pharmaceutical manufacturers which assess the safety, effectiveness and compliance of products necessary for regulatory approvals, commercialization and ongoing product performance evaluations.

In addition, we provide microbial de-contamination and microbial remediation services for the food industry. We currently irradiate a variety of food and food packaging products to guard against harmful bacteria, such as listeria, salmonella, E. coli and other pathogens. We also provide microbial remediation services that stop the progression of damage to products and help make the products safe for distribution.

Medical device

We serve more than 40 of the top 50 medical device companies globally (based on revenue).

The medical device industry manufactures a range of products from simple consumables, such as surgical gloves and other PPE, to more complex devices, such as medical implants, all of which are essential to

 

106


Table of Contents

maintaining human health. Medical devices and implants are typically in contact or even inserted within the human body, making it even more important that they meet rigorous safety and sterility requirements. There is a diverse mix of established, large companies and fast-growing entrants that fuel innovation and adoption of new technologies in the industry.

Prior to 1950, medical device sterilization was often performed in a medical practitioner’s office or by a hospital’s central sterilization department using steam, dry heat or chemical solutions. Sterilization controls were not rigorous, resulting in healthcare-associated infections, and hospital-acquired infections caused by medical procedures. The advent of single-use, disposable medical devices, which are packaged to maintain sterility up to the point of use, provided an effective solution to this problem and shifted the burden of sterilization from the healthcare system to the medical device manufacturer. The introduction of low-cost biocompatible plastic resins with characteristics appropriate for medical devices and packaging as well as the adoption of EO sterilization as an effective, low-temperature process for sterilizing medical devices accelerated this industry shift. According to the FDA in 2019, more than 20 billion devices sold in the United States every year are sterilized with EO, accounting for approximately 50 percent of devices that require sterilization.

Pharmaceuticals

Pharmaceuticals continue to be a key driver for our growth. Today, we serve eight of the top ten global pharmaceutical companies (based on revenue).

Small and large molecule development is regulated by the FDA, and requires a complex and lengthy research and development processes. For approved products, regulatory standards have become increasingly stringent in recent years especially as they relate to the drug manufacturing process and overall supply chain. Pharmaceutical manufacturers look to services providers who are able to satisfy their industry’s rigorous regulatory and quality standards at all stages, from research and development to production and commercialization. Several sector trends have contributed to growth in the pharmaceutical industry, including growth in R&D spending, increased levels of outsourcing by pharmaceutical companies, as well as increased complexity of clinical development and manufacturing given the emergence of large molecule therapeutics.

Food safety

We currently serve several large customers in the food processing industry, such as beverage companies and spice manufacturers.

Food safety testing is a major and necessary step in food processing. Processed foods are the major category of products that are tested for safety and quality profiles. The global food safety testing market is segmented by contaminant type into pathogen testing, mycotoxins, pesticides, residue testing and others. The market is further segmented by technology and application. The rising number of foodborne diseases, adulteration cases and toxicity cases has dramatically increased the need for food safety testing. In 2018, the Centers for Disease Control and Prevention (the “CDC”) estimated that one in six Americans get sick from contaminated foods or beverages every year, and 3,000 Americans die annually. The U.S. Department of Agriculture estimated in 2018 that foodborne illnesses cost almost $16 billion each year. Growing consumer interest in food quality with high technological advancements is further driving the food safety testing market in developed countries.

The CDC, FDA and USDA’s Food Safety and Inspection Service collaborate closely at the federal level to promote food safety. The CDC works with local, state and federal partners to investigate outbreaks and implement systems to better enhance safety. The U.S. Food Safety Modernization Act (“FSMA”) was enacted in 2011 in response to dramatic changes in the global food supply chain and the rise of foodborne illnesses during the 2000s. FSMA has given the FDA new authorities to regulate the way foods are grown, harvested and processed. The law granted the FDA the ability to recall products and includes seven major rules for ensuring the safety of food supply including good manufacturing practice requirements and laboratory accreditation programs.

 

107


Table of Contents

Our Businesses

Sterilization Services

Our sterilization services business is comprised of Sterigenics and Nordion.

Sterigenics

We are a leading global provider of outsourced terminal sterilization services and have provided sterilization services for nearly 90 years. We offer a globally integrated platform for our customers in the medical device and pharmaceutical industries, with facilities strategically located to be convenient to their manufacturing sites or distribution hubs.

Terminal sterilization is the process of sterilizing a product in its final packaging; it is an essential, and often government-mandated, last step in the manufacturing process of healthcare products before they are shipped to end-users. These products include procedure kits and trays, implants, syringes, catheters, wound care products, medical protective barriers, including PPE, laboratory products and pharmaceuticals.

Sterilization Services

We offer our customers a complete range of terminal sterilization services, primarily using the three major commercial terminal sterilization technologies: gamma irradiation, EO processing and E-beam irradiation. We continue to invest in and develop our capabilities and our current methods of sterilization, as well as explore new alternative modalities and technologies. Our primary terminal sterlization technologies include:

 

LOGO

See “Industry Overview—Sterilization overview” for more detail about these technologies. We provide gamma irradiation services at 23 of our facilities, EO processing services at 17 of our facilities and E-beam irradiation services at eight of our facilities.

In addition to the three major technologies, we invest in alternative modalities to serve our customers in niche applications. X-ray irradiation is a process in which products such as medical devices and labware are

 

108


Table of Contents

exposed to machine-generated radiation in the form of X-rays for the purpose of sterilization and decontamination. X-rays are similar in performance to gamma rays and are useful for processing certain materials due to the high penetration capabilities of X-ray. We utilize X-ray irradiation at one of our sterilization facilities for bio-hazard reduction for the United States Postal Service, or USPS. In addition, we are also investing in NO2-based sterilization, which has been effective in the sterilization of prefilled syringes, drug-device combination products and custom implants.

Sterilization Applications

Sterigenics primarily provides sterilization services for medical device manufacturers and the pharmaceutical industry. Sterigenics also provides decontamination services for the food industry. Additionally, Sterigenics provides various advanced applications for other organizations and companies including the USPS and semiconductor manufacturers. Our customers select the sterilization method that meets the needs of their products and requirements of regulators and we deliver sterilization services according to their customer-specific protocols. In most cases, customers are serviced from more than one facility.

 

   

Medical device sterilization. Medical device sterilization is a regulatory requirement in many jurisdictions and an important and last step in the manufacturing of healthcare products such as medical protective barriers, including PPE, procedure kits and trays, implants, syringes, catheters and wound care products. A broad range of single-use, prepackaged medical products, as well as certain consumer products, are required by government regulations to be sterile, or meet certain acceptable microbial levels when sold. These products are not manufactured in a “sterile” or “clean” environment and are thereby inhabited by potentially harmful microbes. Products must be treated as part of the production process before shipment to customers, either in-house by the manufacturer or by an outsourced sterilization provider, such as Sterigenics.

We have developed a consultative approach with medical device manufacturers that expands our service offerings beyond core product sterilization, as we believe they want value-added solutions from their outsourced sterilization partners that reach beyond the traditional scope of sterilization. We offer customers a comprehensive selection of advisory services in design, testing, production and supply chain management for sterile healthcare products before, during and after the sterilization process to ensure and improve a product’s speed to market and compliance with regulatory requirements.

 

   

Pharmaceuticals. We provide comprehensive outsourced terminal sterilization solutions to help our customers in the pharmaceutical industry meet regulatory requirements. Our sterilization expertise covers a variety of pharmaceutical drug products, such as active pharmaceutical ingredients, pre-filled syringes, drug components, excipients and primary packaging and components.

In addition, pharmaceutical companies are starting to market disposable delivery devices, such as auto-inject devices for epinephrine, which are combined medical device and pharmaceutical products. As these disposable delivery devices are subject to both medical device regulations and pharmaceutical regulations, we believe these companies are looking to leading outsourced sterilization providers like us for our expertise in sterilizing these complex devices. We believe that the complementary capabilities and expertise in our Nelson Labs business make Sterigenics an attractive sterilization partner to customers in the pharmaceutical industry. We can provide a full suite of services to help them throughout key stages in the lifecycle of these complex products.

 

   

Food and agricultural products. We provide microbial reduction and microbial remediation services for food and agricultural products. Generally, in a microbial reduction process, products are exposed to lower levels of treatment than in a sterilization process. This process is not intended to render a product free of viable organisms but rather to reduce their number. In connection with our microbial reduction services, we treat a wide array of products such as spices, herbs, animal feed and food packaging materials to address product liability concerns of our customers related to the health of the consumer or to extend shelf life. We currently irradiate a variety of food and food packaging products, ranging from

 

109


Table of Contents
 

orange juice to steaks, to guard against harmful bacteria, such as listeria, salmonella, E. coli and other pathogens. Microbial reduction and irradiation offer producers and processors a method to safeguard against bacteria from the time of packaging of their products to the time they reach consumers. We also provide microbial remediation services that stop the progression of damage to products and help make the products safe for distribution.

 

   

Commercial, advanced and specialty applications. We provide a wide range of advanced applications services for industrial materials to customers that use ionizing radiation to modify materials or products. The advanced applications sterilization industry represents over $1.7 billion of demand, with an outsourced value of approximately $350 million. It is comprised of a large number of distinct segments that can be addressed using our services for radiation processing. Materials that undergo advanced application processes include products such as power semiconductors, polymers and gemstones. In addition, we utilize our ionizing radiation services to provide bio-security services to the USPS by treating and protecting the mail against unwanted pathogens and biohazards. We believe we are the only provider of this service to the USPS. We also treat commercial products, such as cosmetics, with our microbial reduction services. In Canada and Europe, where recreational cannabis, medical cannabis, or both, are legal, we provide commercial gamma and E-beam irradiation services for decontamination of cannabis.

Sterigenics Customers

Sterigenics serves approximately 2,800 customers. We follow extensive validation procedures with our customers to determine the optimal sterilization method for each product, and to validate that the chosen method will achieve the sterility requirement for that product. Once a sterilization process has been validated, we adhere to our customers’ process specifications to treat their product.

Sterilization services are an essential element in our customers’ manufacturing processes but generally represent a small fraction of the total end-product cost of medical devices. We believe this means that our customers choose our services based on quality and consistency of service rather than solely on the cost. These deep, tenured customer relationships are supported by multi-year contracts with cost pass-through provisions, which have resulted in recurring revenue streams.

For many products, our customers are required to include the specific facility used to validate a product’s listing in the FDA (or foreign equivalent) product registration and are typically required to re-register if they switch facilities, making switching locations for a particular product a difficult and expensive process for our customers. This dynamic contributes to low customer churn and long-term relationships within our business.

In addition, Sterigenics has achieved high historical customer retention and renewal rates—Sterigenics has close to 100% renewal rates of its top ten customers over the last five years, and an average tenure of over a decade with its top 25 customers over the last five years—and minimal customer concentration. We have also introduced innovative, advanced processing systems for outsourced sterilization that are designed to enhance operating efficiencies, improve turnaround times and provide for greater processing flexibility without sacrificing quality, consistency or reliability.

Sterigenics Competition

We compete globally with Applied Sterilization Technologies, a segment of STERIS plc, as well as other smaller or regional outsourced sterilization companies. In addition, some manufacturers have invested in in-house sterilization capabilities. We also face competition from other technologies, such as chemical cross-linking of polymers. Our services generally compete on the basis of the quality of technology and services offered, level of expertise in each of the major sterilization methods, level of expertise in the applicable regulatory requirements and proximity to customers.

 

110


Table of Contents

Sterigenics Suppliers

We primarily purchase our supply of Co-60 sources, the key input into the gamma sterilization process, from Nordion. Our supply of Co-60 sources is at times impacted by the global availability of Co-60. Our supply of EO is sourced from various suppliers around the world. There is more than one supplier of EO in most of the countries in which we operate; however, in the United States, there is a single supplier for EO to our industry. We have not historically experienced any supply disruptions and our U.S. supplier has redundant production facilities to help ensure reliable EO supply. We also have a license in the United States to distribute EO to self-supply should the need arise and we determine to make the necessary investments.

Sterigenics Facilities

With 48 facilities in 13 countries, our global network of sterilization facilities represents a significant competitive advantage. We serve many of our sterilization customers at more than one facility, with more than 80% of Sterigenics’ net revenues attributable to customers using more than one of our facilities and more than 50% of Sterigenics’ net revenues attributable to customers using five or more of our facilities in 2019. Extensive capital, technical expertise and regulatory knowledge are required to build and maintain facilities like ours. We estimate that one new facility can cost over $30 million to build, on average, and require extensive and complex licensing approval and regulatory compliance processes. We estimate that the cost to replace the facilities in our network alone could be as high as $1.5 billion or more, in addition to the technical and regulatory requirements.

Our global facility network, built and expanded over several decades, is strategically located convenient to customers’ manufacturing sites and distribution hubs or routes. For many of our customers, the location of our facilities is important because transportation and logistics costs can be meaningful. We also employ proprietary technology to provide customers with increased visibility into our processes. Sterigenics GPS enables customers to monitor the sterilization process in real-time and better manage their supply chain. These features improve the accuracy and visibility of customer order information and quality data, which in turn provide enhanced transparency to regulatory agencies around the world, further enhancing our reputation as a company with regulatory expertise. We are focused on continuing to leverage advanced technology and service offerings to better serve customers, and we believe our capital and resource commitment in this area drives customer loyalty and retention.

By leveraging a global operating system, we drive operational excellence across our network of facilities in order to achieve high levels of safety, quality, operating efficiency and customer satisfaction to provide a uniform customer experience. All facilities are either ISO 13485 certified, ISO 9001 certified or both, as well as licensed and registered in all necessary jurisdictions to comply with government required regulations.

Nordion

Nordion is the leading global provider of Co-60 sources and production irradiators, which are the key components in the gamma sterilization process. Co-60 is a radioactive isotope that emits gamma radiation that sterilizes items by killing contaminating micro-organisms. Production irradiators are the units that house the Co-60 sources within a gamma sterilization facility. We estimate that gamma sterilization, which is a critical component of the global infection control supply chain, represents approximately 30% of single-use medical device sterilization worldwide. Nordion’s customers include both outsourced contract sterilizers, including Sterigenics, as well as medical device manufacturers that sterilize their products in-house.

We provide our customers with high quality, reliable, safe and secure Co-60 source supply at each stage of the source’s life cycle. We support our customers with handling and processing of Co-60, recycling of depleted sources and global logistics enabled by our licensed container fleet. We also provide regulatory and technical service expertise to improve the risk profiles and enhance effectiveness of gamma processing operations. Without this radioactive material, gamma sterilization would not be possible on the global scale at which it is used today, and we are integral to our customers’ operations due to highly coordinated and complex installation processes.

 

111


Table of Contents

Nordion has a long history of innovation in gamma technologies. Nordion designs, installs and maintains production irradiators. Nordion developed the first Co-60 based tele-therapy unit for cancer treatment in 1951 and the first panoramic irradiator in 1964. In addition to selling Co-60 sources for sterilization purposes, Nordion also sells high specific activity Co-60 (“HSA Co-60” or “medical Co-60”) used in stereotactic radiosurgery as a radiation source for oncology applications, specifically in the Gamma Knife® and other similar applications. Today, Co-60 is a critical part of treatment for brain and other cancers because it is noninvasive, reliable, effective and safe to use.

Co-60 Production Process

Nordion’s primary product is Co-60 sources. Co-60 is a radioactive isotope used in radiation sterilization that decays naturally at a rate of approximately 12% annually. Co-60 is produced by placing cobalt-59 (“Co-59”), the most common form of cobalt, into a nuclear power reactor to be activated.

The Co-60 production process requires high purity Co-59. Co-59 is produced globally, primarily as a byproduct of nickel and copper mining, and is used in a variety of industrial applications. The Co-59 used for sterilization accounts for a small portion of overall Co-59 demand. Co-59 is compressed into “targets,” which are pellets and slugs suitable to be activated into Co-60. These targets are then encapsulated and delivered to be installed in nuclear reactors. Depending on the type of reactor and the location of the Co-59 in the reactor, the conversion process can take between 18 months and five years. Once the conversion to Co-60 is complete, the targets are extracted from the nuclear reactor while the reactor is shut down and shipped to Nordion to be processed into Co-60 sources to be sold to customers. See “Risk Factors—Risks Related to the Company—Safety risks associated with the use and disposal of potentially hazardous materials, such as EO and Co-60, may result in accidents or liabilities that materially affect our results of operations.”

Nordion Products

Co-60 is sold to customers by its level of radioactivity, measured in curies. Our customers typically buy low specific activity Co-60 (“LSA Co-60”) for industrial sterilization use and HSA Co-60 for medical use. At our Ottawa facility, we receive and process the targets to form the final Co-60 source product with the desired amount of radioactivity for each customer order. The Co-60 sources undergo stringent and sophisticated quality assurance testing at our facility. The final product is then placed in large regulatory licensed steel and lead shipping containers, which Nordion uses to transport Co-60 to our customers.

We transport the Co-60 sources via proprietary lead and steel containers that are licensed to meet all applicable international shipping requirements. We believe we have the most extensive expertise in Co-60 logistics. There is a significant regulatory burden in the production, management and transportation of fleets of containers of Co-60 sources. Our transportation routes and carriers are highly controlled, and we provide regular and comprehensive training for employees and carriers who are involved in moving the Co-60 globally.

We also design, install and maintain production irradiators, which include radiation shielding, a series of conveyors and control systems that are designed to expose products to the correct gamma radiation dosage in a safe and efficient manner. A production irradiator is the infrastructure that houses the Co-60 sources and makes up a part of a sterilization and warehousing facility. We have designed and built over 100 of the estimated 290 large scale production irradiators active globally. Our installation, physics and engineering teams are comprised of highly trained professionals who provide fast and ongoing technical support from source installation to emergency response.

We also offer our customers a for-fee spent Co-60 source return service for depleted Co-60 sources that have reached end of their useful life, which is often 20 or more years. We also have a source recycling program that extends the useful life of individual slugs from the decayed product up to an additional 20 years, pairing them with new slugs to make new Co-60 sources.

 

112


Table of Contents

Nuclear Reactor Operators

Given the timeline required to produce Co-60, forecasting supply and working closely with nuclear power reactor operators to manage the amount and timing of shipments represents an important business capability of Nordion.

The amount of Co-60 supply is ultimately determined by the number of nuclear reactors that are capable of producing Co-60 at a given point in time. Our access to Co-60 tends to vary on a quarterly basis, due primarily to the nuclear reactor maintenance schedule, length of time required to convert Co-59 into Co-60, the limited number of facilities that can generate Co-60 in an economically efficient manner, and the timing of the removal of Co-60 from reactors. While short-term variability in Co-60 supplier delivery timing can result in variability in our financial performance in one or more fiscal quarters, we work with multiple reactor sites that operate on consistent and predictable discharge and harvest schedules over the long-term.

Nordion currently has access to Co-60 supply at multiple nuclear reactors pursuant to multi-year contracts with three operators that cover 14 reactors at four generating stations, that extend to dates between 2024 and 2064, with our largest supplier under contract until 2064. See “Risk Factors—Risks Related to the Company—We depend on a limited number of counterparties that provide the materials and resources we need to operate our business. Any disruption in the availability of, or increases in the price of, EO, Co-60 or our other direct materials, services and supplies, including as a result of current geopolitical instability arising from U.S. relations with Russia and related sanctions, may have a material adverse effect on our operating results.” The substantial majority of our Co-60 material has historically been produced under multi-year contracts with nuclear reactor operators in Canada and Russia. Nordion provides Co-59 targets to its Canadian and Russian reactor suppliers, manufactured to proprietary specifications customized for each supplier. In addition, we also acquire a portion of our Co-60 supply from reactors that produce Co-60 in Russia, China and India.

The vertical integration of Nordion and Sterigenics has allowed us to more confidently make meaningful long-term investments to expand Co-60 supply for the medical products sterilization industry. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Trends and Key Factors Affecting Our Results of Operations.” Currently, approximately 9% of nuclear reactors worldwide are the type of reactors that have been capable of producing commercial quantities of Co-60. In December 2018, we acquired patents that may allow us to significantly increase our sourcing options for Co-60 and further expand the market for gamma sterilization. Additionally, in February 2020, we announced a collaboration with Westinghouse Electric Company to further develop the technology to produce Co-60 at reactors in the United States. If successful, we believe this collaboration could further diversify our supply with reliable U.S. domestic partners and encourage the implementation of this patented technology at other reactors.

We continue to work closely with Canada Deuterium Uranium (“CANDU”) reactor operators to monitor refurbishment schedules, and to evaluate opportunities for an increase in Co-60 production from both Russian and CANDU reactors. We are exploring partnerships with other CANDU reactor operators in Canada and Romania that would involve investing in their reactor infrastructure to enable long-term production of Co-60.

From time to time we also purchase Co-60 on the spot market and will continue to explore opportunities for supply in the global market.

Nordion Customers

Nordion supplies products and services to approximately 40 customers, including medical device manufacturers and gamma sterilization service providers. Co-60’s consumable nature results in annual natural decay at an approximately 12% annual rate, which creates stable, recurring demand as customers must purchase incremental supply in order to satisfy ongoing needs. We are integral to our customers’ operations due to highly coordinated and complex installation and service processes that require expertise in handling and shipping radioactive material as well as our deep knowledge of the relevant regulatory and compliance requirements. Customer relationships are typically governed by multi-year supply agreements.

 

113


Table of Contents

One of Nordion’s customers is Sterigenics, which competes with several of Nordion’s other gamma sterilization service customers. When we acquired Nordion in 2014, we established information barriers between Nordion and Sterigenics with regard to certain customer information, which are still in place today, and we have certain agreements with Nordion’s customers requiring these barriers. These barriers constrain our ability to manage a pricing strategy across our Sterigenics and Nordion segments with regard to customers.

We are a leading global supplier of HSA Co-60 used in oncology-related stereotactic radiosurgery devices, including the Gamma Knife®, which use directed gamma rays for certain oncology applications. We also supply other medical equipment manufacturers and sub-contractors in the industry who require the concentrated radiation dose capabilities of HSA Co-60.

Nordion Competition

Nordion’s two main competitors in the industrial LSA Co-60 sources supply market include a Russian Co-60 sources producer, which currently supplies certain regions in Europe and Asia, and a China-based producer, which currently supplies the domestic Chinese market. In addition, certain regional competitors have the capability to produce Co-60. These competitors could potentially increase their global competition capabilities in the future. Nordion also competes indirectly with other developing modalities of sterilization, such as X-ray technology, that can sterilize similar products as gamma sterilization but which use electricity to generate radiation and therefore do not require Co-60 sources.

Nordion’s main competitors in the HSA Co-60 industry include suppliers in China, Sweden and North America that have capacity to produce medical Co-60. From 2017 to 2020, growth in our sale of medical Co-60 for the stereotactic radiosurgery device industry benefited from other competitors’ supply disruptions and lack of reliability.

Nordion Facilities

Nordion’s operations are supported by a facility in Kanata, Canada dedicated to processing and shipping cobalt, as well as a European distribution facility in Milton, United Kingdom.

Lab Testing and Advisory Services

Nelson Labs

Lab testing and advisory services are necessary across the medical device and pharmaceutical product lifecycles to evaluate and ensure a product’s safety and effectiveness. We are a global leader in outsourced microbiological and analytical chemistry testing services for the medical device and pharmaceutical industries. In addition to our testing services, our customers often call upon our experts for technical assistance and our advisory services. We go to market leveraging our global footprint and an extensive range of services under our Nelson Labs brand.

We have established ourselves as a critical partner for our customers through our delivery of high quality services, quick testing turnaround times, responsiveness, high-touch support and easy accessibility to our science and service teams. We have an industry-leading brand recognized for the quality and comprehensiveness of service, both of which can take many years to build. Further, we believe that our testing and advisory services offerings and experience across a broad array of products differentiate us from smaller laboratories, as we are able to provide testing and advisory services across the entire lifecycle of our customers’ multitude of products. Our scale combined with our global network enable us to undertake significant and time-sensitive projects for our customers that might typically require them to interface with multiple labs. This allows us to simplify complex issues for our customers and streamline communication and execution. Moreover, the integration across our services and facilities enables us to assist our customers in minimizing their business continuity risk by reducing capacity shortages, turnaround time delays and throughput issues.

 

114


Table of Contents

Nelson Labs Services

Our microbiology and analytical chemistry services include over 800 tests. We also provide for-fee advisory services that position us as thought leaders in the industry and increase the demand for our testing offerings. These can be categorized into three broad categories that address different stages of customers’ product lifecycle:

 

   

Product Development and Validation. Prior to a new medical product or alteration to an existing product being submitted for regulatory approval, Nelson Labs provides a variety of tests to customers during the research and development stage. These include tests that assist the client in:

 

•  Product design

•  Material selection

•  Biological safety evaluation

•  Toxicological risk assessment

•  Sterilization modality selection and sterilization validation

    

•  Cleaning and disinfection validation (for reusable devices)

•  Package barrier properties

•  Distribution simulation

•  Filtration efficiency and physical functionality of PPE (including surgical facemasks, N95 respirators, gowns, drapes and other PPE)

We provide sterilization modality selection and sterilization validation services for a variety of sterilization modalities, including the three major modalities offered by Sterigenics—gamma irradiation, EO processing and E-beam—allowing us to serve our customers in multiple areas.

 

   

Expert Advisory. Bringing a medical product or drug to market can be a long and complex process, especially in the context of constantly evolving standards in a changing regulatory environment. Nelson Labs provides expert advisory services to aid customers in navigating the appropriate standards and regulatory environments. These services include:

 

•  Study design

•  Development and justification of acceptance criteria

•  Onsite facility evaluation and validations

    

•  Technical troubleshooting and scientific problem solving

•  Regulatory compliance related services, including supporting clients through the regulatory submission process

Our expert advisory services provide additional value and expertise at any stage of the product development life cycle. Nelson Labs offers these services on a standalone basis or as a combined offering with our lab testing services, which creates opportunities for cross-selling with our existing customers for both services. Our expert advisory services are also complemented by our ongoing education offerings conducted through webinars, seminars, tailored onsite education sessions and our website.

 

   

Routine Sterility and Quality Control Testing. Once a product has received regulatory approval and is in production, Nelson Labs provides ongoing quality control testing, including production batch verification testing and environmental testing of the client’s production systems and facilities, the requirements for which vary based on applicable standards. Nelson Labs performs bacterial endotoxin testing or quarterly dose audits for devices sterilized using irradiation, and biological indicator testing for devices sterilized with EO. Nelson also provides testing for producers of non-sterile products to ensure they are free of objectionable organisms. Often, Nelson Labs provides this ongoing routine

 

115


Table of Contents
 

quality control testing (based on production lot sizes) for the products for which it performed initial validation testing. These products are often sterilized by Sterigenics.

 

LOGO

The testing process commences when Nelson Labs receives samples and a testing request from the customer. Samples are triaged and assigned to specific lab departments, where laboratory analysts and study directors verify orders and interface with customers directly to clarify, adjust or enhance testing as needed to ensure compliance with regulatory standards. Once the sample has been tested, the order is closed out and results are verified by the study director and a technical reviewer prior to electronic delivery of the final customer report via a secure online customer portal.

We operate in an industry that requires significant regulatory and specialized scientific expertise. At a minimum, providers must maintain the proper certifications and accreditations from key regulatory and accreditation bodies, as well as obtain qualification by each customer as a “qualified supplier,” which is often required at the corporate level and at each of the customer’s operating sites. We employ over 500 scientists, technicians and service specialists, creating a substantial competitive advantage in terms of expertise. Our experts serve in predominant roles on a number of standards writing organizations, including the United States Pharmacopeia, AAMI, American Society of Testing and Materials and ISO. We have established credibility and trust with regulators and standards writing organizations which helps us educate customers about the continually-changing testing requirements in a complex and evolving regulatory landscape. Our regulatory and scientific expertise in laboratory testing allows us to serve as thought leaders within the industry and provide high-quality service to our customers. We focus on providing highly-differentiated services that our customers can rely upon to ensure compliance of and enhance their products. For example, over the course of 14 years, we have developed a proprietary, world-class compound database with over 5,000 known elements which enables our extractables and leachables testing. This database allows us to provide analytical data that differentiates our capabilities from our competitors.

 

116


Table of Contents

Industries Served by Nelson Labs

We provide microbiological and analytical chemistry laboratory tests across the medical device and pharmaceutical industries. Specifically, our medical device lab testing services include microbiology, biocompatibility and toxicology assessments, material characterization, sterilization validation, sterility assurance, packaging validation and distribution simulation, reprocessing validations, facility and process validation and performance validation and verification of PPE barriers and material. Our pharmaceutical lab testing services include microbiology, biocompatibility and toxicology assessments, extractables and leachables evaluations of pharmaceutical containers, sterilization validation, sterility assurance, packaging validation and distribution simulation and facility and process validation.

Nelson Labs benefits from many of the same underlying growth drivers as our sterilization business, including the global utilization of medical devices and pharmaceutical products and the importance of compliance with continuously evolving global regulatory requirements. In particular, recent global regulatory changes, such as the enactment of the European Union Medical Device Regulation 2017/745 (MDR) and the FDA’s modernization of the premarket notification process under Section 510(k) of the Federal Food, Drug and Cosmetic Act, have increased the requirements for the testing and sterilization of medical devices. The COVID-19 pandemic also increased testing demand due to new FDA Emergency Use Authorizations (EUAs), which define testing criteria necessary for the direct release of masks and respirators to hospitals and clinics without FDA submission. Because we provide product development and validation testing services to clients launching new products or altering existing products, this business benefits from the ongoing technological advances and increasing complexity of medical and pharmaceutical products.

Nelson Labs Customers

Nelson Labs serves over 3,800 customers, including many leading medical device manufacturers and pharmaceutical companies. We have recurring and stable customer relationships and benefit from minimal customer concentration. Our services are an essential component in our customers’ research and development and ongoing quality control processes but represent a small portion of end-product cost, which allows us to maintain long-term customer relationships and provide services that are integral to the supply chains of our global customers. We support customers through solutions-focused relationship managers, dedicated service centers and a team-wide service ethic. Nelson Labs has developed a proprietary customer portal that provides our customers quick and convenient access to important product information and customer service. The portal allows our customers to see their tests, status of the tests, estimated completion date and final reports and includes a live chat system connected to our global service center.

Nelson Labs Competition

We primarily compete in the global lab testing services market with a range of providers, from national or international players to other smaller regional or niche laboratories. Our products and services compete on the basis of the quality of services offered, breadth of services, level of expertise in each testing method, delivery time, level of expertise in the applicable regulatory requirements and our reputation with customers and regulators.

Nelson Labs Suppliers

We purchase our lab testing supplies from a number of vendors mainly in the United States and occasionally throughout the world. In many cases we have redundant sources of supplies that minimize our risk of concentration. In addition, some crucial supplies are placed on reserve at specific vendors for our exclusive use.

Nelson Labs Facilities

We operate from a five building campus in Salt Lake City, Utah, with 85 laboratories including metrology, training, media prep labs, five ISO Class V certified clean rooms and customizable lab spaces. We also have

 

117


Table of Contents

facilities in Fairfield, New Jersey; Itasca, Illinois; Leuven, Belgium and nine other laboratories embedded in our Sterigenics sterilization facilities in North America and Asia. We also have one additional lab facility that is under construction in Europe.

Our Patents and Other Proprietary Rights

Our businesses rely on certain proprietary technologies. Most of the proprietary technologies used in our businesses are unpatented. Some of our technologies, including certain processes, methods, algorithms and proprietary data bases, are maintained by the business as trade secrets, which we seek to protect through a combination of physical and technological security measures and contractual measures, such as nondisclosure and confidentiality agreements. We also have limited proprietary technologies that are covered by issued patents or patent applications, in particular related to potential new Co-60 supply opportunities for our Nordion business.

The name recognition of our businesses is a valuable asset. Many of our business names are the subject of trademark registrations or applications in the United States or certain other jurisdictions, or part of registered domain names.

Human Capital Resources

As of September 30, 2020, we employed nearly 2,900 employees worldwide.

None of our U.S. employees are represented by unions. There are employees outside of the United States that are represented by unions or works councils in Canada, Belgium, Brazil, France, Germany and Mexico. One of our values is People. We value our people who are part of a global team that is diverse, respectful, passionate and collaborative. Our human capital strategy is aligned with our strategy and priorities and focuses on developing and delivering global solutions to attract, develop, engage and retain top talent.

Our Values

 

LOGO

Our mission is Safeguarding Global Health®. Our purpose is bigger than the products and services we provide. We ensure that healthcare around the world is consistently and reliably safe every day. Our purpose, our conduct and our values are at the heart of our commitment to employee safety, environmental responsibility and sustainability principles. Our shared values guide how we operate each and every day:

 

   

Safety. We are uncompromising in our commitment to health and well-being.

 

   

Customer focus. We are driven to fulfill our customers’ needs with the highest quality and care.

 

   

People. We value our people who are part of a global team that is diverse, respectful, passionate and collaborative.

 

   

Integrity. We are honest, reliable and accountable in everything we do.

 

   

Excellence. We exceed the expectations of our stakeholders and continue to improve and innovate in everything we do.

 

118


Table of Contents

We are committed to providing a safe work environment for our employees and contractors. We have implemented a health and safety program to manage workplace safety hazards and to protect employees. The program encompasses performance, practices and awareness.

We are driven to fulfill our customers’ needs with highest quality and care to enable their success.

Properties and Facilities

Our corporate headquarters is in Broadview Heights, Ohio, our Sterigenics headquarters is in Oakbrook, Illinois, our Nordion headquarters is in Kanata, Ontario and our Nelson Labs headquarters is in Taylorsville, Utah. As of October 31, 2020, we operated 63 facilities in North America, South America, Europe and Asia. The following chart identified the number of owned and leased facilities, other than our headquarters listed above. We believe that our facilities are adequate for our current needs and that suitable additional or substitute space will be available as needed to accommodate planned expansion of our operations.

 

Segment(1)

   Owned Facilities    Owned/Leased
Facilities(2)
   Leased Facilities

Sterigenics

   27    4    17

Nelson Labs

   6    1    6

Nordion

   1       1

 

(1)

Nine of our Sterigenics and Nelson Labs facilities are located at the same address but are considered separate facilities because they require separate infrastructure. Two of our Sterigenics facilities are located at the same address but are considered separate facilities because they provide different sterilization modalities and require separate infrastructure.

(2)

Owned/leased facilities are comprised of multiple buildings, with some leased and some owned.

Environmental and Regulatory Considerations

We are subject to environmental, health and safety laws and regulations in the jurisdictions in which we operate, including laws, regulations and permit requirements with respect to our use of Co-60, EO and E-beam. These requirements limit emissions of and the exposure of workers to gamma radiation and EO. Nordion’s Kanata facility is licensed as a Class 1B nuclear facility in Canada, regulated by the Canadian Nuclear Safety Commission (“CNSC”), and is audited across various dimensions of this license on an annual basis. In addition to the nuclear aspect of our products, many of the products that we process or manufacture are medical devices directed for human use or products used in the manufacture of medical devices that are directed for human use. Our Nuclear Substance Processing Facility Operating License, CNSC Export license and CNSC Device servicing licenses for our Kanata facility were renewed in October 2015 for a 10-year period. Our facilities hold various International Organization for Standardization’s (“ISO”) certifications including ISO 9002, 9001, 13485 and 17025. We have device facility and specific product registrations with North American (Health Canada and the FDA) and European Drug and Device health regulators. These regulators exert oversight through requirements for a product registration and direct audit of our operations.

Additionally, our operations in the United States and the majority of our facilities outside the United States (to the extent we are processing a product in that facility that will end up in the U.S. market) are regulated by the FDA. We are also regulated by other health regulatory authorities in other countries. Specifically, these operations include some of our sterilization and product testing activities that may constitute “manufacturing” activities and are subject to FDA requirements. These requirements include site, contract drug manufacturer and supplier of active pharmaceutical ingredients registration and listing and manufacturing requirements. Regulations issued by OSHA, the NRC and other agencies also require that equipment used at our facilities be designed and operated in a manner that is safe and with proper safety precautions and practices when handling, monitoring and storing EO and Co-60.

 

119


Table of Contents

While we strive to comply with these regulatory requirements, we may not at all times be in full compliance and, as a result, could be subject to significant civil and criminal fines and penalties. To reduce the risk of noncompliance, we employ engineering and procedural controls and pollution control equipment, and undertake internal and external regulatory compliance audits at our facilities. We have a proactive EH&S program and a culture of safety and quality across all business units, and employ a Senior Vice President of Environmental, Health and Safety that reports directly to the Chief Executive Officer and has a team of more than 30 employees.

For additional information, please see the sections titled “Risk Factors—Risks Related to the Company—We are subject to extensive regulatory requirements and routine regulatory audits in all of our operations. We must receive permits, licenses and/or regulatory clearance or approval for our operations. Failure to comply with all laws and regulations or to receive or maintain permits, licenses, clearances or approvals may hurt our revenues, profitability, financial condition or value” and “Legal Proceedings—Willowbrook, Illinois – Government Litigation.”

EO Regulatory Overview

In addition to general environmental laws and regulations, EO plants and the EO sterilization process are subject to specific regulatory requirements under federal laws in the United States as well as many of the countries in which we operate. Such additional regulations include specific requirements for permissible employee exposure limits, process safety program, approved EO containers and their transportation, facility security, quality system programs, emission control systems and emission limits and products allowed to be treated with EO. Some state and local governments have additional environmental laws, stricter regulations or other requirements including permitting programs that set forth operational parameters for EO sterilization facilities. In the United States, OSHA regulations limit worker exposure to EO. The use of EO for medical device sterilization is regulated by the USEPA under the FIFRA and the CAA. In addition, FDA regulations dictate the acceptable amount of EO residue on different types of sterilized products. Most other countries in which we operate have similar EH&S and worker exposure regulations.

Our EO sterilization facilities evacuate EO from the sterilization chambers and aeration rooms. Most countries in which we operate have varying emission control requirements for EO emissions from our facilities. We are investing in additional voluntary controls on EO emissions at our facilities to outperform current and expected future regulatory requirements and further reduce facility emissions. For example, we have implemented additional controls to meet new German EH&S standards of stricter EO occupational exposure limitations. In the United States, our supplier maintains FIFRA registrations for EO as a medical device sterilant for users of EO across the United States. The USEPA is in the process of reviewing EO’s FIFRA re-registration eligibility in accordance with the provisions of FIFRA. As a condition of continued registration, the USEPA may require enhancements to the processes and equipment for use of EO as a medical device sterilant. The USEPA is also also expected to propose updated NESHAP air emission regulations for EO commercial sterilization facilities, which have not yet been published and with which sterilization facilities like ours will be required to comply. In certain U.S. states, including California, additional regulatory requirements and obligations exist, including requirements for the provision of notices regarding the release of or exposure to certain listed substances, including EO and radioactive sources, and bills have been in introduced in the U.S. Congress to further regulate EO sterilization activity. Each of our EO sterilization facilities utilizes a variety of control technologies (including wet scrubbers, catalytic oxidizers and dry bed scrubbers) to control these emissions, and we are investing in additional control features to further reduce emissions. We consistently meet and outperform regulatory emissions control requirements, although we have experienced instances of emissions exceeding applicable standards, none of which we believe were material. We expect to be able to satisfy any changes to applicable regulatory requirements as they evolve.

In addition to government regulation, there are standards, guidelines and requirements established by industry organizations and other non-governmental bodies that may impact our operations such as the ISO’s limit on the permissible levels of residual EO on sterilized medical devices.

 

120


Table of Contents

Gamma Irradiation Regulatory Overview

In the United States, Sterigenics is subject to NRC and state regulations that govern operations involving radioactive materials at gamma irradiation plants. These NRC and state regulations specify the requirements for, among other things, maximum radiation doses, system designs, safety features and alarms and employee and area monitoring, testing and reporting. Each of our U.S. plants has a radioactive materials license from the NRC or the state in which it operates. Nordion also has NRC licenses to distribute radioactive material within the United States, which permits Nordion to install and remove Co-60 sources and provide other services to its customers, and a license to export radioactive material from the United States to Canada. The NRC recently implemented new security requirements for our U.S. gamma facilities.

Our Nordion segment operates through our subsidiary Nordion (Canada) Inc. in Canada and REVISS Services in the United Kingdom. Through Nordion, we are subject to additional Canadian regulations, including Transport Canada regulations for the Transportation of Dangerous Goods, CNSC regulations for the General Nuclear Safety and Controls, Health Canada requirements for drugs and devices and CNSC and Canadian Department of Foreign Affairs and International Trade requirements for import and export.

Outside North America, the European Union and national authorities have developed regulations pertinent to the operation of gamma irradiators that are similar to those of the NRC. While some specific requirements are different in the various other nations as compared to the United States, the fundamental concepts are consistent among the countries, since all are signatories to the International Atomic Energy Agency (“IAEA”) conventions and have adopted safety standards from the IAEA and recommendations from the International Commission on Radiological Protection (“ICRP”).

E-beam and X-ray Irradiation Regulatory Overview

In the United States, irradiators that use accelerators are regulated by the individual state in which a facility resides. While there is some variability in the content of regulations among states, all are patterned after the general regulations of the NRC. These regulations typically specify the requirements for radiation shielding, system designs, safety features and alarms and employee and area monitoring, testing and reporting.

Outside of the United States, accelerator regulations are similar among various nations. These regulations are based on the IAEA standards and ICRP recommendations, much like those for gamma irradiators.

Legal Proceedings

From time to time, we may be subject to various legal proceedings arising in the ordinary course of our business, including claims relating to personal injury, property damage, workers’ compensation and employee safety. In addition, from time to time, we receive communications from government or regulatory agencies concerning investigations or allegations of noncompliance with laws or regulations in jurisdictions in which we operate. At this time, and except as is noted below, we are unable to predict the outcome of, and cannot reasonably estimate the impact of, any pending litigation matters, matters concerning allegations of non-compliance with laws or regulations and matters concerning other allegations of other improprieties, or the incidence of any such matters in the future. For additional information on risks relating to litigation, please see the section titled “Risk Factors—Risks Related to the Company—We are currently defending certain litigation, and we are likely to be subject to additional litigation in the future.”

Willowbrook, Illinois - Government Litigation

On October 30, 2018, the Illinois Attorney General and the State’s Attorney of DuPage County, Illinois, sued Sterigenics U.S., LLC (the “IAG Action”), alleging that authorized EO air emissions from a commercial sterilization facility Sterigenics formerly operated in Willowbrook, Illinois “cause, threaten, or allow air pollution”

 

121


Table of Contents

in violation of the Illinois Environmental Protection Act. The IAG Action did not assert that Sterigenics violated its permit from the Illinois Environmental Protection Agency (“IEPA”) authorizing Sterigenics’ release of regulated levels of EO at the Willowbrook facility.

On February 15, 2019, the acting IEPA director, John Kim, issued a “Seal Order” effectively precluding Sterigenics’ operations at the Willowbrook facility based on many of the same allegations asserted in the IAG Action. Sterigenics disputed those allegations and opposed the IEPA’s Seal Order. The Seal Order was resolved by a Consent Order entered on September 6, 2019. The Consent Order provided that Sterigenics did not admit the allegations of the IAG Action, provided for the removal of the Seal Order and allowed the Willowbrook facility to reopen upon implementation of supplemental emissions control measures consistent with a new law that became effective in Illinois in June 2019 and an IEPA permit, which the IEPA approved in September 2019. Following entry of the Consent Order, the Seal Order was withdrawn.

On September 30, 2019, Sterigenics announced the closure of the Willowbrook facility due to the inability to reach an agreement with its landlord to renew the facility’s lease and the unstable legislative and regulatory landscape in Illinois. Sterigenics is in the process of decommissioning the facility and completing the work required by the terms of its lease to return the property to the landlord.

On October 20, 2020 Sterigenics, the Illinois Attorney General and the State’s Attorney of DuPage County filed a Joint Motion to Terminate Consent Order, stating that the community projects which Sterigenics voluntarily agreed to fund have been completed and funded as required by the Consent Order, and that Sterigenics has permanently ceased operations and surrendered all permits for its operations in Willowbrook, Illinois. On October 27, 2020 the DuPage County Circuit Court entered the Agreed Order Terminating Consent Order.

Ethylene Oxide Tort Litigation - Illinois

Since September 2018, tort lawsuits on behalf of approximately 835 personal injury plaintiffs (which are further described in the following paragraphs) have been filed in Illinois state courts against Sotera Health LLC, Sterigenics U.S., LLC, GTCR, LLC and other parties related to Sterigenics’ Willowbrook, Illinois operations. Specifically, those plaintiffs allege that they suffered personal injuries including cancer and other diseases, or wrongful death, resulting from purported emissions and releases of EO from the Willowbrook facility. Plaintiffs seek damages in an amount to be determined by the trier of fact. We deny these allegations and intend to vigorously defend against these claims. Plaintiffs have voluntarily dismissed without prejudice a number of cases since September 2018, including certain individual cases alleging personal injuries and two class actions seeking damages for alleged diminution of property values.

Sterigenics sought consolidation of certain of these cases for pretrial purposes, and in October 2019 obtained an order consolidating the then-pending cases before Judge Lawler in the Cook County Circuit Court, Illinois (the “Consolidated Case”). All plaintiffs in the Consolidated Case filed a single Master Complaint on October 24, 2019 by which Sotera Health LLC was added as a co-defendant, followed by a First Amended Master Complaint on January 31, 2020. On April 28, 2020, the defendants filed motions to dismiss the claims in the First Amended Master Complaint. On August 17, 2020, the Court entered an order largely denying the motions to dismiss, and the same day plaintiffs filed a Second Amended Master Complaint.

On August 17, 2020, the plaintiffs sought and received leave of Court to add as defendants Griffith Foods Group, Inc., Griffith Foods, Inc., Griffith Foods International, Inc. and Griffith Foods Worldwide Inc.

On or about August 21, 2020, approximately 768 personal injury plaintiffs filed similar lawsuits against Sotera Health LLC, Sterigenics U.S., LLC, GTCR, LLC and other parties in the Cook County Circuit Court, Illinois (but not in the existing Consolidated Case) and in the DuPage County Circuit Court. Defendants’ motions to transfer, reassign and consolidate the newly filed cases with the above described Consolidated Case in the Cook County Circuit Court, Illinois were granted on October 2, 2020 and October 9, 2020.

 

122


Table of Contents

Having been granted leave of Court on August 17, 2020 to add as defendants Griffith Foods Group, Inc., Griffith Foods, Inc., Griffith Foods International, Inc. and Griffith Foods Worldwide Inc., plaintiffs filed a third amended master complaint, adding those defendants, on October 30, 2020. Defendants’ responses to the third amended master complaint will be due on December 1, 2020. The plaintiffs who filed the new lawsuits in August 2020 (whose cases are now included in the Consolidated Case) are required to file individual short form complaints on or before February 1, 2021. Defendants’ deadline for responding to each short form complaint will be 90-days after entry of an order setting the individual case for trial.

Written and deposition fact discovery is on-going in the Consolidated Case. Currently, there are no dates set for the close of fact discovery, for expert discovery or for dispositive motion practice. Plaintiffs have not yet made any specific damages claims.

A May 3, 2021 trial date has been set for Kamuda v. Sterigenics, the first-filed of the individual cases now included in the Consolidated Case, which is the first scheduled trial in these proceedings. Four additional cases now included in the Consolidated Case are currently scheduled for trials starting in June, August, September and November 2021. We anticipate that additional trials will be scheduled after 2021 in roughly the order in which the individual cases were filed.

Additional personal injury and property devaluation lawsuits may be filed in the future against Sotera Health LLC and Sterigenics U.S., LLC relating to Sterigenics’ Willowbrook facility or other EO sterilization facilities. Sotera Health LLC and Sterigenics U.S., LLC intend to defend themselves vigorously in all such EO tort litigation.

Ethylene Oxide Tort Litigation - Georgia

On May 19, 2020, a lawsuit against Sotera Health LLC, Sterigenics U.S., LLC and other parties was filed in the State Court of Cobb County, Georgia by 53 employees of a contract sterilization customer of Sterigenics. In the operative complaint, Plaintiffs claim personal injuries resulting from alleged exposure to residual EO while working at the customer’s distribution center in Lithia Springs, Georgia, allege they were unaware that they were being exposed to EO in their workplace and seek damages in an amount to be determined by the trier of fact. The deadline for defendants to respond to the operative complaint has not yet been determined. All defendants are being defended and indemnified by Sterigenics’ contract sterilization customer (plaintiffs’ employer and a co-defendant in the lawsuit).

In May 2020, the Cobb County, Georgia Board of Tax Assessors reduced certain residential property value assessments around the Sterigenics Atlanta facility by 10% citing an “Epd-identified environmental issue,” without supporting market data. On August 14, 2020, Sterigenics U.S., LLC filed a lawsuit against members of the Cobb County Board of Tax Assessors in the U.S. District Court for the Northern District of Georgia, seeking a declaration that the reduction in property value assessments is arbitrary and unlawful and is causing Sterigenics reputational and imminent economic harm. The court has stayed the action pending its decision concerning Sterigenics’ standing to bring the lawsuit. That issue has been fully briefed and was argued on September 29, 2020. Additional briefing by the parties on the issue of the court’s discretionary jurisdiction under the Declaratory Judgment Act was filed on October 21, 2020.

Since August 17, 2020, five lawsuits against Sotera Health LLC, Sterigenics U.S., LLC and other parties have been filed by plaintiffs in the State Court of Cobb County, Georgia and the State Court of Gwinnett County, Georgia in which plaintiffs allege that they suffered personal injuries and loss of consortium resulting from emissions and releases of EO from Sterigenics’ Atlanta facility. We are also defendants in a lawsuit alleging that our Atlanta facility has devalued and harmed the plaintiffs’ use of a real property they own in Smyrna, Georgia. In both instances, plaintiffs seek damages in amounts to be determined by the trier of fact. Current deadlines for defendants’ responses to the complaints are in November and December 2020.

 

123


Table of Contents

Additional personal injury and property devaluation lawsuits may be filed in the future against Sotera Health LLC and Sterigenics U.S., LLC relating to Sterigenics’ Atlanta facility or other EO sterilization facilities. Sotera Health LLC and Sterigenics U.S., LLC intend to defend themselves vigorously in all such EO tort litigation.

Suspension of Georgia Facility Operations & Related Litigation

On August 7, 2019, Sterigenics U.S., LLC entered into a voluntary Consent Order with the Georgia Environmental Protection Division (“EPD”) under which Sterigenics agreed to install emissions reduction enhancements at its Atlanta facility to further reduce the facility’s EO emissions below already permitted levels. Sterigenics voluntarily suspended operations at the facility in early September 2019 to expedite completion of the enhancements. Installation of these enhancements is complete, and Sterigenics successfully tested the enhanced emissions controls in cooperation with EPD during the second quarter of 2020 while the facility was in operation.

In October 2019, while Sterigenics had voluntarily suspended the facility’s operations, Cobb County, Georgia officials asserted that the facility had an incorrect “certificate of occupancy” and could not resume operations without obtaining a new certificate of occupancy after a third-party code compliance review they required.

After the Cobb County officials would not allow Sterigenics to resume operations, on March 30, 2020, Sterigenics U.S., LLC filed a lawsuit in the United States District Court for the Northern District of Georgia against Cobb County, Georgia and Cobb County officials Nicholas Dawe and Kevin Gobble. In the lawsuit, Sterigenics sought immediate injunctive relief and permanent declaratory relief to resume normal operations of the Atlanta facility in the interest of public health and on the basis that the positions asserted by Cobb County were unfounded. On April 1, 2020 the Court entered a Temporary Restraining Order prohibiting Cobb County officials from precluding or interfering with the facility’s normal operations. On April 8, 2020, the Court entered a Consent Order extending the Temporary Restraining Order and allowing the facility to continue normal operations until entry of a final judgment in the case. On June 24, 2020 Sterigenics filed an amended complaint, and on July 22, 2020 defendants filed a motion to dismiss the claims. On November 9, 2020, the Court held a hearing on the motion to dismiss and indicated, at the conclusion of the hearing, that an opinion and order denying the motion to dismiss would be issued. No trial date has been set.

*                    *                     *

We carry insurance for alleged environmental liabilities (including personal injury litigation like that pending in Illinois and Georgia described above), with limits of $10.0 million per occurrence and $20.0 million in the aggregate. The per occurrence limit related to the Willowbrook government and EO tort litigations was fully utilized by June 30, 2020. We have not provided for a contingency reserve in connection with these claims.

While we intend to vigorously defend the Illinois and Georgia personal injury and property devaluation proceedings described above and any other claims relating to our EO sterilization facilities, we are not able to predict the outcome of any litigation and there can be no assurance that we will be successful. We are unable to predict the incidence or outcome of such litigation or to reasonably estimate the possible range of any losses that could be incurred. An adverse outcome in one or more of these proceedings could have a material adverse effect on our business, financial condition and results of operations.

Zoetermeer, Holland Criminal Proceedings and Criminal Financial Investigation

In early 2010, the Dutch Public Prosecution Service started criminal proceedings against DEROSS Holding B.V. (“DEROSS B.V.”), formerly known as Sterigenics Holland B.V., in relation to certain EO emissions and alleged environmental permit violations in the period from 2004 to 2009 at its Zoetermeer processing facility. On the basis of the final indictment issued in April 2017, assuming a rarely applied increasing mechanism is not applied in this case, fines in the amount of €0.8 million ($0.9 million USD) may be imposed.

 

124


Table of Contents

In November 2010, the Public Prosecution Service also started a criminal financial investigation against DEROSS B.V. to determine whether it has obtained illegal advantages by committing the alleged criminal offenses noted above. Any illegally obtained advantage could then be recovered from DEROSS B.V. in subsequent confiscation proceedings. According to the October 2013 report of this criminal financial investigation, the Public Prosecution Service estimates the illegally obtained advantage by DEROSS B.V. to be in the amount of €0.6 million ($0.7 million USD).

In January 2018, the trial in first instance took place in the criminal case against DEROSS B.V., and in February 2018, the court discharged DEROSS B.V. from further prosecution on one of the two counts asserted and acquitted DEROSS B.V. on the other count. In March 2018, the public prosecutor filed an appeal against the favorable judgment in first instance for DEROSS B.V., as well as the favorable judgments in first instance for the two individuals overseeing environmental compliance during the time period of the alleged claims and the municipality of Zoetermeer. The appeal procedure is pending.

DEROSS B.V. has agreed to defend and indemnify the two individuals overseeing environmental compliance during the time period of the alleged claims by the Public Prosecutor. Assuming a rarely applied increasing mechanism is not applied in this case, the possible monetary penalties relating to the individuals currently are estimated at a maximum of €0.2 million ($0.2 million USD).

In 2011, former shareholders established an escrow account to satisfy indemnity claims for losses resulting from governmental claims related to this matter, including those relating to environmental law violations, financial advantage claims, as well as criminal and civil fines and penalties. The balance of the special escrow at December 31, 2019 and September 30, 2020, was approximately $2.1 million and the cash collateral held by ABN Amro to provide security for the claims against us was approximately €2.4 million ($2.8 million as of September 30, 2020). These amounts are available to satisfy claims relating to the ongoing matter through its anticipated resolution. At this time, we expect that the appeal of this matter will likely take several years to resolve, barring unforeseen delays. However, we believe the indemnification receivable continues to be recoverable and plan to ensure escrow funds remain in place to cover outcomes of an appeal.

It is possible that individuals living in the vicinity of our former Zoetermeer facility may file civil claims at some time in the future. While we have received letters from a small number of individuals claiming to live or work in the vicinity of the Zoetermeer facility, no civil claims have been filed against DEROSS B.V. or us. We have not provided for a contingency reserve in connection with any civil claims as we are unable to determine the likelihood of an unfavorable outcome and no reasonable estimate of a loss or range of losses, if any, can be made. During 2011, we purchased a ten-year environmental insurance claims-made policy to provide coverage for future civil claims from individuals related to this matter.

 

125


Table of Contents

MANAGEMENT AND BOARD OF DIRECTORS

Directors and Executive Officers

The following table sets forth the name, age and position of individuals who will serve as directors and executive officers of our company. The following also includes certain information regarding our directors and executive officers’ individual experience, qualifications, attributes and skills, and a brief statement of those aspects of our directors’ backgrounds that led us to conclude that they should serve as directors.

 

Name

  Age     

Position

Michael B. Petras, Jr.

    53      Chairman and Chief Executive Officer

Scott J. Leffler

    45      Chief Financial Officer and Treasurer

Michael (Mike) P. Rutz

    49      President of Sterigenics

Matthew J. Klaben

    51      Senior Vice President, General Counsel and Secretary

Ruoxi Chen

    37      Director

Sean L. Cunningham

    45      Director

David A. Donnini

    55      Director

Stephanie Geveda

    41      Director

Ann R. Klee

    59      Director

Constantine S. Mihas

    53      Director

James C. Neary

    55      Director

Vincent K. Petrella

    60      Director

Michael B. Petras, Jr. has served as our Chief Executive Officer since June 2016, as the Chairman of our board of directors since October 2020, as the Chairman of Topco Parent’s board of managers since January 2019 and as a member of Topco Parent’s board of managers since June 2016. Prior to joining Sotera Health, Mr. Petras served as chief executive officer of Post-Acute Solutions at Cardinal Health, Inc., a multinational healthcare services company, from 2015 to 2016 and chief executive officer of Cardinal Health at-Home at Cardinal Health, Inc. from 2013 to 2015. From 2011 to 2013, he was the chief executive officer for AssuraMed Holdings, Inc., a medical products supplier owned by the Clayton, Dubilier & Rice and Goldman Sachs private equity firms, which was sold to Cardinal Health, Inc. in 2013. From 2008 to 2011, Mr. Petras was president and chief executive officer at GE Lighting, a General Electric Company (“GE”) business unit. During his over 20 year career at GE, he held several management positions in multiple disciplines. Mr. Petras holds a B.S.B.A. in finance from John Carroll University and an M.B.A. in marketing from Case Western Reserve University. He was selected to serve on our board of directors because of his perspective as our Chief Executive Officer as well as his extensive commercial, financial and general management experience across many global industries.

Scott J. Leffler has served as our Chief Financial Officer and Treasurer since April 2017. Prior to joining Sotera Health, Mr. Leffler served as chief financial officer at Exal Corporation (now known as Trivium Packaging), a specialty manufacturer of aluminum containers, from September 2016 to March 2017. From September 2008 to September 2016, he held various positions including vice president and treasurer at PolyOne Corporation (now known as Avient), a formulator of specialty chemicals. Prior to that, he served in corporate treasury at Novelis Incorporated, a manufacturer of rolled aluminum. Mr. Leffler holds a B.A. in economics and history from Yale University and an M.B.A. from Emory University. He is a certified public accountant (inactive) and a certified treasury professional (inactive).

Michael (Mike) P. Rutz has served as President of Sterigenics since October 2020. Prior to that, Mr. Rutz was Chief Operating Officer of Sterigenics from May 2020 to October 2020. Prior to joining Sotera Health, he was senior vice president and general manager of the Semiconductor Business Unit at Littlefuse, Inc., a multinational electronic manufacturing company, where he was responsible for leading sales, marketing, product development, operations and business development for power and protection based semiconductor products. Mr. Rutz joined Littlefuse in 2014 as senior vice president of global operations, overseeing the company’s manufacturing, procurement, planning, quality, and operational excellence initiatives. Prior to joining the Littlefuse, Mr. Rutz served as senior vice president global supply chain at WMS Gaming, a Chicago-based

 

126


Table of Contents

manufacturer of equipment and software for the gaming industry. Mr. Rutz also spent 16 years with Motorola in the paging, cellular and networking groups, most recently as vice president, networks supply chain. Mr. Rutz holds a Bachelor’s degree in mechanical engineering from the University of Michigan and Master’s degrees in mechanical engineering and management from the Massachusetts Institute of Technology.

Matthew J. Klaben has served as our Senior Vice President, General Counsel and Secretary since November 2016. Prior to joining Sotera Health, he was the vice president, general counsel and secretary of Chart Industries, Inc., a diversified global manufacturer of highly engineered equipment servicing multiple market applications in energy and industrial gas in Cleveland, Ohio from 2006 to 2016. Prior to that, he was a partner at Calfee, Halter & Griswold LLP, a law firm in Cleveland, Ohio. Mr. Klaben holds a B.A. in international relations and German from Canisius College, a Fulbright Certificate from the University of Bonn (Germany) and a J.D. from Cornell Law School.

Ruoxi Chen has served as a member of our board of directors since November 2020. Mr. Chen is a principal at Warburg Pincus, focusing on investments in the healthcare sector, and joined the firm in 2011. Prior to joining Warburg Pincus, Mr. Chen worked at the Carlyle Group in the U.S. Buyout Fund and in investment banking at Citigroup. He is currently a board member of Silk Road Medical, Inc. and several private companies. He received a B.S. magna cum laude in economics and computer science from Duke University and an M.B.A. from Harvard Business School. He was selected to serve on our board of directors because of his extensive knowledge of strategy and business development in the healthcare sector, his wide-ranging experience as a director and deep familiarity with our company.

Sean L. Cunningham has served as a member of our board of directors since October 2020 and as a member of Topco Parent’s board of managers since 2015. Mr. Cunningham joined GTCR in 2001 and is currently a managing director of the firm. Prior to joining GTCR, he worked as a consultant with The Boston Consulting Group. Mr. Cunningham currently is a director of several private companies. He holds A.B. and B.E. degrees in engineering sciences from Dartmouth College and an M.B.A. from the Wharton School at the University of Pennsylvania. He was selected to serve on our board of directors because of his wide range of experience overseeing and assessing the performance of companies in our industry, decades-long investment practice and extensive knowledge of strategy and business development.

David A. Donnini has served as a member of our board of directors since October 2020 and as a member of Topco Parent’s board of managers since 2015. Mr. Donnini joined GTCR in 1991 and is currently a managing director of the firm. Prior to joining GTCR, he worked as an associate consultant at Bain & Company. He leads GTCR’s business services efforts. He is currently a director of several private companies. Mr. Donnini holds a B.A. in economics, summa cum laude, from Yale University and an M.B.A. from Stanford University, where he was an Arjay Miller Scholar and Robichek Finance Award winner. He was selected to serve on our board of directors because of his significant financial and investment experience, wide-ranging experience as a director and deep familiarity with our company.

Stephanie Geveda has served as a member of our board of directors since October 2020 and as a member of Topco Parent’s board of managers since 2015. Ms. Geveda is a managing director and head of Business Services at Warburg Pincus. Ms. Geveda joined Warburg Pincus in 2010 and has worked in the private equity industry for eighteen years. Prior to joining Warburg Pincus, Ms. Geveda worked as an investment professional at Silver Lake Partners, Fox Paine & Company and J.P. Morgan Partners, where she focused on private equity transactions including leveraged buyouts, growth equity and venture investment opportunities across a wide range of industries. She began her career working in Morgan Stanley’s Investment Banking Division where she advised companies focused on mergers, acquisitions and restructuring transactions. She currently serves on the board of directors of several private companies. She holds a B.B.A., summa cum laude, in finance and economics from the University of Notre Dame and an M.B.A. from the Harvard Business School, where she graduated as a George F. Baker Scholar. She was selected to serve on our board of directors because of her extensive knowledge of strategy and business development, wide-ranging experience as a director and deep familiarity with our company.

 

127


Table of Contents

Ann R. Klee has served as a member of our board of directors since October 2020 and as a member of Topco Parent’s board of managers since May 2020. Since February 2020, Ms. Klee has served as the executive vice president, Business Development & External Affairs at Suffolk Construction, a construction contracting company. Prior to that, she was the vice president, Environmental Health & Safety at General Electric, a multinational conglomerate, from February 2008 to September 2019, and the vice president, Boston Development & Operations at GE from January 2016 to September 2019. At GE, she was also the president of the GE Foundation from August 2015 to September 2019, where she oversaw the company’s $140 million annual charitable contributions. She was a partner at Crowell & Moring in Washington, D.C. from 2006 to 2007, where she served as co-chair of the firm’s Environment and Natural Resources Group. Prior to Crowell & Moring, she served as general counsel to the USEPA, as counselor and special assistant to the Secretary of the U.S. Department of the Interior and as chief counsel to the U.S. Senate’s Environment and Public Works Committee. Ms. Klee is currently a director at Wabtec Corporation. She holds a B.A. in classics from Swarthmore College and a J.D. from the University of Pennsylvania Carey Law School. She was selected to serve on our board of directors because of her extensive experience as an environmental lawyer managing complex litigation, and for her expertise in environmental law, regulation and policy and corporate ESG matters.

Constantine S. Mihas has served as a member of our board of directors since October 2020 and as a member of Topco Parent’s board of managers since 2015. Mr. Mihas joined GTCR in 2001 and is currently a managing director of the firm. Prior to joining GTCR, Mr. Mihas was chief executive officer and co-founder of Delray Farms, a specialty food retailer. Prior to Delray Farms, he was with McKinsey & Company. Mr. Mihas leads the Healthcare group at GTCR and has been instrumental in building the firm’s expertise in life sciences and medical devices. He is currently a director of several private companies. Mr. Mihas holds a B.S. with high distinction in finance and economics from the University of Illinois, Chicago and an M.B.A. with distinction from the Harvard Business School. He was selected to serve on our board of directors because of his significant financial and investment experience, wide-ranging experience as a director and deep familiarity with our company.

James C. Neary has served as a member of our board of directors since October 2020 and as a member of Topco Parent’s board of managers since 2015. Mr. Neary is a managing director and partner at Warburg Pincus and joined the firm in 2000. Mr. Neary is head of the firm’s industrial and business services group and co-head of the firm’s healthcare group as well as a member of the investment management group and the executive management group. From 2010 to 2013, he led the firm’s late-stage efforts in the technology and business services sectors. From 2004 to 2010, he was co-head of the firm’s technology, media, and telecommunications investment efforts. Mr. Neary is the chairman of the board of directors of Endurance International Group Holdings, Inc. and serves on the board of directors of WEX Inc. and several private companies. He holds a B.A. in economics and political science from Tufts University and an M.B.A. from the J.L. Kellogg Graduate School of Management at Northwestern University, where he was the Eugene Lerner Finance Scholar. He was selected to serve on our board of directors because of his extensive knowledge of strategy and business development, wide-ranging experience as a director and deep familiarity with our company.

Vincent K. Petrella has served as a member of our board of directors since November 2020. Mr. Petrella served as the executive vice president, chief financial officer and treasurer at Lincoln Electric Holdings, Inc., a welding, cutting and brazing products manufacturer from 2004 until April 2020. Prior to that role, he served as vice president, corporate controller from 1997 to 2003 and as internal audit manager from 1995 to 1997. Before Lincoln Electric Holdings, Inc., Mr. Petrella was an auditor at PricewaterhouseCoopers. He is currently a board member of Applied Industrial Technologies, Inc. and the Gorman-Rupp Company. Mr. Petrella holds a B.A. in business administration (accounting) from Baldwin Wallace University and is a Certified Public Accountant in Ohio (inactive). He was selected to serve on our board of directors because of his significant global finance, accounting and international business development experience, his expertise with respect to audit committees and his wide-ranging experience as a director.

 

128


Table of Contents

Our Board of Directors

Board Composition

Our business and affairs are managed under the direction of our board of directors. Our board of directors currently consists of nine members. The current members of our board of directors were elected in compliance with the provisions of a stockholders’ agreement among our company and certain holders of our common stock. See “Related Person Transactions—Stockholders’ Agreement.” In particular, investment funds and entities affiliated with Warburg Pincus designated Ms. Geveda, Mr. Neary and Mr. Chen, and may designate up to two additional directors, for election to our board of directors, and investment funds and entities affiliated with GTCR designated Messrs. Cunningham, Donnini and Mihas for election to our board of directors. Our directors hold office until their successors have been elected and qualified or until the earlier of their resignation or removal.

In accordance with the terms of our amended and restated certificate of incorporation and amended and restated bylaws, our board of directors will be divided into three classes, each of whose members will serve for staggered three year terms. Upon the closing of this offering, the members of the classes will be divided as follows:

 

   

the class I directors will be Mr. Mihas, Mr. Neary and Mr. Petras, and their term will expire at the first annual meeting of stockholders held after the closing of this offering;

 

   

the class II directors will be Mr. Chen, Mr. Donnini and Ms. Klee, and their term will expire at the second annual meeting of stockholders held after the closing of this offering; and

 

   

the class III directors will be Mr. Cunningham, Ms. Geveda and Mr. Petrella, and their term will expire at the third annual meeting of stockholders held after the closing of this offering.

Our Stockholders’ Agreement provides that investment funds and entities affiliated with Warburg Pincus will be entitled to designate up to:

 

   

five directors for election to our board of directors for so long as certain investment funds and entities affiliated with Warburg Pincus hold 80% or more of the shares of our common stock that they hold immediately following the closing of this offering;

 

   

four directors for election to our board of directors for so long as certain investment funds and entities affiliated with Warburg Pincus hold 60% or more of the shares of our common stock that they hold immediately following the closing of this offering;

 

   

three directors for election to our board of directors for so long as certain investment funds and entities affiliated with Warburg Pincus hold 40% or more of the shares of our common stock that they hold immediately following the closing of this offering;

 

   

two directors for election to our board of directors for so long as certain investment funds and entities affiliated with Warburg Pincus hold 20% or more of the shares of our common stock that they hold immediately following the closing of this offering; and

 

   

one director for election to our board of directors for so long as certain investment funds and entities affiliated with Warburg Pincus hold 6 2/3% or more of the shares of our common stock that they hold immediately following the closing of this offering.

In addition, our Stockholders’ Agreement provides that investment funds and entities affiliated with GTCR will be entitled to designate up to:

 

   

three directors for election to our board of directors for so long as certain investment funds and entities affiliated with GTCR hold 70% or more of the shares of our common stock that they hold immediately following the closing of this offering;

 

129


Table of Contents
   

two directors for election to our board of directors for so long as certain investment funds and entities affiliated with GTCR hold 40% or more of the shares of our common stock that they hold immediately following the closing of this offering; and

 

   

one director for election to our board of directors for so long as certain investment funds and entities affiliated with GTCR hold 10% or more of the shares of our common stock that they hold immediately following the closing of this offering.

Our amended and restated certificate of incorporation provides that the authorized number of directors may be changed only by our board of directors, subject to the rights of any holders of any series of our preferred stock; provided that, without the consent of Warburg Pincus or GTCR, the authorized number of directors may not exceed eleven as long as investment funds and entities affiliated with either Warburg Pincus or GTCR are entitled to designate at least one director. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one-third of the directors. This classification of our board of directors may have the effect of delaying or preventing changes in our control or management.

In addition, our amended and restated certificate of incorporation provides that our directors may be removed only for cause by the affirmative vote of the holders of at least 75% of the votes that all our stockholders would be entitled to cast in an annual election of directors; provided that for so long as investment funds and entities affiliated with either Warburg Pincus or GTCR, collectively, hold at least a majority of our outstanding capital stock, a director designated by investment funds and entities affiliated with either Warburg Pincus or GTCR, respectively, may be removed with or without cause by the affirmative vote of the holders of a majority of our outstanding capital stock and with the consent of Warburg Pincus or GTCR, respectively.

Upon the expiration of the term of a class of directors, directors in that class will be eligible to be elected for a new three-year term at the annual meeting stockholders in the year in which their term expires. An election of our directors by our stockholders will be determined by a plurality of the votes cast by the stockholders entitled to vote on the election.

Our amended and restated certificate of incorporation does not provide for cumulative voting in the election of directors, which means that the holders of a majority of the outstanding shares of common stock (i.e., our Sponsors) can elect all of the directors standing for election, and the holders of the remaining shares are not able to elect any directors, subject to their rights under our Stockholders’ Agreement discussed above.

Controlled Company

After the completion of this offering, the Sponsors will control a majority of our outstanding shares of our common stock. As a result, we may be considered a “controlled company” within the meaning of the Nasdaq rules. Under the Nasdaq rules, a company of which more than 50% of the voting power is held by an individual, group or another company is a “controlled company” and may elect not to comply with certain Nasdaq corporate governance standards, including:

 

   

the requirement that a majority of the board of directors consist of independent directors;

 

   

the requirement that our director nominations be made, or recommended to the full board of directors, by our independent directors or by a nominations committee that is comprised entirely of independent directors with a written charter addressing the committee’s purpose and responsibilities;

 

   

the requirement that we have a compensation committee that is composed entirely of independent directors with a written charter addressing the committee’s purpose and responsibilities; and

 

   

the requirement for an annual performance evaluation of the nominating and corporate governance and compensation committees.

 

130


Table of Contents

These requirements would not apply to us as long as we remain a “controlled company.” Although we may qualify as a “controlled company” upon completion of this offering, we do not expect to rely on this exemption and intend to fully comply with all corporate governance requirements under the Nasdaq corporate governance standards. However, if we were to utilize some or all of these exemptions, you may not have the same protections afforded to stockholders of companies that are subject to all of the Nasdaq rules regarding corporate governance.

The “controlled company” exception does not modify the independence requirements for the audit committee, and we intend to comply with the audit committee requirements of Rule 10A-3 under the Exchange Act and the Nasdaq rules. Pursuant to such rules, we are required to have at least one independent director on our audit committee during the 90-day period beginning on the date of effectiveness of the registration statement filed with the SEC in connection with this offering. After such 90-day period and until one year from the date of effectiveness of the registration statement, we are required to have a majority of independent directors on our audit committee. Thereafter, our audit committee is required to be comprised entirely of independent directors.

Director Independence

Our board of directors has undertaken a review of the independence of each director. Based on information provided by each director concerning his or her background, employment and affiliations, including family relationships, our board of directors has determined that each of our directors, with the exception of Mr. Petras, do not have relationships that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is “independent” as that term is defined under the listing standards of the Nasdaq. In making these determinations, our board of directors considered the current and prior relationships that each director has with our company and all other facts and circumstances our board of directors deemed relevant in determining their independence, including the beneficial ownership of our capital stock by each director, and the transactions involving them described in the section titled “Certain Relationships and Related Party Transactions.”

Committees of the Board of Directors

Upon completion of this offering, we will have an audit committee, a compensation committee, a nominating and corporate governance committee and a Nordion pricing committee. The composition and responsibilities of each of the committees of our board of directors are described below. Members serve on these committees until their resignation or until otherwise determined by our board of directors. Our board of directors may establish other committees as it deems necessary or appropriate from time to time.

Audit Committee

The audit committee’s main purpose is to oversee our accounting and financial reporting processes, our relationship with our independent auditors, our compliance with legal and regulatory requirements and our policies and procedures with respect to risk assessment and risk management.

In carrying out this purpose, the audit committee will:

 

   

oversee the design, implementation, adequacy and effectiveness of our disclosure controls and procedures, system of internal controls over financial accounting, internal audit function and the preparation and audits of our consolidated financial statements;

 

   

appoint our independent auditors annually, review the annual audit plan, approve audit and pre-approve any non-audit related services provided to us, evaluate their qualifications and performance and ensure their independence;

 

   

oversee procedures for the receipt, retention and treatment of complaints about accounting, internal accounting controls or audit matters, and for the confidential and anonymous submission by employees concerning such matters;

 

131


Table of Contents
   

review and approve or ratify, in accordance with our policies, all related party transactions as defined by applicable rules and regulations;

 

   

oversee legal and regulatory matters and review and approve the adequacy and effectiveness of our compliance policies and procedures, including the Global Code of Conduct;

 

   

approve the annual internal audit plan and budget, review with the internal audit executive the results of the audit work at least annually and more frequently as provided in the policy for reporting financial accounting and auditing concerns, as approved by the committee and at least annually review the performance of the internal audit team; and

 

   

oversee company policies and practices with respect to financial risk assessment and risk management.

The members of the audit committee are Mr. Petrella (chair), Ms. Klee and Ms. Geveda. Upon effectiveness of the registration statement, Mr. Petrella and Ms. Klee will be “independent,” as defined under the Nasdaq rules and Rule 10A-3 of the Exchange Act. Our board of directors has determined that each director appointed to the audit committee is financially literate, and the board has determined that Mr. Petrella is a financial expert. Our board of directors determined that Ms. Geveda, who is a member of our audit committee, does not satisfy applicable independence standards for audit committee membership because of the equity ownership in our company held by investment funds and entities affiliated with Warburg Pincus, of which Ms. Geveda is a managing director, but determined that Ms. Geveda will be permitted to remain on the audit committee for a period of up to one year after this offering in accordance with the phase-in period under the Nasdaq rules.

Our audit committee will operate under a written charter, which will be available on our website.

Compensation Committee

The compensation committee’s main purpose is to oversee the compensation of our directors and employees, including our chief executive officer and other executive officers, and related matters.

In carrying out this purpose, the compensation committee will:

 

   

review and approve our corporate goals relevant to compensation and evaluate the performance of our chief executive officer and other executive officers against those goals;

 

   

determine the compensation of our chief executive officer and other executive officers based on their evaluations;

 

   

review, approve, administer, or, when applicable, make recommendations to our board of directors with respect to, our incentive-based compensation and equity-based plans;

 

   

evaluate any applicable post-service arrangements for our chief executive officer and other executive officers;

 

   

review on a periodic basis the operation and structure of our compensation program, considering our business strategy, the results of the most recent Say-on-Pay vote and relative competitiveness against the market;

 

   

advise the board of directors with respect to our board of directors or committee compensation;

 

   

produce the compensation committee report on executive officer compensation and review and discuss with management any “Compensation Discussion and Analysis” section proposed for inclusion in our SEC filings; and

 

   

oversee short-term and long-term management succession planning and leadership assessment and development.

The members of the compensation committee are Mr. Neary (chair) and Mr. Mihas. Upon effectiveness of the registration statement, each of Mr. Neary and Mr. Mihas will be “independent,” as defined under the Nasdaq rules. Because we may be considered a “controlled company” under the Nasdaq rules, our compensation committee may not be required to be fully independent, although if such rules change in the future or we no

 

132


Table of Contents

longer meet the definition of a controlled company under the current rules and the committee was not then fully independent, we would be required to adjust the composition of the compensation committee as and if necessary in order to comply with such rules.

Our compensation committee will operate under a written charter, which will be available on our website.

Nominating and Corporate Governance Committee

The nominating and corporate governance committee’s main purpose is to identify and evaluate individuals qualified to become board members, consistent with criteria approved by the board and to recommend for the board’s approval the slate of nominees to be proposed to stockholders for election to the board, develop and recommend to the board for approval a set of corporate governance guidelines and lead the annual review of the performance of the board and each of its standing committees.

In carrying out this purpose, the nominating and corporate governance committee will:

 

   

evaluate the composition, size, organization, performance and governance of the board and each of its committees, and make recommendations to the board about the appointment of directors to committees of the board;

 

   

monitor developments and oversee our practices and policies related to environmental and social issues;

 

   

develop policies for considering director nominees for election to the board and establish requisite qualification requirements, including director independence determinations; and

 

   

ensure compliance with the corporate governance guidelines and review and recommend any changes to the board on an annual basis.

The members of the nominating and corporate governance committee are Ms. Klee (chair), Mr. Chen, Mr. Cunningham and Mr. Donnini. Upon effectiveness of the registration statement, each of Ms. Klee, Mr. Chen, Mr. Cunningham and Mr. Donnini will be “independent,” as defined under the Nasdaq rules. Because we may be considered a “controlled company” under the Nasdaq rules, our nominating and corporate governance committee may not be required to be fully independent, although if such rules change in the future or we no longer meet the definition of a controlled company under the current rules and the committee was not then fully independent, we would be required to adjust the composition of the nominating and corporate governance committee as and if necessary in order to comply with such rules.

Our nominating and corporate governance committee will operate under a written charter, which will be available on our website.

Nordion Pricing Committee

The Nordion pricing committee is responsible for overseeing matters related to Nordion’s pricing that require review of sensitive or confidential customer information. The main purpose of this committee is to prevent confidential information relating to Nordion’s customers from being shared with individuals who are involved in the day-to-day operations of Sterigenics. The members of the Nordion pricing committee are Mr. Cunningham and Ms. Geveda.

Compensation Committee Interlocks and Insider Participation

None of the members of our compensation committee is or has been an officer or employee of our company. None of our executive officers currently serves, or in the past year has served, as a member of the board of directors or compensation committee (or other board committee performing equivalent functions) of any entity that has one or more executive officers serving on our board of directors or compensation committee.

Code of Business Conduct and Ethics

Prior to the completion of this offering, our board of directors will adopt procedures and policies to comply with the Sarbanes-Oxley Act of 2002 and the rules adopted by the SEC and the Nasdaq, including a code of business conduct and ethics applicable to all our employees, including our chief executive officer, chief financial

 

133


Table of Contents

officer and other executive and senior financial officers and all persons performing similar functions. Upon completion of this offering, our code of conduct and ethics will be available on our website. We intend to disclose any amendments to the code, or any waivers of its requirements, on our website to the extent required by the applicable U.S. federal securities laws and the corporate governance rules of the Nasdaq.

Non-Employee Director Compensation

2019 Non-Employee Director Compensation Table

The following table sets forth information regarding compensation earned by or paid to each person who served as a non-employee member of Topco Parent’s board of managers during 2019. In 2019, we did not pay any compensation to any person who served as a non-employee member of Topco Parent’s board of managers who is affiliated with the Sponsors, and, except as otherwise described below, we did not pay any fees, make any equity awards, or pay any other compensation to any of the other non-employee members of Topco Parent’s board of managers. We reimburse members of Topco Parent’s board of managers for reasonable out-of-pocket expenses incurred in connection with their service to the board of managers and covered such expenses in 2019. Mr. Petras, our Chairman and Chief Executive Officer, receives no compensation for his service as a member of Topco Parent’s board of managers, and is not included in this table. The compensation received by Mr. Petras as an employee is presented in the “Summary Compensation Table for the Year Ended December 31, 2019” in the “Executive Compensation” section of this prospectus.

 

Name

   Fees earned or
paid in cash ($)
     All other
compensation ($)
     Total ($)  

James C. Neary

     —          —          —    

Stephanie Geveda

     —          —          —    

David A Donnini

     —          —          —    

Constantine S. Mihas

     —          —          —    

Sean L. Cunningham

     —          —          —    

Michael Mulhern(1)

   $ 100,000        —        $ 100,000  

 

(1)

Mr. Mulhern served as chief executive officer of our subsidiary, Sotera Health LLC, and its predecessor from July 2011 to June 2016. Upon his retirement as our chief executive officer, Mr. Mulhern agreed to continue to serve as a member of Topco Parent’s board of managers. For this service, he received an annual cash retainer in the amount of $100,000. As of December 31, 2019, Mr. Mulhern had 1,035,311 unvested Class B-1 Units outstanding. His Class B-1 Units fully vested as of May 15, 2020. He will not be continuing on our board of directors following this offering.

Ann Klee became a member of Topco Parent’s board of managers in May 2020. For her service in advance of this offering, she is entitled to receive an annual cash retainer of $40,000. Following this offering, she will continue as a member of our board of directors and be compensated according to our non-employee director compensation policy. See “Non-Employee Director Compensation Policy.” In addition, upon her election to Topco Parent’s board of managers, Ms. Klee received a grant of 300,000 Class B-1 Units which began vesting on May 27, 2020. In connection with this offering, she will receive an in-kind distribution of Distributed Shares. See “Treatment of Outstanding Topco Parent Equity Awards in Connection with the Initial Public Offering.” Distributed Shares distributed in respect of Ms. Klee’s Class B-1 Units will remain eligible to vest following this offering pursuant to the same vesting schedule as the unvested Class B-1 Units in respect of which they are distributed. As a result, 20% of the unvested Distributed Shares will vest on May 27, 2021 (the one year anniversary of the date of grant), and the remaining unvested Distributed Shares will vest on a daily basis pro rata thereafter, subject to Ms. Klee’s continued service on our board of directors through each such date.

Vincent Petrella and Ruoxi Chen became members of our board of directors in November 2020. For their service on our board, they will be compensated according to our non-employee director compensation policy. See “Non-Employee Director Compensation Policy.”

 

134


Table of Contents

Non-Employee Director Compensation Policy

Our board of directors adopted a compensation policy for non-employee directors, which will become effective in connection with this offering. Pursuant to this policy, our non-employee directors will receive the compensation described below. This non-employee director compensation policy may be amended by our board of directors from time to time.

Cash Compensation

Following the completion of this offering, each non-employee director will be entitled to receive an annual cash retainer of $75,000 as remuneration for service to the company, with an additional $7,500 for service on the audit committee (or, in the case of the chair of such committee, $25,000), an additional $5,000 for service on the compensation committee (or, in the case of the chair of such committee, $20,000), an additional $2,500 for service on the nominating and corporate governance committee (or, in the case of the chair of such committee, $15,000), and an additional $35,000 for service as the lead independent director (to the extent this position exists). There will be no additional compensation for service on the Nordion pricing committee. The annual cash retainer will be paid prospectively on a quarterly basis, pro-rated (i) for any non-employee director whose service (or whose service in any of the additional capacities described above) commences during a calendar year and (ii) for the calendar year in which this offering occurs, such that the retainer is reduced proportionately for any calendar month prior to the month in which such service commenced or this offering occurred, respectively.

Equity Compensation

Following the completion of this offering, each non-employee director will receive an annual grant of restricted stock units (“RSUs”) under our 2020 Plan with a grant date fair value of $225,000. Such RSUs will vest in full on the earlier of (i) the first anniversary of the date of grant, or (ii) the date immediately prior to the company’s next regular annual meeting of stockholders, in each case, subject to the director’s continued service through such date. The first such annual grant of RSUs will be made in connection with this offering and will have a pro-rated grant date fair value of $135,000 to account for the fact that directors will not serve a full year before our next annual meeting. Subsequent annual grants of RSUs will be made on the day immediately after our regular annual meeting of stockholders to non-employee directors who are serving on our board of directors on such date.

Expenses

We intend to reimburse our non-employee directors for all reasonable out-of-pocket expenses that are incurred in connection with attendance at meetings of our board of directors, the board of directors of any of our subsidiaries and any committees thereof, in accordance with the terms of our amended and restated bylaws and our expense reimbursement policy, as in effect from time to time.

 

135


Table of Contents

EXECUTIVE COMPENSATION

Overview

Our “Named Executive Officers,” consisting of our principal executive officer and our two most highly compensated executive officers (other than our principal executive officer), as of December 31, 2019, were:

 

   

Michael B. Petras, Jr., our Chairman and Chief Executive Officer

 

   

Scott J. Leffler, our Chief Financial Officer and Treasurer

 

   

Matthew J. Klaben, our Senior Vice President, General Counsel and Secretary

Summary Compensation Table for the Year Ended December 31, 2019

The following table presents summary information regarding the total compensation that was awarded to, earned by or paid to our Named Executive Officers during the year ended December 31, 2019:

 

Name and principal position

   Year      Salary ($)(1)      Bonus ($)(2)      Non-equity
incentive plan
compensation ($)(3)
     All other
compensation
($)(4)
     Total ($)  
Michael B. Petras, Jr.
Chairman and Chief
Executive Officer
     2019      $ 700,000      $ 1,000,000      $ 759,500      $ 12,600      $ 2,472,100  
Scott J. Leffler
Chief Financial Officer
and Treasurer
     2019      $ 352,135      $ 1,650,000      $ 229,240      $ 12,600      $ 2,243,975  
Matthew J. Klaben
Senior Vice President,
General Counsel and Secretary
     2019      $ 367,221      $ 350,000      $ 162,562      $ 12,600      $ 892,383  

 

(1)

Includes the value of each Named Executive Officer’s base salary during the fiscal year covered.

(2)

Includes the value of one-time discretionary cash bonuses for members of management relating to capital markets activity in 2019. Such bonuses were approved by the board of managers of Topco Parent. In addition, for Mr. Leffler, includes the value of a $1,500,000 retention bonus to which he was entitled under the terms of his CFO Bonus Agreement (as defined below) with the company, which was paid on the first ordinary payroll date following November 18, 2019. See “Employment Agreements—Retention Agreement with Mr. Scott J. Leffler.”

(3)

Includes the value of annual cash incentive awards paid under our Annual Incentive Plan. See “Annual Incentive Plan.”

(4)

Includes the value of company contributions made on behalf of our Named Executive Officers under our 401(k) Plan (as defined below). See “Retirement Plans.”

Narrative Disclosure to Summary Compensation Table

Employment Agreements

Employment Agreement with Mr. Michael B. Petras, Jr.

Mr. Petras entered into an employment agreement with our subsidiary, Sotera Health LLC, dated May 25, 2016 (the “CEO Employment Agreement”), pursuant to which he served as the CEO and as a member of Topco Parent’s board of managers. Under the terms of the CEO Employment Agreement, Mr. Petras’ initial annual base salary in connection with his appointment as CEO was set at $700,000, less applicable withholding taxes. See “Summary Compensation Table for the Year Ended December 31, 2019” for information on Mr. Petras’ base salary paid in 2019. Under the CEO Employment Agreement, Mr. Petras was also eligible to receive an annual bonus based on his attainment of one or more pre-established performance criteria established by Topco Parent’s board of managers, with his annual target bonus opportunity equal to 100% of his then-current annual base salary.

 

136


Table of Contents

In connection with this offering, Sotera Health LLC assigned its rights and obligations under the CEO Employment Agreement to our company and we entered into an amended and restated employment agreement with Mr. Petras which will replace his existing employment agreement effective as of the closing of this offering (the “Amended and Restated CEO Employment Agreement”). Under the terms of the Amended and Restated CEO Employment Agreement, Mr. Petras will serve as our CEO and Executive Chairman of our board of directors. Mr. Petras’ initial annual base salary is set at $1,000,000, less applicable withholding taxes. Mr. Petras is eligible to receive an annual bonus based on the attainment of certain pre-established performance criteria established by our board of directors, with his annual target bonus opportunity equal to 125% of his then-current annual base salary.

Under the Amended and Restated CEO Employment Agreement, Mr. Petras is eligible to receive certain payments and benefits in the event of a termination of his employment by us without “cause” or a termination of employment by him for “good reason” (as each of these terms are defined in the Amended and Restated CEO Employment Agreement), which are described in detail under “Potential Payments upon Termination or Change in Control.”

Employment Agreement with Mr. Scott J. Leffler

Mr. Leffler entered into an employment agreement with our subsidiary, Sotera Health LLC, dated April 3, 2017 (the “CFO Employment Agreement”), pursuant to which he served as Chief Financial Officer (“CFO”). Under the terms of the CFO Employment Agreement, Mr. Leffler’s initial annual base salary in connection with his appointment as CFO was set at $340,000, less applicable withholding taxes. See “Summary Compensation Table for the Year Ended December 31, 2019” for information on Mr. Leffler’s base salary paid in 2019. Under the CFO Employment Agreement, Mr. Leffler was also eligible to receive an annual bonus based on his attainment of one or more pre-established performance criteria established by Topco Parent’s board of managers, with his annual target bonus opportunity equal to 60% of his then-current annual base salary.

In connection with this offering, Sotera Health LLC, assigned its rights and obligations under the CFO Employment Agreement to our company and we entered into an amended and restated employment agreement with Mr. Leffler which will replace his existing employment agreement effective as of the closing of this offering (the “Amended and Restated CFO Employment Agreement”). Under the terms of the Amended and Restated CFO Employment Agreement, he will serve as our CFO. Mr. Leffler’s initial annual base salary is set at $450,000, less applicable withholding taxes. Mr. Leffler is also eligible to receive an annual bonus based on the attainment of certain pre-established performance criteria established by our board of directors, with his annual target bonus opportunity equal to 70% of his then-current annual base salary.

Under the Amended and Restated CFO Employment Agreement, Mr. Leffler is eligible to receive certain payments and benefits in the event of a termination of his employment by us without “cause” or a termination of employment by him for “good reason” (as each of these terms is defined in the CFO Employment Agreement), which are described in detail under “Potential Payments upon Termination or Change in Control” below.

Retention Agreement with Mr. Scott J. Leffler

Mr. Leffler entered into a bonus agreement with our subsidiary, Sotera Health LLC, dated as of November 18, 2019 (the “CFO Bonus Agreement”). Pursuant to the CFO Bonus Agreement, on the first ordinary payroll date following November 18, 2019, Mr. Leffler received a cash retention bonus of $1,500,000 (less applicable tax withholdings) in consideration for his agreement to continue active employment with Sotera Health LLC through November 18, 2021 (the “Retention Date”). If prior to the Retention Date, Mr. Leffler terminates his employment without “good reason” (as described below in “Potential Payments Upon Termination or Change in Control,” but excluding a termination due to Mr. Leffler’s death or disability), Mr. Leffler is obligated to repay, on a pre-tax basis, the full amount of the retention bonus. In connection with this offering, Sotera Health LLC assigned its rights and obligations under the CFO Bonus Agreement to our company and we entered into an amended and restated bonus agreement with Mr. Leffler which reflects such assignment.

 

137


Table of Contents

Employment Agreement with Mr. Matthew J. Klaben

Mr. Klaben entered into an employment agreement with our subsidiary, Sotera Health LLC, dated December 12, 2016 (the “SVP & GC Employment Agreement”), pursuant to which he served as Senior Vice President and General Counsel (“SVP & GC”). Under the terms of the SVP & GC Employment Agreement, Mr. Klaben’s initial annual base salary in connection with his appointment as SVP & GC was set at $345,000, less applicable withholding taxes. See “Summary Compensation Table for the Year Ended December 31, 2019” for information on Mr. Klaben’s base salary paid in 2019. Under the SVP & GC Employment Agreement, Mr. Klaben was also eligible to receive an annual bonus based on the attainment of one or more pre-established performance criteria established by Topco Parent’s board of managers, with his annual target bonus opportunity equal to 40% of his then-current annual base salary.

In connection with this offering, Sotera Health LLC assigned its rights and obligations under the SVP & GC Employment Agreement to our company and we entered into an amended and restated employment agreement with Mr. Klaben which will replace his existing employment agreement effective as of the closing of this offering (the “Amended and Restated SVP & GC Employment Agreement”). Under the terms of the Amended and Restated SVP & GC Employment Agreement, Mr. Klaben’s initial annual base salary is set at $425,000, less applicable withholding taxes. Mr. Klaben is also eligible to receive an annual bonus based on the attainment of certain pre-established performance criteria established by our board of directors, with his annual target bonus opportunity equal to 50% of his then-current annual base salary.

Under the Amended & Restated SVP & GC Employment Agreement, Mr. Klaben is eligible to receive certain payments and benefits in the event of a termination of his employment by us without “cause” or a termination of employment by him for “good reason” (as each of these terms is defined in the SVP & GC Employment Agreement), which are described in detail under “Potential Payments upon Termination or Change in Control” below.

Base Salary

We provide each Named Executive Officer with a base salary for the services that the executive officer performs for us. This compensation component constitutes a stable element of compensation while other compensation elements are variable. Base salaries may be increased based on the individual performance of the Named Executive Officer, company performance, any change in the executive’s position within our business, the scope of his or her responsibilities and any changes thereto. Base salaries may also be increased as provided under the terms of a Named Executive Officer’s employment agreement.

Annual Incentive Plan

We maintain an Annual Incentive Plan (the “Annual Incentive Plan” or “AIP”), which is designed to reward high performance, ensure employees are aligned with our mission, values and priorities and provide market competitive rewards. Our executive officers (including our Named Executive Officers) and key employees are eligible to participate in the Annual Incentive Plan. The Annual Incentive Plan is administered by Topco Parent’s board of managers with respect to our executive officers and by our CEO with respect to employees other than executive officers.

The cash incentive awards made to our Named Executive Officers under the Annual Incentive Plan are based on the company’s achievement of EBITDA goals set by Topco Parent’s board of managers at the beginning of the applicable performance period and individual performance. The company must attain its threshold EBITDA for any payout under the Annual Incentive Plan to occur.

The target metrics for our 2019 AIP are included in the below table. Our 2019 AIP company performance metric was based on the non-GAAP financial measure adjusted EBITDA. We believe that net income is the most

 

138


Table of Contents

comparable GAAP measure to adjusted EBITDA. Adjusted EBITDA in respect of our 2019 AIP was calculated in a manner consistent with the calculation of “Consolidated EBITDA” for purposes of our credit agreement (filed herewith as Exhibit 10.10). AIP performance between threshold, target and maximum goals was determined based on linear interpolation.

 

2019 EBITDA Goal (dollars in millions)

   Performance as Percentage
of Target
    AIP Performance (as % of
Target Opportunity)

Threshold $358.3

     95     75%

Target $377.1

     100   100%

Maximum $422.4

     112   Up to a maximum of 200%

For 2019, the EBITDA goals under the Annual Incentive Plan were achieved at 108.5% of target.

The total target bonus percentages for Messrs. Petras, Leffler and Klaben were 100%, 60% and 40%, respectively, of their base salaries for 2019. Individual bonus payouts for our Named Executive Officers are determined by taking into account both company performance (80% weighting) and individual performance (20% weighting). In 2019, Mr. Klaben received an upward adjustment of 110% to his individual performance target based on his performance being rated “Exceeds Expectations.” Both Mr. Petras and Mr. Leffler received 100% of their individual performance targets for 2019.

The following table provides further detail about the 2019 annual bonus payout under the Annual Incentive Plan for each Named Executive Officer:

 

Name

   2019 Base
Salary
     2019 AIP Target
(expressed as %
of Base Salary)
    2019 AIP Target
Opportunity
     Actual 2019
Annual Incentive
Plan Bonus Earned
 

Michael B. Petras, Jr.

   $ 700,000        100   $ 700,000      $ 759,500  

Scott J. Leffler

   $ 352,135        60   $ 211,281      $ 229,240  

Matthew J. Klaben

   $ 367,221        40   $ 146,888      $ 162,562  

Retirement Plans

We maintain a tax-qualified 401(k) savings plan (the “401(k) Plan”), in which all our employees, including our Named Executive Officers, are eligible to participate. The 401(k) Plan allows participants to contribute up to 100% of their pay on a pre-tax basis (or on a post-tax basis, with respect to elective Roth deferrals) into individual retirement accounts, subject to the maximum annual limits set by the Internal Revenue Service (“IRS”). We have historically made annual contributions to employee 401(k) accounts of up to 4.5% of an employee’s contributions to the 401(k) Plan. In 2019, we contributed up to $12,600 per employee. Participants are immediately fully vested in both their own contributions and our contributions to the 401(k) Plan.

Additionally, we maintain a non-qualified deferred compensation plan (the “Supplemental Retirement Benefit Plan”) under which a select group of management and highly compensated employees are permitted to supplement contributions made under the 401(k) Plan by deferring up to 50% of their bonus or salary. Although permitted by the Supplemental Retirement Benefit Plan, we have not previously provided matching employer contributions under this plan. Participants are immediately fully vested in the contributions to the Supplemental Retirement Benefit Plan. Participants in the Supplemental Retirement Benefit Plan are permitted to elect to invest their accounts in the same investment options as are available under the 401(k) Plan.

Outstanding Equity Awards as of December 31, 2019

There were no outstanding equity awards in respect of our common stock as of December 31, 2019. The following table sets forth information regarding the outstanding Class B-1 Units and Class B-2 Units in Topco Parent (together, the “Class B Units”) held as of December 31, 2019 by each of our Named Executive Officers.

 

139


Table of Contents

The Class B Units represent profits interests in Topco Parent, which will have intrinsic value only if the value of Topco Parent increases following the date on which the awards of such Class B Units are granted and only after preferred return payments have been paid to the holders of Class A Units in Topco Parent and the aggregate amount of capital contributions in respect of all Class A Units have been repaid to the holders of the Class A Units. In connection with the offering, shares of our common stock will be distributed in respect of the Class B Units and, subsequent thereto, Topco Parent will dissolve and the Class B Units will be cancelled. For an additional discussion of this distribution, see “Ownership of Topco Parent and Related Distributions.”

 

     Stock awards  

Name

   Number of
shares or
units of
stock that
have not
vested
(#)(1)(4)
     Market value of
shares or units
of stock that
have not
vested ($)(2)
     Equity
incentive plan
awards:
Number of
unearned
shares, units or
other rights
that have not
vested (#)(3)
     Equity incentive
plan awards:
Market or
payout value of
unearned
shares, units or
other rights
that have not
vested ($)(2)
 

Michael B. Petras, Jr.(5)

     3,773,439      $ 10,644,871        —          —    

Scott J. Leffler

     913,192      $ 2,576,115        675,000      $ 1,904,175  

Matthew J. Klaben

     421,644      $ 1,189,458        375,000      $ 1,057,875  

 

(1)

Represents unvested Class B-1 Units in Topco Parent, which are subject to time-based vesting requirements. See footnote 4 for Class B-1 Unit vesting dates.

(2)

The Class B Units were not publicly traded as of December 31, 2019. The market value of the Class B Units included in this table represents the fair market value of Class B Units that were unvested as of December 31, 2019 as determined by Topco Parent based on an independent third-party valuation.

(3)

Represents unvested Class B-2 Units, which are subject to performance-based vesting requirements. The Class B-2 Units will vest as of the first date on which (i) our Sponsors have received two and one-half times their invested capital in Topco Parent and (ii) the Sponsors’ internal rate of return exceeds twenty percent, subject to the grantee’s continued services through the such date. Mr. Petras only received a grant of Class B-1 Units and does not hold any Class B-2 Units.

(4)

The vesting schedules of the Class B-1 Units are as follows (subject to the Named Executive Officer’s continued employment through each applicable vesting date):

 

Name

   Grant Date   

Vesting Schedule

Michael B. Petras, Jr.

   June 20, 2016    Vest on a daily basis pro rata over the first four years following June 20, 2016.

Scott J. Leffler

   April 3, 2017    Vest on a daily basis pro rata over the first five years following April 3, 2017.

Matthew J. Klaben

   November 15, 2016    Vest on a daily basis pro rata over the first five years following November 15, 2016

 

(5)

Includes Class B Units held by an estate planning trust.

Long-Term Equity Compensation

Our long-term equity compensation program is designed to provide that a portion of compensation granted to our executives and other employees is in the form of equity-based instruments. This long-term equity compensation is important to ensure that the interests of our executives and employees are aligned with those of our stockholders, therefore encouraging value-creation for both our executives and our stockholders.

Class B Units in Topco Parent. Historically, our company has not issued any equity awards. Instead, our employees and other service providers are eligible to be granted long term equity incentive awards in the form

 

140


Table of Contents

of Class B Units under the limited partnership agreement of Topco Parent. Class B Units are “profits interests” having economic characteristics similar to a stock option and allow our employees and other service providers to share in the future appreciation of Topco Parent, subject to certain service-based vesting (based on continued provision of services) and performance-based vesting (based on the return achieved by our Sponsors) conditions, as described in more detail below. In making grants of Class B Units, we aim to foster a long-term commitment to us and our mission, offer a balance to the short-term cash components of our compensation program, promote retention and reinforce our pay-for-performance structure.

The Class B Units are issued pursuant to the terms of a Class B Unit award agreement between Topco Parent and each holder of Class B Units. Class B Units represent an ownership interest in Topco Parent. Pursuant to the limited partnership agreement of Topco Parent, Class B Units share in distributions according to a “waterfall” which provides for distributions to be made in the following order and priority: (1) first, to the holders of Class A Units until they receive an 8% annual return on their remaining unreturned capital contributions, compounded quarterly; (2) second, to the holders of Class A Units until they receive an amount equal to their respective capital contributions on a pro rata basis; and (3) third, to the holders of Class A Units, Class B Units and Class D Units, pro rata, subject to any applicable “participation thresholds.” Each of the Class B Units has a “participation threshold.” A participation threshold in respect of a Class B Unit is determined at the time of issuance or grant and is equal to or greater than the amount payable in respect of a Class A Unit with a participation threshold of zero pursuant to the waterfall of Topco Parent (excluding amounts payable in respect of any preferred return or return of capital to such Class A Unit) in a hypothetical liquidation of Topco Parent at the current business enterprise value of Topco Parent as of immediately prior to such issuance or grant. The effect of the participation threshold in respect of a Class B Unit is that such Class B Unit will not have any intrinsic value on the date of grant since it would not be entitled to any proceeds in the waterfall based on the hypothetical liquidation used to set such threshold. Unit participation thresholds are reduced as Topco Parent makes distributions pursuant to the waterfall. Class B Unit holders were not required to make any capital contribution in exchange for their Class B Units, which were awarded as compensation.

Generally, 75% of the Class B Units subject to each award are designated as Class B-1 Units and are scheduled to vest over a four or five year period (25% or 20% per year, respectively) with 25% or 20% of the Class B-1 Units vesting on the first anniversary of the date of grant and the remainder of the Class B-1 units vesting on a daily basis pro rata thereafter, subject to the grantee’s continued services through each vesting date. Generally, 25% of the Class B Units subject to each award are designated as Class B-2 Units and are scheduled to vest only upon satisfaction of certain performance thresholds. These units vest as of the first date on which (i) our Sponsors have received two and one-half times their invested capital in Topco Parent and (ii) the Sponsors’ internal rate of return exceeds twenty percent, subject to such grantee’s continued services through such date. In the event of a change in control of Topco Parent, 100% of the outstanding and unvested Class B-1 Units will automatically vest and any outstanding and unvested Class B-2 Units that do not vest as a result of the consummation of such change in control will be immediately canceled and forfeited. This offering does not constitute a change in control for these purposes. Our board has the discretion to allocate the portion of a Class B Unit grant between each of Class B-1 Units and Class B-2 Units and has recently made grants that consist entirely of Class B-1 Units. All of the Class B Units granted to Mr. Petras were designated as Class B-1 Units, subject only to service-based vesting.

Generally, in the event that a holder of Class B Units is terminated from service for any reason other than for cause (generally defined as the grantee’s (i) intentional unauthorized use or disclosure of confidential information or trade secrets, (ii) conviction of, or a plea of “guilty” or “no contest” to, a felony, (iii) engagement in any fraud, willful misconduct or gross neglect in the performance of duties or in any other willful misconduct which has directly caused a material injury to Topco Parent, its affiliates, Sponsors or any of their affiliates, (iv) willful engagement in any act or omission involving dishonesty, breach of trust, unethical business conduct or moral turpitude, (v) intentional failure to perform lawful assigned duties after receiving written notification and failing to correct such deficiencies or (vi) breach of restrictive covenants), all unvested Class B Units shall be

 

141


Table of Contents

forfeited as of such individual’s termination date. In the event that a holder of Class B Units is terminated for cause, all Class B Units shall be forfeited and cancelled for no consideration as of such individual’s termination date.

In the event that Mr. Petras had been terminated without “cause” or terminated his employment for “good reason” (in each case as defined in the CEO Employment Agreement) during the vesting period for his Class B-1 Units, (i) the number of Class B-1 Units that would have vested during the period starting on such termination date through the end of the Company’s first fiscal quarter following such date would have vested and (ii) the remaining unvested Class B-1 Units would have remained outstanding and subject to vesting upon a sale of Topco Parent within 180 days following such termination. Mr. Petras’ Class B-1 Units are now fully vested.

Class B Units are subject to repurchase by Topco Parent in the event that a grantee ceases to provide services to Topco Parent or any of its subsidiaries. Topco Parent may elect to repurchase all or any number of Class B Units at a purchase price equal to the fair market value (as determined by Topco Parent in good faith) of such Class B Units as of the date Topco Parent delivers written notice of the election to repurchase. Such written notice must be delivered within three hundred and sixty (360) days of the grantee’s termination date. Topco Parent’s right to repurchase any Class B Units (or any shares of our common stock distributed in respect of such Class B Units—see “Ownership of Topco Parent and Related Distributions” ) shall lapse upon the consummation of this offering.

Class B Units may not be transferred by grantees except for (i) transfers pursuant to Topco Parent’s exercise of its tag-along rights, drag-along rights or repurchase rights, (ii) transfers to which Topco Parent’s board of managers has granted prior consent and (iii) transfers made pursuant to applicable laws of descent of distribution or to a grantee’s legal guardian in the case of mental incapacity.

See the “Outstanding Equity Awards as of December 31, 2019” table above and “Potential Payments Upon Termination or Change in Control” below for more information regarding the Class B Units held by our Named Executive Officers.

Treatment of Outstanding Topco Parent Equity Awards in Connection with the Initial Public Offering

Pursuant to the terms of the corporate reorganization that will be completed prior to the completion of the offering, each holder of Class B Units (including the Named Executive Officers holding any such units) will receive an in-kind distribution of a number of shares of our common stock in accordance with the “waterfall” of Topco Parent described above under “Long Term Equity Compensation,” net of any previously unrecouped tax distributions (such shares, the “Distributed Shares”). For purposes of this distribution, the value of a share of common stock will be measured by the initial public offering price.

As a condition of the distribution, all holders of such shares shall be required to execute and become a party to the Stockholders’ Agreement which governs the rights and obligations of such holders. See “Certain Relationships and Related Party Transactions—Stockholders’ Agreement” for additional information on the terms of such agreement. In addition, each holder of Class B Units who receives shares of our common stock in the corporate reorganization will be required to execute the Restricted Stock Agreement and Acknowledgment (the “RSA”) in the form filed as an exhibit to the registration statement of which this prospectus forms a part. The RSA provides that any shares of our common stock distributed to an individual in respect of any Class B-1 Units that are vested of the distribution will not be subject to any vesting or forfeiture restrictions following the offering. With respect to shares of common stock distributed in respect of any Class B-1 Units that are unvested as of the distribution and all of the Class B-2 Units (since none of the Class B-2 Units have vested or will vest as of the distribution), the RSA generally provides that such shares shall be subject to the same vesting and forfeiture restrictions that applied to such unvested Class B-1 and Class B-2 Units prior to the distribution. Though the corporate reorganization and distribution of the shares of our common stock will not cause the time and/or performance-based vesting restrictions applicable to any shares of common stock to lapse, the

 

142


Table of Contents

achievement of the performance conditions applicable to shares of our common stock distributed in respect of Class B-2 Units will be deemed probable, resulting in recognition of compensation expense. Please see the Share-Based Compensation note to our unaudited consolidated financial statements included elsewhere in this prospectus for additional discussion of such compensation expense recognition.

Following the distribution of the shares of our common stock, Topco Parent will distribute any remaining cash to its limited partners in accordance with the “waterfall” described above. Topco Parent will then wind up and dissolve, as a result of which all of the outstanding Units (including the Class B Units) will be cancelled in their entirety and Topco Parent and the Units (including all Class B Units) will cease to exist.

For an additional discussion of this distribution, see “Ownership of Topco Parent and Related Distributions.”

The table below sets forth an estimate, based on an assumed initial public offering share price of $21.50, the midpoint of the estimated offering price range set forth on the cover page of this prospectus, of the number of shares of our common stock that would have been distributed to each of our Named Executive Officers in respect of Class B Units, before giving effect to this offering and the repurchase (as described in “Use of Proceeds” and “Certain Relationships and Related Party Transactions—Transactions with Certain of Our Executive Officers”), as of September 30, 2020:

 

Name

   Distributed Shares  
     Vested        Unvested  

Michael B. Petras, Jr.

     8,141,731        —    

Scott J. Leffler

     354,218        321,276  

Matthew J. Klaben

     218,224        157,050  

Potential Payments Upon Termination or Change in Control

Potential Payments to Mr. Michael B. Petras, Jr.

In the event of a termination of employment by us without “cause” or by him for “good reason” (each as defined in the Amended and Restated CEO Employment Agreement), Mr. Petras, upon execution of a general release of claims in our favor and subject to continued compliance with the terms of such release and the restrictive covenants set forth in the Amended and Restated CEO Employment Agreement, will be eligible to receive:

 

   

An amount equal to 2 times his then-current annual base salary payable in a lump sum within 60 days following his termination date,

 

   

If Mr. Petras elects COBRA, monthly reimbursement of the COBRA premiums incurred by Mr. Petras in an amount equal to the employer portion of the health insurance coverage provided to active employees for up to 12 months, provided that this benefit will cease if Mr. Petras becomes reemployed with another employer prior to the expiration of the 12 month period, and

 

   

2 years of additional time-based vesting credit with respect to all then outstanding and unvested equity awards.

Under the Amended and Restated CEO Employment Agreement, “cause” generally means Mr. Petras’ (i) disclosure of confidential information or trade secrets of the Company, the Sponsors or any of their affiliates or any of their respective customers or suppliers, which use or disclosure causes or is demonstrably likely to cause a material injury to any of these parties, (ii) conviction of, or a plea of “guilty” or “no contest” to, a felony under the laws of the United States, Canada or any jurisdiction in which Executive resides, (iii) fraud, willful misconduct or gross neglect in the performance of his material duties or engagement in any other willful misconduct or willful engagement in any act or omission involving dishonesty, unethical business conduct or

 

143


Table of Contents

moral turpitude which has caused a material injury to the Company, the Sponsors or any of their affiliates or any of their respective customers or suppliers, (v) intentional failure to perform assigned duties subject to a 30 day cure period or (vi) breach of his non-competition covenant or any material breach of any other restrictive covenants to which Mr. Petras may be subject.

Under the Amended and Restated CEO Employment Agreement, “good reason” generally means (i) any material reduction in Mr. Petras’ title, status or authority, including, following the completion of this offering, the failure to elect Mr. Petras to serve as the Executive Chairman of the board of directors, (ii) any material reduction of Mr. Petras’ responsibilities, annual base salary or annual bonus opportunity, other compensation or the aggregate value of Mr. Petras’ benefits, (iii) the failure to grant the IPO Awards to Mr. Petras, as described below or (iv) the failure to provide for certain time-based vesting protections (as described below under “Treatment of IPO Awards Upon Termination or Change in Control”) in connection with any future equity awards granted to Mr. Petras.

Potential Payments to Mr. Scott J. Leffler

In the event of a termination of employment by us without “cause” or by him for “good reason” (in each case as defined in the Amended and Restated CFO Employment Agreement), Mr. Leffler, upon execution of a general release of claims in our favor and subject to continued compliance with the terms of such release and the restrictive covenants set forth in the Amended and Restated CFO Employment Agreement, will be eligible to receive:

 

   

A continuation of his annual base salary for 18 months,

 

   

Continuation of his health insurance coverage as though he had continued to be an active employee of the company, or if he is unable to so participate and elects COBRA, monthly reimbursement for the difference between the monthly COBRA premium over the monthly premium he would have paid had he continued to be an active employee, for 18 months, provided that this benefit will cease if Mr. Leffler becomes reemployed with another employer that offers medical insurance prior to the expiration of the 18 month period, and

 

   

In the event that such termination takes place within the 12 month period immediately following the grant date of the IPO Awards (as defined below), 1 year of additional time-based vesting credit with respect to such awards.

Under the Amended and Restated CFO Employment Agreement, “cause” generally means Mr. Leffler’s (i) disclosure of confidential information or trade secrets of the company, the Sponsors or any of their affiliates or any of their respective customers or suppliers, which use or disclosure causes or is likely to cause a material injury to any of these parties, (ii) conviction of, or a plea of “guilty” or “no contest” to, a felony under the laws of the United States, Canada or any jurisdiction in which Executive resides, (iii) fraud, willful misconduct or gross neglect in the performance of his duties or engagement in any other willful misconduct or willful engagement in any act or omission involving dishonesty, unethical business conduct or moral turpitude which has caused a material injury to the company, the Sponsors or any of their affiliates or any of their respective customers or suppliers, (v) intentional failure to perform assigned duties after a written notification from our board of directors or (vi) breach of the Amended and Restated CFO Employment Agreement.

Under the Amended and Restated CFO Employment Agreement, “good reason” generally means (i) any material reduction in Mr. Leffler’s title, status or authority, (ii) any material reduction of Mr. Leffler’s responsibilities, annual base salary, annual bonus opportunity, other compensation or the aggregate value of Mr. Leffler’s benefits, (iii) relocation of Mr. Leffler’s primary place of employment by more than 50 miles or (iv) the failure to grant the IPO Awards to Mr. Leffler, as described below.

 

144


Table of Contents

Potential Payments to Mr. Matthew J. Klaben

In the event of a termination of employment by us without “cause” or by him for “good reason” (in each case as defined in the Amended and Restated SVP & GC Employment Agreement), Mr. Klaben, upon execution of a general release of claims in our favor and subject to continued compliance with the terms of such release and the restrictive covenants set forth in the Amended and Restated SVP & GC Employment Agreement, will be eligible to receive:

 

   

A continuation of his annual base salary for 12 months,

 

   

Continuation of his health insurance coverage as though he had continued to be an active employee of the company, or if he is unable to so participate and elects COBRA, monthly reimbursement for the difference between the monthly COBRA premium over the monthly premium he would have paid had he continued to be an active employee, for 12 months, provided that this benefit will cease if Mr. Klaben becomes reemployed with another employer that offers medical insurance prior to the expiration of the 12 month period, and

 

   

In the event that such termination takes place within the 12 month period immediately following the grant date of the IPO Awards, 1 year of additional time-based vesting credit with respect to such awards.

Under the Amended and Restated SVP & GC Employment Agreement, “cause” generally means Mr. Klaben’s (i) disclosure of confidential information or trade secrets of the company, the Sponsors or any of their affiliates or any of their respective customers or suppliers, which use or disclosure causes or is likely to cause a material injury to any of these parties, (ii) conviction of, or a plea of “guilty” or “no contest” to, a felony under the laws of the United States, Canada or any jurisdiction in which Executive resides, (iii) fraud, willful misconduct or gross neglect in the performance of his duties or engagement in any other willful misconduct or willful engagement in any act or omission involving dishonesty, unethical business conduct or moral turpitude which has caused a material injury to the company, the Sponsors or any of their affiliates or any of their respective customers or suppliers, (iv) intentional failure to perform assigned duties after a written notification from our board of directors or (v) breach of the Amended and Restated SVP & GC Employment Agreement.

Under the Amended and Restated SVP & GC Employment Agreement, “good reason” generally means (i) any material reduction in Mr. Klaben’s title, status or authority, (ii) any material reduction of Mr. Klaben’s responsibilities, annual base salary, annual bonus opportunity, other compensation or the aggregate value of Mr. Klaben’s benefits, (iii) relocation of Mr. Klaben’s primary place of employment by more than 50 miles or (iv) the failure to grant the IPO Awards to Mr. Klaben, as described below.

Treatment of IPO Awards Upon Termination or Change in Control

The applicable award agreements pursuant to which the IPO Awards are granted will provide for accelerated vesting of unvested IPO Awards upon certain events.

Each recipient of an IPO Award will receive two (2) years of additional time-based vesting credit upon a termination of employment by reason of the grantee’s death or Disability (as defined in the 2020 Plan).

Certain grantees of IPO Awards, including Messrs. Leffler and Klaben, will receive an additional two years of time-based vesting credit in respect of all outstanding unvested IPO Awards in the event that, following the two year anniversary of the IPO Award grant date, the grantee retires at or older than age 55 with 10 or more years of service to the company. With respect to Mr. Petras, all unvested IPO Awards shall vest in full upon Mr. Petras’ voluntary retirement following the date on which the sum of Mr. Petras’ attained age and years of service with the company equals or exceeds sixty-five (65). Notwithstanding the foregoing, the IPO Awards shall not qualify for such vesting credit to the extent they were granted within the twelve (12) month period immediately prior to a grantee’s retirement.

 

145


Table of Contents

As described above, in the event that Mr. Petras’ employment is terminated by the Company without “cause” or by Mr. Petras for “good reason” (in each case as defined in the Amended and Restated CEO Employment Agreement), subject to execution of a general release of claims in our favor and continued compliance with the terms of such release and the restrictive covenants set forth in the Amended and Restated CEO Employment Agreement, Mr. Petras will receive two (2) years of additional time-based vesting credit with respect to any IPO Awards that remain unvested as of the date of such termination.

As described above, in the event that Mr. Leffler’s or Mr. Klaben’s employment is terminated by the Company without “cause” or by either Named Executive Officer for “good reason” (in each case as defined in the applicable amended and restated employment agreement) within the twelve (12) month period immediately following the grant date of the IPO Awards, the terminated Named Executive Officer will receive one (1) year of additional time-based vesting credit with respect to any IPO Awards that remain unvested as of the date of such termination, subject to execution of a general release of claims in our favor and continued compliance with the terms of such release and the restrictive covenants set forth in the applicable amended and restated employment agreement.

In the event of a Change in Control (as defined in the 2020 Plan) where any outstanding unvested portion of the IPO Awards are not assumed or substituted by the acquiror, such unvested awards will vest as of the date of such Change in Control. In the event of a Change in Control where outstanding IPO Awards are assumed or substituted by the acquiror and (x) a grantee is terminated by the acquiror without Cause (as defined in the 2020 Plan) or (y) with respect to those of our grantees, including our Named Executive Officers, who are party to a written employment agreement with the company that provides for a definition of “good reason”, such grantee terminates his or her employment for “good reason” (as defined in such grantee’s employment agreement), in each case, within the one (1) year period immediately following such Change in Control, any then unvested IPO Award will vest as of the date of such individual’s termination.

Looking Ahead – Post-Initial Public Offering Compensation

In connection with and following this offering, we expect that our Compensation Committee will review with its independent compensation consultant our compensation levels, our incentive compensation programs and the types of compensation we offer to ensure that our programs are based on appropriate measures, goals and targets for our industry and our business objectives and to determine whether any changes to our compensation structures are justified. This review will also be designed to ensure that the overall level of total compensation for our executive officers is reasonable in relation to, and competitive with, the compensation paid by similarly situated peer leaders in our industry, subject to variation for individual factors such as experience, performance, duties, scope of responsibility, prior contributions and future potential contributions to our business.

2020 Omnibus Incentive Plan

On November 10, 2020 our board of directors adopted our 2020 plan, which was subsequently approved by our sole stockholder on November 10, 2020. Our 2020 Plan allows for the grant of incentive stock options to employees, including the employees of any of our subsidiaries, and for the grant of nonstatutory stock options, restricted stock awards, RSUs and other cash-based, equity-based or equity-related awards to employees, directors, and consultants, including employees and consultants of any of our parents or subsidiaries.

Authorized Shares

The maximum number of shares of our common stock that may be issued under our 2020 Plan is 27,900,000 shares. The maximum number of shares of our common stock that may be issued pursuant to the exercise of incentive stock options under our 2020 Plan is also 27,900,000 shares. Shares subject to awards granted under our 2020 Plan that expire, are forfeited, are retained by us in order to satisfy any exercise price or any tax withholding or are repurchased by us at their original purchase price will not reduce the number of shares available for issuance under our 2020 Plan. Further, shares of our common stock covered by awards granted

 

146


Table of Contents

pursuant to the 2020 Plan in connection with the assumption, replacement, conversion or adjustment of outstanding equity-based awards in the context of a corporate acquisition or merger shall not reduce the number of shares available for issuance under our 2020 Plan. Distributed Shares will not be considered “issued” under our 2020 Plan and will not reduce the number of shares available for issuance under the plan. See “Treatment of Outstanding Topco Parent Equity Awards in Connection with the Initial Public Offering.”

Non-Employee Director Compensation Limit

The maximum number of shares of our common stock subject to awards (and of cash subject to cash-based awards) granted under the 2020 Plan or otherwise during any one calendar year to any non-employee director, exclusive of any cash fees paid by us to such non-employee director during such calendar year for service on our board of directors, will not exceed $500,000 in total value.

Plan Administration

Our board of directors or the compensation committee of our board of directors, acting as the plan administrator, will administer our 2020 Plan and the awards granted under it. The plan administrator may also authorize a subcommittee consisting of one or more of our officers to grant awards under the 2020 Plan to employees (other than officers) and consultants, within parameters specified by the plan administrator. Under our 2020 Plan, the plan administrator will have the authority to determine and amend the terms of awards and the applicable award agreements, including:

 

   

selecting the employees, consultants or directors to whom awards may from time to time be granted;

 

   

determining the fair market value of shares of our common stock underlying such awards and setting the exercise or purchase price of such awards, if any;

 

   

setting the number of shares or amount of cash covered by each such award;

 

   

approving the forms of award agreements and other related documents used under the 2020 Plan;

 

   

determining the terms and conditions applicable to each such award, including the vesting conditions, the circumstances (if any) when vesting will be accelerated or forfeiture restrictions will be waived and any other restrictions or limitations regarding any award (including any blackout);

 

   

providing for the accrual of dividends or dividend equivalents on awards;

 

   

amending the terms of outstanding awards, after obtaining the consent of any recipient whose rights would be materially and adversely affected by such amendment; and

 

   

approving addenda for granting awards to employees, consultants or directors who are foreign nationals or employed outside of the United States with such terms and conditions as deemed necessary or appropriate to accommodate any applicable laws, policies or customs.

Stock Options

Incentive stock options and nonstatutory stock options will be granted under stock option agreements adopted by the plan administrator. The plan administrator will determine the exercise price for stock options, within the terms and conditions of the 2020 Plan, provided that the exercise price of a stock option generally cannot be less than 100% of the fair market value of our common stock on the date of grant. Options granted under the 2020 Plan will be subject to vesting criteria specified in the stock option agreement as determined by the plan administrator.

Restricted Stock Unit Awards

RSUs will be granted under restricted stock unit award agreements adopted by the plan administrator. The plan administrator, in its sole discretion, may settle earned RSUs in cash, shares, or a combination of both.

 

147


Table of Contents

Additionally, dividend equivalents may be credited in respect of shares covered by an RSU. RSUs granted under the 2020 Plan will be subject to vesting criteria specified in the restricted stock unit award agreement as determined by the plan administrator.

Restricted Stock Awards

Restricted stock awards will be granted under restricted stock award agreements adopted by the plan administrator. A restricted stock award may be awarded in consideration for services or may be offered by the plan administrator for purchase. The plan administrator will determine the terms and conditions of restricted stock awards, including vesting and forfeiture terms. If a participant’s service relationship with us ends for any reason prior to the vesting of certain shares of common stock held by the participant, we may reacquire any or all of the unvested shares of restricted stock as of the date the participant terminates service with us through a forfeiture condition or a repurchase right (at the original purchase price paid by the shareholder).

Other Awards

The plan administrator is permitted to grant other cash-based, equity-based or equity related awards. The plan administrator will set the number of shares or the amount of cash under the award and all other terms and conditions of such awards. Such other awards granted under the 2020 Plan will be subject to vesting criteria specified in the award agreement as determined by the plan administrator.

Changes to Capital Structure

In the event there is a specified type of change in our capital structure, such as a stock split, reverse stock split, stock dividend, combination, consolidation, recapitalization or reclassification of shares, proportionate adjustments will be made to (1) the number and class (or type) of shares available for issuance under the 2020 Plan (including pursuant to incentive stock options), and (2) the number and class of shares, and the exercise price, strike price or repurchase price, if applicable, of all outstanding awards.

Corporate Transactions

Our 2020 Plan provides that in the event of certain specified significant corporate transactions, generally including (i) a transfer of all or substantially all of our assets, (ii) a merger, consolidation or other similar transaction of the company with or into another corporation, entity or person or (iii) a person or group becoming the beneficial owner of more than 50% of our then outstanding voting power (subject to certain exclusions), each outstanding award will be treated as the plan administrator determines. Such determination may, without limitation, provide for one or more of the following: (A) the assumption, continuation or substitution of such outstanding awards by the company, the surviving corporation or its parent, (B) the cancellation of such awards in exchange for a payment to the recipients equal to the excess of the fair market value of the shares subject to such awards over the exercise price of such awards (if any) or (C) the cancellation of any outstanding awards for no consideration. The plan administrator is not obligated to treat all awards (or portions thereof), even those that are of the same type, or all recipients, in the same manner and is not obligated to obtain the consent of any recipient to effectuate the treatment described above.

Change in Control

The consequences of a change in control, if any, with respect to any award granted under the 2020 Plan will be determined by the plan administrator and set forth in the applicable award agreement.

Shareholder Approval Required for Repricing

The terms of the 2020 Plan prevent (i) any repricing of stock options issued under the 2020 Plan, (ii) the issuance of any new awards in substitution for outstanding stock options previously granted to participants if

 

148


Table of Contents

such action would be considered a repricing or (iii) the reduction in exercise price or purchase by the company of any stock option or stock appreciation right if, on the date of such purchase, the exercise price per share of common stock covered by such stock option or stock appreciation right is less than 100% of the fair market value of a share of our common stock on such date, in the case of each (i)-(iii), unless our shareholders have approved such action.

Transferability

Under our 2020 Plan, awards are generally not transferable (other than by will or the laws of descent and distribution), except as otherwise provided under our 2020 Plan or the applicable award agreements.

Recoupment

Awards granted under the 2020 Plan will be subject to any company policy that is or may be adopted (to the extent permitted or required by any applicable law) and/or the requirements of the Nasdaq, in each case, as in effect from time to time, to recoup compensation of whatever kind paid by the company at any time to a participant under the 2020 Plan.

Plan Amendment or Termination

Our board of directors has the authority to amend or terminate our 2020 Plan, although certain material amendments require the approval of our stockholders, and amendments that would materially and adversely affect the rights of any recipients require the consent of such recipients with respect to their awards.

Equity Grants Made in Connection with This Offering

In connection with this offering, we expect to grant equity awards to certain of our employees and consultants under our 2020 Plan. These equity awards are expected to be in the form of RSUs, nonqualified options to purchase shares of our common stock with grant date fair values based on the initial public offering price and, with respect to certain of our international employees, cash-settled RSUs and stock appreciation rights (the “IPO Awards”). The table below sets forth additional information on the value of the IPO Awards that we intend to grant to our Named Executive Officers. The options will have a per share exercise price equal to the initial public offering price and a term of 10 years. Twenty-five percent (25%) of the IPO Awards will vest on each of the first 4 anniversaries of the grant date, subject to continued employment through each applicable vesting date. The IPO Awards will be subject to the terms and conditions of the 2020 Plan and the applicable award agreements pursuant to which they are granted. These terms and conditions will include accelerated vesting of unvested IPO Awards upon certain events. See “Treatment of IPO Awards Upon Termination or Change in Control.” Our Compensation Committee believes the continued-service based vesting criteria is an appropriate incentive with respect to these awards and intends to consider the potential for future equity awards to include a performance-based vesting component.

Aggregate Grant Date Value of IPO Awards

 

     Aggregate Grant Date Value  
     Stock Options(1)      Restricted Stock Units(2)  

Michael B. Petras, Jr.

   $ 9,000,000      $ 6,000,000  

Scott J. Leffler

   $ 1,800,000      $ 1,200,000  

Matthew J. Klaben

   $ 1,080,000      $ 720,000  

 

(1)

The number of stock options granted pursuant to each IPO Award will be determined by dividing the grant date value by an estimated fair value of a stock option with an exercise price equal to the initial public offering price rounded down to the nearest whole stock option using a Black-Scholes valuation methodology.

 

149


Table of Contents
(2)

The number of RSUs granted pursuant to each IPO Award will be determined by dividing the grant date value by the initial public offering price rounded down to the nearest whole RSU.

Cash IPO Bonuses

We intend to pay approximately $1.9 million in cash bonuses in recognition of the extraordinary efforts of certain of our executives and employees, including in connection with the execution of this offering (the “IPO Bonuses”). Messrs. Petras, Leffler and Klaben will be awarded an IPO Bonus of $700,000, $225,000 and $225,000, respectively. We intend to pay such IPO Bonuses as soon as reasonably practicable following the closing of this offering.

Emerging Growth Company Status

We are an “emerging growth company,” as defined in the JOBS Act. As an emerging growth company, we will be exempt from certain requirements related to executive compensation, including the requirements to hold non-binding advisory votes on executive compensation and to provide information relating to the ratio of annual total compensation of our chief executive officer to the median of the annual total compensation of all of our employees, each as required under Sections 14 and 14A of the Exchange Act.

 

150


Table of Contents

CORPORATE REORGANIZATION

Sotera Health Company, a Delaware corporation, is a direct wholly owned subsidiary of Topco Parent, a Delaware limited partnership. Pursuant to the terms of the corporate reorganization that will be completed prior to the completion of this offering, Topco Parent will distribute the shares of our common stock to its partners in accordance with the limited partnership agreement of Topco Parent.

Ownership of Topco Parent and Related Distributions

Topco Parent currently has four outstanding classes of units: (1) Class A Units, held by the Sponsors and certain of our current and former employees and directors, or their donees, who participated in the Sponsors’ acquisition of the Company in 2015 or subsequently purchased Class A Units; (2) Class B-1 Units, held by certain of our current and former directors and employees, which are subject to time-based vesting; (3) Class B-2 Units, held by certain of our employees, which are subject to performance-based vesting (such Class B-2 Units vest as of the first date on which (i) our Sponsors have received two and one-half times their invested capital in Topco Parent and (ii) the Sponsors’ internal rate of return exceeds twenty percent); and (4) Class D Units purchased and held by certain of our current employees and directors. Each class of units is subject to the terms of the limited partnership agreement of Topco Parent. The Class B-1 Units and Class B-2 Units are referred to collectively as “Class B Units.”

The Class A Units, Class B Units and Class D Units are referred to collectively as the “Units.”

Pursuant to the limited partnership agreement of Topco Parent, Units share in distributions according to a “waterfall” which provides for distributions to be made in the following order and priority: (1) first, to the holders of Class A Units until they receive an 8% annual return on their remaining unreturned capital contributions, compounded quarterly; (2) second, to the holders of Class A Units until they receive an amount equal to their respective capital contributions on a pro rata basis; and (3) third, to the holders of Class A Units, Class B Units and Class D Units, pro rata, subject to any applicable “participation thresholds.” Each of the Class B Units, and certain of the Class A Units, has a “participation threshold.” A participation threshold in respect of a Unit is determined at the time of issuance or grant and is equal to or greater than the amount payable in respect of a Class A Unit with a participation threshold of zero pursuant to the waterfall (excluding amounts payable in respect of any preferred return or return of capital to such Class A Unit) in a hypothetical liquidation of Topco Parent at the current business enterprise value of Topco Parent as of immediately prior to such issuance or grant. The effect of the participation threshold in respect of a Class B Unit is that such Class B Unit will not have any intrinsic value on the date of grant since it would not be entitled to any proceeds in the waterfall based on the hypothetical liquidation used to set such threshold. Unit participation thresholds are reduced as Topco Parent makes distributions pursuant to the waterfall.

As a result of the prior cash distributions to the holders of Units made in 2018 and 2019, as described further in “Certain Relationships and Related Party Transactions—Distributions”, the 8% annual return and the return of capital contributions to the Class A Units contemplated in the first two (2) steps of the waterfall described above has already been achieved. In addition, the participation thresholds of all Class B Units granted prior to March 2018 have been reduced to $0, meaning those Class B Units will participate with Class A Units on a pro rata basis in future waterfall distributions. Class B Units granted in March of 2018 and thereafter will receive less distributions in the waterfall on a per unit basis as a result of their remaining participation thresholds.

Pursuant to the terms of the corporate reorganization that will be completed prior to the completion of the offering, Topco Parent will make an in-kind distribution of shares of our common stock to its limited partners in accordance with the “waterfall” described above, net of any previously unrecouped tax distributions. For purposes of this distribution, the value of a share of common stock will be measured by the initial public offering price. The result is that all shares of our common stock held by Topco Parent will be distributed to the holders of the Units.

 

151


Table of Contents

None of the shares of our common stock distributed in the corporate reorganization will be registered at that time and, as such, all such shares will be “restricted securities” for purposes of the Securities Act. As a condition of the distribution, all holders of such shares will be required to execute and become a party to the Stockholders’ Agreement which governs the rights and obligations of such holders. See “Certain Relationships and Related Party Transactions—Stockholders’ Agreement” for additional information on the terms of such agreement.

In addition, each holder of Units (other than our Sponsors) who receives shares of our common stock in the corporate reorganization will be required to execute the RSA (Restricted Stock Agreement and Acknowledgment) in the form filed as an exhibit to the registration statement of which this prospectus forms a part. The RSA provides that any shares of our common stock distributed to an individual in respect of any Class A and Class D Units, as well as any Class B-1 Units that are vested as of the distribution, will not be subject to any vesting or forfeiture restrictions following the offering. With respect to shares of common stock distributed in respect of any Class B-1 Units that are unvested as of the distribution and all of the Class B-2 Units (since none of the Class B-2 Units have vested or will vest as of the distribution), the RSA generally provides that such shares shall be subject to the same vesting and forfeiture restrictions that applied to such unvested Class B-1 and Class B-2 Units prior to the distribution. Although the corporate reorganization and distribution of the shares of Company common stock will not cause the time and/or performance-based vesting restrictions applicable to any shares of common stock to lapse, the achievement of the performance-conditions applicable to shares of Company common stock distributed in respect of Class B-2 Units will be deemed probable, resulting in recognition of compensation expense. Please see Note 15 to our consolidated financial statements for the period ended September 30, 2020 for additional discussion of such compensation expense recognition. Calculated on the basis of the assumptions described under “Principal Stockholders,” approximately 20,580,487 shares of our common stock distributed in respect of Class B Units will be fully vested as of the distribution and the remaining 5,692,335 shares distributed in respect of Class B Units will be subject to vesting and forfeiture conditions, as described herein.

Following the distribution of the shares of our common stock, Topco Parent will distribute any remaining cash held by it to its limited partners in accordance with the “waterfall” described above. Topco Parent will then wind up and dissolve, as a result of which all of the outstanding Units will be cancelled in their entirety and Topco Parent and the Units will cease to exist.

For information regarding the beneficial ownership of our common stock after giving effect to the reorganization, see “Principal Stockholders.”

Distribution of Common Stock

We will have 232,400,200 shares of common stock outstanding immediately prior to the completion of our corporate reorganization. The number of shares of common stock that a holder of partnership interests in Topco Parent will receive upon its liquidation will be determined by the value such holder would have received under the distribution provisions of the limited partnership agreement of Topco Parent, with our shares of common stock valued by reference to the initial public offering price. Purchasers of common stock in this offering will only receive, and this prospectus only describes the offering of, shares of our common stock. Upon completion of our corporate reorganization and this offering, and based on an assumed initial public offering price of $21.50 per share (the midpoint of the estimated offering price range set forth on the cover page of this prospectus), the former holders of partnership interests in Topco Parent will beneficially own an aggregate of approximately 83.2% of our common stock (or 81.2% if the underwriters’ option to purchase additional shares of common stock is exercised in full). See “Description of Capital Stock” for additional information regarding the terms of our certificate of incorporation and bylaws that will be in effect upon the completion of this offering.

 

152


Table of Contents

Ownership Structure Before and After the Reorganization

The following diagrams indicate our ownership structure prior to this offering and our ownership structure after giving effect to the corporate reorganization and this offering, assuming no exercise by the underwriters of their option to purchase up to an additional 6,990,000 shares from us, and do not include 27,900,000 shares of common stock available for future issuance under our equity compensation plans.

In this prospectus, our “corporate reorganization” refers to the liquidation of Topco Parent and the distribution of shares of our common stock to the partners of Topco Parent in accordance with its limited partnership agreement, including the stock split described above.

Pre-Corporate Reorganization Summary

 

LOGO

 

153


Table of Contents

Post-Corporate Reorganization Summary, After Giving Effect to this Offering

 

LOGO

 

154


Table of Contents

PRINCIPAL STOCKHOLDERS

The following table sets forth information regarding the beneficial ownership of our common stock as of September 30, 2020 (1) immediately prior to the completion of this offering and (2) as adjusted to give effect to this offering and the repurchase (as described in “Use of Proceeds” and “Certain Relationships and Related Party Transactions—Transactions with Certain of Our Executive Officers”) by:

 

   

each person or group who is known by us to own beneficially more than 5% of our outstanding shares of common stock;

 

   

each of our named executive officers;

 

   

each of our directors; and

 

   

all of the executive officers and directors as a group.

Beneficial ownership is determined in accordance with the rules and regulations of the SEC. These rules generally provide that a person is the beneficial owner of securities if such person has or shares the power to vote or direct the voting thereof, or to dispose or direct the disposition thereof or has the right to acquire such powers within 60 days. We have based the calculation of the percentage of beneficial ownership prior to this offering on 232,400,200 shares of common stock outstanding, as of September 30, 2020, after giving effect to the corporate reorganization, and based on an assumed share price of $21.50, the midpoint of the estimated offering price range on the cover page of this prospectus. We have based the calculation of the percentage of beneficial ownership after this offering on 277,331,078 shares of common stock outstanding, after giving effect to this offering and the repurchase. For purposes of calculating each person’s percentage ownership, common stock issuable pursuant to options exercisable within 60 days of September 30, 2020 are included as outstanding and beneficially owned for that person or group, but are not deemed outstanding for purposes of computing the percentage ownership of any person. Except as disclosed in the footnotes to this table and subject to applicable community property laws, we believe that each stockholder identified in the table possesses sole voting and investment power over all shares of common stock shown as beneficially owned by the stockholder.

 

155


Table of Contents

Unless otherwise indicated in the table or footnotes below, the address for each beneficial owner is c/o Sotera Health, 9100 South Hills Blvd, Suite 300 Broadview Heights, Ohio 44147.

 

     Number of
Shares
Beneficially
Owned(1)
     Percentage of
Shares
Beneficially Owned
 
Name of Beneficial Owner    Before
Offering
     After
Offering
     Before
Offering
    After
Offering
 

5% Stockholders:

          

Investment funds and entities affiliated with Warburg Pincus(2)

     119,003,624        119,003,624        51.2     42.9

Investment funds and entities affiliated with GTCR(3)

     79,335,749        79,335,749        34.1     28.6

Named Executive Officers and Directors:

          

Michael B. Petras, Jr.(4)

     8,579,824        7,107,070        3.7     2.6

Scott J. Leffler(5)

     768,730        646,000        *       *  

Matthew J. Klaben(6)

     438,707        365,069        *       *  

Ruoxi Chen(7)

     119,003,624        119,003,624        51.2     42.9

Sean L. Cunningham(3)

     79,335,749        79,335,749        34.1     28.6

David A. Donnini(3)

     79,335,749        79,335,749        34.1     28.6

Stephanie Geveda(7)

     119,003,624        119,003,624        51.2     42.9

Ann R. Klee(8)

     48,169        48,169        *       *  

Constantine S. Mihas(3)

     79,335,749        79,335,749        34.1     28.6

James C. Neary(7)

     119,003,624        119,003,624        51.2     42.9

Vincent K. Petrella

     —          —          —         —    

All Executive Officers and Directors as a group (12 Persons)

     208,723,683        207,054,561        89.8     74.7

 

*

Represents beneficial ownership of less than 1%

(1)

Shares shown in the table above include shares held in the beneficial owner’s name or jointly with others, or in the name of a bank, nominee or trustee for the beneficial owner’s account.

(2)

Consists of (i) 74,322,378 shares held of record by Warburg Pincus Private Equity XI, L.P., a Delaware limited partnership (“WP XI”), (ii) 13,333,077 shares held of record by Warburg Pincus Private Equity XI-B, L.P., a Delaware limited partnership (“WP XI-B”), (iii) 304,756 shares held of record by Warburg Pincus Private Equity XI-C, L.P., a Cayman Islands exempted limited partnership (“WP XI-C”), (iv) 2,514,237 shares held of record by WP XI Partners, L.P., a Delaware limited partnership (“WP XIP”), (v) 4,761,813 shares held of record by Warburg Pincus XI Partners, L.P., a Delaware limited partnership (“WP XI Partners”) and (vi) 23,767,363 shares held of record by Bull Co-Invest L.P., a Delaware limited partnership (“WP Bull”).

Warburg Pincus XI, L.P., a Delaware limited partnership (“WP XI GP”), is the general partner of each of (i) WP XI, (ii) WP XI-B, (iii) WP XI Partners and (iv) WP XIP. WP Global LLC, a Delaware limited liability company (“WP Global”), is the general partner of WP XI GP. Warburg Pincus Partners II, L.P., a Delaware limited partnership (“WPP II”), is the managing member of WP Global. Warburg Pincus Partners GP LLC, a Delaware limited liability company (“WPP GP LLC”), is the general partner of WPP II. Warburg Pincus & Co., a New York general partnership (“WP”), is the managing member of WPP GP LLC.

Warburg Pincus (Cayman) XI, L.P., a Cayman Islands exempted limited partnership (“WP XI Cayman GP”), is the general partner of WP XI-C (WP XI-C and, together with WP XI, WP XI-B, WP XI Partners and WP XIP, the “WP XI Funds”). Warburg Pincus XI-C, LLC, a Delaware limited liability company (“WP XI-C LLC”), is the general partner of WP XI Cayman GP. Warburg Pincus Partners II (Cayman), L.P., a Cayman Islands exempted limited partnership (“WPP II Cayman”), is the managing member of WP XI-C LLC. Warburg Pincus (Bermuda) Private Equity GP Ltd., a Bermuda exempted company (“WP Bermuda GP”), is the general partner of WPP II Cayman.

 

156


Table of Contents

WP Bull Manager LLC, a Delaware limited Liability company (“WP Bull Manager”), is the general partner of WP Bull. WP is managing member of WP Bull Manager.

Warburg Pincus LLC, a New York limited liability company (“WP LLC”), is the manager of the WP XI Funds. The address of the Warburg Pincus entities is 450 Lexington Avenue, New York, New York 10017.

 

(3)

Consists of (i) 62,967,038 shares held of record by GTCR Fund XI/A LP, (ii) 15,864,056 shares held of record by GTCR Fund XI/C LP and (iii) 504,655 shares held of record by GTCR Co-Invest XI LP (collectively, the “GTCR Stockholders”). GTCR Partners XI/A&C LP is the general partner of each of GTCR Fund XI/A LP and GTCR Fund XI/C LP. GTCR Investment XI LLC is the general partner of each of GTCR Co-Invest XI LP and GTCR Partners XI/A&C LP. GTCR Investment XI LLC is managed by a board of managers (the “GTCR Board of Managers”) consisting of Mark M. Anderson, Craig A. Bondy, Aaron D. Cohen, Sean L. Cunningham, Benjamin J. Daverman, David A. Donnini, Constantine S. Mihas and Collin E. Roche, and no single person has voting or dispositive authority over the shares. Each of GTCR Partners XI/A&C LP, GTCR Investment XI LLC and the GTCR Board of Managers may be deemed to share beneficial ownership of the shares held of record by the GTCR Stockholders, and each of the individual members of the GTCR Board of Managers disclaims beneficial ownership of the shares held of record by the GTCR Stockholders except to the extent of his pecuniary interest therein. The address for each of the GTCR Stockholders, GTCR Partners XI/A&C LP and GTCR Investment XI LLC is 300 North LaSalle Street, Suite 5600, Chicago, Illinois, 60654.

 

(4)

Mr. Petras is the grantor and trustee of two estate planning trusts (collectively, the “Petras Trusts”). As a result, Mr. Petras may have voting and investment control over, and may be deemed to be the beneficial owner of, an aggregate of 8,579,824 shares of common stock owned by the Petras Trusts prior to the transaction and 7,107,070 shares of common stock after the repurchase. In connection with this offering, Mr. Petras will receive certain IPO Awards consisting of stock options and RSUs as described in “Executive Compensation—Equity Grants Made in Connection with This Offering.”

 

(5)

Consists of 447,454 shares of common stock and 321,276 shares that will remain subject to vesting prior to the transaction and 324,724 shares of common stock and 321,276 shares that will remain subject to vesting after the repurchase. In connection with this offering, Mr. Leffler will receive certain IPO Awards consisting of stock options and RSUs as described in “Executive Compensation—Equity Grants Made in Connection with This Offering.”

 

(6)

Mr. Klaben is the grantor and trustee of an estate planning trust. As a result, Mr. Klaben may have voting and investment control over, and may be deemed to be the beneficial owner of, an aggregate of 281,656 shares of common stock and 157,050 shares that will remain subject to vesting owned by such trust prior to the transaction and 208,018 shares of common stock and 157,050 shares that will remain subject to vesting after the repurchase. In connection with this offering, Mr. Klaben will receive certain IPO Awards consisting of stock options and RSUs as described in “Executive Compensation—Equity Grants Made in Connection with This Offering.”

 

(7)

Includes 119,003,624 shares of common stock beneficially owned by Warburg Pincus Entities because of the affiliations of Mr. Chen, Ms. Geveda and Mr. Neary with the Warburg Pincus entities. Mr. Chen, Ms. Geveda and Mr. Neary each disclaim beneficial ownership of all shares of common stock owned by the Warburg Pincus entities except to the extent of any indirect pecuniary interests therein.

 

(8)

Consists of 16,209 shares of common stock and 31,960 shares that will remain subject to vesting.

 

157


Table of Contents

CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

Under SEC rules, a related person is an officer, director, nominee for director or beneficial holder of more than 5% of any class of our voting securities since the beginning of the last fiscal year or an immediate family member of any of the foregoing.

Other than the transactions described below, our corporate reorganization described under “Corporate Reorganization,” compensation agreements and other arrangements which are described under “Executive Compensation,” since January 1, 2017, there has not been, and there is not currently proposed, any transaction or series of similar transactions to which we were or will be a party in which the amount involved exceeded or will exceed $120,000 and in which any related person had or will have a direct or indirect material interest. We believe the terms of the transactions described below were comparable to the terms we could have obtained in arms-length dealings with unrelated third parties.

From time to time, we do business with other companies affiliated with certain holders of our common stock. We believe that all such arrangements have been entered into in the ordinary course of business and have been conducted on an arm’s-length basis.

 

Distributions

In 2019, in connection with distributions paid by us to Topco Parent, the following current and former directors and executive officers and 5% stockholders received distributions pursuant to the terms of the limited partnership agreement of Topco Parent, in the aggregate amounts set forth below:

 

Name    Distribution
Amount(1)(2)(3)
 

Investment funds and entities affiliated with Warburg Pincus

   $ 369,698,262  

Investment funds and entities affiliated with GTCR

     246,465,508  

Michael B. Petras, Jr.(4)(5)

     19,404,529  

Scott J. Leffler

     987,240  

Matthew J. Klaben

     717,047  

Philip W. Macnabb(6)(7)

     13,435,018  

Michael J. Mulhern(8)

     12,415,877  

 

(1) 

This table represents distributions made in respect of all partnership interests in Topco Parent held by the above listed current and former directors and executive officers and 5% stockholders. With respect to Warburg Pincus and GTCR, the distributions represent distributions in respect of Class A Units in Topco Parent. With respect to current and former directors and executive officers, the distributions represent distributions in respect of Class A Units and Class B Units. The distributions to Mr. Petras additionally include distributions made in respect of Class C Units.

(2) 

The aggregate distribution amounts disclosed include distributable amounts accrued in respect of unvested Class B Units held by current and former directors and executive officers. Such accrued amounts were allocated to the holder of such unvested Class B Units for tax purposes at the time such amounts would otherwise have been distributed, but the cash payments that would otherwise have been distributed were held back, unless and until the unvested Class B Units vested. To the extent that any previously unvested Class B Units subsequently vested, the held back cash payments in respect of such previously unvested Class B Units would be distributed in the next distribution. Any cash payments held back in respect of unvested Class B Units that have not yet been distributed will be distributed to participants in 2020 in connection with the corporate reorganization in advance of this offering.

(3) 

The aggregate distribution amounts disclosed are net of amounts that were retained by Topco Parent to offset prior tax distributions made in 2018, which are included in the 2018 distribution amounts set forth below. These tax distributions, which reduce future distribution entitlements under the Topco Parent limited

 

158


Table of Contents
  partnership agreement, are intended to enable recipients to satisfy current income tax liabilities in respect of allocations of partnership income where the corresponding cash payment is held back in whole or in part in respect of unvested Class B Units. The aggregate distribution amounts disclosed also include additional tax distributions that were made in 2019, which will reduce any cash payments in respect of unvested Class B Units that will be distributed to participants in 2020 in connection with the corporate reorganization, as discussed in footnote 2 above. Any remaining balance of prior tax distributions following such distribution will reduce the total value of the Distributed Shares. See “Treatment of Outstanding Topco Parent Equity Awards in Connection with the Initial Public Offering” for additional information on the terms of such redemption.
(4) 

Includes distributions made to an estate planning trust.

(5) 

The distribution includes the aggregate amount distributed to Mr. Petras in full satisfaction and settlement of his Class C Units, net of the amount retained by Topco Parent to offset a 2018 tax distribution made to Mr. Petras in respect of his Class C Units.

(6) 

Mr. Macnabb served as the President of Sterigenics until October 1, 2020.

(7) 

Includes distributions made to an estate planning trust.

(8) 

Includes distributions made to an estate planning trust.

In 2018, in connection with distributions paid by us to Topco Parent, the following current and former directors and executive officers and 5% stockholders received distributions pursuant to the terms of the limited partnership agreement of Topco Parent, in the aggregate amounts set forth below:

 

Name    Distribution
Amount(1)(2)
 

Investment funds and entities affiliated with Warburg Pincus

   $ 96,541,809  

Investment funds and entities affiliated with GTCR

     64,361,206  

Michael B. Petras, Jr.(3)

     4,756,392  

Scott J. Leffler

     237,558  

Matthew J. Klaben

     138,335  

Philip W. Macnabb(4)(5)

     2,058,562  

Michael J. Mulhern(6)

     2,153,627  

 

(1)

This table represents distributions made in respect of Class A Units held by the above listed current and former directors and executive officers and 5% stockholders. No distributions, other than the tax distributions referred to herein, were made in respect of Class B Units or Class C Units.

(2)

The aggregate distribution amounts disclosed include tax distributions made in 2018. These tax distributions, which reduce future distribution entitlements under the Topco Parent limited partnership agreement, are intended to enable recipients to satisfy current income tax liabilities in respect of allocations of partnership income where the corresponding cash payment is held back in whole or in part in respect of unvested Class B Units.

(3)

Includes distributions made to an estate planning trust.

(4)

Mr. Macnabb served as the President of Sterigenics until October 1, 2020.

(5)

Includes distributions made to an estate planning trust.

(6)

Includes distributions made to an estate planning trust.

 

159


Table of Contents

In 2017, in connection with a distribution paid by us to Topco Parent, the following current and former directors and executive officers and 5% stockholders received distributions pursuant to the terms of the limited partnership agreement of Topco Parent, in the amounts set forth below:

 

Name    Distribution
Amount(1)
 

Investment funds and entities affiliated with Warburg Pincus

   $ 115,062,497  

Investment funds and entities affiliated with GTCR

     76,708,331  

Michael B. Petras, Jr.(2)

     725,692  

Scott J. Leffler

     152,762  

Matthew J. Klaben

     99,846  

Philip W. Macnabb(3)(4)

     1,670,301  

Michael J. Mulhern(5)

     1,978,720  

 

(1)

This table represents distributions made in respect of Class A Units held by the above listed current and former directors and executive officers and 5% stockholders. No distributions were made in respect of Class B Units or Class C Units.

(2)

Includes distributions made to an estate planning trust.

(3)

Mr. Macnabb served as the President of Sterigenics until October 1, 2020.

(4)

Includes distributions made to an estate planning trust.

(5)

Includes distributions made to an estate planning trust.

Loans to Executive Officers

In April 2017, we loaned Mr. Leffler, our Chief Financial Officer, $500,000 in connection with Mr. Leffler’s purchase of units in Topco Parent. The loan was evidenced by a full recourse promissory note, with interest at a rate of 1.11% per annum, compounded semi-annually, and was secured by any equity interest in our company then or later owned by Mr. Leffler. The outstanding principal and interest due under the loan was fully repaid to us in August 2019 and the pledge was terminated. A total of $4,058.79 in interest was paid under the loan.

Transactions with Certain of Our Executive Officers

We expect to enter into agreements with each of Mr. Petras, Mr. Leffler and Mr. Klaben, to repurchase certain shares of our common stock beneficially owned by them in private transactions at a purchase price per share equal to the initial public offering price per share of our common stock less the underwriting discounts and commissions payable thereon. The repurchase is conditional on the completion of this offering. See “Use of Proceeds.”

The following table sets forth the cash proceeds that our executive officers will receive from the purchase by us of our common stock with the net proceeds of this offering (based on an assumed initial public offering price of $21.50, the midpoint of the estimated offering price range set forth on the cover page of this prospectus):

 

Name    Shares of common
stock held before
this offering
     Shares of common
stock to be sold to us
     Cash
proceeds
 

Michael B. Petras, Jr.

     8,579,824        1,472,754      $ 29,999,999  

Scott J. Leffler

     768,730        122,730        2,500,010  

Matthew J. Klaben

     438,707        73,638        1,500,006  

Registration Rights Agreement

In connection with this offering, we intend to enter into a second amended and restated registration rights agreement (the “Registration Rights Agreement”) with certain holders of our common stock, including the

 

160


Table of Contents

Sponsors, pursuant to which we have agreed to register the sale of shares of our common stock under specified circumstances, and a copy of which has been filed as an exhibit to the registration statement of which this prospectus forms a part. After the closing of this offering, holders of a total of 212,599,684 shares of our common stock will have the right to require us to register these shares under the Securities Act under specified circumstances. After registration pursuant to these rights, these shares will become freely tradable without restriction under the Securities Act.

Beginning on the first date after our initial public offering on which investment funds and entities affiliated with either Warburg Pincus or GTCR are no longer subject to any underwriter’s lock-up or other similar contractual restrictions on the sale of our shares, we may be required by investment funds and entities affiliated with either Warburg Pincus or GTCR to register all or part of their shares of common stock in accordance with the Securities Act and the Registration Rights Agreement. See “Shares Eligible for Future Sale—Lock-up Agreements.” The net aggregate offering price of shares that investment funds and entities affiliated with either Warburg Pincus or GTCR propose to sell in any demand registration must be at least $50 million, or such holder must propose to sell all of such holder’s shares if the net aggregate offering price of such shares is less than $50 million. Each of Warburg Pincus and GTCR is entitled to request unlimited demand registrations, but in each case we are not obligated to effect more than three long-form registrations on Form S-1 or four marketed underwritten shelf take-downs each year at the request of Warburg Pincus or more than three long-form registrations on Form S-1 or four marketed underwritten shelf take-downs each year at the request of GTCR. We also are not obligated to effect more than one marketed underwritten offering in any consecutive 90-day period without the consent of investment funds and entities affiliated with either Warburg Pincus or GTCR. There is no limitation on the number of unmarketed underwritten offerings that we may be obligated to effect at the request of investment funds and entities affiliated with either Warburg Pincus or GTCR. We have specified rights to delay the filing or initial effectiveness of, or suspend the use of, any registration statement filed or to be filed in connection with an exercise of a holder’s demand registration rights.

In addition, if we propose to file a registration statement under the Securities Act with respect to specified offerings of shares of our common stock, we must allow holders of shares subject to registration rights to include their shares in that registration, subject to specified conditions and limitations.

These registration rights are subject to specified conditions and limitations, including the right of the underwriters to limit the number of shares to be included in a registration in certain circumstances and our right to delay a registration statement under specified circumstances. Pursuant to the Registration Rights Agreement, we are required to pay all registration expenses and indemnify each participating holder with respect to each registration of registrable shares that is effected.

Stockholders’ Agreement

We and the Sponsors intend to enter into the Stockholders’ Agreement in connection with this offering. Our Stockholders’ Agreement will provide that, for so long as the Stockholders’ Agreement is in effect, we and the Sponsors are required to take all actions reasonably necessary, subject to applicable regulatory and stock exchange listing requirements (including director independence requirements), to cause the membership of the board and any committees of the board to be consistent with the terms of the agreement. In accordance with the Stockholders’ Agreement, Warburg Pincus has designated Mr. Chen, Ms. Geveda and Mr. Neary to our board of directors and GTCR has designated Messrs. Cunningham, Donnini and Mihas to our board of directors.

Director Designees; Committee Membership

Each of our current directors was elected pursuant to the terms of agreements among our stockholders that will terminate in our corporate reorganization and be replaced by our Stockholders’ Agreement. Under the terms

 

161


Table of Contents

of our Stockholders’ Agreement, investment funds and entities affiliated with Warburg Pincus will be entitled to designate up to:

 

   

five directors for election to our board of directors for so long as certain investment funds and entities affiliated with Warburg Pincus hold 80% or more of the shares of our common stock that they hold immediately following the closing of this offering;

 

   

four directors for election to our board of directors for so long as certain investment funds and entities affiliated with Warburg Pincus hold 60% or more of the shares of our common stock that they hold immediately following the closing of this offering;

 

   

three directors for election to our board of directors for so long as certain investment funds and entities affiliated with Warburg Pincus hold 40% or more of the shares of our common stock that they hold immediately following the closing of this offering;

 

   

two directors for election to our board of directors for so long as certain investment funds and entities affiliated with Warburg Pincus hold 20% or more of the shares of our common stock that they hold immediately following the closing of this offering; and

 

   

one director for election to our board of directors for so long as certain investment funds and entities affiliated with Warburg Pincus hold 6 2/3% or more of the shares of our common stock that they hold immediately following the closing of this offering.

In addition, our Stockholders’ Agreement will provide that investment funds and entities affiliated with GTCR will be entitled to designate up to:

 

   

three directors for election to our board of directors for so long as certain investment funds and entities affiliated with GTCR hold 70% or more of the shares of our common stock that they hold immediately following the closing of this offering;

 

   

two directors for election to our board of directors for so long as certain investment funds and entities affiliated with GTCR hold 40% or more of the shares of our common stock that they hold immediately following the closing of this offering; and

 

   

one director for election to our board of directors for so long as certain investment funds and entities affiliated with GTCR hold 10% or more of the shares of our common stock that they hold immediately following the closing of this offering.

Subject to any restrictions under applicable law or the Nasdaq rules, each of Warburg Pincus and GTCR will be entitled to representation on each board committee proportionate to the number of directors they are entitled to designate on our board of directors. In addition, Warburg Pincus shall be entitled to appoint the chairperson of our compensation committee for so long as Warburg Pincus has the right to designate at least one director for election to our board of directors.

Removal of Directors

For so long as investment funds and entities affiliated with either Warburg Pincus or GTCR, collectively, hold at least a majority of our outstanding capital stock, a director designated by investment funds and entities affiliated with either Warburg Pincus or GTCR, respectively, may be removed with or without cause by the affirmative vote of the holders of a majority of our outstanding capital stock and with the consent of Warburg Pincus or GTCR, respectively.

Quorum

For so long as investment funds and entities affiliated with Warburg Pincus have the right to designate at least one director for election to our board of directors and for so long as investment funds and entities affiliated

 

162


Table of Contents

with GTCR have the right to designate at least one director for election to our board of directors, in each case, a quorum of our board of directors will not exist without at least one director designee of each of Warburg Pincus and GTCR present at such meeting; provided that if a meeting of our board of directors fails to achieve a quorum due to the absence of a director designee of Warburg Pincus or GTCR, as applicable, the presence of at least one director designee of Warburg Pincus or GTCR, as applicable, will not be required in order for a quorum to exist at the next meeting of our board of directors.

Transfer Restrictions

Unless otherwise waived by the compensation committee and except for certain permitted transfers, management stockholders may transfer a number of vested shares of our common stock equal to the product of (i) the number of shares of our common stock then owned by such management stockholder multiplied by (ii) a fraction, the numerator of which is the number of shares of our common stock sold by the Sponsors in a public or private sale to a third party and the denominator of which is the total number of shares of our common stock held by the Sponsors immediately prior to such public or private sale. These transfer restrictions only apply to shares of common stock held by management stockholders at closing of this offering (or securities issued in respect thereof) and remain in effect until the sixth anniversary of the completion of this offering.

Corporate Opportunities

To the fullest extent permitted by law, we have, on behalf of ourselves, our subsidiaries and our and their respective stockholders, renounced any interest or expectancy in, or in being offered an opportunity to participate in, and business opportunity that may be presented to Warburg Pincus, GTCR or any of their respective affiliates, partners, principals, directors, officers, members, managers, employees or other representatives, and no such person has any duty to communicate or offer such business opportunity to us or any of our subsidiaries or shall be liable to us or any of our subsidiaries or any of our or its stockholders for breach of any duty, as a director or officer or otherwise, by reason of the fact that such person pursues or acquires such business opportunity, directs such business opportunity to another person or fails to present such business opportunity, or information regarding such business opportunity, to us or our subsidiaries, unless, in the case of any such person who is a director or officer of ours, such business opportunity is expressly offered to such director or officer in writing solely in his or her capacity as a director or officer of ours.

Indemnification

Under the Stockholders’ Agreement, we have agreed, subject to certain exceptions, to indemnify the Sponsors, and various affiliated persons and indirect equityholders of the Sponsors from certain losses arising out of any threatened or actual litigation by reason of the fact that the indemnified person is or was a holder of our common stock or of equity interests in Sotera Health Company. Public stockholders will not benefit from this indemnification provision. This indemnification is in addition to a similar indemnification provision under Topco Parent’s limited partnership agreement, which will survive the termination of such agreement. Two of our subsidiaries and GTCR, LLC are currently co-defendants in tort lawsuits alleging personal injury and related claims resulting from purported emissions and releases of EO from the Willowbrook facility. See “Business—Legal Proceedings—Ethylene Oxide Tort Litigation—Illinois.” In satisfaction of our indemnity obligations, our legal counsel is jointly engaged to also represent GTCR, LLC in these proceedings and we are bearing the cost of this combined defense effort.

Corporate Reorganization

Concurrently with, or prior to, the completion of this offering, Topco Parent will distribute the shares of our common stock to its partners in accordance with the limited partnership agreement of Topco Parent. See “Corporate Reorganization.”

 

163


Table of Contents

Limitation of Liability and Indemnification of Officers and Directors

Our amended and restated certificate of incorporation will provide for indemnification of directors and officers to the fullest extent permitted by law, including payment of expenses in advance of resolution of any such matter. Our amended and restated certificate of incorporation will eliminate the potential personal monetary liability of our directors to us or our stockholders for breaches of their duties as directors except as otherwise required under the DGCL. Any amendment to, or repeal of, these provisions will not eliminate or reduce the effect of these provisions in respect of any act, omission or claim that occurred or arose prior to that amendment or repeal. If the DGCL is amended to provide for further limitations on the personal liability of directors of corporations, then the personal liability of our directors will be further limited to the greatest extent permitted by the DGCL.

We have entered into or will enter into separate indemnification agreements with our directors and officers that may be broader than the specific indemnification provisions contained in the DGCL. Each indemnification agreement provides, among other things, for indemnification to the fullest extent permitted by law and our amended and restated certificate of incorporation and amended and restated bylaws against any and all expenses, judgments, fines and amounts paid in settlement of any claim. The indemnification agreements provide for the advancement or payment of all expenses to the indemnitee and for reimbursement to us if it is found that such indemnitee is not entitled to such indemnification under applicable law and our amended and restated certificate of incorporation and amended and restated bylaws. We believe that these agreements are necessary to attract and retain qualified individuals to serve as directors and officers.

The limitation of liability and indemnification provisions included in our amended and restated certificate of incorporation and the indemnification agreements that we have entered into or will enter into with our directors and officers may discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against our directors and officers, even though any such action, if successful, might benefit us and other stockholders. Further, a stockholder’s investment may be adversely affected to the extent that we pay the costs of settlement and damage awards against directors and officers as required by these indemnification provisions.

We maintain standard policies of insurance under which, subject to the limitations of the policies, coverage is provided to our directors and officers against loss arising from claims made by reason of a breach of duty or other wrongful acts as a director or officer, including claims relating to public securities matters.

Certain of our non-employee directors may, through their relationships with their employers, be insured or indemnified against certain liabilities incurred in their capacity as members of our board of directors. Although directors designated for election to our board of directors by investment funds and entities affiliated with either Warburg Pincus or GTCR may have certain rights to indemnification, advancement of expenses or insurance provided or obtained by investment funds and entities affiliated with either Warburg Pincus or GTCR, respectively, we have agreed in our Stockholders’ Agreement that we will be the indemnitor of first resort, will advance the full amount of expenses incurred by each such director and, to the extent that investment funds and entities affiliated with either Warburg Pincus or GTCR or their insurers make any payment to, or advance any expenses to, any such director, we will reimburse those investment funds and entities and their insurers for such amounts.

The underwriting agreement will provide for indemnification, under certain circumstances, by the underwriters of us and our officers and directors for certain liabilities arising under the Securities Act or otherwise.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling our company pursuant to the foregoing provisions, we have been informed that, in

 

164


Table of Contents

the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

Policies and Procedures for Related Party Transactions

Pursuant to our written related party transaction policy which will become effective upon the completion of this offering, the audit committee of the board of directors will be responsible for evaluating each related party transaction and making a determination as to whether the transaction at issue is fair, reasonable and within our policy and whether it should be ratified and approved. The audit committee, in making its determination, will consider various factors, including the benefit of the transaction to us, the terms of the transaction and whether they are at arm’s-length and in the ordinary course of our business, whether the transaction would impair the independence of an otherwise independent director, the direct or indirect nature of the related person’s interest in the transaction, the size and expected term of the transaction and other facts and circumstances that bear on the materiality of the related party transaction under applicable law and listing standards. The audit committee will review, at least annually, a summary of our transactions with our directors and officers and with firms that employ our directors, as well as any other related person transactions.

 

165


Table of Contents

DESCRIPTION OF CAPITAL STOCK

The following description summarizes important terms of our capital stock. Because it is only a summary, it does not contain all of the information that may be important to you. For a complete description, you should refer to our amended and restated certificate of incorporation and amended and restated bylaws that will become effective upon or prior to the closing of this offering, copies of which are filed as exhibits to the registration statement of which this prospectus is a part, as well as the relevant portions of the DGCL.

Authorized Capitalization

Upon the completion of this offering, our capital structure will consist of 1,200,000,000 authorized shares of common stock, par value $0.01 per share, and 120,000,000 authorized shares of preferred stock, par value $0.01 per share.

Common Stock

General. Immediately following our corporate reorganization, there will be 232,400,200 shares of our common stock outstanding, held of record by 73 holders.

Voting Rights. Holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders, subject to the restrictions described below under the caption “—Anti-Takeover Effects of Provisions of Our Amended and Restated Certificate of Incorporation, Our Amended and Restated Bylaws and Delaware Law.” The holders of common stock will not have cumulative voting rights in the election of directors. Accordingly, holders of a majority of the shares of common stock entitled to vote in any election of directors may elect all of the directors standing for election. Except for the election of directors, if a quorum is present, an action on a matter is approved if it receives the affirmative vote of the holders of a majority of the voting power of the shares of capital stock present in person or represented by proxy at the meeting and entitled to vote on the matter, unless otherwise required by applicable law, the DGCL, our amended and restated certificate of incorporation or amended and restated bylaws. The election of directors will be determined by a plurality of the votes cast in respect of the shares present in person or represented by proxy at the meeting and entitled to vote, meaning that the nominees with the greatest number of votes cast, even if less than a majority, will be elected. The rights, preferences and privileges of holders of common stock are subject to, and may be impacted by, the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future.

Dividends. Subject to preferences that may be applicable to any then-outstanding preferred stock, holders of our common stock are entitled to receive ratably those dividends, if any, as may be declared by the board of directors out of legally available funds. See “Dividend Policy.”

Liquidation, Dissolution, and Winding Up. Upon our liquidation, dissolution or winding up, the holders of our common stock will be entitled to share equally and ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the prior rights of any preferred stock then outstanding.

No Preemptive or Similar Rights. Holders of our common stock have no preemptive or conversion rights or other subscription rights, and there are no redemption or sinking fund provisions applicable to our common stock.

Assessment. All outstanding shares of our common stock are, and the shares of our common stock to be outstanding upon completion of this offering will be, fully paid and nonassessable.

Preferred Stock

Subject to limitations prescribed by Delaware law and the Nasdaq, our board of directors may issue preferred stock, without stockholder approval, in such series and with such designations, preferences, conversion

 

166


Table of Contents

or other rights, voting powers and qualifications, limitations or restrictions thereof, as the board of directors deems appropriate. Our board of directors could, without stockholder approval, issue preferred stock with voting, conversion and other rights that could adversely affect the voting power and impact other rights of the holders of the common stock. Our board of directors may issue preferred stock as an anti-takeover measure without any further action by the holders of common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, may have the effect of delaying, deferring or preventing a change of control of our company by increasing the number of shares necessary to gain control of the company.

Registration Rights

After the completion of this offering, the holders of 230,731,078 shares of our common stock will be entitled to certain rights with respect to the registration of such shares under the Securities Act. For a description of registration rights with respect to our common stock, see “Certain Relationships and Related Party Transactions—Registration Rights Agreement.”

Anti-Takeover Effects of Provisions of Our Amended and Restated Certificate of Incorporation, Our Amended and Restated Bylaws and Delaware Law

Delaware law contains, and our amended and restated certificate of incorporation and amended and restated bylaws contain, a number of provisions relating to corporate governance and to the rights of stockholders. Certain of these provisions may be deemed to have a potential “anti-takeover” effect in that such provisions may delay, defer or prevent a change of control or an unsolicited acquisition proposal that a stockholder might consider favorable, including a proposal that might result in the payment of a premium over the market price for the shares held by the stockholders. These provisions include:

Classified board of directors; removal of directors. Our amended and restated certificate of incorporation provides that our board of directors will be divided into three classes of directors, with the classes to be as nearly equal in number as possible, and with staggered three-year terms. As a result, approximately one-third of our board of directors will be elected each year.

In addition, our amended and restated certificate of incorporation provides that our directors may be removed only for cause by the affirmative vote of the holders of at least 75% of the voting power of our outstanding common stock; provided that for so long as investment funds and entities affiliated with either Warburg Pincus or GTCR, collectively, hold at least 50% of the outstanding shares of our common stock, a director designated by investment funds and entities affiliated with either Warburg Pincus or GTCR, respectively, may be removed with or without cause by the affirmative vote of the holders of at least a majority of the votes that all the stockholders would be entitled to cast in any annual election of directors or class of directors and with the consent of Warburg Pincus or GTCR, respectively.

Any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a majority of our directors then in office; provided that for so long as investment funds and entities affiliated with either Warburg Pincus or GTCR have the right to designate at least one director for election to our board of directors, any vacancies will be filled in accordance with the designation provisions set forth in our Stockholders’ Agreement.

The classification of our board of directors and the limitations on the removal of directors and filling of vacancies could make it more difficult for a third party to acquire, or discourage a third party from seeking to acquire, control of our company. See the section titled “Management and Board of Directors—Board Composition.”

Advance notice requirements for stockholder proposals and director nominations. Our amended and restated bylaws provide advance notice procedures for stockholders seeking to bring business before our annual

 

167


Table of Contents

meeting of stockholders or to nominate candidates for election as directors at our annual meeting of stockholders, other than nominations made by or at the direction of the board of directors or pursuant to the Stockholders’ Agreement. Our amended and restated bylaws also specify certain requirements regarding the form and content of a stockholder’s notice. These provisions might preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders if the proper procedures are not followed. We expect that these provisions may also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to obtain control of our company.

Amendment of certificate of incorporation and bylaws provisions. Our amended and restated certificate of incorporation provides that approval of stockholders holding a majority of the then-outstanding voting power of our capital stock, so long as investment funds and entities affiliated with either Warburg Pincus or GTCR, collectively, hold at least a majority of our outstanding capital stock, is required for stockholders to amend or adopt certain provisions of our amended and restated certificate of incorporation and any provision of our amended and restated bylaws, and at all other times by the affirmative vote of at least 66 2/3% of the voting power of our outstanding common stock. So long as investment funds and entities affiliated with either Warburg Pincus or GTCR have the right to designate three directors for election to our board of directors, at least 75% of the board must approve any amendments to the amended and restated certificate of incorporation or amended and restated bylaws.

Authorized but unissued or undesignated capital stock. Our authorized capital stock will consist of 1,200,000,000 shares of common stock and 1,200,000 shares of preferred stock. A large quantity of authorized but unissued shares may deter potential takeover attempts because of the ability of our board of directors to authorize the issuance of some or all of these shares to a friendly party, or to the public or in connection with a stockholder rights plan, which would make it more difficult for a potential acquirer to obtain control of us. This possibility may encourage persons seeking to acquire control of us to negotiate first with our board of directors. The authorized but unissued stock may be issued by the board of directors in one or more transactions. In this regard, our amended and restated certificate of incorporation grants the board of directors broad power to establish the rights and preferences of authorized and unissued preferred stock. The issuance of shares of preferred stock pursuant to the board of directors’ authority described above could decrease the amount of earnings and assets available for distribution to holders of common stock and adversely affect the rights and powers, including voting rights, of such holders and may have the effect of delaying, deferring or preventing a change in control.

Stockholder action; special meeting of stockholders. Our amended and restated certificate of incorporation provides that our stockholders will not be able to take action by written consent for any matter and may only take action at annual or special meetings. For so long as investment funds and entities affiliated with either Warburg Pincus or GTCR, collectively, hold a majority of our outstanding capital stock, however, a meeting and vote of stockholders may be dispensed with, and the action may be taken without prior notice and without such meeting and vote if a written consent is signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at the meeting of stockholders. Our amended and restated certificate of incorporation further provides that, except as otherwise required by law, special meetings of our stockholders may be called only by the majority of the board of directors or by the chairman of our board of directors or our chief executive officer, thus limiting the ability of a stockholder to call a special meeting. For so long as investment funds and entities affiliated with either Warburg Pincus or GTCR, collectively, hold a majority of our outstanding capital stock, however, special meetings of our stockholders may be called by the affirmative vote of the holders of a majority of our outstanding voting stock. These provisions might delay the ability of our stockholders to force consideration of a proposal or for stockholders controlling a majority of our capital stock to take any action, including the removal of directors.

No cumulative voting. The DGCL provides that stockholders are not entitled to cumulate votes in the election of directors unless a corporation’s certificate of incorporation provides otherwise. Our amended and

 

168


Table of Contents

restated certificate of incorporation does not provide for cumulative voting. Without cumulative voting, a minority stockholder may not be able to gain as many seats on our board of directors as the stockholder would be able to gain if cumulative voting were permitted. The absence of cumulative voting makes it more difficult for a minority stockholder to gain a seat on our board of directors to influence our board of directors’ decision regarding a takeover.

Supermajority voting on board actions. For so long as investment funds and entities affiliated with either Warburg Pincus or GTCR have the right (individually) to designate at least three directors for election to our board of directors, the following actions may only be effected with the affirmative vote of 75% of our board of directors:

 

   

certain acquisitions, mergers, other business combination transactions and dispositions;

 

   

any amendment, modification or repeal of any provision of the certificate of incorporation or bylaws;

 

   

changes in the size and composition of the board of directors or the compensation of its committees, other than in accordance with the Stockholders’ Agreement;

 

   

any termination of the chief executive officer or designation of a new chief executive officer;

 

   

except for ordinary course compensation arrangements, entering into, or modifying, any compensation arrangements with an executive officers or any of executive officer’s affiliates or associates;

 

   

issuance of additional shares of Company or subsidiaries’ capital stock, subject to certain limited exceptions; or

 

   

incurrence of certain indebtedness.

Delaware Anti-Takeover Statute. Upon completion of this offering, we will not be subject to the provisions of Section 203 of the DGCL. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a “business combination” with an “interested shareholder” for a three-year period following the time that the person becomes an interested shareholder, unless the business combination is approved in a prescribed manner. A “business combination” includes, among other things, a merger, asset or stock sale or other transaction resulting in a financial benefit to the interested shareholder. An “interested shareholder” is a person who, together with affiliates and associates, owns, or did own within three years prior to the determination of interested shareholder status, 15% or more of the corporation’s voting stock.

Under Section 203, a business combination between a corporation and an interested shareholder is prohibited unless it satisfies one of the following conditions: (1) before the shareholder became an interested shareholder, the board of directors approved either the business combination or the transaction which resulted in the shareholder becoming an interested shareholder; (2) upon consummation of the transaction which resulted in the shareholder becoming an interested shareholder, the interested shareholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances; or (3) at or after the time the shareholder became an interested shareholder, the business combination was approved by the board of directors and authorized at an annual or special meeting of the shareholders by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested shareholder.

A Delaware corporation may “opt out” of these provisions with an express provision in its original certificate of incorporation or an express provision in its certificate of incorporation or bylaws resulting from a shareholders’ amendment approved by at least a majority of the outstanding voting shares.

We will opt out of Section 203; however, our amended and restated certificate of incorporation contains similar provisions providing that we may not engage in certain “business combinations” with any “interested

 

169


Table of Contents

shareholder” for a three-year period following the time that the shareholder became an interested shareholder, unless:

 

   

prior to such time, our board of directors approved either the business combination or the transaction which resulted in the shareholder becoming an interested shareholder;

 

   

upon consummation of the transaction that resulted in the shareholder becoming an interested shareholder, the interested shareholder owned at least 85% of our voting stock outstanding at the time the transaction commenced, excluding certain shares; or

 

   

at or subsequent to that time, the business combination is approved by our Board and by the affirmative vote of holders of at least 66 2/3% of our outstanding voting stock that is not owned by the interested shareholder.

Under certain circumstances, this provision will make it more difficult for a person who would be an “interested shareholder” to effect various business combinations with us for a three-year period. This provision may encourage companies interested in acquiring us to negotiate in advance with our board of directors because the shareholder approval requirement would be avoided if our board of directors approves either the business combination or the transaction which results in the shareholder becoming an interested shareholder. These provisions also may have the effect of preventing changes in our board of directors and may make it more difficult to accomplish transactions which shareholders may otherwise deem to be in their best interests.

Our amended and restated certificate of incorporation provides that Warburg and GTCR, and any of their respective direct or indirect transferees and any group as to which such persons are a party, do not constitute “interested shareholders” for purposes of this provision.

Exclusive Forum

Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the sole and exclusive forum, to the fullest extent permitted by law, for (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers or other employees or stockholders to us or our stockholders, (3) any action asserting a claim against us or any of our directors or officers or other employees or stockholders arising pursuant to, any action to interpret, apply, enforce any right, obligation or remedy under, any provision of the DGCL our amended and restated certificate of incorporation or amended and restated bylaws, (4) any action asserting a claim that is governed by the internal affairs doctrine, or (5) any other action asserting an “internal corporate claim” under the DGCL shall be the Court of Chancery of the State of Delaware (or any state or federal court located within the State of Delaware if the Court of Chancery does not have jurisdiction). Notwithstanding the foregoing, our amended and restated certificate of incorporation provides that the Delaware Forum Provision will not apply to suits brought to enforce a duty or liability created by the Exchange Act. Any person or entity purchasing or otherwise acquiring any interest in our securities shall be deemed to have notice of and consented to this provision. Although we believe these provisions benefit us by providing increased consistency in the application of Delaware law for the specified types of actions and proceedings, the provisions may have the effect of discouraging lawsuits against us or our directors and officers.

Additionally, our amended and restated certificate of incorporation provides that unless the Company consents in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of the Company are deemed to have notice of and consented to this provision. The Supreme Court of Delaware has held that this type of exclusive federal forum provision is enforceable. There may be uncertainty, however, as to whether courts of other jurisdictions would enforce such provision, if applicable.

 

170


Table of Contents

Limitation of Liability and Indemnification of Officers and Directors

See the section titled “Certain Relationships and Related Party Transactions—Limitation of Liability and Indemnification of Officers and Directors.”

Transfer Agent and Registrar

The company expects to enter into an agreement with Computershare Trust Company, N.A. to act as transfer agent and registrar for our common stock. The transfer agent and registrar’s address is 118 Fernwood Avenue, Edison, New Jersey 08837.

Exchange

Our common stock has been approved for listing on the Nasdaq under the symbol “SHC.”

 

171


Table of Contents

DESCRIPTION OF CERTAIN INDEBTEDNESS

We summarize below the principal terms of the agreements that govern our existing indebtedness. We refer you to the exhibits to the registration statement of which this prospectus forms a part for copies of agreements governing the indebtedness described below.

Senior Secured Credit Facilities

Overview

On December 13, 2019, SHH entered into new senior secured first lien credit facilities (the “Senior Secured Credit Facilities”) and settled our previously outstanding term loan and senior notes. The Senior Secured Credit Facilities consist of both a senior secured first lien term loan (the “Term Loan”) and a $190.0 million senior secured first lien revolving credit facility (the “Revolving Credit Facility”). The Term Loan matures on December 13, 2026 and the Revolving Credit Facility matures on December 13, 2024. The Senior Secured Credit Facilities also provide SHH the right at any time and under certain conditions to request incremental term loans or incremental revolving credit commitments based on a formula defined in the Senior Secured Credit Facilities. As of September 30, 2020, total borrowings under the Term Loan were $2,109.4 million and the Revolving Credit Facility remained unutilized. As of September 30, 2020, SHH had $64.3 million of letters of credit issued against the Revolving Credit Facility, resulting in total availability under the Revolving Credit Facility of $125.7 million. Subject to market conditions, we are considering upsizing our Revolving Credit Facility in the fourth quarter of 2020 to increase capacity under the facility by approximately $100-150 million.

Interest Rate and Fees

Borrowings under the Revolving Credit Facility bear interest at a rate per annum equal to an applicable margin, plus, at our option, either (a) an alternate base rate or (b) a LIBOR rate. The applicable margin under the Revolving Credit Facility may be reduced by reference to a leverage-based pricing grid with step-downs of 0.25% at a specified senior secured first lien net leverage ratio. In addition to paying interest on any outstanding borrowings under the Revolving Credit Facility, SHH is required to pay a commitment fee to the lenders under the Revolving Credit Facility in respect of the unutilized commitments thereunder and customary letter of credit fees.

The Term Loan is paid in equal quarterly installments in aggregate annual amounts equal to 1.0% of the original Term Loan principal amount, while the remaining balance matures on December 13, 2026. The weighted average interest rate on borrowings under the Term Loan at September 30, 2020 was 5.50%.

Prepayments

The Term Loan requires SHH to prepay outstanding term loans, subject to certain exceptions, with:

 

   

50% of annual excess cash flow, which percentage will be reduced to 25% and 0% of annual excess cash flow based upon the achievement of specified first lien net leverage ratios and which payments may, at the option of the borrower, be reduced on a dollar-for-dollar basis by certain prepayments, capital expenditures, investments, acquisitions, dividends and cash consideration amounts made in the applicable fiscal year;

 

   

100% of the net cash proceeds of all non-ordinary course asset sales or other dispositions of property in excess of a certain amount, subject to reinvestment rights and other exceptions; and

 

   

100% of the net cash proceeds of any incurrence of debt (other than proceeds from debt permitted under the term loan facility, except in respect of refinancing debt).

The foregoing mandatory prepayments apply to the scheduled installments of principal of the Term Loan and any incremental facilities thereunder as directed by the borrower (and absent such direction in direct order of maturity).

 

172


Table of Contents

SHH may voluntarily repay outstanding loans under the Term Loan and the Revolving Credit Facility at any time without premium or penalty, other than customary breakage costs with respect to certain loans.

Guarantee and Security

All of SHH’s obligations under the Senior Secured Credit Facilities are unconditionally guaranteed by the Company and each existing and subsequently acquired or organized direct or indirect wholly-owned domestic restricted subsidiary of SHH (such guarantors, the “Guarantors”), with customary exceptions including, among other things, where providing such guarantees is not permitted by law, regulation or contract or would result in material adverse tax consequences. All obligations under the Senior Secured Credit Facilities, and the guarantees of such obligations, are secured by substantially all of the assets of SHH and the Guarantors, subject to permitted liens and other exceptions and exclusions, as outlined in the Senior Secured Credit Facilities. Such collateral is substantially the same collateral that secures the First Lien Notes and the Second Lien Notes (each as defined below), and any security interest or lien on shared collateral securing the First Lien Notes shall have equal priority with any security interest or lien on shared collateral securing the Senior Secured Credit Facilities.

Outstanding letters of credit are collateralized by encumbrances against the Revolving Credit Facility and the collateral pledged thereunder, or by cash placed on deposit with the issuing bank.

Certain Covenants and Events of Default

The Senior Secured Credit Facilities contain a number of covenants that, among other things, restrict, subject to certain exceptions, the ability of SHH and the ability of its restricted subsidiaries to:

 

   

incur additional indebtedness and guarantee indebtedness;

 

   

create or incur liens;

 

   

engage in mergers or consolidations;

 

   

sell, transfer or otherwise dispose of assets;

 

   

make investments, acquisitions or loans or advances;

 

   

pay dividends and distributions on or repurchase capital stock;

 

   

issue certain shares of preferred stock;

 

   

prepay, redeem or repurchase certain subordinated indebtedness;

 

   

enter into agreements which limit its ability and the ability of the restricted subsidiaries to incur liens on assets;

 

   

change its fiscal year;

 

   

change its lines of business;

 

   

enter into certain transactions with affiliates; and

 

   

change the passive holding company status of the direct parent of the borrower.

The Revolving Credit Facility contains a maximum senior secured first lien net leverage ratio covenant of 9.00 to 1.00, tested on the last day of each fiscal quarter if, on the last day of such fiscal quarter, the sum of (i) the aggregate principal amount of the revolving loans then outstanding under the Revolving Credit Facility, plus (ii) the aggregate amount of letter of credit disbursements that have not been reimbursed within two business days following the end of the fiscal quarter, exceeds the greater of $76.0 million and 40.0% of the aggregate principal amount of the revolving commitments then in effect. Although this covenant did not apply as the conditions were not met, as of September 30, 2020 the first lien net leverage ratio, as defined in the Revolving Credit Facility, was approximately 5.10 to 1.00.

 

173


Table of Contents

The Senior Secured Credit Facilities also contain certain customary affirmative covenants and events of default, including upon a change of control.

First Lien Notes

Overview

On July 31, 2020, SHH issued $100.0 million aggregate principal amount of senior secured first lien notes due 2026 (the “First Lien Notes”). The First Lien Notes bear interest at a rate equal to LIBOR subject to a 1.00% floor plus 6.00% per annum. Interest on the First Lien Notes is payable quarterly in arrears on March 31, June 30, September 30 and December 31 of each year. The First Lien Notes mature on December 13, 2026.

Optional Redemption

SHH is entitled to redeem all or a portion of the First Lien Notes, at any time and from time to time, subject to certain premiums depending on the date of redemption: any time on or prior to July 31, 2021, a customary make-whole premium applies and, thereafter, specified premiums that decline to zero apply (in each case as described in the indenture governing the First Lien Notes).

Guarantee and Security

All of SHH’s obligations under the First Lien Notes are unconditionally guaranteed by the company and each existing and subsequently acquired or organized direct or indirect wholly-owned domestic restricted subsidiary of SHH, with customary exceptions including, among other things, where providing such guarantees is not permitted by law, regulation or contract or would result in material adverse tax consequences. All obligations under the First Lien Notes, and the guarantees of such obligations, are secured by substantially all of the assets of SHH and the guarantors, subject to permitted liens and other exceptions and exclusions, as outlined in the First Lien Notes. Such collateral is substantially the same collateral that secures the Senior Secured Credit Facilities and the Second Lien Notes. Such collateral securing the First Lien Notes ranks pari passu with that of the Senior Secured Credit Facilities and has priority over collateral securing the Second Lien Notes.

Certain Covenants and Events of Default

The indenture governing the First Lien Notes limits the ability of SHH and the ability of most of its subsidiaries to:

 

   

incur additional debt or issue certain preferred shares;

 

   

pay dividends on, repurchase or make distributions in respect of capital stock or make other restricted payments;

 

   

make certain investments;

 

   

sell or transfer certain assets;

 

   

create liens on certain assets to secure debt;

 

   

consolidate, merge, sell or otherwise dispose of all or substantially all of its assets;

 

   

enter into certain transactions with affiliates; and

 

   

designate its subsidiaries as unrestricted subsidiaries.

Subject to certain exceptions, the indenture governing the First Lien Notes permits SHH and its restricted subsidiaries to incur additional indebtedness, including secured indebtedness.

The indenture also contains certain customary affirmative covenants pertaining to notice and filings with the trustee.

 

174


Table of Contents

There are no financial maintenance covenants in the indenture governing the First Lien Notes. Events of default under the indenture include, among others, nonpayment of principal or interest when due, covenant defaults, bankruptcy and insolvency events, change of control and cross defaults. The indenture provides for events of default which, if any of them occurs, would permit the principal of and accrued interest on the First Lien Notes to become due and payable.

Second Lien Notes

Overview

On December 13, 2019, SHH issued $770.0 million aggregate principal amount of senior secured second lien notes due 2027 (the “Second Lien Notes”). The Second Lien Notes bear interest at a rate equal to LIBOR subject to a 1.00% floor plus 8.00% per annum. Interest on the Second Lien Notes is payable quarterly in arrears on March 31, June 30, September 30 and December 31 of each year. The Second Lien Notes mature on December 13, 2027.

Optional Redemption

SHH is entitled to redeem all or a portion of the Second Lien Notes, at any time and from time to time, subject to certain premiums depending on the date of redemption: any time on or prior to December 13, 2020, a customary make-whole premium applies and, thereafter, specified premiums that decline to zero apply (in each case as described in the indenture governing the Second Lien Notes). In addition, under certain circumstances, such as an initial public offering or certain changes of control, SHH has certain additional redemption rights (as described in the indenture governing the Second Lien Notes).

Optional Redemption Following a Permitted Change of Control

If SHH experiences certain permitted changes of control (as described in the indenture governing the Second Lien Notes), SHH is entitled at its option to redeem all or a portion of the Second Lien Notes at a redemption price equal to 100% of the principal amount of the Second Lien Notes to be redeemed and accrued and unpaid interest, if any, plus a premium equal to 3.00% of the principal amount of such Second Lien Notes if redeemed during the first year following the effective date of the permitted change of control, 2.00% of the principal amount of such Second Lien Notes if redeemed during the second year following the effective date of the permitted change of control and 1.00% of the principal amount of such Second Lien Notes if redeemed during the third year following the effective date of the permitted change of control.

Guarantee and Security

All of SHH’s obligations under the Second Lien Notes are unconditionally guaranteed by the company and each existing and subsequently acquired or organized direct or indirect wholly-owned domestic restricted subsidiary of SHH, with customary exceptions including, among other things, where providing such guarantees is not permitted by law, regulation or contract or would result in material adverse tax consequences. All obligations under the Second Lien Notes, and the guarantees of such obligations, are secured by substantially all of the assets of SHH and the guarantors, subject to permitted liens and other exceptions and exclusions, as outlined in the Second Lien Notes. Such collateral is substantially the same collateral that secures the Senior Secured Credit Facilities and the First Lien Notes, and any security interest or lien on shared collateral securing the Senior Secured Credit Facilities or the First Lien Notes shall have priority over any security interest or lien on shared collateral securing the Second Lien Notes.

Certain Covenants and Events of Default

The indenture governing the Second Lien Notes limits the ability of SHH and the ability of most of its subsidiaries to:

 

   

incur additional debt or issue certain preferred shares;

 

175


Table of Contents
   

pay dividends on, repurchase or make distributions in respect of capital stock or make other restricted payments;

 

   

make certain investments;

 

   

sell or transfer certain assets;

 

   

create liens on certain assets to secure debt;

 

   

consolidate, merge, sell or otherwise dispose of all or substantially all of its assets;

 

   

enter into certain transactions with affiliates; and

 

   

designate its subsidiaries as unrestricted subsidiaries.

Subject to certain exceptions, the indenture governing the Second Lien Notes permits SHH and its restricted subsidiaries to incur additional indebtedness, including secured indebtedness.

The indenture also contains certain customary affirmative covenants pertaining to notice and filings with the trustee.

There are no financial maintenance covenants in the indenture governing the Second Lien Notes. Events of default under the indenture include, among others, nonpayment of principal or interest when due, covenant defaults, bankruptcy and insolvency events, change of control and cross defaults. The indenture provides for events of default which, if any of them occurs, would permit the principal of and accrued interest on the Second Lien Notes to become due and payable.

 

176


Table of Contents

SHARES ELIGIBLE FOR FUTURE SALE

Prior to this offering, there has been no public market for our common stock, and we cannot assure you that a liquid trading market for our common stock will develop or be sustained after this offering. Future sales of substantial amounts of our common stock, including shares issued upon exercise of options, warrants or convertible securities, if any, in the public market after this offering, or the anticipation of such sales or perception that such sales may occur, could adversely affect the market price of our common stock prevailing from time to time and could impair our ability to raise capital through sales of our equity securities. No prediction can be made as to the effect, if any, future sales of shares, or the availability of shares for future sales, will have on the market price of our common stock prevailing from time to time.

Sales of Restricted Shares

Upon the closing of this offering, we will have outstanding an aggregate of 277,331,078 shares of common stock, assuming 46,600,000 shares are sold in the offering based on an assumed share price of $21.50 (the midpoint of the estimated offering price range on the cover page of this prospectus). Of these shares, we expect all of the shares of common stock being sold in this offering will be freely tradable without restriction or further registration under the Securities Act, except for any such shares which may be held or acquired by an “affiliate” of ours, as that term is defined in Rule 144 under the Securities Act, which shares will be subject to the volume limitations and other restrictions of Rule 144 described below. The remaining 230,731,078 shares of common stock held by our existing stockholders upon completion of this offering will be “restricted securities,” as that phrase is defined in Rule 144, and may be resold only after registration under the Securities Act or pursuant to an exemption from such registration, including, among others, the exemptions provided by Rules 144 and 701 under the Securities Act, which rules are summarized below.

As a result of the lock-up agreements described below and the provisions of Rule 144 and Rule 701 under the Securities Act, additional shares of our common stock will be available for sale in the public market as set forth below.

Rule 144

In general, under Rule 144, persons who became the beneficial owner of shares of our common stock prior to the completion of this offering may not sell their shares until the earlier of (i) the expiration of a six-month holding period, if we have been subject to the reporting requirements of the Exchange Act and have filed all required reports for at least 90 days prior to the date of the sale, or (ii) a one-year holding period.

At the expiration of the six-month holding period, a person who was not one of our affiliates at any time during the three months preceding a sale is entitled to sell an unlimited number of shares of our common stock provided current public information about us is available, and a person who was one of our affiliates at any time during the three months preceding a sale is entitled to sell within any three-month period only a number of shares of common stock that does not exceed the greater of either of the following:

 

   

one percent of the number of shares of common stock then outstanding, which will equal approximately 2,773,311 immediately after this offering; or

 

   

the average weekly trading volume of the common stock on the Nasdaq during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale.

At the expiration of the one-year holding period, a person who was not one of our affiliates at any time during the three months preceding a sale would be entitled to sell an unlimited number of shares of our common stock without restriction. A person who was one of our affiliates at any time during the three months preceding a sale would remain subject to the volume restrictions described above.

 

177


Table of Contents

All sales under Rule 144 are subject to the availability of current public information about us. In addition, sales under Rule 144 by affiliates or persons who have been affiliates within the previous 90 days are also subject to manner of sale provisions and notice requirements. Upon completion of the 180-day lock-up period, approximately 207,054,561 shares of our outstanding restricted securities will be eligible for sale under Rule 144 subject to limitations on sales by affiliates and other contractual transfer restrictions.

Rule 701

In general, under Rule 701, any of our employees, directors, officers, consultants or advisors who purchased shares from us in connection with a compensatory stock or option plan or other written agreement before the effective date of our initial public offering, or who purchased shares from us after that date upon the exercise of options granted before that date, are eligible to resell such shares in reliance upon Rule 144 beginning 90 days after the date of this prospectus. If such person is not an affiliate, the sale may be made without compliance with its holding period or current public information requirement. If such a person is an affiliate, the sale may be made under Rule 144 without compliance with its one-year minimum holding period, but subject to the other Rule 144 restrictions.

Lock-up Agreements

We, each of our officers, directors and certain holders of our common stock will agree, subject to certain exceptions, with the underwriters not to dispose of or hedge any of the shares of common stock or securities convertible into or exchangeable for shares of common stock during the period from the date of this prospectus continuing through the date 180 days after the date of this prospectus. J.P. Morgan Securities LLC may, in its sole discretion, release any of these shares from these restrictions at any time without notice. For a discussion of these restrictions, see the section titled “Underwriting (Conflicts of Interest).”

Stockholders’ Agreement

For a description of the stockholders’ agreement that we have entered into with certain holders of our common stock, including investment funds and entities affiliated with the Sponsors, see “Certain Relationships and Related Person Transactions—Stockholders’ Agreement.”

Registration Rights

For a description of the registration rights agreement that we have entered into with certain holders of our common stock, including investment funds and entities affiliated with the Sponsors, see “Certain Relationships and Related Party Transaction Registration Rights.”

Equity Plans

We intend to file one or more registration statements on Form S-8 under the Securities Act in connection with the completion of this offering to register all shares of common stock issued or issuable under the 2020 Plan. This registration statement is expected to become effective immediately upon filing and will permit the resale of shares offered pursuant to the 2020 Plan by non-affiliates in the public market without restriction under the Securities Act and the sale by affiliates in the public market, subject to compliance with the resale provisions of Rule 144 and any applicable lock-up agreements. See “Executive Compensation—2020 Omnibus Incentive Plan” for a description of our 2020 Plan.

 

178


Table of Contents

MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR NON-U.S. HOLDERS

The following discussion describes the material U.S. federal income tax considerations that are likely to be relevant to the purchase, ownership, and disposition of shares of our common stock. This discussion deals only with shares of our common stock held as capital assets by investors who purchased shares of our common stock in this offering. This discussion does not cover all aspects of U.S. federal taxation that may be relevant to the purchase, ownership or disposition of shares of our common stock by prospective investors in light of their specific facts and circumstances. In particular, this discussion does not address all of the tax considerations that may be relevant to persons in special tax situations, including banks, insurance companies or other financial institutions, dealers in securities, persons that will hold more than 5% of our common stock, certain former citizens or residents of the United States, a person that is a “controlled foreign corporation,” a person that is a “passive foreign investment company,” persons holding shares of our common stock as part of a hedge, straddle, conversion or other integrated financial transaction, entities that are treated as partnerships for U.S. federal income tax purposes (or partners therein) or persons that are otherwise subject to special treatment under the Internal Revenue Code of 1986, as amended (the “Code”). This section does not address any other U.S. federal tax considerations (such as estate tax, gift taxes or the Medicare tax on net investment income) or any state, local or non-U.S. tax considerations. Except with respect to the discussion in “—Information Reporting and Backup Withholding,” this section addresses only Non-U.S. Holders (as defined below).

You should consult your own tax advisors about the tax consequences of the purchase, ownership and disposition of shares of our common stock in light of your own particular circumstances, including the tax consequences under state, local, non-U.S. and other tax laws and the possible effects of any changes in applicable tax laws.

For purposes of this discussion, a “U.S. Holder” means a beneficial owner of shares of our common stock that is an individual citizen or resident of the United States, a domestic corporation or otherwise subject to U.S. federal income tax on a net basis with respect to income from our common stock. A “Non-U.S. Holder” means any beneficial owner of shares of our common stock that is not a U.S. Holder.

This discussion is based on the tax laws of the United States, including the Code, existing and proposed regulations, and administrative and judicial interpretations, all as currently in effect. Such authorities may be repealed, revoked, modified or subject to differing interpretations, possibly on a retroactive basis, so as to result in U.S. federal income tax consequences different from those discussed below.

Dividends

A distribution of cash or property with respect to shares of our common stock generally will be treated as a dividend to the extent paid out of our current or accumulated earnings and profits. If such a distribution exceeds our current and accumulated earnings and profits, the excess will be first treated as a tax-free return of a Non-U.S. Holder’s investment, up to the Non-U.S. Holder’s tax basis in the shares of our common stock, and thereafter as a capital gain subject to the tax treatment described below in “—Sale, Exchange or Other Taxable Disposition of Common Stock.”

Dividends paid to a Non-U.S. Holder generally will be subject to withholding of U.S. federal income tax at a 30% rate, or such lower rate as may be specified by an applicable tax treaty.

Even if a Non-U.S. Holder is eligible for a lower treaty rate, a withholding agent generally will be required to withhold at a 30% rate (rather than the lower treaty rate) unless the Non-U.S. Holder has furnished a valid Internal Revenue Service (“IRS”) Form W-8BEN or W-8BEN-E, or other documentary evidence establishing the Non-U.S. Holder’s entitlement to the lower treaty rate with respect to such dividend payments, and the withholding agent does not have actual knowledge or reason to know to the contrary.

 

179


Table of Contents

In addition, under the U.S. tax rules known as the Foreign Account Tax Compliance Act (“FATCA”), a Non-U.S. Holder will generally be subject to a 30% U.S. withholding tax on dividends in respect of our common stock if the Non-U.S. Holder is not FATCA compliant or holds its common stock through a foreign financial institution that is not FATCA compliant. In order to be treated as FATCA compliant, a Non-U.S. Holder must provide certain documentation (usually an IRS Form W-8BEN or W-8BEN-E) containing information about its identity, its FATCA status and, if required, its direct and indirect U.S. owners. These requirements may be modified by the adoption or implementation of a particular intergovernmental agreement between the United States and another country or by future U.S. Treasury Regulations. Documentation that Non-U.S. Holders provide in order to be treated as FATCA compliant may be reported to the IRS and other tax authorities, including information about a Non-U.S. Holder’s identity, its FATCA status and, if applicable, its direct and indirect U.S. owners.

If a Non-U.S. Holder is eligible for a reduced rate of U.S. federal withholding tax pursuant to an applicable income tax treaty or otherwise, the Non-U.S. Holder may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS.

Investors should consult their own tax advisors about how these information reporting and withholding tax rules may apply to their investment in shares of our common stock.

Sale, Exchange or Other Taxable Disposition of Common Stock

Non-U.S. Holders generally will not be subject to U.S. federal income tax with respect to gain recognized on a sale, exchange or other taxable disposition of shares of our common stock.

Information Reporting and Backup Withholding

Information returns are required to be filed with the IRS with respect to payments made to certain U.S. and Non-U.S. Holders in connection with distributions or the sale or other disposition of our common stock. In addition, certain U.S. Holders may be subject to backup withholding tax in respect of such payments if they do not provide their taxpayer identification numbers to the applicable withholding agent, fail to certify that they are not subject to backup withholding tax or otherwise fail to comply with applicable backup withholding tax rules. Non-U.S. Holders may be required to comply with applicable certification procedures to establish that they are Non-U.S. Holders in order to avoid the application of certain information reporting requirements or backup withholding tax. Any amount paid as backup withholding may be creditable against the holder’s U.S. federal income tax liability or allowed as a refund, provided that the required information is timely furnished to the IRS.

 

180


Table of Contents

UNDERWRITING (CONFLICTS OF INTEREST)

We are offering the shares of common stock described in this prospectus through a number of underwriters. J.P. Morgan Securities LLC, Credit Suisse Securities (USA) LLC, Goldman Sachs & Co. LLC and Jefferies LLC are acting as representatives of the underwriters. We have entered into an underwriting agreement with the underwriters. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to the underwriters, and each underwriter has severally agreed to purchase, at the public offering price less the underwriting discounts and commissions set forth on the cover page of this prospectus, the number of shares of common stock listed next to its name in the following table:

 

Name

   Number of
Shares
 

J.P. Morgan Securities LLC

  

Credit Suisse Securities (USA) LLC

  

Goldman Sachs & Co. LLC

  

Jefferies LLC

  

Barclays Capital Inc.

  

Citigroup Global Markets Inc.

  

RBC Capital Markets, LLC

  

BNP Paribas Securities Corp

  

KeyBanc Capital Markets Inc.

                           

Citizens Capital Markets, Inc.

  

ING Financial Markets LLC

  

Academy Securities, Inc.

  

Loop Capital Markets LLC

  

Penserra Securities LLC

  

Siebert Williams Shank & Co., LLC

  

Tigress Financial Partners LLC

  
  

 

 

 

Total

     46,600,000  
  

 

 

 

The underwriters are committed to purchase all the common shares offered by us if they purchase any shares. The underwriting agreement also provides that if an underwriter defaults, the purchase commitments of non-defaulting underwriters may also be increased or the offering may be terminated.

The underwriters propose to offer the common shares directly to the public at the initial public offering price set forth on the cover page of this prospectus and to certain dealers at that price less a concession not in excess of $                 per share. Any such dealers may resell shares to certain other brokers or dealers at a discount of up to $                 per share from the initial public offering price. After the initial offering of the shares to the public, if all of the common shares are not sold at the initial public offering price, the underwriters may change the offering price and the other selling terms. The offering of the shares by the underwriters is subject to receipt and acceptance and subject to the underwriters’ right to reject any order in whole or in part. Sales of any shares made outside of the United States may be made by affiliates of the underwriters.

The underwriters have an option to buy up to 6,990,000 additional shares of common stock from us to cover sales of shares by the underwriters which exceed the number of shares specified in the table above. The underwriters have 30 days from the date of this prospectus to exercise this option to purchase additional shares. If any shares are purchased with this option to purchase additional shares, the underwriters will purchase shares in approximately the same proportion as shown in the table above. If any additional shares of common stock are purchased, the underwriters will offer the additional shares on the same terms as those on which the shares are being offered.

The underwriting fee is equal to the public offering price per share of common stock less the amount paid by the underwriters to us per share of common stock. The underwriting fee is $                 per share. The following

 

181


Table of Contents

table shows the per share and total underwriting discounts and commissions to be paid to the underwriters assuming both no exercise and full exercise of the underwriters’ option to purchase additional shares.

 

     Without
option to
purchase
additional shares
exercise
     With full
option to
purchase
additional shares
exercise
 

Per Share

   $                            $                        

Total

   $        $    

We estimate that the total expenses of this offering, including registration, filing and listing fees, printing fees and legal and accounting expenses, but excluding the underwriting discounts and commissions, will be approximately $7.5 million. We have agreed to reimburse the underwriters for expenses up to $35,000, including expenses related to clearance of this offering with FINRA.

A prospectus in electronic format may be made available on the web sites maintained by one or more underwriters, or selling group members, if any, participating in the offering. The underwriters may agree to allocate a number of shares to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by the representatives to underwriters and selling group members that may make Internet distributions on the same basis as other allocations.

We have agreed that, subject to certain exceptions, we will not, without the prior written consent of J.P. Morgan Securities LLC for a period of 180 days after the date of this prospectus, (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, or publicly file with, the SEC a registration statement under the Securities Act relating to, any shares of common stock or any securities convertible into or exercisable or exchangeable for common stock, or publicly disclose the intention to undertake any of the foregoing or (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of common stock or any such other securities.

Our executive officers, directors and certain holders of our common stock have entered into lock-up agreements with the underwriters pursuant to which each of them, subject to certain exceptions, for a period of 180 days after the date of this prospectus, may not, without the prior written consent of J.P. Morgan Securities LLC, (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of our common stock or any securities convertible into or exercisable or exchangeable for our common stock; (ii) enter into any hedging, swap, or other agreement or transaction that transfers, in whole or in part, any of the economic consequences of ownership of the common stock or such other securities; (iii) make any demand for or exercise any right with respect to the registration of any shares of our common stock or any security convertible into or exercisable or exchangeable for our common stock, except as those demands or exercises do not involve any public disclosure or filing; or (iv) publicly disclose the intention to undertake any of the foregoing.

The lock-up restrictions described in the immediately preceding paragraph are subject to certain exceptions including, without limitation: (i) transfers as part of a sale of lock-up securities acquired in this offering or in open market transactions after the closing of this offering, (ii) transfers to us in connection with the vesting, settlement, or exercise of restricted stock units, shares of restricted stock, options, warrants or other rights to purchase shares of common stock, (iii) transfers in connection with existing arrangements disclosed in this prospectus under the heading “Certain Relationships and Related Party Transactions—Transactions with Certain of Our Executive Officers”, (iv) transfers pursuant to an order of a court or regulatory agency related to the lock-up party’s ownership of the lock-up securities; and (v) transfers by pledging, hypothecating or otherwise

 

182


Table of Contents

granting a security interest in any lock-up securities as collateral and transfer such lock-up securities to such lending institution upon foreclosure, among others.

We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act of 1933.

Our common stock has been approved for listing on the Nasdaq under the symbol “SHC.”

In connection with this offering, the underwriters may engage in stabilizing transactions, which involves making bids for, purchasing and selling shares of common stock in the open market for the purpose of preventing or retarding a decline in the market price of the common stock while this offering is in progress. These stabilizing transactions may include making short sales of common stock, which involves the sale by the underwriters of a greater number of shares of common stock than they are required to purchase in this offering, and purchasing shares of common stock on the open market to cover positions created by short sales. Short sales may be “covered” shorts, which are short positions in an amount not greater than the underwriters’ option to purchase additional shares referred to above, or may be “naked” shorts, which are short positions in excess of that amount. The underwriters may close out any covered short position either by exercising their option to purchase additional shares, in whole or in part, or by purchasing shares in the open market. In making this determination, the underwriters will consider, among other things, the price of shares available for purchase in the open market compared to the price at which the underwriters may purchase shares through the option to purchase additional shares. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open market that could adversely affect investors who purchase in this offering. To the extent that the underwriters create a naked short position, they will purchase shares in the open market to cover the position.

The underwriters have advised us that, pursuant to Regulation M of the Securities Act of 1933, they may also engage in other activities that stabilize, maintain or otherwise affect the price of the common stock, including the imposition of penalty bids. This means that if the representatives of the underwriters purchase common stock in the open market in stabilizing transactions or to cover short sales, the representatives can require the underwriters that sold those shares as part of this offering to repay the underwriting discount received by them.

These activities may have the effect of raising or maintaining the market price of the common stock or preventing or retarding a decline in the market price of the common stock, and, as a result, the price of the common stock may be higher than the price that otherwise might exist in the open market. If the underwriters commence these activities, they may discontinue them at any time. The underwriters may carry out these transactions on the Nasdaq, in the over-the-counter market or otherwise.

Prior to this offering, there has been no public market for our common stock. The initial public offering price will be determined by negotiations between us and the representatives of the underwriters. In determining the initial public offering price, we and the representatives of the underwriters expect to consider a number of factors including:

 

   

the information set forth in this prospectus and otherwise available to the representatives;

 

   

our prospects and the history and prospects for the industry in which we compete;

 

   

an assessment of our management;

 

   

our prospects for future earnings;

 

   

the general condition of the securities markets at the time of this offering;

 

   

the recent market prices of, and demand for, publicly traded common stock of generally comparable companies; and

 

   

other factors deemed relevant by the underwriters and us.

 

183


Table of Contents

Neither we nor the underwriters can assure investors that an active trading market will develop for our common shares, or that the shares will trade in the public market at or above the initial public offering price.

Certain of the underwriters and their affiliates have provided in the past to us and our affiliates and may provide from time to time in the future certain commercial banking, financial advisory, investment banking and other services for us and such affiliates in the ordinary course of their business, for which they have received and may continue to receive customary fees and commissions. Certain affiliates of Goldman Sachs & Co. LLC hold (i) approximately $420 million aggregate principal amount of the Second Lien Notes, all of which will be redeemed at the applicable redemption premium, plus accrued and unpaid interest to, but excluding the date of redemption (see “Use of Proceeds”) and (ii) approximately $33.3 million aggregate principal amount of the First Lien Notes. Affiliates of Goldman Sachs & Co. LLC hold less than $1.5 million of the aggregate principal amount of the Term Loan, a portion of which will be repaid. Certain of the underwriters and/or certain of their affiliates are lenders, and/or act as agents or arrangers, under our Senior Secured Credit Facilities, and as a result, will receive a portion of the net proceeds from this offering. See “Use of Proceeds.” In addition, from time to time, certain of the underwriters and their affiliates may effect transactions for their own account or the account of customers, and hold on behalf of themselves or their customers, long or short positions in our debt or equity securities or loans, and may do so in the future.

The underwriters and their affiliates are full service financial institutions engaged in various activities, which may include sales and trading, commercial and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage and other financial and non-financial activities and services. The underwriters and their respective affiliates have provided, and may in the future provide, a variety of these services to the issuer and to persons and entities with relationships with the issuer, for which they received or will receive customary fees and expenses.

In the ordinary course of their various business activities, the underwriters and their affiliates, officers, directors and employees may purchase, sell or hold a broad array of investments and actively traded securities, derivatives, loans, commodities, currencies, credit default swaps and other financial instruments for their own account and for the accounts of their customers, and such investment and trading activities may involve or relate to assets, securities and/or instruments of the issuer (directly, as collateral securing other obligations or otherwise) and/or persons and entities with relationships with the issuer. The underwriters and their affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such assets, securities or instruments and may at any time hold, or recommend to clients that they should acquire, long and/or short positions in such assets, securities and instruments.

Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful.

Conflicts of Interest

Affiliates of Goldman Sachs & Co. LLC hold approximately $420 million aggregate principal amount of the Second Lien Notes, all of which will be redeemed at the applicable redemption premium and less than $1.5 million of the aggregate principal amount of the Term Loan, a portion of which will be repaid plus accrued and unpaid interest to, but excluding the date of redemption, and as a result will receive approximately 45.1% of the net proceeds of this offering (at an assumed initial public offering price of $21.50, the midpoint of the

 

184


Table of Contents

estimated offering price range on the cover of this prospectus), assuming the underwriters do not exercise their option to purchase additional shares. See “Use of Proceeds.” Accordingly, Goldman Sachs & Co. LLC is deemed to have a conflict of interest within the meaning of Rule 5121. Therefore, this offering is being made in compliance with the requirements of Rule 5121. This rule requires, among other things, that a “qualified independent underwriter” participate in the preparation of, and exercise the usual standards of “due diligence” with respect to, the registration statement and this prospectus. J.P. Morgan Securities LLC has agreed to act as qualified independent underwriter for this offering and to undertake the legal responsibilities and liabilities of an underwriter under the Securities Act. J.P. Morgan Securities LLC will not receive any additional fees for serving as qualified independent underwriter in connection with this offering. We have agreed to indemnify J.P. Morgan Securities LLC against liabilities incurred in connection with acting as qualified independent underwriter, including liabilities under the Securities Act. Pursuant to FINRA Rule 5121, Goldman Sachs & Co. LLC will not confirm sales of our common stock to any account over which it exercises discretionary authority without the prior written approval of the customer.

Notice to Prospective Investors in the European Economic Area and the United Kingdom

In relation to each Member State of the European Economic Area and the United Kingdom (each a “Relevant State”), no shares have been offered or will be offered pursuant to this offering to the public in that Relevant State prior to the publication of a prospectus in relation to the shares which has been approved by the competent authority in that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that offers of shares may be made to the public in that Relevant State at any time under the following exemptions under the Prospectus Regulation:

 

  a.

to any legal entity which is a qualified investor as defined under the Prospectus Regulation;

 

  b.

to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or

 

  c.

in any other circumstances falling within Article 1(4) of the Prospectus Regulation,

provided that no such offer of shares shall require the company or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation.

Each person in a Relevant State (other than a Relevant State where there is a permitted public offer) who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with the company and the underwriters that it is a qualified investor within the meaning of the Prospectus Regulation.

In the case of any shares being offered to a financial intermediary as that term is used in Article 5(1) of the Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a non-discretionary basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer to the public other than their offer or resale in a Relevant State to qualified investors, in circumstances in which the prior consent of the underwriters has been obtained to each such proposed offer or resale.

The company, the underwriters and their affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgements and agreements.

For the purposes of this provision, the expression an “offer to the public” in relation to any shares in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any shares, and the expression “Prospectus Regulation” means Regulation (EU) 2017/1129 (as amended).

 

185


Table of Contents

References to the Prospectus Regulation includes, in relation to the UK, the Prospectus Regulation as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018.

Notice to Prospective Investors in the United Kingdom

In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may only be directed at persons who are “qualified investors” (as defined in the Prospectus Regulation) (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”) and/or (ii) who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”) or otherwise in circumstances which have not resulted and will not result in an offer to the public of the shares in the United Kingdom within the meaning of the Financial Services and Markets Act 2000.

Any person in the United Kingdom that is not a relevant person should not act or rely on the information included in this document or use it as basis for taking any action. In the United Kingdom, any investment or investment activity that this document relates to may be made or taken exclusively by relevant persons.

Notice of Prospective Investors in Switzerland

This prospectus is not intended to constitute an offer or solicitation to purchase or invest in the shares. The shares may not be publicly offered, directly or indirectly, in Switzerland within the meaning of the Swiss Financial Services Act (“FinSA”) and no application has or will be made to admit the shares to trading on any trading venue (exchange or multilateral trading facility) in Switzerland. Neither this prospectus nor any other offering or marketing material relating to the shares constitutes a prospectus pursuant to the FinSA, and neither this prospectus nor any other offering or marketing material relating to the shares may be publicly distributed or otherwise made publicly available in Switzerland.

Notice to Prospective Investors in the Dubai International Financial Centre

This prospectus relates to an Exempt Offer in accordance with the Markets Rules 2012 of the Dubai Financial Services Authority (“DFSA”). This prospectus is intended for distribution only to persons of a type specified in the Markets Rules 2012 of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility for the prospectus. The shares to which this prospectus relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares offered should conduct their own due diligence on the shares. If you do not understand the contents of this prospectus you should consult an authorized financial advisor.

In relation to its use in the DIFC, this prospectus is strictly private and confidential and is being distributed to a limited number of investors and must not be provided to any person other than the original recipient, and may not be reproduced or used for any other purpose. The interests in the securities may not be offered or sold directly or indirectly to the public in the DIFC.

Notice to Prospective Investors in Australia

This prospectus:

 

   

does not constitute a disclosure document or a prospectus under Chapter 6D.2 of the Corporations Act 2001 (Cth) (the “Corporations Act”);

 

   

has not been, and will not be, lodged with the Australian Securities and Investments Commission (“ASIC”), as a disclosure document for the purposes of the Corporations Act and does not purport to

 

186


Table of Contents
 

include the information required of a disclosure document for the purposes of the Corporations Act; and

 

   

may only be provided in Australia to select investors who are able to demonstrate that they fall within one or more of the categories of investors, available under section 708 of the Corporations Act (“Exempt Investors”).

The shares may not be directly or indirectly offered for subscription or purchased or sold, and no invitations to subscribe for or buy the shares may be issued, and no draft or definitive offering memorandum, advertisement or other offering material relating to any shares may be distributed in Australia, except where disclosure to investors is not required under Chapter 6D of the Corporations Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application for the shares, you represent and warrant to us that you are an Exempt Investor.

As any offer of shares under this document will be made without disclosure in Australia under Chapter 6D.2 of the Corporations Act, the offer of those securities for resale in Australia within 12 months may, under section 707 of the Corporations Act, require disclosure to investors under Chapter 6D.2 if none of the exemptions in section 708 applies to that resale. By applying for the shares you undertake to us that you will not, for a period of 12 months from the date of sale of the shares, offer, transfer, assign or otherwise alienate those shares to investors in Australia except in circumstances where disclosure to investors is not required under Chapter 6D.2 of the Corporations Act or where a compliant disclosure document is prepared and lodged with ASIC.

Notice to Prospective Investors in Hong Kong

The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a) to “professional investors” as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the “SFO”) of Hong Kong and any rules made thereunder; or (b) in other circumstances which do not result in the document being a “prospectus” as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32 of Hong Kong) (the “CO”) or which do not constitute an offer to the public within the meaning of the CO. No advertisement, invitation or document relating to the shares has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to “professional investors” as defined in the SFO and any rules made thereunder.

Notice to Prospective Investors in Japan

The shares have not been and will not be registered pursuant to Article 4, Paragraph 1 of the Financial Instruments and Exchange Law of Japan. Accordingly, none of the shares nor any interest therein may be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any “resident” of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for re-offering or resale, directly or indirectly, in Japan or to or for the benefit of a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan in effect at the relevant time.

Notice to Prospective Investors in Singapore

Each underwriter has acknowledged that this prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, each underwriter has represented and agreed that it has not offered or sold any shares or caused the shares to be made the subject of an invitation for subscription or

 

187


Table of Contents

purchase and will not offer or sell any shares or cause the shares to be made the subject of an invitation for subscription or purchase, and has not circulated or distributed, nor will it circulate or distribute, this prospectus or any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares, whether directly or indirectly, to any person in Singapore other than:

 

  (a)

to an institutional investor (as defined in Section 4A of the Securities and Futures Act (Chapter 289) of Singapore, as modified or amended from time to time (the “SFA”)) pursuant to Section 274 of the SFA;

 

  (b)

to a relevant person (as defined in Section 275(2) of the SFA) pursuant to Section 275(1) of the SFA, or any person pursuant to Section 275(1A) of the SFA, and in accordance with the conditions specified in Section 275 of the SFA; or

 

  (c)

otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.

Where the shares are subscribed or purchased under Section 275 of the SFA by a relevant person which is:

 

  (a)

a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or

 

  (b)

a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor,

securities or securities-based derivatives contracts (each term as defined in Section 2(1) of the SFA) of that corporation or the beneficiaries’ rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to an offer made under Section 275 of the SFA except:

 

  (i)

to an institutional investor or to a relevant person, or to any person arising from an offer referred to in Section 275(1A) or Section 276(4)(i)(B) of the SFA;

  (ii)

where no consideration is or will be given for the transfer;

 

  (iii)

where the transfer is by operation of law;

 

  (iv)

as specified in Section 276(7) of the SFA; or

 

  (v)

as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and Securities-based Derivatives Contracts) Regulations 2018.

Notice to Prospective Investors in Canada

The shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws.

Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser’s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser’s province or territory for particulars of these rights or consult with a legal advisor.

Pursuant to section 3A.3 of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply with the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering.

 

188


Table of Contents

LEGAL MATTERS

Cleary Gottlieb Steen & Hamilton LLP, New York, New York will pass upon the legality of the shares of common stock to be issued in this offering. Certain legal matters will be passed upon for the underwriters by Simpson Thacher & Bartlett LLP, New York, New York.

EXPERTS

The consolidated financial statements and schedules of Sotera Health Company (formerly known as Sotera Health Topco, Inc.) as of December 31, 2019 and 2018, and for each of the years then ended, appearing in this prospectus and the registration statement of which this prospectus is a part, have been audited by Ernst & Young LLP, independent registered public accounting firm, as set forth in their report thereon appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing.

 

189


Table of Contents

WHERE YOU CAN FIND MORE INFORMATION

We have filed with the SEC a registration statement on Form S-1 under the Securities Act, with respect to our common stock offered by this prospectus. This prospectus, which forms part of the registration statement, does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. Some items are omitted in accordance with the rules and regulations of the SEC. For further information about us and our common stock, we refer you to the registration statement and the exhibits to the registration statement filed as part of the registration statement. The SEC maintains an Internet site at www.sec.gov, from which you can electronically access the registration statement, including the exhibits to the registration statement.

As a result of this offering, we will become subject to the full informational requirements of the Exchange Act. We will fulfill our obligations with respect to such requirements by filing periodic reports and other information with the SEC. We intend to furnish our stockholders with annual reports containing financial statements that have been examined and reported on, with an opinion expressed by an independent registered public accounting firm. We also maintain an Internet site at http://www.soterahealth.com. Our website is not a part of this prospectus.

 

190


Table of Contents

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

 

Audited Consolidated Financial Statements of Sotera Health Company

  

Report of Independent Registered Public Accounting Firm

     F-2  

Consolidated Balance Sheets as of December 31, 2019 and December  31, 2018

     F-3  

Consolidated Statements of Operations and Comprehensive Income (Loss) for the years ended December 31, 2019 and December 31, 2018

     F-4  

Consolidated Statements of Cash Flows for the years ended December  31, 2019 and December 31, 2018

     F-5  

Consolidated Statements of Equity (Deficit) for the years ended December 31, 2019 and December 31, 2018

     F-6  

Notes to Consolidated Financial Statements

     F-7  

Schedule I – Condensed Financial Information of the Registrant

     F-52  

Condensed Balance Sheets as of December 31, 2019 and December  31, 2018

     F-52  

Condensed Statements of Operations and Comprehensive Loss for the years ended December 31, 2019 and December 31, 2018

     F-53  

Condensed Statements of Cash Flows for the years ended December  31, 2019 and December 31, 2018

     F-54  

Notes to Condensed Financial Information

     F-55  

Schedule II – Valuation and Qualifying Accounts

     F-57  

Unaudited Consolidated Financial Statements of Sotera Health Company

  

Consolidated Balance Sheets as of September  30, 2020 (Unaudited) and December 31, 2019

     F-58  

Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) for the nine months ended September 30, 2020 and 2019

     F-60  

Consolidated Statements of Cash Flows (Unaudited) for the nine months ended September 30, 2020 and 2019

     F-62  

Consolidated Statements of Equity (Unaudited) for the nine months ended September 30, 2020 and 2019

     F-63  

Notes to Consolidated Financial Statements (Unaudited)

     F-64  

 

F-1


Table of Contents

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Shareholders and the Board of Directors of Sotera Health Company (formerly known as Sotera Health Topco, Inc.)

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Sotera Health Company (the Company) as of December 31, 2019 and 2018, the related consolidated statements of operations and comprehensive income (loss), equity (deficit) and cash flows for the years then ended, and the related notes and schedules (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2019 and 2018, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ Ernst & Young LLP

We have served as the Company’s auditor since 2019.

Akron, Ohio

September 2, 2020, except as to Note 21, as to which the date is November 18, 2020.

 

F-2


Table of Contents

Sotera Health Company

Consolidated Balance Sheets

(in thousands)

 

     As of  
     December 31,     December 31,  
     2019     2018  

Assets

    

Current assets:

    

Cash and cash equivalents

   $ 62,863     $ 96,272  

Restricted cash short-term

     162       514  

Accounts receivable, net of allowance for uncollectible accounts of $787 in 2019 and $928 in 2018

     88,644       100,010  

Inventories, net

     37,396       37,599  

Prepaid expenses and other current assets

     52,644       57,359  

Income taxes receivable

     10,645       17,840  

Assets held for sale

     —         3,268  
  

 

 

   

 

 

 

Total current assets

     252,354       312,862  

Property, plant, and equipment, net

     581,954       586,436  

Deferred income taxes

     2,252       15,764  

Other assets

     12,243       4,154  

Other intangible assets, net

     696,006       766,054  

Goodwill

     1,035,865       1,023,314  
  

 

 

   

 

 

 

Total assets

   $ 2,580,674     $ 2,708,584  
  

 

 

   

 

 

 

Liabilities and equity

    

Current liabilities:

    

Accounts payable

   $ 42,004     $ 46,355  

Accrued liabilities

     58,536       75,709  

Deferred revenue

     3,631       4,615  

Current portion of long-term debt

     16,331       15,343  

Current portion of capital lease obligations

     1,288       1,352  

Current portion of asset retirement obligations

     2,200       —    
  

 

 

   

 

 

 

Total current liabilities

     123,990       143,374  

Long-term debt, less current portion

     2,800,873       2,189,563  

Capital lease obligations, less current portion

     29,883       31,535  

Noncurrent asset retirement obligations

     42,996       40,543  

Deferred lease income

     21,375       20,955  

Post-retirement obligations

     31,266       19,411  

Mandatorily redeemable noncontrolling interest

     13,625       13,625  

Noncurrent liabilities

     20,563       32,605  

Deferred income taxes

     137,235       171,482  
  

 

 

   

 

 

 

Total liabilities

     3,221,806       2,663,093  

See Commitments and contingencies note

    

Equity:

    

Common stock, with $0.01 par value, 232,400 shares authorized, 232,400 shares issued and outstanding at December 31, 2019, and December 31, 2018

     2,324       2,324  

Additional paid-in capital

     —         162,409  

Retained earnings (deficit)

     (550,511     (10,417

Accumulated other comprehensive loss

     (94,387     (109,957
  

 

 

   

 

 

 

Total equity (deficit) attributable to Sotera Health Company

     (642,574     44,359  

Noncontrolling interests

     1,442       1,132  
  

 

 

   

 

 

 

Total equity (deficit)

     (641,132     45,491  
  

 

 

   

 

 

 

Total liabilities and equity (deficit)

   $ 2,580,674     $ 2,708,584  
  

 

 

   

 

 

 

Share amounts and per share data give retroactive effect to the forward stock split as described in the Subsequent Events footnote effective November 18, 2020.

See notes to consolidated financial statements.

 

F-3


Table of Contents

Sotera Health Company

Consolidated Statements of Operations and Comprehensive Income (Loss)

(in thousands, except per share amounts)

 

    Year Ended  
    December 31,     December 31,  
    2019     2018  

Revenues:

   

Service

  $  673,037     $  615,510  

Product

    105,290       130,639  
 

 

 

   

 

 

 

Total net revenues

    778,327       746,149  

Cost of revenues:

   

Service

    333,290       326,559  

Product

    49,606       62,338  
 

 

 

   

 

 

 

Total cost of revenues

    382,896       388,897  
 

 

 

   

 

 

 

Gross profit

    395,431       357,252  

Operating expenses:

   

Selling, general and administrative expenses

    147,480       133,363  

Amortization of intangible assets

    58,562       57,975  

Impairment of long-lived assets

    5,792       34,981  

Impairment of GA-MURR intangible assets

    —         50,086  
 

 

 

   

 

 

 

Total operating expenses

    211,834       276,405  
 

 

 

   

 

 

 

Operating income

    183,597       80,847  

Interest expense, net

    157,729       143,326  

Loss on extinguishment of debt

    30,168       —    

Foreign exchange loss

    3,862       13,075  

Gain on sale of Medical Isotopes business

    —         (95,910

Other income, net

    (7,246     (3,866
 

 

 

   

 

 

 

Income (loss) before income taxes

    (916     24,222  

Provision for income taxes

    19,509       30,098  
 

 

 

   

 

 

 

Net loss

    (20,425     (5,876

Less: Net income (loss) attributable to noncontrolling interests

    425       (6
 

 

 

   

 

 

 

Net loss attributable to Sotera Health Company

  $ (20,850   $ (5,870
 

 

 

   

 

 

 

Other comprehensive (loss) income net of tax:

   

Pension and post-retirement benefits (net of taxes of ($4,085) and $294, respectively)

  $ (12,126   $ 873  

Interest rate swaps (net of taxes of $63 and $0, respectively)

    179       —    

Foreign currency translation

    27,402       (67,917
 

 

 

   

 

 

 

Comprehensive income (loss)

    (4,970     (72,920

Less: comprehensive income (loss) attributable to noncontrolling interests

    310       (186
 

 

 

   

 

 

 

Comprehensive loss attributable to Sotera Health

   

Company

  $ (5,280   $ (72,734
 

 

 

   

 

 

 

Loss per share attributable to Sotera Health Company

   

Basic and diluted

  $ (0.09   $ (0.03)  

Pro forma basic and diluted (unaudited)

    (0.08                   

Weighted average number of shares outstanding attributable to Sotera Health Company

   

Basic and diluted

    232,400       232,400  

Pro forma basic and diluted (unaudited)

    246,152                     

Share amounts and per share data give retroactive effect to the forward stock split as described in the Subsequent Events footnote effective November 18, 2020.

See notes to consolidated financial statements.

 

F-4


Table of Contents

Sotera Health Company

Consolidated Statements of Cash Flows

(in thousands)

 

     Year Ended  
     December 31,     December 31,  
     2019     2018  

Operating activities

    

Net loss

     $ (20,425)       $ (5,876)  

Adjustments to reconcile net loss to net cash provided by operating activities:

    

Depreciation

     66,671       66,910  

Amortization of intangible assets

     80,048       79,906  

Impairment of long-lived assets

     5,792       34,981  

Impairment of GA-MURR intangible assets

     —         50,086  

Loss on extinguishment of debt

     30,168       —    

Deferred income taxes

     (18,993     (45,317

Share-based non-cash compensation expense

     6,882       6,943  

Accretion of asset retirement obligations

     2,051       1,330  

Unrealized foreign exchange (gains) / losses

     3,325       13,460  

(Gain)/loss on embedded derivative instruments

     (1,200     1,019  

Amortization of debt issuance costs

     8,291       7,270  

Gain on sale of Medical Isotopes business

     —         (95,910

Other

     (5,218     726  

Changes in operating assets and liabilities:

    

Accounts receivable

     11,764       (2,906

Inventories

     (282     (7,041

Other current assets

     15,322       2,500  

Accounts payable

     (8,968     15,125  

Accrued liabilities

     (18,405     (6,935

Income taxes payable/receivable

     (7,771     4,724  

Other liabilities

     724       (2,627

Other long-term assets

     (735     1,195  
  

 

 

   

 

 

 

Net cash provided by operating activities

     149,041       119,563  

Investing activities

    

Purchases of property, plant and equipment

     (57,257     (72,613

Purchase of Gibraltar Laboratories, net of cash acquired

     —         (50,603

Purchase of Nelson Labs NV, net of cash acquired

     —         432  

Proceeds from sale of the Medical Isotopes business

     —         212,993  

Other

     —         6,429  
  

 

 

   

 

 

 

Net cash provided by (used in) investing activities

     (57,257     96,638  

Financing activities

    

Proceeds from borrowings

     3,144,600       —    

Payments of debt issuance costs and prepayment premium

     (17,034     —    

Dividends and distributions to shareholders

     (691,170     (175,845

Payments on debt

     (2,561,084     (14,634

Other

     (1,342     (1,378
  

 

 

   

 

 

 

Net cash used in financing activities

     (126,030     (191,857

Effect of exchange rate changes on cash and cash equivalents

     485       (3,676
  

 

 

   

 

 

 

Net increase (decrease) in cash and cash equivalents, including restricted cash

     (33,761     20,668  

Cash and cash equivalents, including restricted cash, at beginning of period

     96,786       76,118  
  

 

 

   

 

 

 

Cash and cash equivalents, including restricted cash, at end of period

   $ 63,025     $ 96,786  
  

 

 

   

 

 

 

Supplemental disclosures of cash flow information

    

Cash paid during the period for interest

   $ 151,005     $ 138,850  

Cash paid during the period for income taxes, net of tax refunds received

     44,614       68,610  

Property and equipment acquired under capital leases

     1,337       617  

Equipment purchases included in accounts payable

     5,197       3,487  

See notes to consolidated financial statements.    

 

F-5


Table of Contents

Sotera Health Company

Consolidated Statements of Equity (Deficit)

(in thousands)

 

                Additional
Paid-In
Capital
    Retained
Earnings /
(Accumulated
Deficit)
    Accumulated
Other
Comprehensive
(Loss) Income
    Noncontrolling
Interests
    Total
Equity
 
    Shares     Amount  
    Common     Common  
    Stock     Stock  

Balance at January 1, 2018

    232,400     $ 2,324     $ 304,286     $ 22,630       $(43,093     $1,318     $ 287,465  

Dividends and distributions to shareholders

    —         —         (148,668     (27,177     —         —         (175,845

Purchase of noncontrolling interests in Sterigenics Belgium Fleurus, S.A.

    —         —         (152     —         —         —         (152

Non-cash share-based compensation

    —         —         6,943       —         —         —         6,943  

Comprehensive income (loss):

             

Pension and post-retirement plan adjustments, net of tax

    —         —         —         —         873       —         873  

Foreign currency translation

    —         —         —         —         (67,737     (180     (67,917

Net income (loss)

    —         —         —         (5,870     —         (6     (5,876
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Balance at December 31, 2018

    232,400       2,324       162,409       (10,417     (109,957     1,132       45,491  

Cumulative-effect adjustment upon adoption of ASU 2014-09 (Note 2)

    —         —         —         2,635       —         —         2,635  

Dividends and distributions to shareholders

    —         —         (169,291     (521,879     —         —         (691,170

Non-cash share-based compensation

    —         —         6,882       —         —         —         6,882  

Comprehensive income (loss):

             

Pension and post-retirement plan adjustments, net of tax

    —         —         —         —         (12,126     —         (12,126

Foreign currency translation

    —         —         —         —         27,517       (115     27,402  

Interest rate swaps

    —         —         —         —         179       —         179  

Net income (loss)

    —         —         —         (20,850     —         425       (20,425
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Balance at December 31, 2019

    232,400     $ 2,324     $ —       $ (550,511   $ (94,387   $ 1,442     $ (641,132
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Share amounts and per share data give retroactive effect to the forward stock split as described in the Subsequent Events footnote effective November 18, 2020.

See notes to consolidated financial statements.    

 

F-6


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

1. Significant Accounting Policies

Principles of Consolidation – Sotera Health Company (formerly known as Sotera Health Topco, Inc.) (also referred to herein as the “Company,” “we,” “our,” “us” or “its”), is a fully integrated provider of mission-critical health sciences, lab services and sterilization solutions with operations primarily in the Americas, Europe and Asia.

The accompanying consolidated financial statements include the assets, liabilities, operating results, and cash flows of the Company and its wholly owned subsidiaries prepared in accordance with U.S. generally accepted accounting principles (“GAAP”).

We operate and report in three segments, Sterigenics, Nordion and Nelson Labs. We describe our reportable segments in the Segment and Geographic Information note. All significant intercompany balances and transactions have been eliminated in consolidation.

Noncontrolling interests represents the noncontrolling stockholders’ proportionate share of the total equity in the Company’s consolidated subsidiaries. On February 28, 2018, we purchased the remaining 3.8% of equity in Sterigenics Belgium Fleurus, S.A. from noncontrolling stockholders for $0.3 million. As of December 31, 2019, our subsidiaries were wholly owned by us, except for noncontrolling interests of 15% and 33% in our two China subsidiaries. In addition, a 15% noncontrolling interest remains from the August 2018 acquisition of Gibraltar Laboratories, Inc. (now known as Nelson Laboratories Fairfield, Inc.). See the Acquisitions and Dispositions note for additional details. We consolidate the results of operations of these subsidiaries with our results of operations and reflect the noncontrolling interests in our two China subsidiaries on our consolidated statements of operations and comprehensive income (loss) as “Net income (loss) attributable to noncontrolling interests.” Our required future purchase of 15% noncontrolling interest in Gibraltar Laboratories, Inc., is considered mandatorily redeemable, and therefore no earnings are allocated to this noncontrolling interest.

Use of Estimates – In preparing our consolidated financial statements in conformity with GAAP, we make estimates and assumptions that affect the amounts reported and the accompanying notes. We regularly evaluate the estimates and assumptions used and revise them as new information becomes available. Actual results may vary from those estimates.

Cash and Cash Equivalents – We consider all highly liquid investments purchased with an original maturity of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents may include various deposit accounts and money market funds.

Allowance for Uncollectible Accounts Receivable – We maintain an allowance for uncollectible accounts receivable for estimated losses in the collection of amounts owed to us by customers. We estimate the allowance based on analyzing a number of factors, including amounts written off historically, customer payment practices, and general economic conditions. We also analyze significant customer accounts on a regular basis and record a specific allowance when we become aware of a specific customer’s inability to pay, and generally require no collateral from our customers. We generally do not charge interest on accounts receivable. We record write-offs against the allowance for uncollectible accounts receivable when all reasonable efforts for collection have been exhausted. As a result, the related accounts receivable are reduced to an amount that we reasonably believe is collectible. These analyses require judgment. If the financial condition of our customers worsens, or economic conditions change, we may be required to make changes to our allowance for uncollectible accounts receivable.

Inventories – Inventories as of December 31, 2019 and 2018 are held at Nordion. Finished goods and work-in-process include the cost of material, labor, and certain manufacturing overhead such as insurance,

 

F-7


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

repairs and maintenance, and property taxes, and are recorded on a weighted average cost basis at the lower of cost or net realizable value. We review inventory on an ongoing basis, considering factors such as deterioration and obsolescence. We record a reserve for excess and obsolete inventory, which was immaterial at December 31, 2019 and 2018, when the facts and circumstances indicate that particular inventories will not be usable. If future market conditions vary from those projected, and our estimates prove to be inaccurate, we may be required to write-down inventory values and record an adjustment to cost of revenues.

Property, Plant, and Equipment – Property, plant, and equipment is carried at cost, or initially at fair value if acquired in an acquisition, less accumulated depreciation and amortization. Except for Cobalt 60 (“Co-60”), a radioactive isotope used in gamma radiation sterilization, all property, plant, and equipment depreciation is computed using the straight-line method over estimated useful lives. Leasehold improvements are amortized over their estimated useful lives or the term of the related lease, whichever is shorter. Co-60 is amortized using an accelerated method, which relates to the natural radioactive decay of the isotope over its estimated useful life which is approximately twenty years. Amortization of Co-60 is included within depreciation expense as a cost of revenue. Expenditures for major software purchases and software developed for internal use are capitalized and depreciated using the straight-line method over the estimated useful lives of the related assets, which are generally three to five years. For software obtained or developed for internal use, all external direct costs for materials and services and certain personnel costs incurred to develop the software during the application development stage are capitalized. At December 31, 2019 and 2018, we had undepreciated software costs of $4.7 million and $5.2 million, respectively, included in property, plant, and equipment, net. We recognized $3.0 million and $3.3 million, of depreciation expense related to software costs for the years ending December 31, 2019 and 2018, respectively.

Depreciation is computed using the assets’ estimated useful lives as presented below:

 

Buildings and building improvements

     15–44 years  

Machinery and equipment

     3–30 years  

Leasehold improvements

     2–20 years  

Furniture and fixtures

     3–10 years  

Computer hardware and software

     2–7 years  

From time to time, we build or expand facilities. The cost of construction of these facilities is reflected as construction-in-progress until the asset is ready for its intended use, at which time the costs are reclassified to the appropriate depreciable category of property, plant, and equipment and depreciation commences. Fixed asset projects requiring one or more years to complete construction qualify for capitalization of interest costs in accordance with our policy. Interest related to property, plant and equipment projects with a construction period of less than one year are not capitalized and are immaterial. Repairs and maintenance costs that do not extend the useful life of an asset are expensed as incurred.

Upon sale or retirement of assets, the cost and related accumulated depreciation is removed from the consolidated balance sheet, and the resulting gain or loss is reflected as a component of operating income.

Long-Lived Assets Other than Goodwill – We review long-lived assets, including finite-lived intangibles for impairment whenever events or circumstances indicate that the carrying amount of the asset or asset group may be impaired. Events or circumstances which would result in an impairment assessment include operating losses, a significant change in the use of an asset or asset group, or the planned disposal or sale of the asset or asset group. The asset or asset group would be considered impaired when the future net undiscounted cash flows generated by the asset or asset group are less than its carrying value. An impairment loss would be recognized based on the amount by which the carrying value of the asset or asset group exceeds its estimated fair value.

 

F-8


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

Amortization of intangible assets is computed using the asset’s estimated useful lives as presented below:

 

Land-use rights

     50 years  

Customer contracts and related relationships

     10–15 years  

Proprietary technology

     8–20 years  

Trade name/trademark

     10–15 years  

Sealed source and supply agreements

     7–20 years  

Goodwill and Other Indefinite-Lived Intangibles – Goodwill and other indefinite-lived intangible assets, primarily certain regulatory licenses and tradenames, are tested for impairment annually as of October 1. If circumstances change during interim periods between annual tests that would indicate that the carrying amount of such assets may not be recoverable, the Company would test such assets at an interim date for impairment. Factors which would necessitate an interim impairment assessment include prolonged negative industry or economic trends and significant underperformance relative to historical or projected future operating results.

We performed a quantitative assessment of all reporting units (Sterigenics, Nordion and Nelson Labs) as of October 1, 2019. The fair value of each reporting unit was calculated using a discounted cash flow analysis which was dependent on subjective market participant assumptions determined by management. We further corroborated such discounted cash flow analyses utilizing a market approach to determine the estimated enterprise fair value. Assumptions used in the analyses included discount rates and projected operating cash flows. Estimates of future cash flows are based upon relevant data at a point-in-time, are subject to change, and could vary from actual results. The estimated fair value of each reporting unit exceeded its carrying amount (including goodwill) by a minimum of 60% as of October 1, 2019. We performed a qualitative impairment assessment to evaluate any potential impairment to the indefinite-lived intangible assets. We considered significant events and circumstances that could affect the significant inputs used to determine the estimated fair value of the indefinite-lived intangible assets, and determined, after considering the totality of evidence that it is not more likely than not that the indefinite-lived intangible assets are impaired. In addition, there have been no significant events or circumstances that occurred since the annual assessment date of October 1 that would change the conclusions reached above.

Derivative Instruments – We may enter into derivative instruments and hedging activities to manage, where possible and economically efficient, commodity price risk, foreign currency exchange rate risk and interest rate risk related to borrowings. We also have identified embedded derivatives in certain supply and customer contracts. Certain interest rate swaps were designated as cash flow hedges allowing for changes in fair value to be recorded through comprehensive income (loss). Amounts in accumulated other comprehensive income (loss) will be reclassified into earnings in the same periods during which the hedged transaction affects earnings and are presented in “Interest expense, net” within the consolidated statements of operations and comprehensive income (loss). With the exception of aforementioned interest rate swaps, we currently do not designate any other contracts as hedges for accounting purposes. Derivatives not designated as hedges are recorded at fair value on the consolidated balance sheets, with any changes in the value being recorded in the consolidated statements of operations and comprehensive income (loss) in the same line item as the corresponding hedged item. We classify cash flows from derivative instruments and hedging activities as cash flows from operating activities in the consolidated statements of cash flows. To the extent derivative arrangements are with the same counterparty and contractual right of offset exists under applicable master agreements, we offset assets and liabilities for reporting on the consolidated balance sheets.

Pension, Post-Retirement and Other Post-Employment Benefit Plans – We sponsor a defined-contribution retirement plan that covers substantially all U.S. employees. We also sponsor various post-employment benefit plans at our Nordion business in Canada including defined benefit and defined contribution pension plans, retirement compensation arrangements and plans that provide extended health care coverage to retired

 

F-9


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

employees. In addition, we provide other benefit plans at our foreign subsidiaries including a supplemental retirement arrangement, a retirement and termination allowance and post-retirement benefit plans, which include contributory healthcare benefits and contributory life insurance coverage. All non-pension post-employment benefit plans are unfunded.

These costs and obligations are affected by assumptions including the discount rate, expected long-term rate of return on plan assets, the annual rate of change in compensation for eligible employees, estimated changes in costs of healthcare benefits, and other demographic and economic factors. We review the assumptions used on an annual basis.

We recognize the over/under funded status of defined benefit pension and post-retirement benefits plans in our consolidated balance sheets. This amount is measured as the difference between the fair value of plan assets and the projected benefit obligation. Changes in the funded status of the plans are recorded in other comprehensive income (loss) in the year they occur. We measure plan assets and obligations as of the balance sheet date. We provide additional information about our pension and other post-retirement benefits plans in the Employee Benefits note.

Asset Retirement Obligations (“ARO”) – ARO are legal obligations associated with the retirement of long-lived assets or the exit of a leased facility. We recognize a liability for an ARO in the period in which it is incurred if a reasonable estimate of fair value can be made, and the associated asset retirement costs are then capitalized as part of the carrying amount of the long-lived asset. We lease various facilities where sterilization and ionization services are performed. Under the lease agreements, we are required to return the facilities to their original condition and to perform decommissioning activities. In addition, certain of our owned facilities are required to be decommissioned when we vacate the facility. Accretion expense is recognized in cost of revenues in the consolidated statements of operations and comprehensive income (loss) over time as the discounted liability is accreted to its expected settlement value.

Deferred Financing Costs – We have incurred deferred financing fees associated with our long-term debt. The portion of these fees that are capitalized are recorded as a reduction of debt on the consolidated balance sheets and amortized into interest expense over the term of the debt agreement using the effective interest method. Deferred financing costs associated with the Company’s revolving credit facilities are classified as assets unless there are outstanding borrowings under such arrangements.

Concentration of Credit Risk, Other Risks and Uncertainties – We maintain cash and cash equivalents in the form of demand deposits in accounts with major financial institutions in the U.S. and in countries where our subsidiaries operate. Deposits in these institutions may exceed amounts of insurance provided on such accounts. We have not experienced any losses on our deposits of cash and cash equivalents.

Our net revenues and accounts receivable are derived from customers located primarily in North America and Europe.

No customer accounted for 10% or more of accounts receivable at December 31, 2019 and 2018, or 10% or more of net revenues for the years ended December 31, 2019 and 2018.

Income Taxes –We use the liability method of accounting for income taxes whereby we recognize deferred tax assets and liabilities for the future tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements. Deferred tax assets will be reduced by a valuation allowance if, based on management’s estimate, it is more likely than not that a portion of the deferred tax assets will not be realized in a future period. The estimates used in the recognition of deferred tax assets are subject to revision in future periods based on new facts and circumstances.

 

F-10


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

We determine whether it is more likely than not that a tax position will be sustained upon examination, including resolution of related appeals or litigation processes, based on the technical merits of the position. In evaluating whether a tax position has met the more-likely-than-not recognition threshold, we presume that the position will be examined by the appropriate taxing authority and that the taxing authority will have full knowledge of all relevant information. A tax position that meets the more-likely-than-not recognition threshold is measured at the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. Determining what constitutes an individual tax position and whether the more-likely-than-not recognition threshold is met for a tax position are matters of judgment based on the individual facts and circumstances of that position evaluated in light of all available evidence. We review and adjust tax estimates periodically because of ongoing examinations by, and settlements with, the various taxing authorities, as well as changes in tax laws, regulations, and precedent.

Our policy is to recognize interest and penalties related to income tax matters as a component of the provision for income taxes in our consolidated statements of operations and comprehensive income (loss).

Foreign Currency Translation – The functional currency of our foreign subsidiaries is generally the local currency. Accordingly, assets and liabilities are generally translated into U.S. dollars at the current rates of exchange as of the balance sheet date, and revenues and expenses are translated using weighted-average rates prevailing during the period. Adjustments from foreign currency translation are included as a separate component of accumulated other comprehensive income (loss). The foreign exchange loss in our consolidated statements of operations and comprehensive income (loss) relates primarily to U.S. denominated intercompany indebtedness in certain of our European and Canadian subsidiaries.

Revenue Recognition – The majority of our sales agreements contain performance obligations satisfied at a point-in-time when control of promised goods or services have transferred to our customers. For agreements with multiple performance obligations, judgment is required to determine whether performance obligations specified in these agreements are distinct and should be accounted for as separate revenue transactions for recognition purposes. In these types of agreements, we generally allocate the sales price to each distinct obligation based on the relative price of each item sold in stand-alone transactions. Sales recognized over time are generally accounted for using an input measure to determine progress completed as of the end of the period.

Refunds, returns, warranties and other related obligations are not material to any of our segments, nor do we incur material incremental costs to secure customer contracts.

Our Sterigenics segment provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets. We typically have multiyear service contracts with our significant customers, and these sales contracts are primarily based on a customer’s purchase order. Given the relatively short turnaround times, performance obligations are generally satisfied at a point-in-time upon the completion of sterilization or irradiation processing once approved by our quality assurance process at which time the service is complete. Sterigenics segment revenues are included in service revenues in our consolidated statements of operations and comprehensive income (loss).

Our Nordion segment is a global provider of Co-60 and gamma irradiators, which are key components to the gamma sterilization process. Revenue from the sale of Co-60 sources is recognized as product revenue at a point-in-time upon satisfaction of our performance obligations for delivery of existing sources. Revenue from the production of equipment is recognized as product revenue over time using an input measure of costs incurred and is immaterial to the overall business. Revenues from Co-60 installation and disposal and production irradiator refurbishments and installations are recognized as service revenue.

 

F-11


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

Our Nelson Labs segment provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. We provide our customers mission-critical lab testing services, which assess the product quality, effectiveness, patient safety and end-to-end sterility of products. These services are necessary for our customers’ regulatory approvals, product releases and ongoing product performance evaluations. Nelson Labs services are generally provided on a fee-for-service or project basis, and we recognize revenues over time using an input measure of time incurred to determine progress completed at the end of the period. Nelson Labs segment revenues are included in service revenues in our consolidated statements of operations and comprehensive income (loss).

We do not capitalize sales commissions as substantially all of our sales commission programs have an amortization period of one year or less. Furthermore, costs to fulfill a contract are not material.

Provisions for discounts, rebates to customers, and other adjustments are provided for as reductions in net revenues in the period the related sale is recorded. Shipping and handling charges billed to customers are included in net revenues, and the related shipping and handling costs are included in cost of net revenues on the consolidated statements of operations and comprehensive income (loss). Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by us from a customer, are excluded from net revenue.

Payment terms vary by the type and location of the customer and the products or services offered. Generally, the time between when revenue is recognized and when payment is due is not significant. We do not evaluate whether the selling price contains a financing component for contracts that have a duration of less than one year.

On January 1, 2019, the Company adopted accounting standard update (“ASU”) 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), as further described in the Recent Accounting Standards note. Prior to its adoption, revenue was recognized upon the completion of sterilization or irradiation processing once approved by our quality assurance process at which time the service was considered complete. Product revenue from the sale of Co-60 was recognized upon delivery, whereas related service revenue from installation and disposal services was recognized when services were completed. Nelson Labs services were recognized upon finalization of each test, typically evidenced with the shipment of a technical laboratory report.

Share-Based Compensation – Equity-based awards issued to employees include restricted unit awards, which vest based on either time or the achievement of certain performance and market conditions (“performance awards”). These equity-based awards represent an interest in our parent, Sotera Health Topco Parent, L.P., and are granted in respect of services provided to the Company and its subsidiaries. Compensation expense resulting from time vesting based awards is recognized in the consolidated statements of operations and comprehensive income (loss), primarily within general and administrative expenses at the grant date fair value over the requisite service period (typically five years on a straight-line basis for time vested awards). Compensation expense resulting from awards that vest upon satisfaction of a performance condition is recognized at grant date fair value when the performance condition is deemed probable, which may cause volatility in the timing of expense recognition. The calculated compensation expense for performance awards is adjusted based on an estimate of awards ultimately expected to vest. For awards with market conditions, the market condition is taken into account when calculating grant date fair value.

The fair value of performance based restricted unit awards is estimated using a simulation-based option valuation model incorporating multiple and variable assumptions over time, including assumptions such as unit price volatility, dividend and other assumptions.

 

F-12


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

Earnings (Loss) Per Share – Basic earnings (loss) per common share is computed by dividing net loss attributable to Sotera Health Company by the weighted average number of common shares outstanding during the period. Diluted income (loss) per common share incorporates the dilutive effect of common stock equivalents on an average basis during the period. For the periods presented, there were no dilutive effects of common stock equivalents.

Commitments and Contingencies – Certain conditions may exist as of the date of the consolidated financial statements which may result in a loss to the Company but will only be resolved when one or more future events occur or fail to occur. Such liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources, are recorded when management assesses that it is probable that a future liability has been incurred and the amount can be reasonably estimated. Recoveries of costs from third parties, which management assesses as being probable of realization, are recorded to the extent related contingent liabilities are accrued. Legal costs incurred in connection with matters relating to contingencies are expensed in the period incurred. We record gain contingencies when realized.

2. Recent Accounting Standards

Adoption of Accounting Standard Updates

Effective January 1, 2019, we adopted ASU 2014-09, Revenue from Contracts with Customers, and all related amendments, with new guidance on recognizing revenue from contracts with customers. Under this guidance, revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 also requires expanded disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. The new guidance primarily affects the Nelson Labs segment.

We applied the new guidance to all contracts that were not yet completed at the date of adoption using the modified retrospective method. We recognized the cumulative effect of initially applying the new guidance as an adjustment to the opening balance of retained earnings (deficit). Comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods.

The adjustments made to our January 1, 2019 consolidated balance sheet for the adoption of the standards update were as follows:

 

(thousands of U.S. dollars)

   Balance at
December 31,
2018
    Adjustments for
New Standard
     Balance at
January 1, 2019
 

Prepaid expenses and other current assets

   $ 57,359     $ 3,613      $ 60,972  

Deferred income taxes

     171,482       978        172,460  

Retained earnings (deficit)

     (10,417     2,635        (7,782

The impact of the adoption of the new revenue requirements on our consolidated statement of operations and comprehensive income (loss) for the year ended December 31, 2019 was an increase of $1.0 million to net revenues and a benefit of $0.8 million to net loss.

 

F-13


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

The impact of adoption of the new revenue requirements on our consolidated balance sheet as of December 31, 2019 was as follows:

 

(thousands of U.S. dollars)

   As Reported     Less Effect of
Adoption
    Balance without
Adoption
 

Prepaid expenses and other current assets

   $ 52,644     $ 4,622     $ 48,022  

Income tax receivable

     10,645       (1,204     11,849  

Deferred income taxes

     137,235       (37     137,198  

Retained earnings (deficit)

     (548,187     (3,381     (551,568

Accounting Standard Updates Issued But Not Yet Adopted

Under the Jumpstart Our Business Startups Act of 2012, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. As an emerging growth company, we have elected to take advantage of the extended transition period for complying with new or revised accounting standards until those standards would otherwise apply to private companies or at which time we conclude it is appropriate to avail ourselves of early adoption provisions of applicable standards. As a result, our results of operations and financial statements may not be comparable to the results of operations and financial statements of other companies who have adopted the new or revised accounting standards.

In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-02, Leases (“Topic 842”). The updated standard requires substantially all leases to be reported on the balance sheet as right-of-use assets and lease obligations. Topic 842 is effective for private companies for annual periods beginning after December 15, 2021. Early adoption is permitted. Topic 842 permits a modified retrospective transition method with the option to elect a package of practical expedients. We elected to early adopt the new standard as of January 1, 2020 resulting in the recognition of right-of-use assets and lease liabilities of $47.4 million and $48.9 million, respectively. The standard did not have a material impact on our consolidated statements of operations and comprehensive income (loss) or on our consolidated statements of cash flows. The level of disclosures related to leases will increase and require changes to our internal controls to support recognition and disclosure requirements under Topic 842.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (“ASU 2016-13”): Measurement of Credit Losses on Financial Instruments, and subsequently issued additional guidance that modified ASU 2016-13. The standard requires an entity to change its accounting approach in determining impairment of certain financial instruments, including trade receivables, from an “incurred loss” to a “current expected credit loss” model. The standard will be effective for private companies for fiscal years beginning after December 15, 2022, including interim periods within such fiscal years. Early adoption is permitted. We are currently assessing the effect that ASU 2016-13 will have on our financial position, results of operations, and disclosures.

In December 2019, the FASB issued ASU 2019-12 - Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The standard simplifies the accounting for income taxes and makes a number of changes meant to add or clarify guidance on accounting for income taxes. This update is effective for annual financial statement periods beginning after December 15, 2021 and interim periods beginning after December 15, 2022, with early adoption permitted in any interim period for which financial statements have not yet been filed. We are currently assessing the effect that ASU 2019-12 will have on our financial position, results of operations, and disclosures.

 

F-14


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

3. Revenue Recognition

The following table shows disaggregated net revenues from contracts with external customers by timing of revenue and by segment for the year ended December 31, 2019:

 

     Sterigenics      Nordion      Nelson Labs      Consolidated  

Point in time

   $ 471,708      $ 116,165      $ —        $ 587,873  

Over time

     —          —          190,454        190,454  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 471,708      $ 116,165      $ 190,454      $ 778,327  
  

 

 

    

 

 

    

 

 

    

 

 

 

Contract Balances

As of December 31, 2019, and January 1, 2019, contract assets included in prepaid expenses and other current assets on the consolidated balance sheet totaled approximately $8.5 million and $8.4 million, respectively, resulting from revenue recognized over time in excess of the amount billed to the customer.

When we receive consideration from a customer prior to transferring goods or services under the terms of a sales contract, we record deferred revenue, which represents a contract liability. Deferred revenue totaled $3.6 million and $4.6 million at December 31, 2019 and 2018, respectively. We recognize deferred revenue after we have transferred control of the goods or services to the customer and all revenue recognition criteria are met.

4. Acquisitions and Dispositions

Acquisition of Gibraltar Laboratories (now known as Nelson Laboratories Fairfield, Inc.)

On August 7, 2018, we acquired 85% of the outstanding shares of Gibraltar Laboratories, Inc. (“Gibraltar”) for $50.6 million, net of cash acquired of $0.5 million. Pursuant to the transaction agreement, we are required to acquire the 15% noncontrolling interest within three years from the date of acquisition. As a result of our requirement to purchase the noncontrolling interest in the future, it represents a mandatorily redeemable financial instrument and the related liability was initially recorded at its estimated fair value of $13.6 million. Subsequent changes in fair value have been immaterial. Based on the mandatory nature of the obligation, no earnings are allocated to the noncontrolling interest.

Gibraltar’s operations are in the New Jersey tri-state area, home to many of the top pharmaceutical manufacturers in the U.S., and it provides microbiological and analytical chemistry testing for pharmaceutical and medical device manufacturers. We acquired Gibraltar primarily for its expertise and customer relationships in testing and servicing the pharmaceutical industry. Additionally, its analytical testing capabilities expanded our presence in the Northeast region of the U.S. and enhanced Nelson Labs’ existing strengths in medical device microbiology and expert advisory services.

The opening balance sheet for the Gibraltar acquisition reflects the net tangible and intangible assets acquired and liabilities assumed at their estimated fair values at the acquisition date.

 

F-15


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

The fair value of the underlying acquired assets and assumed liabilities at August 7, 2018, the date of the Gibraltar acquisition, was as follows:

 

(thousands of U.S. dollars)

Allocation of purchase price to the fair

value of net assets acquired (net of cash

acquired):

   Amounts
Recognized as
of December 31,
2018
    Measurement
Period
Adjustments
    Final Acquisition
Date Fair Value
 

Goodwill

   $ 32,586     $ 1,589     $ 34,175  

Intangibles

     34,582       (762     33,820  

Property, plant, and equipment

     5,444       (866     4,578  

Working capital, net

     646       —         646  

Deferred income tax liability

     (8,875     39       (8,836

Other assets/liabilities, net

     (155     —         (155
  

 

 

   

 

 

   

 

 

 

Total estimated purchase price

   $ 64,228     $ —       $ 64,228  
  

 

 

   

 

 

   

 

 

 

Approximately $34.2 million of goodwill was recorded related to the Gibraltar acquisition, representing the excess of the purchase price over estimated fair values of all the assets acquired and liabilities assumed. The fair value allocated to goodwill and tangible and intangible assets are not deductible for tax purposes. The qualitative elements of goodwill primarily represent the expanded future growth opportunities for the combined company, resulting from contributing factors such as synergies related to cross-selling opportunities with our other businesses, and the addition of Gibraltar’s highly skilled workforce. We recorded $33.8 million for intangible assets as part of the acquisition related to customer relationships, proprietary technology, and the Gibraltar tradename.

Gibraltar’s results of operations are included in our consolidated financial statements from the date of the transaction within the Nelson Labs segment. Had the transaction occurred on January 1, 2018, unaudited pro forma consolidated results for 2018, would have been as follows:

 

(thousands of U.S. dollars)

Year Ended December 31,

   2018  

Net revenues

   $ 755,955  

Net loss

     (2,672

The unaudited pro forma consolidated results are based on our historical financial statements and those of Gibraltar, and do not necessarily indicate the results of operations that would have resulted had the acquisition been completed at the beginning of 2018. The unaudited pro forma consolidated results do not give effect to any synergies of the acquisition and are not indicative of the results of operations in future periods.

Net revenues and net income from the Gibraltar Laboratories acquisition included in the Company’s results since August 7, 2018, the date of the acquisition, are as follows:

 

(thousands of U.S. dollars)

Year Ended December 31,

   2019      2018  

Net revenues

   $ 17,549      $ 6,593  

Net income

     3,833        1,318  

In connection with the Gibraltar acquisition, we incurred approximately $0.5 million and $1.3 million in transaction costs for the years ended December 31, 2019 and 2018, respectively, which were included in selling, general and administrative expenses in the consolidated statements of operations and comprehensive income (loss).

 

F-16


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

Disposition of the Medical Isotopes Business

On July 30, 2018 we finalized the sale of our Medical Isotopes (“MI”) business to a subsidiary of BWX Technologies, Inc. (“BWXT”) for $213.0 million. Through the agreement, BWXT acquired essentially all the former medical isotope net assets, including the medical isotope operation and contract manufacturing services in Kanata, Ontario and the medical isotope operation in Vancouver, British Columbia. Both companies continue to operate from Nordion’s licensed facility in Kanata, Ontario, and approximately 150 employees transitioned to BWXT at the close of the sale. As a result of the transaction, we recorded a gain on sale of approximately $95.9 million, net of transaction expenses totaling $3.5 million during the year ended December 31, 2018. In addition, we recorded deferred income of $22.7 million and $2.0 million related to the lease of the Kanata facility and its associated regulatory licenses, respectively. The deferred income related to the lease of the Kanata facility is being recognized on a straight-line basis over the 40-year lease period, including lease extensions deemed probable of occurring. The deferred income on the associated operating licenses is included within “Deferred lease income” on the consolidated balance sheets and will be recognized over a period not to exceed 2 years from the date the transaction closed in accordance with the period of time by which BWXT is expected to obtain its own regulatory licenses for the site. The disposition of the MI business does not, nor is it expected to, have a major effect on the Company’s consolidated operations and financial results. Prior to its divestiture, MI revenue was $25.4 million and income before income taxes, excluding the gain on sale, was not material in 2018.

5. Inventories

Inventories consist primarily of the following:

 

(thousands of U.S. dollars)

            

As of December 31,

   2019     2018  

Raw materials and supplies

   $ 29,640     $ 31,037  

Work-in-process

     1,961       1,371  

Finished goods

     5,892       5,284  
  

 

 

   

 

 

 
     37,493     37,692  

Reserve for excess and obsolete inventory

     (97     (93
  

 

 

   

 

 

 

Inventories

   $ 37,396     $ 37,599  
  

 

 

   

 

 

 

 

F-17


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

6. Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist primarily of the following:

 

(thousands of U.S. dollars)

             

As of December 31,

   2019      2018  

Prepaid taxes

   $ 18,614      $ 14,459  

Prepaid business insurance

     3,422        3,511  

Prepaid rent

     1,088        1,164  

Accrual for revenue from customers

     8,508        4,755  

Insurance and indemnification receivables

     2,751        16,516  

Current deposits

     5,060        4,800  

Prepaid maintenance contracts

     397        305  

Derivative instruments (see Financial Instruments note)

     242        752  

Value added tax receivable

     1,034        2,491  

Prepaid software licensing

     1,089        985  

Stock supplies

     2,263        1,943  

Other

     8,176        5,678  
  

 

 

    

 

 

 

Prepaid expenses and other current assets

   $ 52,644      $ 57,359  
  

 

 

    

 

 

 

The reduction in insurance and indemnification receivables is primarily a result of the final judgment and settlement of litigation at Nordion. Refer to the Accrued Liabilities note.

7. Property, Plant and Equipment and Capital Leases

Property, plant, and equipment, net, consists of the following:

 

(thousands of U.S. dollars)

            

As of December 31,

   2019     2018  

Land and buildings

   $ 279,913     $ 252,472  

Leasehold improvements

     44,808       47,119  

Machinery, equipment, including Co-60

     459,728       428,755  

Furniture and fixtures

     6,984       6,432  

Computer hardware and software

     38,602       31,591  

Asset retirement costs

     4,313       3,888  

Construction-in-progress

     42,168       50,796  
  

 

 

   

 

 

 
     876,516     821,053  

Less accumulated depreciation

     (294,562     (234,617
  

 

 

   

 

 

 

Property, plant and equipment, net

   $ 581,954     $ 586,436  
  

 

 

   

 

 

 

Depreciation and amortization expense for property, plant, and equipment, including property under capital leases, was $66.7 million and $66.9 million for the years ended December 31, 2019 and 2018, respectively. Capitalized interest totaled $0.1 million and $1.1 million for the years ended December 31, 2019 and 2018, respectively, and was recorded as a reduction in “Interest expense, net” in the consolidated statements of operations and comprehensive income (loss).

 

F-18


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

Capital Leases

Included in the table above are certain assets we lease that are classified as capital leases with various terms. Assets held under such lease arrangements are included in property, plant, and equipment, net, as follows:

 

(thousands of U.S. dollars)

            

As of December 31,

   2019     2018  

Machinery and equipment

   $ 4,970     $ 4,800  

Buildings

     34,226       34,569  
  

 

 

   

 

 

 
     39,196     39,369  

Less accumulated depreciation

     (8,121     (5,774
  

 

 

   

 

 

 

Capital leases, net

   $ 31,075     $ 33,595  
  

 

 

   

 

 

 

As discussed in the Commitments and Contingencies note, we have been involved in litigation related to our ethylene oxide sterilization operations in Willowbrook, Illinois. On September 30, 2019, we announced plans to exit our operations in Willowbrook citing the unstable legislative and regulatory landscape in Illinois as well as the expiration of the primary Willowbrook facility lease. Prior to this decision, we had approximately $9.8 million in net book value of fixed assets at the Willowbrook facilities, including $1.8 million of construction in process. Based on our initial estimate of fixed assets that can be transferred to other Sterigenics’ facilities, we recorded a fixed asset impairment of approximately $5.8 million as recognized in “Impairment of long-lived assets” in the consolidated statement of operations and comprehensive income (loss) for the year ended December 31, 2019. Further, in conjunction with the decision not to reopen our Willowbrook facilities, we incurred certain restructuring costs consisting of employee termination benefits totaling $1.2 million in the year ended December 31, 2019. The $1.2 million in costs represents all termination benefits costs expected to be incurred in connection with the Willowbrook closure, and are included in “Cost of revenues” on the consolidated statement of operations and comprehensive income (loss) and are included in our Sterigenics segment. Decommissioning of the Willowbrook facilities began in October 2019 and is anticipated to take until the end of 2020. At December 31, 2019, we had an ARO of approximately $2.9 million representing our estimate of the costs to decommission the Willowbrook operations, of which $2.2 million is anticipated to be spent in the next 12 months as included in the “Current portion of asset retirement obligations” within the consolidated balance sheet as of December 31, 2019. This amount reflects incremental expense to increase the ARO in 2019 by $1.1 million based on higher expected demolition costs and is included in “Cost of revenues” on the consolidated statement of operations and comprehensive income (loss).

In 2015, we began working with General Atomics (“GA”) and the Missouri University Research Reactor (“MURR”) on a joint project (“GA-MURR project”) to replace our supply of Molybdenum-99 (“Mo-99”) utilized in our former MI operations, the production of which ceased after the previous supplier exited the market. This was a multi-year capital project to construct assets dedicated to the production of Mo-99. As a result of a strategic review of the MI business and other factors, we withdrew from the project in early April 2018. We wrote off $32.7 million of long-lived assets and inventory of $0.3 million. We incurred $2.4 million related to contract termination and exit costs associated with the project which were paid in the year recognized. The total fixed asset impairment charge of $32.7 million was recognized as a component of “Impairment of long-lived assets” in the consolidated statement of operations and comprehensive income (loss) for the year-ended December 31, 2018. The $0.3 million of inventory write-offs and $2.4 million of contract termination and exit costs were included in “Cost of revenues” and “Selling, general and administrative expenses”, respectively, in the consolidated statement of operations and comprehensive income (loss) for the year ended December 31, 2018. The aforementioned expenses related to the GA-MURR project are reflected as a component of Other within the Segment and Geographic Information note.

 

F-19


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

In the first quarter of 2018, management made plans to pursue the sale of a Nordion office building and associated land. As a result, these assets were classified as held-for-sale and an impairment of $2.3 million was recorded for the year ended December 31, 2018 based on the estimated selling price for the property and was recognized as a component of “Impairment of long-lived assets” in the consolidated statement of operations and comprehensive income (loss). The then estimated fair value of approximately $3.3 million is reported as “Assets held for sale” in the consolidated balance sheet as of December 31, 2018. In 2019, management determined this asset was no longer held for sale and decided to pursue other uses of the property.

8. Goodwill and Other Intangible Assets

Changes to goodwill during the years ended December 31, 2019 and 2018 were as follows:

 

(thousands of U.S. dollars)

   Sterigenics     Nordion     Nelson Labs     Other     Total  

Goodwill at January 1, 2018

   $ 638,029     $ 292,293     $ 87,954     $ 70,926     $ 1,089,202  

Gibraltar Laboratories acquisition1

     —         —         32,586       —         32,586  

Disposition of Medical Isotopes business

     —         —         —         (68,156     (68,156

Toxikon Europe acquisition measurement period adjustments

     —         —         1,428       —         1,428  

Reallocation of goodwill

     (20,000     —         20,000       —         —    

Changes due to foreign currency exchange rates

     (4,392     (23,021     (1,563     (2,770     (31,746
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Goodwill at December 31, 2018

     613,637       269,272       140,405       —         1,023,314  

Gibraltar Laboratories acquisition1 measurement period adjustments

     —         —         1,589       —         1,589  

Changes due to foreign currency exchange rates

     (948     12,618       (708     —         10,962  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Goodwill at December 31, 2019

   $ 612,689     $ 281,890     $ 141,286     $ —       $ 1,035,865  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

1 

Gibraltar Laboratories is now known as Nelson Laboratories Fairfield, Inc.

Of the gross balances outstanding as of December 31, 2019, $490.8 million, $69.1 million and $235.7 million of customer relationships, proprietary technology, and sealed source and supply agreements, respectively, were initially recorded upon the recapitalization of the Company in connection with the acquisition by the Sponsors in 2015. We recorded additional customer relationship and proprietary technology intangibles of $121.3 million and $18.9 million, respectively, in conjunction with acquisitions in the period from 2015 through 2018, the majority of which related to the 2016 acquisition of Nelson Laboratories.

 

F-20


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

Other intangible assets consist of the following:

 

(thousands of U.S. dollars)

As of December 31, 2019

   Gross Carrying
Amount
     Accumulated
Amortization
 

Finite-lived intangible assets

     

Customer relationships

   $ 612,068      $   248,931  

Proprietary technology

     87,971        30,224  

Trade names

     7,201        1,860  

Land-use rights

     8,896        1,011  

Sealed source and supply agreements

     235,706        74,825  

Other

     336        243  
  

 

 

    

 

 

 

Total finite-lived intangible assets

     952,178        357,094  

Indefinite-lived intangible assets

     

Regulatory licenses and other1

     80,103        —    

Trade names / trademarks

     20,819        —    
  

 

 

    

 

 

 

Total indefinite-lived intangible assets

     100,922        —    
  

 

 

    

 

 

 

Total

   $ 1,053,100      $ 357,094  
  

 

 

    

 

 

 

 

As of December 31, 2018

   Gross Carrying
Amount
     Accumulated
Amortization
 

Finite-lived intangible assets

     

Customer relationships

   $ 611,529      $ 193,077  

Proprietary technology

     86,948        23,020  

Trade names

     7,209        1,371  

Land-use rights

     9,013        803  

Sealed source and supply agreements

     225,084        56,017  

Other

     343        134  
  

 

 

    

 

 

 

Total finite-lived intangible assets

     940,126        274,422  

Indefinite-lived intangible assets

     

Regulatory licenses and other1

     76,493        —    

Trade names / trademarks

     23,857        —    
  

 

 

    

 

 

 

Total indefinite-lived intangible assets

     100,350        —    
  

 

 

    

 

 

 

Total

   $ 1,040,476      $ 274,422  
  

 

 

    

 

 

 

Amounts include the impact of foreign currency translation. Fully amortized amounts are written off.

 

1 

Includes certain transportation certifications, a class 1B nuclear license and other intangibles related to obtaining such licensure. These assets are considered indefinite-lived as the decision for renewal by the Canadian Nuclear Safety Commission is highly based on a licensee’s previous assessments, reported incidents, and annual compliance and inspection results. New applications for license can take a significant amount of time and cost; whereas an existing licensee with a historical record of compliance and current operating conditions more than likely ensures renewal for another 10 year license period as Nordion has demonstrated over its 70 years of history.

As referenced in the Property, Plant and Equipment and Capital Leases note, we withdrew from the GA-MURR project in early April 2018. In addition to the impairment of fixed assets, an intangible asset initially recorded at

 

F-21


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

its estimated fair value in connection with the Company’s 2015 change in control related to the Company’s MURR supply agreement with a carrying value of $50.1 million was written off. The resulting impairment charge of $50.1 million was recognized in “Impairment of GA-MURR intangible assets” in the consolidated statement of operations and comprehensive income (loss) for the year ended December 31, 2018.

Amortization expense for other intangible assets was $80.0 million ($21.5 million is included in “Cost of revenues” and $58.5 million in “Selling, general and administrative expenses” in the consolidated statements of operations and comprehensive income (loss)) and $79.9 million ($21.9 million is included in “Cost of revenues” and $58.0 million in “Selling, general and administrative expenses” in the consolidated statements of operations and comprehensive income (loss)) for the years ended December 31, 2019 and 2018, respectively.

The estimated aggregate amortization expense for finite-lived intangible assets for each of the next five years and thereafter is as follows:

 

(thousands of U.S. dollars)

      

2020

   $ 80,854  

2021

     80,426  

2022

     76,486  

2023

     76,476  

2024

     75,696  

Thereafter

     205,146  
  

 

 

 

Total

   $ 595,084  
  

 

 

 

The weighted-average remaining useful life of the finite-lived intangible assets was approximately 10 years as of December 31, 2019.

9. Accrued Liabilities

Accrued liabilities consist of the following:

 

(thousands of U.S. dollars)

             

As of December 31,

   2019      2018  

Accrued employee compensation

   $ 28,912      $ 26,895  

Legal reserves

     2,751        18,506  

Accrued interest expense

     10,648        9,998  

Embedded derivatives

     3,478        5,248  

Professional fees

     4,329        5,390  

Accrued utilities

     1,135        1,049  

Insurance accrual

     1,241        1,478  

Accrued taxes

     2,363        2,651  

Other

     3,679        4,494  
  

 

 

    

 

 

 

Accrued liabilities

   $ 58,536      $ 75,709  
  

 

 

    

 

 

 

The reduction in legal reserves is a result of the final judgment and settlement of litigation at Nordion in early 2019 for which we had insurance and indemnification receivables for a significant portion. Refer to the Prepaid Expenses and Other Current Assets note.

 

F-22


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

10. Long-Term Debt and Capital Lease Obligations

Long-term debt and capital lease obligations consist of the following:

 

(thousands of U.S. dollars)

            

As of December 31,

   2019     2018  

Term loan, due 2022

   $ —       $ 1,350,303  

Senior notes, due 2023

     —         450,000  

Term loan, due 2026

     2,120,000       —    

Senior notes, due 2027

     770,000       —    

Senior PIK Toggle notes due 2021

     —         425,000  

Capital lease obligations

     31,171       32,887  

Other long-term debt

     881       2,049  
  

 

 

   

 

 

 

Total long-term debt and capital lease obligations

     2,922,052       2,260,239  

Less current portion

     (17,619     (16,695

Less unamortized debt issuance costs and debt discounts

     (73,677     (22,446
  

 

 

   

 

 

 

Total long-term debt and capital lease obligations, less current portion and debt issuance costs and debt discounts

   $ 2,830,756     $ 2,221,098  
  

 

 

   

 

 

 

Debt Facilities

1st Lien Senior Secured Credit Facilities

On December 13, 2019, Sotera Health Holdings, LLC (“SHH”), our wholly owned subsidiary, entered into new Senior Secured 1st Lien Credit Facilities (the “1st Lien Credit Facilities”) and settled its previously outstanding term loan and senior notes.

The 1st Lien Credit Facilities consist of both a 1st Lien Term Loan (“Term Loan”) and Revolving Credit Facility that provide for additional senior secured financing of $190.0 million. The Term Loan matures on December 13, 2026, and the Revolving Credit Facility matures on December 13, 2024. The 1st Lien Credit Facilities also provide SHH the right at any time and under certain conditions to request incremental term loans or incremental revolving credit commitments based on a formula defined in the 1st Lien Credit Facilities. As of December 31, 2019, total borrowings under the Term Loan were $2,120.0 million and the Revolving Credit Facility remained unutilized. The Term Loan may bear interest at LIBOR or an alternate base rate (“ABR”) subject to a 1.00% floor plus, an incremental margin of 4.50% in the case of LIBOR loans and 3.50% in the case of ABR loans.

Beginning on June 30, 2020, the Term Loan is paid in equal quarterly installments in aggregate annual amounts equal to 1.0% of the Term Loan original principal amount, while the remaining balance matures on December 13, 2026. The weighted average interest rate on borrowings under the Term Loan at December 31, 2019 was 6.29%.

As of December 31, 2019, capitalized debt issuance costs and debt discounts totaled $4.7 million and $44.0 million, respectively, related to the 1st Lien Credit Facilities. Such costs are recorded as a reduction of debt on our consolidated balance sheets and amortized as a component of interest expense over the term of the debt agreement.

Borrowings under the Revolving Credit Facility bear interest at a rate per annum equal to an applicable margin, plus, at our option, either (a) an ABR or (b) a LIBOR rate. The applicable margin under the Revolving Credit Facility may be reduced by reference to a leverage-based pricing grid with step-downs of 0.25% at a specified

 

F-23


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

senior secured first lien net leverage ratios. In addition to paying interest on any outstanding borrowings under the Revolving Credit Facility, SHH is required to pay a commitment fee to the lenders under the Revolving Credit Facility in respect of the unutilized commitments thereunder and customary letter of credit fees. As of December 31, 2019, there are no borrowings on the Revolving Credit Facility. The Revolving Credit Facility contains a maximum senior secured first lien net leverage ratio covenant of 9.00 to 1.00, tested on the last day of each fiscal quarter if, on the last day of such fiscal quarter, the sum of (i) the aggregate principal amount of the revolving loans then outstanding under the Revolving Credit Facility, plus (ii) the aggregate amount of letter of credit (“LC”) disbursements that have not been reimbursed within two business days following the end of the fiscal quarter, exceeds the greater of $76.0 million and 40.0% of the aggregate principal amount of the revolving commitments then in effect. Although this covenant did not apply as the conditions were not met, as of December 31, 2019 the first lien net leverage ratio, as defined in the Revolving Credit Facility, was approximately 5.40 to 1.00.

The 1st Lien Credit Facilities contain additional covenants that, among other things, restrict, subject to certain exceptions, our ability and the ability of our restricted subsidiaries to engage in certain activities, such as incur indebtedness or permit to exist any lien on any property or asset now owned or hereafter acquired, as specified in the debt facility. The 1st Lien Credit Facilities also contain certain customary affirmative covenants and events of default, including upon a change of control. As of December 31, 2019, we were in compliance with all the 1st Lien Credit Facilities covenants.

All of SHH’s obligations under the 1st Lien Credit Facilities are unconditionally guaranteed by the Company and each existing and subsequently acquired or organized direct or indirect wholly-owned domestic restricted subsidiary of the Company, with customary exceptions including, among other things, where providing such guarantees is not permitted by law, regulation or contract or would result in material adverse tax consequences. All obligations under the 1st Lien Credit Facilities, and the guarantees of such obligations, are secured by substantially all assets of the borrower and guarantors, subject to permitted liens and other exceptions and exclusions, as outlined in the 1st Lien Credit Facilities.

Outstanding letters of credit are collateralized by encumbrances against the Revolving Credit Facility and the collateral pledged thereunder, or by cash placed on deposit with the issuing bank. As of December 31, 2019, the Company had $62.5 million of letters of credit issued against the Revolving Credit Facility, resulting in total availability under the Revolving Credit Facility of $127.5 million.

In October 2017, SHH entered into two interest rate cap agreements with a total notional amount of $400.0 million for a total premium of $0.6 million. The interest rate caps limit the Company’s cash flow exposure related to the LIBOR base rate under the variable rate term loan borrowings to 3.0%. The interest rate cap agreements terminate on September 30, 2020. The interest rate caps were not designated as hedges and are recorded at fair value on the consolidated balance sheets, with any changes in the value being recorded in the consolidated statements of operations and comprehensive income (loss). See the Financial Instruments and Financial Risk note for a summary of the activity of the interest rate caps for the periods presented.

During the third quarter of 2019, SHH entered into two interest rate swap agreements to hedge exposure to interest rate movements and to manage interest expense related to outstanding variable-rate debt. These swaps were designated as hedges against the changes in cash flows attributable to changes in LIBOR, the benchmark interest rate being hedged. We receive interest at one-month LIBOR and pay a fixed interest rate under the terms of the swap agreement. The swap agreements terminated on August 31, 2020. The notional amount of the interest rate swap agreements totals $1,000.0 million. See the Financial Instruments and Financial Risk note for a summary of the activity of the interest rate swaps for the periods presented.

 

F-24


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

2nd Lien Senior Secured Notes

On December 13, 2019, SHH issued $770.0 million of 2nd Lien Senior Secured Notes (the “2nd Lien Notes”), which mature on December 13, 2027. The 2nd Lien Notes bear interest at a rate equal to LIBOR subject to a 1.00% floor plus 8.00% per annum. The weighted average interest rate on the 2nd Lien Notes at December 31, 2019 was 9.89%.

SHH is entitled to redeem all or a portion of the 2nd Lien Notes, at any time and from time to time, subject to certain premiums depending on the date of redemption: any time prior to December 13, 2020, a customary make-whole premium applies and, thereafter, specified premiums that decline to zero apply (in each case as described in the indenture governing the 2nd Lien Notes). In addition, under certain circumstances, such as an initial public offering or certain changes of control, SHH has certain additional redemption rights (as described in the indenture governing the 2nd Lien Notes).

All of SHH’s obligations under the 2nd Lien Notes are unconditionally guaranteed by the Company and each existing and subsequently acquired or organized direct or indirect wholly-owned domestic restricted subsidiary of the Company, with customary exceptions including, among other things, where providing such guarantees is not permitted by law, regulation or contract or would result in material adverse tax consequences. All obligations under the 2nd Lien Notes, and the guarantees of such obligations, are secured by substantially all of the assets of the borrower and guarantors, subject to permitted liens and other exceptions and exclusions, as outlined in the 2nd Lien Notes. Such collateral is substantially the same collateral that secures the 1st Lien Credit Facilities, and any security interest or lien on shared collateral securing the 1st Lien Credit Facilities has priority over any security interest or lien on shared collateral securing the 2nd Lien Notes.

As of December 31, 2019, capitalized debt issuance costs and debt discounts were $1.8 million and $23.2 million, respectively, related to the 2nd Lien Notes, which are recorded as a reduction of debt on our consolidated balance sheet and amortized into interest expense over the term of the debt agreement.

2019 Refinancing

In conjunction with the December 2019 refinancing, the Company redeemed, in full, the previously outstanding $1,659.0 million aggregate Term Loan due 2022, its $450.0 million Senior Notes due 2023 (“Senior Notes”) and $425.0 million Senior PIK (“paid in kind”) Toggle Notes due 2021. In total, we wrote off $13.5 million of debt issuance and discount costs and recognized $14.6 million representing premiums paid in connection with the early extinguishment of the Senior Notes. In connection with the refinancing, we also recognized an additional $2.1 million of expense related to debt issuance and discount costs. We recognized these costs within the loss on extinguishment of debt in our consolidated statements of operations and comprehensive income (loss). Any additional proceeds were used to fund a dividend to shareholders of $275.0 million.

Prior to the refinancing referenced above, the Company had the following long-term debt:

 

   

Senior secured credit facilities consisting of a term loan and a revolving credit facility that provided for additional senior secured financing of $172.5 million. Borrowings under the term loan bore interest at either (i) an alternative base rate (“ABR”) plus an additional margin of 2.00% or (ii) LIBOR plus an additional margin of 3.00%. Each of ABR and LIBOR were subject to a floor of 1.00%,

 

   

$450 million aggregate principal amount of senior notes, at an interest rate of 6.5% per annum, payable semi-annually, and

 

   

$425 million aggregate principal amount of Senior PIK (“paid in kind”) Toggle notes at a rate of 8.125%/8.875% per annum, payable semi-annually.

 

F-25


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

Aggregate Maturities

Aggregate maturities of the Company’s long-term debt, including capital leases, and excluding debt discounts, as of December 31, 2019, are as follows:

 

(thousands of U.S. dollars)

      

2020

   $ 17,619  

2021

     22,304  

2022

     22,300  

2023

     22,833  

2024

     22,523  

Thereafter

     2,814,473  
  

 

 

 

Total

   $ 2,922,052  
  

 

 

 

Aggregate Future Minimum Lease Payments Under Capital Leases

As of December 31, 2019, aggregate future minimum lease payments under capital leases are as follows:

 

(thousands of U.S. dollars)

      

2020

   $ 3,158  

2021

     2,900  

2022

     2,824  

2023

     2,833  

2024

     2,892  

Thereafter

     36,453  
  

 

 

 

Total minimum lease payments

     51,060  

Less amounts representing interest

     (19,889
  

 

 

 

Present value of net minimum lease payments

   $ 31,171  
  

 

 

 

11. Income Taxes

The geographic sources of income (loss) before income taxes were as follows:

 

(thousands of U.S. dollars)

            

Year ended December 31,

   2019     2018  

U.S.

   $ (99,733   $ (45,134

Foreign

     98,817       69,356  
  

 

 

   

 

 

 

Income (loss) before income taxes

   $ (916   $ 24,222  
  

 

 

   

 

 

 

 

F-26


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

Provision for income taxes consists of the following:

 

(thousands of U.S. dollars)

            

Year ended December 31,

   2019     2018  

Current

    

Federal U.S.

   $ 17,954     $ 22,302  

State U.S.

     3,662       4,882  

Foreign

     16,886       48,233  
  

 

 

   

 

 

 

Total current provision

     38,502       75,417  
  

 

 

   

 

 

 

Deferred

    

Federal U.S.

     (18,177     (15,437

State U.S.

     (5,958     (2,396

Foreign

     5,142       (27,486
  

 

 

   

 

 

 

Total deferred benefit

     (18,993     (45,319
  

 

 

   

 

 

 

Total provision for income taxes

   $ 19,509     $ 30,098  
  

 

 

   

 

 

 

The provision for income taxes is reconciled with the U.S. federal statutory rate as follows:

 

(thousands of U.S. dollars)

            

Year ended December 31,

   2019     2018  

(Benefit) provision computed at federal statutory rate

   $ (192   $ 5,088  

(Decrease) increase in taxes as a result of:

    

State taxes, net of federal benefit

     (2,681     (247

Valuation allowance

     5,147       (641

Global intangible low-tax income (GILTI)

     10,349       4,902  

Nondeductible share-based compensation

     3,545       1,458  

Foreign tax rate

     5,550       5,571  

Impact of rate changes on deferred tax balances

     (559     5,296  

Tax holiday

     (571     (456

Audit settlement

     879       2,517  

Other

     (1,958     6,610  
  

 

 

   

 

 

 

Total provision for income taxes

   $ 19,509     $ 30,098  
  

 

 

   

 

 

 

 

F-27


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

The components of the tax effects of temporary differences and carryforwards that gave rise to significant portions of the deferred tax assets and liabilities are as follows:

 

(thousands of U.S. dollars)

            

As of December 31,

   2019     2018  

Net operating loss carryforwards

   $ 10,876     $ 11,173  

Net capital loss carryforwards

     3,916       —    

Reserves and accruals

     14,246       16,700  

Employee benefits and compensation

     8,279       5,434  

Unrealized foreign currency exchange

     3,083       2,464  

Asset retirement obligation

     10,535       9,380  

Disallowed interest carryforward

     41,723       21,161  

Other

     5,393       5,130  
  

 

 

   

 

 

 

Deferred tax assets before valuation allowance

     98,051       71,442  

Valuation allowance

     (22,962     (16,678
  

 

 

   

 

 

 

Net deferred tax assets

     75,089       54,764  
  

 

 

   

 

 

 

Depreciation and amortization

     (210,010     (178,764

Partnership basis difference

     —         (31,627

Other

     (62     (91
  

 

 

   

 

 

 

Total deferred tax liabilities

     (210,072     (210,482
  

 

 

   

 

 

 

Net deferred tax liabilities

   $ (134,983   $ (155,718
  

 

 

   

 

 

 

Noncurrent net deferred tax assets

   $ 2,252     $ 15,764  

Noncurrent net deferred tax liabilities

     (137,235     (171,482
  

 

 

   

 

 

 

Noncurrent net deferred tax liabilities

   $ (134,983   $ (155,718
  

 

 

   

 

 

 

At December 31, 2019 and 2018, the Company had available state net operating loss carryforwards of $11.8 million and $0, respectively, of which $11.5 million have no expiration date, and foreign net operating loss carryforwards of approximately $44.2 million and $46.7 million, respectively, the majority of which have no expiration date. At December 31, 2019 and 2018, a valuation allowance was established against foreign net operating loss carryforwards for $12.4 million and $12.1 million, respectively. Based on management’s assessment, it is not more likely than not that these deferred tax assets will be realized through future taxable income.

At December 31, 2019 and 2018, no deferred tax liability has been recorded for repatriation of earnings for purposes of the Company’s consolidated financial statements as these earnings are deemed to be indefinitely reinvested. Determining the amount of unrecognized deferred tax liability related to any remaining undistributed foreign earnings not subject to the transition tax and additional outside basis difference in these entities (i.e., basis difference in excess of that subject to the one-time transition tax) is not practicable.

As of December 31, 2019, and 2018, the gross reserve for uncertain tax positions, excluding accrued interest and penalties, was $0 and $9.9 million, respectively, as noted in the following reconciliation. In 2018 an allowance of $8.8 million was established relating to the uncertainty of the deductibility of certain assets in relation to Nordion’s sale of its Medical Isotopes business, which uncertainties were resolved in 2019. The uncertain tax positions were reversed in 2019 once full deductibility was confirmed.

 

F-28


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

The Company’s unrecognized income tax benefits were as follows:

 

(thousands of U.S. dollars)

            

For the period from January 1 – December 31,

   2019     2018  

Gross unrecognized tax benefits, beginning of year

   $ 10,239     $ 1,383  

Additions related to current year

     —         8,832  

Changes related to prior years

     —         300  

Settlements

     (9,939     —    

Other

     —         (276
  

 

 

   

 

 

 

Gross unrecognized tax benefits, end of period

   $ 300     $ 10,239  
  

 

 

   

 

 

 

The Company recognizes interest and penalties as part of the provision for income taxes. For the years ended December 31, 2019 and 2018, interest and penalties related to uncertain income tax positions that were recognized in the consolidated statements of operations and comprehensive income (loss) were not material.

The Company, which represents all of its subsidiaries, files income tax returns in the U.S. federal jurisdiction and various states and foreign jurisdictions. The Company is no longer subject to U.S. federal, state, and local tax examinations before 2015, and non-U.S. income tax examinations by tax authorities for years before 2010. Tax years through December 31, 2016 have been audited by the Internal Revenue Service (“IRS”) and are effectively closed for U.S. federal income tax purposes. The 2017 tax year is currently under audit. For Nordion’s Canadian tax, all tax years through October 31, 2014 have been closed through audit or statute, and fiscal year 2016 is currently under audit.

A portion of the Company’s foreign operations benefit from a tax holiday, which is set to expire in 2025. This tax holiday may be terminated early if certain conditions are not met. The tax benefit attributable to this holiday was $0.6 million and $0.5 million for the fiscal years ended December 31, 2019 and 2018, respectively.

12. Employee Benefits

Employee Retirement Benefits in the U.S.

We have a defined-contribution retirement plan that covers all U.S. employees upon date of hire. Contributions are directed by each participant into various investment options. Under this plan, we match participants’ contributions based on plan provisions. The Company’s contributions, which are expensed as incurred, were $3.8 million and $3.5 million for the years ended December 31, 2019 and 2018, respectively, and are recorded in the same line as the respective employee’s wages. Administrative expenses related to the plan are paid by the Company and are not material.

Employee Retirement Benefits Outside the U.S.

The Company participates in qualified supplemental retirement and savings plans in various countries outside the U.S. where we operate. Under these defined-contribution plans, funding and costs are generally based upon a predetermined percentage of employee compensation. The Company’s contributions, which are expensed as incurred and recorded in the same line as the respective employee’s wages were $1.1 million and $0.9 million for the years ended December 31, 2019 and 2018, respectively.

 

F-29


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

Defined Benefit Pension Plans

The Company also sponsors various post-employment benefit plans including, in certain countries outside the U.S., defined benefit and retirement compensation arrangements, and plans that provide extended health care coverage to retired employees, the majority of which relate to Nordion.

Defined Benefit Pension Plan

The interest cost and expected return on plan assets are recorded in “Other income, net” and the service cost component is included in the same financial statement line item as the applicable employee’s wages in the consolidated statements of operations and comprehensive income (loss). The components of net periodic benefit cost for the defined benefit pension plans were as follows.

 

Year ended December 31,

            

(thousands of U.S. dollars)

   2019     2018  

Service cost

   $ 1,147     $ 2,258  

Interest cost

     8,521       8,690  

Expected return on plan assets

     (13,218     (13,170
  

 

 

   

 

 

 

Net periodic benefit

   $ (3,550   $ (2,222
  

 

 

   

 

 

 

The following weighted average assumptions were used in the determination of the projected benefit obligation and the net periodic benefit:

 

Year ended December 31,

   2019     2018  

Projected benefit obligation

    

Discount rate

     3.07     3.67

Rate of compensation increase

     3.00     3.00

Periodic benefit

    

Discount rate

     3.67     3.59

Expected return on plan assets

     5.50     5.00

Rate of compensation increase

     3.00     3.00

 

F-30


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

The changes in the projected benefit obligation, fair value of plan assets, and the funded status of the plans are as follows:

 

(thousands of U.S. dollars)

            

As of December 31,

   2019     2018  

Change in projected benefit obligation

    

Projected benefit obligation, as of beginning of the year

   $ 246,922     $ 284,977  

Service cost

     1,353       2,684  

Interest cost

     8,521       8,690  

Benefits paid

     (10,663     (10,954

Actuarial loss (gain)

     35,813       (12,375

Curtailments

     —         (4,313

Foreign currency exchange rate changes

     12,329       (21,787
  

 

 

   

 

 

 

Projected benefit obligation, end of year

   $ 294,275     $ 246,922  
  

 

 

   

 

 

 

Change in fair value of plan assets

    

Fair value of plan assets as of the beginning of the year

     238,204       272,835  

Actual return on plan assets

     35,045       (4,726

Benefits paid

     (10,663     (10,954

Employer contributions

     725       1,576  

Employee contributions

     205       426  

Foreign currency exchange rate changes

     11,732       (20,953
  

 

 

   

 

 

 

Fair value of plan assets, end of year

   $ 275,248     $ 238,204  
  

 

 

   

 

 

 

Underfunded status at end of year

   $ (19,027   $ (8,718
  

 

 

   

 

 

 

Accumulated benefit obligation, end of year

   $ 288,355     $ 241,983  
  

 

 

   

 

 

 

All defined benefit pension plans are underfunded as of December 31, 2019 and 2018.

The funded status measured as the difference between the fair value of the plan assets and the projected benefit obligation are included in post-retirement obligations in the consolidated balance sheets.

A reconciliation of the funded status to amounts recognized in the consolidated balance sheets is as follows:

 

(thousands of U.S. dollars)

            

As of December 31,

   2019     2018  

Projected benefit obligation

   $ 294,275     $ 246,922  

Fair value of plan assets

     275,248       238,204  
  

 

 

   

 

 

 

Plan assets less than projected benefit obligation

     (19,027     (8,718

Unrecognized net actuarial loss

     36,166       20,922  
  

 

 

   

 

 

 

Net amount recognized at year end

   $ 17,139     $ 12,204  
  

 

 

   

 

 

 

Noncurrent liabilities

   $ (19,027   $ (8,718

Accumulated other comprehensive (income) loss

     36,166       20,922  
  

 

 

   

 

 

 

Net amount recognized at year end

   $ 17,139     $ 12,204  
  

 

 

   

 

 

 

 

F-31


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

The following table illustrates the amounts in accumulated other comprehensive (income) loss that have not yet been recognized as components of pension expense:

 

(thousands of U.S. dollars)

            

As of December 31,

   2019     2018  

Net actuarial loss

   $ 36,166     $ 20,922  

Deferred income taxes

     (9,136     (5,285
  

 

 

   

 

 

 

Accumulated other comprehensive loss – net of tax

   $ 27,030     $ 15,637  
  

 

 

   

 

 

 

The weighted average asset allocation of the Company’s pension plans was as follows:

 

Asset Category

   Target     2019     2018  

Cash

     0     0.2     0.3

Fixed income

     40     39.5     43.5

Equities

     37     37.6     56.2

Hedge Funds

     23     22.7     0
  

 

 

   

 

 

   

 

 

 

Total

     100     100     100
  

 

 

   

 

 

   

 

 

 

The Company maintains target allocation percentages among various asset classes based on investment policies established for the pension plans, which are designed to maximize the total rate of return (income and appreciation) after inflation, within the limits of prudent risk taking, while providing for adequate near-term liquidity for benefit payments. Such investment strategies have adopted an equity-based philosophy in order to achieve their long-term investment goals by investing in assets that often have uncertain returns, such as Canadian and other foreign equities, and non-government bonds. However, the Company also attempts to reduce its overall level of risk by diversifying the asset classes and further diversifying within each individual asset class.

The Company’s expected return on asset assumptions are derived from studies conducted by actuaries and investment advisors. The studies include a review of anticipated future long-term performance of individual asset classes and consideration of the appropriate asset allocation strategy given the anticipated requirements of the plans to determine the average rate of earnings expected on the funds invested to provide for the pension plans benefits. While the study considers recent fund performance and historical returns, the assumption is primarily a long-term, prospective rate.

 

F-32


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

The following table provides a basis of fair value measurement for plan assets held by the Company’s pension plans that are measured at fair value on a recurring basis. Refer to the discussion of fair value hierarchy in the Financial Instruments and Financial Risk note.

 

As of December 31, 2019

(thousands of U.S. dollars)

   Level 1      Level 2      Total  

Cash and cash equivalents

   $ 550      $ —        $ 550  

Fixed income securities

     —          108,723        108,723  

Equity securities

     —          92,208        92,208  

Hedge Funds

     —          73,767        73,767  
  

 

 

    

 

 

    

 

 

 

Total

   $ 550        $274,698      $ 275,248  
  

 

 

    

 

 

    

 

 

 

As of December 31, 2018

   Level 1      Level 2      Total  

Cash and cash equivalents

   $ 714      $ —        $ 714  

Fixed income securities

     —          103,619        103,619  

Equity securities

     —          133,871        133,871  
  

 

 

    

 

 

    

 

 

 

Total

   $ 714      $ 237,490      $ 238,204  
  

 

 

    

 

 

    

 

 

 

Expected future benefit payments from plan assets are as follows:

 

Year ended December 31

(thousands of U.S. dollars)

      

2020

   $ 11,126  

2021

     11,647  

2022

     12,034  

2023

     12,314  

2024

     12,584  

2025 – 2029

     66,160  
  

 

 

 
   $ 125,865  
  

 

 

 

Other Post Retirement Benefit Plans

Other benefit plans are all related to our foreign subsidiaries and include a supplemental retirement arrangement, a retirement and termination allowance, and post-retirement benefit plans, which include contributory health and dental care benefits and contributory life insurance coverage. All, but one, non-pension post-employment benefit plans are unfunded.

 

F-33


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

The interest cost and amortization of net actuarial (gain) loss are recorded in “Other income, net” and the service cost component is included in the same financial statement line item as the applicable employee’s wages in the consolidated statements of operations and comprehensive income (loss). The components of net periodic benefit cost for the other post-retirement benefit plans were as follows:

 

(thousands of U.S. dollars)

Year Ended December 31,

   2019      2018  

Service cost

   $ 30      $ 61  

Interest cost

     372        358  

Amortization of net actuarial (gain) loss

     123        1  
  

 

 

    

 

 

 

Net periodic benefit cost

   $ 525      $ 420  
  

 

 

    

 

 

 

The weighted average assumptions used to determine the projected benefit obligation and net periodic pension cost for these plans were as follows:

 

Year Ended December 31,

   2019     2018  

Projected benefit obligation

    

Discount rate

     3.13     3.52

Rate of compensation increase

     3.0     3.0

Initial health care cost trend rate

     7.0     5.72

Ultimate health care cost trend rate

     4.0     4.5

Years until ultimate trend rate is reached

     13       14  

Benefit cost

    

Discount rate

     3.52     3.55

Rate of compensation increase

     3.0     3.0

Assumed health care cost trend rates have a significant effect on the amounts reported for the health care plans. A one-percentage point change in assumed health care cost trend rates would have had the following impact on our consolidated financial statements in 2019:

 

(thousands of U.S. dollars)

   1% Increase      1% Decrease  

Change in net periodic benefit cost

   $ 27      $ (25

Change in projected benefit obligation

     979        (802

 

F-34


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

The changes in the projected benefit obligation and the funded status of the other post-retirement plans were as follows:

 

(thousands of U.S. dollars)

            

As of December 31,

   2019     2018  

Change in projected benefit obligation

    

Projected benefit obligation

   $ 11,019     $ 12,842  

Service cost

     30       61  

Interest cost

     372       358  

Benefits paid

     (676     (752

Actuarial loss (gain)

     1,166       (603

Curtailments

     170       88  

Foreign currency exchange rate changes

     540       (975
  

 

 

   

 

 

 

Projected benefit obligation, end of year

   $ 12,621     $ 11,019  
  

 

 

   

 

 

 

Change in fair value of plan assets

    

Fair value of plan assets as of the beginning of the year

   $ 325     $ 306  

Benefits paid

     (676     (752

Employer contributions

     546       628  

Employee contributions

     170       168  

Foreign currency exchange rate changes

     16       (25
  

 

 

   

 

 

 

Fair value of plan assets, end of year

   $ 381     $ 325  
  

 

 

   

 

 

 

Underfunded status at end of year

   $ (12,240   $ (10,694
  

 

 

   

 

 

 

Accumulated benefit obligation, end of year

   $ 12,473     $ 10,880  
  

 

 

   

 

 

 

All other post-retirement benefit pension plans are underfunded as of December 31, 2019 and 2018.

A reconciliation of the funded status to the net plan liabilities recognized in the consolidated balance sheets is as follows:

 

(thousands of U.S. dollars)

            

As of December 31,

   2019     2018  

Projected benefit obligation

   $ (12,621   $ (11,019

Fair value of plan assets

     381       325  
  

 

 

   

 

 

 

Plan assets less than projected benefit obligation

     (12,240     (10,694

Unrecognized actuarial gains (losses)

     107       (913
  

 

 

   

 

 

 

Net amount recognized at year end

   $ (12,133   $ (11,607
  

 

 

   

 

 

 

Noncurrent liabilities

   $ (12,240   $ (10,694

Accumulative other comprehensive income (loss)

     107       (913
  

 

 

   

 

 

 

Net amount recognized at year end

   $ (12,133   $ (11,607
  

 

 

   

 

 

 

The other benefit plan liabilities are presented on the consolidated balance sheets as post retirement obligations.

 

F-35


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

The following table illustrates the amounts in accumulated other comprehensive income (loss) that have not yet been recognized as components of other benefit plan expense:

 

(thousands of U.S. dollars)

            

As of December 31,

   2019     2018  

Net actuarial income (loss)

   $ 107     $ (913

Deferred income taxes

     (27     229  
  

 

 

   

 

 

 

Accumulated other comprehensive income (loss) – net of tax

   $ 80     $ (684
  

 

 

   

 

 

 

Based on the actuarial assumptions used to develop the Company’s benefit obligations as of December 31, 2019, the following benefit payments are expected to be made to plan participants:

 

Years ended December 31 (thousands of U.S. dollars)

      

2020

   $ 617  

2021

     610  

2022

     614  

2023

     590  

2024

     565  

2025 – 2029

     2,783  
  

 

 

 

Total

   $ 5,779  
  

 

 

 

We currently expect funding requirements of approximately $3.0 million in each of the next five years to fund the regulatory solvency deficit, as defined by Canadian federal regulation, which require solvency testing on defined benefit pension plans.

During the years ended December 31, 2019 and 2018, we contributed $0.7 million and $0.6 million, respectively, to defined benefit plans on behalf of our employees.

The Company may obtain a qualifying letter of credit for solvency payments, up to 15% of the market value of solvency liabilities as determined on the valuation date, instead of paying cash into the pension fund. As of December 31, 2019 and 2018, we had letters of credit outstanding relating to the defined benefit plans totaling $41.0 million and $38.0 million, respectively. The deficit has risen due to falling real interest rates where the pension liabilities increased more than the increase in the value of pension assets. The actual funding requirements over the five-year period will be dependent on subsequent annual actuarial valuations. These amounts are estimates, which may change with actual investment performance, changes in interest rates, any pertinent changes in Canadian government regulations and any voluntary contributions.

13. Related Parties

The immediate family of a member of management are 25% owners of a facility that is under lease by the Company through June 2024, with one five-year renewal option through June 2029. The rental expense related to this facility is approximately $1.0 million per year.

During 2017, the Company issued loans totaling $0.6 million to two members of management to assist with the purchase of Class A Units. The loans are interest-bearing, and repayment of each loan is required within 3 years from the date of its execution. The total value of the loans as of December 31, 2018 was $0.1 million, and they were fully paid off in 2019.

 

F-36


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

In addition, we do business with a number of other companies affiliated with Warburg Pincus and GTCR, our Sponsors. All transactions with these companies have been conducted in the ordinary course of our business and are not material to our operations.

14. Other Comprehensive Income (Loss)

Amounts in accumulated other comprehensive income (loss) are presented net of the related tax. Foreign currency translation is not adjusted for income taxes.

Changes in our accumulated other comprehensive income (loss) balances, net of tax, were as follows:

 

(thousands of U.S. dollars)

   Defined
Benefit
Plans
    Foreign
Currency
Translation
    Interest
Rate
Swaps
     Total  

Beginning balance – January 1, 2019

   $ (14,987   $ (94,970   $ —        $ (109,957

Other comprehensive income (loss) before reclassifications

     (676     27,517       179        27,020  

Amounts reclassified from accumulated other comprehensive income (loss)

     (11,450     —         —          (11,450
  

 

 

   

 

 

   

 

 

    

 

 

 

Net current-period other comprehensive income (loss)

     (12,126     27,517       179        15,570  
  

 

 

   

 

 

   

 

 

    

 

 

 

Ending balance – December 31, 2019

   $ (27,113   $ (67,453     $179      $ (94,387
  

 

 

   

 

 

   

 

 

    

 

 

 

Beginning balance – January 1, 2018

   $ (15,860   $ (27,233   $ —        $ (43,093

Other comprehensive income (loss) before reclassifications

     443       (67,737     —          (67,294

Amounts reclassified from accumulated other comprehensive income (loss)

     430       —         —          430  
  

 

 

   

 

 

   

 

 

    

 

 

 

Net current-period other comprehensive income (loss)

     873       (67,737     —          (66,864
  

 

 

   

 

 

   

 

 

    

 

 

 

Ending balance – December 31, 2018

   $ (14,987   $ (94,970     $—        $ (109,957
  

 

 

   

 

 

   

 

 

    

 

 

 

15. Share-Based Compensation

The Company’s equity-based awards issued to employees include restricted unit awards which vest based on either time or the achievement of certain performance and market conditions. These equity-based awards represent an interest in our parent, Sotera Health Topco Parent, L.P. (“Topco Parent”), and are granted in respect of services provided to the Company and its subsidiaries.

Class B-1 time vesting units vest on a daily basis pro rata over a five-year period (20% per year), subject to the grantee’s continued services on each vesting date. Upon the occurrence of a change in control of the Company, all then outstanding unvested Class B-1 Units held by Unitholders will become vested as of the date of consummation of such change in control, subject to the Unitholder’s continued services through the consummation of the change in control.

Class B-2 Units are considered performance vesting units, and are scheduled to vest only upon satisfaction of certain thresholds. These units vest as of the first date on which (i) our Sponsors have received two and one-half times their invested capital in Topco Parent and (ii) the Sponsors’ internal rate of return exceeds twenty percent, subject to such grantee’s continued services through such date. No compensation expense has been recorded on the Class B-2 Units at this time as the related performance conditions are not considered probable of achievement. In the event of a change in control of the Company, any outstanding Class B-2 Units that remain

 

F-37


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

unvested immediately following the consummation of such a change in control of the Company shall be immediately canceled and forfeited without compensation.

Class C Units were issued in June 2016, are considered performance and time vesting units, and were accounted for as liability awards. No compensation expense was recorded on the Class C Units prior to the third quarter of 2019, as the related performance conditions were not considered probable of achievement. In the third quarter of 2019, all Class C Units vested based on the achievement of the aggregate distributions to the A Unitholder Partners and approval of the Board of Sotera Health Topco Parent, L.P. for accelerated vesting, and $10.0 million of stock-compensation expense was recognized and paid in accordance with the terms for redemption of outstanding Class C Units. No Class C Units remain outstanding.

The Company recognized $16.9 million ($10.0 million related to Class C Units and $6.9 million related to Class B-1 Units) and $6.9 million (related to Class B-1 units) of stock-based compensation for the years ended December 31, 2019 and 2018, respectively.

Fair value of the Class B-1 time vesting, B-2 performance vesting, and C Performance vesting units granted is estimated on the date of grant using a simulation-based option valuation model incorporating multiple and variable assumptions over time, including assumptions such as employee forfeitures, unit price volatility and dividend assumptions.

The assumptions used to calculate the fair value of the Class B-1, Class B-2, and Class C units were as follows:

 

     2019     2018  

Risk-free interest rate

     2.7     1.8

Expected volatility

     49     59

Expected dividends

     None       None  

Expected time until exercise (years)

     1.5       2.5  

A summary of the activity for the years ended December 31, 2019 and 2018 related to the Class B-1, B-2 and C units issued to Company employees is presented below:

 

     B-1
Time Vesting
    B-2
Performance
Vesting
    C
Performance
Vesting
 

At January 1, 2018

     53,344,377       17,004,885       4  

Granted

     225,000       75,000       —    

Forfeited

     (1,734,173     (578,058     —    

Vested

     (19,651,070     —         —    
  

 

 

   

 

 

   

 

 

 

At December 31, 2018

     32,184,134       16,501,827       4  

Granted

     3,387,500       987,500       —    

Forfeited

     (4,028,843     (2,478,071     —    

Vested

     (17,092,528     —         (4
  

 

 

   

 

 

   

 

 

 

At December 31, 2019

     14,450,263       15,011,256       —    
  

 

 

   

 

 

   

 

 

 

 

F-38


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

The following table provides a summary of the weighted average unit grant date fair value, weighted average remaining contractual term, total compensation cost and unrecognized compensation cost:

 

December 31, 2019

(dollars in millions, except per award values)

   B-1 Time
Vesting
     B-2
Performance
Vesting
     C
Performance
Vesting
     All
Awards
 

Weighted average grant date fair value per unit of unvested units

   $ 0.41      $ 0.34        N/A      $ 0.37  

Weighted average remaining contractual term

     0.8 years        N/A        N/A        N/A  

Total compensation cost recognized during 2019

   $ 6.9      $  —        $ 10.0      $ 16.9  

Unrecognized compensation cost at December 31

   $ 6.0      $ 5.1        N/A      $ 11.1  

N/A – not applicable

16. Supplemental Pro Forma Loss Per Share (unaudited)

As further discussed in the Subsequent Events note, on November 18, 2020, the Company effected a forward stock split to reclassify all 3,000 shares of its common stock outstanding as 232,400,200 shares. The unaudited supplemental pro forma earnings per share data for the year ended December 31, 2019 is presented below giving effect to the stock split.

Under SEC SAB Topic 1.B.3, a dividend declared in the twelve months preceding an initial public offering would be deemed to be in contemplation of the offering with the intention of repayment out of offering proceeds to the extent that the dividend exceeded earnings during the same period. In December 2019, the Company paid $275.0 million of dividends to Sotera Health Topco Parent L.P. As the Company had a net loss in the twelve months preceding the initial public offering, no amount of the dividend was considered paid out of recent earnings, and as such, the unaudited supplemental pro forma loss per share and pro forma equivalent shares give effect to the issuance of the number of shares that would be required to generate net proceeds sufficient to pay the dividends of $275.0 million in December 2019. The number of incremental shares that would be required to be issued to pay the dividend is based on the assumed initial public offering price of $21.50 per share, the midpoint of the estimated offering price range set forth on the cover of the Company’s prospectus, net of underwriting discount and commissions of $1.13 per share. As a result, 13,500,245 shares to be issued in the offering (the estimated proceeds from which are greater than the amount of the December 2019 dividends) have been included in the denominator for purposes of pro forma loss per share calculations for the year ended December 31, 2019.

The following table sets forth a computation of unaudited supplemental pro forma basic and diluted loss per share for the year ended December 31, 2019:

 

     (unaudited)
December 31, 2019
 

Weighted average common shares outstanding—Basic and Diluted

     232,400,200  

Additional pro forma shares required to be issued in the offering necessary to pay the dividend

     13,500,245  
  

 

 

 

Supplemental pro forma weighted average common shares outstanding—Basic and Diluted

     245,900,445  
  

 

 

 

Supplemental pro forma net loss per share—Basic and Diluted

   $ (0.08
  

 

 

 

 

F-39


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

17. Asset Retirement Obligations (“ARO”)

Our ARO represent the present value of future remediation costs and an increase in the carrying amounts of the related assets in property, plant and equipment in the consolidated balance sheets. The capitalized future site remediation costs are depreciated and the ARO are accreted over the life of the related assets which is included in depreciation and amortization expense, respectively.

The fair value of the ARO is determined based on estimates requiring management judgment. The key assumptions include the timing and estimated decommissioning costs of the remediation activities and credit adjusted risk free interest rates. Changes in the assumptions based on future information may result in adjustments to the estimated obligations over time. No market risk premium has been included in the calculation for the ARO since no reliable estimate can be made by the Company. Any difference between costs incurred upon settlement of an ARO and the liability recognized for the estimated cost of asset retirements will be recognized as a gain or loss in our current period operating results.

Each year, we review decommissioning costs and consider changes in marketplace rates. The following table describes changes to our ARO liability during the years presented:

 

(thousands of U.S. dollars)

             

For the Year Ended

   2019      2018  

ARO – beginning of period

   $ 40,543      $ 41,297  

Changes in estimates

     1,640        61  

Accretion expense

     2,051        1,366  

Foreign currency exchange and other

     962        (2,181
  

 

 

    

 

 

 

ARO – end of period

     45,196        40,543  
  

 

 

    

 

 

 

Less current portion of ARO

     2,200        –    
  

 

 

    

 

 

 

Noncurrent ARO – end of period

   $ 42,996      $ 40,543  
  

 

 

    

 

 

 

We recorded depreciation expense on the ARO of $0.3 million and $0.2 million, for the years ended December 31, 2019 and 2018, respectively.

We are obligated to provide financial assurance to local and state licensing authorities for possible future decommissioning costs associated with the various facilities that hold Co-60. At December 31, 2019 and 2018, $49.3 million and $47.8 million, respectively, of the standby letters of credit referenced above and surety bonds were outstanding in favor of the various local and state licensing authorities in the event we defaulted on our decommissioning obligation.

 

F-40


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

18. Commitments and Contingencies

Leases

We lease certain facilities and equipment under various operating leases that expire through October 2034. At December 31, 2019, aggregate future minimum lease payments, net of sublease income, under all operating leases is shown below:

 

(thousands of U.S. dollars)

Years ended December 31,

   Operating
Leases
 

2020

   $ 11,782  

2021

     10,283  

2022

     9,151  

2023

     6,413  

2024

     4,286  

Thereafter

     18,258  
  

 

 

 

Total

   $ 60,173  
  

 

 

 

Most of our real property leases provide for renewal periods and rent escalations and stipulate that we pay taxes, maintenance, and certain other operating expenses applicable to the leased premises. We recognize rent expense on a straight-line basis over the lease period and accrue for rent expenses incurred but not paid.

Total rent expense for all operating leases for the years ended December 31, 2019 and 2018 was $13.3 million and $13.6 million, respectively.

We depend on a limited number of suppliers for certain of our supply and direct material costs. This includes obligations under various supply agreements in our Nordion segment for Co-60 that are enforceable and legally binding on us. As of December 31, 2019, we had minimum purchase commitments primarily with domestic and international suppliers of raw materials for the Nordion business totaling $1,619 million. The terms of these long-term supply or service arrangements range from 1 to 45 years. In addition, our Sterigenics segment has obligations to purchase ethylene oxide (“EO”) gas. Our contract to purchase EO gas in the U.S. requires us to purchase all of our requirements from one supplier, and our contracts to purchase EO gas outside the U.S. generally require that we purchase a specified percentage of our requirements for our operations in the countries covered by those contracts. Although our EO gas contracts generally do not contain fixed minimum purchase volumes, we estimate the amounts based on the percentage of our requirements specified in the contracts and our budgeted purchase volumes for future periods covered under the contracts to be $28.2 million as of December 31, 2019. Such volumes are expected to be utilized in the normal course of our business and are not recognized on the consolidated balance sheets as a liability.

From time to time, we may be subject to various lawsuits and other claims in the ordinary course of our business. In addition, from time to time, we receive communications from government or regulatory agencies concerning investigations or allegations of noncompliance with laws or regulations in jurisdictions in which we operate.

We establish reserves for specific liabilities in connection with regulatory and legal actions that we determine to be probable and reasonably estimable. No material amounts have been accrued in our consolidated financial statements with respect to any loss contingencies. In certain of the matters described below, we are not able to make a reasonable estimate of any liability because of the uncertainties related to the outcome and/or the amount or range of loss. While it is not possible to determine the ultimate disposition of each of these matters, we do not

 

F-41


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

expect that the ultimate resolution of pending regulatory and legal matters in future periods, including the matters described below, will have a material effect on our financial condition or results of operations. Despite the above, the Company may incur material defense and settlement costs, diversion of management resources and other factors.

FM Global Business Interruption Claim (NRU Outage)

Nordion, due to the shutdown of AECL’s NRU reactor in 2009, suffered a cessation of supply of radioisotopes and business interruption loss. Nordion, by Statement of Claim dated October 22, 2010, issued in Ontario Superior Court an action against the insurer, Factory Mutual Insurance Company (FM Global), claiming $25.0 million USD in losses resulting from the shutdown of AECL’s reactor and its inability to supply radioisotopes through the specified period of approximately 15 months. FM Global objected to Nordion’s claim.

Trial commenced in March 2019 and was completed in September 2019. On March 30, 2020, Nordion received a favorable judgment in the amount of $25.0 million USD, plus pre-judgment interest, for a total judgment value of $39.8 million USD, or $56.4 million CAD based on then prevailing exchange rates should Nordion opt for conversion to Canadian funds. In addition, costs and disbursements have been assessed and awarded by the trial court in favor of Nordion in the approximate amount of $1.1 million CAD ($0.8 million USD) and $161,863 CAD ($0.1 million USD), respectively. On April 27, 2020, FM Global filed notice to appeal the judgment before the Court of Appeal of Ontario. Pending a favorable judgment in the appellate court, any final proceeds would be subject to a contingent fee owed to legal counsel and applicable taxes. As the judgment is considered a contingent gain, any favorable outcome will be recognized in a future period when all appeals are exhausted. It is anticipated that the appeal process could take a year or more to complete.

Willowbrook, Illinois – Government Litigation

On October 30, 2018, the Illinois Attorney General and the State’s Attorney of DuPage County, Illinois, sued Sterigenics U.S., LLC (the “IAG Action”) alleging that authorized EO air emissions from a commercial sterilization facility Sterigenics formerly operated in Willowbrook, Illinois “cause, threaten, or allow air pollution” in violation of the Illinois Environmental Protection Act. The IAG Action did not assert that Sterigenics violated its permit from the Illinois Environmental Protection Agency (“IEPA”) authorizing Sterigenics’ release of regulated levels of EO at the Willowbrook facility.

On February 15, 2019, the acting IEPA director, John Kim, issued a “Seal Order” effectively precluding Sterigenics’ operations at the Willowbrook facility based on many of the same allegations asserted in the IAG Action. Sterigenics disputed those allegations and opposed the IEPA’s Seal Order. The Seal Order was resolved by a Consent Order entered on September 6, 2019. The Consent Order provided that Sterigenics did not admit the allegations of the IAG Action, provided for the removal of the Seal Order and allowed the Willowbrook facility to reopen upon implementation of supplemental emissions control measures consistent with a new law that became effective in Illinois in June 2019 and an IEPA permit that was approved in September 2019. Following entry of the Consent Order, the Seal Order was withdrawn.

On September 30, 2019, Sterigenics announced the closure of the Willowbrook facility due to the inability to reach an agreement to renew the facility’s lease and the unstable legislative and regulatory landscape in Illinois. Sterigenics is in the process of decommissioning the facility and completing the work required by the terms of its lease to return the property to the landlord.

 

F-42


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

Ethylene Oxide Tort Litigation – Illinois

Since September 2018, tort lawsuits on behalf of nearly 800 plaintiffs (which are described further in the following paragraphs) have been filed in Illinois state court against Sotera Health LLC, Sterigenics U.S., LLC and other parties related to Sterigenics’ Willowbrook, Illinois operations. Specifically, those plaintiffs allege that they suffered personal injuries including cancer and other diseases, or wrongful death, resulting from purported emissions and releases of EO from the Willowbrook facility. Plaintiffs seek damages in an amount to be determined by the trier of fact. Plaintiffs have voluntarily dismissed without prejudice a number of cases since September 2018, including certain individual cases alleging personal injuries and two class actions seeking property damages.

Sterigenics successfully sought consolidation of certain of these cases for pretrial purposes, which cases have now been consolidated before Judge Lawler in the Cook County Circuit Court, Illinois (the “Consolidated Case”). At present, 71 individual personal injury claims remain pending in the Consolidated Case. All plaintiffs in the Consolidated Case filed a single Master Complaint on October 24, 2019 by which Sotera Health LLC was added as a co-defendant, followed by a First Amended Master Complaint on January 31, 2020. On April 28, 2020, the defendants filed motions to dismiss the claims in the First Amended Master Complaint. On August 17, 2020, the Court entered an order largely denying the motions to dismiss, and the same day plaintiffs filed a Second Amended Master Complaint. Fact discovery is taking place in the Consolidated Case. A May 3, 2021 trial date has been set for Kamuda v. Sterigenics, the first-filed of the individual cases now included in the Consolidated Case, which is the first scheduled trial in these proceedings. Four additional cases now included in the Consolidated Case are currently scheduled for trials starting in June, August, September and November 2021. We anticipate that additional trials will be scheduled after 2021 in roughly the order in which the individual cases were filed.

On or about August 21, 2020, approximately 750 plaintiffs filed similar personal injury lawsuits against Sotera Health LLC, Sterigenics U.S., LLC and other parties in the Cook County Circuit Court, Illinois (but not in the existing Consolidated Case). We expect that most or all of these newly filed cases will be consolidated for pre-trial purposes with the Consolidated Case. There is currently no date set for the defendants to answer or otherwise respond to these newly filed cases.

On August 19, 2020, a lawsuit against Sotera Health LLC, Sterigenics U.S., LLC and other parties was filed by seven plaintiffs in the DuPage County Circuit Court, Illinois. The plaintiffs allege that they suffered personal injuries including but not limited to cancer resulting from purported emissions and releases of EO from the Willowbrook facility. Plaintiffs seek damages in an amount to be determined by the trier of fact. It is possible that this case will also be transferred to and consolidated with the above described Consolidated Case pending in Cook County, Illinois.

Additional personal injury and property damage lawsuits may be filed in the future against Sotera Health LLC and Sterigenics U.S., LLC relating to Sterigenics’ Willowbrook facility or other EO processing facilities. Sotera Health LLC and Sterigenics U.S., LLC intend to defend themselves vigorously in all such EO tort litigation.

The Company carries insurance to cover alleged environmental liabilities with limits of $10.0 million per occurrence and $20.0 million in the aggregate. The per occurrence limit related to the Willowbrook EO tort litigations was fully utilized by June 30, 2020. We have not provided for a contingency reserve in connection with these claims. While we intend to vigorously defend the Willowbrook proceedings, there can be no assurance that we will be successful. We are unable to predict the incidence or outcome of such litigation or to reasonably estimate the possible range of any losses that could be incurred. An adverse outcome in one or more of these proceedings could have a material adverse effect on our business, financial condition and results of operations.

 

F-43


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

Ethylene Oxide Tort Litigation – Georgia

On May 19, 2020 a lawsuit against Sotera Health, LLC, Sterigenics U.S., LLC and other parties was filed in the State Court of Cobb County, Georgia by 53 employees of a contract sterilization customer of Sterigenics. Plaintiffs claim personal injuries resulting from alleged exposure to residual ethylene oxide while working at the customer’s distribution center in Lithia Springs, Georgia and seek damages in an amount to be determined by the trier of fact. Motions to dismiss were filed by all defendants in August 2020. All defendants are being defended and indemnified by Sterigenics’ contract sterilization customer (plaintiffs’ employer).

In May 2020, the Cobb County, Georgia Board of Tax Assessors reduced certain residential property value assessments around the Sterigenics Atlanta facility by 10% citing an “Epd-identified environmental issue,” without providing the requisite factual support for the reduction. On August 14, 2020, Sterigenics U.S., LLC filed a lawsuit against members of the Cobb County Board of Tax Assessors in the U.S. District Court for the Northern District of Georgia, seeking a declaration that the reduction in property value assessments is unlawful and is causing Sterigenics reputational and imminent economic harm. Defendants’ responses to the complaint are due in September 2020, at which time the Court will also receive submissions by the parties on issues of standing and jurisdiction.

On August 17, 2020 a lawsuit against Sotera Health LLC, Sterigenics U.S., LLC and other parties was filed by two plaintiffs in the State Court of Cobb County, Georgia. Plaintiffs allege that they suffered personal injuries and loss of consortium resulting from purported emissions and releases of EO from Sterigenics’ Atlanta facility. Plaintiffs seek damages in an amount to be determined by the trier of fact.

The Company carries insurance to cover alleged environmental liabilities with limits of $10.0 million per occurrence and $20.0 million in the aggregate, which is the same policy referred to under Ethylene Oxide Tort Litigation - Illinois above. We have not provided for a contingency reserve in connection with these claims.

Additional personal injury and property damage lawsuits may be filed in the future against Sotera Health LLC and Sterigenics U.S., LLC relating to Sterigenics’ Atlanta facility or other EO processing facilities. Sotera Health LLC and Sterigenics U.S., LLC intend to defend themselves vigorously in all such EO tort litigation. While we intend to vigorously defend these proceedings, there can be no assurance that we will be successful. We are unable to predict the incidence or outcome of such litigation or to reasonably estimate the possible range of any losses that could be incurred. An adverse outcome in one or more of these proceedings could have a material adverse effect on our business, financial condition and results of operations.

Suspension of Georgia Facility Operations & Related Litigation

On August 7, 2019, Sterigenics U.S., LLC entered into a voluntary Consent Order with the Georgia Environmental Protection Division (“EPD”) under which Sterigenics agreed to install emissions reduction enhancements at its Atlanta facility to further reduce the facility’s EO emissions below already permitted levels. Sterigenics voluntarily suspended operations at the facility in early September 2019 to expedite completion of the enhancements. Installation of these enhancements is complete, and Sterigenics successfully tested the enhanced emissions controls in cooperation with EPD during the second quarter of 2020 while the facility was in operation.

In October 2019, while Sterigenics had voluntarily suspended the facility’s operations, Cobb County, Georgia officials asserted that the facility had an incorrect “certificate of occupancy” and could not resume operations without obtaining a new certificate of occupancy after a third-party code compliance review they required.

After the Cobb County officials would not allow Sterigenics to resume operations, on March 30, 2020, Sterigenics U.S., LLC filed a lawsuit in the United States District Court for the Northern District of Georgia

 

F-44


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

against Cobb County, Georgia and Cobb County officials Nicholas Dawe and Kevin Gobble. In the lawsuit, Sterigenics sought immediate injunctive relief and permanent declaratory relief to resume normal operations of the Atlanta facility in the interest of public health and on the basis that the positions asserted by Cobb County were unfounded. On April 1, 2020 the Court entered a Temporary Restraining Order prohibiting Cobb County officials from precluding or interfering with the facility’s normal operations. On April 8, 2020, the Court entered a Consent Order extending the Temporary Restraining Order and allowing the facility to continue normal operations until entry of a final judgment in the case. On June 24, 2020 Sterigenics filed an amended complaint, and on July 22, 2020 defendants filed a motion to dismiss the claims. Sterigenics has responded in opposition to the motion, and the motion will be fully briefed by September 16, 2020. A ruling on the motion to dismiss is expected by November 2020. No trial date has been set. Sterigenics’ EO processing facilities have consistently operated in compliance with air emission permits issued by state authorities and applicable USEPA air emission regulations. The USEPA is expected to propose updated air emission regulations for EO processing facilities in the coming months, and Sterigenics intends to make appropriate investments in its facilities to ensure compliance with new regulatory requirements.

19. Financial Instruments and Financial Risk

Derivative Instruments

We do not use derivatives for trading or speculative purposes and are not a party to leveraged derivatives.

We have embedded derivatives in certain of our customer and supply contracts as a result of the currency of the contract being different from the functional currency of the parties involved. Changes in the fair value of the embedded derivatives are recognized in “Other income, net” in the consolidated statements of operations and comprehensive income (loss).

In October 2017, we entered into two interest rate cap agreements with a total notional amount of $400.0 million for a total option premium of $0.6 million. The interest rate cap agreements terminate on September 30, 2020.

During the third quarter of 2019, we entered into two interest rate swap agreements to hedge our exposure to interest rate movements and to manage interest expense related to our outstanding variable-rate debt. These swaps were designated as hedges against the changes in cash flows attributable to changes in LIBOR, the benchmark interest rate being hedged. We receive interest at one-month LIBOR and pay a fixed interest rate under the terms of the swap agreement. The termination date of the swap agreements was August 31, 2020. The notional amount of the interest rate swap agreements totals $1,000.0 million.

The following table provides the fair values of our derivative instruments:

 

(thousands of U.S. dollars)

   December 31,
2019
     December 31,
2018
 

Assets

     

Interest rate caps

   $ 1      $ 335  

Interest rate swaps

     242        —    

Embedded derivatives(a)

     —          752  

Liabilities

     

Embedded derivatives(a)

   $ 3,478      $ 5,248  
(a)

As of December 31, 2019, and 2018, total notional amounts for certain of the Company’s supply and sales contracts for embedded derivatives were approximately $96 million and $117 million, respectively.

 

F-45


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

The interest rate caps are included in “Other assets” as of December 31, 2018 whereas interest rate swaps and embedded derivatives assets are included in “Prepaid expenses and other current assets” on our consolidated balance sheets. Embedded derivative liabilities are included in “Accrued liabilities” on the consolidated balance sheets.

The following tables summarize the activities of our derivative instruments for the periods presented, and the line item in the consolidated statements of operations and comprehensive income (loss):

 

(thousands of U.S. dollars)

            

Year Ended December 31,

   2019     2018  

Unrealized loss on interest rate caps recorded in interest expense, net

   $ 335     $ 76  

Unrealized (gain) loss on embedded derivatives recorded in other expense (income), net

     (1,200     1,019  

In addition, during the year-ended December 31, 2019, we recognized $0.2 million of gains in accumulated other comprehensive income (loss) related to the change in fair value of the interest rate swaps. The amounts included in accumulated other comprehensive income will be reclassified to interest expense should the hedge no longer be considered effective. No amount of ineffectiveness was included in net income (loss) for the period ended December 31, 2019.

Credit Risk

Certain of our financial assets, including cash and cash equivalents, are exposed to credit risk.

We are also exposed, in our normal course of business, to credit risk from our customers. As of December 31, 2019 and 2018, accounts receivable was net of an allowance for uncollectible accounts of $0.8 million and $0.9 million, respectively.

Credit risk on financial instruments arises from the potential for counterparties to default on their contractual obligations to us. We are exposed to credit risk in the event of non-performance, but do not anticipate non-performance by any of the counterparties to our financial instruments. We limit our credit risk by dealing with counterparties that are considered to be of high credit quality. In the event of non-performance by counterparties, the carrying value of our financial instruments represents the maximum amount of loss that would be incurred.

Fair Value Hierarchy

The fair value of our financial instruments is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The valuation techniques we would use to determine such fair values are described as follows: Level 1—fair values determined by inputs utilizing quoted prices in active markets for identical assets or liabilities; Level 2—fair values based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable; Level 3—fair values determined by unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by other market participants.

 

F-46


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

The following table discloses the Company’s financial assets and liabilities measured at fair value on a recurring basis:

 

As of December 31, 2019

                          

(thousands of U.S. dollars)

   Level 1      Level 2     Level 3      Total  

Interest rate caps

   $ —        $ 1     $ —        $ 1  

Interest rate swaps

     —          242       —          242  

Embedded derivative liabilities

     —          (3,478     —          (3,478

 

As of December 31, 2018

                          

(thousands of U.S. dollars)

   Level 1      Level 2     Level 3      Total  

Interest rate caps

   $ —        $ 335     $ —        $ 335  

Embedded derivative assets

     —          752       —          752  

Embedded derivative liabilities

     —          (5,248     —          (5,248

The fair value of our 1st Lien Term Loan due 2026 and the 2nd Lien Secured Notes due 2027 was $2,130.6 million and $770 million, respectively as of December 31, 2019. The fair value of our Term Loan (including current maturities), Secured Notes, and Senior PIK Toggle Notes was $1,299.0 million, $432.0 million, and $403.8 million at December 31, 2018, respectively. The fair values were calculated using external pricing information, which is considered a Level 2 input as described above.

20. Segment and Geographic Information

We identify our operating segments based on the way we manage, evaluate and internally report our business activities for purposes of allocating resources and assessing performance. We currently have three reportable segments: Sterigenics, Nordion and Nelson Labs. We have determined our reportable segments based upon an assessment of organizational structure, service types, and internally prepared financial statements. Our chief operating decision maker evaluates performance and allocates resources based on net revenues and segment income after the elimination of intercompany activities. The accounting policies of our reportable segments are the same as those described in the Significant Accounting Policies note.

Sterigenics

The Sterigenics segment provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets.

Nordion

Nordion is a global provider of Co-60 and gamma irradiators, which are key components to the gamma sterilization process.

Nelson Labs

Nelson Labs provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and biopharmaceutical industries.

Other

The other reportable segment consisted of the Medical Isotopes business, a global supplier of critical medical isotopes for research, healthcare diagnostic and therapeutic uses. On July 30, 2018, we finalized the sale of the Medical Isotopes assets for $213.0 million.

 

F-47


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

For the year ended December 31, 2019, four customers reported within the Nordion segment individually represented 10% or more of the segment’s total net revenues. These customers represented 14.1%, 12.9%, 12.7%, and 10.1% of the total segment’s external net revenues for the year ended December 31, 2019.

 

(thousands of U.S. dollars)

     Year Ended December 31, 2019  
     Sterigenics      Nordion      Nelson Labs      Other      Consolidated  

Net revenues1

   $ 471,708      $ 116,165      $ 190,454      $ —        $ 778,327  

Segment income2

     244,904        62,196        72,832        —          379,932  

Capital expenditures

     51,123        2,034        4,100        —          57,257  

 

                   Year Ended December 31, 2018  
     Sterigenics      Nordion      Nelson
Labs
     Other      Consolidated  

Net revenues1

   $ 435,733      $ 118,829      $ 166,217      $ 25,370      $ 746,149  

Segment income2

     216,490        60,288        58,915        4,944        340,637  

Capital expenditures

     61,297        4,261        6,661        394        72,613  
1

Revenues are reported net of intersegment sales. Our Nordion segment recognized $40.9 million and $33.4 million in revenues from sales to our Sterigenics segment for the years ended December 31, 2019 and 2018, respectively, that is not reflected in net revenues in the table above. Intersegment sales for Sterigenics and Nelson Labs are immaterial for both periods.

2 

Segment income is only provided on a net basis to the chief operating decision maker and is reported net of intersegment profits.

Corporate operating expenses for executive management, accounting, information technology, legal, human resources, treasury, corporate development, tax, purchasing, and marketing are allocated to the segments based on total revenue.

Total assets and depreciation and amortization expense by segment are not readily available and are not reported separately to the chief operating decision maker.

 

F-48


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

A reconciliation of segment income to consolidated income (loss) before taxes is as follows:

 

(thousands of U.S. dollars)

Year Ended December 31,

   2019     2018  

Segment income

   $ 379,932     $ 340,637  

Less adjustments:

    

Interest expense, net

     157,729       143,326  

Depreciation and amortization(a)

     146,719       146,816  

Impairment of long-lived assets and intangible assets(b)

     5,792       85,067  

Gain on sale of Medical Isotopes business(c)

     —         (95,910

Share-based compensation(d)

     16,882       6,943  

One-time bonuses(e)

     2,040       —    

(Gain) loss on foreign currency and embedded derivatives(f)

     2,662       14,095  

Acquisition and divestiture related charges, net(g)

     (318     1,168  

Business optimization project expenses(h)

     4,195       8,805  

Plant closure expenses(i)

     1,712       —    

Loss on extinguishment of debt(j)

     30,168       —    

Professional services relating to Willowbrook and Atlanta facilities(k)

     11,216       4,739  

Accretion of asset retirement obligation(l)

     2,051       1,366  
  

 

 

   

 

 

 

Consolidated income (loss) before taxes

   $ (916   $ 24,222  
  

 

 

   

 

 

 
(a) 

Includes depreciation of Co-60 held at gamma irradiation sites.

(b) 

For 2019, represents impairment charges related to the decision to not reopen the Willowbrook, Illinois facility in September 2019. For 2018, represents impairment charges associated with the withdrawal of the GA-MURR project.

(c) 

Represents the gain on the divestiture of the Medical Isotopes business in July 2018.

(d) 

Represents non-cash share-based compensation expense. In 2019, also includes $10.0 million of one-time cash share-based compensation expense related to the Class C Performance Vesting Units, which vested in the third quarter of 2019 based on the achievement of the aggregate distributions to the A Unitholder partners and the approval of the board of Topco Parent for accelerated vesting.

(e) 

Represents one-time cash bonuses for members of management relating to capital markets activity in 2019.

(f) 

Represents the effects of (i) fluctuations in foreign currency exchange rates, primarily related to remeasurement of intercompany loans denominated in currencies other than subsidiaries’ functional currencies, and (ii) non-cash mark-to-fair value of embedded derivatives relating to certain customer and supply contracts at Nordion.

(g) 

Represents (i) certain direct and incremental costs related to the acquisition of Toxikon Europe NV (“Nelson Europe”) in 2017, Gibraltar Laboratories, Inc. (“Nelson Fairfield”) in 2018 and Iotron Industries Canada, Inc. in July 2020, and certain related integration efforts as a result of those acquisitions, (ii) the earnings impact of fair value adjustments (excluding those recognized within amortization expense) resulting from the businesses acquired, and (iii) transition services income and non-cash deferred lease income associated with the terms of the divestiture of the Medical Isotopes business in 2018.

(h) 

Represents professional fees, contract termination and exit costs, severance and other payroll costs, and other costs associated with business optimization and cost savings projects relating to the integrations of Nordion and Nelson Labs, including the divestiture of the Medical Isotopes business, the withdrawal from the GA-MURR project, the Sotera Health rebranding, operating structure realignment and other process enhancement projects.

(i) 

Represents professional fees, severance and other payroll costs, and other costs associated with the closure of the Willowbrook, Illinois facility.

 

F-49


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

(j) 

Represents one-time expenses incurred in connection with the refinancing of our debt capital structure in December 2019, including accelerated amortization of prior debt issuance and discount costs, premiums paid in connection with early extinguishment and debt issuance and discount costs incurred for the new debt.

(k) 

Represents professional fees related to litigation associated with our EO sterilization facilities in Willowbrook, Illinois and Atlanta, Georgia and other related professional fees. See “Commitments and Contingencies” note.

(l) 

Represents the non-cash accretion of asset retirement obligations related to Co-60 and gamma processing facilities, which are based on estimated site remediation costs for any future decommissioning of these facilities (without regard for whether the decommissioning services would be performed by employees of Nordion, instead of by a third party) and are accreted over the life of the asset.

Geographic Information

Net revenues for geographic area are reported by the country’s origin of the revenues.

 

(thousands of U.S. dollars)

             

Year Ended December 31,

   2019      2018  

United States

   $ 473,958      $ 434,731  

Canada

     130,469        152,191  

Europe

     122,606        114,228  

Other

     51,294        44,999  
  

 

 

    

 

 

 

Total

   $ 778,327      $ 746,149  
  

 

 

    

 

 

 

The ‘Other’ category above is primarily comprised of net revenues from Asian and Latin American countries that each represent 2% or less of our total net revenues.

Long-lived assets are based on physical locations and are comprised of the net book value of property, plant, and equipment.

 

(thousands of U.S. dollars)

             

As of December 31,

   2019      2018  

United States

   $ 305,090      $ 316,566  

Europe

     121,771        124,581  

Canada

     86,163        77,417  

Other

     68,930        67,872  
  

 

 

    

 

 

 

Total

   $ 581,954      $ 586,436  
  

 

 

    

 

 

 

The ‘Other’ category above is primarily comprised of long-lived assets in Asian and Latin American countries that each represent 4% or less of our total long-lived assets.

21. Subsequent Events

We have evaluated events occurring subsequent to December 31, 2019 through September 2, 2020, which is the date the consolidated financial statements were originally issued, and through November 18, 2020, the date the consolidated financial statements were reissued.

 

F-50


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

 

On November 18, 2020, the Company filed an amendment to its certificate of incorporation, effecting a forward stock split to reclassify all 3,000 shares of its common stock outstanding as 232,400,200 shares, which was approved by the Company’s board of directors and sole stockholder on November 10, 2020. The accompanying financial statements and related notes and schedules to the financial statements give retroactive effect to the stock split for all periods presented.

Iotron Industries Canada, Inc. Acquisition

On July 31, 2020, we acquired Iotron Industries Canada, Inc. (“Iotron”) for approximately $145.0 million Canadian dollars (“CAD”) (approximately $108.1 million USD), subject to customary working capital and other adjustments. Iotron is an independent contact sterilizer with two North American locations in Vancouver, Canada, and Columbia City, Indiana. Each location uses proprietary high energy electron beam technology to process products for orthopedic, medical device, plastics, and agricultural businesses. Sales for Iotron’s fiscal year-ended September 30, 2019 were $22.8 million CAD ($16.7 million USD) and will be part of the Sterigenics segment. The acquisition was financed by the issuance of $100.0 million of 1st lien notes due 2026 by SHH. This new issuance is privately placed and bears an interest rate of 3-month LIBOR, which cannot be less than 1.00%, plus a margin of 6.00%. Interest is payable on a quarterly basis with no principal due until maturity.

 

F-51


Table of Contents

Sotera Health Company (Parent company only)

Schedule I – Condensed Financial Information of Registrant

Condensed Balance Sheets

(in thousands, except per share amounts)

 

     As of  
     December 31,      December 31,  
     2019      2018  
     

Assets

     

Current assets:

     

Income taxes receivable

   $ 448      $ —    
  

 

 

    

 

 

 

Total current assets

     448        —    

Deferred income taxes

     12,209        8,939  

Investments in subsidiaries

     —          473,599  
  

 

 

    

 

 

 

Total assets

   $ 12,657      $ 482,538  
  

 

 

    

 

 

 

Liabilities and equity

     

Current liabilities:

     

Accrued interest

   $ —        $ 5,637  
  

 

 

    

 

 

 

Total current liabilities

     —          5,637  

Long-term debt

     —          419,385  
  

 

 

    

 

 

 

Total liabilities

     —          425,022  

Equity:

     

Common stock, with $0.01 par value, 232,400 shares authorized, issued and outstanding at December 31, 2019, and December 31, 2018

     2,324        2,324  

Other equity

     10,333        55,192  
  

 

 

    

 

 

 

Total equity

     12,657        57,516  
  

 

 

    

 

 

 

Total liabilities and equity

   $ 12,657      $ 482,538  
  

 

 

    

 

 

 

Share amounts and per share data give retroactive effect to the forward stock split effective November 18, 2020.

See notes to condensed financial information.

 

F-52


Table of Contents

Sotera Health Company (Parent company only)

Schedule I – Condensed Financial Information of Registrant

Condensed Statements of Operations and Comprehensive Loss

(in thousands)

 

     Year Ended  
     December 31,     December 31,  
     2019     2018  

Interest expense, net

   $ 34,824     $ 36,519  

Loss on extinguishment of debt

     3,718       —    
  

 

 

   

 

 

 

Loss before income taxes

     (38,542     (36,519

Benefit for income taxes

     (4,589     (9,226
  

 

 

   

 

 

 

Net loss and comprehensive loss

   $ (33,953   $ (27,293
  

 

 

   

 

 

 

See notes to condensed financial information.

 

F-53


Table of Contents

Sotera Health Company (Parent company only)

Schedule I – Condensed Financial Information of Registrant

Condensed Statements of Cash Flows

(in thousands)

 

     Year Ended  
     December 31,     December 31,  
     2019     2018  

Operating activities

    

Net cash used in operating activities

   $ (37,693   $ (34,484

Investing activities

    

Dividends received from subsidiaries

     1,153,863       209,874  
  

 

 

   

 

 

 

Net cash provided by investing activities

     1,153,863       209,874  

Financing activities

    

Dividends to shareholders

     (691,170     (175,845

Payments on debt

     (425,000     —    
  

 

 

   

 

 

 

Net cash used in financing activities

     (1,116,170     (175,845

Net increase (decrease) in cash and cash equivalents, including restricted cash

     —         (455

Cash and cash equivalents, including restricted cash, at beginning of period

     —         455  
  

 

 

   

 

 

 

Cash and cash equivalents, including restricted cash, at end of period

   $ —       $ —    
  

 

 

   

 

 

 

Supplemental disclosures of cash flow information:

    

Cash paid during the period for interest

   $ 38,560     $ 34,531  

See notes to condensed financial information.

 

F-54


Table of Contents

Sotera Health Company (Parent company only)

Schedule I – Condensed Financial Information of Registrant

Notes to Condensed Financial Information

1. Basis of Presentation

Sotera Health Company conducts substantially all of its activities through its direct wholly owned subsidiary, Sotera Health Holdings, LLC (“SHH”) and its subsidiaries. In the parent company only financial statements, Sotera Health Company’s investment in subsidiaries is stated at cost plus equity in undistributed earnings of subsidiaries less dividends received in excess of subsidiaries’ retained profits since the date of acquisition. The parent company only financial statements should be read in conjunction with Sotera Health Company’s consolidated financial statements.

2. Guarantees and Restrictions

As of December 31, 2019, SHH had $2,120.0 million of debt outstanding under its 1st Lien Senior Secured Credit Facilities and $770.0 million outstanding under its 2nd Lien Senior Secured Notes (the “Debt Agreements”). All obligations under the Debt Agreements are unconditionally guaranteed by Sotera Health Company and each existing and subsequently acquired or organized direct or indirect wholly-owned domestic restricted subsidiary of SHH with customary exceptions including, among other things, where providing such guarantees is not permitted by law, regulation or contract or would result in material adverse tax consequences. All obligations under the Debt Agreements, and the guarantees of such obligations, are secured by substantially all assets of the borrower and guarantors, subject to permitted liens and other exceptions and exclusions, as outlined in the Debt Agreements.

Both the Debt Agreements contain additional covenants that, among other things, restrict, subject to certain exceptions, the ability of Sotera Health Holdings, LLC and the ability of its restricted subsidiaries to engage in certain activities, such as incur indebtedness and liens in connection therewith, pay dividends and make certain other restricted payments, make certain investments, enter into transactions with affiliates, dispose of property or assets, and enter into unrelated lines of business. The Debt Agreements also contain certain customary affirmative covenants and events of default, including upon a change of control.

SHH is permitted to pay dividends to Sotera Health Company under the Debt Agreements subject to certain limits and ratios. In general, as long as there is no default, the Debt Agreements permit SHH to pay dividends to Sotera Health Company:

(1) without limit if SHH does not exceed a maximum leverage ratio related to senior secured debt of 6.00 to 1.00, as specified in the Debt Agreements; or

(2) if SHH does not exceed a maximum leverage ratio related to total debt of 7.50 to 1.00, as specified in the Debt Agreements, then generally in amounts up to a basket that builds based on the sum of (a) 25% of SHH’s Consolidated EBITDA (as defined in the Debt Agreements) for the preceding 12-month test period, or $96.0 million if greater, plus (b) 50% of SHH’s Consolidated Net Income (as defined in the Debt Agreements) from October 1, 2019 through the end of such test period (or, if greater, retained Excess Cash Flow (as defined in the Debt Agreements)), plus (c) the net proceeds of certain qualified equity offerings and equity contributions to SHH by Sotera Health Company; or

(3) following an initial public offering of Sotera Health Company, in an amount equal to 6.00% annually of the cash proceeds of the initial public offering that are contributed to SHH.

Prior to 2019, Sotera Health Company had $425 million aggregate principal amount of Senior PIK (“paid in kind”) Toggle notes outstanding at a rate of 8.125%/8.875% per year.

 

F-55


Table of Contents

Sotera Health Company (Parent company only)

Schedule I – Condensed Financial Information of Registrant

Notes to Condensed Financial Information

 

Since the restricted net assets of Sotera Health Holdings, LLC and its subsidiaries exceed 25% of the consolidated net assets of Sotera Health Company, the accompanying condensed parent company financial statements have been prepared in accordance with Rule 12-04, Schedule 1 of Regulation S-X.

3. Dividends from Subsidiaries

During 2019 and 2018, Sotera Health Company received dividends from its subsidiaries primarily consisting of amounts received to redeem, in full, previously outstanding $425.0 million Senior PIK (“paid in kind”) Toggle Notes due 2021, pay interest on previously outstanding debt, and to issue dividends to its sole stockholder, Sotera Health Topco Parent L.P.

 

F-56


Table of Contents

Sotera Health Company

Schedule II – Valuation and Qualifying Accounts

Schedule II – Valuation and Qualifying Accounts

 

Description

   Balance at
Beginning of
Period
     Charges
(credits) to
costs and
expense
    Deductions(1)     Translation
Adjustments(2)
    Balance at End
of Period
 

(In thousands of dollars)

           

Year Ended December 31, 2019

           

Deducted from asset accounts:

           

Allowance for uncollectible accounts receivable

   $ 928      $ 482     $ (591   $ (32   $ 787  

Deferred tax asset valuation allowance

     16,678        6,318       —         (34     22,962  

Year Ended December 31, 2018

           

Deducted from asset accounts:

           

Allowance for uncollectible accounts receivable

   $ 824      $ 473     $ (334   $ (35   $ 928  

Deferred tax asset valuation allowance

     23,573        (6,804     —         (91     16,678  

 

(1) 

Uncollectible accounts written off, net of recoveries

(2) 

Change in foreign currency exchange rates

 

F-57


Table of Contents

Sotera Health Company

Consolidated Balance Sheets

(in thousands)

 

     As of  
     September 30,
2020
     December 31,
2019
 
     (Unaudited)         

Assets

     

Current assets:

     

Cash and cash equivalents

   $ 108,276      $ 62,863  

Restricted cash short-term

     169        162  

Accounts receivable, net of allowance for uncollectible accounts of $791 in 2020 and $787 in 2019

     87,083        88,644  

Inventories, net

     29,153        37,396  

Prepaid expenses and other current assets

     60,050        52,644  

Income taxes receivable

     23,774        10,645  
  

 

 

    

 

 

 

Total current assets

     308,505        252,354  

Property, plant, and equipment, net

     581,239        581,954  

Operating lease assets

     46,903        —    

Investment in unconsolidated affiliate

     12,857        —    

Deferred income taxes

     2,354        2,252  

Other assets

     9,436        12,243  

Other intangible assets, net

     647,129        696,006  

Goodwill

     1,091,581        1,035,865  
  

 

 

    

 

 

 

Total assets

   $  2,700,004      $  2,580,674  
  

 

 

    

 

 

 

Liabilities and equity

     

Current liabilities:

     

Accounts payable

   $ 43,673      $ 42,004  

Accrued liabilities

     64,707        58,536  

Deferred revenue

     4,080        3,631  

Current portion of long-term debt, including revolver

     21,200        16,331  

Current portion of finance lease obligations

     1,044        1,288  

Current portion of operating lease obligations

     9,371        —    

Current portion of asset retirement obligations

     620        2,200  
  

 

 

    

 

 

 

Total current liabilities

     144,695        123,990  

Long-term debt, less current portion

     2,888,780        2,800,873  

Finance lease obligations, less current portion

     30,743        29,883  

Operating lease obligations, less current portion

     39,918        —    

Noncurrent asset retirement obligations

     43,115        42,996  

Deferred lease income

     20,404        21,375  

Post-retirement obligations

     26,440        31,266  

Mandatorily redeemable noncontrolling interest

     13,625        13,625  

Noncurrent liabilities

     17,283        20,563  

Deferred income taxes

     137,002        137,235  
  

 

 

    

 

 

 

Total liabilities

     3,362,005        3,221,806  

See Commitments and contingencies note

     

Equity:

     

Common stock, with $0.01 par value, 232,400 shares authorized, 232,400 shares issued and outstanding at

     

 

F-58


Table of Contents

Sotera Health Company

Consolidated Balance Sheets

(thousands of U.S. dollars)

 

     As of  
     September 30,
2020
    December 31,
2019
 
     (Unaudited)        

September 30, 2020, and December 31, 2019

     2,324      
2,324
 

Additional paid-in capital

     4,019       —    

Retained deficit

     (545,448     (550,511

Accumulated other comprehensive loss

     (124,753     (94,387
  

 

 

   

 

 

 

Total equity (deficit) attributable to Sotera Health Company

     (663,858     (642,574

Noncontrolling interests

     1,857       1,442  
  

 

 

   

 

 

 

Total equity (deficit)

     (662,001     (641,132
  

 

 

   

 

 

 

Total liabilities and equity (deficit)

   $ 2,700,004     $ 2,580,674  
  

 

 

   

 

 

 

Share amounts and per share data give retroactive effect to the forward stock split as described in the Subsequent Events footnote effective November 18, 2020.

See notes to unaudited consolidated financial statements.

 

F-59


Table of Contents

Sotera Health Company

Consolidated Statements of Operations and Comprehensive Income (Loss)

(in thousands, except per share amounts)

 

     Nine Months Ended  
     September 30,
2020
    September 30,
2019
 
     (Unaudited)  

Revenues:

    

Service

   $  524,025     $  501,875  

Product

     77,288       82,967  
  

 

 

   

 

 

 

Total net revenues

     601,313       584,842  

Cost of revenues:

    

Service

     247,386       248,406  

Product

     30,932       38,226  
  

 

 

   

 

 

 

Total cost of revenues

     278,318       286,632  
  

 

 

   

 

 

 

Gross profit

     322,995       298,210  

Operating expenses:

    

Selling, general and administrative expenses

     125,369       110,360  

Amortization of intangible assets

     43,989       43,942  

Impairment of long-lived assets

     —         5,781  
  

 

 

   

 

 

 

Total operating expenses

     169,358       160,083  
  

 

 

   

 

 

 

Operating income

     153,637       138,127  

Interest expense, net

     167,142       114,478  

Foreign exchange (gain) loss

     (5,370     8,444  

Other income, net

     (4,353     (4,746
  

 

 

   

 

 

 

Income (loss) before income taxes

     (3,782     19,951  

Provision (benefit) for income taxes

     (9,677     12,630  
  

 

 

   

 

 

 

Net income

     5,895       7,321  

Less: Net income attributable to noncontrolling interests

     832       271  
  

 

 

   

 

 

 

Net income attributable to Sotera Health Company

   $ 5,063     $ 7,050  
  

 

 

   

 

 

 

Other comprehensive (loss) income net of tax:

    

Pension and post-retirement benefits (net of taxes of $236 and $137), respectively)

   $ 700     $ (409

Interest rate swaps (net of taxes of ($63), and $172, respectively)

     (179     509  

Foreign currency translation

     (31,304     10,968  
  

 

 

   

 

 

 

Comprehensive income (loss)

     (24,888     18,389  

Less: comprehensive income attributable to noncontrolling interests

     832       156  
  

 

 

   

 

 

 

Comprehensive income (loss) attributable to Sotera Health Company

   $ (25,720   $ 18,233  
  

 

 

   

 

 

 

Earnings per share attributable to Sotera Health Company

    

Basic and diluted

   $ 0.02     $ 0.03  

Pro forma basic and diluted (unaudited)

     0.02    

Weighted average number of shares outstanding attributable to Sotera Health Company

    

Basic and diluted

     232,400       232,400  

Pro forma basic and diluted (unaudited)

     246,152    

 

F-60


Table of Contents

Share amounts and per share data give retroactive effect to the forward stock split as described in the Subsequent Events footnote effective November 18, 2020.

See notes to unaudited consolidated financial statements.

 

F-61


Table of Contents

Sotera Health Company

Consolidated Statements of Cash Flows

(in thousands)

 

     Nine Months Ended  
     September 30,
2020
    September 30,
2019
 
     (Unaudited)  

Operating activities

    

Net income

   $ 5,895     $ 7,321  

Adjustments to reconcile net income to net cash provided by operating activities:

    

Depreciation

     47,334       50,085  

Amortization of intangible assets

     59,824       60,043  

Impairment of long-lived assets

     —         5,781  

Deferred income taxes

     (178     (13,023

Share-based non-cash compensation expense

     4,019       5,120  

Accretion of asset retirement obligations

     1,502       1,507  

Unrealized foreign exchange (gains) / losses

     (10,006     11,655  

(Gain)/loss on embedded derivative instruments

     579       (153

Amortization of debt issuance costs

     8,828       5,901  

Other

     (5,096     (3,719

Changes in operating assets and liabilities:

    

Accounts receivable

     4,533       10,488  

Inventories

     7,175       1,203  

Other current assets

     (2,697     10,942  

Accounts payable

     (7,848     (13,985

Accrued liabilities

     3,030       3,266  

Income taxes payable/receivable

     (20,057     (2,741

Other liabilities

     412       (799

Other long-term assets

     1,491       82  
  

 

 

   

 

 

 

Net cash provided by operating activities

     98,740       138,974  

Investing activities

    

Purchases of property, plant and equipment

     (33,640     (36,636

Purchase of Iotron Industries Canada, Inc., net of cash acquired

     (106,280     —    
  

 

 

   

 

 

 

Net cash used in investing activities

     (139,920     (36,636

Financing activities

    

Proceeds from borrowings

     150,000       318,400  

Payments of debt issuance costs

     (3,898     (3,461

Dividends and distributions to shareholders

     —         (411,053

Payments on debt

     (61,025     (11,696

Other

     (1,116     (1,001
  

 

 

   

 

 

 

Net cash provided by (used in) financing activities

     83,961       (108,811

Effect of exchange rate changes on cash and cash equivalents

     2,639       (4,030
  

 

 

   

 

 

 

Net increase (decrease) in cash and cash equivalents, including restricted cash

     45,420       (10,503

Cash and cash equivalents, including restricted cash, at beginning of period

     63,025       96,786  
  

 

 

   

 

 

 

Cash and cash equivalents, including restricted cash, at end of period

   $ 108,445     $ 86,283  
  

 

 

   

 

 

 

Supplemental disclosures of cash flow information:

    

Cash paid during the period for interest

   $ 163,965     $ 92,448  

Cash paid during the period for income taxes, net of tax refunds received

     9,650       26,638  

Equipment purchases included in accounts payable

     8,494       3,820  

See notes to unaudited consolidated financial statements.

 

F-62


Table of Contents

Sotera Health Company

Consolidated Statements of Equity (Unaudited)

(in thousands)

 

    Shares
Common
Stock
    Amount
Common
Stock
    Additional
Paid-In
Capital
    Retained
(Deficit)
Earnings
    Accumulated
Other
Comprehensive
(Loss) Income
    Noncontrolling
Interests
    Total
Equity
(Deficit)
 

Balance at January 1, 2019

    232,400     $  2,324     $ 162,409     $ (10,417   $ (109,957   $  1,132     $ 45,491  

Cumulative-effect adjustment upon adoption of ASU 2014-09

    —         —         —         2,635       —         —         2,635  

Distributions to shareholders

        (167,529     (243,524         (411,053

Share-based compensation

    —         —         5,120       —         —         —         5,120  

Comprehensive income (loss):

             

Pension and post-retirement plan adjustments, net of tax

    —         —         —         —         (409     —         (409

Foreign currency translation

    —         —         —         —         10,968       (115     10,853  

Interest rate swaps

    —         —         —         —         509       —         509  

Net income

    —         —         —         7,050       —         271       7,321  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Balance at September 30, 2019

    232,400     $ 2,324     $ —       $ (244,256   $ (98,889   $ 1,288     $ (339,533
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Balance at January 1, 2020

    232,400     $ 2,324     $ —       $ (550,511   $ (94,387    $ 1,442     $ (641,132

Share-based compensation

    —         —         4,019       —         —         —         4,019  

Comprehensive income (loss):

             

Pension and post-retirement plan adjustments, net of tax

    —         —         —         —         700       —         700  

Foreign currency translation

    —         —         —         —         (30,887     (417     (31,304

Interest rate swaps

    —         —         —         —         (179     —         (179

Net income

    —         —         —         5,063       —         832       5,895  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Balance at September 30, 2020

    232,400     $ 2,324     $ 4,019     $ (545,448   $ (124,753   $ 1,857     $ (662,001
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Share amounts and per share data give retroactive effect to the forward stock split as described in the Subsequent Events footnote effective November 18, 2020.

See notes to unaudited consolidated financial statements.

 

F-63


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements (Unaudited)

1. Basis of Presentation

Sotera Health Company (formerly known as Sotera Health Topco, Inc.) (also referred to herein as the “Company,” “we,” “our,” “us” or “its”), is a fully integrated provider of mission-critical health sciences, lab services and sterilization solutions with operations primarily in the Americas, Europe and Asia.

The accompanying consolidated financial statements include the assets, liabilities, operating results, and cash flows of the Company and its wholly owned subsidiaries prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. These unaudited interim financial statements should be read in conjunction with the Company’s annual consolidated financial statements and accompanying notes for the year ended December 31, 2019.

The accompanying interim financial statements are unaudited, but reflect all adjustments, consisting of normal recurring adjustments, that, in the opinion of management, are necessary for a fair presentation of the financial statements. The preparation of financial statements in conformity with GAAP requires management to make periodic estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities. We regularly evaluate the accounting policies and estimates used. Actual results could differ from these estimates. The reported results of operations are not necessarily indicative of results of operations for any future period.

We operate and report in three segments, Sterigenics, Nordion and Nelson Labs. We describe our business segments in the Segment Information note. All significant intercompany balances and transactions have been eliminated in consolidation.

Noncontrolling interests represents the noncontrolling stockholders’ proportionate share of the total equity in the Company’s consolidated subsidiaries. As of September 30, 2020, our subsidiaries were wholly owned by us, except for noncontrolling interests of 15% and 33% in our two China subsidiaries. In addition, a 15% noncontrolling interest remains from the August 2018 acquisition of Gibraltar Laboratories, Inc. (now known as Nelson Laboratories Fairfield, Inc.). We consolidate the results of operations of these subsidiaries with our results of operations and reflect the noncontrolling interests in our two China subsidiaries on our consolidated statements of operations and comprehensive income (loss) as “Net income (loss) attributable to noncontrolling interests.” Our required future purchase of 15% noncontrolling interest in Nelson Laboratories Fairfield, Inc. is considered mandatorily redeemable, and therefore no earnings are allocated to this noncontrolling interest.

In the third quarter of 2020, we identified an immaterial error in previously issued financial statements as a result of incorrectly recording the foreign exchange (gain)/loss in a U.S. dollar denominated loan between a U.S. subsidiary and European subsidiary. We have evaluated this error and concluded it to be immaterial in consideration of the September 30, 2020 financial statements and previously issued financial statements, based on an analysis of quantitative and qualitative factors affecting each prior reporting period. We reflected the correction of this immaterial error within these financial statements for the period ended September 30, 2020, the effect of which increased foreign exchange (gain)/loss and net income by $2.2 million.

2. Recent Accounting Standards Updates

Adoption of New Accounting Standards

Effective January 1, 2020, we adopted Accounting Standards Update (“ASU”) No. 2016-02, Leases (“Topic 842”) which was issued by the Financial Accounting Standards Board (“FASB”) in 2016. The new standard

 

F-64


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements (Unaudited)

 

requires substantially all leases to be reported on the balance sheet as right-of-use assets and lease obligations. It also increases disclosure of key information about leasing arrangements. We adopted the new guidance using the optional transition method, which required application of the new guidance to only leases that existed at the date of adoption. We also elected the “package of practical expedients,” which permitted us to not reassess under the new standard our prior conclusions about lease identification, lease classification and initial direct costs. The adoption of the new standard resulted in the recognition of right-of-use assets and lease liabilities of $47.4 million and $48.9 million as of January 1, 2020, respectively. The standard did not have a material impact on our consolidated statements of operations and comprehensive income (loss) or on our consolidated statements of cash flows.

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. This ASU provides optional guidance for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting due to the cessation of the London Interbank Offered Rate (“LIBOR”). The amendments in this update are effective for the Company as of March 12, 2020 through December 31, 2022. The Company adopted this standard effective March 12, 2020. The adoption of this standard had no effect in the nine months ended September 30, 2020, and its future impact will depend on the manner in which the Company and its lenders ultimately address the removal of LIBOR as it relates to the long-term debt arrangements described in the Debt Obligations note.

Accounting Standards Issued But Not Yet Adopted

Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. As an emerging growth company, we have elected to take advantage of the extended transition period for complying with new or revised accounting standards until those standards would otherwise apply to private companies or at which time we conclude it is appropriate to avail ourselves of early adoption provisions of applicable standards. As a result, our results of operations and financial statements may not be comparable to the results of operations and financial statements of other companies who have adopted the new or revised accounting standards.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (“ASU 2016-13”): Measurement of Credit Losses on Financial Instruments and subsequently issued additional guidance that modified ASU 2016-13. The standard requires an entity to change its accounting approach in determining impairment of certain financial instruments, including trade receivables, from an “incurred loss” to a “current expected credit loss” model. The standard will be effective for private companies for fiscal years beginning after December 15, 2022, including interim periods within such fiscal years. Early adoption is permitted. We are currently assessing the effect that ASU 2016-13 will have on our financial position, results of operations, and disclosures.

In December 2019, the FASB issued ASU 2019-12—Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The standard simplifies the accounting for income taxes and makes a number of changes meant to add or clarify guidance on accounting for income taxes. This update is effective for annual and interim financial statement periods beginning after December 15, 2022, with early adoption permitted in any interim period for which financial statements have not yet been filed. We are currently assessing the effect that ASU 2019-12 will have on our financial position, results of operations and disclosures.

 

F-65


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements (Unaudited)

 

3. Revenue Recognition

The following table shows disaggregated net revenues from contracts with external customers by timing of revenue and by segment for the nine months ended September 30, 2020 and 2019:

 

     Nine months ended September 30, 2020  
     Sterigenics      Nordion      Nelson Labs      Consolidated  

Point in time

   $  363,955      $  86,034      $ —      $  449,989  

Over time

     —          —          151,324        151,324  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 363,955      $ 86,034      $ 151,324      $ 601,313  
  

 

 

    

 

 

    

 

 

    

 

 

 
     Nine months ended September 30, 2019  
     Sterigenics      Nordion      Nelson Labs      Consolidated  

Point in time

   $  350,387      $ 91,869      $ —      $ 442,256  

Over time

     —          —          142,586        142,586  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 350,387      $ 91,869      $ 142,586      $ 584,842  
  

 

 

    

 

 

    

 

 

    

 

 

 

Contract Balances

As of September 30, 2020 and December 31, 2019, contract assets included in “Prepaid expenses and other current assets” on the consolidated balance sheets totaled approximately $14.0 million and $8.5 million, respectively, resulting from revenue recognized over time in excess of the amount billed to the customer.

When we receive consideration from a customer prior to transferring goods or services under the terms of a sales contract, we record deferred revenue, which represents a contract liability. Deferred revenue totaled $4.1 million and $3.6 million at September 30, 2020 and December 31, 2019, respectively. We recognize deferred revenue after we have transferred control of the goods or services to the customer and all revenue recognition criteria are met.

4. Acquisitions

Iotron Industries Canada, Inc. Acquisition

On July 31, 2020, we acquired Iotron Industries Canada, Inc. (“Iotron”) for approximately $106.3 million, subject to customary working capital and other adjustments. Iotron is an independent contact sterilizer with two North American locations in Vancouver, Canada, and Columbia City, Indiana. Each location uses proprietary high energy electron beam technology to process products for orthopedic, medical device, plastics, and agricultural businesses. As part of this acquisition, we also acquired Iotron’s 60% equity ownership interest in a joint venture to construct an E-beam facility in Alberta, Canada. The E-beam facility is under construction and is not expected to be operating until mid-2021. The joint venture is accounted for using the equity method. The acquisition was financed by the issuance of $100.0 million of First Lien Notes. Refer to the Debt Obligations note for additional details.

The opening balance sheet for the Iotron acquisition reflects the net tangible and intangible assets acquired and liabilities assumed at their estimated fair values at the acquisition date.

 

F-66


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements (Unaudited)

 

The preliminary estimated fair value of the underlying acquired assets and assumed liabilities at July 31, 2020, the date of the Iotron acquisition, was as follows:

 

(thousands of U.S. dollars)

Preliminary allocation of purchase price to the fair

value of net assets acquired (net of cash acquired):

   Amounts
Recognized as
of July 31,
2020
 

Goodwill

   $ 64,235  

Other intangible assets

     16,427  

Property, plant, and equipment

     13,799  

Working capital, net

     1,105  

Investment in unconsolidated affiliate

     12,881  

Assumed long-term liabilities

     (1,270

Other assets/liabilities, net

     (897
  

 

 

 

Total estimated purchase price

   $  106,280  
  

 

 

 

The fair value of all the above assets acquired and liabilities assumed are preliminary in nature since the fair value analyses are not yet complete. Changes to the allocation of the purchase price may occur as these analyses are completed.

Approximately $64.2 million of goodwill was recorded related to the Iotron acquisition, representing the excess of the purchase price over estimated fair values of all the assets acquired and liabilities assumed. The fair values allocated to goodwill and tangible and intangible assets are deductible for tax purposes. The qualitative elements of goodwill primarily represent the expanded future growth opportunities for the combined company and the addition of Iotron’s highly skilled workforce. We recorded $14.0 million, $0.9 million, and $1.5 million for intangible assets as part of the acquisition related to customer relationships, proprietary technology, and employee non-compete agreements, respectively. The estimated useful lives of the identifiable finite-lived intangible assets range from 5 to 15 years.

Iotron’s results of operations are included in our consolidated financial statements from the date of the transaction within the Sterigenics segment. The unaudited pro forma consolidated results for the nine-month periods ending September 30, 2020 and 2019, are reflected in the pro forma table below had the transaction occurred on January 1, 2019. The following unaudited supplemental pro forma financial information is based on our historical consolidated financial statements and Iotron’s historical consolidated financial statements, as adjusted for amortization of acquired intangible assets, an increase in interest expense resulting from interest on the First Lien Notes to finance the acquisition, and to reflect the change in the estimated income tax rate for federal and state purposes.

 

(thousands of U.S. dollars)    Nine months ended September 30,  

Nine Months Ended September 30,

   2020      2019  

Net revenues

   $  616,144      $  598,935  

Net income

     7,840        4,941  

Net revenues and net income from the Iotron acquisition included in the Company’s results since July 31, 2020, the date of the acquisition, were $3.6 million and $0.9 million, respectively.

In connection with the Iotron acquisition, we incurred approximately $2.8 million in transaction costs for the nine months ended September 30, 2020, which were included in selling, general and administrative expenses in the consolidated statements of operations and comprehensive income (loss).

 

F-67


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements (Unaudited)

 

5. Inventories

Inventory consists primarily of the following:

 

(thousands of U.S. dollars)

   September 30, 2020      December 31, 2019  

Raw materials and supplies

   $ 22,385      $  29,640  

Work-in-process

     1,067        1,961  

Finished goods

     5,795        5,892  
  

 

 

    

 

 

 

Inventories

     29,247        37,493  

Reserve for excess and obsolete inventory

     (94      (97
  

 

 

    

 

 

 

Inventories, net

   $  29,153      $ 37,396  
  

 

 

    

 

 

 

The inventories as of September 30, 2020 and December 31, 2019 are held at Nordion.

6. Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist primarily of the following:

 

(thousands of U.S. dollars)

   September 30, 2020      December 31, 2019  

Prepaid taxes

   $ 23,929      $  18,614  

Prepaid employee payroll

     3,443        773  

Prepaid business insurance

     1,744        3,422  

Prepaid rent

     1,145        1,088  

Accrual for revenue from customers

     14,022        8,508  

Insurance and indemnification receivables

     2,751        2,751  

Current deposits

     651        5,060  

Prepaid maintenance contracts

     300        397  

Derivative instruments (see Financial Instruments and Financial Risk note)

     159        242  

Value added tax receivable

     732        1,034  

Prepaid software licensing

     1,471        1,089  

Stock supplies

     2,529        2,263  

Other

     7,174        7,403  
  

 

 

    

 

 

 

Prepaid expenses and other current assets

   $ 60,050      $ 52,644  
  

 

 

    

 

 

 

7. Property, Plant and Equipment

As discussed in the Commitments and Contingencies note, we have been involved in litigation related to our ethylene oxide sterilization operations in Willowbrook, Illinois. On September 30, 2019, we announced plans to exit our operations in Willowbrook citing the unstable legislative and regulatory landscape in Illinois as well as the expiration of the primary Willowbrook facility lease. Prior to this decision, we had approximately $9.8 million in net book value of fixed assets at the Willowbrook facilities, including $1.8 million of construction in process. Based on our initial assessment of fixed assets that can be transferred to other Sterigenics’ facilities,

 

F-68


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements (Unaudited)

 

we recorded a fixed asset impairment of approximately $5.8 million as recognized in “Impairment of long-lived assets” in the consolidated statement of operations and comprehensive income (loss) for the nine months ended September 30, 2019. Further, in conjunction with the decision not to reopen our Willowbrook facilities, we incurred certain restructuring costs consisting of employee termination benefits totaling $1.1 million in the nine months ended September 30, 2019. The $1.1 million in costs represents all termination benefits costs expected to be incurred in connection with the Willowbrook closure, and were included in “Cost of revenues” on the consolidated statement of operations and comprehensive income (loss) and are included in our Sterigenics segment. Decommissioning of the Willowbrook facilities began in October 2019 and is anticipated to take until the end of 2020. At September 30, 2020 and December 31, 2019, we had an asset retirement obligation of approximately $0.6 million and $2.2 million representing our estimate of the costs to decommission the Willowbrook operations. This liability is included in “Current portion of asset retirement obligations” and “Noncurrent asset retirement obligations” within the consolidated balance sheets.

8. Goodwill and Other Intangible Assets

Changes to goodwill for the nine months ended September 30, 2020 were as follows:

 

(thousands of U.S. dollars)

   Sterigenics      Nordion      Nelson Labs      Total  

Goodwill at December 31, 2019

   $  612,689      $  281,890      $  141,286      $  1,035,865  

Iotron acquisition, preliminary estimate

     64,235        —          —          64,235  

Changes due to foreign currency exchange rates

     (2,812      (7,278      1,571        (8,519
  

 

 

    

 

 

    

 

 

    

 

 

 

Goodwill at September 30, 2020

   $ 674,112      $ 274,612      $ 142,857      $ 1,091,581  
  

 

 

    

 

 

    

 

 

    

 

 

 

Other intangible assets consist of the following as of:

 

(thousands of U.S. dollars)

September 30, 2020

   Gross
Carrying
Amount
     Accumulated
Amortization
 

Finite-lived intangible assets

     

Customer relationships

   $ 628,115      $  292,310  

Proprietary technology

     88,627        35,527  

Trade name

     144        92  

Land-use rights

     9,111        1,203  

Sealed source and supply agreements

     229,579        84,688  

Other

     1,848        392  
  

 

 

    

 

 

 

Total finite-lived intangible assets

     957,424        414,212  
  

 

 

    

 

 

 

Indefinite-lived intangible assets

     

Regulatory licenses and other (1)

     78,021        —    

Trade name / trademark

     25,895        —    
  

 

 

    

 

 

 

Total indefinite-lived intangible assets

     103,916        —    
  

 

 

    

 

 

 

Total

   $ 1,061,340      $ 414,212  
  

 

 

    

 

 

 

 

F-69


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements (Unaudited)

 

December 31, 2019

   Gross
Carrying
Amount
     Accumulated
Amortization
 

Finite-lived intangible assets

     

Customer relationships

   $ 612,068      $  248,931  

Proprietary technology

     87,971        30,224  

Trade name

     7,201        1,860  

Land-use rights

     8,896        1,011  

Sealed source and supply agreements

     235,706        74,825  

Other

     336        243  
  

 

 

    

 

 

 

Total finite-lived intangible assets

     952,178        357,094  
  

 

 

    

 

 

 

Indefinite-lived intangible assets

     

Regulatory licenses and other (1)

     80,103        —    

Trade name / trademark

     20,819        —    
  

 

 

    

 

 

 

Total indefinite-lived intangible assets

     100,922        —    
  

 

 

    

 

 

 

Total

   $  1,053,100    $ 357,094  
  

 

 

    

 

 

 

 

  (1) 

Includes certain transportation certifications, a class 1B nuclear license and other intangibles related to obtaining such licensure. These assets are considered indefinite-lived as the decision for renewal by the Canadian Nuclear Safety Commission is highly based on a licensee’s previous assessments, reported incidents, and annual compliance and inspection results. New applications for license can take a significant amount of time and cost; whereas an existing licensee with a historical record of compliance and current operating conditions more than likely ensures renewal for another 10 year license period as Nordion has demonstrated over its 70 years of history.

Amounts include the impact of foreign currency translation. Fully amortized amounts are written off.

Amortization expense for other intangible assets was $59.8 million and $60.0 million for the nine months ended September 30, 2020 and 2019, respectively. Of the amortization expense referenced above, $15.8 million and $16.1 million is included in “Cost of revenues” for the nine months ended September 30, 2020 and 2019, respectively. The remainder of the amortization in each of the aforementioned periods is included in “Selling, general and administrative expenses” in the consolidated statements of operations and comprehensive income (loss).

The estimated aggregate amortization expense for finite-lived intangible assets for each of the next five years and thereafter is as follows:

 

(thousands of U.S. dollars)

      

For the remainder of 2020

   $ 20,181  

2021

     81,065  

2022

     77,215  

2023

     77,208  

2024

     76,432  

Thereafter

     211,111  
  

 

 

 

Total

   $  543,212  
  

 

 

 

 

F-70


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements (Unaudited)

 

The weighted-average remaining useful life of the finite-lived intangible assets was approximately 10 years as of September 30, 2020.

9. Accrued Liabilities

Accrued liabilities consist of the following at:

 

(thousands of U.S. dollars)

   September 30, 2020      December 31, 2019  

Accrued employee compensation

   $  31,876      $  28,912  

Legal reserves

     2,751        2,751  

Accrued interest expense

     2,014        10,648  

Embedded derivatives

     4,271        3,478  

Professional fees

     14,051        4,329  

Accrued utilities

     1,281        1,135  

Insurance accrual

     1,195        1,241  

Accrued taxes

     3,202        2,363  

Other

     4,066        3,679  
  

 

 

    

 

 

 

Accrued liabilities

   $ 64,707      $ 58,536  
  

 

 

    

 

 

 

10. Debt Obligations

Long-term debt obligations consist of the following:

 

(thousands of U.S. dollars)

   September 30, 2020      December 31, 2019  

Term loan, due 2026

   $  2,109,400      $  2,120,000  

Senior notes, due 2027

     770,000        770,000  

Senior notes, due 2026

     100,000        —    

Other long-term debt

     450        881  
  

 

 

    

 

 

 

Total debt

     2,979,850        2,890,881  

Less current portion

     (21,200      (16,331

Less unamortized debt issuance costs and debt discounts

     (69,870      (73,677
  

 

 

    

 

 

 

Total long-term debt, less current portion and debt issuance costs and debt discounts

   $ 2,888,780      $ 2,800,873  
  

 

 

    

 

 

 

Debt Facilities

Senior Secured Credit Facilities

On December 13, 2019, Sotera Health Holdings, LLC (“SHH”), our wholly owned subsidiary, entered into new senior secured first lien credit facilities (the “Senior Secured Credit Facilities”) and settled its previously outstanding term loan and senior notes.

The Senior Secured Credit Facilities consist of both a senior secured first lien term loan (the “Term Loan”) and a $190.0 million senior secured first lien revolving credit facility (the “Revolving Credit Facility”). The Term Loan

 

F-71


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements (Unaudited)

 

matures on December 13, 2026, and the Revolving Credit Facility matures on December 13, 2024. The Senior Secured Credit Facilities also provide SHH the right at any time and under certain conditions to request incremental term loans or incremental revolving credit commitments based on a formula defined in the Senior Secured Credit Facilities. As of September 30, 2020, total borrowings under the Term Loan were $2,109.4 million.

Beginning on June 30, 2020, the Term Loan is paid in equal quarterly installments in aggregate annual amounts equal to 1.00% of the Term Loan original principal amount, while the remaining balance matures on December 13, 2026. The Term Loan may bear interest at LIBOR or an alternate base rate (“ABR”) subject to a 1.00% floor plus, an incremental margin of 4.50% in the case of LIBOR loans and 3.50% in the case of ABR loans. The weighted average interest rate on borrowings under the Term Loan at September 30, 2020 was 5.50%.

As of September 30, 2020, and December 31, 2019, capitalized debt issuance costs totaled $4.3 million and $4.7 million, respectively, and debt discounts totaled $39.3 million and $44.0 million, respectively, related to the Senior Secured Credit Facilities. Such costs are recorded as a reduction of debt on our consolidated balance sheets and amortized as a component of interest expense over the term of the debt agreement.

Borrowings under the Revolving Credit Facility bear interest at a rate per annum equal to an applicable margin, plus, at our option, either (a) an ABR or (b) a LIBOR rate. The applicable margin under the Revolving Credit Facility may be reduced by reference to a leverage-based pricing grid with step-downs of 0.25% at a specified senior secured first lien net leverage ratio. In addition to paying interest on any outstanding borrowings under the Revolving Credit Facility, SHH is required to pay a commitment fee to the lenders under the Revolving Credit Facility in respect of the unutilized commitments thereunder and customary letter of credit fees. The Revolving Credit Facility contains a maximum senior secured first lien net leverage ratio covenant of 9.00 to 1.00, tested on the last day of each fiscal quarter if, on the last day of such fiscal quarter, the sum of (i) the aggregate principal amount of the revolving loans then outstanding under the Revolving Credit Facility, plus (ii) the aggregate amount of letter of credit (“LC”) disbursements that have not been reimbursed within two business days following the end of the fiscal quarter, exceeds the greater of $76.0 million and 40.0% of the aggregate principal amount of the revolving commitments then in effect. Although this covenant did not apply as the conditions were not met, as of September 30, 2020 the first lien net leverage ratio, as defined in the Revolving Credit Facility, was approximately 5.10 to 1.00.

As of September 30, 2020, there were no borrowings on the Revolving Credit Facility. SHH borrowed $50.0 million on the Revolving Credit Facility during the first quarter of 2020 which was repaid in the second quarter of 2020. The interest rate on the borrowings under the Revolving Credit Facility averaged approximately 5.0%.

The Senior Secured Credit Facilities contain additional covenants that, among other things, restrict, subject to certain exceptions, our ability and the ability of our restricted subsidiaries to engage in certain activities, such as incur indebtedness or permit to exist any lien on any property or asset now owned or hereafter acquired, as specified in the debt facility. The Senior Secured Credit Facilities also contain certain customary affirmative covenants and events of default, including upon a change of control. As of September 30, 2020, we were in compliance with all the Senior Secured Credit Facilities covenants.

All of SHH’s obligations under the Senior Secured Credit Facilities are unconditionally guaranteed by the Company and each existing and subsequently acquired or organized direct or indirect wholly-owned domestic restricted subsidiary of SHH, with customary exceptions including, among other things, where providing such guarantees is not permitted by law, regulation or contract or would result in material adverse tax consequences.

 

F-72


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements (Unaudited)

 

All obligations under the Senior Secured Credit Facilities, and the guarantees of such obligations, are secured by substantially all of the assets of the borrower and guarantors, subject to permitted liens and other exceptions and exclusions, as outlined in the Senior Secured Credit Facilities.

Outstanding letters of credit are collateralized by encumbrances against the Revolving Credit Facility and the collateral pledged thereunder, or by cash placed on deposit with the issuing bank. As of September 30, 2020, the Company had $64.3 million of letters of credit issued against the Revolving Credit Facility, resulting in total availability under the Revolving Credit Facility of $125.7 million.

First Lien Notes

On July 31, 2020, SHH issued $100.0 million aggregate principal amount of senior secured first lien notes due 2026 (the “First Lien Notes”), which mature on December 13, 2026. The First Lien Notes bear interest at a rate equal to LIBOR subject to a 1.00% floor plus 6.00% per annum. Interest is payable on a quarterly basis with no principal due until maturity. The weighted average interest rate on the First Lien Notes at September 30, 2020 was 7.00%.

SHH is entitled to redeem all or a portion of the First Lien Notes, at any time and from time to time, subject to certain premiums depending on the date of redemption: any time on or prior to July 31, 2021, a customary make-whole premium applies and, thereafter, specified premiums that decline to zero apply (in each case as described in the indenture governing the First Lien Notes).

All of SHH’s obligations under the First Lien Notes are unconditionally guaranteed by the Company and each existing and subsequently acquired or organized direct or indirect wholly-owned domestic restricted subsidiary of SHH, with customary exceptions including, among other things, where providing such guarantees is not permitted by law, regulation or contract or would result in material adverse tax consequences. All obligations under the First Lien Notes, and the guarantees of such obligations, are secured by substantially all of the assets of the borrower and guarantors, subject to permitted liens and other exceptions and exclusions, as outlined in the First Lien Notes. Such collateral is substantially the same collateral that secures the Senior Secured Credit Facilities and Second Lien Notes. Such collateral securing the First Lien Notes ranks pari passu with that of the Senior Secured Credit Facilities and has priority over the collateral securing the Second Lien Notes.

At September 30, 2020, capitalized debt issuance costs were $0.7 million and debt discounts were $2.9 million, respectively, related to the First Lien Notes, which are recorded as a reduction of debt on our consolidated balance sheets and amortized into interest expense over the term of the debt agreement.

Second Lien Notes

On December 13, 2019, SHH issued $770.0 million aggregate principal amount of senior secured second lien notes due 2027 (the “Second Lien Notes”), which mature on December 13, 2027. The Second Lien Notes bear interest at a rate equal to LIBOR subject to a 1.00% floor plus 8.00% per annum. The weighted average interest rate on the Second Lien Notes at September 30, 2020 was 9.00%.

SHH is entitled to redeem all or a portion of the Second Lien Notes, at any time and from time to time, subject to certain premiums depending on the date of redemption: any time on or prior to December 13, 2020, a customary make-whole premium applies and, thereafter, specified premiums that decline to zero apply (in each case as described in the indenture governing the Second Lien Notes). In addition, under certain circumstances, such as an initial public offering or certain changes of control, SHH has certain additional redemption rights (as described in the indenture governing the Second Lien Notes).

 

F-73


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements (Unaudited)

 

All of SHH’s obligations under the Second Lien Notes are unconditionally guaranteed by the Company and each existing and subsequently acquired or organized direct or indirect wholly-owned domestic restricted subsidiary of SHH, with customary exceptions including, among other things, where providing such guarantees is not permitted by law, regulation or contract or would result in material adverse tax consequences. All obligations under the Second Lien Notes, and the guarantees of such obligations, are secured by substantially all of the assets of the borrower and guarantors, subject to permitted liens and other exceptions and exclusions, as outlined in the Second Lien Notes. Such collateral is substantially the same collateral that secures the Senior Secured Credit Facilities and the First Lien Notes, and any security interest or lien on shared collateral securing the Senior Secured Credit Facilities or the First Lien Notes shall have priority over any security interest or lien on shared collateral securing the Second Lien Notes.

At September 30, 2020 and December 31, 2019, capitalized debt issuance costs were $1.6 million and $1.8 million and debt discounts were $21.0 million and $23.2 million, respectively, related to the Second Lien notes, which are recorded as a reduction of debt on our consolidated balance sheets and amortized into interest expense over the term of the debt agreement.

11. Income Taxes

Income tax expense is provided on an interim basis based upon our estimate of the annual effective income tax rate. In determining the estimated annual effective income tax rate, we analyze various factors, including projections of our annual earnings and the taxing jurisdictions where the earnings will occur, the impact of state and local taxes, our ability to utilize tax credits and net operating loss carryforwards and available tax planning alternatives.

Our effective tax rate was (255.9%) and 63.3% for the nine months ended September 30, 2020 and 2019, respectively. Income tax expense (benefit) for the nine months ended September 30, 2020 and 2019 differs from the statutory rate primarily due to the impact of global intangible low-taxed income (“GILTI”) (including final 951A regulations), the foreign rate differential, and non-deductible expenses.

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted in response to the COVID-19 pandemic, and among other things, provides tax relief to businesses. Tax provisions of the CARES Act include retroactive increases in the limitation on the deductibility of interest expense from 30% to 50% for tax years beginning in 2019 or 2020, and other provisions. As a result of the increased limitation on the deductibility of interest expense, we recognized a current tax benefit of $8.7 million in the nine months ended September 30, 2020 related to 2019 interest expense previously recorded as deferred. In addition, we currently estimate an additional $8.2 million current tax benefit for the 2020 tax year, which will be recognized in the fourth quarter. The increased limitation under the CARES Act resulted in a first quarter 2020 reversal of the $5.6 million valuation allowance recorded at the end of the 2019 tax year.

On July 23, 2020, final 951A regulations were published that exempts income subject to a high rate of foreign tax from inclusion as GILTI for tax years beginning after December 31, 2017. The reduction in Adjusted Taxable Income (“ATI”) realized as a result of the final 951A regulations resulted in a $36.2 million valuation allowance recorded in the quarter ended September 30, 2020.

Our current estimate of 2020 current tax expense related to GILTI is $1.5 million, a reduction of $11.2 million from prior estimates, and is considered as a component of our estimated annual effective tax rate calculation. In 2019 and 2018, we recognized GILTI current tax expense of $10.3 million and $5.6 million, respectively. As a

 

F-74


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements (Unaudited)

 

result of final 951A regulations, the 2019 and 2018 GILTI tax was reduced to $2.4 million and $0, respectively, and was recognized as a reduction to income tax expense in the third quarter of 2020.

12. Employee Benefits

The Company sponsors various post-employment benefit plans including, in certain countries outside the U.S., defined benefit and defined contribution pension plans, retirement compensation arrangements, and plans that provide extended health care coverage to retired employees, the majority of which relate to Nordion.

Defined benefit pension plan

The interest cost and expected return on plan assets are recorded in “Other income, net” and the service cost component is included in the same financial statement line item as the applicable employee’s wages in the consolidated statements of operations and comprehensive income (loss). The components of net periodic pension cost for the plans for the nine months ended September 30, 2020 and 2019 were as follows:

 

(thousands of U.S. dollars)    Nine months ended
September 30,
 
Pension    2020      2019  

Service cost

   $ 821      $ 859  

Interest cost

     5,974        6,379  

Expected return on plan assets

     (10,712      (9,896

Amortization of net actuarial (gain) loss

     588        —    
  

 

 

    

 

 

 

Net periodic (benefit) cost

   $  (3,329    $  (2,658
  

 

 

    

 

 

 

Other benefit plans

Other benefit plans include a supplemental retirement arrangement, a retirement and termination allowance, and post-retirement benefit plans, which include contributory health and dental care benefits and contributory life insurance coverage. All non-pension post-employment benefit plans are unfunded.

The components of other post-retirement benefit plans for the nine months ended September 30, 2020 and 2019 were as follows:

 

(thousands of U.S. dollars)    Nine months ended
September 30,
 
Other post-retirement benefits    2020      2019  

Service cost

   $ 21      $ 23  

Interest cost

     218        236  

Amortization of net actuarial (gain) loss

     39        (16
  

 

 

    

 

 

 

Net periodic (benefit) cost

   $  278      $  243  
  

 

 

    

 

 

 

We currently expect funding requirements of approximately $3.0 million in each of the next five years to fund the regulatory solvency deficit, as defined by Canadian federal regulation, which require solvency testing on defined benefit pension plans.

 

F-75


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements (Unaudited)

 

We may obtain a qualifying letter of credit for solvency payments, up to 15% of the market value of solvency liabilities as determined on the valuation date, instead of paying cash into the pension fund. As of September 30, 2020, and December 31, 2019, we had letters of credit outstanding totaling $42.8 million and $41.0 million, respectively, related to these liabilities. The deficit has decreased due to an increase in the value of the pension assets more than the increase in the value of pension liabilities. The actual funding requirements over the five-year period will be dependent on subsequent annual actuarial valuations. These amounts are estimates, which may change with actual investment performance, changes in interest rates, any pertinent changes in Canadian government regulations, and any voluntary contributions.

13. Other Comprehensive Income (Loss)

Changes in our accumulated other comprehensive income (loss) balances, net of tax, were as follows:

 

     Nine Months Ended September 30, 2020  
(thousands of U.S. dollars)    Benefit
Plans
     Foreign
Currency
Translation
     Interest
Rate
Swaps
     Total  

Beginning balance – January 1, 2020

   $ (27,113    $ (67,453    $ 179      $ (94,387

Other comprehensive income (loss) before reclassifications

     700        (30,887      (5,234      (35,421

Amounts reclassified from accumulated other comprehensive income (loss)

     —          —          5,055        5,055  
  

 

 

    

 

 

    

 

 

    

 

 

 

Net current-period other comprehensive income (loss)

     700        (30,887      (179      (30,366
  

 

 

    

 

 

    

 

 

    

 

 

 

Ending balance – September 30, 2020

   $ (26,413    $  (98,340    $ —        $ (124,753
  

 

 

    

 

 

    

 

 

    

 

 

 
     Nine Months Ended September 30, 2019  
(thousands of U.S. dollars)    Benefit
Plans
     Foreign
Currency
Translation
     Interest
Rate
Swaps
     Total  

Beginning balance – January 1, 2019

   $  (14,987    $  (94,970    $ —      $  (109,957

Other comprehensive income (loss) before reclassifications

     (409      10,968        509      11,068  
  

 

 

    

 

 

    

 

 

    

 

 

 

Ending balance – September 30, 2019

   $  (15,396    $  (84,002    $ 509    $ (98,889
  

 

 

    

 

 

    

 

 

    

 

 

 

14. Related Party Activity

In April 2020, the Company approved a loan to a member of management for approximately $0.5 million to assist with personal taxes incurred on share-based grants received. The loan is collateralized by the shares, and proceeds of distributions will be applied against the loan.

The immediate family of a member of management are 25% owners of a facility that is under lease by the Company through June 2024, with one five-year renewal option through June 2029. The rental expense related to this facility is approximately $1.0 million per year.

In addition, we do business with a number of other companies affiliated with Warburg Pincus and GTCR, our Sponsors. All transactions with these companies have been conducted in the ordinary course of our business and are not material to our operations.

 

F-76


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements (Unaudited)

 

15. Share-Based Compensation

The Company’s equity-based awards issued to employees include restricted limited partnership units in our parent, Sotera Health Topco Parent, L.P. (“Topco Parent”). These units are referred to as “Class B Units” and are granted in respect of services provided to the Company and its subsidiaries. Class B-1 Units are Class B Units which vest based on time and Class B-2 Units are Class B Units which vest based on the achievement of certain performance and market conditions.

Compensation expense resulting from time vesting based awards is recognized in our consolidated statements of operations and comprehensive income (loss), primarily within “Selling, general and administrative expenses,” at grant date fair value over the requisite service period (typically five years on a straight-line basis for time vested awards). Compensation expense resulting from performance awards that vest upon satisfaction of a performance condition is recognized at grant date fair value when the performance condition is deemed probable, which may cause volatility in the timing of expense recognition. The calculated compensation expense for performance awards is adjusted based on an estimate of awards ultimately expected to vest. For awards with market conditions, the market condition is taken into account when calculating grant date fair value.

Class B-1 Units vest on a daily basis pro rata over a four or five-year period (25% or 20% per year, respectively), subject to the grantee’s continued services on each vesting date. Upon the occurrence of a change of control of the Company, all then outstanding unvested Class B-1 Units held by Unitholders will become vested as of the date of consummation of such change of control, subject to the Unitholder’s continued services through the consummation of the change of control. An initial public offering (“IPO”) does not constitute a change of control for these purposes.

Class B-2 Units are considered performance vesting units, and are scheduled to vest only upon satisfaction of certain thresholds. These units vest as of the first date on which (i) our Sponsors have received two and one-half times their invested capital in Topco Parent and (ii) the Sponsors’ internal rate of return exceeds twenty percent, subject to such grantee’s continued services through such date. No compensation expense has been recorded on the Class B-2 Units at this time as the related performance conditions are not considered probable of achievement. The listing and public trading of our common stock, resulting from a successful IPO, would be a change in facts and circumstances that would result in us concluding that the performance condition would be probable of occurring. Accordingly, even though the IPO will not cause the Class B-2 Units to vest, unrecognized compensation expense of $4.9 million related to the Class B-2 Units would be recognized in the period immediately following a successful IPO.

In the event of a change in control of the Company, any outstanding Class B-2 Units that remain unvested immediately following the consummation of such a change in control of the Company shall be immediately canceled and forfeited without compensation. An IPO does not constitute a change of control for these purposes.

Class C Units were issued in June 2016, are considered performance and time vesting units, and were accounted for as liability awards. No compensation expense was recorded on the Class C Units prior to the third quarter of 2019, as the related performance conditions were not considered probable of achievement. In the third quarter of 2019, all Class C Units vested based on the achievement of the aggregate distributions to the Class A Unitholders and approval of the board of managers of Topco Parent for accelerated vesting, and $10.0 million of stock-compensation expense was recognized and paid in accordance with the terms for redemption of outstanding Class C Units. No Class C Units remain outstanding.

Fair value of the Class B-1 time vesting and B-2 performance vesting units is estimated on the date of grant using a simulation-based option valuation model incorporating multiple and variable assumptions over time, including assumptions such as employee forfeitures, unit price volatility and dividend assumptions.

 

F-77


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements (Unaudited)

 

A summary of the activity for the nine months ended September 30, 2020 related to the Class B-1 and B-2 units issued is presented below:

 

     B-1 Time
Vesting
     B-2
Performance
Vesting
 

As of December 31, 2019

     14,450,263        15,011,256  

Granted

     11,450,000        —    

Forfeited

     (84,390      (407,381

Vested

     (10,201,706      —    
  

 

 

    

 

 

 

As of September 30, 2020

     15,614,167        14,603,875  
  

 

 

    

 

 

 

The Company recognized $4.0 million and $15.1 million ($10.0 million related to Class C Units and $5.1 million related to Class B-1 Units) of share-based compensation for the nine months ended September 30, 2020 and 2019, respectively.

The following table provides a summary of the weighted average unit grant date fair value, weighted average remaining contractual term, total compensation cost and unrecognized compensation cost:

 

September 30, 2020

(dollars in millions, except per award values)

   B-1 Time
Vesting
     B-2
Performance
Vesting
     All
Awards
 

Weighted average grant date fair value per unit of unvested units

   $ 0.65      $ 0.34      $ 0.50  

Weighted average remaining contractual term

     2.6 years        N/A        N/A  

Total compensation cost recognized in the nine months ended September 30

   $ 4.0      $ —        $ 4.0  

Unrecognized compensation cost at September 30

   $ 10.2      $ 4.9      $ 15.1  

N/A – not applicable

16. Supplemental Pro Forma Earnings Per Share (unaudited)

As further discussed in the Subsequent Events note, on November 18, 2020, the Company effected a forward stock split to reclassify all 3,000 shares of common stock outstanding as 232,400,200 shares. The unaudited supplemental pro forma earnings per share data for the nine months ended September 30, 2020 is presented below giving effect to the stock split.

Under SEC SAB Topic 1.B.3, a dividend declared in the twelve months preceding an initial public offering would be deemed to be in contemplation of the offering with the intention of repayment out of offering proceeds to the extent that the dividend exceeded earnings during the same period. In December 2019, the Company paid $275.0 million of dividends to Sotera Health Topco Parent L.P. As the Company had a net loss in the twelve months preceding the initial public offering, no amount of the dividend was considered paid out of recent earnings, and as such, the unaudited supplemental pro forma earnings per share and pro forma equivalent shares give effect to the issuance of the number of shares that would be required to generate net proceeds sufficient to pay the dividends of $275.0 million in December 2019. The number of incremental shares that would be required to be issued to pay the dividend is based on the assumed initial public offering price of $21.50 per share, the midpoint of the estimated offering price range set forth on the cover of the Company’s prospectus, net of underwriting discount and commissions $1.13 per share. As a result, 13,500,245 shares to be issued in the

 

F-78


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements (Unaudited)

 

offering (the estimated proceeds from which are greater than the amount of the December 2019 dividends) have been included in the denominator for purposes of pro forma earnings per share calculations for the nine months ended September 30, 2020.

The following table sets forth a computation of unaudited supplemental pro forma basic and diluted earnings per share for the nine months ended September 30, 2020:

 

     (unaudited)
September 30, 2020
 

Weighted average common shares outstanding—Basic and Diluted

     232,400,200  

Additional pro forma shares required to be issued in the offering necessary to pay the dividend

     13,500,245  
  

 

 

 

Supplemental pro forma weighted average common shares outstanding—Basic and Diluted

     245,900,445  
  

 

 

 

Supplemental pro forma net earnings per share—Basic and Diluted

   $ 0.02  
  

 

 

 

17. Leases

We lease certain facilities and equipment under various non-cancelable operating leases that expire through October 2034. Most of our real property leases provide for renewal periods and rent escalations and stipulate that we pay taxes, maintenance, and certain other operating expenses applicable to the leased premises. We made an accounting policy election whereby leases with an initial term of 12 months or less are recognized as lease expense on a straight-line basis over the lease term and not recorded on the consolidated balance sheet.

We determine if an agreement contains a lease and classify our leases as operating or finance at the lease commencement date. Finance leases are those in which we will pay substantially all the underlying asset’s fair value or will use the asset for all or a major part of its economic life, including circumstances in which we will ultimately own the asset. Lease assets arising from finance leases are included in “Property, plant and equipment, net” and the liabilities are included in “Finance lease obligations” on the consolidated balance sheets. For finance leases, we recognize interest expense using the effective interest method and we recognize amortization expense on the lease asset over the shorter of the lease term or the useful life of asset. Finance leases are accounted for as if the assets were owned and financed, with associated expense recognized in “Interest expense, net” and “Cost of revenues” or “Selling, general and administrative expenses” within the consolidated statements of operations and comprehensive income (loss) depending on the nature of the underlying asset.

Operating lease assets and liabilities are recognized at the commencement date of the lease based on the present value of lease payments over the lease term. Lease assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. As most leases do not provide an implicit interest rate, we estimate an incremental borrowing rate to determine the present value of lease payments. Our estimated incremental borrowing rate reflects a secured rate based on recent debt issuances, our estimated credit rating, and lease term.

We recognize operating lease costs on a straight-line basis over the term of the lease in “Cost of revenues” or “Selling, general and administrative expenses” on the consolidated statements of operations and comprehensive income (loss) depending on the nature of the underlying asset. Non-lease components are accounted for separately from the lease components for all asset classes.

 

F-79


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements (Unaudited)

 

The components of lease expense were as follows for the nine months ended September 30, 2020:

 

(thousands of U.S. dollars)

   Nine Months Ended
September 30, 2020
 

Operating lease costs (1)

   $  10,610  

Finance lease costs:

  

Amortization of right of use assets

     1,930  

Interest on lease liabilities

     1,423  
  

 

 

 

Total finance lease costs

     3,353  
  

 

 

 

Total lease costs

   $ 13,963  
  

 

 

 

 

  (1)

Includes $0.7 million of short-term lease costs in the nine-months ended September 30, 2020.

Operating lease expense for the nine months ended September 30, 2019 was $10.6 million.

Lease terms and discount rates were as follows:

 

     Nine Months Ended
September 30, 2020
 

Weighted average remaining lease term:

  

Operating leases

     6.6 years  

Finance leases

     16.3 years  

Weighted average discount rate:

  

Operating leases

     6.16

Finance leases

     6.13

Supplemental cash flow information related to leases was as follows:

 

(thousands of U.S. dollars)

   Nine Months Ended
September 30, 2020
 

Cash paid for amounts included in the measurement of lease liabilities:

  

Operating cash flows for operating leases

   $  9,048  

Operating cash flow for finance leases

     1,562  

Finance cash flows for finance leases

     1,116  

 

F-80


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements (Unaudited)

 

Maturities of lease liabilities as of September 30, 2020 are as follows:

 

(thousands of U.S. dollars)

   Operating
Leases
     Finance
Leases
     Total  

Remainder of 2020

   $ 3,279      $ 788      $ 4,067  

2021

     11,789        3,134        14,923  

2022

     10,642        2,979        13,621  

2023

     8,629        2,995        11,624  

2024

     6,019        3,047        9,066  

2025 and Thereafter

     20,470        37,911        58,381  
  

 

 

    

 

 

    

 

 

 

Total lease payments

     60,828        50,854        111,682  

Less imputed interest

     (11,539      (19,067      (30,606
  

 

 

    

 

 

    

 

 

 

Total lease liabilities

   $ 49,289      $ 31,787      $ 81,076  
  

 

 

    

 

 

    

 

 

 

18. Commitments and Contingencies

From time to time, we may be subject to various lawsuits and other claims in the ordinary course of our business. In addition, from time to time, we receive communications from government or regulatory agencies concerning investigations or allegations of noncompliance with laws or regulations in jurisdictions in which we operate.

We establish reserves for specific liabilities in connection with regulatory and legal actions that we determine to be probable and reasonably estimable. No material amounts have been accrued in our consolidated financial statements with respect to any loss contingencies. In certain of the matters described below, we are not able to make a reasonable estimate of any liability because of the uncertainties related to the outcome and/or the amount or range of loss. While it is not possible to determine the ultimate disposition of each of these matters, we do not expect that the ultimate resolution of pending regulatory and legal matters in future periods, including the matters described below, will have a material effect on our financial condition or results of operations. Despite the above, the Company may incur material defense and settlement costs, diversion of management resources and other factors.

FM Global Business Interruption Claim (NRU Outage)

Nordion, due to the shutdown of AECL’s NRU reactor in 2009, suffered a cessation of supply of radioisotopes and business interruption loss. Nordion, by Statement of Claim dated October 22, 2010, issued in Ontario Superior Court an action against the insurer, Factory Mutual Insurance Company (FM Global), claiming $25.0 million USD in losses resulting from the shutdown of AECL’s reactor and its inability to supply radioisotopes through the specified period of approximately 15 months. FM Global objected to Nordion’s claim.

Trial commenced in March 2019 and was completed in September 2019. On March 30, 2020, Nordion received a favorable judgment in the amount of $25.0 million USD, plus pre-judgment interest, for a total judgment value of $39.8 million USD, or $56.4 million CAD based on then prevailing exchange rates should Nordion opt for conversion to Canadian funds. In addition, costs and disbursements have been assessed and awarded by the trial court in favor of Nordion in the approximate amount of $1.1 million CAD ($0.8 million USD) and $161,863 CAD ($0.1 million USD), respectively. On April 27, 2020, FM Global filed notice to appeal the judgment before the Court of Appeal of Ontario. Defendant’s appeal brief was received in September 2020 and Nordion is in the process of preparing its response. Hearing before the Court of Appeal is expected in late Spring of 2021. Pending

 

F-81


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements (Unaudited)

 

a favorable judgment in the appellate court, any final proceeds would be subject to a contingent fee owed to legal counsel and applicable taxes. As the judgment is considered a contingent gain, any favorable outcome will be recognized in a future period when all appeals are exhausted. It is anticipated that the appeal process could take a year or more to complete.

Willowbrook, Illinois – Government Litigation

On October 30, 2018, the Illinois Attorney General and the State’s Attorney of DuPage County, Illinois, sued Sterigenics U.S., LLC (the “IAG Action”), alleging that authorized EO air emissions from a commercial sterilization facility Sterigenics formerly operated in Willowbrook, Illinois “cause, threaten, or allow air pollution” in violation of the Illinois Environmental Protection Act. The IAG Action did not assert that Sterigenics violated its permit from the Illinois Environmental Protection Agency (“IEPA”) authorizing Sterigenics’ release of regulated levels of EO at the Willowbrook facility.

On February 15, 2019, the acting IEPA director, John Kim, issued a “Seal Order” effectively precluding Sterigenics’ operations at the Willowbrook facility based on many of the same allegations asserted in the IAG Action. Sterigenics disputed those allegations and opposed the IEPA’s Seal Order. The Seal Order was resolved by a Consent Order entered on September 6, 2019. The Consent Order provided that Sterigenics did not admit the allegations of the IAG Action, provided for the removal of the Seal Order and allowed the Willowbrook facility to reopen upon implementation of supplemental emissions control measures consistent with a new law that became effective in Illinois in June 2019 and an IEPA permit, which the IEPA approved in September 2019. Following entry of the Consent Order, the Seal Order was withdrawn.

On September 30, 2019, Sterigenics announced the closure of the Willowbrook facility due to the inability to reach an agreement with its landlord to renew the facility’s lease and the unstable legislative and regulatory landscape in Illinois. Sterigenics is in the process of decommissioning the facility and completing the work required by the terms of its lease to return the property to the landlord.

On October 20, 2020 Sterigenics, the Illinois Attorney General and the State’s Attorney of DuPage County filed a Joint Motion to Terminate Consent Order, stating that the community projects which Sterigenics voluntarily agreed to fund have been completed and funded as required by the Consent Order, and that Sterigenics has permanently ceased operations and surrendered all permits for its operations in Willowbrook, Illinois. On October 27, 2020 the DuPage County Circuit Court entered the Agreed Order Terminating Consent Order.

Ethylene Oxide Tort Litigation - Illinois

Since September 2018, tort lawsuits on behalf of approximately 835 personal injury plaintiffs (which are further described in the following paragraphs) have been filed in Illinois state courts against Sotera Health LLC, Sterigenics U.S., LLC, GTCR, LLC and other parties related to Sterigenics’ Willowbrook, Illinois operations. Specifically, those plaintiffs allege that they suffered personal injuries including cancer and other diseases, or wrongful death, resulting from purported emissions and releases of EO from the Willowbrook facility. Plaintiffs seek damages in an amount to be determined by the trier of fact. Sterigenics denies these allegations and intends to vigorously defend against these claims. Plaintiffs have voluntarily dismissed without prejudice a number of cases since September 2018, including certain individual cases alleging personal injuries and two class actions seeking damages for alleged diminution of property values.

Sterigenics sought consolidation of certain of these cases for pretrial purposes, and in October 2019 obtained an order consolidating the then-pending cases before Judge Lawler in the Cook County Circuit Court, Illinois (the

 

F-82


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements (Unaudited)

 

“Consolidated Case”). All plaintiffs in the Consolidated Case filed a single Master Complaint on October 24, 2019 by which Sotera Health LLC was added as a co-defendant, followed by a First Amended Master Complaint on January 31, 2020. On April 28, 2020, the defendants filed motions to dismiss the claims in the First Amended Master Complaint. On August 17, 2020, the Court entered an order largely denying the motions to dismiss, and the same day plaintiffs filed a Second Amended Master Complaint.

On August 17, 2020, the plaintiffs sought and received leave of Court to add as defendants Griffith Foods Group, Inc., Griffith Foods, Inc., Griffith Foods International, Inc. and Griffith Foods Worldwide Inc.

On or about August 21, 2020, approximately 768 personal injury plaintiffs filed similar lawsuits against Sotera Health LLC, Sterigenics U.S., LLC, GTCR, LLC and other parties in the Cook County Circuit Court, Illinois (but not in the existing Consolidated Case) and in the DuPage County Circuit Court. Defendants’ motions to transfer, reassign and consolidate the newly filed cases with the above described Consolidated Case in the Cook County Circuit Court, Illinois were granted on October 2, 2020 and October 9, 2020.

Having been granted leave of Court on August 17, 2020 to add as defendants Griffith Foods Group, Inc., Griffith Foods, Inc., Griffith Foods International, Inc. and Griffith Foods Worldwide Inc., plaintiffs filed a third amended master complaint, adding those defendants, on October 30, 2020. Defendants’ responses to the third amended master complaint will be due on December 1, 2020. The plaintiffs who filed the new lawsuits in August 2020 (whose cases are now included in the Consolidated Case) are required to file individual short form complaints on or before February 1, 2021. Defendants’ deadline for responding to each short form complaint will be 90-days after entry of an order setting the individual case for trial.

Written and deposition fact discovery is on-going in the Consolidated Case. Currently, there are no dates set for the close of fact discovery, for expert discovery or for dispositive motion practice. Plaintiffs have not yet made any specific damages claims.

A May 3, 2021 trial date has been set for Kamuda v. Sterigenics, the first-filed of the individual cases now included in the Consolidated Case, which is the first scheduled trial in these proceedings. Four additional cases now included in the Consolidated Case are currently scheduled for trials starting in June, August, September and November 2021. We anticipate that additional trials will be scheduled after 2021 in roughly the order in which the individual cases were filed.

Additional personal injury and property devaluation lawsuits may be filed in the future against Sotera Health LLC and Sterigenics U.S., LLC relating to Sterigenics’ Willowbrook facility or other EO sterilization facilities. Sotera Health LLC and Sterigenics U.S., LLC intend to defend themselves vigorously in all such EO tort litigation.

The Company carries insurance to cover alleged environmental liabilities with limits of $10.0 million per occurrence and $20.0 million in the aggregate. The per occurrence limit related to the Willowbrook EO tort litigations was fully utilized by June 30, 2020. We have not provided for a contingency reserve in connection with these claims. While we intend to vigorously defend the Willowbrook proceedings, there can be no assurance that we will be successful. We are unable to predict the incidence or outcome of such litigation or to reasonably estimate the possible range of any losses that could be incurred. An adverse outcome in one or more of these proceedings could have a material adverse effect on our business, financial condition and results of operations.

 

F-83


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements (Unaudited)

 

Ethylene Oxide Tort Litigation – Georgia

On May 19, 2020, a lawsuit against Sotera Health LLC, Sterigenics U.S., LLC and other parties was filed in the State Court of Cobb County, Georgia by 53 employees of a contract sterilization customer of Sterigenics. In the operative complaint, Plaintiffs claim personal injuries resulting from alleged exposure to residual EO while working at the customer’s distribution center in Lithia Springs, Georgia, allege they were unaware that they were being exposed to EO in their workplace and seek damages in an amount to be determined by the trier of fact. The deadline for defendants to respond to the operative complaint has not yet been determined. All defendants are being defended and indemnified by Sterigenics’ contract sterilization customer (plaintiffs’ employer and a co-defendant in the lawsuit).

In May 2020, the Cobb County, Georgia Board of Tax Assessors reduced certain residential property value assessments around the Sterigenics Atlanta facility by 10% citing an “Epd-identified environmental issue,” without supporting market data. On August 14, 2020, Sterigenics U.S., LLC filed a lawsuit against members of the Cobb County Board of Tax Assessors in the U.S. District Court for the Northern District of Georgia, seeking a declaration that the reduction in property value assessments is arbitrary and unlawful and is causing Sterigenics reputational and imminent economic harm. The court has stayed the action pending its decision concerning Sterigenics’ standing to bring the lawsuit. That issue has been fully briefed and was argued on September 29, 2020. Additional briefing by the parties on the issue of the court’s discretionary jurisdiction under the Declaratory Judgment Act was filed on October 21, 2020.

Since August 17, 2020, five lawsuits against Sotera Health LLC, Sterigenics U.S., LLC and other parties have been filed by plaintiffs in the State Court of Cobb County, Georgia and the State Court of Gwinnett County, Georgia in which plaintiffs allege that they suffered personal injuries and loss of consortium resulting from emissions and releases of EO from Sterigenics’ Atlanta facility. We are also defendants in a lawsuit alleging that our Atlanta facility has devalued and harmed the plaintiffs’ use of a real property they own in Smyrna, Georgia. In both instances, plaintiffs seek damages in amounts to be determined by the trier of fact. Current deadlines for defendants’ responses to the complaints are in November and December 2020.

Additional personal injury and property devaluation lawsuits may be filed in the future against Sotera Health LLC and Sterigenics U.S., LLC relating to Sterigenics’ Atlanta facility or other EO sterilization facilities. Sotera Health LLC and Sterigenics U.S., LLC intend to defend themselves vigorously in all such EO tort litigation. While we intend to vigorously defend these proceedings, there can be no assurance that we will be successful. We are unable to predict the incidence or outcome of such litigation or to reasonably estimate the possible range of any losses that could be incurred. An adverse outcome in one of these proceedings could have a material adverse effect on our business, financial condition and results of operations.

Suspension of Georgia Facility Operations & Related Litigation

On August 7, 2019, Sterigenics U.S., LLC entered into a voluntary Consent Order with the Georgia Environmental Protection Division (“EPD”) under which Sterigenics agreed to install emissions reduction enhancements at its Atlanta facility to further reduce the facility’s EO emissions below already permitted levels. Sterigenics voluntarily suspended operations at the facility in early September 2019 to expedite completion of the enhancements. Installation of these enhancements is complete, and Sterigenics successfully tested the enhanced emissions controls in cooperation with EPD during the second quarter of 2020 while the facility was in operation.

In October 2019, while Sterigenics had voluntarily suspended the facility’s operations, Cobb County, Georgia officials asserted that the facility had an incorrect “certificate of occupancy” and could not resume operations without obtaining a new certificate of occupancy after a third-party code compliance review they required.

 

F-84


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements (Unaudited)

 

After the Cobb County officials would not allow Sterigenics to resume operations, on March 30, 2020, Sterigenics U.S., LLC filed a lawsuit in the United States District Court for the Northern District of Georgia against Cobb County, Georgia and Cobb County officials Nicholas Dawe and Kevin Gobble. In the lawsuit, Sterigenics sought immediate injunctive relief and permanent declaratory relief to resume normal operations of the Atlanta facility in the interest of public health and on the basis that the positions asserted by Cobb County were unfounded. On April 1, 2020 the Court entered a Temporary Restraining Order prohibiting Cobb County officials from precluding or interfering with the facility’s normal operations. On April 8, 2020, the Court entered a Consent Order extending the Temporary Restraining Order and allowing the facility to continue normal operations until entry of a final judgment in the case. On June 24, 2020 Sterigenics filed an amended complaint, and on July 22, 2020 defendants filed a motion to dismiss the claims. On November 9, 2020, the Court held a hearing on the motion to dismiss and indicated, at the conclusion of the hearing, that an opinion and order denying the motion to dismiss would be issued. No trial date has been set.

19. Financial Instruments and Financial Risk

Derivative Instruments

We do not use derivatives for trading or speculative purposes and are not a party to leveraged derivatives.

We have embedded derivatives in certain of our customer and supply contracts as a result of the currency of the contract being different from the functional currency of the parties involved. Changes in the fair value of the embedded derivatives are recognized in “Other income, net” in the consolidated statements of operations and comprehensive income (loss).

In June 2020, SHH entered into two interest rate cap agreements with notional amounts of $1,000.0 million and $500.0 million, respectively, for a total option premium of $0.3 million. These terminate on August 31, 2021 and February 28, 2022, respectively. The interest rate caps limit our cash flow exposure related to the LIBOR base rate under a portion of our variable rate borrowings to 1.0%. In October 2017, SHH entered into two interest rate cap agreements with a total notional amount of $400.0 million for a total option premium of $0.6 million; these agreements terminated on September 30, 2020. The interest rate caps limited the Company’s cash flow exposure related to the LIBOR base rate under the variable rate Term Loan borrowings to 3.0%. The interest rate caps were not designated as hedges and were recorded at fair value on the consolidated balance sheets, with any changes in the value being recorded in the consolidated statement of operations and comprehensive income (loss).

During the third quarter of 2019, SHH entered into two interest rate swap agreements with a total notion amount of $1,000 million to hedge our exposure to interest rate movements and to manage interest expense related to our outstanding variable-rate debt. These swaps were designated as hedges against the changes in cash flows attributable to changes in LIBOR, the benchmark interest rate being hedged, and any changes in the fair value of the swap are recorded in other comprehensive income (loss). We received interest at one-month LIBOR and paid a fixed interest rate under the terms of the swap agreement. The swap agreements terminated on August 31, 2020.

 

F-85


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements (Unaudited)

 

The following table provides the fair values of our derivative instruments:

 

(thousands of U.S. dollars)

   September 30, 2020      December 31, 2019  

Assets

     

Interest rate caps

   $ 28      $ 1  

Interest rate swaps

     —          242  

Embedded derivatives (a)

     131        —    

Liabilities

     

Embedded derivatives (a)

   $  4,271      $  3,478  

 

  (a)

As of September 30, 2020, and December 31, 2019, total notional amounts for certain of the Company’s supply and customer contracts for embedded derivatives were approximately $90.4 million and $96.0 million, respectively.

The interest rate caps and embedded derivative assets are included in “Prepaid expenses and other current assets” on our consolidated balance sheets. Embedded derivative liabilities are included in “Accrued liabilities” on the consolidated balance sheets.

The following tables summarize the activities of our derivative instruments for the periods presented, and the line item where the activity is included in the consolidated statements of operations and comprehensive income (loss):

 

     Nine months ended September 30,  

(thousands of U.S. dollars)

       2020              2019      

Unrealized loss / (gain) on interest rate caps recorded in Interest expense, net

   $ 230      $ 333  

Unrealized loss / (gain) on embedded derivatives recorded in Other income, net

     (1,464      (153

Realized loss on interest rate swap recorded in Interest expense, net

     5,055        —    

Credit Risk

Certain of our financial assets, including cash and cash equivalents, are exposed to credit risk.

We are also exposed, in our normal course of business, to credit risk from our customers. As of September 30, 2020, and December 31, 2019, accounts receivable was net of an allowance for uncollectible accounts of $0.8 million.

 

F-86


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements (Unaudited)

 

Credit risk on financial instruments arises from the potential for counterparties to default on their contractual obligations to the Company. We are exposed to credit risk in the event of non-performance, but do not anticipate non-performance by any of the counterparties to our financial instruments. We limit our credit risk by dealing with counterparties that are considered to be of high credit quality. In the event of non-performance by counterparties, the carrying value of our financial instruments represents the maximum amount of loss that would be incurred.

Fair Value Hierarchy

The fair value of our financial instruments is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The valuation techniques we would use to determine such fair values are described as follows: Level 1—fair values determined by inputs utilizing quoted prices in active markets for identical assets or liabilities; Level 2—fair values based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable; Level 3—fair values determined by unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by other market participants.

The following table discloses our financial assets and liabilities measured at fair value on a recurring basis:

 

As of September 30, 2020

(thousands of U.S. dollars)

   Level 1      Level 2      Level 3      Total  

Interest rate caps

   $  —        $ 28      $  —        $ 28  

Embedded derivative assets

        131           131  

Embedded derivative liabilities

     —          (4,271      —          (4,271

 

As of December 31, 2019

(thousands of U.S. dollars)

   Level 1      Level 2     Level 3      Total  

Interest rate caps

   $  —        $ 1     $  —        $ 1  

Interest rate swaps

     —          242       —          242  

Embedded derivative liabilities

     —          (3,478     —          (3,478

The fair value of our Term Loan, First Lien Notes, and Second Lien Notes was $2,104.1 million, $97.6 million, and $712.6 million, respectively as of September 30, 2020. The fair value of our Term Loan and the Second Lien Notes was $2,130.6 million and $770.0 million, respectively as of December 31, 2019. The fair values were calculated using external pricing information, which is considered a Level 2 input as described above.

20. Segment Information

We identify our operating segments based on the way we manage, evaluate and internally report our business activities for purposes of allocating resources and assessing performance. We have three reportable segments: Sterigenics, Nordion and Nelson Labs. We have determined our reportable segments based upon an assessment of organizational structure, service types, and internally prepared financial statements. Our chief operating decision maker evaluates performance and allocates resources based on net revenues and segment income after the elimination of intercompany activities.

Sterigenics

The Sterigenics segment provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets.

 

F-87


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements (Unaudited)

 

Nordion

Nordion is a global provider of Co-60 and gamma irradiators, which are key components to the gamma sterilization process.

Nelson Labs

Nelson Labs provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and biopharmaceutical industries.

For nine months ended September 30, 2020, five customers reported within the Nordion segment individually represented 10% or more of the segment’s total net revenues. These customers represented 15.5%, 14.5%, 11.4%, 11.2% and 10.3% of the segment’s external net revenues for the nine months ended September 30, 2020.

Financial information for each of our segments is presented in the following table:

 

(thousands of U.S. dollars)

   Nine Months Ended September 30, 2020  
   Sterigenics      Nordion      Nelson Labs      Consolidated  

Net revenues (1)

   $  363,954      $  86,034      $  151,325      $ 601,313  

Segment income (2)

     192,803        50,692        63,302        306,797  

Capital expenditures

     29,090        1,809        2,741        33,640  

 

(thousands of U.S. dollars)

   Nine Months Ended September 30, 2019  
   Sterigenics      Nordion      Nelson Labs      Consolidated  

Net revenues (1)

   $  350,387      $  91,869      $  142,586      $  584,842  

Segment income (2)

     180,362        49,698        55,397        285,457  

Capital expenditures

     32,240        1,472        2,924        36,636  

 

  (1) 

Revenues are reported net of intersegment sales. Our Nordion segment recognized $22.9 million and $35.0 million in revenues from sales to our Sterigenics segment for the nine months ended September 30, 2020 and 2019, respectively, that is not reflected in net revenues in the table above. Intersegment sales for Sterigenics and Nelson Labs are immaterial for both periods.

  (2) 

Segment income is only provided on a net basis to the chief operating decision maker and is reported net of intersegment profits.

Corporate operating expenses for executive management, accounting, information technology, legal, human resources, treasury, corporate development, tax, purchasing, and marketing are allocated to the segments based on total net revenue.

Total assets and depreciation and amortization expense by segment are not readily available and are not reported separately to the chief operating decision maker.

 

F-88


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements (Unaudited)

 

A reconciliation of segment income to consolidated income (loss) before taxes is as follows:

 

     Nine Months Ended September 30,  

(thousands of U.S. dollars)

   2020      2019  

Segment income

   $  306,797      $ 285,457  

Less adjustments:

     

Interest expense, net

     167,142        114,478  

Depreciation and amortization (a)

     107,158        110,128  

Share-based compensation (b)

     4,019        15,120  

One time bonuses (c)

     —          530  

(Gain) loss on foreign currency and embedded derivatives (d)

     (4,791      8,298  

Acquisition and divestiture related charges, net (e)

     2,970        (704

Impairment of long-lived assets and intangible assets (f)

     —          5,781  

Business optimization project expenses (g)

     2,484        1,485  

Plant closure expenses (h)

     2,388        1,145  

Professional services relating to Willowbrook and Atlanta facilities (i)

     25,370        7,788  

Accretion of asset retirement obligation (j)

     1,476        1,457  

COVID-19 expenses (k)

     2,363        —    
  

 

 

    

 

 

 

Consolidated income (loss) before taxes

   $ (3,782    $ 19,951  
  

 

 

    

 

 

 

 

  (a) 

Includes depreciation of Co-60 held at gamma irradiation sites.

  (b) 

Includes non-cash share-based compensation expense. In 2019, also includes $10.0 million of one-time cash share-based compensation expense related to the Class C Performance and Time Vesting Units, which vested in the third quarter of 2019 based on the achievement of the aggregate distributions to the Class A unitholders and the approval of the board of Topco Parent for accelerated vesting.

  (c)

Represents one-time cash bonuses for members of management relating to capital markets activity in 2019.

  (d) 

Represents the effects of (i) fluctuations in foreign currency exchange rates, primarily related to remeasurement of intercompany loans denominated in currencies other than subsidiaries’ functional currencies, and (ii) non-cash mark-to-fair value of embedded derivatives relating to certain customer and supply contracts at Nordion.

  (e) 

Represents (i) certain direct and incremental costs related to the acquisition of Iotron Industries Canada, Inc. in July 2020, and certain related integration efforts as a result of acquisitions, (ii) the earnings impact of fair value adjustments (excluding those recognized within amortization expense) resulting from the businesses acquired, and (iii) transition services income and non-cash deferred lease income associated with the terms of the divestiture of the Medical Isotopes business in 2018.

  (f) 

Represents impairment charges related to the decision to not reopen the Willowbrook, Illinois facility in September 2019.

  (g)

Represents professional fees, contract termination and exit costs, severance and other payroll costs, and other costs associated with business optimization and cost savings projects relating to the integrations of Nordion and Nelson Labs, including the divestiture of the Medical

 

F-89


Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements (Unaudited)

 

  Isotopes business, the Sotera Health rebranding, operating structure realignment and other process enhancement projects.
  (h) 

Represents professional fees, severance and other payroll costs, and other costs including ongoing lease and utility expenses associated with the closure of the Willowbrook, Illinois facility.

  (i) 

Represents professional fees related to litigation associated with our EO sterilization facilities in Willowbrook, Illinois and Atlanta, Georgia and other related professional fees. See Commitments and Contingencies note.

  (j) 

Represents the non-cash accretion of asset retirement obligations related to Co-60 and gamma processing facilities, which are based on estimated site remediation costs for any future decommissioning of these facilities (without regard for whether the decommissioning services would be performed by employees of Nordion, instead of by a third party) and are accreted over the life of the asset.

  (k) 

Represents non-recurring costs associated with the COVID-19 pandemic, including donations to related charitable causes and special bonuses for front-line personnel working on-site during lockdown periods.

21. Subsequent Events

We have evaluated events occurring subsequent to September 30, 2020 through November 18, 2020, which is the date the consolidated financial statements were available to be issued.

On November 18, 2020, the Company filed an amendment to its certificate of incorporation, effecting a forward stock split to reclassify all 3,000 shares of its common stock outstanding as 232,400,200 shares, which was approved by the Company’s board of directors and sole stockholder on November 10, 2020. The accompanying financial statements and related notes and schedules to the financial statements give retroactive effect to the stock split for all periods presented.

 

F-90


Table of Contents

 

 

46,600,000 Shares

 

 

LOGO

Common Stock

 

 

Prospectus

            , 2020

 

 

J.P. Morgan

Credit Suisse

Goldman Sachs & Co. LLC

Jefferies

 

 

Barclays

Citigroup

RBC Capital Markets

BNP PARIBAS

KeyBanc Capital Markets

Citizens Capital Markets

ING

Academy Securities

Loop Capital Markets

Penserra Securities LLC

Siebert Williams Shank

Tigress Financial Partners

Through and including                 , 2020 (the 25th day after the date of this prospectus), all dealers effecting transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to each dealer’s obligation to deliver a prospectus when acting as an underwriter and with respect to unsold allotments or subscriptions.

 

 

 


Table of Contents

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

 

Item 13.

Other Expenses of Issuance and Distribution.

Estimated expenses payable in connection with the sale of the common stock in this offering are as follows:

 

SEC registration fee

   $ 134,470  

FINRA filing fee

     185,390  

Stock exchange listing fee

     295,000  

Printing and engraving expenses

     400,000  

Legal fees and expenses

     4,500,000  

Accounting fees and expenses

     1,500,000  

Transfer agent and registrar fees and expenses

     10,000  

Miscellaneous

     500,000  
  

 

 

 

Total

   $ 7,524,860  
  

 

 

 

We will bear all of the expenses shown above.

 

Item 14.

Indemnification of Directors and Officers.

Section 145 of the DGCL provides that a corporation may indemnify directors and officers as well as other employees and individuals against expenses, including attorneys’ fees, judgments, fines and amounts paid in settlement in connection with specified actions, suits and proceedings whether civil, criminal, administrative or investigative, other than a derivative action by or in the right of the corporation, if they acted in good faith and in a manner they reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe their conduct was unlawful. A similar standard is applicable in the case of derivative actions, except that indemnification extends only to expenses, including attorneys’ fees, incurred in connection with the defense or settlement of such action and the statute requires court approval before there can be any indemnification where the person seeking indemnification has been found liable to the corporation. The statute provides that it is not exclusive of other indemnification that may be granted by a corporation’s certificate of incorporation, bylaws, disinterested director vote, stockholder vote, agreement or otherwise.

Our amended and restated certificate of incorporation will provide for indemnification of directors and officers to the fullest extent permitted by law, including payment of expenses in advance of resolution of any such matter. Our amended and restated certificate of incorporation will eliminate the potential personal monetary liability of our directors to us or our stockholders for breaches of their duties as directors except as otherwise required under the DGCL. Any amendment to, or repeal of, these provisions will not eliminate or reduce the effect of these provisions in respect of any act, omission or claim that occurred or arose prior to that amendment or repeal. If the DGCL is amended to provide for further limitations on the personal liability of directors of corporations, then the personal liability of our directors will be further limited to the greatest extent permitted by the DGCL.

We have entered into or will enter into separate indemnification agreements with our directors and officers that may be broader than the specific indemnification provisions contained in the DGCL. Each indemnification agreement provides, among other things, for indemnification to the fullest extent permitted by law and our amended and restated certificate of incorporation and amended and restated bylaws against any and all expenses, judgments, fines and amounts paid in settlement of any claim. The indemnification agreements provide for the advancement or payment of all expenses to the indemnitee and for reimbursement to us if it is found that such indemnitee is not entitled to such indemnification under applicable law and our amended and restated certificate

 

II-1


Table of Contents

of incorporation and amended and restated bylaws. We believe that these agreements are necessary to attract and retain qualified individuals to serve as directors and officers.

The limitation of liability and indemnification provisions expected to be included in our amended and restated certificate of incorporation and the indemnification agreements that we have entered into or will enter into with our directors and officers may discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and other stockholders. Further, a stockholder’s investment may be adversely affected to the extent that we pay the costs of settlement and damage awards against directors and executive officers as required by these indemnification provisions.

We maintain standard policies of insurance under which, subject to the limitations of the policies, coverage is provided to our directors and officers against loss rising from claims made by reason of breach of duty or other wrongful acts as a director or officer, including claims relating to public securities matters.

Certain of our non-employee directors may, through their relationships with their employers, be insured and/or indemnified against certain liabilities incurred in their capacity as members of our board of directors. Although directors designated for election to our board of directors by investment funds and entities affiliated with either Warburg Pincus or GTCR may have certain rights to indemnification, advancement of expenses or insurance provided or obtained by investment funds and entities affiliated with either Warburg Pincus or GTCR, respectively, we have agreed in our Stockholders’ Agreement that we will be the indemnitor of first resort, will advance the full amount of expenses incurred by each such director and, to the extent that investment funds and entities affiliated with either Warburg Pincus or GTCR or their insurers make any payment to, or advance any expenses to, any such director, we will reimburse those investment funds and entities and their insurers for such amounts.

The underwriting agreement, filed as Exhibit 1.1 to this registration statement, will provide for indemnification, under certain circumstances, by the underwriters of us and our officers and directors for certain liabilities arising under the Securities Act or otherwise.

 

Item 15.

Recent Sales of Unregistered Securities.

In the three years preceding the filing of this registration statement, we have issued the following securities that were not registered under the Securities Act:

On November 18, 2020, we effected a forward stock split to reclassify all 3,000 shares of our common stock outstanding as 232,400,200 shares.

PIK Toggle Notes

On November 24, 2017, Sotera Health Company (formerly known as Sotera Health Topco, Inc.) issued an aggregate principal amount of $75.0 million of 8.125%/8.875% Senior PIK Toggle Notes due 2021 (the “PIK Toggle Notes”), which was used to pay a cash distribution to Topco Parent, which, in turn, used such proceeds for distributions, equity repurchases and other payments to its equity holders. The initial purchasers for the PIK Toggle Notes were Jefferies LLC and Goldman Sachs & Co. LLC.

The PIK Toggle Notes were offered and sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act or to non-U.S. investors outside the United States in compliance with Regulation S of the Securities Act.

 

II-2


Table of Contents
Item 16.

Exhibits and Financial Statement Schedules.

(a) Exhibits: The list of exhibits is set forth in beginning on page II-4 of this Registration Statement and is incorporated herein by reference.

(b) Financial Statement Schedules: No financial statement schedules are provided because the information called for is not applicable or is shown in the financial statements or notes thereto.

 

Item 17.

Undertakings.

* (h) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers, and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer, or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer, or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

* (i) The undersigned registrant hereby undertakes that:

 

   

For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by us pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.

 

   

For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

  *

Paragraph references correspond to those of Regulation S-K, Item 512.

 

II-3


Table of Contents

EXHIBIT INDEX

 

Exhibit No

  

Description of Exhibits

  1.1**    Form of Underwriting Agreement
  3.1**    Form of Certificate of Incorporation of the Registrant
  3.2**    Form of Bylaws of the Registrant
  4.1    [Reserved]
  4.2**    Form of Amended and Restated Registration Rights Agreement
  4.3**    Indenture, dated as of December  13, 2019, among Sotera Health Holdings, LLC, the Registrant, the intermediate parents and subsidiary note parties thereto and Wilmington Trust, National Association, as second lien notes collateral agent, calculation agent and trustee
  4.4**    Indenture, dated as of July  31, 2020, among Sotera Health Holdings, LLC, the Registrant, the intermediate parents and subsidiary note parties thereto and Wilmington Trust, National Association, as first lien notes collateral agent, calculation agent and trustee
  4.5**    Form of Senior Secured Second Lien Floating Rate Note due 2027 (included in Exhibit 4.3)
  4.6**    Form of Senior Secured First Lien Floating Rate Note due 2026 (included in Exhibit 4.4)
  4.7**    First Supplemental Indenture, dated as of July  31, 2020, among Sotera Health Holdings, LLC, the additional guarantors party thereto and Wilmington Trust, National Association, as trustee and second lien notes collateral agent
  4.8**    Second Supplemental Indenture, dated as of October  9, 2020, among Sotera Health Holdings, LLC and Wilmington Trust, National Association, as trustee and second lien notes collateral agent
  5.1**    Opinion of Cleary Gottlieb Steen & Hamilton LLP
10.1+**   

Employment Agreement by and between Sotera Health Company and Michael B. Petras, Jr., dated as of November 10, 2020

10.2+**   

Employment Agreement by and between Sotera Health Company and Scott J. Leffler, dated as of November 10, 2020

10.3+**   

Employment Agreement by and between Sotera Health Company and Matthew J. Klaben, dated as of November 10, 2020

10.4+**   

Sotera Health Company Supplemental Retirement Benefit Plan, effective as of January 1, 2018

10.5+**    Sotera Health Company 2020 Omnibus Incentive Plan
10.6+**   

Form of Sotera Health Company 2020 Omnibus Incentive Plan Restricted Stock Unit Grant Notice and Agreement

10.7+**   

Form of Sotera Health Company 2020 Omnibus Incentive Plan Stock Option Grant Notice and Agreement

10.8**    Form of Indemnification Agreement entered into between the Registrant and each director and executive officer
10.9**    Form of Stockholders’ Agreement
10.10**    Credit Agreement, dated as of December  13, 2019, among the Registrant, Sotera Health Holdings, LLC, the lenders and issuing banks party thereto and Jefferies Finance LLC, as first lien administrative agent and first lien collateral agent
10.11**    Guarantee Agreement, dated as of December  13, 2019, among the Registrant, Sotera Health Holdings, LLC, the other guarantors party thereto and Jefferies Finance LLC, as first lien collateral agent

 

II-4


Table of Contents

Exhibit No

  

Description of Exhibits

10.12**    Collateral Agreement, dated as of December  13, 2019, among the Registrant, Sotera Health Holdings, LLC, the other guarantors party thereto and Jefferies Finance LLC, as first lien collateral agent
10.13**    Patent Security Agreement, dated as of December  13, 2019, between Sterigenics U.S., LLC and Jefferies Finance LLC, as collateral agent
10.14**    Trademark Security Agreement, dated as of December  13, 2019, between Sterigenics U.S., LLC and Jefferies Finance LLC, as collateral agent
10.15**    Trademark Security Agreement, dated as of December  13, 2019, between Nelson Laboratories, LLC and Jefferies Finance LLC, as collateral agent
10.16**    Trademark Security Agreement, dated as of December  13, 2019, between Sotera Health LLC and Jefferies Finance LLC, as collateral agent
10.17**    Copyright Security Agreement, dated as of December 13, 2019, among Jefferies Finance LLC and Nelson Laboratories, LLC, as collateral agent
10.18**    Second Lien Collateral Agreement, dated as of December  13, 2019, among the Registrant, Sotera Health Holdings, LLC, the other grantors party thereto and Wilmington Trust, National Association, as second lien notes collateral agent
10.19**    Patent Security Agreement, dated as of December  13, 2019, between Sterigenics U.S., LLC and Wilmington Trust, National Association, as second lien notes collateral agent
10.20**    Trademark Security Agreement, dated as of December  13, 2019, between Sterigenics U.S., LLC and Wilmington Trust, National Association, as second lien notes collateral agent
10.21**    Trademark Security Agreement, dated as of December  13, 2019, between Nelson Laboratories, LLC and Wilmington Trust, National Association, as second lien notes collateral agent
10.22**    Trademark Security Agreement, dated as of December  13, 2019, between Sotera Health LLC and Wilmington Trust, National Association, as second lien notes collateral agent
10.23**    Copyright Security Agreement, dated as of December  13, 2019, between Nelson Laboratories, LLC and Wilmington Trust, National Association, as second lien notes collateral agent
10.24**    First/Second Lien Intercreditor Agreement, dated as of December 13, 2019, among the Registrant, Sotera Health Holdings, LLC, the other grantors party thereto, Jefferies Finance LLC, as first lien collateral agent and Wilmington Trust, National Association, as initial second priority representative
10.25**    First Lien Pari Passu Intercreditor Agreement, dated as of July 31, 2020, among Sotera Health Holdings, LLC, the Registrant, Jefferies Finance LLC as Collateral Agent and Authorized Representative, and Wilmington Trust, National Association as Additional First Lien Collateral Agent and Initial Authorized Representative
10.26**    First Lien Collateral Agreement, dated as of July  31, 2020, among the Registrant, Sotera Health Holdings, LLC, the other grantors party thereto and Wilmington Trust, National Association, as first lien notes collateral agent
10.27**    Patent Security Agreement, dated as of July  31, 2020, between Sterigenics U.S., LLC and Wilmington Trust, National Association, as first lien notes collateral agent
10.28**    Trademark Security Agreement, dated as of July  31, 2020, between Sotera Health Holdings LLC and Wilmington Trust, National Association, as first lien notes collateral agent
10.29**    Copyright Security Agreement, dated as of July  31, 2020, between Nelson Laboratories, LLC and Wilmington Trust, National Association, as first lien notes collateral agent

 

II-5


Table of Contents

Exhibit No

  

Description of Exhibits

10.30†    Restated Supply Agreement, dated as of October 6, 2020, between Balchem Corporation and Sterigenics U.S., LLC, Sterigenics S.  De R.L. De C.V., Sterigenics Costa Rica S.R.L. and Sterigenics EO Canada, Inc.
10.31+**    Form of Restricted Stock Agreement and Acknowledgement
10.32+**    Non-Employee Director Compensation Policy
21.1**    List of Subsidiaries
23.1**    Consent of Cleary Gottlieb Steen & Hamilton LLP (included in Exhibit 5.1)
23.2    Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm
24.1**    Powers of Attorney (included on signature page to Registration Statement on Form S-1 filed on October 23, 2020)
24.2**    Powers of Attorney (included on signature page to Registration Statement on Form S-1 filed on November 12, 2020)

 

+

Denotes management contract or compensatory plan or arrangement.

**

Previously filed.

Certain confidential portions of this exhibit have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K. The omitted information is (i) not material and (ii) would likely cause us competitive harm if publicly disclosed. We agree to furnish supplementally an unredacted copy of the exhibit to the Securities and Exchange Commission on its request.

 

II-6


Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Broadview Heights, State of Ohio on November 18, 2020.

 

SOTERA HEALTH COMPANY
By:   /s/ Michael B. Petras, Jr.
Name:   Michael B. Petras, Jr.
Title:   Chairman and Chief Executive Officer

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed below by the following persons in the capacities and on the dates indicated.

 

Name

 

Title

 

Date

/s/ Michael B. Petras, Jr.

Michael B. Petras, Jr.

 

Chairman and Chief Executive Officer (Principal Executive Officer)

  November 18, 2020

/s/ Scott J. Leffler

Scott J. Leffler

 

Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer)

  November 18, 2020

*

Ruoxi Chen

 

Director

 

November 18, 2020

*

  Director   November 18, 2020
Sean L. Cunningham    

*

  Director   November 18, 2020
David A. Donnini    

*

  Director   November 18, 2020
Stephanie Geveda    

*

  Director   November 18, 2020
Ann R. Klee    

*

  Director   November 18, 2020
Constantine S. Mihas    

*

  Director   November 18, 2020
James C. Neary    

*

  Director  

November 18, 2020

Vincent K. Petrella    

 

*By:  

/s/ Michael B. Petras, Jr.

  Attorney-in-Fact

 

II-7

EX-10.30 2 d93452dex1030.htm EX-10.30 EX-10.30

Exhibit 10.30

[Certain confidential portions of this exhibit have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K and marked with asterisks. The omitted information is (i) not material and (ii) would likely cause us competitive harm if publicly disclosed.]

RESTATED SUPPLY AGREEMENT

BALCHEM CORPORATION / STERIGENICS U.S., LLC., STERIGENICS S. DE R.L. DE C.V., STERIGENICS COSTA RICA S.R.L., STERIGENICS EO CANADA, INC.

Effective Date: October 6, 2020

BALCHEM CORPORATION acting through its ARC Specialty Products segment, located at 52 Sunrise Park Road, New Hampton, New York 10958 (“Seller”), agrees to sell and each of STERIGENICS U.S., LLC (“Sterigenics U.S.”), STERIGENICS S. DE R.L. DE C.V. (“Sterigenics Mexico”), STERIGENICS COSTA RICA S.R.L. (“Sterigenics Costa Rica”) and STERIGENICS EO CANADA, INC. (“Sterigenics Canada”) (collectively, Sterigenics U.S., Sterigenics Mexico, Sterigenics Costa Rica and Sterigenics Canada are referred to as “Buyer” or “Sterigenics”) agrees to purchase for and use by its contract sterilization facilities in its respective territory Product described in this Agreement at the prices and upon the terms set forth in the Agreement.

DEFINITIONS:

 

  A.

Term: This Agreement will be in effect October 6, 2020 and will continue in effect until December 31, 2030, unless extended as set forth in Paragraph K.

 

  B.

Requirements:

 

  1.

Sterigenics U.S. and Sterigenics Canada - [***] of requirements of ethylene oxide for use by Sterigenics U.S. and Sterigenics Canada by and at their respective ethylene oxide contract sterilization facilities in the USA and Canada.

 

  2.

Sterigenics Costa Rica - [***] of requirements of ethylene oxide for use by Sterigenics Costa Rica by and at its ethylene oxide contract sterilization facilities in Costa Rica, subject to the forecast applicable to Sterigenics Costa Rica in Terms and Conditions, Paragraph D, Volume Estimate.

 

  3.

Sterigenics Mexico - Seller will provide ethylene oxide, when ordered by Sterigenics Mexico, subject to the forecast applicable to Sterigenics Mexico in Terms and Conditions, Paragraph D, Volume Estimate.

 

  C.

Product: Ethylene Oxide.

 

  D.

Volume Estimate: For planning purposes only. These volume estimates are not a requirement or guarantee:

 

  1.

Sterigenics U.S and Sterigenics Canada- [***] pounds annually.


  2.

Sterigenics Mexico and Sterigenics Costa Rica will provide Seller with an annual forecast each November to determine volumes for upcoming calendar year. Sterigenics Mexico and Costa Rica will provide an updated rolling quarterly forecast, which will include four (4) quarters; the upcoming current quarter and the three (3) following quarters. The current quarter will be based on mutually agreeably lead times. This rolling forecast shall be submitted to Seller thirty (30) days prior to the commencement of the upcoming quarter to be forecasted.

 

  E.

Specifications: See Schedule A.

 

  F.

Container(s):

 

  1.

Sterigenics U.S. and Sterigenics Canada -All containers and packaging, including, but not limited to, 400-pound UN-1A1 drums, 175-pound cylinders, 0.5-pound DOT 3E 1800 lecture bottles, will fully comply with current and future applicable laws, regulations and rules, including but not limited to U.S. DOT Spec and Transport Canada requirements.

 

  2.

Sterigenics Mexico - All containers and packaging, including, but not limited to, 400-pound UN-1A1 drums, will fully comply with current applicable laws, regulations and rules, including but not limited to U.S. DOT Spec.

 

  3.

Sterigenics Costa Rica -All containers and packaging, including, but not limited to, 400-pound UN-1A1 drums, DOT Spec packaging, 0.5-pound DOT 3 E 1800 lecture bottles, will fully comply with current applicable laws, regulations and rules, including but not limited to U.S. DOT Spec.

 

  4.

In the event of future changes in applicable laws, regulations or rules requiring changes in the Container(s) in Costa Rica and Mexico, the Parties agree to discuss jointly in good faith regulatory implications, required changes and cost impacts associated therewith.

 

  G.

Delivery and Shipment:

 

  1.

Sterigenics U.S. and Sterigenics Canada - DAP (INCOTERMS 2010) Sterigenics U.S. and Sterigenics Canada respective facilities, shipped via Seller’s trucks or via common carrier.

 

  2.

Sterigenics Mexico - DAP (INCOTERMS 2010), Sterigenics Mexico’s Cuautitlan, Mexico facility, shipped via common carrier.

 

  3.

Sterigenics Costa Rica- DAP (INCOTERMS 2010), Sterigenics Costa Rica Alajuela, Costa Rica facility, shipped via ocean container, [***] drums minimum per shipment.)

 

  H.

Price And Price Adjustments: Schedule B shall remain effective until December 31, 2021. Thereafter, Schedule C will apply effective on January 1, 2022.


  I.

Demurrage: Sterigenics U.S. and Sterigenics Canada are each entitled to utilize any of the shipping Containers for sixty (60) days free of charge from the date of receipt at each of their respective plants until the Containers are received back at Seller’s plant. Sterigenics Mexico and Sterigenics Costa Rica are each entitled to utilize any of the shipping Containers for one hundred twenty (120) days free of charge from the date of receipt at each of their respective plants until the Containers are received back at Seller’s plant. A demurrage fee of [***] per day per. Container will be assessed and billed for all days in excess of the respective limit until the return of the Containers to the Seller’s plant.

 

  J.

Terms of Payment: Net [***] from receipt of invoice, beginning 14 days after the signing of this Agreement until December 31, 2021. Beginning on January 1, 2022, payment terms shall be Net [***] from receipt of invoice.

 

  K.

Extension Period(s): This contract will automatically renew for successive one (1) year periods unless either party notifies the other party in writing eighteen (18) months prior to the then applicable contract expiration date of its desire to terminate this contract as of that expiration date. The pricing provisions set forth in Paragraph H shall continue to apply to such renewal periods.

THIS CONTRACT IS SUBJECT TO THE FOLLOWING TERMS AND CONDITIONS WHICH ARE SPECIFICALLY INCORPORATED INTO AND MADE A PART OF THIS AGREEMENT.

TERMS AND CONDITIONS

 

1.

ACCEPTANCE

(A) The terms and conditions set forth herein and on the cover page(s) of any particular order(s) or contract to which these Terms and Conditions relate contain the sole, entire and exclusive agreement between the Seller and the Buyer with respect to the sale and purchase of Product covered by any such order(s) or contract, superseding all prior discussions, proposals, negotiations, representations and agreements. Any additional or conflicting terms, whether or not material, shall not in any manner, by implication, by waiver, or otherwise, govern the relationship between Seller and Buyer. Any waiver, modification or amendment of these Terms and Conditions shall only be effective if such waiver, modification or amendment is contained in a written instrument duly executed by or on behalf of Seller and Buyer. Requested Specification changes are subject to express written acceptance by Seller in its discretion, and to price revisions and to any adjustments deemed necessary by Seller to cover material procured, processed and labor expended in connection with such changes.

(B) Acceptance of any order by Seller is specifically conditioned upon the terms and conditions set forth herein. No modification hereof shall be effected by Seller’s receipt of any proposed purchase order containing additional or different terms or conditions.

 

2.

SALE AND PURCHASE LOCATION(S)

On the terms and conditions set forth herein, Sterigenics U.S. and Sterigenics Canada shall purchase from Seller and Seller shall sell to each of Sterigenics U.S. and Sterigenics Canada their total present and future Requirements of Product for use by Sterigenics U.S. and Sterigenics Canada at each of their respective contract sterilization facilities in the U.S. and Canada and if any of Sterigenics U.S.’s and Sterigenics Canada’s contract sterilization operations are hereafter conducted at new or expanded contract sterilization facilities in the U.S. and Canada locations, then the Requirements of Product at such locations will be supplied by Seller to Sterigenics U.S. and Sterigenics Canada and purchased by Sterigenics U.S. and Sterigenics Canada pursuant hereto. Additionally, on


the terms and conditions set forth herein, Sterigenics Mexico and Sterigenics Costa Rica shall purchase from Seller and Seller shall sell to each of Sterigenics Mexico and Sterigenics Costa Rica Product as ordered pursuant to the forecasts provided under Paragraph D by Sterigenics Mexico and Sterigenics Costa Rica, respectively.

 

3.

PRICE AND PAYMENT

Seller will invoice Buyer and Buyer will pay Seller for Product in accordance with the Price of Product and Terms of Payment set forth in Paragraphs H & J of the Definition section of the Agreement hereto. If Buyer fails to make timely payment in accordance with the terms of this Agreement, or Buyer’s credit becomes impaired, as set forth in paragraph 11 hereof, Seller reserves the right to:

 

  (a)

Refuse to supply Product to Buyer under any order unless Buyer pays cash in advance with order and/or makes payment in full of all outstanding charges; and/or

 

  (b)

At the discretion of the Seller, assess and collect from Buyer a late charge on any delinquent balance, computed as follows: 1.0% per month on balances over 45 days; and/or

 

  (c)

Terminate or suspend this Agreement upon thirty (30) days written notice to Buyer, if Buyer does not rectify within a forty-five (45) day period.

Buyer shall receive no credit or refund for Product which meets the Specifications set forth in Schedule A which is delivered to Buyer but not used. This does not supersede mechanical defects of Seller’s cylinders.

 

4.

DELIVERY OF PRODUCT: TITLE

(A) Product shall be delivered by Seller in accordance with the Delivery and Shipment provisions of Paragraph G of the Definition section of the Agreement. Title and risk of loss shall pass to Buyer F.O.B. Buyer’s facility. Seller’s quantity measurements taken at Seller’s facility shall govern. Except as otherwise provided for hereunder, all drums, cylinders and other containers in which Product is delivered are and shall remain the property of Seller and are returnable in good condition promptly after being emptied, considering ordinary wear and tear

(B) Seller will:

 

  (a)

Excluding supply to Sterigenics Costa Rica and Sterigenics Mexico, upon receipt of reasonable advance notice, deliver to Buyer’s location quantities of Product as are necessary to satisfy and supply Buyer’s Requirements at such locations, and subject to the provisions of Paragraph 10 of the Terms and Conditions, if Seller is unable to supply Product as required within sixty (60) days when required, Buyer has the right to obtain Product to satisfy its Requirements from another source for that particular order only, subject to the terms of Paragraph 9C. Should Seller fail to supply Product as required to the same location on more than two (2) occasions in the same calendar year, the adversely affected Buyer shall have the right to terminate this Agreement without recourse by or liability to the Seller, subject to the provisions of Paragraph 10 of the Terms and Conditions.


(C) Buyer will:

 

  (a)

Monitor the inventory of Product at Buyer’s location and regularly advise Seller of the level thereof at each such location.

 

  (b)

Reimburse Seller upon Seller’s request, reasonable additional costs incurred if, during Product deliveries, Seller experiences frequent delays within Buyer’s control and not arising out of Seller’s acts or omissions.

 

  (c)

Deliveries may be made twenty-four (24) hours per day, seven (7) days per week.

(D) Deliveries which may be made during a strike or other labor disturbance affecting Buyer’s plants shall be at Buyer’s sole risk, and Buyer hereby indemnifies and holds Seller harmless from and against all of the costs, damages, liabilities or claims arising out of or associated with any such delivery which are not regularly incurred by Seller in the ordinary course of normal deliveries hereunder and which do not arise out of Seller’s negligent acts or omissions.

 

5.

SPECIFICATIONS

All Product delivered by Seller under this Agreement shall strictly conform to the Specification set forth in Schedule A hereto.

 

6.

PRICE ADJUSTMENT

See Paragraph H of the Definition section of the Agreement

 

7.

TAXES

Taxes imposed upon the storage, sale, transportation, delivery, use or consumption of Product, or any other tax, howsoever denominated and measured involving Product, shall be paid directly by Buyer, or if paid by Seller, shall be invoiced to Buyer as a separate item and paid by Buyer to Seller.

 

8.

SELLER’S WARRANTY

Seller warrants that the Product delivered to Buyer shall conform to the Specifications set forth on Schedule A hereto and that at the time of delivery Seller shall have good title to and the right to transfer such Product and that the same shall be delivered free of encumbrances and that the Containers in which the Product will be delivered will be appropriate for containing and shipping the Product and will be free from defects and leaks. THE FOREGOING WARRANTIES ARE IN LIEU OF ALL OTHER WARRANTIES, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.

 

9.

LIMITATION OF LIABILITY

(A) Buyer acknowledges that there are hazards associated with the use of the Product, that it has received Seller’s current Material Safety Data Sheet, that it understands such hazards, and that it is the Buyer’s responsibility to warn and protect its employees, independent contractors, invitees, and others exposed to such hazards through Buyer’s storage and use of the Product.


(B) Seller’s sole liability and Buyer’s exclusive remedy for the non-delivery of Product or for the delivery of Product not conforming to the specification (and which Seller does not elect to replace with conforming Product) shall be limited to the purchase price of the quantity of Product. IN NO CIRCUMSTANCES SHALL SELLER BE LIABLE, WHETHER IN CONTRACT OR TORT OR OTHERWISE, FOR ANY INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING LOSS OF USE, LOSS OF WORK IN PROCESS, DOWN TIME OR LOSS OF PROFITS.

(C) In the case where Seller is unable to satisfy Requirements or any portion thereof, Seller shall be liable for: (i) the difference between the purchase price of the Product, if the seller had supplied, and the price actually paid by the Buyer for the Product from another source and (ii) additional shipping and container costs incurred by Buyer.

(D) Buyer will receive documents from Seller, including Seller’s Material Safety Data Sheet and any revision thereof, containing safety and health information pertaining to Product, and Buyer will incorporate such information into Buyer’s safety program. This information is available to Buyer.

(E) Each party hereby agrees to indemnify, defend and hold the other party, its affiliates and their respective employees, officers and directors harmless from any actions, lawsuits, demands, claims, losses, expenses, costs, including but not limited to reasonable legal fees, and damages, arising out of or in connection with this Agreement, and to the extent arising out of the other party’s negligence or its breach of its obligations hereunder.

(F) IN NO EVENT WHATSOEVER SHALL BUYER BE LIABLE, WHETHER IN CONTRACT OR TORT OR OTHERWISE, FOR ANY INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING BUT NOT LIMITED TO LOSS OF PROFITS.

 

10.

FORCE MAJEURE

(A) Neither party hereto shall be considered in default in the performance of its obligations hereunder (other than its obligation to make any payment of money hereunder), or be liable in damages or otherwise for any failure or delay in performance which is due to strike, lockout, concerted act of worker’s or other industrial disturbance, fire, explosion, flood or other natural catastrophe, civil disturbance, riot or armed conflict, whether declared or undeclared, acts of terrorism, curtailment, shortage, rationing or allocation of normal sources of supply of labor, materials, transportation, energy, or utilities, machinery or equipment breakdown, abnormal transportation, energy, or utilities, machinery or equipment breakdown, abnormal demand, lack of transportation or distribution equipment, accident, Act of God, sufferance of or voluntary compliance with acts of government and government regulations (whether or not valid), embargoes or any other similar or dissimilar cause which is beyond the reasonable control of the party affected.

(B) Neither party hereto shall be required to make any concession or grant any demand or request to bring to an end any strike or other concerted act of workers.

(C) Either party affected by an event described in this paragraph shall, promptly upon learning of such event and ascertaining that it has or will affect its performance hereunder, give notice to the other party, stating the nature of the event, its anticipated duration and any action being taken to avoid or minimize its effect.


(D) Seller may during any period of Product shortages prorate the Product among its various customers.

(E) In the event Seller is unable, due to any such cause or otherwise, to fulfill Buyer’s total requirements of Product in addition to payments set forth in 9(c), Buyer agrees to accept, as full and complete performance by Seller, deliveries in accordance with such allocations as Seller may make.

Provided, however, that Buyer shall have the right to satisfy its unfilled requirements from any available approved supplier without any liability to or recourse by Seller.

 

11.

IMPAIRMENT OF CREDIT

An impairment of credit is: (i) any action that is brought by or against Buyer under any present or future bankruptcy or insolvency laws seeking any reorganization, arrangement, readjustment, liquidation, dissolution or similar relief with respect to Buyer, (ii) Buyer makes any assignment for the benefit of creditors, (iii) a receiver is appointed for Buyer, (iv) Buyer shall fail to make payments in accordance with the terms of this Agreement.

 

12.

PRODUCT CLAIMS

Buyer shall inspect Product immediately after Product arrives at Buyer’s location(s). Buyer’s failure to give notice to Seller of any claim regarding Product within thirty (30) days after the arrival of Product at Buyer’s location(s) shall constitute an acceptance by Buyer of such Product and a waiver of Buyer’s claims in respect thereof.

 

13.

ASSIGNMENT

This Agreement shall be binding upon the parties and their heirs, administrators, executors, acquirers, successors, and assignees of either party. No party hereto may assign this Agreement without the written consent of the other party, which shall not be unreasonably withheld, except to an affiliate of a party or in the case of a merger or sale of all or substantially all of its stock or assets of the business to which this Agreement relates.

 

14.

NOTICE

Any notices, unless otherwise provided herein, will be in writing or facsimile provided that a return facsimile is received confirming the receipt of said facsimile. Any notice by letter under this Agreement will be deemed given on the date such correspondence is postmarked.

 

15.

APPLICABLE LAW

This Agreement is to be interpreted in accordance with the laws of the State of New York as in effect for agreements made and performed in New York. Seller assumes full liability and responsibility for compliance with Federal (including EPA, FIFRA), State, Municipal and local


laws, ordinances and regulations prior to unloading of Product at Buyer’s site. Buyer assumes full liability and responsibility for compliance with Federal (including, EPA, FIFRA), State, Municipal and local laws, ordinances and regulations governing the use, unloading, discharge, storage, and handling of product supplied by Seller under this Agreement.

 

16.

CONFIDENTIALITY

Each Party hereby agrees to keep information learned, discovered or disclosed by the other Party during the term of this Agreement and for a period of five (5) years after its termination, confidential and shall not disclose to any third party or use any of the information for any purpose other than in connection with this Agreement. Such confidential information shall be revealed to only those directors, officers and employees of the receiving party who have a need to know the information in order to engage in the transactions contemplated by this Agreement and who have agreed to be bound by the terms hereof. Upon termination of this Agreement, each Party shall promptly return to the other Party all materials, in any tangible or intangible form (including, without limitation, electronic media) in its possession or control, which contains any confidential information.

 

17.

PRIOR AGREEMENT

This Agreement supersedes any prior agreement or agreements between Buyer and Seller for delivery of Product to Buyer’s Location(s).

 

18.

INSURANCE

Buyer and Seller agree to maintain sufficient insurance to cover their potential liabilities hereunder, but in no event shall its commercial general liability insurance policies be written to include per occurrence limits of liability less than $2,000,000. Buyer’s applicable commercial general liability insurance policies shall name Seller as an additional insured and Seller’s applicable commercial general liability insurance policies shall name Buyer as an additionally insured. Buyer and Seller shall provide a certificate evidencing such insurance, acceptable to the other, upon request.

 

19.

ENTIRE AGREEMENT

The entire Agreement is contained herein and in the Schedule(s) hereto. No modification or waiver of this Agreement shall bind Seller or Buyer unless expressly set forth in writing and signed and accepted by an authorized representative of Seller and Buyer.

 

20.

WAIVER AND RELEASE

Seller hereby waives and releases any and all claims it may have against Sterigenics International, Buyer and their successors for failure to satisfy any and all Mexico volume requirements prior to January 1, 2014.

 

21.

COUNTERPARTS.

This Agreement may be executed in counterparts, each of which shall be deemed to be an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.


22.

ACKNOWLEDGEMENT

Buyer and Seller hereby acknowledge that this Agreement restates and replaces in its entirety that certain Supply Agreement, dated as of January 1, 2010, and as amended on June 1, 2011, November 1, 2012, September 25, 2013 and August 31, 2020.

IN WITNESS WHEREOF, the respective parties hereunto are legally empowered to enter into this Agreement in accordance with their individual company’s policies and/or by-laws and so set their signatures the day and year of acceptance.

 

STERIGENICS U.S., LLC

   BALCHEM CORPORATION

By: /s/ Michael P. Rutz

  

By: /s/ Theodore L. Harris

Name: Michael P. Rutz

  

Name: Theodore L. Harris

Date: October 6, 2020

  

Date: October 8, 2020

STERIGENICS EO CANADA, INC.

   STERIGENICS S. DE R.L. DE C.V.

By: /s/ Philip W. Macnabb

  

By: /s/ Philip W. Macnabb

Name: Philip W. Macnabb

  

Name: Philip W. Macnabb

Date: October 6, 2020

  

Date: October 6, 2020

STERIGENICS COSTA RICA S.R.L.

  

By: /s/ Philip W. Macnabb

  

Name: Philip W. Macnabb

  

Date: October 6, 2020

  
EX-23.2 3 d93452dex232.htm EX-23.2 EX-23.2

Exhibit 23.2

Consent of Independent Registered Public Accounting Firm

We consent to the reference to our firm under the caption “Experts” and to the use of our report dated September 2, 2020 (except as to Note 21, as to which the date is November 18, 2020), in the Registration Statement (Amendment No. 4 to Form S-1 No. 333-249648) and related Prospectus of Sotera Health Company (formerly known as Sotera Health Topco, Inc.) for the registration of shares of its common stock.

/s/ Ernst & Young LLP

Akron, Ohio

November 18, 2020

GRAPHIC 4 g93452g13t08.jpg GRAPHIC begin 644 g93452g13t08.jpg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Ł Y*<(V5& N\/"K5RQ-PMZS%8P[0ERTG.&E@:'T9^@TTW#N=6[I MP^QA+.O8CB>)5E)"R4/B;/3-D),!X M%A^*53J>2&J?18C)!NMJJ9CH" M?HSMZ0T<-;)U;740+0QS;5,]Q*R0LC):)($WTO(VK&!Z;>D>UX-I8F]*]S@6N(>UMPUMCD3UA1",?6E8KJ*(& L^!N^R MZ)TSRU\3KDEVY89WN!?>.H%O/LI@M-+TLTV(/CBI\0DZ&2O M#O>F4<,?_I_J_U\N*0D55.6 MBYZ5EAU[P5K6@&DJ X@-Z%]R= +F_JW/)>FUW\*5.,CUE1^.HZ.I2_.C_B/ M]M]<[H[(GF;IW[,?;OGW):J:>=M\YQKG.,:XQC.,>\]@:?&YOP155;C'1Q0_ M#& ;/!IY&-OPR):<@,QG9>"ML*_9Z"LQ+#Z(-EKYY2#*=TD%D@>_0DWM<=OS2LB8][S9C&%SW9_" "2;#,V&=AGPST6A11232LCB;O2/<&M -B7$BP MOD!>VI( M++:N-2;=%^@X23^"ELGO\ W'9!-+7SHAHP<)+#LHZ9^$ELTRFE_U=O7.=U95K'B;IG/$HJ&-E9( M!N@M(W2T#^#T3FF(M!<&;@ .Z6DYFO<1[$_AV)6-?E0^#J'TAL-V1PZU\(N? M"NGQT7">WMQ[]?;G7&=MM\8\^/.FVM;8"J?!A(HI(HIOPQ3;KY][H[=!5@@[ MCFN%[V&8((%\KJ^PCW,1XL:Z&:>#\%3AS("P2"\U/\0#V/:X6NT@@@W&0U7> MFI6/6B&]>JLM191F"D-A8LX#%0S1H[A]7NXB5DEJN6^A_5P M6CT5?-7:.R#-OA758XUU3\_XOM[ME!MA4[.B&@JJ6GDHC)&R@JIWSLJ(VO:&WTA6= ?HS]FW MZQ5+,=?5P4#PR2K]Q#"VHAE;*U[!3 O=-#%CU70 ;%)G/I,M4Y8% M!_PFCI2Z;PHJVW%2FK9C'X.8B:[@:@WUV.F3LICJ(%+.?!)N12=H;ZHZ.,Z9 MD;<-#J>FI6X_#/4?@]U'&ZLCDZ>'$::6>&=L\8 M.RLMIMIMB:#VDXHV'"8:[$:IU971023RM=1"" 5,TE/ \0"+I7?9#Y1$)#&R MSG %UEEZ[V:89TV*S8=AM''1TV]#E9Y"GI%^3#:#B"+N-H M.W[].//RK@8FBCJZ2PY5^C8RU'[1ZR45'O\ 65E/2PTE?50SS4D$K*QV'R]! M/!3[DH._OE@C,C6,<7&Y;N[QPV(^S2B IVT%%13U4U70TLL$%5/$^C&(1&>" M>HWXBW7%HXT-54*]%/6K"V!:T@&D7[:0#'[<,/* M&A95L0A?+FQ$8W2+-W0LBRW<-'J7B1CS\0V;QG:NFG+I,$FC MAFHWQ1,>9J@---**FDG>U\#NE:7[A!C#W2A?++?9 M7G"3&=J-EJV*#&F45>9\!&T41P^$/F92F7HJALH?*2>BC#Y@XO!+&O !+KMY MQ8=L?MM1&KP2;$L-CH]IW[*RC$97Q4\E;T'2PN@W(; 2R;E.6EC@U[VW+0"' M7P-K=L[)&:X#HA#!F.637M<2IP3+%$$XI)Y5')(?)1YNVR!4%2!02U&I;'"X M\UHS&N6KADPP57^-JCB9]N;U-+B#3+!02TN)S@B!@DJVT;H6PRQ.$N\P2/Q\[GQ4CZR.5T\4P?&YDABC:U[Y M(R;9[@=\14<<453UC!8$9@.J,I!F(-:DW.RD1&K#5=DV<)L$/"V^H>#:@TI< M[=:."6K)-NS"^"&,8*MUUAF='>]S1>UC%Z*7$9:I]3%3LDPZ*@HG,I>F:ZII MI99-^9[NC+'-CZ3?>X[MVM: 2;8?%O8ELSB]/AT--244]9+'B,M=6B:L%.YM M-4Q11[D,5GE['/$98QK=XASB[(7V0ZB08+7MU%8>U%,=WD65>!'#\;NZ7:;* M8^ \QLDLX5]V/I#=VW=9261371^)G15-)3"B>EGMOCTFT6S Q05UC=6EI:"'V((()&9N=@=F*+9+:R'!683%'+1034[*N'IWP;A> MZ8/8^65PWI@X/<',:\9WTLNX+G0*]+)PB<(G")PB<(M4.Z,H5A]"2\V@JFBH MU:[;:*JXWSIKG&/&,Y^&FIOC\OY==,YQ_1]O-GV0H1B&.4M,6N<'N (:0"03 M8ZD"WS6%Q_$CA6&SU@>UAC:2'/!+0>O=:XCG< ]87H;=GYR^L&SOGKYVF\4U M"-V.JJ?Q_&J*)$FKHG_X0DCO^)E?;'V:YQXSC/G.?/CU&<-CPID5+'&Z,=&V M0AVY=SG7!<"QS@0=T#//+AHK?V;8Q+C>"UM9+,R=PQ:IB#H]^S&M@I7B,[[& M'>!D).1&ECSJ*(__ (IY_?\ C*@#&?9MIKY\R@)C'G.^<8\8SGSKX_)O[=MO M&N,YQ9U?V699_CA>_P#Y$A%_F ;C@#\^P':6O:_/L)^[NNLZUU\?#SCW^?JN M'SGSOIXQKFQF&N/.-/.^$_/G^]_NGQ,^[QX\9Y:$DM<1ITDPME:_N1-LCF=; M$VR%LKY<

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g93452g37e29.jpg GRAPHIC begin 644 g93452g37e29.jpg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̆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g93452g41o14.jpg GRAPHIC begin 644 g93452g41o14.jpg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

)U,0''S],#SR#R>-U0TD#(.",;-\P7_=XLB,5R*GT7_M M[+^O\OK_ "X^R]9/9BD6;FJU>.?MS_OW7A?;^O2$>'?JGU]^.?U7].?;[E_5_-WA%%47Z\<_?[_=.?=>%^R]4N"[FY/A 8\G9[[?>$47 MO_B:J*GLGNG/W_3VY7CVY_3GJH%]3F^QY;6^K_2\(HK[_3E?9>%X^OW3GG^B M^W'WY3[=7>_W][&$4NL)##K>QLSL+@O?D!?=XIYCE]'.<_-AMO?XJ\)S]>A+ M#%N3C.QO89:S.Q##:EG!< NSXVN][XMR<>IXM>Q>6\\IQ].??GA$X1.5YXXY M_P#IU4,?B!2DY47 =]G##/+$6J4< %1_P#$Y^C/>["VV(PLJ2-KE#'XD'X< MJB:Y$8QS?JCW+_\ $3Z*/W=SRB<\=:%37TU,X*];;)(VP[LSDV.W6-J12S9N M$E/FYL^ _J 3B\8\@E56?..C&(KO(HN2H D8JHUHW,17D_Y%*5GJ^HJ*W[ M]0>NXU45@\:RC/QA]LVN.0YWWB3T7"44Q&I4LAR,$&W2[&P+BOX:C?%$7CGVZZ/98O,J\$Z02 MH8)UW(\S?:S.'C7X_I[NF"6 2I0+6U')CFR94]!1-0E:3LH?4'(/415*BDA2201@@M]HYE^]G_P / M^4+[?8?99>.,UQ)$V1I#,+!&^FURN,X&#YC),Q6M:J>E%I,BV0M:GH. MA'%NRA5_>XY7((IQR1(V1'D-&] M\>4)OR\P#'D KAI[0FKI)U),,FIEJ0IR",@;W4 0!BYL8D4J+9GDN#S$FX]<&A *T;R0GKYP)0B<.<(L1S$"55G N6BIK0J,1HB+Y5\LCU1/(1^!N%RO'B$S7-15;XO;_ #A=,=L+G&[D>18ORB%$Q;&" M5P2D0:M.R-(8PJ1[&$;EHY$"4A/)A'.]'Q,M0M%2G3,2DHREF)T_E+"Z2UR"+/>'FZ][J:R<0-/LV +')_+ MR2O";\ M%D%/\_]_7_/K8U"UC?I MU;Z1K#Q)"@S'#D#&;$]1'Q6JGNJ?[_G^G^/0+22P=_(M\V]^<'NWZ%OGCZQ\ MX153E$5.4Y_I_OGJ[2E7A462;$W+#G:\(3#8^H,(VS"-&[E="1F$KLVJ(M=ZH96=8<1MU7@;(FP&8* AS!T^,\*H.T$I2>*TTJ MK4H'PS$A@^=*RS$9!>[M=A'1X5Q"IX40:*8NC5;Q2U$LQ>^DG?HQVR74["MK MX\9VMYV53<=Q*E->9%84>R:G)&WNC=@)ED>Y^5_!,Y>UH\"LYEO9-CCQ38Q( M$>.P;8%3G.83V%1OSCVU_HM42OQ%?P((,NH"9BY F(E*I@F8B8B7+"U)"TH2 M#+24.HA))2 _MO9/^J1F)11<6G+:G2F2)W=K6J;H24%:@A!+J/B+L2[[7RN M.66;6]CK>BH:25B+83MB0+#*#83RH(C3@L+%(-43R" MHEM0G0?7C7$.&R^%RZ\<03,7/F3J12)4L* JVN&5LPT:)&!74\0BF8R.)J\OPU\BJXN MJ=H2$48XC0*0F64I *4,I12YF%0ND%>I9!(2H[[83)X<55,XI,Q$B9+TDZG* MR[!@Q#M10V&1#:J.1,?KJ\Q7%\O M!R'-9/ALC"]5SAO>WR%OC.HLHNRL+81UH:I'+YV, M\/DX[&O5COPZ&BL?/1SVJP4H)6U[GT)A.#^& M-56#*QD)HW->QJ%D'8WQ+JSY^@ZG(18. <^['E81EE)U(U!F"BDO9R&=MSD7 MQZ0BPJ4-R1B8VIBS"(1RT4I6+8?D&Y[TKI VH"U8QC7JHO2AS/#Q=\J16D)U M614!9 ))*_AL<.0=F#6=VSG:*+! U8TC[MN#ZV^31(QV#[B>TEEIV\.1R>G* MO\2(]SWH'APW7E0Y%]PM<[$$%GN/+?#WQ%J""'& M&9VO;T?TO9@,%Y+[6-43:V?&NHL&942HA06<:SC@D5\F"8;Q2 S@RF/C'BO" M\C#B.UXG#UK>)!70H:#(*1$+.;YBZ0C+18 HR^JYY94I6JU\R4YI)#DZO?:7]N.N99',\958H*-(E"C3+@@X8FM"&/&C1 -8]H'/*B@Y^?WSEL>QB-I)CPWY7#RA)+V MDAX_/H&Q$8BL>*=85\]QW%5WEY,=7C8C/'A457*JKQPBL)7N_8%=CE >C&U\ MR_L3T[H%8!CBR9*"MHB!"AC>0D\_[9?U H.R4RCI M#+G5'$JZ:95-)13SIDL%*)Q[*SL?_ ,T-D\3J/#:LL:PCH:C% NH5)F*F AX.XV206R[Z+'P@4TF(3:VFV%Q83K>VL)MK:V$@LN?964D\R?-DG?Y&D2I M\I'N8+MY@W&"; \BVV^[X<%L7<6L2QH<( MQ$X>/T]U]^?U_DB<= ,BQ8B_H0#O89N6#-O 6.&<>3X< 6O9K9)<- MB*2(-W**B?3Z\?1?_MS[_P"7'0L;!K?IN[ GFP<6WA?+= MXW>ZHGMRB_5/M[?X\I_3C]/KS=?<'.;=&_("=)CSHAWQ[%(K4 MK9%K4EJ;657.^0ES)4)% W!,DZB2 '&"6VQN_3(Z\HRZP]R[="X&^7%QS<7M MF&H=T[LYH,<6CU'091AN)Y=A-3C^\*FM#4 U_DLW'"U"4\R R+832R6OF5ZS MH,FQJ:.SH8L@./&EV;8?XI8I*%(7J6&#M9CN>6[N_4QV.ZH MD69*[@+H:W(8PYPQD (KHYAQ"%B\QB/?'0D=6"-Z?KMC0T*D,'>X9624H&K2 M)H4000#9A<68'R%K6V')FR)MW3X')!020#J+/'8P3S!)Q/:YS1,>/R4D9S$?)"5J*U1HYR+EXGW%9+!2'6 M@%*P$L")I2$DD@)D6"ISQSRG'OPG^^?Z=4()P6] 813=RG MW7GZ?7[<)[\?SX_Z?SZM:VS.^&WODMT\L.UT4G)RB\(G/Z_[_P#?JKWWL6-[ M[,6%BY?;KY(MG,>BI[_;]4Y^_P"G'^?5JRV]L$"Y^0\V8Y^L&+$ARV6_;/6W M+I%+V_5%_HO/^G_V^OZ=6 A1)NP *B0W3RB-X_7E.L:ZFGD)4NH7IEIY)4J^ P MR[LQ_B,\JEF5,Q,I"7405.2$EDWS8!N5MNL8IQ2R?)Q">A$&[Q6.)ZM*8CT5 MR,*]$:7A4HP#_%RM'PQ" M-,]5:P;D\&.\U1%CT]4U9\2R?(ZAMRSR#&.R)>CX$) &+@%L[FS[1)'V;?"N M[E>\:179+54G]G&HY9$*7:6:0RQH$@!7A(I\0H%;#N,J.^.]Q8TJ.L:B(JM] M6U:JM1-R@X)/K;SD:$AG42&%MB'+VP 3S87.E6\1DR;)7WBB"R0""0]W9@,L MY:[YWZ]NR/X?ND>Q;&K2NUQ^,Y#F>5180XI^ MRV\,!KLB=%$9M'D\5K:W,<9*9$1QZ#(X[$GPO)S6N+%<\T&2K&I)BF1J(FE6 M4%-72URY\L'6D)*P )@ ((91!-B/E:-BGJIU,L+E*(8OI).DGJD$ YCDR[V? M@B=P?;JMQF^DB3NX#5 G$D^A45SV[3QB$U7O0=QC,() 9* #$8PEOCBI*DKR M0M%!;Y/Z\]XOV0FRAWM+KFI#J(EI4I7AN 4),C%:Y$X(-G=P;V(%F=XR2JA5.K4M8-R6?%\&[.#8BW6'18IGE-EZ M"'$EM2:14$2OF.&*U"U51/W:(U16<9%7W6.U[AJJN>HU7P;@5+")BEA\!U-R M W'RWQSCK4U5*FEQ,VUQ8-+BUTKJE'JZP MH9@4?4R2?HL#$:UK$OEUU1(F),M2@@"X#L2^2!8VZX MQ!-'(K43$SD@ J(2LMI;2EO$<]1>S&S@P^S6F_<2SYHH%AQB>1N8C5K;0[60 M9AVM3R;5V3D8QZE7EPHTP4>0Y51H'2$HFG5K0@DDH+AF#.P/SN-G=H71[5:GYO)../XD5/JB*GLOT\D_- M]?;E$_GU*I,]$^5J0 7(.M+,'O=K XZG/-HQ,DS*::4+2I*0&*E@BYYDL')? MSVBG_P#;_%/JG^'5=27;4ES8!P[\F>+F+.Q;GM\X.KHI![I[HJHOM[HJHJ<. M1R<*G"HJ.:B\I[^W2$-RS#M[@_B-WENH[F/K++L@:\N3UR5 \AU;L0I&N0[- MCZT+)KZZYER6.< F1U,RFR5&%(A["=&18A;DK1+24S4=[+5^5G !V-CTSBS" M+$ZT**I9T$ER>9MNM3[4I6XWD=)CBR8$A^4$Q9N0R8NV*J8H2OA7V"Y.3 M!*]T ;+RV0_JU[^9V4_I1PRBKYM163I$R2E$&SN]V(AQNW.]35.A\5VL[14JG M@9]KBO1]UL';]@'Y6=B3R0VVG]F<&POZB=DU;-L*X=#CT"B_9? 9>1!CHR\L M&5TULOW6DES)\JF$N0J5*DS3+ *%( E!"@%@$ :'%E'PD[\O+YM0:F<:B<=, MQ9-B2%.2[L;OT.1<-F(D5Q+N<^*IN/%M^=J^/7%#BM3+IURO=^\K%:?$,#S. MK-CM@.#1@YLJLU%C21%AUN/8[1EDW%E9V4Z9"D?, EQNQ05:*$UB%3?#,20E M 4"5D:C8.<65J+ 6*N<:,^C35+"C^6X:[@7))8/R](F2;YO <1FS+@M,Q)(!2(TN7:2#?-1Q3 Q8)/ MEACU.!"5.XS)[TV5527!(&MYR04-^9Q9ADGUBO$-2J*;+2XTR9H!:Z? J^+, MPNUF^34^Q/,+*E2I*T)UD.$$#T+-L [-=HP\'242!WBM09+7?;+8OT MRW/"R&W%@N<[9O-5XQ'N\JW#60$R',,'Q4,8\"BC+)'&)*O44X@]:=-P2>J=+F52)DB6NXF3D*EH)OA:P 7=K;7!.(Z/_ M %"24*E)4A2P".[!!6S6=*;C8@M8,2;-#9^R+NAWMD>QNX:JV%22R69/P\99MSY.62;GRBO C ]=GC]%+X9(H$R ME)5WJ$%T$$, M,+ L<336DM,8?G?[(93)V+DME?;"V!E;$OA Q_7L>-'QVN'9R859838 9I%: MY6-1YI9'AB/MG\-E?@4+) FK 7I)&JX<%LML"VQ ,;4JL3-6I(P%*2 &_*SF MY)W!STWB3:/:XU46F3:LT_B-CM;8T*'-K,UK<:M:^%4X"TL-SS'WIN.R%)Q3 M5,04=SI9*)P+;-9 &-)7Z^L8C"SA<.6E,F9+ 25#Q!1TOINE@>3W;8MB-^8 MJ6&-U _H7Z[Y(8^4))VF]OUE51\3IM"FD=Q^0X%:-GU6S+#(Q<5EN*V%.@.'A48P3#JWZB*5(#MJ;,$Q;!+!B06Y$ #D^\6 M(LD.P+W^@WVY8ZC!CH'@8W(5T27DT[]HK>,@GJY(9(&/Q9?LI)510OEV#8K_ M %5$5?RHGLQJ*U.&HSE%??OVT5ND(A@^)IG%D':/;W34MC+K7T,[-IA),*0 M6)(;9FIJJ2%PC@(UZ+&&*(5BIX/&=4(UZ/8U.L4V0N>@Z"4I2X4H/I3_ .XB MP9CGITBY*2;Z5'& =]WQ;]>476C^_7*L5=$HMKQSY;0M1 LR&(HVY%!8UK6M M?+$Y$%A+GHF6!TJN="O"MO\M)8MU9G!Y1801_M_?.+?9>L,3V MQA^1X5E8;,=7E%-,H;&?CMU9XQD8*^>UC)+*S)**5!N:PA6C8UY(-VO5<,H*UB;,EOH6I+Y8YSMZ MGYQS*]U?P:=CZ:C3\I[;2'V=KV(I9*80*$(&P,?CJYQRLBPX04@Y6%"*XCY5 M>&';N\RJZKED(>07?2F6E+2TIEI2 @ -R9. &&V1LYBQ:BLZE$J)+DDD[OF MY8>[1#;/AS*R=*K;2%+K+*'()$EUT^,6'-B2A*J$C28DAK#QY#$1?4"1OJ#5 M'>2*B<]7A0'J>=SU8 WV9P#M:,)!Y.UGQ9CO86+G%PSEXMN%_1?\NKW%PXY$ M?3]6BUC;YCTC[YN3_FXY]OLG^_\ ?Z=& OZ.2?U, ^U]\/[]\X/-KO95]_NJ MK[<\+[_Y_9/OU34':WFY_8#ZQ< >19L,Q-PXM?U.VT>E:QS51%Y145.>?]5^ MB?7^O5;$9?Y'^+Q:7!PWO(N_KB,>\'YO=>$^RI[_ /7_ #^_^?//6(VR" ;@ M#P_OCESN#SR!S@@DW(C86+A\?96K]?=%]_\_P!?O]>JDC( ZOWT^W'\^.??].>>FV<*P]@!YASB MWV=Q%.3!W&6NYP7#'-WP+[>([!L?+?PVBQ(-S%5>.454X7CE$^R\JGTY]OKQ_VZ MO27%S^A&^S?RQ\@(NUP&.-VO8'SMDOT8Q9R B>-S'C:YCT49&*GDPC'(J*TC M53QXOC:Q+,U;9':_A&4 M6,+(::NKX5G7V<.R)5&:K:*U'#DCE2($H0>31&6+1NCE)'882L,Y7Q_IUC_N MCO&4PN0,6;:Y?K^C000%'^V;[@$ W#\WW^N8;KWI:SQ*QVA$L-)XK<_(V]1, MN,@JH^)VE*#%#L.CHM39/;5QJ TZ*TA*L\['Y=A268X,2SC31?B"1V6\/5.E MSE=X2$:BH%9TC&') Q>UKOM%T\I7*2-)*@P-G+&P+9!&V #O";:5[8-%%-I6A1%B2=_" +[!C>[XVB5EW@_P#AY8[E M%7EW/^"^W^J(G\OMUP0E1*IA4SDC2R^R\*OW]_LGMQS_4_O/S'H?]X-U)]]&BU>)J(GBB_=.5^O M^7/'LG/^7/0X/-BWO](K%FJ?JB\>Z_?]>?I[<*O*I[^_M]NK;C.[.>1;?F 0 M",!RQ,(HNY1%X1>>/9%_^W_;_/JCI4HAPX8VR[#!=\-MCK>*L6=BQP=HI/*, M3%>=[1I]/SJC57V]T3[JOVX:BK[_ $YX1:3BF2GO5*2G2'TK(!(PXU%R,CE9 MO)+)5,"4.H&Q8.-7(_IYQB)!Y)%

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end GRAPHIC 10 g93452g70i49.jpg GRAPHIC begin 644 g93452g70i49.jpg M_]C_X 02D9)1@ ! 0(!>0%Y #_[2!,4&AO=&]S:&]P(#,N, X0DE-! 0 M (#"^@D X0DE-! 0 #@< 5H QLE1QP!6@ #&R5'' ( ( !P" M4 $0T=32!P"!0 307,@9FEL960@=VET:"!T:&4@53A"24T$)0 $$*D M)I-_*)P>?T-U3]3]?' X0DE-!#H .4 0 0 "W!R:6YT M3W5T<'5T !0 !0&Q ;CX7!E $YO;F4 )=&]P M3W5T)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F M=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$ @(! @0$ P0%!@<'!@4U 0 "$0,A M,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:V MQM;F]B7I[?'_]H # ,! (1 Q$ /P#U5#R'VUTO?37ZMC1+:YVR M?ZR(DDIP<[-LR'['4VTV4N],FG*I8X%^PQ8SU/I.]FS MQOIK(H8YKZQZ+0VYPKL:SIQ9H2"-]GJEC6,=[_\ ";'L3P12%6-N%I;7=DVM M#G;'59E(!8/9]!XJV\?V/],E7FW>O7D@WO; >*W9F.*R T4;WL:[^:<]KWO_ M .["C6W;75L8ZMU;(:T]-,,(#FVV5-K/L=?N]_Z6S_@U=PNCX=U)MLQZ',

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end GRAPHIC 11 g93452g72i83.jpg GRAPHIC begin 644 g93452g72i83.jpg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end GRAPHIC 13 g93452g87t78.jpg GRAPHIC begin 644 g93452g87t78.jpg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g93452g99i99.jpg GRAPHIC begin 644 g93452g99i99.jpg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b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

Q.6[G(]3#:<8/0?#)[IU=S+O[FVEPW!4]+%V_> M?T.[/ZWO%_2\!Z7M!=IN1UF*^V+N8#:7V:=H1Q?=1O7ZH[C2^\;'?]P$6>*1 MG$^E$0R(D89'U#.36,:CY2CM?XW7SR.O/AEI7X.O+"V1XH?^?A91FZ^,_P#O MK7VO\BE6 >&5Y/YA+QG [#Z%">@__AFR=7;AA[XWEPWQ+Z23?W9]#\+>N[1' MJN8])W =YN)U0+[8_P#X]RE]F?E#]S&U?JGX9/>,!'O[>S\:>Z/4@^[^VWO$ MP,/VL)%/!(1VX^-JN(DGKE@QA<_[WS(A;,R-4CY/_@O[52V0Q*;7@-^2?\NI MS"B?YT?RQ?S>7H?9_P!Z_P X^L?3[1>ZPDV%[P;L?3^O)@X,/4_N7IPI$'A] MY/.L^2LN(],T?8?UGNP&'NJYL\#6]4740OS_ E]G'NPQ9#[EPU?J8WUG]7'[K]_L+(KO$*/=&0&.6-S;[9KE80P M.K&*GV>MD'6<2P%>O\)8C98:T;#<&UBR'&Y56K1^MF!,&D1K:@HP,LTMF)88 M\L]+0U,#R70A*MS1\Z*_(Y.KW^B*$N:DIP=62"QA;%'$":]2JM'>NU+M:Q+D MWH=AIZ4;24WCJQDQV$6U!=BFBD5=:B]AO:UF:_2D.2N>S>!J75='+]3-5Q&4 MR"38C%9+%7J5? 19H7(ZF5FCAR<4V1F5)Z,KX^UBK%6Q#))JTW.&UZ]KHDX: MB TA 2[EA4Z#+AI?PG*\LJDQW&<.X3A2,JRWE?GPG"T95Y?#"D^/CB/;@-FK M9K!^V;%>: 2 SA295H3][X64?EB([B4*' M+$X03<3*<2Y&PJ*KSGI[!>T;!=/0X09SH^U)B\9C,;A;4N"S9/&CV8)9LL/N M@#6Y)J43!35-,+;82L&B!A.MKP9*O76#OTG,4444#F"?Y1\5+3#U'QED!_ * M;/Y.X\:VM<#?WIUK"+/J/#S27/N]2J7<,MSEY+25M9KB<7G"AB< \Q(R\$E% MWIE66P:9L:4@8R(6\5C>PZ3#!*<'FN[6D-R%JYRK^_^%Q$QXGBE6HE)GN-%.C)"CP2 M..2WE^EH\2&[ [$^ZGFO'NGU&S@1\@P0(2Y5@0H*GIR!_8C(P,B):M.(,-ND M,V!^11[FX.DLJ?9R+2(BMWUJ3"<9C8D(GJF2YR9#RF7(Z(R$+;7AEK>TPU:* MPY?H=;JM9]Y228#.O5E0R(:@I0KU$DL#)%W%L&>>P)9"C1B)596H5R?"/C+0 M#[MW2:]@H1N.'; L@J0-^7)FW.Q&P\:R3L+>.3%C6Q8M6) NQBN*E&=J%K66 M@RUK3D*Y89B+FB&3CQT>;!-H=!%N2U9PJ*[#QC*']BLA8+<>U::38DD""B4IZC7189X4IB!@4S"@ MHOR)L>>S(237/DOSY$>2R]!;CQHJX[[DF(];VFFA76/,=#C)BS9-J9^G\ZU% MZ9CKBG'7KKU&L\=F.46VLRR698Y4DKK'%$T4C2V%3\R:]CME-DX M!5%D,&!#EB6((*@ ;$G+.0MVY/$G&[#J]-86.G($PUU*TJ.,%E"%MC7R!#%Q M3 DCVCODDS8T<=%D/BL+AL2H\M6)R9K0=>^\;3IDNDAB35L"E V&R[9".X:1 M6K):LC.+7EK)D>,MB**K#++3!@CEBF(L"\K?[CD24Q#Q;MJ8)C('X;(786 I M42;,P" E/A!#'F,3D?V)^"2WBU:;^Y?EEK5+S1KI\)D'F&A*(R8'W][[!7$_ M#CJIF2.8F8F4,XA8>3E]4+TWM-]WA1E^AO>GK&8S?<_G?0>[^PH6(5ONC]0+ M@L7/EYY<^/'QQW\ZRR8 M6[ON&.ZJQ:OS5<#HZ9<)-2M.#ZRV 2&Y;T 8;+C(M<&/"S216CG#62LV5Y31Q/5>5:&U M9IGL V3?QR'=4F2GV>(Y+V9N[S[>S%7]1Q"F7<@%"1'\));X]8EL?V*P#E-N MVK36;)DI"7"EMT:Z)"MA4Q9Z2,>3!5?E3G2;LU0QR%+:(,Q6(K,YE^'(=D,/ M1H2UO:;[OE5\OT,RJ;7WQUALXT%6"63S4CLUK;PI\,TD[?%J\+D M.Y$3)3[05.\!#-W&;;Z0Q,;'%5)_ #JY4?A%M8J*/[$X$ED3+5IMPZM\9D%) MC4>Z-"HT9"Y>3"2L-V^O2YC[Z%0<#5Q)L)$5; @G&+KC$D2)4AR5&<;B-9Q7]H7J,23E.C_ $B1 MUAG4&#S/J+$HMRFXV)D]_=NG')1,,=9;D5UHK2RS2M+"Z0)=QR/*'Z6EP 3U M [$_)CS//LGU&R IQ"^BV!S92P?62,GNQ1U"#5 H M&*)O5-;+6UDF'&%E@5QR6T7TM'<;]_Z"QLWQG;M?MGX/H]@>?/X]S^"0HY?8 M[X]W:%?NS/?>WI%6&@:9L:8V+8$+?*.19C+ MC$5EV$]?Z?VA][+GWIT=Z=XYQ@D]QYKO5I3\?4;.!'R#! A+D,"%!4].2/[$9%A MT0[3IQLTVZ1R?D2*/P4(W'#@HLAE(&_+DS;G;;B-QK)O0MWY,V-QBQ:N37 MW8I7%2BNU&U++PIJ_#X1RPS47)$,E%C_ )?DVAT$6[+_ ">U=A_EQR5)!U\; MV3:/)](C&O#;&&B?"YAKM>=MO0-DIQG%@M11^?5I5KTWF_X&2#;S>5R'M[3?00+'F.AQE M!:L-9F?I_.F@](Q5Q4C@KCJ-;$=I)A;:Q*]F2*6.2ND<,312/+85RG;7::AW M>;U8/)*EQF!L>0\'PN$S*8F*Q/3,:#KTY&PZY/I(8DUIQ M5@.&RYR"7#19:SV+(S@KR5DR7&::*.K%+)2!KI-'.18%Y7(=QB):8AXMP'9F M,H?MD*6;O\"HEV9@$!*#B"&^+6)^/[%?!8;^ZM-?_0WO7UO+O_<_G?0>[^QM MVO3?='ZCUGJ=W[_J>SV?H^QS^D-G'*=O;NT.[S_"]/8[?;X_+CZGESY>>7/C MQ\<=_.LJF%N[Y^(ZJQ:OS5TCHJ)\--1M.#KA9(1#\86.3Z2.)%6%;$ PN7&1>X* 6>2&RDG'E057Y4UXD],4+<@RFI[,:/& M9G-/Q)#LAAZ-#2M[3?03*^7Z&.3-NNU>9>G\\**TA%9%N.:N>HS.]IYS4:O, MEB.***.PDD,K2QO%8%RG;;>:AW>:\2*]CM]O9N89?5/&76)=/&=6-GL;DLKF<2^-IX2:I9QN,QEJL;F9MM2:>ZT]J_;:.G M :L@HUU'=1+$@LS6&X/'>D5LV(I9IH3&D#(T443KSFS'D M6.Q$L\['4S5<.T>H+ONC7(0#KBXA*/=JGM+56TZZ8LPK<@CK"\![FP&L MH&;KI66&,K%8@$6(9>&\]%=<92\UZGK-;O 9*IC+LLUZK+;JV,?D,?-%!+'# M.J7ZDM4RPR313QK+$).:%HV 8 [';B>6ZOPF0SV+KUL7>KX_(4LOA\Q5GMP3 M6*K2XC(07E@LPU[%69X)S#VY5CGC9D8J&7?D-2( ^^*JW561>RNI[-N9E'LW M:?/TUMN37B,-V3!S66ZP+8W=&(B),.(DDV<=*%3+1"0]!=@LC6X[[,F0DO2( MGL&2CU":Q6'TJ)E,H$E@=(Q*+#336%E=HS&L01E?8I0CN-FUWUZ% M?>MS='DCK*C6(Z5JS9;MI#%G\5L8F)\/EFN03M_N%LA.N;6&S%'_^])6@JO+X[3P_7KHC4,,0AC7*8T65L!Y>^TDIQ)B:%HS (D6%'1U ME+R.'14BO7]H_H853+=%C)"S8-B9L#FS2:F8ZXJQPUQU")TLI,+33RO9DBDC M>!(X8VCD>39G!/OG94Q,",2L9F9S]WI'U7+T/47H^QMV_>F-]3ZKN$ ME^[[I[78[6R]OL]SN;MW./PZB>G]HWH./O;HOWGZLMWO<.;]#Z'L@"+T_P!T M/?\ 5^HW?O>I[79^#L<_I-;,V)[A8O N2[?.N*M;H C6S(AO5VR4W219D5!M M@O,&GU;94$B W[[AXF/'RJ],GQ:DIL-()2BZ5'%8#)TUZ2114S8O&9S%(8&P=9C@^^>*<48E;+ZFKOR[$&=#$V-, M[<;J,>IMCC2;!!)!7-X.&)=@E%7*\^')1CL0=!'Q3,:8+GR)T*4/SM+TCZF, MK1ZB%,0RB6,Y3&FRU@O$87CE&)$2PK&)A)&T+.[M&RR(J,KPUK^T;T,ROENC M#DC:@:O,N!S0HK3$4XLQS5SU 9WLO,:S03)92*.-)T>&1I$>/98@CN&FW4-^ M=?.N#E%C#*TC9HV+JW93-K,&66O"WR*.9=VR\)KXV>]^=7(AT)8Y(MO\PE,+ M*_/Y@:3IKTUL+4S8MM).:$C9"B:\<1/[66W$,<))I$'B=H98%D/E$C^6I:0= M<"[CFDR72QQR0U!EHDP^56[/.H_;S8^I1\IC6G=R$].8)!B52-482=X21REP4 M"&,JQ:+%7]HPJ7%FRW1C7F>L6=Y$,(KM#/ L3+( M9%E#J$S& _=/Y?7"\[!ZR?!1(85.VXV-3;0P5.$&[(1=L+NO)F=PYB5B)*J* MQ,$.Q8H5J>@V)@@4F/SQLF.*BXN[TOV[P]'GN\S2^[F]XT.W$A@00BZONSE. MRV1(\I@:N'@*1H$=6D;/V.O>_BC[SZ3].B5QFT]RY?O6)!:D:T<7)[\X5$>D M88X%M1W&CM+)+(TL3+"O2:"]X\1+ZE_8W5E4^3B+^#!UK3^UD1 ZDV2([-^^ MF5;H6]8<.5%,^#&P!?K>6;$Y$)NY>',O"GKC+TIRI[4NH."\O7@Y+'%I?H&" M>D(Q8$&UG@[=Y9]X0T8V\5.>+6M MZ(DC3TS5.-HI,>42M"WX\$[R9AT-,?8_5A)",F7^$UU[3^UEQ#"U6.8["S1F M4;I0]7DMU)4"#*P=?LF7K"W+)M99'/,BF*B7I3E)$#^]RV#S)2<^KD:/W]D/W3^7V.O&P>LGP4N&:3J2-G4VT/E09!RR#G:\[L. M9C<.(EFB1:B@K!,,5V%57IUB?'DX;\ ;&D"I5G=Z7[=(&GGNZK1>\6]XX_MR MH('$PI+[LY0,UDQO&9WL!( \;*[LLBY.QU[W\J?>?27IGCL#")[ER_>KRFU$ MU5LI)[\X6T2D)HYUJQTVEM-'+&T42M"^'(@^^2ZS5V16R^IS%P9E'U72>0TS MMN37"$)U\?FKMUD7'W?%)"94*,DH@ZZ3+&&B+[T!R R-1&D-R MHFK%8?3(F4QJSHX#^H,\AQ+)(KL8^R(XXB@#AS(64K@EK^T8U*:PY;HQ;RO9 M.0EEP6:>K+&S1>C%2%>H$E@>-!,++33SB5FC,:PA&5]DEB>X:K=?'X-\ZX-T M62,LJ-9#96KME/6L.8>:\*?(O!EK;+ FP#8#WYUCB @E4S/)*<28FA:,PB.-85='65F MD=754B-7]HWH853+=&#)"U.UB9L#FC1:F8H!6CAKCJ 3I92866GF>R\4D;P( MD,;1N\FS.">X.;P4DM7SKBG6ZP))L*(7J[9*KI'LRZ@XP(EDSZ=LI"2P;%]R MR3(#XM>ASY522X&CD8I=23B, DZ:]+&IJ9LW1,AEE]X415: 609%CA]V]U9C M3WC1VG9%L;2LC1CLF68.N/>,S+DNEABC6E$$)P^5.06V:)6"2:S[Z].]=D?5B]/MV_>F-]3ZKN;\^][I M[78[6Z]OL]SN?%W>/P:B>G]HWH./O;HOWGZL-WO<.;]#Z'LD&+T_W0]_U?J- MG[WJ>UV?@['/Z36S-">X6+L%D/WSKBK7+8$2W81+6KMDHN#$8AR% @P8IF/-&$'YT*2/D-+TCZF,K1ZB%0 M0RB6-LIC39:P7B[#1RC$B)85C$XE1H6=W:)DD14=7B)7]HWH9E?+=&')&S7- M>5<#FQ22F([ M1S5SU"T\EEY35:"5+$<4<:3K)%*TD;1[)%$=QDVNA/3;[UN MI20=<^MQS29 M+I4X](J@RT28?++TT/_"O-K71X/ODBN6EH MILOJ<_;7I(+-*G0--;;C5X=$:DSLV5%G&/[ODD2\B9#4.;".BRH9L?):FNSF MB+;[#,?.\O2)GKF.AU$*P6;U2/E,>[K/*<Q1]Y])>G2. 9M?B8(X%M) M=:.TLLSM)$Z0IM>D*-N*I3MKF-Q[#K-YGWK8:[%4QU/J\VK@:/3XM; @!M;8 M:*&3I,C-=>$2C18A+(.(>)DY7LFHD'V\&+'RMO&65Q\6,I3U$J4Q#8>S86Q- M;LM/--).QCBAC10)%BC14!$<:\RS[NTSI_'YRE)FI\YDZF0DR.3-JE%1J25* MV/HI4K5HJJK-/9EDD9H'L3R/*0TTS]L)'QC2>N:C71Z<::<::<::<::<::<: M:<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<: M:<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<: M:<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<: M:<::<::<::<::<::<::<::<::<::Z3DA_.7$Q&&W\M.>DYYWO2\J_(ASP_\ M(5X_FN)S_P#]XTUP^N4_0&/VS'\+C33URGZ Q^V8_A<::>N4_0&/VS'\+C33 MURGZ Q^V8_A<::>N4_0&/VS'\+C33URGZ Q^V8_A<::>N4_0&/VS'\+C33UR MGZ Q^V8_A<::>N4_0&/VS'\+C33URGZ Q^V8_A<::>N4_0&/VS'\+C33URGZ M Q^V8_A<::>N4_0&/VS'\+C33URGZ Q^V8_A<::>N4_0&/VS'\+C33URGZ Q M^V8_A<::>N4_0&/VS'\+C33URGZ Q^V8_A<::>N4_0&/VS'\+C33URGZ Q^V M8_A<::>N4_0&/VS'\+C33URGZ Q^V8_A<::>N4_0&/VS'\+C33URGZ Q^V8_ MA<::>N4_0&/VS'\+C33URGZ Q^V8_A<::>N4_0&/VS'\+C33URGZ Q^V8_A< M::>N4_0&/VS'\+C33URGZ Q^V8_A<::>N4_0&/VS'\+C33URGZ Q^V8_A<:: M>N4_0&/VS'\+C33URGZ Q^V8_A<::>N4_0&/VS'\+C33URGZ Q^V8_A<::>N M4_0&/VS'\+C33URGZ Q^V8_A<::>N4_0&/VS'\+C33URGZ Q^V8_A<::>N4_ M0&/VS'\+C33URGZ Q^V8_A<::>N4_0&/VS'\+C33URGZ Q^V8_A<::>N4_0& M/VS'\+C33URGZ Q^V8_A<::>N4_0&/VS'\+C33URGZ Q^V8_A<::>N4_0&/V MS'\+C33URGZ Q^V8_A<::>N4_0&/VS'\+C33URGZ Q^V8_A<::>N4_0&/VS' M\+C33URGZ Q^V8_A<::>N4_0&/VS'\+C33URGZ Q^V8_A<::>N4_0&/VS'\+ MC33URGZ Q^V8_A<::>N4_0&/VS'\+C33URGZ Q^V8_A<::>N4_0&/VS'\+C3 M3URGZ Q^V8_A<::>N4_0&/VS'\+C33URGZ Q^V8_A<::>N4_0&/VS'\+C33U MRGZ Q^V8_A<::>N4_0&/VS'\+C33URGZ Q^V8_A<::>N4_0&/VS'\+C33URG MZ Q^V8_A<::>N4_0&/VS'\+C33URGZ Q^V8_A<::>N4_0&/VS'\+C33URGZ MQ^V8_A<::PHRWC2!\S6<.-I, AF;!C$8^,J\$_^7$EL.?E3C_R M\8_^-=CL#]1_]?\ -JFXWV^O[/U_]]9H=_YTI_VCC_Z? Y35=9/C33C33C33 MC33C34/;PWIK_KY2FKQL.66Q#(6 +4*T"K80C9[?=+I99"HM>IU.K(AF02/6 M,R^V[B' BMXPEF/*F2G8T*+)DM;#&8RWEK)K5%CY)%)8FEFE2"O6K0@--8L3 M2$)%#&".3L?F550690=3F"O#)9MW+EABM>I4K1*TD]B M8@\(U'R5G8JBLPT[3O:G6&XY-U"QXUQUK==->;CK$G7=TKT>WX<^T2 MCXXJ\Y!G![.ME]@*3$$B,65*97#4MJ7EME/G6W6 ME-<_MA Z ,LD((,B2(C*I#;%=R(F)ZFQN7:Y$JV\=<&0T0I<6!DK)C M2UR)3:8\B.+QDD^R]E#C,#&9CB4Q\9,(Q5S)-&@1EC[K*Y9AQ98OI"#L1'\9''SKG M,6:MUX,YB,M39LAB,X[*QC.8[:'5+>QC.6\ M*Y2.&:9S'%#++( Q*1QN[@+^$2J@L O[XD;#Z]72V*\$8EGGAAB8JJR2RI'& M6?\ !4.[*I+?O0#NWU;Z^95JJ\$P-KTVR (9\RRJ0(!RC Z.8*L)\_F?&C'I M")LYE/IN>9R*PZC'D7XJQY5>!8)VC>5896BB.TDJQN8XR?D'< JA.X\,0?.J M-9K)+'7>Q L\HY10M+&LLBC?=HXRP=QX/E5(\'[-?D*UUXT;JG)E#JO(@+NR$.!ON5(8>"#HEJM))VH[$$DH5G,22QM)P1S&S<%8MQ6 M16C9MM@X*$A@1J,-C]A]4ZRHI?8A:RPSM= VNETLRNG2AUEF#;!?+F"H@*'. MC09_A$5@[81^)R9#K3T6'B3)RTYZ.6U3J>(OW;4=2.%HII8+-B,6%>%7BJUY M;4K*S)\7T43\=@0S;+N-]]:W(9[&8VE+?EL+/7AM5*.>[;AI0HZH_ MPD3SIS#$%$Y-L=MM; 9VW4!:J(J [-ML'8-O=I8DO2VHUE##B<<0<,299XE MEJC#!,9L!,@2)N5/>B5>AP7&DN2/%&&.A8?U7(+ U2N+,D=DM#(Z-)%&JQ(R M\G=C*KA=AO&&<'9?.>;*U(O1%"]I+ULTXI:86Q%'(L,\S-/)&Q6.)1 Z,^YV ME*(1NWB 17?+K]/UQ!VZ1(6NKZU(ZSJ&TH=OL=6F113XB\W,G0Z\!95 =(R' M[?(L W*9(*.P]F&/FP24F2W# <#(S M6FGCV:%5/!'CD9@A8K/8G;]+)R]@M293]>%ZX*A!)>TV?$0'4BF;!7Q%C'D: MY8)'%-X6O5OC[*+4*J)GN1R21P0<196G(U\,S018^6&*6S9X0U9._7AL1R5YV?A+$5 MF1"^X'=#(-R-SN!"W5,4X%9*6>O#7;&XAFO-$#0V&X>==PTIMH*B1);44<<2 M^SE"(.'U+P\UE.,X<1XQTKSR"0I!,XA!,Q2-V$0&^YD(4A -CN6VVV/V:ER6 MJL1B$MF",V"! ))HT,Q.VPB#,#(3N-@G(G<;?,:V'F'6?6LP+K32HXH7%VVL MDA(1O,DDH!C1XI%>0-X4HI4,X8^ 5!W^K4:.Y4ECDEBM5I(H2PFECGB>.(H-V$ MCJQ5"H\MR(V'D[#7#)OM%A!AUCF72IQ*\8=;8$GI-C#L!BC[N7$M,CBCLQ$& M:ZZIIU+;<9]U:\MN82G.4*\*BK::1X5K3M-&"9(A#(9$ VW+H%Y*!N-RP &X MU1KU)(8[#W*JP2D+%.UB%89&.^RQREPCD['8*Q)V.WRUI8K>FNRNP-N:XR56 M+,Z1$Z^-WTD;Q&%5R$-V6.-DZU(BFY,I,9]&8M?GY(+>Q&;AN>W1YW?6QE,F M3%W(ZF/N=L/'DY+<55(^3S,])XHYE:)5Y \IDX DF"Q5TCR,'O05M>NB:U-;<5&$ MLR"5;$31ET5G=1('*EE16=EWW559B 2. OL*D@ZXQ;)]I ) 3F%O"22#(Q4 M4ZK$9Z6U% R,RTQR\R6S'=S#C07GG92DYPUA7AG.+HZEF68UU@E[JG:1#&_* M+X@I:5>/*-5)')F "_7JDM^G#76T]F#L.I,4@FC*SGB6"P-S"RNX4\%0DL1X MU#SW:S5+&B=;=B5N6+\'6U9>KH547@-C)M3VWK %K50^1%^[\(:5$CT#!-6) M+WLF/6=QA[T\(5L!@KYRES$ 0^LHK=:<=SZ("A%)-8X/Q^+X(FX?".1V'C?6 MI/4V,7"X_/DV/09-L:E8]GZ;?*SPUZOQ) ME3[C5H,:$\1CS)$RPB8S$20'7&;+,277I:&V'A;DR(@BTZI"X2Y49,E+2GVL M*UJU;+E52O.S,$*A89&+"0,8RH"DD2!6*$?A!6X[['6X>[3C5F>W614,BNSS MQ*J-$5656);CUY$XP/B*/2'4- MN-,!4R)#>2CSB'FEMM0DP$IS*8:0MQUI"$YSBG:E ) M,4FP02$\&V$;'99"=M@C$@!_P23L#JX3P$A1-$6,C0A1(FYE0%GB WW,B*"6 M0?$H!) .HD&]C-2E-IV/4+%HA,VBM5VCV5^7+F#8]>*QMA$K4)K8^OF5S_2 M,&GIU-.-2!<5O,AK+#>$>JI2TMSWQ%]*,.0,+&"::S"%57:6-JB023/+&%WC MB"V(B)&/$[^=O&^KCS^+ER5C%+906:]>E8+N\:P2K?DLQ5T@E,FTTQ>I,&C4 M1?J3/0] MNCRJ\SF/+GP@B"9H^\(93#S$?=$;F/F?DG,#CS/U+ON?LULS9KK-Z=K$*S\# M+V#+&)NV/G)VRW/@-CN_'B-O)U\*M=72SF2JR $Q\!VK#E]1@=AG !Y>6V3F M75>R<7C*4OY5C...Q.3L(92>X8MNV^_= W,6VV_< \E/P@/ MF-4]56X\O40<>T+'+O1\>PQV$V_+;M$@@2?@$C8-KZ.VBLU>(P0LMB!5V!*D M-1(LTZ7'B(DF6_A2F(K$DA(CLO2'DI4IIEM:G',)5E"1E4?-B$!(4?62-A]>JS6:]9%DL6(8$9@BO-+'$C.P)559V4%B 2%!)( M!V&OQVU5A@FT%?L8%DR\EQ;(ETP/;)NH:A*)NJ:@+D8E.):'(40<4EK.$0DJ MEJSAC&7,!!,4,HAE,8V!D$;E 2W N!Q&[_"//EOA^?C5#:K+((6L0+,VY6( MRQB1@$,A(C+6ZVR3"D894>ZXPXII M]# M0=O(\C5T,\-B,2UYHIXB2!)#(DL9*G8@.A920000#X/@^==45;:J=E/P0EFK MYB;&AQB,B&*,CB$J./FXSF'.?CQ)+SS4.7C&5DKSQ*& MEAEC5F9%:2-T4NOX2@LH!9=QR4'<;^0-6Q6JT[LD-B"9U579(IHY'5'\H[*C M$A7'X+$ -]1.H^O>_P#3>MZ'/V9:]A5R/21QX/5I)T;/;/1DV4^9@5\2"3@' MD@YDE)+DX49UG*4I@-.N3B2X8Z-*EL2ZN*R-RTE*"I,;+Q23K$Z&(]F*-I9) M3W> X"-&(._QD!$Y.RJ8%W.8G'TGR-J_76G'/#6::-Q.OJ)YD@BAVA[A[C2R M(I&WP EY"D:LRR.5LE= BT&SA\*&"N9C)07*E8(X6M4S*4PTHGS'V8BLR\K1 MB-C#N'BK'C5()Y$DDCAE>.(;RND;LD0\^9 M&"E4'@_A$?(ZI):K1/%'+8@CDG.T,? (VM@?"B*F95BOLROD,.26_(B&EYIE$AY]AM+F/53G- MZ59W[+=ITBGD6*.>1'2 NS!?W4KPV4^6V)*@$D>-8Y;M6,V%[T-6;O0@E1S,S)")[40_!;2[ M-8)R/6]& ]#:6AV4W*6TN.VM*WDH2K&#_O4H?&P[+CN_P![>90O\G,GIK/Q M_M>?Z.-99/HI/HXF&ZR/\/PQL/*NVRD>03K'ZVG]'^VZWTLK0Q?3Q?23(>+P MQ_'\0P\^EMMYM2K>Q.(S*891$ K&3MOVPKDJA+[<0'96523LQ M4@;D'5WJ:QE$ L0&9BZB'NQ]TM&JO(HCYI]E/ZKM$ F2]X\U"*/66)+D!H:L+R1"19!+ MSL8:4SS97\+;QW>%EJ_."2E&T43)"K2;KMMJ7<7^B* /6 MM-UJ2JM'?5%D67%D#Y ,24.I87'>,XF_'-/I>6AE3*Y*7$NJ2WE.%JQC,#TE MH2B UK'?8 C.K?Q)H[!.()2:9) M-H4+=3*E2O4APVICDZ3 BS22(WQ\99AMQLE&8*A=F8J%5RJ$\R%U&&9QC9*/$+1XU*%RFT#6 M1:K&LA(>P)XC A4A6#2A^VI#$*06!!(!\G6HZFW+2MTPKN1H[\^3#H&SKOJ4 MZ_.B(BMN6N@$4"SRQBVWY")PA4E:5#B*5(3,8SAU+2,9QC.>_CK..:LED(&M MTJU^(*W(B"VG>)\;G47%Y>GETNO29V6ADKF+G+IQ!M47$<_; M(9@\7(CMR#8./( U*W(.MGK"S[)719(6&)G@HXP<6ZV%%3RD&&2,+9QA3R!< M&0^W*(+9QG&74Q&GLMXSC*\8QG',BPRNCR)%(\<6QDD5&9(P?D78 JF_UQ!')'#)/#'+-N(8GD19)2/F(T9@S[?7Q!V^O7W]P@/-Y/G _GP8Q7LI M^3A>;!_+6'\ _+Z_C\QEG.'L#/#WN6LX<]#R9\>.S+\^U)MV^]OP;]RWV[OR M_<]_'/\ !W\;[ZKZB#?;O1;]WT^W<3?O[V(*P23D+$YM;T+,M$-]Y4;$QEM;L7+V$8D-H6MKSI3G.$D,T M04RQ21A^7 R1L@;B=FXE@.7$D!MM]B=CMJD5BO.6$$\,Q3B7$4J2% X)0L$8 M\>8!*[[<@"1N!KIQ+K39[,Z1!MM9FQQA-H(2?B'A4AD>9>>1&9$3G69:T1"; MLAUN.U D*;E./.(:2UEQ:4YN:M84J&@F4NAD0-$X+Q@$F105!9 27&Z@ DG M8:L6Y4=79+59UCD$,C+/$RQS%@HB%AS2)FUUH M2/&$$"2,XF=%P(8\JXVV\V,FRI4IIB(06T\RZB$^MN2IMUM:6LI<3G)*UB5E M2.":1W0R(B1.[/&"07554ED!!!8 KN#Y\:K)2>)$CE(! M$;LS )(000C$,000-B-:FQNG6,K:CVE(MN&2-EQZ'#V9(K;2G5.,TPD3DB1Q M;,[T\#7:-4< M1NSQ2($#$-R8#;/.K4NTY'BCCMU7DG0R0HEB)GFC&^[Q M*'+2(.+;L@*^#Y\'6-V1LRF:HJARX78U#%C 8&PV%45?%].E9OSQ5ZT;.\LL,/+BQCC:>18HVE=5 M81H78 NW@?E/C5F0R-3&5IK=R9(HX89Y^)9!+*M>)YY$@C9E,L@C1B$70- .ASL&/^$VFA;Y4 969"'V4E7#HB,;B2D W)2IJU,093>9V( MZ)#41U#J%NYPWE7*V*-FM+;BDB<^BL25;$L:L\*312-&RF4+Q&[*>.^Q8;$# MSJVIDJ=V"C/#.B^\:D-VI#*Z1V)*\\2S(PA+2Y)3%8)L/CGI&6L--3F78BUID-K;Q MA>"=$[CPRHG(+S>-U3D5#A>1 '(H0X&^Y4AAX(.I"6JTLABCL022A2YC26-Y M BN8FY]G]Q?< GX+W?NO9>U^6]W[#W/O?\$]#W'J^Z_P '\OJ_ MFSZ>?O<>7:[4G=X\>7+M\>7'C\6^VW'SOMYU3UM/L^I]76]/RX=_O MQ=GGRX<>[SX6_+X=M_&M2T_N2E[OH2-D4EZ?BL*L%WK?KFHB!DA!#7 MUO.TBPK<9R^^A$-!JNDLQ).7O+(A89E92UAS*$Y\AC[.-M&G9"]\15IMHVY@ MK;KQ6H0#L"6,4R*58Q':M820Q/!,DJKR:-HG60+X^(H5#!?(\D;>1YU+6Y M4>(3):KO"S]M95GB:)G&^Z"0,5+C8_"#OX/CQK*"3 D^.BEP10<:$S4*-98)8YHG!*21.LD; $@E70E6 ((.Q/D$:Q42Z M4Z?"(DH-LK,T<(F_&%B$0\+D0A9+UFX_QY&4S*6Q"F^N\RQ[22XT_P"LZVWZ M?G<2G-[5["LB-!,KR+SC1HG#.FQ/-%*@LNP)Y*"-@3OL-8UMU'221+5=XXG[ MW(P8JC\F"\&(;<@;;D:Y2%NJ@E,U96SUX8D:][8BH@:&PDP)' MQSICV\U4F2WB*]\0R\4])_+;GQS3L[R^V;4[BB5YY"HCAE/MMQD[DT:<&[9FXOR8<6[0,NS;'M@O^"" M=9QA]B4PS)C/-2(TAIM^/(8<0\P^P\C#C3S+K>5-NM.MJ2MMQ"E(6A6%)SE. M<9YC(()!!!!(((V((\$$'R"#X(/RUG5E90RD,K ,K*0592-P01X((\@CP1Y& MN7E-5TXTTXTTXTTXTU4RBJ5GLWOE.&/'\F/'6M1SGPQ_[\_E_P#C MS(?W-?X?Z6U8/PV_-_FU: =_YTK_ -HX_P#IX_F/5^LGQIIQIIQIIQIIQIJG MW<32FQ-K@M.VS4BZS*V5U_WA4MW5BL70A-$5:\)!";%73=0(FX \M(K\LH#L M\]P(?P)(MC3,6%B3'3#?DOL]!T_DJE&7(07Q,*>5QL^-FFKHLD]4RR0S16$C M9XQ*L4ZLP]_)PXFUBC7;(X+,UI7:/L$GL!NRW5/6] VE;@'6ZH:JTT.V M)*LHW%8T'O$=NHT[=]C-U,4.^Y+F0:GC "QU??'@HF(;!*6]AU^1'Z6AGL'B M?=6-@L7+5&"7,6+^1>FL+][*XQ\;&*U/U$CF&NI1Y>1N111X!X_*=+]2Y MT9W,6ZN/HY.W!T]4QF(COM8C%;"9F/,3&YD!5B3U%N021P&.N8X4"+(QY%D1 M^CNV=F[5BW;=^N-72*=8N[1'L-;M>3K)&OX9% ?ZQ1=9"19%HG6AH^QF(EUA M0/DQ;@S Q:&'I4=^;!2RY(H>I:%*BU;&7+RV(NFDQ->VL)J2>J&::[(Z%)G> M&-JSL$MT'L+>A%%NG$QT44@DKQQV) M4N1IW8C'VR 65G0 M8ON7UXO>R[WH?8%.U5K'?%7U< W%5CNB]H'(U9JTZ5L MJNUX16[J/=FUVQ!G)=0R#G#),:1 :(-!+#.579,>;ZJ7M/T]EJM*KE*EB]=Q M<]Z7'SQ9.C&TTZK3FEDFK,%FAD"V.ZKJP;@9(5[P*[;;_JW W"*OQ"7JF%XV#()!#8?L,K\MZ@[-Z-=E;?M?6 MMAB4+1P@)KHMTV. Y^OI]: MA1VDR &3L6J_*VW6]AW(<>%28Y6'K%J)LRH5 M/[+RTFPP)EBQB"_T-+J;#5Z-R)K>3DEMQ]112I;2:4R/DEE6I.(Z]R''1"12 MCWBU*Q/ZG?LN(?B'*Y'HSJ*UE,=86EA8H:$O2,T#T'K0"&/#O"V0K=VUCI\O M.8F$J8T)D:E7T>WJ(WL;HT=]<.KVXKL>#WRF:FU7KV50^S?=^Z2]VV$C*3=- MB1K,4VUK^M:SM54C5>$=?J$\X5%$2[CEDF@G::%@3Q"1@8#IO+7)XK MU/%XR@U+J/K*V^8L2-ZR^EF3*4:^.LU5K),]22>6)Y2;+PFI"CQ?3,4UAAWT MW>SDS7.X@,VBZH%D=E:SZI5M=478Z&'I)2T:4WR/O5X;("=5:DHH<+4"-81- MC5A+PBZ6]8=+<:QV8H:EN1XN1^L,*MS'RK:O.E.[G9A/V;4EI(,EBWJUBLEZ M_:DDL)-P:TBO=;;+IT@5%21];KH:9:;U;)T.QEQ8@/#C,Q'67GI;LUN3'9TUO MJ3'-2EI"US=M.EB:.*)5"$,6+A ME$"R?IH[\F:&=HA2O:U.649TSZ\:D$#R9^-)'/;.U+V6N.V+'"CSI0:2V/A% M*0<^$@6#+&&WI)::/E-M052G%[,=98M-@$YDR3MGHCONYGKA=P-9J <-.[%ZGW#!TJ*L.O'1TRK5 MWJT!TY- P'-@ZKV%JO!77]N8E*K$2T:YGU\@$B.SQV !7(=V)$H=48NO%7K2 MS6))%P]['MD9(K8=9Y:&XDJ2L%?NQ]P-/RG1.;MSVK MD%:I%"^?Q>63#Q3T#&]:OTW!B7@C-[&7\9W:-H-Z9;./>!X4+Q]B7LE=%V-] M.'?:Z-H(90:W52%VH6F'=>/$[QL37VPJ> FRMI&]@PZK=Z5>.NZJW:=>U>.< M1#"&=8A:-;83(UFO,C90P6#*IDT^L,6+.5>U-.E:UD1<"5JENI9E5:,=1IZU MJKE^]#..&5?7H>0O6U*=ORCVVAQ*^L<3M.KZ MK.DF;","[,"3M=U^1FWLRV@D(U6!$RPV,W6'E!%6-TQ-68P]\QFN[Q32-X'D!1OIX=F >J MM@TK[:UDQ6FR_60^'U?<#5 +%=K-Z.OCMFM>M+MM77NH*0Z6U6>!89%5%&Q: M]:K"@EA:SN!D%^:N3Z!:ZMPTMZI9[UTS&/-127:\=I$HG)U1#!=KT;=^R([T M4N\ECTEO8/:&OJO6:[U\ZUZQ"$I7925.H%+)T MV3*H)3:D*OQ*84=MNP-3WT/&BD5CB=(S%QW4>) MI6YIYLMF;LB+AE6U92PJVDH-,UA!!4OU9"R!T6DC4DJ,U"3)I72I*;5[%WHE63MR/DAB:U28L(15E3:1M82 MU?3Y[(G:H5\CU<5/9&?3L(2ZQBS5N3C8+_6#6UTJVSZE/E76BWZD9_\ Q%9! M5BJLFZTNT5@X2 0EF1+3"E*:RP=68>*>,;3!.?5R+/V)AZ49JY6GI6$6M:JV M?W&&2&=:UF">)96[4A(&^&QT)U!-5D\URZQ] N];U%=O7'IO'6ZN2JR-:2!#-$ =Q;^C]:-M4;H'L31%>%U'\*-M#[;E J=L4Q7;WKX M-+V+8SAM-3F+K&MM<4Y(/VQ:1Y0 ;7T.E@RDYT7#AD*S$;P]SUG,T+/553*2 MO/Z*"2@LMBG'-5M2+3ABB-A1/=N6.[O&/I9+;6)44.S).QVZNET[DZ70]_"5 MXZ@R5N+*M#4ORP7:$+Y">:;TK&MCL?4[/&5OH(J"4X97,:))60I4O0MU9A\Y+3EFHRIZ.G@KF/LI)!1 MQN.Q[3-:>%S#!2CA>-MBTI1Y).VW]/WT-" M*5KX3V$VDY;]:['K;:JA8QZ7Z]76?@CX0:+AF!<(AZ5>?D/(>RS;]U>.F>VW MK\ECYYUZ;L/?K0&2S;EQ%(07*S/#'$LL:/M 6(/&P5RZ>;[K=66U-6F*,#+%'$[UR4V:14W'G M4>TCH%=4.]5*5LRBZIMVO^M<;N%49\ZX0I-G8G2EDHKD>5:ZJK'WY9I6;U>UF6Z>L*B%T-.2B9_7TXI MUD#"K'R5:@7B#7982JA&!U]/H>YOTS3R-'&6Z'3J=5U'>012+D(LDE48O(35 M7B*F[,$=KY?DRVE:PKN9%*P@0^G9V'3K"JTXQKC3&XCIGI32^L,$S?KN]%G+U>2R6R%(FI.98]IX9@:QBL]ZI&FXCXD;/NOZ=W:)[9UB MO.F=A W4TZ!4-TZ??.&)0F05[7OPM,ZWVC8+@PVW)PD):M7ZOL9!;R7W%KM. MQ"3V7,Y8\R,.-ZMP8I0ULC4E'J'LX[(".-9 F"#Y&[2AKG==Y(+MV% " !!4 M0;;';4G,=!=2-DK%W$WX6%1*F8Q+32M$TO4Y3$8_)3VU /T-K&XVPY8,?VQ? MD.^Z[CM['^E]89%*W)4J;5]>')R.GO7/2&C+38'H;9H3L?6-DL9F[69J=)&R M)=5D')$L686<@.(ESYZWT*2WAO.%6U.M818Q\]B>W$IZAR^3R<$08QO3NPPQ M5H2JN%G$05X^TX*JFWD[ZOR'LWG:GEJM2M0F<=*8##86S.4$T5_'6+$UVR': M-GJM,S12F:,AWD+;@;:WHMT[1M]J)-D6O;HC5PB M(8E]>&JT[5G3#T)Z$-F46,PFX9H+M,+R)4\,HEAT>]%CZFQZ8F.+U%Y6CZC,M)GY9S3QCI-U?!U(. MIFL'WK%C(DB5L"*YK&5D*1M24>K-(TY79XNYNC00-^EOV$:MXYB?;ZR_KAN_ M-=?R@E1J:](G?3ZK6R:UN&IUOV[C&8[-T=-@Y5,FP$(4VR"+35*D2&7E9QM' MZWQ)KN5KSBYZ0Y6-Q$BJG5XNQF=>!] M=5;7=CK<*I;B 'I%E^Q(-IK]ANP **JI(6KDMSVX9FGQTL0A]4T$L56662='BJW:)>QLR>F-B22 MJ-Y.[$VXW[+KSI[+=0>@AH5J%BNE;+0SM9]$EF">Y!#%5DCFO8W)B.IND@N" MG%#>;:'LSH VU;X?TWMF6#6?8R#8H5 $;>OW4_K%IC5>P)LQDX7K%EUSI1=" MVZ):L2!,DO6J_>YK>*P<+!VW'['6)JW2 ^6U&0.5N6ZQIQ7,0T+VWQ]7.YK( MWJB*8HYH;F2]50D,)D6.::JA[T4R[;73$2EQ[3K(Z*&)KM+%59XO'$Z>TEH[7M;G&UP6VIC(2NSGRL$2')F M9J#3I!"^>ZHR];*/02M*+"TJ\T;63!=B>3O69)Q&7R.2R=N5(N9*F291&TDB M1J8@FW6]$X&YA8LK)<@]&V0M5Y4IK9QT\40KU(JQE6+$X?"T*[S&,!UAKN9$ MBBDE<3&3>C5.^F3MJN:GU?3JNC7^KKYCI5V-T/M.]5J;B/.+;&V58:D6I;QD MH(&,F+,";8%%H<\L[F1-!P9.6AD1W.&&$]+8ZSH37[MB?U=VK]TF'RE&K,O) M8Z=.*Q'9$:2.8X927C98QLDK+N[ ;G7&5/9UE*^,QU2L*.,N_%&VB4_"-=>U_3UV_>=?[CEP-!Z%U%(+UGJL M#J77^JVD86I=RM&AMHHMETV0;.8I D)7SMLHLXOK< ^L01*SJY(EQ+=,99GO MLNW0=68^K;QRME,ID!'-G)9\K/ Z6:\&4I&O6IQQ>J>2:*O:6.[*.XB+,%:N MI* BVUT'E;M'+.F#P>+::MTS#5P=:S'+4MV<)DO57,A-/Z**&":U2>7'PL8I M)7KLR67"NRFW/=[K%M+>HWK6;H->!O1-1R[<_;-+Y*ZSC"I6+CK]%6$N Y.T M]2;8U=-?U_,Q)'Q,&==^90$R6E5N2%+M0<\T'36:HXN3,16II5:^M=8,EPNF M1?3V^_()%HWZ%Y1;7B[=NYXECC682QEQKJ>L>G,GFH^GIJ->$IBFMM:P_=QR MQ/ZN@*T1A;)8K*8US1?E&O>H?N$TK5VAE"$4TVI]/'LP MMM:K5PFVVBR;F",ZEV$JWVVO6/8![2*-C6>##@^F)UDY0B^H0*(ZI4BXCYR_ M*/D='1ZMPLO-#4BR1IP,S[R71:CR$O(*M M9E_#')9/H/J*:#'5((*,R4,3T_6K6WM4FN038N_ZNU!/?GPPR%E%3:+'&C+B M8 O)K<;GZ-I*1T8WV,[,[:OU5KE##4>_3NRY@L0LE@IMZ=*O;CI-@& I&O"$ MW58C;VM+&5LQ,:[> \W81BBCP[!4>#<*#UCAS4+[IL6^&H59YK0H\O!^;G8#HO-Q=1Y.]5KT8:=Z3J*: M:2Q/4NF4Y:I/' U"1\9%E#64M!1[LYU#"V\BW7QP\.*?G*8MI^1&I8J9KY;*U*E-)98+.8ZL?))+P@087J"6NAE=Y) N\$0-EUWW1XD MVY'6MR/3EO X*_>R#P0VJ> Z%CPSP]RU(>H^EH;<@@2.*(N5M3,M2-]MI(K$ MF_#YZNS7>LFPI/TX-DZ9>C0<;\W]JK;5KOJRS^1T>1N_?<4Y9['&,35O/G78U^G+[>S_ "&(*I[\SF,REJ\93VU;,YM9K-A97V)589[ MK!B"1'"NX\:JMV$^FG>+#9J&SJBH5"+KS/72IZ:G5>LG-7ZYSKF\C;L_:[1L M8<3M>A]MSXSUFS/9GD+;K-%7V?(L=:'2IACJ@[S$]95HH;1O6+#6_>]C M(K//'>M^LJO6$$%-TKY2@I6'B46O<[](0S.JQH0W+F<][/+MBQ27&5*BT#@* MN)>M7FQN/]!=CN-9LY".2U@\K(ILER33UT9Y9 5*:]4^LNR]H=C-W M$*YK"E055+ZC="V+-[*V4O\ &[/"5'5U'U8L7HHIYI#/QB>L0 M)&#PF95B@,3DLP7#6ZWDH:N,I8R>>K7B%7G- M'<5GA1H["P.\]I9XU6-2^:S].KL22UJ]26C=4JA>7UE[GZH^9CV*6[':L^\> MUL/I$5\/:Y\5EYX5\C*BMPB"D^5S%]UV(2Z+1BGGC7-=.7 M^V85#=C&8%L;9=0S\>]%:820(642<%;FGS&8]!9Z7'FFLU6K*W3W5^,[RV&* MBQFNIUR].-BD?/T\],&&TZJ6B[CJJ2;#??K;U4WK:J/%B5OJIU@TV*G;NIML ML6L*,5HQ\](K];U65I;ML'G]@ZFMNFP]HR>F1(D=^%JJ2:9H34S"9RK7(3(1 M%@SF,@M,TVP\52_7R,D':5F8->$9M%=U$ *F9 M;Z8S5JDJ5^F>F\3&^9J6K&-I2TIIF@KXN6F;4<][%V\3%9[[(B,N,:440WQB MR0PA2J?34W\&J%4K*Z_K$?:9_1S=768KLF-9(SA/7=\-[!N]CIMC'2VZHT;, M@+)2S$+7$R8&2*, *P=,QEPSS.Q5*M8P8U++]&9?IR7(+8'U_59DX?V$ZZ M[4+=?K1L'5RJ#L^M:8I5GJ1T4]%U7U[U7KFMS#,NS"BT%PS6[4NR(U[5G;D,1E\!7FJ38W'009#J#-Y*:.G= M)AQ=.TJS48:L?I(O4@2J*I0"J(8@)0NP[(LL,M>_7QM5?*Z?I8\H0IUW)VZ! M&VPY/CUR["G8Z:%51D[-&BYL FW,KDN&;,J,+555L-MI#&_6RMO3208H/.(\ MA9=$L5DKNU *9JSAO53R+ZENU)7(41PAG[X))DBVV/0QVLXT=9I<53CDDJ79 M+4:Y,NM>Y$5]#6C?T2]^*T"QFL\8S6*@=F;EN/,CL5TM[!;LO.U;0[K33Y"P M]AZ%UV@!-F'[[(DVSI3:-:X;F7B-K>1FE9+V<>Z;>EV.MEZ:1I$LU9,O*LD. M(.=96WV>(ZCQ6-K48/6Y!8<1:RSR4HJH6#J."Y\-9KB^I[<#B,+#-'82RL4. MW99G!!\ZSW2&=S%W*63C\3)/GJ. 2'(SW6:UT?9QVS75Q[>C[ME#,SV*\U22 MD\MC?U"+&01M+_4SL@QM]V!&KM%FZO1]1P!W7SL1Z^.,V"75G]>PJ@2I[5%3 M5\>0X)FQY$Z62=/L0I;2HT<;"D>L_(A8!GL.<>&::TMW[D)>FQ4%4&)9Q;:P ME@VC.=XI$(14$193R9V&P#26Z7Z@&5*+7I/C1[08.L?7M=(G>L:*5)*@I"L- MIXG5I&D,ZHX*K&AW9DGKJIU$(Z3Z8DM*_'U37>Y[G3-BAKGL"F1XKI*39[(1 MNN*K9B=CA18)6PRZN.L4#(IR:\MT4Q&P,'*CQF&D8U>)^84;2$\WY,2=;OICI63#](R8?MUL?E[E._#G%@.GL9=I0=,(CT[CF7.V.Q'&QKM/!/; M]1-)ZF81A=N'8'1SL)L()L.S6*@5EFXVKN!<]_ 0=3VU6I,RL5NV:,I>N8;* MOPCZDM>L[M*:)!9X^U [158#>!V7YE7-8<>2F76IU-B:DM2&&W.:\'3];%2R MST9E6::OD[-QC^TK\%VLI21'@D@G_6LK-=BCF[F\K M*3*97DE%DW0>>F1T,.%AMW>A(>GYLA2$=-*63K3VG(C@AJ(_I;M*2OC9Y:PB MXP+(%@$*10G+/= ]JW:8?,R-+Z5TA2;7N#IB1+]=*7981^C3*GH.WD2>T+L9 MS$J5>KLHS;:V637!82*(5*+A L9NRR\S'T-LV+U51K+%&,CDLE:AQ_42)E[, M+165GRM=$I5H^5B:81P31]YY6?:.61NRO >D9)>GZ M=A)Z;U<';DER5R;A5KUVFM5Y17BA6,M+#"HL/R( R8/Z<%YKMN@G:4$UWK0G MGLOWDN";M4O8CS];U#OC5NPZ9J"$+4,'0Y>6*R8L%>G_ &9&DQQ@#,-R1"3Z MK>5+LEZOJRUWBLR6[L?N;IFN:T_-XIK^+O5+.0:3N.R[S1PS)Z@@O+R ;P?& M2'V?W8+23TXIFO"8=%\UL_2[^+TGN@%>+M:G@>N]!ZK4TM MZN1SD>N&]@F;OLPVT7EA[89D9CP2+D^SUEC3DJEJ&>:2.*;/7$E-6Z+-23)8 MV:K6@$EO*W@0)FB::.I'6I1&-9*\8#,@UE/V=Y@8:]0L5Z\OM7T MZ@PKKHTS(=G/Z^+T,=4]:P88PW'':K-:FE6K7EZ'"XC\&B$-0W\*">D/0C!? M(0DLJZ]JJ?4]-^GYZ&4MW;%IJV3C4*MN.T]BX[21%[T5]8+=5YDR%6255 M#1Q]U!&%W5_HJ^G5=;)X:AC:E%+F%E8R-0FHQU<=&D4PCQDV*:U0O1Q(R4I, M7>BA9F2:4PR=TMOW=[J7M#=.TR5VJ>M]5[C!VKJIL3KX.";1L:03.G;W9CRS MPW<=;:DU:T(FSWHRV!4OX3 2RL2 83VIF'"=E28L7IK/4L;12M/0KQC;LF&P&@A"31H7=:XA?IU[[A;HUE9S>8!< M# '],9SEH#7C78,IJJ9UQU_5ZY;:Z/D6'1%[V3/@$K!7B1<(/UUL&B5RU,6L MR-NK<9$F21?V\G5V+;'78(@T-K&$NY"1))Z M\DT*4+]&O:%F6.X%#,[1SUYZA;?VM! 'ZI1:3I#(';'?>83[%0R\B-MNVL[( M(;BU=5ZO/K3-9'%T01!PL+LK=9C,\9>2)'A(6%)>[-*D@,:JS:_ ]*Y;)I!/5I4\- MV,GUN\F?29ERMH9!\MC:U9ZPK1RA(9I8K 9[$D/8K020[3.478Z+]-7=C&GK M;2;#5JV((EVNH-/+ ,WG6DNEWD)HK;0RX7>S.@-Q6>LL:SS,#$VZ=BM6BDF7I2G+!ZW'O3NPX7*16[EEH*&#Q M@!:#NI!+=EN9"=':*U*2B.TP'NA^RJ_:REBJNK-1WO6P'N_<-]@NN)DR-J^O M[;0;GU] :MBD%Q%58W6 EEIMV8(VP<%F@7X3[>),IJ2U/>CL/Z^+JBG+ D,] MZ_5N2],U\5+F(XWGMP6JV6FO%.7>CGEAL5BD#R+,K*>*E2@)7:S]$Y""S+/5 MQF*O8^'K*WG(

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�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g93452g79m18.jpg GRAPHIC begin 644 g93452g79m18.jpg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end GRAPHIC 7 g93452g48t69.jpg GRAPHIC begin 644 g93452g48t69.jpg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end GRAPHIC 8 g93452g49q73.jpg GRAPHIC begin 644 g93452g49q73.jpg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end GRAPHIC 9 g93452g50f25.jpg GRAPHIC begin 644 g93452g50f25.jpg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